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Preface
This volume of the Handbook of Experimental Pharmacology is the ﬁrst handbook
on sleep-wake pharmacology in which both sleep- and wake-promoting compounds
are discussed and within the context of the neuroscience of sleep-wake regulation.
We have organized the volume in ﬁve parts: (I) Basic Principles; (II) Optogenetics
and Pharmacogenetics; (III) Sleep-Wake Pathologies; (IV) Current and New
Targets, and Therapeutic Prospects; and (V) Outlook and Perspectives.
The alternation of sleep and wakefulness represents a fundamental biological
rhythm, and undisturbed good quality sleep is indispensable for physical and mental
health, cognitive functioning, and good quality of life. Although it is widely
accepted that sleep must serve at least one basic function across a wide range of
species, general consensus about the unique function(s) of sleep is lacking. Frank
and Heller provide an overview of current hypotheses on sleep functions and
categorize them into those serving higher order cognitive functions and restorative
processes. They conclude that the strongest support for a primary function of sleep
goes to learning and memory and the underlying process of synaptic plasticity.
Furthermore, they suggest that impaired sleep-dependent brain energy reserve
replenishment and clearance of brain metabolism-related waste products may con-
tribute to cognitive decline with aging.
While signiﬁcant gaps in the understanding of sleep-wake regulation remain, the
knowledge base for a rational pharmacology of sleep-wake disorders is much
stronger now than a decade ago. Luppi and Fort summarize the current understand-
ing of the neuroanatomical and neurochemical bases responsible for the generation
of wakefulness, non-rapid eye movement (NREM) sleep and rapid eye movement
(REM) sleep, as well as the putative networks responsible for the switch between
wakefulness and NREM and REM sleep states. Then, O’Callaghan, Green, Franken,
and Mongrain review the insights derived from powerful “omics” approaches
applied to sleep regulation, including transcriptomics, epigenomics, proteomics,
and metabolomics. They emphasize that the complexity of sleep regulation observed
at the neuronal level also extends to the molecular level. Future integration of this
accumulating knowledge at a systems level will eventually lead to an understanding
of the information ﬂow from the genome via molecules to networks regulating
wakefulness and sleep in health and disease.
v
Additionally, important new concepts and model systems, such as astroglial
regulation of sleep, sleep as a local-use dependent process, and occurrence of
sleep-like states in vitro, have recently emerged. In the chapter dedicated to
gliotransmission and sleep-wake regulation, Frank discusses the emerging evidence
that not only neuronal but also glial brain cells play fundamental roles in the
expression, regulation, and functions of wakefulness and sleep. McKillop and
Vyazovskiy continue by focusing on recent advances achieved from using small
neuronal networks as model systems to study the electrophysiology and pharmacol-
ogy of ion channels, receptors, and intracellular pathways controlling and regulating
the sleep-wake cycle. The convergent evidence suggests that neuronal-glial
networks can exhibit wake- and sleep-like activity, which is consistent with the
view that activity-dependent modulation of local networks underlies global behav-
ioral states.
In the last decade, optogenetic, chemogenetic, and pharmacogenetic techniques
have been established as powerful tools to interrogate sleep regulatory mechanisms.
Optogenetics allows the remote, optical control of activity in genetically targeted
neuronal circuits with physiologically relevant spatial and temporal resolution.
Adamantidis and Lüthi provide a step-by-step review of optogenetic studies
mapping the functional circuits underlying sleep-wake states and the switching
between states and investigations of the neural substrates of neurophysiological
sleep rhythms and their functions. Inspired by the introduction of optogenetics,
pharmacosynthetics approaches such as DREADDs (Designed Receptors Exclu-
sively Activated by Designer Drugs) offer pharmacological tools to selectively
control neuronal activity and to probe causal roles of neuronal populations in
regulating waking and sleep states. Varin and Bonnavion illustrate how DREADDs
expand our understanding of discrete neuronal subpopulations in brain structures
that are critical in controlling the vigilance state architecture. Their comprehensive
review highlights the emergence of a large, complex network of strongly
interconnected and heterogenous neuronal subpopulations controlling the sleep-
wake cycle. It is a challenging task to decipher the complexity and unscramble the
hierarchical organization of this sleep-wake regulatory network and to translate this
knowledge into rational novel therapies of sleep-wake disorders. Nevertheless, as
outlined by Landolt, Holst, and Valomon, based upon insights from opto-/
chemogenetic strategies in animal models and human genetic studies, circuit
mechanisms regulating distinct sleep-wake functions may also be identiﬁed in
humans. Such an approach may reveal novel targets for the development of rational
sleep-wake therapeutics.
Sleep-wake disorders rank third in the prevalence of brain disorders, which
together cause an estimated economic cost of roughly 800 billion Euros per year
in Europe. We have included two reviews summarizing clinical sleep-wake
pathologies. While Baumann focuses on central disorders of hypersomnolence and
sleep-related movement disorders and their current pharmacotherapies,
Spiegelhalder, Nissen, and Riemann emphasize the high prevalence and pronounced
disease burden associated with insomnia and circadian rhythm sleep-wake disorders
in modern 24/7 societies, which are now present around the globe. Because of the
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unknown neurobiology of insomnia, the current pharmacological treatments of
insomnia disorders are almost entirely symptomatic. This is in contrast to the
treatment of delayed sleep phase and jet lag disorder, which is based on an under-
standing of the circadian disruption underlying these disorders and the effect of
melatonin and light on the circadian system.
A set of reviews covers current and new targets of sleep-wake pharmacology and
discusses their therapeutic prospects. This volume highlights ﬁve neurochemical
systems: GABA (γ-amino-butyric acid), melatonin, glutamate, dopamine, and aden-
osine. Based on pharmacogenetic evidence, Wisden, Yu, and Franks emphasize the
possibility that the development of subunit-selective modulators of GABAA
receptors could lead to novel hypnotics and anxiolytics. Alston, Cain, and
Rajaratnam conclude that melatonin and melatonin receptor agonists provide a
promising alternative option to pharmacologically treat sleep and mood disorders,
particularly when the patient’s circadian phase position is misaligned with the
desired sleep-wake schedule. These authors discuss that the phase-shifting and
sleep-promoting effects of melatonin, plus additional effects of certain melatonin
receptor agonists on serotonin receptors, can provide an advantage over traditional
sleep and depression treatments. Ketamine, a drug recently approved for rapid
antidepressant treatment in a subset of patients with major depressive disorders
(MDD), also appears to alter the timing and amplitude of circadian activity patterns
in rapid responders vs. nonresponders with MDD. In addition, ketamine has well-
described effects on slow wave sleep. The review by Duncan, Ballard, and Zarate
emphasizes that ketamine treatment elevates extracellular glutamate in the prefrontal
cortex, suggesting that central glutamatergic circuits may be targeted in the search
for novel interventions to improve sleep-wake mechanisms and mood.
In contrast to the neuromodulators serotonin, noradrenaline, histamine, and
hypocretin, dopamine has long been thought to play a minor role in the regulation
of sleep-wake states. Wisor, however, summarizes opto- and chemo-genetic
experiments in animal models and pharmacogenetic ﬁndings in humans that high-
light a central role of dopaminergic signaling in the maintenance of wakefulness and
individual responses to wake-promoting medications. Finally, Lazarus, Chen,
Huang, Urade, and Fredholm present an overview of the current knowledge of the
role of the widely accepted somnogen, adenosine, and its receptors in sleep-wake
regulation. Although several aspects of the sleep-promoting action of adenosine are
still unclear, there is an active search for natural compounds, including caffeine, that
could interact with adenosine receptors for the treatment of sleep-wake disorders.
We conclude this volume with two informative reviews on two contemporary
hypotheses of sleep function and their potential for pharmacotherapy, and a timely
overview of recent ﬁndings on sleep-wake neurobiology and their relevance for the
development of novel therapeutics. First, Hladky and Barrand provide background
on the processes affecting elimination of metabolites created by brain cell activity
and how these processes differ between wakefulness and sleep. They provide
evidence that sleep increases clearance for amyloid-β, possibly suggesting that
pharmacological agents promoting physiological sleep could have potential to
reduce the formation of plaques and cerebral arterial deposits and their consequences
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for neurodegenerative processes. Then, Heller and Ruby present convincing evi-
dence that sleep and circadian rhythms functionally interact in the processes of
learning and memory consolidation. Partly based on pharmacological studies in
two distinct rodent models of learning disability, they posit the intriguing new
hypothesis that the circadian system dampens neuroplasticity during the sleep
phase, in order to stabilize labile memory transcripts during their transfer to long-
term memory stores. Finally, Dijk and Landolt highlight in their concluding chapter
that a better understanding of the neurobiology of sleep-wake regulation and circa-
dian rhythmicity, and in particular its relation to the subjective experience of sleep
and the subjective and objective quality of wakefulness, is necessary for the proper
evaluation of sleep-wake therapeutics. Persistent societal demands and demographic
changes will continue to be associated with a high prevalence of sleep-wake
disturbances, and this will lead to a continued need for novel pharmacological and
nonpharmacological therapeutic approaches.
We believe that the present volume provides an informative view on our current
understanding of the neurobiology and pharmacology of wakefulness and sleep. It
connects current ideas and concepts about sleep functions, sleep homeostasis, and
circadian rhythms with the search for novel target-selective sleep-wake therapeutics.
Towards this goal, it provides a timely overview of sleep-wake mechanisms in health
and disease, ongoing developments in drug discovery, and their prospects for the
clinical treatment of sleep-disordered patients. Special attention is given to the
concept that sleep and wakefulness mutually affect each other. Thus, future thera-
peutic interventions with either sleep- or wake-promoting agents are expected to
improve the quality of sleep as well as waking behavior, cognition, mood, and other
sleep-associated physiological functions. We hope that the chapters in this book are
helpful in identifying some directions for this important and exciting “work in
progress.”
Zürich, Switzerland Hans-Peter Landolt
Guildford, UK Derk-Jan Dijk
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Abstract
Sleep is a highly conserved phenomenon in endotherms, and therefore it must
serve at least one basic function across this wide range of species. What that
function is remains one of the biggest mysteries in neurobiology. By using the
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word neurobiology, we do not mean to exclude possible non-neural functions of
sleep, but it is difﬁcult to imagine why the brain must be taken ofﬂine if the basic
function of sleep did not involve the nervous system. In this chapter we discuss
several current hypotheses about sleep function. We divide these hypotheses into
two categories: ones that propose higher-order cognitive functions and ones that
focus on housekeeping or restorative processes. We also pose four aspects of
sleep that any successful functional hypothesis has to account for: why do the
properties of sleep change across the life span? Why and how is sleep
homeostatically regulated? Why must the brain be taken ofﬂine to accomplish
the proposed function? And, why are there two radically different stages of sleep?
The higher-order cognitive function hypotheses we discuss are essential
mechanisms of learning and memory and synaptic plasticity. These are not
mutually exclusive hypotheses. Each focuses on speciﬁc mechanistic aspects of
sleep, and higher-order cognitive processes are likely to involve components of
all of these mechanisms. The restorative hypotheses are maintenance of brain
energy metabolism, macromolecular biosynthesis, and removal of metabolic
waste. Although these three hypotheses seem more different than those related
to higher cognitive function, they may each contribute important components to a
basic sleep function. Any sleep function will involve speciﬁc gene expression and
macromolecular biosynthesis, and as we explain there may be important
connections between brain energy metabolism and the need to remove metabolic
wastes.
A deeper understanding of sleep functions in endotherms will enable us to
answer whether or not rest behaviors in species other than endotherms are
homologous with mammalian and avian sleep. Currently comparisons across
the animal kingdom depend on superﬁcial and phenomenological features of
rest states and sleep, but investigations of sleep functions would provide more
insight into the evolutionary relationships between EEG-deﬁned sleep in
endotherms and rest states in ectotherms.
Keywords
Glycogen · Glymphatic system · Hippocampal place cells · Learning · Memory ·
Ocular dominance plasticity · Synaptic homeostasis · Synaptic plasticity
1 Introduction
Sleep researchers frequently begin talks with the statement that we spend one-third
of our lives sleeping, and we don’t know why. There is no other area of human
biology that can make such a claim, but that is not a claim to fame. Many great minds
and much excellent research have been focused on the question – what is the
function of sleep? Reasonable hypotheses have been advanced, but a deﬁnitive
answer still eludes us. In this chapter, we outline what we consider essential criteria
for identifying sleep function, and we apply those criteria to several leading
hypotheses.
4 M. G. Frank and H. C. Heller
We should deﬁne sleep before discussing what its function is. Prior to about 2000,
the word sleep was reserved for those animals – namely, mammals and birds – that
shared certain EEG correlates of behavioral states. For all other animals, including
invertebrates, rest state or sleep-like state was often the descriptor used (reviewed in
Tobler 2005). But in 2000, two seminal papers appeared that made a strong case for
rest in Drosophila being homologous with sleep (Hendricks et al. 2000a; Shaw et al.
2000). Also in 2000, Hendricks, Sehgal, and Pack published a paper titled: “The
Need for a Simple Animal Model to Understand Sleep” (Hendricks et al. 2000b).
They made a convincing argument that a phylogenetic approach would bring
powerful molecular genetic tools to the investigation and identiﬁcation of evolution-
arily conserved mechanisms and functions of sleep. They proposed a list of criteria
(Table 1) for identifying a sleep-like state in animals other than mammals and birds.
However, all but one of these criteria are phenotypic features and are not mechanistic
or functional characteristics. Their one mechanistic criterion, homeostatic regulation,
could conceivably lead to a function through understanding the feedback signals that
connect some functions to the expression of the homeostatic response.
Why is it critical to identify mechanistic and functional homologies between
sleep-like states in different phylogenetic groups? Daily cycles of the physical
environment are a feature of our planet and circadian rhythms of organisms are a
ubiquitous adaptation to that fact. Daily cycles of rest and activity, whether circadian
or not, can serve many functions, and they may share many characteristics such as
quiescence, increased arousal thresholds, typical postures, and safe resting places.
But, they may not serve the same essential function that sleep serves in mammals and
birds. We therefore have a chicken and egg problem. If we knew a function of
EEG-deﬁned sleep, we could ask if sleep-like states in other organisms served that
same function and are therefore truly homologous with avian and mammalian sleep.
If so, we could use those simpler organisms to investigate the underlying
mechanisms of that sleep function.
In this chapter, we review key ﬁndings that support different hypotheses of
EEG-deﬁned sleep function in mammals. For each hypothesis, we will apply four
criteria that should be satisﬁed for it to be considered as deﬁning a primary function
of sleep:
Table 1 Criteria for identifying a sleep-like state
Characterized by an absence of voluntary movements
Spontaneous, occurring with a circadian rhythm
Reversible
Characterized by a species-speciﬁc posture and/or resting place that minimizes sensory
stimulation
Have an increased arousal threshold
Regulated by a homeostatic mechanism that is modulated by circadian regulation
State-related changes in neural function, including those leading to decreased sensory input to the
CNS
The state should be identiﬁable as a stable species characteristic
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1. Ontogeny: Does it account for changes in sleep throughout development?
2. Homeostasis: Does it explain the homeostatic regulation of sleep?
3. Necessity and sufﬁciency: Does it explain why having the brain “ofﬂine” during
sleep is necessary and sufﬁcient for the proposed function?
4. Two states: How does the proposed function explain the two extremely different
EEG states of sleep, NREM and REM sleep?
We recognize, of course, that sleep in mammals and birds may serve more than
one function, and sleep-like states on other organisms may serve a variety of
functions that may be similar or different. However, if we want to take a phyloge-
netic approach to understand sleep, and if we want to make the case that sleep is a
basic, primitive, evolutionarily conserved feature of animal life as are circadian
rhythms, we must identify one or more core functions. We also focus on hypotheses
that concern the brain rather than the body. This is because, as far as we know, the
most evolutionarily conserved effects of sleep and sleep loss are neural and not
somatic (Frank 2010). It is difﬁcult to explain why the brain would have to be taken
ofﬂine if the primary function of sleep were not neural.
Brain hypotheses of sleep function can be broadly subdivided into cognitive
(higher-order) and housekeeping (restorative and detoxiﬁcation) categories. Cogni-
tive hypotheses propose that sleep serves functions such as memory or brain
plasticity. Housekeeping hypotheses instead propose that the function of sleep is
related to essential neural processes that support higher-order cognitive functions.
Restorative hypotheses propose that sleep restores and repairs neural substrates
degraded by wakefulness. Detoxiﬁcation hypotheses propose that sleep detoxiﬁes
substances that accumulate during wake. As each of these putative functions of sleep
have been extensively reviewed elsewhere (Rechtschaffen 1998; Frank 2006), only
ﬁndings from selected studies are discussed below. We also emphasize that these
different hypotheses are not mutually exclusive.
2 Learning and Memory
The importance of sleep for learning and memory has been abundantly documented
in animals and humans (Stickgold 2005; Rasch and Born 2013), and virtually all of
us can attest to that fact through personal experience. In recent years the neurophysi-
ological mechanisms underlying the encoding of experience and its consolidation
into long-term memory have been increasingly elucidated. The pioneering study of
Wilson and McNaughton (1994) demonstrated in rats that ensembles of hippocam-
pal “place cells,” which ﬁre in relationship to speciﬁc positions in a maze, repeat
their patterns of ﬁring when the rats were in subsequent NREM sleep. Those
observations led the authors to the hypothesis, “. . .initial storage of event memory
occurs through rapid synaptic modiﬁcation, primarily within the hippocampus.
During subsequent slow-wave sleep, synaptic modiﬁcation within the hippocampus
itself is suppressed, and the neuronal states encoded within the hippocampus are
‘played back’ as part of a consolidation process by which hippocampal information
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is gradually transferred to the neocortex.” Those original results have been nicely
summarized by Mehta (2007) and reprinted as Fig. 1.
Much excellent work between 1994 and the present has supported the neural
replay during sleep hypothesis and ﬁlled out details. The replay ﬁring patterns of
hippocampal CA1 ensembles, called low-probability sequences, occur during both
quiescent wake and NREM sleep, and they run about ﬁfteen 6–20 times the speed of
the same sequence during active spatial experience (Davidson et al. 2009). These
replay events are associated with hippocampal local ﬁeld potentials (LFPs) called
sharp-wave ripples (Lee and Wilson 2002). Thus, the replay sequences contained in
sharp-wave ripples appear to spatially and temporally code information into short-
term memory.
A little background information helps explain why replay events are associated
with speciﬁc electrophysiological signatures recorded locally (LFPs) and more
globally. Ripples are 100–200 Hz waves generated by local neuronal activity.
Their detection denotes highly active neurons nearby. During waking and REM
sleep (when acetylcholine is present), ripples occur at the depolarized peaks of
hippocampal theta waves (6–10 Hz). During task-disengaged quiet wakefulness
and NREM sleep (when acetylcholine is absent), ripples are associated with peaks
of depolarization called sharp waves. Peaks of theta and sharp waves occur because
of summed dendritic depolarization that brings neurons in the local ﬁeld close to
action potential threshold. The troughs following theta waves and sharp waves
coincide with membrane hyperpolarization when neuronal spiking is least likely.
Ripples do not appear at the troughs of slow waves (NREM sleep) or theta waves
because the hyperpolarized membranes do not support high neuronal activity.
Fig. 1 Firing of “hippocampal place cells” corresponds to speciﬁc locations in space. (a)
Recordings of a population of place cells during sleep in a naive animal show no obvious pattern
of ﬁring. (b) However, during wake activity running in a maze sequence patterns of place cell ﬁring
are observed. (c) During subsequent NREM sleep, those ﬁring patterns are replayed but at a speed
that is about seven times faster (reprinted from Mehta 2007 with permission)
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Communication of the information between the hippocampus and the cortex that
is necessary for memory consolidation is enabled by coupling between ripple events
in the hippocampus and the cortex. The hippocampus slightly leads the cortex,
indicating directionality of information ﬂow (Siapas et al. 2005; Khodagholy et al.
2017). During NREM sleep, another LFP, the slow oscillation (0–3 Hz), may
organize the information exchange between the hippocampus and the cortex
(Fujisawa and Buzsáki 2011). Sharp-wave ripples (100–200 Hz) are expressed
during the up-states (depolarized phases) of the slow oscillation in both the cortex
and the hippocampus. Thus, the slow oscillation appears to create sequential frames
for the replay of information contained in the sharp-wave ripples. A single long
replay sequence may span more than one frame. Importantly, the speciﬁc sequences
expressed in the cortical and hippocampal ensembles during any one sharp-wave
ripple correspond. Thus, it appears as if, during NREM sleep, there is a communica-
tion between the hippocampus and the cortex about the prior wake experience.
Whereas the phase relationships of the theta oscillations of the hippocampus and
the cortex during wake experience indicated a direction of information ﬂow from
hippocampus to cortex, the phase relationships between the slow (0–3 Hz)
oscillations in these two structures do not clearly support a unidirectional ﬂow of
information (Ji and Wilson 2007). However, during the NREM state called NREM
stage 2 when slow oscillations are interrupted by faster 10–15 Hz spindles lasting
~1.5 s, the direction of communication is clearly from the hippocampus to the cortex,
and the cortex reverberates to hippocampal neuronal activity with a spindle fre-
quency response (Wierzynski et al. 2009).
The very elegant studies of unit activity and LFPs in the hippocampus and cortex
during experience and sleep support the model proposed by Born and Wilhelm
(2012). This model proposes that both the cortex and the hippocampus acquire
information about experience during wake with the cortical representation being
weak and the hippocampal being strong. Then during sleep, the hippocampus tutors
the cortex to strengthen or consolidate the information into long-term memory.
There are hippocampal replays of waking experiences during REM sleep as well
(Louie and Wilson 2001; Poe et al. 2000), with the main difference being that REM
replays occur without compression and the neuronal ﬁring coincides with the peaks
of the theta rhythm. One interesting feature of REM replay in the dorsal region of the
hippocampus CA1 output region is that the ﬁring of neurons associated with older
memories that have already been consolidated to the neocortex is delayed so that
they coincide with the troughs of the theta rhythm, a time consistent with the
weakening of those familiar synapses in the hippocampus (Huerta and Lisman
1996), possibly to recycle the synapses so they may be free to encode novel
memories in subsequent waking (Poe et al. 2000).
The idea that episodic memory encoding and consolidation involves the transfer
of packets of information between the hippocampus and the cortex in the form of
ripples gains support from studies showing that disruption of sharp-wave ripples
during sleep following training impairs spatial learning and memory (Girardeau et al.
2009; Ego-Stengel and Wilson 2010). No one has yet attempted to disrupt theta
ripple replay during REM sleep. Indirect evidence for the signiﬁcance of replay
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events comes from studies that used classical conditioning to reactivate memories
during sleep. Memories that are reactivated in sleep are signiﬁcantly strengthened
(Rasch and Born 2007; Rudoy et al. 2009; van Dongen et al. 2012; Oudiette and
Paller 2013; Rolls et al. 2013). Rolls et al. (2013) went on to demonstrate that the
consolidation of the reactivated memory was an active process requiring protein
synthesis (Fig. 2).
Using an odor as the conditioned stimulus (CS) and foot shock as the uncondi-
tioned stimulus (US), they showed that reintroduction of the CS during sleep
resulted in a heightened, context-independent fear response to the CS during
subsequent wake. In similar experiments, they injected a protein synthesis inhibitor
(PSI) into the amygdalas of the mice following the fear conditioning and just prior to
sleep. These animals were then exposed to the CS or a control odor stimulus during
sleep. During the next wake phase, the mice that received the PSI injections and were
exposed to the CS during sleep had decreased fear responses in comparison to mice
that had received vehicle injections and also in comparison to mice that had received
PSI injections but were exposed to a control stimulus during sleep. These results
(ﬁrst three bars in Fig. 2) were interpreted to mean that interfering with the active
process of memory reactivation and consolidation during sleep reduced the strength
of the memory. The very interesting result, however, was that when the conditioned
stimulus was introduced during natural wake episodes during the sleep phase, the
Fig. 2 Protein synthesis inhibitor (anisomycin) in combination with cued fear memory replay
during sleep weakens the strength of that fear memory when cued during subsequent wake. In each
case, the treatment (vehicle or anisomycin) was administered prior to the sleep phase, and during
sleep the animal was exposed to the CS odor or a control odor. The strength of the cued fear
response was determined during the subsequent wake phase as % of time displaying freezing
behavior following the CS exposure. The anisomycin had no effect if the animal was only exposed
to the control odor cue during sleep, but if the animal was exposed to the CS during sleep, the
strength of the cued fear memory was considerably reduced during the subsequent wake phase.
However, if the CS was delivered to the anisomycin-treated animals only when they were awake
during the sleep phase, there was no effect on the strength of the cued fear memory during the
subsequent wake phase
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PSI had no effect on the strength of the memory (Fig. 2, fourth bar, Rolls et al.
unpublished). Thus, the inﬂuence of cued memory replay on the strength of the
memory depends on sleep and not just on experiencing the CS during the sleep
phase. Taken together, there is strong evidence that hippocampal encoded memories
are reactivated during subsequent sleep and that reactivation involves communica-
tion with the cortex resulting in the formation and strengthening of a long-term
memory transcript.
3 Synaptic Plasticity
Synaptic plasticity refers to changes in the strength of existing synapses, changes in
synapse number or size, or changes in morphological structures that contain or form
synapses (e.g., dendritic spines and synaptic boutons). Synaptic plasticity is thought
to be the cellular basis of memory and also has historically been associated with
sleep. Scientists have traditionally examined this relationship in two ways. “Top-
down” approaches involve an organizing principle or hypothesis that attempts to
explain the role of sleep in plasticity in a comprehensive way. “Bottom-up”
approaches instead ask simpler questions about how sleep or sleep loss impacts
classic models of plasticity in vivo or in vitro. The results of the latter investigations
do not require that any particular “top-down” hypothesis be true. However, any “top-
down” hypothesis must account for “bottom-up” results.
3.1 Synaptic Plasticity in the Hippocampus
The role of sleep in brain plasticity has traditionally been investigated using classic
forms of tetany-induced Hebbian long-term synaptic potentiation (LTP) and long-
term depression (LTD). Overall, sleep deprivation inhibits the induction or mainte-
nance of LTP in vivo and in vitro. Sleep deprivation impairs hippocampal LTP in
anesthetized or awake rodents (Romcy-Pereira and Pavlides 2004; Kim et al. 2005;
Marks and Wayner 2005). Several studies also show that in vitro hippocampal LTP
(either the induction or maintenance) is reduced in rodents that undergo varying
amounts of REM sleep deprivation, total sleep deprivation, or sleep restriction prior
to sacriﬁce (Campbell et al. 2002; Davis et al. 2003; McDermott et al. 2003, 2006;
Chen et al. 2006; Ishikawa et al. 2006; Kopp et al. 2006; Ravassard et al. 2006, 2009;
Tartar et al. 2006; Arrigoni et al. 2009; Vecsey et al. 2009; Florian et al. 2011).
Interestingly, when REM sleep is restored (after prior deprivation) or increased in
rodents, this reverses deﬁcits in hippocampal LTP (Ravassard et al. 2009, 2015).
The underlying mechanisms mediating the effects of sleep loss on LTP and LTD
are not understood. They do not appear to be simply due to indirect effects of the
sleep deprivation procedures. For example, these deﬁcits can be dissociated from
changes in stress hormones (Kopp et al. 2006; Ravassard et al. 2009, 2015).
Diminished plasticity may instead be linked to decrements in hippocampal NMDA
receptor function (Chen et al. 2006; Kopp et al. 2006; McDermott et al. 2006;
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Longordo et al. 2009) and ERK/MAPK activation (Ravassard et al. 2009) combined
with reductions in hippocampal dendritic spines (Havekes et al. 2016), plasticity-
related mRNAs or proteins (Davis et al. 2006; Guzman-Marin et al. 2006; Ravassard
et al. 2015), and elevated concentrations of PDE4 (Vecsey et al. 2009) and extracel-
lular adenosine (Arrigoni et al. 2009; Florian et al. 2011). This may also involve
changes in protein synthesis, as the translational machinery in the hippocampus is
suppressed during sleep deprivation but recovers with subsequent sleep (Havekes
and Abel 2017) (Fig. 3).
3.2 Synaptic Plasticity in the Visual Cortex: Ocular Dominance
Plasticity (ODP) and Stimulus-Selective Response Plasticity
(SRP)
ODP refers to synaptic changes in visual cortical neurons in vivo triggered by
monocular deprivation (MD) or other changes in patterned vision (Wiesel and
Hubel 1963; Hubel and Wiesel 1970). ODP is more easily induced during a critical
period of development, but it shares in common numerous mechanisms that mediate
Hebbian and non-Hebbian plasticity in the adult hippocampus and non-sensory
cortex. ODP is considered physiological for the following reasons. It occurs in the
intact, unanesthetized brain in response to changes in sensory input that animals
actually experience. The resulting plasticity involves naturally occurring changes in
synaptic proteins and molecules as part of an adaptive response to this change in
vision. Third, the underlying plasticity governs cortical adjustments to visual input
that normally occur during the critical period. These adjustments are thought to be
essential for the development of binocular vision, acuity, and other visual response
properties in cortical neurons (for review see Spolidoro et al. 2008; Smith et al. 2009;
Tropea et al. 2009; Espinosa and Stryker 2012).
In the cat during the peak of the critical period, sleep signiﬁcantly enhances the
effects of MD on cortical neurons, a process that does not occur when animals are
instead sleep-deprived (Frank et al. 2001). The precise mechanisms governing this
process are similar to those that mediate LTP. For example, both acute (Aton et al.
2009a, b) and chronic recording (Aton et al. 2013) of single neurons show responses
to the non-deprived eye become stronger after sleep. In comparison, sleep has little
to no effect on the magnitude of depression observed in the deprived-eye pathway.
This process is activity-dependent (Jha et al. 2005), and inhibiting the N-methyl-D-
aspartate receptor (NMDAR), protein kinase A (PKA), the extracellular-regulated
kinase (ERK), or the mammalian target of rapamycin (mTOR) during post-MD sleep
inhibits this potentiated response (Aton et al. 2009a, b; Seibt et al. 2012). In addition,
post-MD sleep is accompanied by activation of several kinases implicated in LTP
and phosphorylation of the α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid
receptor (AMPAR) that lead to trafﬁcking and insertion of this receptor into the post-
synaptic membrane (Aton et al. 2009a, b). Post-MD sleep also promotes the synthe-
sis or phosphorylation of several proteins implicated in LTP (Seibt et al. 2012;
Dumoulin et al. 2015) (Fig. 4).
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Fig. 3 The molecular impact of sleep deprivation. A schematic overview of hippocampal signaling
pathways whose modulation by sleep deprivation may contribute to effects on memory formation.
Sleep deprivation has been reported to reduce glutamatergic signaling while increasing adenosine
levels. Sleep deprivation also attenuates cAMP signaling, CREB-mediated gene transcription,
translational processes through mTOR signaling, and structural plasticity through modulation of
the PKA-LIMK-coﬁlin pathway. All of these molecular events are shown in a single connected
pathway in order to demonstrate how the effects of sleep deprivation could potentially interact to
impact learning and memory. Dashed black lines and blue arrows pointing down indicate attenua-
tion of the signaling pathway. Red lines and upward pointing arrows indicate an increase of the
signaling pathway. Reproduced with permission from Havekes and Abel (2017)
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Fig. 4 Effect of sleep on the magnitude of the ocular dominance shift induced by monocular
deprivation. The ﬁrst two columns depict the rearing conditions of kittens employed by Frank et al.
(2001). The right-most column schematically shows ocular dominance maps obtained from primary
visual cortex under the various conditions. All kittens were monocularly deprived for 6 h, and one
group was tested immediately afterward (MD6h). A second group was allowed to sleep as much as
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Stimulus-selective response plasticity (SRP) is a form of in vivo LTP also
induced by changes in visual input but occurring in the developing and adult visual
cortex. In mice, brief exposure to a visual stimulus (phase-reversing, oriented
gratings) results in enhanced cortical (V1) responses to stimuli of the same orienta-
tion (Frenkel et al. 2006). SRP is considered an in vivo form of LTP of cortical
glutamatergic synapses because it requires the same cellular mechanisms as LTP
in vitro (Frenkel et al. 2006) and occludes tetany-induced thalamocortical LTP
(Cooke and Bear 2010). SRP is not present immediately after training in an awake
mouse. It is only observed after a subsequent period of sleep and suppressed by sleep
deprivation (Aton et al. 2014). A follow-up investigation (Durkin and Aton 2016)
showed that these changes could not be explained as a form of synaptic weakening in
excitatory synapses, as recently suggested (Cirelli and Tononi 2015). Instead they
require thalamocortical spindles and likely involve mechanisms implicated in classic
LTP (Durkin et al. 2017). In support of this interpretation, calcium in cortical
dendrites is elevated during NREM spindles in a manner that may promote Hebbian
synaptic modiﬁcations (Seibt et al. 2017) (Fig. 5). Nevertheless, there are several
unknown mechanisms that likely are important in this process, including changes in
intracortical inhibition (Kaplan et al. 2016).
3.3 The Synaptic Homeostasis Hypothesis (SHY)
SHY proposes that sleep promotes global (or “net’) synaptic weakening that offsets
global synaptic strengthening that occurs during wake (Tononi and Cirelli 2003,
2006, 2014). This global synaptic weakening in sleep preserves the relative strength
between synapses, allows for further synaptic changes, and prevents maladaptive
metabolic costs associated with excessive synaptic maintenance. These are intui-
tively appealing aspects of SHY. If indeed all or most learning results in synaptic
strengthening (but see Frank 2012), then eventually the brain’s ability to learn or
store information would saturate at some point. There should be other forms of
plasticity that restore a set point of synaptic strength to the network. This problem
was recognized many years before SHY was proposed and several mechanisms
including heterosynaptic adjustments (e.g., a sliding threshold for plasticity) and
synaptic homeostasis were proffered as solutions (reviewed in Turrigiano 2007;
Hulme et al. 2014).
Fig. 4 (continued) they liked during the following 6 h (MD + S), while a third group was kept
awake in the dark (MD  S). A fourth group was deprived for 12 h and then tested (MD12h). The
ocular dominance maps obtained by intrinsic signal imaging (Bonhoeffer and Grimwald 1996) dis-
play cortical regions dominated by the deprived eye in black and those dominated by the
non-deprived eye in white. The MD + S group shows a loss of territory dominated by the deprived
eye well beyond that is observed in the MD6h group, while the sleep-deprived group (MD  S)
does not. In fact, the consolidation of the MD shift in the MD + S group amounts to about the same
magnitude as is observed after 12 h of monocular deprivation (MD12h). Reproduced with permis-
sion from Sengpiel (2001)
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Therefore the core concept of SHY is not new; what is new is the idea that this
renormalization of synaptic weights predominantly occurs in sleep and that it should
manifest as a global reduction in synaptic strength. Although the most recent
formulation of SHY allows for subsets of synapses to be preserved against the
downscaling process (“selective down-selection”), the latter does not involve
synaptogenesis or new synaptic strengthening during sleep.
A number of changes in proteins, synaptic efﬁcacy, and synapse and dendrite
morphology are consistent with predictions of SHY (Vyazovskiy et al. 2008; Liu
et al. 2010; Maret et al. 2011; de Vivo et al. 2017). In homogenized tissue, markers
of synaptic potentiation (e.g., changes in AMPAR subunit number or phosphoryla-
tion) are higher in rats sacriﬁced at the end of the active phase or after sleep
deprivation, compared to animals sacriﬁced at the end of the rest phase (Vyazovskiy
et al. 2008). Similar results are reported for measures of synaptic efﬁcacy (EPSPs
and mini EPSPs) and neuronal ﬁring rates, which are also elevated at the end of the
active phase (or after sleep deprivation) relative to sleep (Vyazovskiy et al. 2009; Liu
et al. 2010). Two imaging studies of cortical dendrite spine morphology showed that
the ratio of spines eliminated to those formed was greater after sleep (Maret et al.
2011; Yang and Gan 2011). However, these results were restricted to stages of
development when there is an overall pruning of synapses and were not detected in
adult mice (Maret et al. 2011). It was also shown using electron microscopy in ﬁxed
mouse tissue (layer 2–3 of the cortex) that many synapses shrink in size when
examined after a long period of sleep, relative to sleep deprivation or the wake
phase (de Vivo et al. 2017). These studies were also conducted in juvenile mice;
therefore, it is unclear if this reﬂects a general sleep-dependent process that occurs in
adult animals. It is also reported that hippocampal sharp waves during sleep lead to
synaptic downscaling (Norimoto et al. 2018), ﬁndings which are surprising consid-
ering the role of sharp-wave ripples and replay in synaptic potentiation (Sadowski
et al. 2016).
There are a number of important caveats to SHY. The ﬁrst is that the effects of
sleep on synaptic plasticity are not uniform. They vary based on a number of factors,
including the brain region under examination, the age of the animal, the types of
waking experience that precede sleep, and circadian phase (Ribeiro 2011; Frank
2012; Frank and Cantera 2014; Areal et al. 2017; Puentes-Mestril and Aton 2017;
Timofeev and Chauvette 2017). For example, the decrease in neuronal ﬁring rates
during sleep (Vyazovskiy et al. 2009) does not occur in the visual cortex in juvenile
and adult rodents (Aton et al. 2014; Hengen et al. 2016) or developing cats (Aton
et al. 2013). In the frontal cortex of rats, neuronal ﬁring rates across bouts of sleep are
inconsistent with only “selective down-selection.” Instead, sleep appears to promote
ﬁring rate adjustments consistent with a preservation of the weaker synapses
(Watson et al. 2016). Sleep has also been shown to increase or decrease cortical
dendritic spines in adult mice, depending on the type of learning that precedes sleep
and the cortical region under examination (Yang et al. 2014; Li et al. 2017). In
contrast to what is reported in rodent cortex, extended wakefulness reduces morpho-
logical and biochemical markers of hippocampal synapses, events that are reversed
during recovery sleep (Havekes et al. 2007, 2016; Hagewoud et al. 2009). Changes
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in cortical AMPAR subunits reported after sleep deprivation in rats (Vyazovskiy et
al. 2008) are not found in mice (Diering et al. 2017) or cats (Seibt et al. 2012). The
conclusion from these various studies is that SHY does not accommodate several
basic ﬁndings from “bottom-up” approaches.
A second caveat is that some ﬁndings cited in support of SHY are based on
nonphysiological conditions and/or are rely heavily on ex vivo preparations. As
discussed elsewhere (Holscher 1999; Albensi et al. 2007), plasticity is considered
nonphysiological when it involves forms of stimulation not naturally experienced by
the intact brain or measurement conditions that do not reproduce the conditions of
the intact brain (Holscher 1999; Albensi et al. 2007). Studies cited in support of SHY
employ nonphysiological approaches, including exogenous, transcallosal electrical
stimulation (Vyazovskiy et al. 2008), intracranial infusions of chemicals that cause
cortical spreading depression (Faraguna et al. 2010), intracortical infusions of
neurotrophins and antibodies (Faraguna et al. 2008), transcranial electromagnetic
ﬁelds (Huber 2007), and measurements in vitro that require the use of tetrodotoxin
and picrotoxin (Liu et al. 2010). A recent study reporting sharp-wave-mediated
synaptic downscaling relies heavily on in situ preparations and not actual direct
measurements of spines or synapses in vivo (Norimoto et al. 2018).
The third caveat is that virtually nothing is known concerning the sleep-
dependent mechanisms that purportedly weaken synapses during sleep (Frank
2012, 2013). Homer 1a has been implicated in synaptic downscaling during sleep,
but this study did not examine sleep per se. It instead measured changes in synapses
or proteins at two different times of day in a strongly circadian species (mice) in the
absence of quantitative measures of sleep or wakefulness or controls for circadian
inﬂuences (Diering et al. 2017). Therefore the results may be due to sleep or
circadian rhythms.
NREM SWA has been proposed to directly weaken synapses in SHY (Tononi
and Cirelli 2003, 2006). However, there is no direct evidence that SWA in vivo
weakens synapses (Steriade and Timofeev 2003; Frank 2012) while several studies
indicate that SWAmight strengthen synapses (Tsanov and Manahan-Vaughan 2007;
Watson et al. 2016; Timofeev and Chauvette 2017). As mentioned above, SWA
appears to be critical in the transfer of information from the hippocampus to the
cortex (Fujisawa and Buzsáki 2011), which seems to be incompatible with a synaptic
weakening function. If, as suggested, there is extensive transfer of information
between the hippocampus and cortex during sleep in support of memory consolida-
tion, and that those communications are organized by speciﬁc local ﬁeld potentials
makes it unlikely that those LFPs are functioning to weaken synapses (and see above
discussion).
A ﬁnal caveat is that there is no direct evidence for a functional signiﬁcance of the
synaptic weakening associated with SHY (Tononi and Cirelli 2014). Currently,
evidence supporting a functional signiﬁcance comes primarily from computational
models (Hill et al. 2008; Olcese et al. 2010; Nere et al. 2013). Computational models
depend critically on what variables are included and the assumptions made about
how actual neurons operate in vivo. Other computational models of memory consol-
idation during sleep do not employ “selective down-selection” or “renormalization”
as described in SHY (O’Donnell and Sejnowski 2014; Blanco et al. 2015). A
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remaining challenge is the need for direct in vivo evidence for adaptive functions
(behaviorally or otherwise) of synaptic down-selection during sleep.
To summarize, it appears that sleep does more than simply weaken synapses.
Rather, during sleep, there is a mixture of synaptic weakening and strengthening that
is circuit-speciﬁc and determined in large part by the experience that precedes sleep
(Frank 2015).
4 Restorative Functions
We commonly refer to a good night of sleep as “restorative sleep,” but we don’t
know what is being restored. The most ubiquitous conceptualization of a sleep
restorative function in the sleep literature is Process S based on the changing
expression of EEG slow-wave activity (SWA) as a function of prior wake and
subsequent sleep duration (Borbely and Achermann 1992). Process S is quantiﬁed
by the EEG spectral power in the 0.5–4.5 Hz range, which is highest following
prolonged wake and decays exponentially during subsequent sleep. Varying the
duration of wake prior to sleep indicates that Process S builds as an exponentially
saturating curve. The dynamics of Process S reﬂect a negative feedback mechanism –
some condition accumulates during wake and that condition produces a signal that
controls the intensity of subsequent sleep and presumably the restorative process that
returns the condition to its normative state. Identifying the feedback signal should
lead to identiﬁcation of that condition and the restorative process.
4.1 Brain Energy
The prevalent and age-old use of adenosine A1-receptor antagonist caffeine and
theophylline to promote wakefulness presaged the scientiﬁc demonstration that
adenosine A1-receptor agonists promote sleep (Radulovacki et al. 1984; Benington
et al. 1995). Moreover, in sleep satiated rats, adenosine agonists promote dose-
dependent increases in SWA that have spectral proﬁles identical to those following
different durations of prior wake, and these increases in SWA show a monotonic
decline similar to that seen in recovery from prolonged prior wake (Benington et al.
1995). Adenosine concentrations and the activity of adenosine synthetic and degra-
dative enzymes show diurnal variations in the rat brain with adenosine highest
during the rest phase and lowest during the active phase (de Sanchez et al. 1993).
Microdialysis studies in cats revealed increases in adenosine in the basal forebrain
and cortex with prolonged wake and decline during subsequent sleep
(Porkka-Heiskanen et al. 1997). The mechanisms whereby adenosine can regulate
SWA are established. Acting through adenosine A1 receptors throughout the thala-
mus and cortex, adenosine promotes increased K+ conductance, hyperpolarization,
and de-inactivation of low-threshold Ca++ channels that are the basis for the
synchronized bursting that produces the slow waves in the cortical EEG (reviewed
in Benington and Heller 1995). These observations and many more
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(Palchykova et al. 2010; Greene et al. 2017) clearly support adenosine as being a
critical feedback variable in the homeostatic regulation of SWA.
What does the identiﬁcation of adenosine as the critical feedback variable for
control of SWA suggest as to the function of sleep? Adenosine is a central player in
energy exchanges. When metabolic demand reduces the ATP/ADP ratio, excess
ADPs are scavenged to produce ATP with adenosine being a leftover. Thus,
increased adenosine release reﬂects energy depletion. The hypothesis presented by
Benington and Heller (1995) was that the major brain energy reserve, glycogen, is
regionally depleted during wake resulting in local transient energy deﬁcits and
adenosine release. Adenosine release promotes NREM sleep with increased SWA
during which glycogen reserves are restored. The hypothesis was supported by a
study in rats showing sleep deprivation depletes brain glycogen and recovery sleep
restores brain glycogen (Kong et al. 2002). However, attempts to replicate those
ﬁndings in mice produced equivocal results (Gip et al. 2002; Franken et al. 2003).
Supporting molecular genetic data came from a study by Petit et al. (2002) showing
that 6 h of sleep deprivation in mice elevated expression of glycogen synthase-a and
protein targeted to glycogen which serves as a scaffolding bringing glycogen and
glycogen metabolic enzymes together. However, many subsequent studies reviewed
by Petit et al. (2015) have shown that the relationships between sleep-wake and brain
energy metabolism are more complex with both glycogen synthesis and degradation
occurring during sleep or wake. Thus, measures of rate of turnover might be more
informative than time point measures of glycogen concentrations.
Whether or not glycogen replenishment is a major function of sleep, adenosine is
clearly an important controlling element and perhaps a feedback signal. The role
of adenosine in modulating the SWA response to prior waking activity was
demonstrated in a study in which the ability of astrocytes to release ATP was
reversibly impaired by means of a conditional double negative SNARE transgene.
The release of ATP by astrocytes is a major factor in control of extracellular
adenosine. This study showed that baseline sleep was normal in the mice expressing
the dnSNARE, but these mice did not show the enhanced SWA response to sleep
deprivation (Halassa et al. 2009). These results provide further evidence that adeno-
sine is the feedback signal controlling the sleep homeostatic response, but if that
adenosine is the result of ATP release from astrocytes, what could the restorative
function be?
4.2 Macromolecular Synthesis
Sleep may also serve a restorative process by promoting the synthesis of proteins,
peptides, or lipids necessary for normal waking function. NREM sleep has histori-
cally been viewed as the “restorative” sleep state (Benington and Heller 1995).
Though far from conclusive, there are a number of ﬁndings that support this view.
NREM sleep amounts are positively correlated with cerebral protein synthesis in
adult rats, monkeys, and the ovine fetus (Ramm and Smith 1990; Nakanishi et al.
1997; Czikk et al. 2003; Vazquez et al. 2008). Studies in rabbits show positive
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correlations between RNA synthesis in puriﬁed nuclear fractions of neocortical
neurons and EEG synchronization during sleep (Giuditta et al. 1980a, b). In cats
and rodents, NREM sleep promotes the synthesis of a number of synaptic proteins
and neurotrophins (Seibt et al. 2012; Vecsey et al. 2012; Tudor et al. 2016).
Molecular studies show that recovery sleep after total sleep deprivation
upregulates cortical and medullary expression of genes that may play a role in
protein biogenesis in the endoplasmic reticulum (ER) (Terao et al. 2003). Comple-
mentary results have been reported after 6 h of total sleep deprivation in mice, which
induces cellular events that decrease protein synthesis (Naidoo et al. 2005). Other
studies have found sleep-related increases in several genes implicated in cholesterol
synthesis, membrane trafﬁcking, and vesicle maintenance and transport (Taishi et al.
2001; Cirelli et al. 2004; Basheer et al. 2005; Mackiewicz et al. 2007). Total sleep
deprivation is also reported to reduce cell proliferation in the hippocampus
(Guzman-Marin et al. 2003, 2005; Hairston et al. 2005; Tung et al. 2005). This
latter effect does not appear to be simply due to stress accompanying sleep depriva-
tion because it persists even when stress hormones are clamped (Mueller et al. 2008).
The evidence for macromolecule synthesis in REM sleep is not as clear. REM
sleep deprivation also reduces hippocampal neurogenesis (Guzman-Marin et al.
2008), but it has inconsistent effects on protein synthesis, with some investigators
reporting no effects (Bobillier et al. 1971) and others showing reductions, chieﬂy in
non-cortical structures (Denin et al. 1980; Shapiro and Girdwood 1981).
An important caveat applies to all studies that employ selective REM sleep
deprivation. Even very short-term REM sleep deprivation on the order of hours
compromises the quality of NREM sleep as the attempts to enter REM sleep come at
increasingly shorter intervals (Benington and Heller 1994). Nevertheless, selective
REM sleep deprivation has continued to be used in many studies, so this caveat has
to be kept in mind while attempting to interpret the results of these studies.
REM sleep deprivation alters the expression of several genes associated with
REM sleep mechanisms, but there is little evidence that REM sleep enhances the
expression of genes other than those located in REM sleep circuits (Merchant-Nancy
et al. 1992; Toppila et al. 1995; Maloney et al. 2002). Although REM sleep is
accompanied by reduced monoaminergic activity (Hobson 1999), the signiﬁcance of
this interaction in terms of neuro-regeneration is unclear. For example, short-term
REM sleep deprivation (96 h) has been shown to increase noradrenergic activity and
downregulate beta-adrenergic receptors (Pedrazzoli and Benedito 2004; Andersen
et al. 2005), but extended total sleep deprivation or REM sleep deprivation mini-
mally impacts monoamine levels and receptor number (Porrka-Heiskanen et al.
1995; Farooqui et al. 1996; Hipolide et al. 1998; Rechtschaffen et al. 2002) and
only modestly affects neuronal morphology in cholinergic and noradrenergic
neurons (Majumdar and Mallick 2005). However, REM sleep deprivation has
been shown to profoundly reduce the activity of the kinase extracellular signal-
related kinase (ERK). ERK works synergistically with the mammalian target of
rapamycin (mTOR) to activate protein synthesis in neurons (Dumoulin Bridi et al.
2015; Dumoulin et al. 2015). Studies in cultured cortical neurons also show that
conditions that simulate the biochemical environment present in REM sleep can lead
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to pulses of protein synthesis (Soulé et al. 2012). Intriguingly, oligodendrocytes
(a glial cell that manufactures myelin) proliferate during REM sleep, suggesting that
myelination may be promoted by this sleep state (Bellesi et al. 2013).
5 Neural Detoxification
Restoration can involve replacement of something depleted as in the energy hypoth-
esis above, or it can involve the elimination of something accumulated above a
desirable level. Elimination of waste products of metabolism is the focus of a
relatively new hypothesis on sleep function – the glymphatic clearance hypothesis
(Xie et al. 2013). The term glymphatic was introduced in 2012 in a description of the
newly characterized system in the brain for exchange of cerebral spinal ﬂuid (CSF),
interstitial ﬂuid (ISF), and blood. In summary, the evidence supports a model in
which subarachnoid CSF enters the brain through perivascular spaces around
penetrating arteries (Fig. 6).
These spaces are bounded by the end-feet of astrocytes and the endothelium and
smooth muscle of the vessel walls (Iliff and Nedergaard 2013). Water and small
molecular solutes enter the astrocytes through aquaporin (Aqp4) channels in the
astrocyte end-feet membranes. From the astrocytes the water and small molecular
solutes are distributed to the ISF. The ISF along with its solutes leaves the brain
parenchyma through the perivascular spaces around venules and veins draining into
cervical lymphatics and venous blood in the dural sinuses. This drainage of ISF
carries with it waste products of brain metabolism such as beta amyloid, soluble
proteins, lipids, ions, and small molecules such as lactate (Lundgaard et al. 2016).
The connection of the newly described glymphatic system with sleep comes from
the observation that the perivascular spaces and therefore the ﬂow through them
expand dramatically (up to 60%) during sleep in comparison to wake facilitating the
ﬂow of ISF through the brain parenchyma. The volume of the interstitium and hence
the ﬂow of ISF appear to be controlled by at least one neuromodulator that is high
during wake and low during sleep – norepinephrine (Xie et al. 2013).
The glymphatic clearance hypothesis for the function of sleep has possible
connections with the brain energy restoration hypothesis discussed above. The
brain depends on glucose and its breakdown product lactate for energy, and the
astrocytes mediate the delivery of these energy substrates to the neurons. First,
glucose is transferred to astrocytes from the blood via glucose 1 transporters
(Glut1). The astrocytes deliver glucose to the ISF and thereby to neurons via
Glut1. Second, astrocytes also synthesize glucose into glycogen by means of series
of enzymatically controlled steps notably including glycogen synthase. Third, astro-
cytic glycogen is an important and rapidly activated energy reserve, but the process
of glycogenolysis produces glucose-6-phosphate moieties that cannot leave the
astrocyte. Instead, they enter glycolysis producing lactate molecules that can leave
the astrocyte and be an energy source for neurons (reviewed in Falkowska et al.
2015).
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The high-energy demands of neural activations during wake call upon the
glycogen reserves of the astrocytes causing increases in lactate levels in the ISF,
and indeed studies have shown higher brain lactate levels during wake than during
sleep (Lundgaard et al. 2016). In addition, neuronal activations are associated with
transient rises in glycolysis resulting in neuronal contributions of lactate to the ISF
(Prichard et al. 1991). Thus, sleep-related clearance of lactate from the brain is one
potential function of the glymphatic system (Lundgaard et al. 2016) and that
clearance function would pertain to many other components of the ISF as well.
6 Discussion
There are two main categories of brain-based hypotheses of sleep function. Cogni-
tive hypotheses propose that sleep is important for complex brain functions such as
learning, memory, and plasticity. Housekeeping hypotheses (restoration and
Fig. 6 The glymphatic hypothesis for clearance of brain metabolic waste involves the ﬂow of CSF
from the subarachnoid space into the brain along the periarterial spaces around penetrating arteries
and arterioles. Aquaporins in the end-feet of the astrocytes lining the blood vessels allow water and
small molecular solutes to enter the astrocytes and from the extensions of the astrocytes into the
interstitial ﬂuid (ISF) of the brain parenchyma. The ISF along with metabolic wastes and toxins
leaves the parenchyma through perivascular spaces around the venules and veins. This ISF ﬂow
increases by about 60% during sleep due to widening of the perivascular spaces (ﬁgure from
Herculano-Houzel 2013)
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detoxiﬁcation) instead propose that sleep governs more basic, homeostatic functions
necessary for normal operation of neurons. How do these hypotheses fare when one
considers our criteria for a core function of sleep?
6.1 Ontogeny
Both categories of hypotheses appear to explain many aspects of sleep across the
lifespan. Early development is a time of rapid and extensive learning. If sleep is
necessary to consolidate and strengthen the effects of experience on the brain, it is
reasonable that sleep amounts should be high in young animals. Similarly, if sleep
plays a critical role in brain plasticity, then one might expect the amount of sleep to
parallel developmental changes in brain plasticity. This is indeed the case across a
wide range of animal species (Frank 2005). Sleep is maximal during periods of
development when the brain is most plastic. With respect to SHY, it might explain
the need for sleep function during speciﬁc developmental windows when overall
pruning exceeds synaptogenesis. These periods of rapid growth, learning, and
plasticity are likely accompanied by greater metabolic demands and increased
rates of macromolecule synthesis. This in turn could theoretically require greater
amounts of glymphatic clearance of waste products.
6.2 Homeostasis
Not all hypotheses offer explanations for homeostatic regulation. Cognitive
hypotheses have yet to provide a convincing link between learning or plasticity
and Process S. There is no clear feedback variable resulting from memory consoli-
dation or brain plasticity per se that then determines sleep need or expression. It has
been suggested that BDNF could play that role. BDNF concentrations in the brain
are higher during wake reﬂecting the level of neural activity. Unilateral applications
of BDNF into the rat brain promote higher slow-wave activity in that side of the
brain during subsequent sleep. However, these studies rely on nonphysiological
manipulations of BDNF (Faraguna et al. 2008).
There is a link between cortical slow-wave activity and memory consolidation.
The expression of hippocampal sharp-wave ripples that are believed to be the
conduit for information transfer between the hippocampus and the neocortex during
memory consolidation is linked to the up-states of the slow-wave oscillations.
Therefore, the cortical slow-wave activity appears to synchronize the neocortical-
hippocampal interplay that is fundamental to the formation of long-term memories
(Molle et al. 2006). There is elegant evidence that regional brain activation during
wake inﬂuences SWA in that region during sleep, and the subsequent improvement
in the task related to that activation is proportional to the change in SWA (Huber
et al. 2004). However, no feedback signal related to cognitive demand related to
memory consolidation has been identiﬁed.
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Stronger linkages exist between some housekeeping hypotheses and Process
S. As proposed by Benington and Heller (1995), wake promotes regional energy
deﬁcits that result in a negative feedback signal, adenosine, that promotes sleep and
in particular the EEG delta power that is the primary measure of Process S. During
sleep energy reserves are restored, and the negative feedback signal is decreased.
The higher energetic demands during waking could be related to regional synaptic
activity, maintaining ion gradients, and/or macromolecule turnover; all are energetic
processes.
It is also conceivable that the synthesis of macromolecules during sleep includes
molecules that enable sustained wakefulness; an interruption of this process would
then lead to heightened sleep pressure.
At present, there is no direct evidence linking glymphatic clearance with Process
S; however, a clearance hypothesis for sleep function implies that there is a buildup
during wake of one or more substances that are cleared during sleep, and any such
substance could serve as a feedback variable in the homeostatic regulation of sleep.
There is a potential connection between glymphatic clearance and brain energetics
that could relate to Process S. During wake, brain lactate levels are higher than
during sleep (Lundgaard et al. 2016). When regional metabolic demand of neurons
exceeds the available blood glucose supply, the astrocytes break down glycogen and
through glycolysis supply lactate to the interstitial ﬂuid to serve the metabolic needs
of the neurons. Thus, wakeful brain activities could generate the need for extracellu-
lar lactate clearance during sleep, but that lactate production could be coincident
with energetic demands resulting in adenosine release.
6.3 Necessity and Sufficiency
Very few brain hypotheses for sleep function demonstrate why sleep is necessary
and sufﬁcient and why the brain must be ofﬂine for the proposed function. The best
case can be made for sleep being necessary for learning and memory. New informa-
tion is coded during wake, and signiﬁcant information is consolidated and integrated
during subsequent sleep. Although studies have shown that simple cued fear mem-
ory may not require sleep (Graves et al. 2003; Cai et al. 2009), their strengthening
and integration may require sleep. Rolls et al. (2013) showed that the intensity of
cued fear memories is dependent on replay occurring during sleep. The interesting
dichotomy between the wake and sleep response to the cue is that repeated exposure
to the cue during wake leads to extinction but repeated exposure during sleep results
in intensiﬁcation. Clearly working memory and short-term memory do not require
sleep. Certain forms of replay also occur in quiet waking (Foster 2017), and
emotional valence may extend the duration of those memories. Sleep, however, is
necessary for higher-order memory consolidation and integration.
The necessity of sleep for learning and memory consolidation may involve the
importance of stabilizing memory transcripts during hippocampal/neocortical
interactions, thus separating the encoding of new information from the consolidation
of prior information (Heller et al. 2014). The vulnerability of those memory
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transcripts has been demonstrated by the ability to alter their emotional valence
(Rolls et al. 2013) and by the ability to manipulate them during sleep to create false
memories (Ramirez et al. 2013). Having the brain ofﬂine during higher cognitive
processing blocks new inputs and protects the ﬁdelity of the memories being
consolidated.
Few restorative and detoxiﬁcation hypotheses have been able to demonstrate
necessity and sufﬁciency and the need for ofﬂine brain states. Ofﬂine states would
seem to promote glycogenesis. The neuromodulators promoting wake activate
glycogen phosphorylase promoting glycogenolysis, and the neuromodulators pro-
moting sleep activate the enzymes of glycogen synthesis. Short-term sleep loss has
been shown to reduce cerebral glycogen content in rats (Kong et al. 2002) but not in
other rodent studies (Gip et al. 2002; Franken et al. 2003). In Drosophila, if sleep loss
is maintained for longer periods, glycogen synthesis resumes even though the
animals are awake (Zimmerman et al. 2004). Thus, sleep may be sufﬁcient, but
not necessary, for glycogen synthesis. Similarly, it is not yet clear if sleep is
necessary and sufﬁcient for glymphatic clearance or why the brain must be ofﬂine
for this to occur. It is conceivable that because the control of the perivascular
resistance to ﬂow is under adrenergic control, and adrenergic tone is high during
wake, sleep is needed to decrease adrenergic tone. Yet, it is unknown what happens
to clearance if wakefulness is extended. Given that clearance does occur during
wakefulness, but at a lower rate (Xie et al. 2013), it is possible that during sleep
deprivation, clearance rates simply increase even in the absence of sleep.
There is some evidence that sleep may be necessary and sufﬁcient for the
synthesis of certain types of cerebral proteins. This has been demonstrated in the
hippocampus and visual cortex. In both brain regions, activation of some enzymes
important for mRNA translation (and protein synthesis) only proceeds in sleep (Seibt
et al. 2012; Tudor et al. 2016). Ofﬂine brain states may be necessary for optimal
protein synthesis because waking may inhibit the upstream activation of mTOR. The
higher consumption of ATP during waking states may shift the AMP/ATP ratio
toward AMP thus activating AMP-kinase, leading to inhibition of mTOR (Inoki
et al. 2012).
6.4 The Presence of Two Sleep States
No current hypothesis of sleep function has adequately explained the presence of
REM and NREM sleep. Several proposals have been made that posit that the
interplay between the two states is required for memory consolidation (Giuditta
et al. 1995; Smith 2001). However, the supporting evidence is not strong
(Ackermann and Rasch 2014). There is evidence that supports a role for both
brain states in brain plasticity and macromolecular synthesis, but it is not clear if
they govern the same or different plastic processes.
Other proposals are largely mute when it comes to REM sleep (Xie et al. 2013;
Tononi and Cirelli 2014). This may in part stem from the difﬁculty in examining the
role of each state in isolation. Experimentally, this is very hard to do as selective
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REM sleep deprivation (which is commonly used to probe the role of REM sleep)
disrupts NREM sleep (Endo et al. 1997, 1998). In addition, REM sleep periods in
mice (which are the more commonly used animal model) are very short in duration,
which makes measurements selectively in this state difﬁcult.
The problem of accommodating both sleep states in a hypothesis of sleep function
only exists if we assume that the functions of both sleep states are in relationship to
wake. Therefore, the problem disappears if we view REM sleep as serving a need
generated during NREM sleep as proposed by Benington and Heller (1994). They
produced convincing evidence for a homeostatic relationship between NREM and
REM sleep with the need for REM sleep building up during episodes of NREM sleep
until that need forces a transition to REM to dissipate that need.
7 Synthesis and Concluding Remarks
None of the hypotheses of sleep function that we have discussed convincingly
satisfy all of the criteria we set forth at the beginning of this review. The least
satisfactory challenge for all hypotheses is explaining the two different states of
sleep. Perhaps this difﬁculty is due to a wrong assumption that all sleep functions are
in relationship to waking. If REM sleep serves a need created by NREM sleep rather
than waking (Benington and Heller 1994), then all hypotheses of sleep function
explain the existence of the two sleep states. The question converts to what
conditions or needs created by NREM sleep require the alternations of that state
with REM sleep.
The macromolecular synthesis hypothesis appears to accommodate the ontogeny
criterion well since early life is a time of rapid and extensive growth and remodeling
of the nervous system and also a time of maximum sleep amounts. It also has the
potential of satisfying the homeostasis criterion since it postulates that many gene
products are depleted during wake and replenished during sleep. However, no
speciﬁc feedback signal has been identiﬁed that relates biosynthetic functions to
Process S. Problems arise for the macromolecular synthesis hypothesis with respect
to necessity and sufﬁciency with respect to gene transcription. Although thousands
of genes have been shown to alter expression levels between wake and sleep, the
observed changes in levels are subtle (Mackiewicz et al. 2007). It is difﬁcult to
explain why the brain must be taken ofﬂine to achieve those subtle changes. There is
also a logical problem in postulating that biosynthesis serves as the primary function
of sleep. All of the other hypotheses of sleep function could be expected to be
facilitated by changes in gene or protein expression, so it seems that the evolution of
those functions would have preceded the associated changes in macromolecular
synthesis.
The other two restorative hypotheses, brain energy reserve replenishment and
brain clearance of waste products, are compatible with increased demands during
early life. Decrease in these functions reﬂected in less sleep in the aged could also be
factors in cognitive capacity senescence. A strong feature of the brain energy
hypothesis is that it identiﬁes a feedback molecule (adenosine) that explains Process
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S and a mechanism (glycogen depletion) that relates the production of that feedback
molecule to events during waking. However, it is difﬁcult to conclude that the brain
energy hypothesis meets the necessity and sufﬁciency criterion. Although glycogen
metabolism is strongly affected by the neuromodulators associated with sleep/wake
regulation, it has been shown that glycogen synthesis occurs in both sleep and wake
(Petit et al. 2015). Conversely, the glymphatic clearance hypothesis does not identify
a feedback molecule that explains Process S, but mechanistically it satisﬁes the
criterion of sufﬁciency. It is tempting, however, to see a link between the energy and
the clearance processes. Lactate is a signiﬁcant component of the glymphatic
clearance process, and its accumulation in the interstitial ﬂuid should correlate
with the energy demands placed on the brain.
Our conclusion is that the strongest support for a primary function of sleep
hypothesis goes to learning and memory along with the requisite underlying pro-
cesses of synaptic plasticity. Obviously synaptic plasticity is a feature of wake;
otherwise, new information could not be encoded, and practice would not have an
effect on subsequent recall/performance. However, sleep surely involves unique
properties of synaptic plasticity that underlie complex memory consolidation and
integration that are fundamental to higher cognitive functions. Evidence shows that
sleep is necessary and sufﬁcient for these higher cognitive functions. A reason for
why the brain must be ofﬂine for these functions to occur likely resides in the brain
processes that communicate memory transcripts from one brain region to another.
The ﬁdelity of these memory transcripts could be compromised by intrusion of new
information that is constantly being encoded during wake. A feedback signal
controlling sleep homeostasis in response to accumulation of information during
wake has not been identiﬁed, but a major feature of sleep homeostasis, cortical slow-
wave activity, may play an important role in coordinating the information processing
involved in memory consolidation.
As we learn more about the complex neural mechanisms underlying sleep and its
relationships to wake, we are likely to ﬁnd that the ﬁnal answer to what is the primary
function of sleep involves a combination of aspects of the current leading
hypotheses. A ﬁnal consideration is that pharmacologically induced brain states
resembling sleep (e.g., hypnotic induced sleep) may not accomplish the normal
functions of sleep. For example, hypnotic agents that have relatively modest effects
on sleep architecture can profoundly inhibit sleep-dependent brain plasticity in
animals (Seibt et al. 2008; Aton et al. 2009a, b) and reduce sleep-dependent memory
in humans (Hall-Porter et al. 2014). Therefore, the secret of sleep function must lie
beyond the superﬁcial metrics such as EEG that we use to measure its outward
appearance. Conversely, as we learn more about speciﬁc functions normally
subserved by sleep, it may be possible to stimulate them or improve them without
replicating the superﬁcial manifestations of sleep.
We end this brief review of the search for sleep function with a quote from our
esteemed colleague who engaged in that search for many years, Allan
Rechtschaffen: “If sleep does not serve an absolutely vital function, then it is the
biggest mistake the evolutionary process has ever made.”
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Abstract
In the present chapter, hypotheses on the mechanisms responsible for the
genesis of the three vigilance states, namely, waking, non-rapid eye movement
(non-REM) also called slow-wave sleep (SWS), and REM sleep also called
paradoxical sleep (PS), are presented. A huge number of studies ﬁrst indicate
that waking is induced by the activation of multiple waking systems, including
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the serotonergic, noradrenergic, cholinergic, and hypocretin systems. At the
onset of sleep, the SWS-active neurons would be activated by the circadian
clock localized in the suprachiasmatic nucleus and a hypnogenic factor, adeno-
sine, which progressively accumulates in the brain during waking. A number
of studies support the hypothesis that SWS results from the activation of
GABAergic neurons localized in the ventrolateral preoptic nucleus (VLPO).
However, new GABAergic systems recently described localized in the parafacial,
accumbens, and reticular thalamic nuclei will be also presented. In addition, we
will show that a large body of data strongly suggests that the switch from SWS
to PS is due to the interaction of multiple populations of glutamatergic and
GABAergic neurons localized in the posterior hypothalamus and the brainstem.
Keywords
Acetylcholine · Adenosine · Brainstem · GABA · Glycine · Histamine · Hypocretin ·
Melanin-concentrating hormone · Muscle atonia · Norepinephrine · Orexin ·
Serotonin
1 Introduction
In most mammals, there are three vigilance states characterized by distinct
differences in electroencephalogram (EEG), electromyogram (EMG), and electrooc-
ulogram (EOG) recordings. The waking state is characterized by high-frequency
(40–300 Hz), low-amplitude (desynchronized) activity on the EEG, sustained
EMG activity, and ocular movements; non-rapid eye movement (non-REM), also
named slow-wave (SWS) sleep (synchronized), is characterized by low-frequency
(0.5–4 Hz), high-amplitude delta oscillations on the EEG, low muscular activity on
the EMG, and no ocular movement; and rapid eye movement (REM), also called
paradoxical sleep (PS), is characterized by a predominant theta (6–9 Hz) and gamma
(30–300 Hz) rhythms similar to waking EEG but with complete disappearance of
postural muscle tone and the occurrence of rapid eye movements (REMs) and
muscle twitches.
Neuropathological evidence from the nineteenth century indicates that altered
states of vigilance can be induced by focal brain lesions and that different neuro-
chemical mechanisms are responsible for the succession of the three vigilance states
across the 24 h day (Fort et al. 2009). The aim of this review is to examine possible
neuronal networks and mechanisms responsible of the switch from waking to SWS
and PS.
2 Neuronal Network and Mechanisms Involved in Waking
The activated cortical state during waking is induced by the activity of multiple
waking neurochemical systems. Some of these belong to the ascending reticular
activating system. These neurochemical systems include the serotonergic neurons
mainly localized in the dorsal raphe nucleus, noradrenergic neurons in the locus
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coeruleus, cholinergic neurons in the pontine brainstem, glutamatergic neurons of
the medial parabrachial nucleus (Anaclet et al. 2014), and dopaminergic neurons of
the ventral tegmental area (Eban-Rothschild et al. 2016), while other systems are
located more rostrally in the forebrain. These systems include the cholinergic
neurons in the basal forebrain, the histaminergic neurons localized in the tubero-
mammillary nucleus, and GABAergic and orexin (hypocretin) neurons in the lateral
hypothalamus (Fort et al. 2009; Herrera et al. 2016).
Altogether, these systems control wakefulness and arousal through their wide
projections to the thalamus and/or the neocortex. When these waking systems are
inactivated, the thalamocortical network is no longer activated and return to its
default mode characterized by oscillations in the delta range (i.e., the slow-wave
mode of activity typical of SWS) (Fort et al. 2009).
A number of studies strongly suggest that sleep is induced by neurons inhibiting
the waking systems, possibly by gamma-aminobutyric acid (GABA), the main
inhibitory neurotransmitter in the brain. It is well known that serotonergic neurons
discharge during wakefulness decrease their activity during SWS to become
completely silent during sleep (Gervasoni et al. 2000). It has also been shown that
the local application during SWS and PS of bicuculline, a competitive antagonist of
GABA-A receptors, restores the waking activity of the neurons. Similar results have
been obtained for the noradrenergic neurons of the locus coeruleus (Gervasoni et al.
1998) (Figs. 1 and 2).
3 Mechanisms Involved in Non-REM (Slow-Wave Sleep, SWS)
Induction and Maintenance
A large number of studies localized the GABAergic neurons in charge of inhibiting
the waking systems during sleep in the preoptic area as described below.
3.1 The Forebrain (Preoptic) Sleep Center
Following studies of patients with postinﬂuenza encephalitis, the neuropathologist
von Economo reported that inﬂammatory lesions of the preoptic area were often
associated with insomnia and therefore proposed that the preoptic area was critical
for the production of normal sleep (von Economo 1926). This was further conﬁrmed
in monkeys, rats, and cats where preoptic area lesions consistently induced a
profound and persistent insomnia (Fort et al. 2009). Consistent with these results,
preoptic area electrical stimulation induces EEG slow-wave activity and sleep
(SWS) (Fort et al. 2009). A recent study using pharmacogenetics in mice to
functionally mark neurons activated in the preoptic area during recovery sleep or
alpha-2 adrenergic receptor-induced sedation elegantly demonstrated that selective
reactivation of these neurons induces SWS (Zhang et al. 2015). Finally, putative
sleep-promoting neurons in the preoptic area displaying an elevated discharge rate
during SWS were recorded in freely moving cats (Fort et al. 2009). Altogether, these
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studies support the hypothesis that the preoptic area contains neurons that promote
sleep, in particular SWS.
In the following years, to more precisely identify the sleep active neurons,
researchers mapped in the preoptic area the localization of the neurons with
increased expression of the immediate early gene c-Fos, a marker of neuronal
activity. They found out that these neurons are distributed in the preoptic area but
are more densely packed in the median preoptic nucleus (MnPn) and the ventrolat-
eral preoptic nucleus (VLPO). Interestingly, the number of c-Fos-immunoreactive
neurons in the VLPO and MnPn positively correlated with sleep quantity and sleep
consolidation during the last hour preceding sacriﬁce. Numerous c-Fos-positive
neurons were also observed in sleep-deprived rats in the MnPn but not in VLPO
(Sherin et al. 1996; Gvilia et al. 2006), suggesting that VLPO neurons are responsi-
ble for the induction of sleep while MnPn neurons serve a homeostatic role in
sleep. It was later demonstrated that VLPO and the suprachiasmatic nucleus
(SCN), responsible for the circadian organization of the sleep-waking cycle,
have synchronized activity (Fort et al. 2009). Considering that both areas are
interconnected and receive inputs from the retinal ganglion cells, it is, thus, possible
that circadian- and photic-linked information may be conveyed to modulate VLPO
activity (Fort et al. 2009) (Fig. 3).
Electrophysiological experiments in behaving rats have shown that neurons
recorded in the VLPO and MnPn are active before and after the onset of SWS and
their ﬁring rate is positively correlated with sleep depth and duration, suggesting that
they participate to SWS induction and stability. Some of these neurons are also
active during PS with a higher ﬁring frequency than during the preceding SWS. In
addition, VLPO and MnPn neurons display a ﬁring pattern reciprocal to the wake-
active neurons (see below). Retrograde and anterograde tract-tracing studies indicate
that VLPO and MnPn neurons are reciprocally connected with wake-active neurons
such as those containing histamine in the tuberomammillary nucleus (TMN),
hypocretins in the perifornical hypothalamic area (PeF), serotonin in the dorsal
raphe nuclei (DRN), noradrenaline in the locus coeruleus (LC), acetylcholine in
the pontine (LDT/PPT), and basal forebrain nuclei. In these wake-promoting areas,
extracellular levels of GABA increase during SWS compared to W. It has also been
shown that c-Fos-positive neurons in the VLPO express galanin mRNA and 80% of

Fig. 1 (continued) activation, and also, importantly, inhibit the GABAergic SWS (non-REM
sleep)-active neurons of the VLPO and MnPn. 5HT 5-hydroxytryptamine (serotonin), Ach acetyl-
choline, ADA adenosine, BF basal forebrain, DPGi dorsal paragigantocellular reticular nucleus,
dDPMe deep mesencephalic reticular nucleus, DRN dorsal raphe nucleus, GABA gamma-
aminobutyric acid, GiV ventral gigantocellular reticular nucleus, Gly glycine, Hcrt hypocretin
(orexin)-containing neurons, His histamine, LC locus coeruleus, LdT laterodorsal tegmental
nucleus, MCH melanin-concentrating hormone-containing neurons, NA noradrenaline, PH poste-
rior hypothalamus, PPT pedunculopontine tegmental nucleus, PS paradoxical sleep, RT reticular
thalamic neurons, SCN suprachiasmatic nucleus, SLD sublaterodorsal nucleus, SWS slow-wave
sleep, TMN tuberomamillary nucleus, vlPAG ventrolateral periaqueductal gray, VLPO ventrolateral
preoptic nucleus, W waking
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VLPO neurons projecting to the TMN contain both galanin and glutamic acid
decarboxylase (GAD), the GABA-synthesizing enzyme. In addition, electrical stim-
ulation of the VLPO area evokes a GABA-mediated inhibition of TMN neurons,
suggesting that VLPO and MnPn efferents to the wake-promoting systems are
inhibitory (Fort et al. 2009). Finally, a new study demonstrated that optogenetic
activation or inhibition of GABAergic neurons of the VLPO projecting to the TMN
enhances or suppresses sleep (Chung et al. 2017). Further, they showed that these
neurons are signiﬁcantly more active during PS and SWS than W and contain
cholecystokinin, corticotropin-releasing hormone, and tachykinin 1 (Chung et al.
2017).
3.2 Mechanisms Controlling the Activity of the Preoptic
SWS-Inducing Neurons
Electrophysiological whole-cell recordings showed that VLPO contains neuronal
groups with speciﬁc intrinsic membrane properties and distinct chemo-morphology
and that they are inhibited by most of the waking neurotransmitters (Gallopin et al.
2000). Sleep-active neurons are GABAergic and galaninergic in nature and multi-
polar triangular shaped and exhibit a potent low-threshold calcium potential.
These neurons are always inhibited by noradrenaline (NA), via postsynaptic
alpha2-adrenoceptors. Interestingly, NA-inhibited neurons are also inhibited by
acetylcholine, through muscarinic postsynaptic and nicotinic presynaptic actions
on noradrenergic terminals. In contrast, histamine and hypocretin did not modulate
the activity of the sleep-active neurons (Gallopin et al. 2000). Finally, serotonin
induced either excitation (50%, Type 2) or inhibition (50%, Type 1) of VLPO
neurons (Fort et al. 2009).
Homeostatic regulators, involving natural sleep-promoting factors accumulating
during waking, play a crucial role in triggering sleep. Among these factors, prosta-
glandin D2 and adenosine have been functionally implicated in sleep, although their
neuronal targets and mechanisms of action remain largely unknown. In this context,
it has been shown that application of an adenosine A2A receptor (A2AR) agonist
evoked direct excitatory effects speciﬁcally in 50% of the sleep-active neurons that
are also activated by serotonin (Fort et al. 2009). Additional results further suggested
that adenosine might directly activate VLPO neurons at sleep onset via an action on
postsynaptic A2AR. Indeed, pharmacological infusion of an A2AR agonist into the
subarachnoid space rostral to the VLPO increases SWS and induces c-Fos

Fig. 2 (continued) neurons of the lateral hypothalamic area (LH) would inhibit during waking the
GABAergic neurons of the reticular thalamic nucleus (RT). Finally, the glutamatergic (GLU)
neurons of the medial parabrachial nucleus (MPB) would induce waking by their excitatory
projection to the basal forebrain (BF) cholinergic and GABAergic neurons. The relationship
between these systems as well as between them and the VLPO GABAergic neurons remains to
be identiﬁed
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expression in VLPO neurons (Lazarus et al. 2011) (Fig. 3). It has also recently been
shown that VLPO GABAergic neurons are excited by glucose (Varin et al. 2015).
Further, injection of glucose in the VLPO promotes SWS and selectively increases
the density of c-Fos+ neurons in the VLPO (Varin et al. 2015). These results suggest
that glucose likely contributes to sleep onset facilitation by increasing the excitability
of sleep-promoting GABAergic neurons in the VLPO.
Besides, a number of studies showed that adenosine A1 receptors (A1R) promote
sleep through inhibition of the wake-promoting neurons, in particular cholinergic
and hypocretin neurons (Porkka-Heiskanen et al. 2000). However, transgenic mice
that lack A1R exhibit normal homeostatic regulation of sleep. In contrast, the lack of
A2AR prevents normal sleep regulation and blocks the wake-inducing effect of
caffeine, suggesting that the activation of A2AR is crucial in SWS (Huang et al.
2005; Lazarus et al. 2017).
3.3 The Sleep GABAergic Neurons of the Nucleus Accumbens
Rather than through the VLPO, a recent study provides convincing evidence that the
waking effect induced by caffeine is mediated by GABAergic neurons located in the
nucleus accumbens and expressing adenosine A2AR and dopamine D2 receptors.
Indeed, it has been shown that the induction of waking by caffeine was abolished in
rats in which the expression of the A2AR mRNAs was removed from the shell of the
nucleus accumbens (Lazarus et al. 2011). Further, chemogenetic or optogenetic
activation of adenosine A2A receptor-expressing GABAergic neurons in the nucleus
accumbens induces SWS, while their chemogenetic inhibition prevents sleep induc-
tion (Oishi et al. 2017). GABAergic neurons of the nucleus accumbens might induce
sleep via their inhibitory projections to the waking systems such as the hypothalamic
hypocretin and histaminergic neurons and the ventral tegmental dopaminergic and
the noradrenergic locus coeruleus neurons (Lazarus et al. 2013). These observations
are of great interest. Unit recording experiments are nevertheless necessary to
demonstrate that adenosine A2A receptor-expressing GABAergic neurons of the
nucleus accumbens are speciﬁcally active during sleep. Further, the effect on sleep of
their optogenetic or pharmacogenetic manipulation needs to be determined.

Fig. 3 (continued) homeostatic (adenosine), and circadian drives (suprachiasmatic input). These
activated neurons, through the reciprocal GABAergic inhibition of all wake-promoting systems,
would be in a position to suddenly unbalance the “ﬂip-ﬂop” network, as required for switching from
W (drowsiness) to a consolidation of SWS sleep. Conversely, the slow removal of excitatory
inﬂuences would result in a progressive ﬁring decrease in VLPO neurons and therefore an activation
of wake-promoting systems leading to the awakening event
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3.4 The Sleep GABAergic Neurons of the Thalamic Reticular
Nucleus
It is well accepted that GABAergic reticular thalamic (RT) neurons are responsible
for spindle generation during NREM sleep (Huguenard and McCormick 2007).
Their repetitive spike bursts cause rhythmic inhibitory postsynaptic potentials in
thalamocortical neurons. In turn, spike-burst activity in thalamocortical neurons due
to a post-inhibitory rebound generates excitatory postsynaptic potentials in cortical
cells (Steriade 1999). It has recently been shown that strong phasic optogenetic
stimulation of RT neurons during SWS, unlike in the awake state, induces spindles
(Halassa et al. 2011, 2014). In contrast, tonic and low-power activation of the RT
induces slow waves and sleep in awake mice without affecting power in the spindle
band (Lewis et al. 2015). In addition, RT inhibition reduces slow waves in mice
during SWS (Lewis et al. 2015). Further, it has also recently been shown that
silencing of RT GABAergic neurons using optogenetics during SWS induces
rapid sleep-to-wake transitions (Herrera et al. 2016). Altogether, these results indi-
cate that RT GABAergic neurons play a key role in sleep induction and maintenance,
as well as the genesis of spindles and delta activity. It has been shown recently that
during waking RT GABAergic neurons are inhibited by GABAergic neurons
located in the lateral hypothalamic area, in addition to cholinergic, serotoninergic,
noradrenergic, and histaminergic inhibitory inputs (Herrera et al. 2016). Optogenetic
and/or pharmacogenetic experiments are still needed to determine the respective
roles of each of the inhibitory inputs from the multiple waking systems, as well as the
pathways and mechanisms responsible for the activation of RT GABAergic neurons
during sleep.
3.5 The Sleep Nitric Oxide Synthase/GABAergic Neurons
of the Cortex
Interestingly, a subpopulation of GABAergic cortical interneurons, which express
the enzyme neuronal nitric oxide synthase (nNOS) and the neurokinin-1 receptor,
has been found to be activated during SWS using c-Fos. The extent of activation of
these nNOS neurons has been shown to be proportional to SWS sleep time, SWS
bout duration, and EEG delta power during SWS, an index of homeostatic sleep
drive (Gerashchenko et al. 2008; Morairty et al. 2013). Transgenic mice knockout
for the nNOS gene shows reduced SWS time, shorter SWS bouts, and decreased
power in the low delta range during SWS. These observations strongly suggest a role
for nNos/GABAergic cortical interneurons in SWS regulation. Unit recording and
speciﬁc optogenetic or pharmacogenetic manipulations of these neurons are now
needed to conﬁrm that they play a role in homeostatic sleep regulation and delta
oscillations. Furthermore, the speciﬁc role of GABA in these interneurons still needs
to be assessed using genetic inactivation.
44 P.-H. Luppi and P. Fort
3.6 The Sleep GABAergic Neurons of the Medullary
Parafacial Zone
It has been recently shown that GABA/glycinergic neurons located lateral and dorsal
to the descending branch of the facial nerve, a region termed the parafacial zone
(PZ), could play a role in sleep induction and maintenance (Anaclet et al. 2012).
Indeed, these inhibitory PZ neurons express c-Fos after sleep but not after waking,
and lesions of these neurons induce an increase in waking (Anaclet et al. 2012).
Their pharmacogenetic activation promotes SWS and inhibits both waking and PS
for 3 h, whereas their inhibition strongly decreases SWS and PS (Anaclet et al.
2014). GABAergic PZ neurons directly inhibit glutamatergic neurons within the
pontine medial parabrachial nucleus. Further, the glutamatergic medial parabrachial
neurons project to and excite cortically projecting magnocellular basal forebrain
neurons. Since lesions of the latter two structures induce a coma state, it has been
proposed that GABA/glycinergic neurons of the parafacial zone would induce sleep
by inhibiting this pontine-basal forebrain-cortical pathway (Anaclet et al. 2014).
Altogether, these results are strongly in favor of a role for the GABA/glycinergic
neurons located in the parafacial zone in the induction and maintenance of SWS.
However, unit recordings of PZ neurons recently showed that they are not selectively
active during SWS (Sakai 2017).
In summary, a number of new sleep-inducing systems have been recently
identiﬁed in addition to the VLPO. It is of great importance to conﬁrm that they
are really involved in sleep control and to determine their speciﬁc roles in compari-
son with the classical preoptic SWS-inducing neurons.
3.7 Overview of the Neuronal Network Responsible for SWS
(Non-REM) Sleep
A large body of evidence suggested that both the VLPO and the MnPn contain
neurons responsible for sleep onset and maintenance. It has been proposed that
during wakefulness, VLPO GABAergic neurons are inhibited by inputs from
waking systems such as the noradrenergic and cholinergic inputs. Conversely,
emergence from sleep would result from a rapid reactivation of arousal circuits,
concomitant with the inhibition of VLPO neurons (Fort et al. 2009). However, the
recent years have seen the discovery of new structures and pathways involved in
sleep and waking such as the parafacial zone, reticular thalamic nucleus, nNOS
GABAergic cortical interneurons, or the nucleus accumbens. We illustrate all
pathways in Fig. 2. Further work is now necessary to ﬁnd out the role of each of
the pathways identiﬁed and the relationships among them (Fig. 4).
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4 Mechanisms Involved in Paradoxical (REM) Sleep
(PS) Genesis
4.1 The Neurons Generating PS Are Localized in the Pontine
Reticular Formation
It was ﬁrst shown that a state characterized by muscle atonia and rapid eye
movements persists following decortication, cerebellar ablation, or brainstem
transections rostral to the pons and in the “pontine cat,” a preparation in which all
the structures rostral to the pons have been removed (Jouvet 1962). These results
suggested that brainstem structures are necessary and sufﬁcient to trigger and
maintain the state of PS. Electrolytic and chemical lesions showed that the dorsal
part of pontis oralis (PnO) and caudalis (PnC) nuclei also named peri-locus coeruleus
α (peri-LCα), pontine inhibitory area (PIA), and subcoeruleus nucleus (SubC)
contains the neurons responsible for PS onset (Jouvet 1962). More recently, a
corresponding area has been identiﬁed in rats and named the sublaterodorsal
tegmental nucleus (SLD) (Boissard et al. 2002). It was also shown that bilateral
injection in cats of a cholinergic agonist, carbachol, into the SLD dramatically
increases PS quantities in cats (Vanni-Mercier et al. 1989). In addition, the SLD
and the adjacent laterodorsal (LDT) and pedunculopontine tegmental (PPT) cholin-
ergic nuclei contain many neurons that show a tonic ﬁring selective to PS state
(called “PS-on” neurons) (Sakai and Koyama 1996). From these early 1970s to
1980s studies, it was hypothesized that the PS-on neurons generating PS were
cholinoceptive and cholinergic.
4.2 Paradoxical (REM) Sleep-Generating Neurons: The Switch
from Acetylcholine to Glutamate
However, in contrast to cats, carbachol iontophoresis into the rat SLD failed to
induce a signiﬁcant increase in PS quantities (Boissard et al. 2002). Further, only a
few cholinergic neurons were immunostained for c-Fos in the LDT, PPT, and SLD
after PS hypersomnia (Verret et al. 2005). Finally, neurochemical lesions in rats of
both the LDT and PPT had no effect on PS and cortical activation (Lu et al. 2006). It
has been recently further demonstrated that most of the c-Fos-positive neurons
localized in the SLD after PS recovery express vGlut2 (Clement et al. 2011),

Fig. 4 (continued) They would be driven by the increase of adenosine excitation through A2a
adenosine receptors. The GABAergic neurons of the reticular thalamic nucleus would also be
activated when the wake-active GABAergic neurons of the lateral hypothalamic area stop to inhibit
them. They would induce SWS by means of their inhibitory projections to the other thalamic nuclei.
The parafacial (PZ) GABAergic neurons would induce sleep by means of their inhibition of the
glutamatergic neurons of the medial parabrachial nucleus (MPB). The mechanisms responsible for
their activation remain to be identiﬁed
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suggesting that the PS-on SLD neurons triggering PS are glutamatergic. Conﬁrming
this hypothesis, we recently showed that genetic inactivation of glutamatergic
transmission in SLD neurons induces a 30% decrease of PS quantities and the
abolition of muscle atonia and the occurrence of violent movements (Valencia
Garcia et al. 2017).
A number of recent results further suggest that PS-on glutamatergic neurons
located in the SLD generate muscle atonia via descending projections to PS-on
GABA/glycinergic premotoneurons located at medullary level rather than directly in
the spinal cord. First, using intracellular recordings during PS, it has been shown that
trigeminal, hypoglossal, and spinal motoneurons are tonically hyperpolarized by
large inhibitory postsynaptic potentials (IPSPs) during PS (Chase et al. 1989).
Furthermore, local iontophoretic application of strychnine (a speciﬁc antagonist
of the inhibitory neurotransmitter, glycine) decreased the hyperpolarization of
motoneurons, suggesting that they are tonically inhibited by glycinergic neurons
during PS (Chase et al. 1989). Interestingly, it has then been shown that the levels of
glycine but also that of GABA increase within hypoglossal and spinal motor pools
during PS-like atonia suggesting that GABA, in addition to glycine, might contribute
to motoneurons hyperpolarization during PS (Kodama et al. 2003). Finally, it has
been recently shown that combined microdialysis of bicuculline, strychnine, and
phaclophen (a GABA-B antagonist) in the trigeminal nucleus is necessary to restore
jaw muscle tone during PS (Brooks and Peever 2012) and that mice with impaired
glycinergic and GABAergic transmissions display PS without muscle atonia
(Brooks and Peever 2011).
In addition, SLD neurons send direct efferent projections to GABA/glycinergic
medullary neurons located in the nucleus raphe magnus (RMg) and the ventral
(GiV), alpha (Gia) gigantocellular, and lateral paragigantocellular (LPGi) reticular
nuclei (Boissard et al. 2002; Valencia Garcia et al. 2017). Besides, GABA/
glycinergic neurons of the Gia, GiV, LPGi, and RMg express c-Fos after induction
of PS by bicuculline (Bic, a GABA-A antagonist) injection in the SLD (Boissard
et al. 2002). In addition, nearly all c-Fos-labeled neurons localized in these nuclei
after 3 h of PS hypersomnia following 72 h of PS deprivation express GAD67
mRNA (Sapin et al. 2009).
In view of all these results, it can be proposed that the SLD glutamatergic PS-on
neurons induce muscle atonia during PS by means of direct projections to medullary
RMg/GiA/GiV/LPGi GABA/glycine neurons. These neurons hyperpolarize moto-
neurons mainly using glycine but also to a minor extent GABA acting on GABA-A
and GABA-B receptors.
It has ﬁnally also been shown that cholinergic and non-cholinergic neurons
located in the SLD and pedunculopontine and laterodorsal tegmental nuclei and
glutamatergic neurons located in the reticular formation are active both during
waking and PS and project rostrally to the thalamus and hypothalamus and play a
role in cortical activation during PS (Boissard et al. 2002; Fort et al. 2009). In
addition to these systems, we recently demonstrated that only a few limbic cortical
structures including the dentate gyrus, the anterior cingulate, and retrosplenial
(Koike et al. 2017) and medial entorhinal cortices are activated during PS (Renouard
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et al. 2015). We further showed that the lateral part of the supramammillary nucleus
activates the dentate granule cells during PS, while the claustrum activates the other
cortical structures (Renouard et al. 2015; Billwiller et al. 2016). The link between
these structures and the other nuclei generating PS remains to be identiﬁed.
4.3 Mechanisms Responsible for the Activation of SLD PS-on
Neurons During PS
In cats and rats, microdialysis administration in the SLD of kainic acid, a glutamate
agonist, induces a PS-like state (Boissard et al. 2002). A long-lasting PS-like
hypersomnia can also be pharmacologically induced with a short latency in head-
restrained unanesthetized rats by iontophoretic application into the SLD of
bicuculline or gabazine, two GABA-A receptor antagonists (Boissard et al. 2002).
Further, application of kynurenate, a glutamate antagonist, reverses the PS-like state
induced by bicuculline (Boissard et al. 2002). In the head-restrained rat, neurons
within the SLD speciﬁcally active during PS and excited following bicuculline or
gabazine iontophoresis have been recorded. Taken together, these data indicate that
the activation of SLD PS-on neurons is mainly due to the removal during PS of a
tonic GABAergic tone present during W and SWS combined with the continuous
presence of a glutamatergic input. Combining retrograde tracing, c-Fos, and gluta-
mate decarboxylase 67 (GAD67) staining, it was recently demonstrated that the
ventrolateral part of the periaqueductal gray (vlPAG) and the adjacent dorsal part of
the deep mesencephalic nucleus (dDPMe) are the only ponto-medullary structures
containing a large number of GABAergic neurons activated during PS deprivation
and projecting to the SLD (Sapin et al. 2009). Further, injection of a GABAa agonist
(muscimol) in the vlPAG and/or the dDpMe induces strong increases in PS
quantities in cats (Sastre et al. 1996) and rats (Sapin et al. 2009). In addition,
neurochemical lesion of these two structures induces profound increases in PS
quantities (Lu et al. 2006). Further, optogenetic stimulation of PS-off GABAergic
neurons within the vlPAG and the dDpMe almost completely suppresses PS onset
and shortens the duration of PS episodes (Weber et al. 2015). DREADD activation
of vlPAG/dDPMe GABAergic neurons reduces PS and increases SWS (Hayashi
et al. 2015). Conversely, their pharmacogenetic inhibition increases PS, mainly by
increasing the number of PS episodes (Hayashi et al. 2015). These congruent
experimental studies strongly support our hypothesis that PS-off GABAergic
neurons located in the vlPAG and the dDpMe gate PS by tonically inhibiting
PS-on neurons of the SLD during W and SWS. Our results indicate that these
GABAergic neurons are crucial to gate PS although they do not rule out a secondary
role for monoaminergic neurons since increases in monoaminergic transmission
either by reuptake blockers or agonists is well known to inhibit PS (Luppi et al.
2011). Monoamines are known to project to most of brain structures including those
controlling PS (Dahlström 1964). It is therefore challenging to identify the targets of
monoaminergic neurons responsible for their inhibitory effects on PS. They can
either excite PS-off neurons or inhibit PS-on neurons. One possibility is that the
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monoaminergic neurons are exciting the GABAergic vlPAG and dDpMe PS-off
neurons during waking to preclude PS onset.
4.4 Neurons Inhibiting the GABAergic and Monoaminergic PS-off
Neurons at the Onset and During PS
It has been previously reported that bicuculline application on serotonergic and
noradrenergic neurons during SWS or PS restores a tonic ﬁring pattern in both
types of neurons (Gervasoni et al. 1998, 2000). These results strongly suggest that an
increased GABA release is responsible for the PS-selective inactivation of monoam-
inergic neurons. This hypothesis is well supported by microdialysis experiments in
cats, which measured a signiﬁcant increase in GABA release in the dorsal raphe
(DRN) and locus coeruleus (LC) during PS as compared to W and SWS but no
detectable changes in glycine concentration (Nitz and Siegel 1997a, b).
By combining retrograde tracing with CTb and GAD immunohistochemistry in
rats, it has been found that the vlPAG and the dorsal and lateral paragigantocellular
nuclei (DPGi and LPGi) (Gervasoni et al. 2000) contained numerous GABAergic
neurons projecting both to the DRN and LC. It has then demonstrated by combining
c-Fos and retrograde labeling that these nuclei contain numerous LC-projecting
neurons selectively activated during PS rebound following PS deprivation (Verret
et al. 2006). Further, it has been found that the DPGi contains numerous PS-on
neurons that are increasing their activity speciﬁcally during PS (Luppi et al. 2011).
Taken together, these data strongly suggest that the DPGi and the LPGi contains the
neurons responsible for the inactivation of LC noradrenergic neurons during PS
(Luppi et al. 2011). A contribution from the vlPAG in the inhibition during PS of
LC noradrenergic and dorsal raphe serotonergic neurons is also likely. Indeed, an
increase in the number of c-Fos/GAD immunoreactive neurons has been reported in
the vlPAG after a PS rebound following deprivation in rats (Sapin et al. 2009). In
summary, a large body of data indicates that GABAergic PS-on neurons localized
in the vlPAG and the LPGi/DPGi hyperpolarize the monoaminergic neurons
during PS.
It has been ﬁrst proposed that these neurons might also be responsible of the
inhibition of the dDPMe/vlPAG PS-off GABAergic neurons during PS. To test this
hypothesis, neurons active during PS hypersomnia projecting to the dDPMe/vlPAG
PS-off GABAergic neurons were localized (Clement et al. 2012). It has been found
out that the vlPAG and the DPGi, respectively, contained a substantial and a small
number of CTb/c-Fos double-labeled neurons in PS hypersomniac rats. Although,
the GABAergic nature of these neurons remains to be demonstrated, our results
indicate that the vlPAG and the DPGi might contain PS-on GABAergic neurons
inhibiting the vlPAG/dDPMe PS-off GABAergic neurons at the onset and during
PS. At variance with our hypothesis, it has recently been proposed that ascending
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PS-on neurons located in the LPGi play a key role in that matter. Indeed, optogenetic
stimulation during SWS of ascending ﬁbers of GABAergic LPGi neurons located in
the vlPAG/dDPMe induced PS (Weber et al. 2015). However, we did not ﬁnd in the
LPGi neurons activated during PS hypersomnia and projecting to the vlPAG/dDPMe
(Clement et al. 2012). One possibility is that the ﬁbers projecting to the LC were
stimulated in Weber’s experiments. We further demonstrated that the lateral hypo-
thalamic area (LH) is the only brain structure containing a very large number of
neurons activated during PS hypersomnia and projecting to the VLPAG/dDpMe
(Clement et al. 2012). We further demonstrated that 44% of these neurons express
the neuropeptide melanin-concentrating hormone (MCH). These results indicate that
LH hypothalamic neurons might play a crucial role in PS onset and maintenance by
means of descending projections to the vlPAG/dDPMe PS-off GABAergic neurons
(Clement et al. 2012). They conﬁrmed previous data discussed below indicating that
the posterior hypothalamus contains neurons implicated in PS control.
4.5 Role of the MCH/GABAergic Neurons of the Lateral
Hypothalamic Area in PS Control
To localize all the brain areas activated during PS, an extensive mapping of the
distribution of c-Fos-positive neurons in control rats, rats selectively deprived of PS
for 72 h and rats allowed to recover from such deprivation, has been done (Verret
et al. 2003). Surprisingly, a very large number of c-Fos-positive cells were observed
in the posterior hypothalamus (PH), including zona incerta (ZI), perifornical area
(PeF), and the lateral hypothalamic area (LH). This result is in agreement with the
fact that (1) bilateral injection of muscimol in the cat mammillary and tuberal
hypothalamus induce a drastic inhibition of PS (Lin et al. 1989) and (2) neurons
speciﬁcally active during PS were recorded in the posterior hypothalamus of cats or
head-restrained rats (Goutagny et al. 2005). By using double immunostaining, it has
been further shown that around 75% of posterior hypothalamus cells labeled for
c-Fos after PS rebound express GAD67 mRNA and are therefore GABAergic (Sapin
et al. 2010). One third of these GABAergic neurons were also immunoreactive for
the neuropeptide, MCH. Almost 60% of all the MCH-immunoreactive neurons
counted in PeF, ZI, and LHA were c-Fos-positive (Verret et al. 2003). It has been
recently demonstrated that these neurons co-express the peptide nesfatin (Jego et al.
2012). In support of our c-Fos data, it has then been shown in head-restrained rats
that MCH neurons ﬁre exclusively during PS (Hassani et al. 2009). Importantly,
MCH neurons start to ﬁre at the onset of PS and, therefore, can play a role in PS
maintenance but not in PS induction. Nevertheless, rats receiving intracerebro-
ventricular (icv) administration of MCH showed a strong dose-dependent increase
in PS and, to a minor extent, SWS quantities, possibly due to an increased number of
PS bouts (Verret et al. 2003). Further, subcutaneous injection of an MCH antagonist
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decreases SWS and PS quantities (Ahnaou et al. 2008). The increase in sleep
induced by MCH system activation was recently conﬁrmed using chronic (24 h)
optogenetic activation (Konadhode et al. 2013). Of interest, mice with genetically
inactivated MCH signaling exhibit altered vigilance state architecture and sleep
homeostasis (Jego et al. 2013). In addition, disruption of nesfatin-1 signaling by
icv administration of nesfatin-1 antiserum or antisense against the nucleobindin2
(NUCB2) prohormone suppressed PS, whereas the infusion of nesfatin-1 antiserum
after a selective PS deprivation precluded PS recovery (Jego et al. 2012). Finally, it
has been recently shown that optogenetic activation of MCH neurons speciﬁcally
during SWS episodes did not increase SWS duration but increase the probability of
SWS-to-PS transitions PS. Further, optogenetic stimulation of MCH neurons during
PS signiﬁcantly prolonged the duration of PS episodes (Jego et al. 2013). In
agreement with our results showing that MCH neurons constitute only one third
of the GABAergic neurons activated during PS hypersomnia, it has been recently
shown that a large population of GABAergic neurons, but not expressing MCH, are
localized in the LH area discharge maximally during PS (Hassani et al. 2010). These
neurons are mostly silent during active W with high muscle tone and progressively
increase their discharge from quiet W through SWS to be maximally active during
PS. Since these neurons anticipate PS onset, they could play a role in triggering PS
state. Supporting this hypothesis, it has recently been shown that a genetic activation
and inhibition of a subset of the GABAergic neurons of the zona incerta which
express the LIM homeodomain factor Lhx6 of Lhx6-positive bidirectionally regulate
PS in adult mice (Liu et al. 2017).
To determine the function of the MCH+/GABA+ and MCH/GABA+ neurons
in PS control, all lateral hypothalamic area neurons were inactivated with muscimol
(a GABA-A agonist) or only those bearing alpha-2 adrenergic receptors using
clonidine. Such inactivation induced an inhibition of PS with or without an increase
in SWS quantities, respectively. It has been further shown that after muscimol
injection in the LH, the vlPAG/dDpMe region contains a large number of c-FOS/
GAD67+ and of c-FOS/CTb+ neurons in animals with a CTb injection in the SLD.
These results indicate that the activation of PS-on MCH/GABAergic neurons
localized in the LH is a necessary step for PS to occur. They further suggest that
MCH/GABAergic PS-on neurons localized in the LH control PS onset and mainte-
nance by means of a direct inhibitory projection to vlPAG/dDpMe PS-off
GABAergic neurons. From these results, it can be proposed that MCH/GABAergic
neurons of the LH constitute a “master” generator of PS that controls a “slave”
generator located in the brainstem. To reconcile the Jouvet hypothesis (i.e.,
brainstem is necessary and sufﬁcient to generate a state characterized by muscle
atonia and REM, Jouvet 1962) with these new results, it can be proposed that after
removal of the forebrain, the brainstem generator is sufﬁcient to induce a state with
muscle atonia and REM by means of a reorganization of the brainstem systems
generating PS. However, the brainstem generator would be under control of the LH
generator in intact animals.
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In addition to the descending pathway to the PS-off GABAergic neurons, the
MCH/GABAergic PS-on neurons might also promote PS by means of other
pathways to the histaminergic neurons, the monoaminergic PS-off neurons, and
the hypocretinergic neurons (Boissard et al. 2002; Jego et al. 2013; Liu et al.
2017). Indeed, Jego et al. (2013) recently showed that optogenetic activation of
MCH neurons inhibit postsynaptic targets, including histaminergic cells in the TMN,
through activation of GABAA receptor.
The mechanisms at the origin of the activation of the MCH/GABAergic neurons
of the LH at the entrance into PS remain to be identiﬁed. A large number of studies
indicate that MCH neurons also play a key role in metabolism control. Therefore, the
activation of these neurons at the onset and during PS could be inﬂuenced by the
metabolic state. In addition, it is likely that yet undiscovered endogenous cellular or
molecular clocklike mechanisms may play a role in their activation.
The cessation of activity of the MCH/GABAergic PS-on neurons and more
largely of all the PS-on neurons at the end of PS episodes may be due to a different
mechanism than the entrance into the state, possibly the reactivation of the waking
systems, which are known to silence MCH neurons in vitro (van den Pol et al. 2004).
Indeed, animals are entering PS slowly from SWS, while in contrast they exit from it
abruptly by a micro-arousal. This indicates that the end of PS episodes is induced by
the activation of the W systems like the monoaminergic, hypocretin, or the hista-
minergic neurons. However, the precise mechanisms responsible for their activation
remain to be identiﬁed.
4.6 A Network Model for PS Onset and Maintenance (Fig. 5)
The onset of PS would be due to the activation of PS-on MCH/GABAergic neurons
localized in the lateral hypothalamic area (LH) by intrinsic and extrinsic factors. At
PS onset, these neurons would inhibit the PS-off GABAergic neurons localized in
the vlPAG and the dDpMe tonically inhibiting during W and SWS the glutamatergic
PS-on neurons from the SLD. The disinhibited descending glutamatergic PS-on
SLD neurons would induce muscle atonia via their excitatory projections to GABA/
glycinergic premotoneurons localized in the raphe magnus, alpha, and ventral
gigantocellular reticular nuclei. PS-on GABAergic neurons localized in the LH
(including the MCH neurons), DPGi, and vlPAG would also inactivate the PS-off
orexin (hypocretin) and aminergic neurons during PS. The exit from PS would be
due to the activation of waking/arousal systems since PS episodes are almost always
terminated by a transition to wakefulness state. The waking systems would recipro-
cally inhibit the GABAergic PS-on neurons localized in the LH, vlPAG, and DPGi.
Since the duration of PS is negatively coupled with the metabolic rate, it can be
proposed that the activity of the waking systems is triggered to end PS to restore
crucial physiological parameters like thermoregulation.
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Abstract
Although sleep seems an obvious and simple behaviour, it is extremely complex
involving numerous interactions both at the neuronal and the molecular levels.
While we have gained detailed insight into the molecules and neuronal networks
responsible for the circadian organization of sleep and wakefulness, the molecular
underpinnings of the homeostatic aspect of sleep regulation are still unknown and
the focus of a considerable research effort. In the last 20 years, the development
of techniques allowing the simultaneous measurement of hundreds to thousands
of molecular targets (i.e. ‘omics’ approaches) has enabled the unbiased study of
the molecular pathways regulated by and regulating sleep. In this chapter, we
will review how the different omics approaches, including transcriptomics,
epigenomics, proteomics, and metabolomics, have advanced sleep research. We
present relevant data in the framework of the two-process model in which
circadian and homeostatic processes interact to regulate sleep. The integration
of the different omics levels, known as ‘systems genetics’, will eventually lead to
a better understanding of how information ﬂows from the genome, to molecules,
to networks, and ﬁnally to sleep both in health and disease.
Keywords
Circadian timing system · Epigenomics · Metabolomics · Proteomics · Sleep
homeostasis · Transcriptomics
1 Introduction
Sleep plays a multitude of roles in physiology. In the past two decades, it has become
possible to study the molecular and cellular consequences of sleep and sleep loss at a
much deeper and broader level with the advent of so-called ‘omics’ technologies.
In essence, ‘omics’ refers to the entirety of technologies used to characterize and
quantify, in an unbiased manner, the various types of molecules and their
interactions at the ‘genome-wide’ level which hitherto was impossible. Yet, translat-
ing this new wealth of data into useful knowledge about the structure, function, and
dynamics of a cell, a system, or a whole organism remains a challenge. In this
chapter, we will review the contribution these technologies have made to the
understanding of the regulation of sleep at the molecular level, considering the
factors and genes that regulate the many aspects of sleep, including the molecular
consequences of sleep deprivation. Identifying these factors represents a pivotal step
in developing interventions to target the adverse consequences of sleep loss that are
so prevalent in today’s ‘24/7’ society or to alleviate sleep-wake disturbances in the
context of disease.
The study of genome sequence – genomics – was the ﬁrst ‘omics’ technology to
be developed. Genomic analyses yielded a wealth of data on sequence variants
among individuals that could be directly exploited to infer causal relationships
with sleep traits and sleep disorders. Such studies include genome-wide association
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studies (GWAS) and quantitative trait locus (QTL) analysis, which have been
applied to diverse sleep phenotypes and served to elucidate some of the genetic
architecture underpinning the sleep machinery (Nicod et al. 2016; Gottlieb et al.
2015; Ollila et al. 2014; Winrow et al. 2009; Franken et al. 2001; Tafti et al. 1999;
Toth and Williams 1999). GWAS have also contributed to the understanding of
genetic variations associated with sleep disorders (Faraco et al. 2013; Hor et al.
2010). Although relevant to understand the molecular wiring of sleep regulation, the
genetics of sleep disorders will be covered elsewhere (i.e. Part III. Sleep-Wake
Pathologies), and this chapter will speciﬁcally focus on data obtained from ‘healthy’
sleepers and directed towards the understanding of the physiological sleep-wake
regulation.
GWAS and QTL analysis interrogate the full genome. However, these
approaches mostly yield very few and often single targets that typically explain a
minor portion of the phenotypic variance when considered individually, which is in
line with the fact that sleep and its regulation are complex, involving multiple
interacting networks in a variety of brain regions and cellular compartments.
Moreover, although linkage and association studies can establish gene variant-to-
phenotype correlations, the ﬂow of information from the genome to transcriptome,
proteome, and metabolome, and ﬁnally phenotype, cannot be assessed. To capture
the complexity of sleep, systems genetics should be favoured to quantify, at a
genome-wide level, gene expression (transcriptomics), epigenetic marks
(epigenomics), proteins (proteomics), and metabolites (metabolomics), in a geneti-
cally well-characterized population as pictured in Fig. 1. The main techniques used
Fig. 1 Intricately interacting networks underlying sleep. Left: Epigenetic modiﬁcations of the
genome lead to changes in transcription, which associate with changes in the levels of proteins and
metabolites, which feed back into further changes in gene expression. Sleep, loss of sleep, and the
environment can inﬂuence these molecular interactions that, in turn, affect sleep. Right: Networks
underlying a particular behaviour interact with each other through shared network components to
produce an integrative behavioural pattern
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and the overall contributions to knowledge on sleep-wake regulation of these main
layers of omics approaches will be emphasized in the following sections.
The contributions of transcriptomics, epigenomics, and proteomics/
metabolomics to knowledge on sleep will more precisely be described in the context
of models by which wakefulness and sleep duration and quality are regulated by the
interactions between a circadian timing system and a sleep homeostat (Daan et al.
1984). To identify molecules impacted by or impacting the circadian timing system,
measurements are usually performed at different circadian times under constant
environmental conditions, whereas sleep deprivation with sampling at the same
‘time’ as undisturbed controls is used to identify molecular components linked to
sleep homeostasis. However, because the distribution of wakefulness and sleep
varies simultaneously with endogenous circadian time, disentangling circadian
determinants and sleep-wake-driven (‘homeostatic’) components can only be
achieved by speciﬁc experimental designs such as the forced desynchrony protocol
or by combining circadian sampling and sleep deprivation, which are only rarely
performed (Archer et al. 2014; Maret et al. 2007). Data concerning both the
independent and combined strategies will be highlighted in the present chapter.
2 Transcriptomics
To understand the complex interplay between circadian time and homeostatic sleep
drive, researchers have studied the dynamic response of an organism to these two
factors by quantifying the ensemble of RNA transcripts. The transcriptome
represents the levels of all RNAs (including protein-coding messenger RNAs
[mRNAs] and non-coding RNAs such as microRNAs) at a particular time (Wang
et al. 2009). Although techniques can be adapted to quantify nascent transcripts,
usually steady-state RNA levels are measured in transcriptomic studies, including
both actively transcribed genes and stored RNA pools. While the relationship
between a gene’s transcription and its protein levels is often not linear, a
transcriptomic analysis can nevertheless be seen as the genome’s active components
(to contrast functional components covered in the proteomics section below).
Transcriptomic studies have contributed to elucidate the role of speciﬁc genes and
intracellular signalling pathways in regulating sleep and in mediating the
consequences of sleep loss and thereby have identiﬁed potential therapeutic targets
for sleep and associated brain disorders. Quantifying the transcriptome of a sample
has been achieved using two main technologies that will ﬁrst be summarized below:
hybridization-based and, more recently, sequencing-based technologies.
2.1 Microarrays and RNA Sequencing
In hybridization-based technologies, a high-density array of oligonucleotides
(i.e. microarray) is incubated with ﬂuorescently labelled complementary DNA
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(cDNA) synthetized from an RNA sample. The ﬂuorescence quantifying the
amount of cDNA binding each oligo spot (probe set) on the array is then read.
Although it is possible to design custom arrays for organisms lacking a reference
genome, commercial microarrays rely on high-density synthesis of oligonucleotides
of deﬁned sequences onto the slide, allowing inferences to be made as to the
expression of various predicted gene isoforms (Wang et al. 2009; Okoniewski and
Miller 2006). Thus, a key shortcoming of this technology is its dependence on high-
quality genome annotation to optimally design oligonucleotide probes, which also
limits this technology to the identiﬁcation of known rather than novel transcripts.
Despite these shortcomings, most of our understanding of the molecular under-
pinnings of sleep regulation comes from microarray studies performed in a number
of organisms, including the fruit ﬂy (Zimmerman et al. 2006; Cirelli et al. 2005),
birds (Jones et al. 2008), rodents (Mackiewicz et al. 2007; Cirelli et al. 2004), as well
as humans (Archer et al. 2014; Möller-Levet et al. 2013; Pellegrino et al. 2012).
The recent development of high-throughput DNA sequencing methods has
provided novel techniques for quantifying transcriptomes. In this technique, the
expressed RNA is reversed transcribed to form cDNA, which is used to make a
platform-speciﬁc DNA library ready for sequencing (commonly involving DNA
fragmentation and adapter ligation) (Syed et al. 2009). As next-generation sequenc-
ing generates short read lengths that must be assembled, this is sometimes called
whole transcriptome shotgun sequencing, or more commonly RNA sequencing
(RNA-Seq). Compared to microarray techniques, this technology is both more
sensitive and accurate due to its higher dynamic range, with little or no background
noise that otherwise would limit the detection of rare transcripts, and less signal
saturation for highly expressed transcripts (Darlington et al. 2013; Marguerat and
Bähler 2010; Wang et al. 2009). RNA-Seq is also more informative in that it can
detect previously unannotated splice variants and single-nucleotide polymorphisms.
Nevertheless, the use of this technology has been limited by the signiﬁcant bioinfor-
matic skills required to analyse the data. In addition, RNA-Seq also depends on high-
quality genome annotation to perform genomic alignment. To date, RNA-Seq has
been used in few sleep studies (Sabir et al. 2015; Darlington et al. 2013), but given its
advantages and the high-quality information it outputs, it is evident that future sleep
research will increasingly utilize this method. In planning future research using
transcriptomics (as well as other omics), we wish to direct readers to recently
published methodological and analytical guidelines for genome-wide circadian-
related studies (Hughes et al. 2017).
2.2 The Circadian Transcriptome
Many microarray studies have reported on the extent of 24-h variations in the
transcriptome in numerous organisms and tissues (Keegan et al. 2007; Storch et al.
2007; Akhtar et al. 2002). We will focus here on mammalian datasets only. In the
mouse forebrain, more than 2,000 rhythmic probe sets have been reported under
normal light-dark (LD) conditions (Maret et al. 2007), while in the pineal gland, the
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brain structure responsible for melatonin secretion, more than 600 genes showed
differential day-night expression in the rat (Bailey et al. 2009). However, many
genes that show a cycling pattern of expression in the brain will directly or indirectly
respond to the light-dark cycle (or the feeding schedule). Accordingly, genes directly
regulated by circadian time need to be distinguished by performing experiments in
constant darkness (DD), here referred to as circadian studies. For instance, in an
organ specialized to respond to light, the eye, only about 10% of the transcripts that
were rhythmic under 24-h LD conditions remained rhythmic under DD conditions,
which represented 120 genes (Storch et al. 2007). Circadian studies have notably
revealed a high tissue speciﬁcity of the circadian transcriptome (Miller et al. 2007;
Dufﬁeld 2003), and the dependency of the peripheral circadian transcriptome on the
integrity of the brain, or in particular of the main mammalian clock located in the
hypothalamic suprachiasmatic nuclei (SCN) (Kolbe et al. 2016; Hughes et al. 2012;
Akhtar et al. 2002).
Overall, circadian studies have described hundreds of genes cycling with internal
(circadian) time. However, as highlighted in the introduction, among the strongest
confounding factors in these studies is the distribution of wakefulness and sleep that
covaries with circadian time. A consensus is even emerging that the sleep-wake-
driven transcriptome is larger than the ensemble of circadian transcripts. For
instance, of the >2,000 rhythmic probes in the mouse forebrain under baseline
conditions, fewer than 400 retained a rhythmic expression proﬁle when the sleep-
wake inﬂuence was accounted for by submitting animals to a 6-h sleep deprivation
prior to around-the-clock tissue sampling (Maret et al. 2007). A similar >80%
reduction of the number of rhythmic transcripts was observed in the human blood
transcriptome: of the ~1,400 genes that showed circadian rhythmicity, the expres-
sion of only 230 genes remained rhythmic when sleep no longer occurred at the
correct circadian phase (Archer et al. 2014). This underscores the predominance of
the sleep-wake distribution in driving cycling gene expression. Nevertheless, a more
recent study by the same group using 19 transcriptome datasets available from
humans and mice identiﬁed circadian transcripts that were not inﬂuenced by the
sleep-wake cycle (Laing et al. 2015). The genes identiﬁed were related to processes
involved in lipid metabolism, glucocorticoid signalling, and immune function.
Given the complexity of adequately quantifying the circadian transcriptome, the
circadian genome-wide gene expression pattern that is independent of the sleep-
wake cycle remains to be deﬁned for most brain structures regulating sleep.
2.3 Brain Transcriptomic Response to Sleep Loss
The quantiﬁcation of the transcriptome after sleep deprivation has been used to ﬁnd
molecular correlates of sleep need as well as to identify molecular pathways
associated with functions of sleep. Early studies examined rat cerebral cortex
transcript expression and found that during spontaneous wakefulness or enforced
wakefulness (i.e. sleep deprivation), various genes were upregulated relative to their
levels during sleep. These included immediate early genes, genes involved in
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metabolism, neurotransmission and synaptic function, and genes coding for heat
shock proteins or chaperones (Cirelli and Tononi 2000). Additional studies have
corroborated the impact of sleep deprivation on these gene categories, showing
thousands of genes being up- and downregulated (Mongrain et al. 2010; Maret
et al. 2007; Mackiewicz et al. 2007; Terao et al. 2003). Some additional genes
identiﬁed by these studies included genes involved in intracellular calcium homeo-
stasis and glutamate signalling suggesting a role for sleep in neuroprotection
(Mongrain et al. 2010; Maret et al. 2007).
Some of the sleep deprivation-driven changes in the transcriptome are observed at
the level of the whole brain in mammals (Mongrain et al. 2010; Maret et al. 2007).
However, sleep transcriptomic studies have also characterized alterations in the
cerebral cortex as indicated above (Mackiewicz et al. 2007; Terao et al. 2003; Cirelli
and Tononi 2000) and also in the hypothalamus and hippocampus (Porter et al. 2012;
Vecsey et al. 2012; Mackiewicz et al. 2007). The hippocampus is a brain region
particularly sensitive to the effect of sleep loss (Havekes and Abel 2017), and its
transcriptomic signature after sleep deprivation is indicative of impaired protein
synthesis (Vecsey et al. 2012). Such studies may shed light on the molecular origin
of sleep loss-induced alterations in memory processes.
Collectively, these studies and those in non-mammalian models contributed to
hypotheses regarding the functions of sleep, which include to respond to cellular
stress and to maintain metabolism and synaptic plasticity (Mackiewicz et al. 2009).
One meta-analysis identiﬁed immediate early gene families (Egr, Nr4a) as
conserved sleep deprivation-affected genes in insects, birds, and mammals and
showed the cAMP-responsive element (CRE) to be one of the primary cis-regulatory
elements in the enhancers of those genes (Wang et al. 2010). However, one limita-
tion of sleep deprivation studies is the observation that many transcripts previously
thought to be affected by sleep loss are actually responding to the corticosterone
surge induced by sleep deprivation (Mongrain et al. 2010). Removal of the cortico-
sterone surge using adrenalectomy resulted in the identiﬁcation of protein synthesis,
RNA post-transcriptional modiﬁcation, and neuroprotection pathways as likely to be
more directly linked to sleep need (Mongrain et al. 2010). MicroRNAs, small
non-coding RNAs controlling mRNA expression, also featured in the list of potential
direct correlates of the sleep homeostat, which is reminiscent of other studies linking
microRNAs to sleep regulation (Davis et al. 2007, 2012).
2.4 Sleep Loss Affects the Peripheral Transcriptome
In mice, microarray studies have shown that sleep loss affects the transcriptome in
the heart and lung similar to the brain (Anaﬁ et al. 2013). In the liver, however, a
higher number of transcripts showed sleep deprivation-induced alterations than in
the brain (Maret et al. 2007). Such ﬁndings challenge the historical view that sleep is
solely required for the brain (Hobson 2005). Peripheral organs, and in particular
blood, are better suited for human studies because of easier accessibility and the
possibility to assay biomarkers for sleep need. A comprehensive review outlined the
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state of the literature in humans (Archer and Oster 2015). In the human blood,
prolonging wakefulness to 60 h changed the expression of over 500 genes, including
genes involved in the immune system, stress response, and DNA damage repair,
with many downregulated following sleep loss and subsequently showing a recovery
with sleep (Pellegrino et al. 2012). More recently, an attempt was made to identify
molecular correlates of sleep loss-sensitive and sleep loss-resistant phenotypes in
humans using transcriptomics (Arnardottir et al. 2014). This microarray study
described that subjects resistant to sleep loss showed a reduction in the amplitude
of expression of rhythmic transcripts in comparison to sleep loss-sensitive subjects.
Such ﬁndings may eventually allow predicting whether an individual will be able to
perform under high sleep pressure conditions.
2.5 Future of Sleep Transcriptomics and Limitations
Besides assessing the sleep/wake-dependent transcriptome of discrete brain regions,
research has now come to the study of speciﬁc cell types (Yelin-Bekerman et al.
2015; Bellesi et al. 2013, 2015). Worth mentioning are studies of the oligodendro-
cyte and astrocyte transcriptomes in the cerebral cortex assessed using the combina-
tion of microarray and translating ribosome afﬁnity puriﬁcation (Bellesi et al. 2013,
2015), which captures mRNAs that are actively being translated by ribosomes.
During wakefulness, genes translated in oligodendrocytes included genes involved
in apoptosis, cellular stress response, and cell differentiation, whereas astrocyte-
translated genes were involved in metabolism, extracellular matrix, and elongation
of peripheral astrocytic processes. In both cell types, the team also described
pathways linked to genes that are transcribed speciﬁcally during sleep.
Although we now have a clear portrait of how gene expression changes with the
distribution of sleep and wakefulness, most of these transcriptomic studies remain
limited by the fact that they cannot establish if alterations in gene expression proﬁles
are merely a consequence of the behavioural state or if the genes are causally
involved in regulating the behavioural state. To overcome this limitation, application
of transcriptomics to inbred strains or genetically modiﬁed animals with alterations
in sleep seems a promising avenue to identify networks of genes speciﬁcally
involved in sleep regulation (Freyburger et al. 2016; Hasan et al. 2014; Massart
et al. 2014; Darlington et al. 2013; Maret et al. 2007). Studies using mutant mice
with deﬁcits in neural development and plasticity highlighted that the transcriptome
response to sleep deprivation is only slightly impacted by these mutations and is thus
extremely robust (Freyburger et al. 2016; Massart et al. 2014). Yet, Fgf1 (ﬁbroblast
growth factor 1) was identiﬁed as a potential cell-speciﬁc element contributing to
recovery sleep using the combination of transcriptomics with genetic engineering
(Massart et al. 2014).
Another area of transcriptomic research with important clinical relevance
concerns the consequence of chronic sleep loss. In fact, the gene expression response
to multiple days of sleep restriction was shown to differ from the acute effects of
sleep loss measured at the end of the prolonged wakefulness episode (Cirelli et al.
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2006). In humans, sleep restriction was shown to disturb the circadian regulation of
the blood transcriptome and to impact on biological processes like gene-expression
regulation, metabolism, and inﬂammatory and stress responses (Aho et al. 2016;
Möller-Levet et al. 2013). More research is clearly needed to understand how the
impact of acute total sleep loss on the transcriptome relates to that of chronic sleep
restriction better mimicking clinical scenarios seen in patients with sleep, psychiat-
ric, or neurological disorders. Lastly, a noticed limitation of transcriptomic studies is
that changes in mRNA expression may not be reﬂected in protein expression and
therefore might not be indicative of functional observations. This will partly be
addressed in the following sections.
3 Epigenomics
In the previous section, we have emphasized that the transcriptome of both the brain
and the periphery changes over the sleep/wake cycle and is altered following sleep
deprivation. Mechanisms underlying these changes in gene expression are inevitably
involving epigenetic modiﬁcations, which are required for modifying the state of a
gene (e.g. silent vs. primed vs. actively transcribed). The epigenome refers to the
genome-wide pattern of speciﬁc marks found on DNA and histones, which
determine the state of chromatin (heterochromatin vs. euchromatin), and thus
DNA accessibility and gene expression (McGowan and Szyf 2010; Wolffe and
Kurumizaka 1998). In general, epigenetic modiﬁcations comprise all changes to
DNA (chemical or physical due to histone modiﬁcations) that do not alter the DNA
sequence.
Epigenetic modiﬁcation of gene expression operates across very different
timescales. For instance, epigenetic mechanisms play important roles in determining
cell fate and behaviour during development (Khalyfa et al. 2014; Koh and Rao 2013;
McGowan and Szyf 2010), which implicates stable modiﬁcations that will last
throughout the existence of an organism. However, epigenetic changes can be
much more dynamic (Qureshi and Mehler 2014) and respond to changes in environ-
mental conditions lasting a few weeks or even minutes (Azzi et al. 2014; Zhao et al.
2010). In addition, the fact that epigenetic mechanisms are profoundly linked to the
establishment of brain circuitry and neuronal plasticity (Bale 2015; Miller and
Sweatt 2007) places the epigenome at a central position to regulate wakefulness
and sleep. We will here present speciﬁc epigenetic modiﬁcations and methodologies
for their genome-wide quantiﬁcation and, in addition, review ﬁndings linking
epigenomics to the circadian timing system and the sleep homeostat.
3.1 Epigenetic Marks and Techniques
We will ﬁrst provide a brief description of DNA methylation and derivatives and of
histone post-translational modiﬁcations. DNA methylation consists of the addition
of a methyl group to the 50 position of cytosine (5-methylcytosine or 5mC). In
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general, 5mC correlates with gene silencing when occurring in the promoter of genes
because the methyl group prevents the binding of transcription factors required
for gene expression and attracts methylated DNA-binding proteins that recruit
corepressors, histone methyltransferases, and histone deacetylases promoting a
closed chromatin conﬁguration (McGowan and Szyf 2010). This of course applies
to the mammalian brain (Massart et al. 2017). DNA methyltransferases (DNMTs)
catalyse the 5mC reaction and have thus themselves been implicated in all functions
attributed to 5mC, including in plasticity of the central nervous system (Miller and
Sweatt 2007).
The methylated cytosine can undergo further chemical modiﬁcations that have
also been shown to regulate gene expression and cellular functions, including
hydroxymethylation (5hmC), formylation (5fC), and carboxylation (5caC). These
modiﬁcations are mediated by DNA hydroxylases (i.e. ten-eleven translocation
methylcytosine dioxygenase or TETs) (Koh and Rao 2013). The exact roles of
these additional modiﬁcations remain to be determined, which is a particular chal-
lenge for 5fC and 5caC because of the difﬁculty to precisely quantify these marks
(Koh and Rao 2013). The 5hmC mark has been proposed to serve as an intermediate
to demethylation or as a mark diversifying 5mC (Koh and Rao 2013; Wu et al. 2011)
and is highly abundant in the adult brain, particularly in the cerebral cortex (Münzel
et al. 2010). Importantly, TETs have been involved in neurogenesis and brain
function (Zhang et al. 2013).
Histone post-translational modiﬁcations also represent a major category of
epigenetic marks. These include phosphorylation, ubiquitination, acetylation, and
methylation, the last two of which are controlled by histone acetyltransferases
and deacetylases and histone methyltransferases and demethylases, respectively
(Qureshi and Mehler 2014). Histone modiﬁcations exert their effects on gene
expression by directly inﬂuencing chromatin structure via shaping chromatin com-
paction and regulating the binding of effector molecules (Bannister and Kouzarides
2011). An extensive literature exists on the role of histone modiﬁcations in brain
development and plasticity, and some speciﬁc examples relevant to the regulation of
sleep and wakefulness will be highlighted hereafter.
A standard technique to study the role of histones, DNMTs, and TETs is
chromatin immunoprecipitation (ChIP) that allows enrichment of DNA associated
with these speciﬁc epigenetic elements. To achieve an omic (genome-wide) resolu-
tion, the DNA captured by ChIP can be assayed using microarrays (ChIP-chip) or
high-throughput sequencing (ChIP-Seq) (Takahashi et al. 2015). Similarly, genome-
wide quantiﬁcation of 5mC is generally achieved using methylated DNA immuno-
precipitation (MeDIP) (Massart et al. 2014). These techniques all depend on
effective antibodies that will speciﬁcally recognize the targeted epigenetic elements.
Sequencing can also be combined with bisulﬁte treatment (Bis-Seq) to measure the
genome-wide methylation landscape (Massart et al. 2017), but this technique does
not allow to distinguish between 5mC and 5hmC (Koh and Rao 2013), which
requires the use of Tet-assisted bisulﬁte sequencing (Tab-Seq) (Yu et al. 2012).
Future studies on the regulation of sleep will also feature data from ATAC-Seq that
assesses genome-wide chromatin accessibility (Buenrostro et al. 2015).
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3.2 The Circadian Epigenome
The circadian ﬁeld has a considerable advance compared to the sleep ﬁeld with
regard to understanding the function of epigenetic mechanisms in physiology (Sahar
and Sassone-Corsi 2013; Takahashi et al. 2015). In particular, genome-wide
quantiﬁcations of the circadian epigenetic landscape have portrayed the profound
implication of epigenetic mechanisms in the circadian timing system (Valekunja
et al. 2013; Koike et al. 2012; Le Martelot et al. 2012). Most, if not all, histone
modiﬁcations play roles in circadian transcription. For example, the circadian
expression and activity pattern of histone acetyltransferase p300 and histone
methyltransferases MLL1 and MLL3 are essential in generating circadian rhythms
(Valekunja et al. 2013; Katada and Sassone-Corsi 2010; Etchegaray et al. 2003). An
important discovery was that the core circadian protein CLOCK is itself a histone
acetyltransferase that binds other chromatin modiﬁers such as MLL1 and the histone
deacetylase SIRT1 to regulate circadian gene expression (Sahar and Sassone-Corsi
2013). Although most currently available datasets have been obtained from the
mouse liver, these observations suggest that similar mechanisms will govern circa-
dian timekeeping in the brain, implying this might also regulate sleep.
With regard to 5mC mechanisms, DNMTs were shown to both be regulated by
molecular clock mechanisms and to play roles in clock outputs. In fact, on the one
hand, the mRNA expression of DNMTs was shown to cycle with time-of-day in the
mouse liver (Xia et al. 2015; Maekawa et al. 2012). On the other hand, DNA
methylation regulates the expression of core circadian clock components in the
mouse SCN (Azzi et al. 2014; Ji et al. 2010). Importantly, genome-wide
reprogramming of 5mC in the SCN was shown to change the rhythmic locomotor
activity pattern, which was prevented when a methyltransferase inhibitor was
administered (Azzi et al. 2014). This indicated that epigenetic mechanisms coordi-
nate plasticity of the main circadian clock. Another important study using a genome-
wide design reported on rhythmic 5mC in the human prefrontal cortex and on its
relationship with the transcriptome (Lim et al. 2014). Moreover, the authors
observed that the amplitude of the DNA methylome rhythm was positively linked
to the amplitude of activity rhythms before death, suggesting a functional role for
5mC rhythm in the human brain. Nonetheless, similar to the transcriptome, further
experiments will be required to understand the contribution of the wake/sleep
distribution to the circadian epigenome.
3.3 The Epigenome Responds to Sleep Loss
Transcriptomic studies suggest that epigenetic mechanisms and the sleep homeostat
are also fundamentally linked, as sleep deprivation and mistimed sleep extensively
modify gene expression including expression of genes coding for histones, histone-
modifying enzymes, and DNMTs (Archer et al. 2014; Massart et al. 2014;
Möller-Levet et al. 2013; Mongrain et al. 2010). Furthermore, sleep deprivation
impacts genome-wide 5mC and 5hmC patterns with, respectively, hundreds and
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thousands of genes being affected (Massart et al. 2014). More precisely, 5mC
modiﬁcations were found in genes involved in neuritogenesis and synaptic plastic-
ity, whereas 5hmC alterations were found in genes involved in cytoskeleton organi-
zation, signalling, and neurotransmission. These biological functions are in line with
the results of transcriptomic studies (previous section). In addition, a signiﬁcant
proportion of 5hmC changes observed in this study correlated with changes in gene
expression assessed using RNA-Seq (Fig. 2a). In a follow-up experiment, our group
has also observed a signiﬁcant association between sleep deprivation-driven changes
in 5mC located at enhancers (i.e. bound to H3K4me1) and gene expression (Fig. 2b),
supporting a role for 5mC in regulating gene expression under high sleep need
conditions. A recent study making use of omics approaches in human blood samples
(Nilsson et al. 2016) and studies looking at individual targets (Ventskovska et al.
2015) also support this notion.
The relationship between sleep regulation and the epigenome is further supported
by studies showing that modiﬁcations of epigenetic elements alter markers of the
sleep homeostat in rodents (Wither et al. 2012) and sleep in ﬂies and humans
(Pirooznia et al. 2012; Winkelmann et al. 2012). Moreover, epigenetic mechanisms
have been shown to be involved in the impact of sleep loss on progeny in mice
(Khalyfa et al. 2014). This study showed that 5mC and 5hmC, the expression of
DNMTs and TETs, and histone acetyltransferase activity are all altered in visceral
adipose tissue of the offspring of pregnant mice exposed to sleep fragmentation.
Some of these changes applied to adiponectin, which is involved in insulin resistance
and obesity, and were associated with metabolic dysfunction observed in the off-
spring during adulthood. This dataset highlights a mechanism by which sleep
disruption can impact physiology on the long term, namely, through epigenetic
modiﬁcations.
Fig. 2 (a) Venn diagram showing the overlap between genes differentially hydroxymethylated
(5hmC) after a 6-h sleep deprivation (SD) in comparison to control condition (false discovery rate
[FDR] < 0.15) and genes differentially expressed (mRNA) after SD (FDR < 0.05) in the mouse
cerebral cortex. DNA 5hmC data are from Massart et al. (2014). Gene expression was quantiﬁed by
high-throughput sequencing (RNA-Seq) using three pools of three control and three SD mice.
22.3% of changes in DNA 5hmC overlap with changes in gene expression. (b) Overlap between
genes differentially expressed (mRNA) after SD (see also a) and genes showing signiﬁcant changes
in methylation (5mC) at H3K4me1 enhancers measured by combining chromatin immunoprecipi-
tation, bisulﬁte treatment, and high-throughput sequencing (ChIP-Bis-Seq). 36.7% of changes in
5mC at enhancers overlap with changes in gene expression (unpublished data)
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3.4 Future of Sleep Epigenomics
To understand how sleep impacts brain function and health via epigenetic
mechanisms is an exciting and promising area of future sleep research. In blood,
the analysis of the genome-wide methylation landscape in shift-workers revealed
epigenetic modiﬁcations, which included genes with roles in circadian physiology as
well as genes belonging to cancer-associated pathways (Shi et al. 2013; Zhu et al.
2011). Alterations in blood 5mC are also seen in obstructive sleep apnoea patients
(Kim et al. 2012). Various epigenetic changes are also expected to occur in the
central nervous system in response to the above perturbations of sleep and to many
others, including insomnia, and to underlie, at least in part, the relationships between
sleep and psychiatric or neurological disorders. The potential for epigenetic marks to
serve as biomarkers for diseases showing sleep and circadian disturbances is clear,
and identifying relevant molecular targets could facilitate the development of novel
interventions that will allow targeting networks of genes. Nevertheless, much
remains to be done before we understand how the epigenome, and particularly the
brain epigenome, regulates the normal wakefulness and sleep cycle.
Non-coding RNAs represent another class of molecules playing epigenetic roles
in regulating gene expression. Non-coding RNAs are divided on the basis of
their size and of particular interest are long non-coding RNAs (lncRNAs, >200
nucleotides) and piwi-associated non-coding RNAs (piRNAs, 26–32 nucleotides)
because they play roles in 5mC and chromatin remodelling (Gomes et al. 2013;
Rajasethupathy et al. 2012). One lncRNA was speciﬁcally shown to regulate sleep in
ﬂies (Soshnev et al. 2011). Their role in sleep regulation remains to be explored in
mammals, in which investigation is supported by observation that sleep deprivation
alters the expression of some lncRNAs in the mouse hypothalamus (Davis et al.
2016).
4 Proteomics and Metabolomics
The last category of omics approaches that will be covered in this chapter could be
seen as functional outputs from transcriptomics and epigenomics. However, proteo-
mics and metabolomics can reveal additional/different networks of components not
necessarily identiﬁable in transcriptomic/epigenomic studies because there is not
always a direct correlation between the expression of a gene and of the protein
product that it produces. Indeed, in circadian rhythm research, a rhythmic protein can
be associated with a nonrhythmic mRNA expression, and the opposite has also been
observed (Chiang et al. 2014; Mauvoisin et al. 2014; Reddy et al. 2006). Similarly,
an impact of sleep or sleep loss can be observed only at the level of protein amount
and not for mRNA expression or vice versa (Tudor et al. 2016; Seibt et al. 2012).
In addition, post-translational modiﬁcations shaping the activity of functional
components can only be captured at the proteome level (Tudor et al. 2016; Lück
et al. 2014; Seibt et al. 2012). This emphasizes the need for the different
measurements to be performed in parallel (i.e. systems genetics).
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Although metabolites clearly differ from proteins, methodologies used for the
quantiﬁcation of the metabolome are nevertheless very similar to those for the
proteome except that they are applied to physiological ﬂuids containing metabolites
such as blood and urine. To simultaneously quantify the expression of hundreds to
thousands of proteins or metabolites, two-dimensional difference gel electrophoresis
(2D-DiGE) is generally used with the gold standard technique of liquid chromatog-
raphy combined with mass spectrometry (LC-MS) (Kim et al. 2014; Ang et al. 2012;
Deery et al. 2009; Reddy et al. 2006), of which different technologies exist such as
high-performance liquid chromatography-electrospray tandem mass spectrometry
(Chiang et al. 2014).
Assessment of the metabolome is particularly suitable for human studies because
metabolites measured in the blood can be sampled easily, are a reliable index of
the physiology, and can be directly compared to research in other mammals
(Weljie et al. 2015). In addition, metabolites might eventually serve as accessible
biomarkers. Studies have unequivocally reported that the brain proteome, the
peripheral proteome, and the metabolome change with circadian time and sleep
need, as will be summarized below.
4.1 The Circadian Proteome/Metabolome
The circadian proteome has been assayed in both the central and peripheral clocks,
with the liver being particularly well-studied (Mauvoisin et al. 2014; Masri et al.
2013; Reddy et al. 2006). Pioneer work by Reddy et al. (2006) identiﬁed 60 proteins
with a strong circadian variation among the 642 proteins reliably measured. The
rhythmic hits included proteins involved in fundamental liver functions like urea
formation and sugar metabolism, which highlighted that the liver is a functionally
different organ at different endogenous times (Reddy et al. 2006). More recent data
emphasized the contribution of the feeding schedule to these 24-h variations of the
liver proteome (Mauvoisin et al. 2014). Post-translational modiﬁcation can also be
targeted in proteomic analyses. In particular, the rhythmic acetylated proteome
(acetylome) differs in animals lacking a functional molecular clock, with differences
including proteins linked to amino acid metabolism, nitrogen metabolism, and
glycolysis/gluconeogenesis (Masri et al. 2013).
In the murine SCN, about 20% of the ~2,100 proteins identiﬁed showed a time-
of-day abundancy pattern (Chiang et al. 2014). These were linked to neurotransmit-
ter release, neural plasticity, and mitochondrial function. Among these, 48 proteins
speciﬁcally showed a circadian (LD cycle-independent) rhythm (Chiang et al. 2014).
These observations mostly corroborated earlier ﬁndings concerning synaptic vesicle
cycling as a major biological pathway showing circadian rhythmicity in the mouse
SCN proteome (Deery et al. 2009). A recent observation also indicates that the level
of many amino acids shows a circadian rhythm in the mouse SCN (Fustin et al.
2017). Day-night variations in the proteome have also been reported for the pineal
gland (Møller et al. 2007). Together, these studies underline the important
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contribution of proteomics to the current understanding of roles of circadian
processes in different tissues.
In the human blood, the level of 15–19% of metabolites reliably detected was
observed to vary with time-of-day (Ang et al. 2012; Dallmann et al. 2012), similar in
extent to circadian results obtained using saliva (Dallmann et al. 2012). Notably,
such studies allowed for the identiﬁcation of novel rhythmic metabolites such as
acylcarnitines and phospholipids (Ang et al. 2012). In a follow-up study utilizing
human urine, authors have reported that the sleep-wake cycle impacts on circadian
variations of several metabolites by measuring 24-h levels under undisturbed sleep-
wake cycle and during total sleep deprivation (Giskeødegård et al. 2015). This
observation is not surprising given data showing the impact of sleep loss on the
proteome and metabolome that will be presented in the next section.
4.2 The Proteomic/Metabolomic Response to Sleep Deprivation
A number of proteomic studies have reported on the impact of sleep loss in several
brain areas, including the cerebral cortex, the hypothalamus, and the basal forebrain.
In the basal forebrain, an area particularly involved in sleep regulation (sleep
homeostasis), 89 proteins were shown to have a twofold or greater difference after
an acute 6-h sleep deprivation in rats, including many synaptic and cytoskeleton
proteins (Basheer et al. 2005). In the mouse cerebral cortex, sleep deprivation was
shown to speciﬁcally affect the level of three proteins: alpha tubulin, heat shock
cognate 71, and lactate dehydrogenase (Pawlyk et al. 2007). These two studies
identiﬁed elements in line with neurotransmission, cytoskeleton, metabolism, and
heat shock pathways identiﬁed in microarray studies. In rats, sleep was shown to be
associated with higher level of the C-terminal fragment of histone 4 in the cerebral
cortex (Cirelli et al. 2009), again emphasizing the link between the epigenome and
sleep deprivation. It thus seems that there is convergence of transcriptomics and
proteomics data on the impact of sleep deprivation even if, in general, fewer proteins
are signiﬁcantly changed by sleep deprivation compared to reported changes in gene
expression presented earlier (unit to dozens vs. hundreds to thousands, respectively).
Technical reasons likely explain such a difference, which may also be due to mixing
distinct cell types. For instance, a more recent study examining only hypothalamic
astrocytes has identiﬁed as many as 139 proteins with signiﬁcantly altered levels
after chronic sleep restriction that were related to glial activation and
gliotransmission (Kim et al. 2014).
The blood metabolome was also shown to be altered by sleep loss. Indeed, recent
studies indicate that the level of many lipids, in particular phospholipids, is modiﬁed
by both acute and chronic sleep loss (Weljie et al. 2015; Davies et al. 2014).
Interestingly, metabolomics have identiﬁed potential biomarkers of chronic sleep
loss encompassing different mammalian species, namely, oxalic acid and
diacylglycerol 36:3 (Weljie et al. 2015). Equally interesting is the observation that
acute sleep deprivation increases human plasma levels of serotonin, tryptophan, and
taurine, potentially relevant to the antidepressive effect of acute sleep deprivation
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(Davies et al. 2014). Similar to transcriptomic studies, these studies emphasized the
fact that sleep loss not only impacts the brain but also importantly affects peripheral
organs. Future research should determine whether and how these changes participate
in regulating sleep and how this information can contribute to establish sleep’s
function(s).
4.3 Future of Sleep Proteomics/Metabolomics
As mentioned for transcriptomic studies, most of these studies are solely descriptive,
cataloging the changes in protein and metabolite levels across circadian time and
sleep need. How changes in protein amount underlie functions of sleep such as
neuronal plasticity is beginning to be addressed at the level of individual targets
(Tudor et al. 2016; Seibt et al. 2012), but the use of strategies targeting networks of
elements should eventually be favoured. In addition, to fully delineate the complex-
ity of sleep/wake regulation, combinations of omics approaches (i.e. systems genet-
ics) are increasingly being used such as transcriptomics with proteomics or
metabolomics (Aho et al. 2016; Lück et al. 2014; Eckel-Mahan et al. 2012) and
integrating the acetylome with the transcriptome, proteome, and metabolome (Masri
et al. 2013). New related technologies including breathomics and lipidomics
(Martinez-Lozano Sinues et al. 2014; Thimgan et al. 2015) may also shed light on
sleep regulation.
5 Conclusions and Perspectives
Overall, this chapter has highlighted the power of speciﬁc omics approaches to
identify molecular networks associated with circadian and homeostatic sleep regula-
tion. Yet, the exact contribution of sleep-wake-driven changes to ‘circadian’
genome-wide oscillations still remains to be determined for distinct brain areas
and peripheral tissues using adequate study design. It is evident that these
technologies offer the potential to comprehensively investigate impacts of pharma-
cological agents and evaluate their suitability to mimic or restore a normal or
pathological molecular ‘landscape’. Such studies have only begun to be available,
and a good example is found in the description of the genome-wide signature of
different wake-promoting pharmacotherapies (i.e. pharmacogenomics) (Hasan et al.
2009). This study even used the more promising approach of systems genetics by
studying different inbred strains and thus combining transcriptomics with genetics.
In order to adapt treatment in diseases, assessing circadian/sleep-dependent genome-
wide effects of the numerous drugs reported to affect sleep variables (e.g. Monti
et al. 2017; Schwartz et al. 2016; Arbon et al. 2015; Bettica et al. 2012) seems
required. In addition, the combination of pharmacogenomics with pharmacogenetics
(i.e. considering genetic variations in pharmacological interventions) is of impor-
tance for personalized treatment of sleep disorders as highlighted recently (Holst
et al. 2016). In the long term, omics will without doubt permit to develop
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therapeutics that simultaneously target networks of relevant pathways, which seems
particularly promising with regard to epigenomics.
The present work has focused on transcriptomics, epigenomics, and proteomics/
metabolomics approaches and their contributions to wakefulness and sleep regula-
tion. Nevertheless, some omics approaches that have not been speciﬁcally discussed
in the present chapter and that are equally relevant to the regulation of sleep include
microbiomics and connectomics. Microbiomics generally consists in sequencing the
bacterial ﬂora of different tissues, most often the gut. The use of such approach is
exponentially increasing and has revealed that the deregulation of the gut microbiota
due to circadian disruption and consequent abnormal feeding schedule crucially
impacts metabolism in both humans and mice (Thaiss et al. 2014). Considering the
importance of the gut-brain axis in brain functions (Montiel-Castro et al. 2013), this
type of research will certainly reveal additional determinants of the normal regula-
tion of wakefulness and sleep, in addition to increase the understanding of diseases
of sleep such as sleep apnoea (Durgan et al. 2016).
At probably the most macroscopic level of omics approaches stands
connectomics, which is applied to the mammalian brain. The brain connectome is
deﬁned as the global connectivity between all brain areas and is generally measured
with imaging techniques such as functional magnetic resonance imaging, but also
using electrophysiological methods (Liu et al. 2015). This approach has notably
revealed that functional connectivity during sleep in children seems less complex
than in adults (Manning et al. 2013) and that, not surprisingly, sleep deprivation
radically alters the connectivity of a number of brain networks including hippo-
campal networks (Kaufmann et al. 2016). The application of these other omics
methodologies to sleep research and their use in combination with genomics and
pharmacological testing will also allow the development of more efﬁcient strategies
to regulate wakefulness and sleep. Overall, we have deﬁnitely entered a ‘sleepomics’
era, which will contribute tremendously to understanding the determinants of brain
functions and health.
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Abstract
The cellular mechanisms governing the expression, regulation, and function of
sleep are not entirely understood. The traditional view is that these mechanisms
are neuronal. An alternative view is that glial brain cells may play important roles
in these processes. Their ubiquity in the central nervous system makes them well
positioned to modulate neuronal circuits that gate sleep and wake. Their ability
to respond to chemical neuronal signals suggests that they form feedback loops
with neurons that may globally regulate neuronal activity. Their potential role in
detoxifying the brain, regulating neuronal metabolism, and promoting synaptic
plasticity raises the intriguing possibility that glia mediate important functions
ascribed to sleep.
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1 Introduction
Glia refers to nonneuronal cells of the nervous system. The three main classes of
glia in the mammalian brain include astrocytes, microglia, and oligodendrocytes.
Astrocytes perform a number of “housekeeping” functions in the brain, including
buffering ions, recycling neurotransmitter, and regulating metabolism. Microglia are
the immune cells of the central nervous system and play critical roles in the response
to neural injury and cellular stress. Oligodendrocytes produce myelin and enwrap
axons and dysfunction in these cells leads to demyelination and disease. They are
considered non-excitable, as they do not produce action potentials and respond
linearly to current injections. For these reasons, they have historically been viewed
as supportive brain cells with no special or direct roles in brain activity or behavior.
However, through several different mechanisms, including neurotransmitter uptake,
ion transport, and direct chemical signaling (i.e., gliotransmission), glial cells can
alter the activity of surrounding neurons. This provides a means of inﬂuencing
behavior and brain activity (Fiacco et al. 2009; Halassa and Haydon 2010; Hamilton
and Atwell 2010). Therefore, glia are well positioned to control not only the
expression and regulation of sleep but also sleep functions (Fig. 1).
2 Glial Cells and Sleep Homeostasis
Sleep homeostasis refers to a regulatory mechanism that increases sleep drive, sleep
amounts, and sleep intensity as a function of prior time awake (Borbély and
Achermann 2000; Dijk and Lockley 2002). In contrast to the circadian clock,
which is well characterized anatomically and molecularly, the biological substrates
of sleep homeostasis are poorly understood. Several sets of ﬁndings support a role
for glia in this type of sleep regulation.
Fig. 1 Glial cells involved in sleep expression, regulation, and function. The three main classes of
glia in the mammalian brain include astrocytes, microglia, and oligodendrocytes. All three types of
glia may play important roles in mammalian sleep, either by the secretion of somnogenic
substances, uptake of neurotransmitter, detoxiﬁcation of metabolic wastes, or providing energy
substrates to neurons
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2.1 Exocytosis of Somnogenic Substances
Glial cells in vitro release a variety of molecules that when injected either systemi-
cally or into the brain can increase sleep time or non-rapid eye movement (NREM)
slow-wave activity (SWA). For example, the cytokine IL-1 derived from cultured
mouse astrocytes increases NREM sleep in rats when administered into the ventric-
les (Tobler et al. 1984). Cultured astrocytes also secrete neurotrophins (e.g., brain-
derived neurotrophin factor (BDNF)), prostaglandins (PGD2), and the cytokine
tumor necrosis factor (TNFα) that increase sleep time or intensity (e.g., NREM
SWA) when injected intraventricularly and/or infused applied to the neocortex
(Kushikata et al. 1999; Hayaishi 2002; Huang et al. 2007; Faraguna et al. 2008;
Krueger 2008). Astrocytes exocytose additional chemical transmitters that modulate
neuronal excitability, including adenosine triphosphate (ATP) which is hydrolyzed
to adenosine in the extracellular space (Pascual et al. 2005; Halassa et al. 2009a).
This latter observation is particularly important because adenosine is considered a
key mediator of mammalian sleep homeostasis.
Although these ﬁndings are intriguing, astrocytes in vitro often show very
different properties than cells in vivo (Yamamoto et al. 1988; Inagaki and Wada
1994). In addition, although mutant mice lacking the TNFα, interleukin (IL)-1, and
purinergic receptors have sleep phenotypes consistent with this general hypothesis
(i.e., reduced NREM sleep amounts and intensity), it is not known if this reﬂects
neuronal or astrocytic inﬂuences, as neurons release and respond to many cytokines
as well. Therefore, determining the precise role of astrocyte cytokine signaling in
sleep requires selective manipulations of these signaling pathways in vivo.
This was achieved by manipulating one mechanism of astrocytic exocytosis
in vivo. Gliotransmission involves the vesicular release of substances such as ATP
via proteins similar to those involved in synaptic release of neurotransmitters
(Pascual et al. 2005; Halassa et al. 2009a). The precise mechanisms of gliotrans-
mission are debated (Parpura and Zorec 2010; Nedergaard and Verkhratsky 2012),
but for some gliotransmitters, exocytosis may depend on the formation of a SNARE
complex between vesicles and the target membrane (Scales et al. 2000). Conditional
astrocyte-selective expression of a soluble SNARE domain of the protein synaptob-
revin II prevents both tonic and activity-dependent extracellular accumulation of
adenosine that acts on A1 receptors in situ (Pascual et al. 2005). The expression of
this mutation acts as a dominant/negative (dn)protein which inhibits the normal
function of the endogenous SNARE.
The role of SNARE-dependent gliotransmission in sleep homeostasis was
investigated in vivo using the tet-off system (Morozov et al. 2003). This allows
for conditional expression of a dnSNARE transgene selectively in astrocytes in
adult mice (Pascual et al. 2005). Suppressing gliotransmission in vivo had surpris-
ingly little effect on baseline sleep-wake architecture (Halassa et al. 2009b), but
behavioral and EEG indices of sleep homeostasis (NREM SWA) were attenuated.
More speciﬁcally, inhibiting gliotransmission signiﬁcantly reduced compensatory
increases in NREM SWA, sleep time, and sleep continuity. These results are best
interpreted as a reduction in adenosine. For example, the dnSNARE phenotype was
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“phenocopied” in wt mice via antagonism of the A1 receptor (Halassa et al. 2009b).
The dnSNARE mutation reduces the normal accumulation of adenosine during
sleep deprivation (Schmitt et al. 2012) and produces a phenotype similar to that in
mice with abnormal purinergic signaling (Huang et al. 2005; Krueger et al. 2010). A
role for gliotransmission in sleep homeostasis is further supported by studies using
optogenetic activation of astrocytes in vivo. This technique increases gliotrans-
mission of ATP (Losi et al. 2017), and optogenetic activation of astrocytes surround-
ing waking circuits (i.e., histaminergic neurons) increases sleep time and intensity
(Pelluru et al. 2016). Gliotransmission of other molecules (D-serine and glutamate)
may also play a key role in producing cortical oscillations typical of NREM sleep
(Fellin et al. 2009; Poskanzer and Yuste 2016) (Fig. 2).
Cerebral microglia and oligodendrocyte cells also secrete a number of substances
in vitro known to inﬂuence sleep or brain activity in sleep (e.g., cytokines,
prostaglandins, and nitric oxide) (Matsui et al. 2010). Because sleep deprivation is
associated with an increase in markers of cellular stress, it has been proposed that
substances secreted by microglia may play a central role in sleep regulation (Wisor
et al. 2011a, b). For example, attenuation of microglia reactivity with minocycline
reduces the normal compensatory increases in NREM SWA in mice following sleep
deprivation (Wisor and Clegern 2011). Interestingly, microglia contain membrane-
bound purinergic receptors, providing a means of interaction with astrocyte-derived
ATP and adenosine (Haynes et al. 2006; Gyoneva et al. 2009). On the other hand,
Fig. 2 Astrocytes as integrators of sleep need. Astrocytes respond to neurotransmitters and
neuromodulators with slow changes in intracellular calcium concentrations. Consequently,
astrocytes may use intracellular calcium oscillations to register and integrate surrounding neuronal
activity during wakefulness. This may lead to progressively higher rates of negative feedback (e.g.,
via gliotransmission) that dampen the “waking” signal and promote sleep. One prediction of this
hypothesized relationship is that the amplitude or period of intracellular calcium oscillations should
be proportional to sleep drive. Therefore, intracellular calcium concentrations (or period frequency)
are predicted to be low at the end of the sleep period and maximal at the end of the active period.
Alternatively (or in conjunction), astrocytes may respond to waking signals by expanding and then
contracting their distal processes. This can bring glial neurotransmitter uptake or gliotransmitter
release mechanisms in closer proximity to synapses as a function of synaptic activity (adapted)
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a putative transducer of microglial-mediated effects (the toll-like receptor 4 (TLR4))
does not appear to play a central role in sleep brain activity. Constitutive deletion of
TLR4 minimally impacts NREM SWA under baseline conditions or after sleep
deprivation (Wisor et al. 2011a). Oligodendrocytes are a source of prostaglandin
D2 in the mature brain, which has been shown to be a potent sleep-inducing
substance when applied exogenously (Urade and Hayaishi 2011). In addition to
increasing behavioral indices of sleep, stimulation of D2 receptors increases NREM
SWA in a physiological manner (Urade and Hayaishi 2011). However, in contrast to
astrocytes, much less is known about how microglia and oligodendrocytes exocytose
somnogenic substances. It is also unknown what signals normally trigger the release
of these substances across the sleep-wake cycle.
2.2 Uptake and Transport
Glia can also modulate synaptic activity by passive and active transport of ions,
neurotransmitters/neuromodulators, and movement of molecules via gap junctions.
In addition to gliotransmission of ATP, astrocytes can control extracellular adeno-
sine concentrations via adenosine kinase (ADK). Deletion of ADK in astrocytes
results in an accumulation of adenosine in the extracellular space and an attenuation
of the normal discharge of sleep need (as measured by NREM SWA). Whether this
reﬂects direct effects on sleep homeostasis is unclear, as this also results in a general
“leakage” of SWA into all brain states (Greene et al. 2017). The movement of small
molecules between glial cells may also promote SWA. Blockade of cortical astro-
cytic gap junctions in vivo reduces anesthesia-induced neuronal synchronization,
which is similar (though not identical) to the synchronization underlying NREM
SWA (Szabó et al. 2017).
Astrocytes buffer ions which may further facilitate synchronized neuronal activ-
ity necessary for NREM SWA (Crunelli et al. 2002). For example, astrocytes in
thalamic slices (in situ) exhibit spontaneous intracellular calcium oscillations that
fall within “slow” EEG bands (<0.1 Hz). These oscillations can propagate within the
slice and elicit NMDA currents in neighboring neurons. This particular coupling
between neurons and astrocytes may not be related to the EEG rhythms of sleep, as it
predominates at ages when thalamocortical and intracortical EEG activities typical
of adult sleep are absent (Crunelli and Hughes 2010). The thalamus also does not
appear to be required for NREM cortical slow-wave activity (SWA) (Fuller et al.
2011; but see Crunelli et al. 2011). More compelling evidence that astrocytes
contribute to slow, EEG rhythms of sleep via ion buffering comes from studies
using dual intracellular recording in cortical astrocytes and neurons (Amzica and
Neckelmann 1999; Amzica 2002; Amzica and Massimini 2002). These investigators
showed that astrocyte membrane polarization and capacitance oscillate in phase with
NREM SWA, suggesting that the cation buffering by these cells may also contribute
to cortical oscillations in sleep.
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2.3 Morphological Changes in Glia
Glia can be quite dynamic either by proliferating rapidly or extending and retracting
their processes in response to changes in the neural environment. This can bring their
membranes and the embedded transporters, uptake mechanisms, and vesicle release
apparatus closer or further to synapses. Therefore, as originally suggested by Ramon
y Cajal (reviewed in García-Marín et al. 2007), morphological changes in glia across
the sleep-wake cycle may be a key step in glial control of sleep. Morphological
changes in astrocytes have been reported following acute and chronic sleep depriva-
tion in mice. In these studies, serial block face scanning electron microscopy was
used to reconstruct astrocytic processes that surround synapses (peri-synaptic pro-
cesses: PAPs). It was found that sleep deprivation caused the PAPs to move closer to
synapses in layer 2 of the cortex. Molecular analyses of astrocytes further revealed
that a number of genes implicated in PAP extension were also upregulated by
waking (Bellesi et al. 2015). In addition, an important molecule involved in PAP
morphology (Fabp7) was shown to cycle in tandem with the sleep-wake cycle in
rodents (Gerstner et al. 2012), and mutations in the Fabp7 gene reduced sleep bout
length in ﬂies, man, and mice (Gerstner et al. 2017). Interestingly, oligodendrocytes
were shown to proliferate during sleep (with positive correlations with REM sleep).
This was accompanied by an increase in the cortical expression of oligodendrocyte
genes implicated in phospholipid synthesis and myelination (Bellesi et al. 2013).
3 Glial Cells and Sleep Function
Glia mediate several neural processes that have historically been theorized to be
important functions of sleep. These include brain metabolism, neural detoxiﬁcation
and repair, and synaptic plasticity. Therefore in addition to potentially playing
central roles in sleep regulation, glia may also govern critical functions ascribed to
sleep.
3.1 Metabolism
Sleep is thought to be a restorative brain state that relieves the metabolic cost of
wakefulness (Frank 2010). How sleep achieves this putative function (and what is
restored) is unknown, but this idea is supported by several ﬁndings. For example,
brain metabolism is reduced (overall) during sleep compared to wakefulness (Hyder
et al. 2013; but see Shannon et al. 2012). Sleep is also accompanied by increased
synthesis of proteins and neural energy substrates (Ramm and Smith 1990; Kong
et al. 2002; Dworak et al. 2010; Clegern et al. 2012; Seibt et al. 2012). Astrocytes are
well positioned to inﬂuence these processes. In many parts of the brain, astrocytic
processes not only surround synapses but are in close approximation to blood vessels
(via “end feet”). This provides for nutrient uptake and the regulation of blood ﬂow
via constriction and dilation of vessels (Takano et al. 2006; Kreft et al. 2012).
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Astrocytes also contain energy substrates than can be rapidly mobilized and used by
neurons (lactate and glycogen) (Magistretti 2011).
Early and suggestive ﬁndings that support a role for glia in sleep-mediated
metabolism were reported by Hyden and Lange. They found sleep-wake rhythms
in succinooxidase (a key enzymatic step in the Krebs cycle) activity in neurons and
glia (type not speciﬁed). Glia showed reduced succinooxidase activity and neurons
heightened activity during sleep (Hyden and Lange 1965). The authors proposed that
“neuron and glia form a functional unit” and that an exchange of signaling molecules
between these cell types might inﬂuence sleep.
According to the Benington-Heller hypothesis, the transferred molecules
included glucose. It was proposed that astrocytic glycogen – which acts as a reserve
glucose store for neurons – is depleted during wakefulness and restored during
NREM sleep. The depletion of glycogen was mediated by the heightened release
of excitatory neurotransmitters during wake which through enzymatic mechanisms
convert astrocytic glycogen into glucose. The utilization of this glucose by neurons
(and the subsequent hydrolysis of ATP to adenosine monophosphate) leads
to an increase in neuronal adenosine production – which diffuses across the cell
membrane. Adenosine, acting on adenosine1 receptors, then reduces neuronal
excitability. The restoration of glycogen is favored by states with reduced release
of excitatory neurotransmitters, such as NREM sleep (Benington and Heller 1995).
In support of the theory, sleep deprivation increases the concentration of mRNA
transcripts involved in glycogen metabolism and glycogen synthase activity (Petit
et al. 2002, 2010). However, studies of cerebral glycogen across sleep and wakeful-
ness generally do not support this theory. While one study showed decreases in brain
glycogen content following sleep deprivation and increases following recovery sleep
(Kong et al. 2002), these ﬁndings were not replicated by other labs (Gip et al. 2002,
2004; Franken et al. 2003; Zimmerman et al. 2004; Petit et al. 2010).
One alternative mechanism is the neuronal-glial “lactate shuttle,” according to
which synaptic glutamate release triggers lactate production and release in astrocytes
(reviewed in Magistretti 2011). In support of this idea, brain lactate levels increase
during wakefulness and decrease during NREM sleep in parallel with NREM SWA
(Dash et al. 2012; Naylor et al. 2012; Wisor et al. 2012). A number of genes
important in cerebral metabolism (Bellesi et al. 2015) and the lactate shuttle are
speciﬁcally upregulated in cortical astrocytes after sleep deprivation (Petit et al.
2013). This is consistent with observations that astrocytic metabolic pathways are
activated to a greater degree during wakefulness. Astrocytes may also provide
energetic support speciﬁcally to neurons involved in wakefulness. Astrocytes pro-
vide energetic support (via lactate) to hypocretin neurons involved in wakefulness
and state stability. Mice with a mutation in this process are unable to sustain normal
amounts of wakefulness (Clasadonte et al. 2017).
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3.2 Detoxification and Repair
As originally proposed at the beginning of the twentieth century, the “hypnotoxin”
theory of sleep function posited that sleep removes a noxious by-product of the waking
brain (Ishimori 1909). Modern versions of this theory propose that sleep reverses or
protects against neuronal damage caused by prolonged glutamate release or oxidative
processes that occur during wakefulness (Reimund 1994; Inoue et al. 1995; Schulze
2004). The evidence in support of the hypnotoxin theory has been rather mixed. For
example, there is no compelling evidence that sleep loss produces neural damage as
might be expected by unchecked oxidative processes or the accumulation of a toxin
(reviewed in Frank 2006). However, more subtle but important detoxiﬁcation/repair
processes may occur during sleep due to astrocytic and microglia activation. It was
shown that during sleep (or anesthesia) there is an increased clearance of extracellular
proteins from the brain interstitial ﬂuid. This involves a ﬁltration system provided by
astrocytes (the “glymphatic” system) (Xie et al. 2013). The bulk ﬂow/convective ﬂow
of brain interstitial ﬂuid is greatly attenuated by sleep deprivation (Achariyar et al.
2016), which may lead to the accumulation of proteins such as beta-amyloid and
apolipoprotein E, isoforms of which are linked to neurodegeneration (Yulug et al.
2017). Sleep deprivation also produces microglial activation and astrocytic phagocy-
tosis. These latter changes may play an important role in the removal of metabolic
waste products and/or synaptic proteins and membranes that accumulate during
waking (Bellesi et al. 2017).
3.3 Synaptic Plasticity
Synaptic plasticity is deﬁned as changes in the strength of existing synapses (synap-
tic efﬁcacy), changes in synapse number or size, or changes in morphological
structures that contain synapses (e.g., dendritic spines and presynaptic boutons)
(De Roo et al. 2008; Sala and Segal 2014). Sleep has long been suspected to play
an important role in synaptic plasticity, and glial cells may mediate this important
putative function. Astrocytes and microglia profoundly inﬂuence synaptogenesis
and synaptic pruning during early development. There is also accumulating evidence
that these glial cells modulate both Hebbian and non-Hebbian forms of plasticity
in vitro and in vivo (Volterra 2013; Stogsdill and Eroglu 2017). Glia cells inﬂuence
plasticity through several processes, including metabolic support; glutamate uptake;
exocytosis of growth factors, adhesion molecules, and gliotransmitters; and phago-
cytosis (Volterra 2013; Stogsdill and Eroglu 2017).
It is currently unknown if glial cells mediate sleep-dependent plasticity. However,
this is suggested by several ﬁndings. Sleep deprivation increases glial-mediated
phagocytosis of cortical synapses, which is consistent with synaptic pruning during
sleep (Bellesi et al. 2017). Sleep is also accompanied by higher brain concentrations
of the glial-derived cytokine TNF-α, which promotes non-Hebbian synaptic poten-
tiation (Krueger 2008). In addition astrocytes (Imamura et al. 1993) and microglia
(Sipe et al. 2016) are required for a classic form of visual cortical plasticity (ocular
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dominance plasticity) that is highly sleep-dependent and involves both synaptic
weakening and strengthening (Frank 2015). Collectively, these ﬁndings suggest
that glia may mediate diverse forms of plastic remodeling in the sleeping brain.
4 Conclusions
The precise role of glia in sleep regulation and function is only now beginning to be
explored. Consequently, there are many important unanswered questions. The relative
contribution of different glia subtypes to sleep is poorly understood, as is the relative
importance of various glial mechanisms (e.g., gliotransmission, ion buffering, gluta-
mate clearance, metabolic support, and non-vesicle-mediated exocytosis (Magistretti
2011; Nedergaard and Verkhratsky 2012; Verkhratsky et al. 2012)). It is also not clear
where in the brain glia exert their effects on sleep. Astrocytes, for example, are
dispersed widely in subcortical and cortical brain areas (Zhang and Haydon 2005)
including regions known to trigger sleep and wakefulness (Halassa et al. 2009b).
Therefore, they may regulate sleep and brain activity by acting globally throughout the
cerebrum, via modulation of canonical sleep and arousal centers, or both (Benington
and Heller 1995; Strecker et al. 2000; Szymusiak et al. 2007; Krueger et al. 2008).
The precise signaling pathways linking neuronal activity and glial-mediated sleep
processes are also unknown. Astrocytes and microglia in vivo express a number of
membrane-bound receptors for neurotransmitters and peptides, which could mediate
neuronal-glial transduction pathways critical for sleep regulation and function.
Theoretically, these receptors as well as other membrane-bound peptides could
provide new pharmacological targets for arousal and sleep disorders. For example,
the astrocyte-speciﬁc water transporting protein aquaporin 4 inﬂuences processes
that could impact sleep and wake (neuronal excitation and neuroinﬂammation).
Several laboratories are developing compounds that target this protein (Verkman
et al. 2017). A different strategy is to repurpose existing compounds (which may
have failed as neuronal-targeted compounds) as novel glial pharmacopeia (Dale et al.
2016). The development of novel delivery systems that speciﬁcally deliver drugs to
glial cells provides yet another strategy. This may be achieved through the develop-
ment of nanoparticles or polymers coated with surface peptides or lipids that result in
the selective uptake by glia (Madhusudanan et al. 2017). Despite these promising
steps, the development of glial-speciﬁc compounds remains very challenging
(Möller and Boddeke 2016; Madhusudanan et al. 2017).
Investigating glia in vivo with the same precision as used in neurons has histori-
cally been very difﬁcult. This situation is rapidly improving with the development
of new tools designed for use in glia. A number of glial-speciﬁc promoters have
been identiﬁed, and when expressed in conjunction with Cre-Lox, or viral vector
strategies, they can be used to selectively delete or express molecules of interest in
glial cells in vivo. The use of calcium indicator ﬂuorescent proteins (i.e., GCaMPs)
has revolutionized the study of astrocytes, as these cells are electrically silent and
instead signal with changes in intracellular calcium (Bazargani and Attwell 2016,
2017; Kjaerby et al. 2017; Losi et al. 2017). Optogenetics has also been used to
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trigger gliotransmission (although the mechanisms at play are unclear) (Bazargani
and Attwell 2016, 2017; Kjaerby et al. 2017; Losi et al. 2017). The future application
of these techniques in freely behaving animals will be key to a deeper understanding
of how glia and neurons contribute to sleep regulation and function.
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Abstract
Wakefulness and sleep are highly complex and heterogeneous processes, involv-
ing multiple neurotransmitter systems and a sophisticated interplay between
global and local networks of neurons and non-neuronal cells. Macroscopic
approaches applied at the level of the whole organism, view sleep as a global
behaviour and allow for investigation into aspects such as the effects of insufﬁ-
cient or disrupted sleep on cognitive function, metabolism, thermoregulation and
sensory processing. While signiﬁcant progress has been achieved using such
large-scale approaches, the inherent complexity of sleep-wake regulation has
necessitated the development of methods which tackle speciﬁc aspects of sleep
in isolation. One way this may be achieved is by investigating speciﬁc cellular or
molecular phenomena in the whole organism in situ, either during spontaneous or
induced sleep-wake states. This approach has greatly advanced our knowledge
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about the electrophysiology and pharmacology of ion channels, speciﬁc
receptors, intracellular pathways and the small networks implicated in the control
and regulation of the sleep-wake cycle. Importantly though, there are a variety of
external and internal factors that inﬂuence global behavioural states which are
difﬁcult to control for using these approaches. For this reason, over the last few
decades, ex vivo experimental models have become increasingly popular and
have greatly advanced our understanding of many fundamental aspects of sleep,
including the neuroanatomy and neurochemistry of sleep states, sleep regulation,
the origin and dynamics of speciﬁc sleep oscillations, network homeostasis as
well as the functional roles of sleep. This chapter will focus on the use of small
neuronal networks as experimental models and will highlight the most signiﬁcant
and novel insights these approaches have provided.
Keywords
Global · In vitro · In vivo · Local · Sleep · Small networks
1 Introduction: From Global Sleep to Small Networks
Waking and sleep are distinguished by characteristic changes in behaviour, sensory
processing and brain activity. The majority, if not all organisms investigated to date
exhibit sleep-like behaviour, which spans a diverse range of vertebrate and inverte-
brate species from the well-studied rodent models to the microscopic nematode
worms (Allada and Siegel 2008; Campbell and Tobler 1984; Raizen et al. 2008;
Tobler 2005). While the minimum requirements and sufﬁcient conditions for sleep
remain unclear, a prevailing view is that sleep occurs in any organism with a
neuronal/glial network (Krueger et al. 2016). This view suggests that the size of
the network and/or its speciﬁc cellular composition may play a signiﬁcant role in
determining the amount, architecture and spatio-temporal dynamics of sleep, as well
as many other characteristics. The size of the nervous system in general, and the
brain in particular, differs several orders of magnitude among mammalian species,
and even more so if invertebrates are included (Buzsaki et al. 2013). According to
recent estimates, human brains are around ﬁve times larger than would be expected
for a mammal of its body size, consisting of approximately 86 billion neurons, of
which 16 billion are located in the cerebral cortex and 69 billion in the cerebellum
(Azevedo et al. 2009). On the other hand, the entire nervous system of C. elegans
consists of only 302 neurons, yet these simple organisms are still able to enter
putative sleep-like states (Mackiewicz et al. 2008). Human studies have shown
that large-scale brain networks exhibit complex dynamics during waking and
sleep, including the emergence of stage-speciﬁc spatial patterns of functional
organisation during sleep (Ramot et al. 2013; Watanabe et al. 2014). The many
complex and highly dynamic interactions between neuronal networks, as well as
their biochemical and genetic underpinnings, represent signiﬁcant obstacles for
investigating the cellular and network properties of sleep, its possible functions
and how pharmacological interventions may be used to manipulate sleep. As
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human studies are limited by numerous technical and ethical implications, in vitro
and in vivo models have instead been developed to perturb localised networks and
therefore further our basic understanding of sleep. Importantly, these approaches
also enable external factors such as the environmental conditions to be controlled,
which are known to have profound inﬂuences on many aspects of sleep and
associated network dynamics.
The functional role of sleep in larger-scale processes, such as behaviour or
metabolism, can be investigated using in vivo approaches, through stimulation,
ablation or recording speciﬁc neuronal populations in situ, during physiological
waking, sleep or a sleep-like state such as anaesthesia. Although these approaches
typically only target small parts of the network, their function can be investigated in
the context of the rest of the brain. These models are however constrained by
technical limitations, such as the number of neurons or brain regions that can be
recorded simultaneously. Furthermore, the causal relationship between speciﬁc
patterns of activity in a small brain region and global changes in behaviour are
usually difﬁcult to ascertain using these methodologies. It is therefore important to
utilise small network model systems, both in vitro and in vivo, to provide further
insights into the neural circuitry and the biochemical molecules governing sleep
regulation.
Simple ex vivo/in vitro/in silico models have reliably reproduced several of the
essential characteristics of sleep, allowing relevant phenomena to be studied at the
level of small circuits, rather than across the entire brain. Importantly, these
methodologies have important shortcomings, namely, that the afferent and efferent
connectivity of the network is largely disrupted, which may result in the occurrence
of nonphysiological activity patterns, such as epileptic discharges or a persistent
hyperpolarisation, not present under physiological conditions in vivo (Lemieux et al.
2014). Furthermore, while such a reductionist approach is necessary for understand-
ing sleep as a whole, it is becoming increasingly clear that local level activity likely
dictates larger-scale brain organisation. Therefore, it is crucial to utilise an integrated
approach which takes into account the complex nonlinear interactions between
smaller and simpler processes at many spatial and temporal scales. In this chapter
we highlight some of the most important advancements these model systems have
provided to the sleep ﬁeld and discuss their pharmacological applications.
2 Local Network Activity and Sleep Regulation
Brain activity during waking and sleep is traditionally studied by recording the
electroencephalogram (EEG, electrodes typically on cortical surface) or local
ﬁeld potentials (LFP, electrodes in deeper brain structures) (Buzsaki et al. 2012). It
is now well established that rhythmic activity in the neocortex arises from speciﬁc
interactions between excitatory and inhibitory neurons, intrinsic membrane
properties and synaptic activity (Buzsáki 2006). The interaction between a positive
feedback loop (e.g. recurrent excitation) and negative feedback control
(e.g. inhibition) contributes to the generation of oscillatory activities in the neocortex
Sleep- and Wake-Like States in Small Networks In Vivo and In Vitro 99
and subcortical areas (Buzsaki et al. 2012; McGinley et al. 2015). There are several
types of brain oscillations during waking and sleep, which are arranged in a hierar-
chical system to maintain the local-global integration of network activity (Buzsáki
2006; Molle and Born 2011; Staresina et al. 2015). Notably, these network
oscillations are conserved across organisms, regardless of brain size (Buzsaki et al.
2013), and so the results obtained from various laboratory animals are likely to
generalise across species.
The brain is generally more metabolically and electrically active during waking
(Braun et al. 1997; Kennedy et al. 1982; McKillop et al. 2018; Vyazovskiy et al.
2009). During sleep, slow waves recorded with cortical EEG or LFP electrodes
reﬂect the synchronous occurrence of periods of reduced spiking and synaptic
activity within thalamocortical networks (Crunelli et al. 2015; Destexhe et al.
1999; Neske 2016; Timofeev 2013; Vyazovskiy and Harris 2013). These so-called
OFF periods become increasingly frequent the longer the duration of preceding
wakefulness and are most prominent during the initial deep NREM sleep occurring
immediately after periods of wakefulness (McKillop et al. 2018). These changes at
the network level modulate the amplitude and incidence of EEG or LFP slow waves
in a sleep-dependent manner, observed both in laboratory animals and humans
(Lazar et al. 2015; Riedner et al. 2007; Vyazovskiy et al. 2009). This in turn
underpins the well-established dynamics of EEG slow-wave activity (SWA,
0.5–4 Hz), which increases as a function of preceding wake duration and decreases
during subsequent sleep (Borbély 1982; Dijk et al. 1987; Franken et al. 1991;
Guillaumin et al. 2018; Vyazovskiy 2015; Vyazovskiy et al. 2002, 2007). Sleep
homeostasis is a ubiquitous phenomenon found in all animal species carefully
studied so far, suggesting that it is a fundamental function (Tobler 2005).
The notion that sleep is not a global process, but rather concerns local circuitries
or speciﬁc parts of the brain goes back almost a century. Maria Manasseina noted
that “the scientists recognizing sleep for stopping or diastole of cerebral activity are
mistaken, for during sleep the brain as a whole does not sleep at all, it does not stay
idle entirely, but only those parts of it which constitute an anatomical basis, anatomic
substrate of consciousness are under the process of sleeping” (Kovalzon 2009).
Similarly, Giuseppe Moruzzi suggested that “sleep concerns primarily not the
whole cerebrum, nor even the entire neocortex, but only those neurons or
synapses . . . which during wakefulness are responsible for, or related to, the brain
functions concerned with conscious behavior” (Moruzzi 1972). In vitro studies have
provided the most consistent evidence for sleep being a fundamentally local process,
showing that cortical networks are capable of generating localised activity indepen-
dent of the rest of the brain. In 1949 Kristiansen and Courtois observed the
occurrence of sleep- and wake-like states in isolated portions of the cortex, similar
to that observed in the intact cortex. An important impetus for this research direction
was provided by the theory of local, activity-dependent regulation of sleep, which
postulated that rather than being a global process that is bottom-up regulated, sleep
instead originates locally in neuronal circuits and it is rather the synchronisation of
many circuits together which leads to global sleep at the macroscopic level (Krueger
and Obal 1993; Krueger et al. 2008; Roy et al. 2008; Van Dongen et al. 2011).
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According to the early version of this theory, “sleep serves to stimulate the use of
structures insufﬁciently activated during wakefulness”, or in other words, the func-
tion of sleep is to reinforce speciﬁc synapses relative to others (Krueger and Obal
1993). This theory was subsequently developed to take a broader view in which
global sleep and wake states are the result of bottom-up processes whereby large
numbers of localised yet highly interconnected semi-autonomous cellular networks
of neurons and glia oscillate in a semi-autonomous manner (Krueger et al. 2013).
Considerable evidence for the local regulation of sleep was provided by studies
in which multiple electrodes were used to simultaneously record activity from
multiple brain regions (Finelli et al. 2001; Siclari et al. 2014). These studies revealed
that EEG or LFP slow-wave activity (SWA, 0.5–4 Hz) occurs in a regional
use-dependent fashion, with brain regions more active during wakefulness showing
higher SWA during subsequent sleep (Kattler et al. 1994; Riedner et al. 2007;
Vyazovskiy et al. 2011a). For example, unilateral vibration of the hand of human
subjects or whiskers of rodents led to an increase in SWA during subsequent sleep,
speciﬁcally in those cortical areas stimulated by the vibration (Kattler et al. 1994;
Vyazovskiy et al. 2000). Localised sleep-like activity in the EEG has also been
shown to occur in behaviourally awake animals, with the increased incidence of
localised slow waves leading to a reduced performance in a food pellet reaching task
(Vyazovskiy et al. 2011b). This led to the theory that optimal performance involves
an interaction between multiple networks and that the occurrence of sleep-like
activity in one or more of these networks can have a detrimental effect on perfor-
mance (Krueger et al. 2013; Vyazovskiy 2013). Therefore, given the extensive
evidence for the local regulation of sleep in both cortical and subcortical networks
(see below), multiple aspects of sleep can be understood by investigating sleep
network dynamics in simple models.
The idea that sleep is locally controlled is now supported by numerous studies
that utilised in vivo small network systems and in vitro studies to investigate the
cellular and network properties of sleep initiation and regulation. In vivo chronic
recordings have been instrumental in investigating the activity of localised distinct
cortical regions, without disrupting the connectivity to other brain networks. For
example, Pigarev et al. (1997) was one of the ﬁrst studies to suggest that sleep may
indeed initiate at the level of local small cortical networks. This study showed that in
monkeys a topographically deﬁned subset of neurons in the visual cortex failed to
ﬁre in response to stimulation while performing a visual task. Individual cortical
columns have also been shown to have localised state-dependent activity, oscillating
between sleep- and wake-like states, as deﬁned by the amplitude of event related
potentials (ERPs), with higher amplitude ERPs identiﬁed during sleep (Krueger et al.
2013; Rector et al. 2005, 2009). Cortical columns have therefore been suggested to
be the most basic unit capable of oscillating between sleep and wake states (Rector
et al. 2005). Asynchronous transitions between waking and sleep have also been
shown at the level of individual cortical neurons (Vyazovskiy et al. 2014), while
local slow waves have also been observed in awake behaviourally active animals
(Einstein et al. 2017; Fisher et al. 2016; Polack et al. 2013; Vyazovskiy and Harris
2013; Vyazovskiy et al. 2011b).
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The local occurrence of sleep-like states has a profound implication for sensory
processing and cognitive function in general. Various aspects of behaviour, brain
state and network activity account for the trial-to-trial variability in response to
stimuli (Ahissar et al. 1992; Arieli et al. 1996; Crochet et al. 2005; Fontanini and
Katz 2008; Haider et al. 2007; Krueger et al. 2008; Rector et al. 2005; Sanchez-
Vives and McCormick 2000; Scheeringa et al. 2011; Vyazovskiy et al. 2013).
Important determinants of neuronal responsiveness are preceding activity (Abbott
and Nelson 2000) and the brain-state-speciﬁc levels of neuromodulators
(McCormick et al. 1991), which impose both global and local synapse-speciﬁc
control (Gil et al. 1997; Laplante et al. 2005; Lawrence 2008; Marrocco et al.
1987). It is well established that brain states have a great inﬂuence on information
processing and local neuronal interactions (Zagha and McCormick 2014). Slow
oscillations have also been shown to affect the response of networks to synaptic
inputs (Reig et al. 2015), although this may depend on the cortical area being studied
and the type of stimulus (Sela et al. 2016). As during OFF periods all or most local
neurons are simultaneously deactivated or inhibited (Chauvette et al. 2011; Sanchez-
Vives et al. 2010; Timofeev et al. 2001) and do not produce spikes (Logothetis et al.
2010; Vyazovskiy et al. 2009), it is perhaps not surprising that the occurrence of
OFF periods would result in a disruption of short-range neuronal coordination which
may therefore contribute to behavioural lapses or a loss of consciousness
(Castelnovo et al. 2018; Nir et al. 2017; Pigorini et al. 2015; Vyazovskiy et al.
2011b).
It is important to remember that although local and global states likely represent a
continuum, the mechanistic origin of “local sleep” or “local wake” and global states
of vigilance may be fundamentally distinct. While more research is needed in this
area, there is little doubt that considering multiple levels of organisation may provide
important advancements in our understanding of sleep and its complexity (Olbrich
et al. 2011; Vyazovskiy 2015; Vyazovskiy and Delogu 2014). A recent study
provided evidence that in contrast to humans, where ageing is associated with
substantial changes in global sleep characteristics, including its architecture and
the EEG (Landolt and Borbely 2001; Mander et al. 2017), cortical neural activity
and local signatures of sleep homeostasis remain intact in laboratory rodents across
the lifespan (McKillop et al. 2018). Such studies highlight the importance of
investigating the network activity underpinning well-established global phenomena,
such as the reduction in SWA or increase in spindle-frequency spectral power after
administration of commonly used hypnotics and related substances (Borbely et al.
1985; Kopp et al. 2004a; Lancel 1999; Seibt et al. 2008).
3 Cortical Activity During Sleep: Insights from In Vivo
Approaches
A broad range of techniques are available for investigating network activity in vivo
at several spatio-temporal scales (Olcese and Faraguna 2015). These techniques
often involve the implantation of electrodes into the brain to record neuronal activity
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from either head ﬁxed (Blumberg et al. 2015; Saleem et al. 2010; Seibt et al. 2017;
Yüzgeç et al. 2018) or freely moving animals (Fisher and Vyazovskiy 2014;
McKillop et al. 2018; Meisel et al. 2017; Vyazovskiy et al. 2013; Watson et al.
2016). Early studies identiﬁed that during NREM sleep, oscillatory activity in the
slow-wave activity frequency range (SWA, 0.4–5 Hz) predominates the EEG/LFP
signal. At the neuronal level, this activity is underpinned by a bistable slow (<1 Hz)
oscillatory alternation in the membrane potential of cortical neurons, from a
depolarised up state caused by active neuronal ﬁring and synaptic activity to a
hyperpolarised down state where both spiking and synaptic activity are absent
(Neske 2016; Steriade 1978; Steriade et al. 1993). These hyperpolarisation periods
of synaptic silence and the decrease in neuronal ﬁring (named OFF periods when
referring to the synchronous silence across neuronal populations recorded extracel-
lularly) are important deﬁning features of NREM sleep and are largely the result of a
disfacilitation process, with leak currents (predominantly potassium currents)
dominating the underlying activity in the absence of other synaptic currents
(Timofeev et al. 2001). Rodent studies have performed continuous chronic
recordings of extracellular neuronal activity have been performed in rodents,
allowing for the association between ongoing vigilance state and network activity
to be investigated in vivo. These studies have shown that network down states in the
neocortex are consistently associated with surface negativity in the EEG signal or
positive potentials if recordings are performed from deeper cortical layers (using
LFP recordings), while slow waves correlate with near-synchronous transitions
between up and down states across cortical neurons (Steriade et al. 1993;
Vyazovskiy et al. 2009). Importantly, evidence suggests that the higher the spatial
synchrony and the longer the network down state, the larger the amplitude and
steeper the slope of the resultant EEG/LFP slow waves (Vyazovskiy et al. 2009). As
SWA is used as a physiological correlate of sleep homeostasis (Borbély 1982), this
indicates that both neuronal activity and global network EEG can reﬂect the homeo-
static regulation of sleep.
Importantly, these techniques have technical limitations which only allow a small
number of cortical or subcortical networks to be recorded simultaneously. In con-
trast, calcium imaging has provided a relatively unbiased way of simultaneously
imaging a large area of the cortex; although such recordings typically only record
from superﬁcial cortical layers, where neuronal population activity may differ from
deeper layers (Beltramo et al. 2013; Sakata and Harris 2012). Calcium imaging has
also been useful for recording cortical activity from zebraﬁsh (Leung et al. 2013) and
drosophila (Bushey et al. 2015); however recordings of small networks during
physiological sleep remain scarce. In vivo calcium imaging has revealed a global
reduction in neuronal network activity during sleep compared to waking in mice,
both in superﬁcial and deep cortical layers (Niethard et al. 2016). Curiously during
REM sleep neuronal activity was found to be further reduced (Niethard et al. 2016),
contradicting the increase identiﬁed by electrophysiological recordings (McKillop
et al. 2018; Vyazovskiy et al. 2009).
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4 Cortical Activity During Sleep: Insights from In Vitro
Approaches
In vitro and ex vivo studies have utilised neuronal cultures and brain slices to study
network phenomena, such as the slow oscillation. In vitro brain slice experiments
have provided important insights into the processes underlying sleep oscillations,
such as the role of rhythmic dendritic Ca2+ entry in thalamocortical neurons
(Errington et al. 2012), low-threshold discharges (Connelly et al. 2015), and network
bistability (Crunelli et al. 2005). Both in vivo and in vitro studies have consistently
shown that deep layers of the neocortex contribute substantially to the generation of
network slow oscillations (Beltramo et al. 2013; Chauvette et al. 2010; Fiath et al.
2016; Sakata and Harris 2012; Sanchez-Vives and McCormick 2000). It has also
been established that slow waves and their cellular counterpart – the slow oscillation
– have a preferential origin within frontal cortical areas and higher-order and
intralaminar thalamic regions (Sheroziya and Timofeev 2014). Therefore, different
dynamics may be identiﬁed depending on the cortical area used to prepare the brain
slices or neuronal cultures. It is possible that some cortical areas may be capable of
intrinsically generating slow oscillations, while others merely follow a driver or
modulatory inputs from distant areas. Notably, excitatory pyramidal neurons and
inhibitory interneurons in the neocortex exhibit different activity levels during
waking and likely have distinct contributions to the network slow oscillation
(Beltramo et al. 2013; Funk et al. 2017; Lemieux et al. 2015; Neske 2016; Timofeev
2013; Zucca et al. 2017). Many types of inhibitory neurons come together to form
the local inhibitory circuitry and have unique and distinct contributions to cortical
network activity and the regulation of global states (Gerashchenko et al. 2008;
Isaacson and Scanziani 2011; Jackson et al. 2016; Kvitsiani et al. 2013; Lemieux
et al. 2015; Morairty et al. 2013; Neske and Connors 2016; Staiger et al. 2009).
The main shortcoming of cortical slice preparations is that they may lack impor-
tant inputs from other cortical areas, and different cortical layers may be affected to
different extents (Stepanyants et al. 2009). It has been shown that the beginning of an
up state is associated with increased excitatory currents (Haider et al. 2006) and is
characterised by highly structured activity within a population of neurons (Luczak
et al. 2007). Notably, it has been shown that early EPSPs evoked by long-range
inputs arising from supragranular levels are remarkably voltage-dependent (Hirsch
and Gilbert 1991). Speciﬁcally, at the resting membrane potential, EPSPs are too
small and brief to lead to action potentials but grow several hundred folds with
membrane depolarisation (Hirsch and Gilbert 1991). Such state dependency implies
that speciﬁc long-range connections between distant cortical areas may only be fully
functional in an alert waking state, when supragranular neurons across the neocortex
are tonically depolarised (Petersen et al. 2003; Poulet and Petersen 2008). Severing
these inputs in slices could therefore make it impossible to achieve the full manifes-
tation of an alert wake state.
Finally, in silico small network models have also provided important insights
into various aspects of sleep research, including the generation of network slow
oscillations within the thalamocortical network and the roles of speciﬁc ionic
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conductances, such as persistent sodium and Ca2+-dependent K+ currents in
synaptic plasticity (Bazhenov et al. 2002; Esser et al. 2007; Hill and Tononi
2005). More recently, modelling approaches have been used to investigate the
relationship between synaptic pruning and the decline of slow-wave activity, well
documented to occur during adolescence (Hoel et al. 2016). Consistent with experi-
mental data, this model was capable of producing a reorganisation of intralaminar
connections to establish preferential connectivity between neurons with similar
receptive ﬁelds and preferred orientations, which in turn resulted in a reduction in
slow-wave activity and changes to slow-wave characteristics (Hoel et al. 2016).
5 Sleep as a Default State of Cortical Networks
It has recently been suggested that sleep has features of a “default state” (Sanchez-
Vives and Mattia 2014). This is supported by experimental evidence which showed
that neuronal cultures or isolated cortical slabs deprived of synaptic inputs can
spontaneously generate slow oscillations, usually characteristic of a sleep-like state
(Corner 2013; Hinard et al. 2012; Lemieux et al. 2014; Saberi-Moghadam et al.
2018). Therefore, in vitro mammalian cortical cell cultures have been useful for
providing a detailed understanding of the network dynamics of states reminiscent of
sleep (Wagenaar et al. 2005). It has been shown that after approximately 4 days of
cell culture, neocortical cells from embryonic day 18 rats begin to ﬁre and soon after
globally synchronise their ﬁring to form a recurring burst-pause ﬁring pattern around
0.5–2 s in duration (Wagenaar et al. 2005). In addition, after 2 weeks in culture,
dissociated cortical primary cultures from 3-day-old mice show action potential
burstiness and a synchronisation of slow electrical potentials between recording
electrodes (Jewett et al. 2015). High-density cultures of dissociated mammalian
neuronal/glial cell cultures show properties of sleep-like burst-pause ﬁring patterns
in vitro, reminiscent of that seen during NREM sleep in vivo (Chiappalone et al.
2006; Corner 2008; Hinard et al. 2012; Jewett et al. 2015; Krueger et al. 2016). It
should be noted that these cultures have longer inter-burst intervals compared to
in vivo recordings, and this can persist for the lifetime of the culture. It was proposed
that burst-ﬁring activity in culture may be due to the deafferentation of
thalamocortical neurons which in turn strengthens network connectivity (Wagenaar
et al. 2005). This view is consistent with the emergence of sleep-like activity in
deafferented cortical slabs (Lemieux et al. 2014; Timofeev et al. 2000).
Synchronised bursting is a network phenomenon, reﬂecting synaptic interactions
between a large number of disperse cells (Hinard et al. 2012; Saberi-Moghadam
et al. 2018; Wagenaar et al. 2005). The extent of synchronisation is dependent on the
fraction of active, tonically ﬁring cells, with evidence that a reduction in the number
of steadily ﬁring cells leads to bursting activity (Latham et al. 2000). Application of a
mixture of excitatory neurotransmitters (chemical stimulation) was able to change
the default sleep-like bustiness activity into a transient tonic ﬁring wake-like state,
which then spontaneously returned to a sleep-like state (Hinard et al. 2012; Saberi-
Moghadam et al. 2018). Cholinergic neuromodulation has been shown to play a
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signiﬁcant role in spontaneous rhythmic activity in neuronal cultures (Hammond
et al. 2013). Interestingly, application of excitatory neurotransmitters to cultures also
caused them to exhibit a gene expression proﬁle (transcriptome) similar to that of an
awake mouse or that seen after sleep deprivation (Hinard et al. 2012). However, this
study only applied the excitatory neurotransmitters to cultures once sleep-like
activity was observed and not before.
Electrical pulse stimulation of mature cultures has also been shown to result in
wake-like ﬁring patterns, suggesting that electrical stimulation is a sufﬁcient substi-
tute for natural afferent inputs to neurons, enabling the transition into wake-like
cortical activity (Jewett et al. 2015; Wagenaar et al. 2005). Notably, a subsequent
rebound was found in both the synchronisation between electrodes and slow-wave
power values poststimulation, suggesting that some manifestations of sleep homeo-
stasis can also be observed in vitro (Jewett et al. 2015; Saberi-Moghadam et al. 2018;
Wagenaar et al. 2005). Consistently, in vitro optogenetic stimulation of mature
neuronal cultures induced the release of adenosine triphosphate (ATP) and the
expression of interleukin-1 beta (IL1) and tumour necrosis factor (TNF) (Jewett
et al. 2015), all of which are known to be involved in sleep regulation (Clinton et al.
2011; Krueger et al. 2008; Van Dongen et al. 2011). Furthermore, application of
TNF to the culture was able to enhance burstiness, synchronisation and the magni-
tude of slow-wave power, suggesting that TNF application can induce a sleep-like
state reminiscent of deeper sleep stages (Jewett et al. 2015).
6 Thalamocortical Networks and Sleep Spindles
The thalamocortical network is essential for generating the full manifestation of
cortical activity patterns observed during sleep (Crunelli et al. 2015; David et al.
2013; Sheroziya and Timofeev 2014). According to the traditional model, the dorsal
thalamus receives inputs from ascending sensory pathways, including brainstem
cholinergic, noradrenergic or serotoninergic modulatory systems (Franks 2008;
Jones 2009; Steriade and Amzica 1998; Steriade et al. 1990). Thalamocortical
neurons send excitatory glutamatergic projections to the reticular (RE) thalamic
nucleus and the cerebral cortex, where they terminate in layers III, IV and VI of
the neocortex. The RE thalamic nucleus receives collaterals of thalamocortical
neurons, as well as corticothalamic glutamatergic inputs originating from layer VI
of the cortex (Steriade et al. 1986). All neurons within the RE thalamic nucleus are
GABAergic, although functional diversity between these neurons has been reported
(Halassa et al. 2014). In vitro brain slice experiments have been useful for
investigating intrathalamic network activity patterns and synaptic plasticity (Pigeat
et al. 2015). Speciﬁcally, it has been demonstrated that stimulation of brain slices in
the slow-wave activity frequency range during sleep leads to the development of
long-term depression (LTD) in the inhibitory synaptic connections between RE and
TC neurons (Pigeat et al. 2015). On the other hand, slice preparations have also been
useful for investigating the functional relationship between the thalamus and the
neocortex during slow oscillations (Crunelli and Hughes 2009; Neske 2016).
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Speciﬁcally, slices containing thalamocortical and cortical networks showed reduced
postsynaptic potentials during cortical up states, suggesting a reduction in the
thalamocortical input and a functional disconnection during network activity
(Watson et al. 2008). However, conﬂicting results have also shown that paired-
pulse facilitation was signiﬁcantly larger during network up states and persisted for
longer as compared to silent slices (Reig and Sanchez-Vives 2007).
Although the cellular and network mechanisms of the slow oscillation have been
extensively investigated using simple model preparations, other thalamocortical
oscillations are more difﬁcult to study. A notable example of a sleep-related phe-
nomenon which is difﬁcult to reproduce in vitro is the sleep spindle. EEG spindles
are oscillatory events (Olbrich and Achermann 2005) that occur predominantly
during NREM sleep (Astori et al. 2013; Vyazovskiy et al. 2004) and have been
described in several mammalian species (Buzsaki et al. 2013). Spindles are
generated within the reticular thalamic nuclei, where neurons typically exhibit a
bursting discharge pattern at frequencies 7–14 Hz (Bartho et al. 2014; Halassa
et al. 2014; Marks and Roffwarg 1993; Steriade et al. 1986). The rhythmic
hyperpolarisation of thalamocortical neurons leads to rebound spike bursts, which
are transferred to the neocortex as spindles (Steriade and Amzica 1998). As it is
difﬁcult to replicate, and therefore study sleep spindles in vitro, this has slowed the
advancement of understanding their functional role in normal brain function, as well
as how spindle deﬁcits may underlie diseases such as schizophrenia (Manoach et al.
2016).
7 Recordings Local Network Activity from Subcortical Areas
In Vivo and In Vitro
Simple model approaches usually target cortical networks and so other brain regions
remain under investigated. According to the prevailing view, global sleep and wake
are generated and maintained via a set of subcortical sleep- and wake-promoting
areas (Eban-Rothschild et al. 2018; Saper et al. 2010). Numerous subcortical areas
have been shown to play important roles in global sleep-wake control (Lee and Dan
2012) including the locus coeruleus (Aston-Jones and Bloom 1981), the tubero-
mammillary nucleus of the hypothalamus (Liu et al. 2010; Scammell et al. 2000),
dorsal raphe nuclei (Gervasoni et al. 2000; Jones 2004), the orexinergic area of the
hypothalamus (Kosse et al. 2015; Mileykovskiy et al. 2005), preoptic area of the
hypothalamus (Suntsova et al. 2007; Szymusiak et al. 1998) and other areas. These
subcortical neuromodulatory systems exert local inﬂuences on other wake- and
sleep-promoting neurons but also send distant projections to the neocortex, thalamus
and hippocampus, thus contributing fundamentally to the regulation of sleep
oscillations, local cortical states and global behaviours. The extensive projections
of these nuclei make it especially difﬁcult to investigate their functional role in sleep-
wake control, both in vitro and in vivo. Nevertheless, several studies have been
successful in investigating the response of speciﬁc neurons to common
neuromodulators and other substances.
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Most studies addressing the role of the ventrolateral preoptic area (VLPO) in
sleep regulation have utilised Fos immunoreactivity experiments (Sherin et al. 1996)
or electrophysiological recordings in slice preparations or neuronal cultures
(Tabarean 2013). VLPO neurons have been shown to produce powerful
low-threshold Ca2+ spikes (LTS) and are inhibited by the major wakefulness-related
neurotransmitters such as noradrenaline. Use of isolated VLPO tissue in acute slices
allows the potential interactions between subtypes of VLPO neurons to be studied.
VLPO neurons can be identiﬁed by their coexpression of GABA and galanin, their
low-threshold spike ﬁring and their sensitivity to noradrenaline (Chamberlin et al.
2003; Gallopin et al. 2000; Li et al. 2009; Liu et al. 2010). In vitro electrophysiologi-
cal classiﬁcation of VLPO neurons has been performed in mice, according to their
response to bath application of noradrenaline (NA) (Moore et al. 2012). These
experiments revealed that the VLPO contains a mixed population of both
noradrenaline-hyperpolarised (NA) and depolarised (NA+) neurons, in an approx-
imate 2:1 ratio, of which NA VLPO neurons are thought to be the putative sleep-
promoting subset.
Local network activity has also been successfully recorded from several other
subcortical structures in vivo. For example, it has been shown that the discharging of
neurons in the pedunculopontine tegmentum, although highly diverse, generally
correlates with wakefulness and REM sleep (Datta and Siwek 2002). VTA
GABAergic neurons were especially active during waking and movement, reduced
their spiking activity during NREM sleep and increased it again during periods of
REM sleep (Lee et al. 2001). Calcium imaging studies have shown that
glutamatergic neurons in the dorsal pons are also active during REM sleep (Cox
et al. 2016). Finally, local network interactions between MCH and orexin neurons in
the lateral hypothalamus have been investigated using localised recordings and
optogenetic stimulation (Apergis-Schoute et al. 2015).
8 Anaesthesia as a Sleep-Like State Model to Investigate
Network Activity
Anaesthesia is a widely used tool to study the circuit mechanisms of sleep
oscillations, subcortical control of sleep-wake states and the role of sleep in plasticity
(Beltramo et al. 2013; Ferron et al. 2009; González-Rueda et al. 2018; Kroeger and
Amzica 2007; Neske 2016; Zhang et al. 2015). Much of the existing knowledge
about the cellular and network mechanisms of slow oscillations was originally
obtained using anesthesia preparations. As anaesthesia shares several important
similarities with sleep, including the patterns of cortical activity and the involvement
of speciﬁc subcortical circuits, both electrophysiological and imaging approaches
often use anaesthesia as an experimental model for studying physiological
sleep (Civillico and Contreras 2012; Franks 2008; Hwang et al. 2013; Kuki et al.
2013; Neske 2016; Zhang et al. 2015). In addition, comparisons between sleep
and anesthesia have furthered our understanding of the mechanisms underlying
the effects of anaesthetics (Franks 2008). Two-photon calcium imaging of
neuronal activity in layer 2/3 of the mouse barrel cortex revealed that there is an
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increased network synchronisation under isoﬂurane, ketamine and urethane anaes-
thesia (Lissek et al. 2016). Cross-correlation analysis identiﬁed stable temporal
relationships between neurons under ketamine anaesthesia, where individual
neurons preferentially ﬁred during population up states (Luczak and Bartho 2012).
Putative inhibitory interneurons were found to be more active at the beginning
of up states, while the spiking activity of putative pyramidal cells was evenly
distributed across the entire up state (Luczak and Bartho 2012). Interestingly, the
slow oscillation has similar dynamics across several cortical areas (primary visual,
somatosensory, motor and medial prefrontal cortex), with the exception of the
prefrontal cortex which shows faster down-to-up state transitions and higher ﬁring
rates during up states (Ruiz-Mejias et al. 2011). Another study found that the
propagation of slow-wave activity in anesthetised animals shows a clear preferred
direction and often originates from the same location in the neocortex (Fucke et al.
2011). Under anesthesia the membrane potential during active states shows a low
correlation between distant neurons, despite transitions between periods of activity
and silence being synchronised (Volgushev et al. 2011). Importantly, properties of
slow waves are also used to clinically assess the depth of anaesthesia, through the
use of automated systems which provide continuous estimations of anaesthesia
depth using spectral analysis of the EEG (Berezowskyj et al. 1976; Olofsen et al.
2008; Voss and Sleigh 2007).
As different anaesthetics as well as anaesthesia depth may have differential
effects on parameters of slow waves, important differences between anaesthesia
and physiological sleep may be expected. However, surprisingly, only a few studies
have quantitatively addressed this. A recent study showed that cats under ketamine-
xylazine anaesthesia had slower slow waves that were more rhythmic and more
synchronous across the cortex (Chauvette et al. 2011). In contrast, the same study
found that down states were longer with a larger amplitude difference in membrane
potential around transitions between active and silent states, as compared to sleep. It
is well known that neuronal excitability is strongly correlated with ongoing network
ﬂuctuations between up and down states (Steriade 2001). This was highlighted by a
study which showed that in anesthetised animals the shape of evoked responses
varied signiﬁcantly from one trial to the next, with the variation highest under
medium levels of anaesthesia where cortical activity exhibits rhythmic population
bursting activity (Kisley and Gerstein 1999).
9 Pharmacological Manipulation of Sleep and Associated
Network Activities
Sleep disorders are highly prevalent in the population, commonly classiﬁed
into insomnia, hypersomnia and parasomnias. There are a number of ways to
improve sleep ranging from behavioural techniques using cognitive behavioural
therapy (CBT) for insomnia (Espie et al. 2007; Freeman et al. 2015; Morin
et al. 2006) or physiological techniques either targeting the circadian system
through chronotherapeutics (Wirz-Justice 2009) or sleep through pharmacological
interventions (Olfson et al. 2015). Although the use of drugs to improve sleep is
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associated with a number of disadvantages such as dependency and tolerance,
hypnotic drugs remain a prevalent treatment for improving sleep (Kripke 2000;
Olfson et al. 2015; Schutte-Rodin et al. 2008; Watson et al. 2010). Historically
these drugs have been developed using largely empirical approaches, where the
mechanisms of actions are often not well understood (Watson et al. 2010). This has
led to the development of drugs which often have serious side effects associated with
their use, further highlighting the necessity to learn more about the interactions drugs
may have with sleep-wake system and the mechanisms underlying their efﬁcacy.
Over the past few decades, there have been great advancements in the ﬁeld of sleep
medicine, and it is now more widely recognised that rational drug discovery
approaches are necessary for the development of drugs which not only have less
adverse effects but also have more desirable ones (Watson et al. 2010). For example,
drugs may instead be developed based on known principles of the receptor-binding
properties of a molecule as well as the network activity underlying sleep and
wakefulness.
Simple model systems have provided important new insights into the effects of
common drugs, such as psychostimulants and hypnotics, crucial for the development
of new pharmacological treatments. Many of the current drugs either act on the
sleep-promoting GABAergic system (including benzodiazepines and barbiturates)
and wake-promoting systems such as histaminergic, serotonergic and orexinergic
systems or modulate arousal through systems such as melatonin or adenosine (Amar
2018). It is now well established that these systems act through a complex interaction
between various neurons and neurotransmitters to control sleep and wakefulness
(Amar 2018; Watson et al. 2010).
Most of the hypnotic drugs currently available target GABA type A (GABAA)
receptors, which are well studied, and their physiology and pharmacology are
reviewed elsewhere (Mohler 2011; Winsky-Sommerer 2009). Sedative/hypnotic
drugs that target GABAA receptors can be subdivided into two main kinds: tradi-
tional benzodiazepines and non-benzodiazepines or Z-drugs, both of which are
discussed below. Benzodiazepines are among the most common drugs used for the
treatment of insomnia; however these have important adverse effects associated with
their use such as tolerance and addiction. Benzodiazepines act to potentiate inhibi-
tory GABAergic neurotransmission by increasing the afﬁnity of GABA for GABAA
receptors. In vitro studies have revealed that the binding of benzodiazepines
increases GABA-induced chloride inﬂux resulting in a general inhibitory effect on
neuronal activity (Rudolph and Mohler 2006). This has downstream effects on
speciﬁc brain oscillations, leading to a reduction in EEG power in the slow-wave
activity range (0.5–4 Hz) and an enhancement of activity in the spindle frequency
range (9–14 Hz) during NREM sleep, which has been noted in both humans and
rodent studies (Aeschbach et al. 1994; Borbely et al. 1985; Kopp et al. 2003, 2004a;
Lancel 1999; Lancel et al. 1996, 1997; Tobler et al. 2001). However,
benzodiazepines do not affect the homeostatic regulation of sleep, as evidence
suggests they do not greatly affect the time course of SWA, despite reducing
absolute power (Aeschbach et al. 1994). Non-benzodiazepine “Z” drugs, such as
zolpidem, are also widely used as sedative drugs (Dijk et al. 2010; Lancel 1999;
Sanger et al. 1996), but these can have adverse effects on memory and cognitive
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function. Calcium imaging using a miniaturised ﬂuorescent microscope revealed
a state-independent suppression of neuronal activity after systemic administration
of zolpidem in freely behaving mice (Berdyyeva et al. 2014). However,
benzodiazepines do not affect the homeostatic regulation of sleep, as evidence
suggests they do not greatly affect the time course of SWA, despite reducing
absolute power (Aeschbach et al. 1994).
It is well established that the molecular structure of GABAA receptors is highly
heterogeneous, with a large repertoire of receptor subtypes identiﬁed (Mohler 2011;
Winsky-Sommerer 2009). Investigations into these distinct subtypes has revealed
great diversity in their function and pharmacological properties which provides a
great opportunity to develop drugs that may have more speciﬁc effects. In vitro
studies using Xenopus oocytes or cell culture systems in which GABAA receptors
are expressed have been crucial in the proﬁling of the speciﬁcity of sedative drugs
(Dämgen and Lüddens 1999; Winsky-Sommerer 2009). In vivo studies have also
aided the identiﬁcation of the GABAA receptor subtypes involved in the efﬁcacy of
common benzodiazepine and Z-drugs. As α1 and α3 GABAA subtypes are known to
be present in the corticothalamic network (Jean-Marc and Hanns 2004), which is
involved in the generation of delta and spindle oscillations (McCormick and Bal
1997; Saper et al. 2001; Steriade et al. 1987), these subtypes were originally thought
to be responsible for the efﬁcacy of benzodiazepines. However, in vivo studies in
which mice were genetically modiﬁed so that they were insensitive to α1 or α3
GABAA receptors revealed that these mice still showed the typical reduction in delta
power postinjection of diazepam (Kopp et al. 2004a; Tobler et al. 2001). It is now
more widely thought that α2 GABAA receptors may instead be responsible for the
action of benzodiazepines as they are present or project from the basal forebrain or
preoptic regions of the ascending system (Jean-Marc and Hanns 2004) and they
are involved in the generation of slow oscillations during NREM sleep through
the hyperpolarisation of ascending projections to the corticothalamic system
(McCormick and Bal 1997; Steriade et al. 1987). Importantly, mice genetically
modiﬁed to be insensitive to diazepam showed an attenuation of the reduction in
delta power, an increase in theta activity and an absence of the increase in high
frequencies (above 16–18 Hz) after diazepam injection (Tobler et al. 2001). In
contrast, the Z-drug, zolpidem, has been shown to preferentially bind to the α1
receptor subtype in vitro (Dämgen and Lüddens 1999). This was conﬁrmed in vivo
using α1(H101R) mice (Crestani et al. 2000), which did not show the reduction in
SWA classically observed after zolpidem administration (Kopp et al. 2004b). There-
fore, it is likely that the sleep EEG effects of zolpidem are mediated through the α1
subunit, while the sleep-promoting effects have instead been shown to involved
α2 and α3 subtypes (Winsky-Sommerer 2009).
Together the combination of in vitro and in vivo studies have highlighted the
complexity in interpreting the mechanisms of action of sedative drugs. With a single
drug targeting numerous subtypes it is not surprising that the currently used drugs
have diverse and unwanted effects associated with their use. Further studies to
investigate the molecular and physiological mechanisms of drugs and their targets,
as well as the sleep-wake system in general, should allow for the development of
drugs with more speciﬁc actions.
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10 Conclusions
In order to address the complex and dynamic processes involved in sleep, it has been
essential to develop small network model systems to break sleep networks into
smaller components and address each of them individually. Evidence suggests that
in vitro cultured mature neuronal-glial networks can display (induced and
controlled) sleep- and wake-like activity similar to that seen in vivo, suggesting
that sleep is an activity-dependent emergent local network property. Combining the
use of these systems with whole animal in vivo experiments allows us to gain a fuller
understanding of sleep-wake networks and address fundamental, yet still unan-
swered, questions such as “what is the function of sleep?” Though over the past
few decades, much progress has been made to address these questions, there remains
much to learn in this ever-expanding ﬁeld of sleep research.
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Abstract
Optogenetic tools have revolutionized insights into the fundamentals of brain
function. This is particularly true for our current understanding of sleep-wake
regulation and sleep rhythms. This is illustrated here through a comprehensive and
step-by-step review over the major brain areas involved in transitions between sleep
and wake states and in sleep rhythmogenesis.
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1 Introductory Remarks
1.1 Identify Brain Areas That Are Key for Transitions Between
Vigilance States
Sleep or sleep-like activity is present in practically all animals studied to date and
the vital necessity of sleep has been demonstrated in organisms ranging in complex-
ity from fruit ﬂies to humans (Siegel 2008). Over the past half-century several
potential functions of sleep have been identiﬁed including, but not limited to,
restoration and homeostasis (Siegel 2008), adaptive energy conservation (Schmidt
2014), development and brain clearance (Xie et al. 2013), and memory consolidation
(Rasch and Born 2013). However, despite the overt prevalence and importance of
sleep throughout the animal kingdom, its speciﬁc function(s) remain(s) to be
clariﬁed (Krueger et al. 2016; Siegel 2009; Tononi and Cirelli 2014). The basic
neurobiological processes involved in sleep are still the subject of intense studies that
resulted in the identiﬁcation of the genetic basis of neural circuits and their correlated
activity across sleep-wake states (Fort et al. 2009; Pace-Schott and Hobson 2002).
A fundamental role of sleep for the “brain,” the “mind,” and the “body” has been
supported by its conservation throughout evolution. Indeed, ﬂuctuating levels of
consciousness and circulating factors (hormones, metabolites, etc.) as well as
changes in ionic composition of the interstitial ﬂuid (Ding et al. 2016) occur during
sleep.
Since the seminal experiment in the 1930s that identiﬁed the brainstem as
a critical area for sleep-wake control (Moruzzi and Magoun 1949) and suggested
sleep as a default, or passive, behavioral state, pieces of experimental evidence from
the last decades have progressively deﬁned a revised framework wherein sleep is
considered an active brain state that results from the coordinated activity of multiple
neuronal circuits distributed across the brain. In this view, the neural underpinnings
of the sleep-wake state involve interactions between sleep-promoting areas such as
the anterior hypothalamus, and arousal systems (most are wake-promoting) located
in the posterior hypothalamus, the basal forebrain and the brainstem (Brown et al.
2012; Lee and Dan 2012; Saper et al. 2010). The arousal systems include the
histaminergic cell group in the tuberomammillary nucleus (TMN) of the hypothala-
mus and the hypocretinergic (Hcrt) neurons in the lateral hypothalamus, the cholin-
ergic neurons, located in the pedunculopontine tegmentum (PPT) and the basal
forebrain (BF), the noradrenergic neurons of locus coeruleus (LC), the dopaminergic
and serotonergic raphe neurons of the brainstem (Aston-Jones and Bloom 1981;
Dahan et al. 2007; Hassani et al. 2009; Takahashi et al. 2008). Further details on the
neurobiology of sleep-wake states are reviewed in other chapters of this book.
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1.2 Principal Goals of Using Optogenetic Techniques
for Sleep-Wake Studies
In an effort to draw more causal evidence from experimental testing, genetic
engineering, pharmacology, and electrical stimulation strategies have been used
to identify molecular/cellular mechanisms of sleep-wake systems in the brain.
However, achieving high temporal and spatial resolutions simultaneously has been
challenging due to the inherent limitations of the existing techniques. Importantly,
genetic engineering approaches target single gene mutations (i.e., high “spatial”
resolution in the gene domain) from early embryonic ages in the whole, or in part
of the organism (conditional gene targeting). Although conditional approaches or
viral targeting limit the genetic modiﬁcation to the desired brain areas and may
additionally reduce the temporal window of action, their timescale remains longer
than most of the physiological changes and processes occurring during sleep-
wake states. Finally, transient pharmacological approaches, although selective to
precisely identiﬁed receptors, often rely on non-physiological doses of (ant)agonists
molecules that stay in the synaptic cleft where they induce long and persistent
(in-)activation of the targeted receptors, as well as, to a lesser extent, other nonse-
lective targets. Thus, the advent of optogenetic technologies to both image and
control the activity of neural circuits has overcome most of those limitations through
high temporal (millisecond timescale) and spatial (genetic targeting) resolution
offering temporally precise activation/silencing of cells/circuits.
Why Is Optogenetics an Appropriate Tool for Experimental Sleep Research?
Both hypothalamus and brainstem, nodal points of sleep-wake control, consist of
intricate networks of excitatory and inhibitory neuronal populations, each of which
has a speciﬁc chemical nature and has separate roles in vigilance state control. All of
the evidence supporting a functional role for these circuits in sleep and wakefulness
stems from in vitro and in vivo techniques (electrical stimulation, pharmacological
approaches, unit recordings, knockout/knockin models, etc.) that have low spatial
and temporal resolution and that suffer from possible compensatory mechanisms.
Optogenetic technology (“opto” for optical control/recording and “genetics” for
genetically targeted cells/cell activities) is a system neuroscience tool that allows
remote control of speciﬁc neural circuits with physiologically relevant spatial and
temporal resolution. When expressed in a genetically targeted neuronal population,
the light-sensitive proteins Channelrhodopsin-2 (ChR2, E123T mutation in ChR2 –
ChETA, etc.) and the halo- or archeo-rhodopsin (eNpHR and ArchT, respectively)
allow bimodal modulation of electrical signals (activation or inhibition) with milli-
second timescale precision. ChR2/ChETA is a monovalent cation channel that
allows cations to enter the cell following exposure to ~473 nm blue light and activate
cells, whereas the eNpHR and ArchT are a chloride and a proton pump, respectively,
that activates upon illumination with ~580 nm yellow light and silences cells.
Their fast temporal kinetics makes it possible to drive reliable trains of high
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frequency action potentials in vitro and in vivo using ChR2 or suppress single action
potentials within high frequency spike trains using NpHR or ArchT in vitro/vivo.
Hence, optogenetics allow for frequency-dependent interrogation of the neural system
properties in vitro and in vivo without inadvertent stimulation of neighboring neurons.
Ten years after the birth of optogenetics (Adamantidis et al. 2015; Boyden 2015;
Deisseroth 2015; Hegemann and Nagel 2013; Miesenbock 2009), major implemen-
tations have overcome some biological limitations, however, some experimental
challenges remain that will be discussed further in this chapter. Here, we summarize
the rise of optogenetics-based experimental studies that are progressively identifying
key circuits in the brain controlling sleep-wake state architecture, oscillations, and
function(s). We describe key studies that used neuron-inspired patterns of optical
stimulation to optogenetically investigate the neural substrate of sleep-wake states,
from ChR2-assisted functional circuit mapping to state switching, sleep rhythms, and
sleep functions. This chapter is divided into distinct sections, including: (1) optogenetic
dissection of sleep-wake state initiation, maintenance, and termination; (2) optogenetic
unraveling of circuit mechanisms of sleep homeostasis; (3) optogenetic identiﬁcation
of neural substrates of sleep rhythms and their biological function.
2 Optogenetics and Sleep-Wake Transitions
The recurrent cycle of sleep-wake episodes results from a coordinated activation/
inhibition of distributed, yet partially deﬁned, neural networks in the brain that are
under a strong internal and external modulation (e.g., hormone, metabolism, homeo-
static, circadian, environment, etc.). In mammals, after a consolidated period of wake-
fulness, the activity of wake-promoting systems slowly decreases and the organism
progressively enters into NREM sleep (or slow-wave sleep). A transition back to
wakefulness signals the termination of NREM sleep. Depending on species, NREM
sleep is followed by REM sleep (or paradoxical sleep) that is usually terminated by a
transition to wakefulness (see Fig. 1 for representative cortical EEG/EMG traces typical
for the different vigilance states). It is hypothesized that the neural circuits involved are
highly specialized in controlling the initiation, maintenance, and termination of distinct
states or oscillations in the sleeping brain. Therefore, the following sections will focus
on speciﬁc transitions and hallmark brain oscillations that are typical for NREM or
REM sleep states. For each transition, we summarized recent ﬁndings and emphasized
optogenetic dissection of neural circuits communication in vitro (example shown in
Fig. 2a–d) and in vivo (Fig. 2e–k).
2.1 Transitions from Sleep to Wakefulness
Classically, the onset of wakefulness follows the activation of the reticular ascending
system from the brainstem, which projects to forebrain cortical and subcortical
structures (Brown et al. 2012; Fort et al. 2009). We will review here some of the
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Fig. 1 Brain oscillations during sleep-wake states. A complete sleep-wake cycle in rodents is
composed of repeated transitions from wakefulness to NREM sleep and then to REM sleep.
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main ﬁndings related to the identiﬁcation of wake-promoting circuitry in the mam-
malian brain following a somewhat chronological order of experimental optogenetic
ﬁndings, rather than a sequence based on their individual importance or hierarchical
positions, should there be any.
Hcrt/Ox (LHHcrt/Ox) In the ﬁrst in vivo optogenetic study (Adamantidis et al.
2007), the role of lateral hypothalamic hypocretins/orexins (LHHcrt/Ox)-expressing
neurons in arousal and sleep-to-wake transitions was investigated. After genetic
targeting of ChR2 expression to LHHcrt/Ox neurons using a lentivirus, optical stimu-
lation of Hcrt neurons at frequencies between 5 and 30 Hz during NREM and REM
sleep induced a reduction of the latency of transition to wakefulness of ChR2-
mCherry animals compared to controls (Adamantidis et al. 2007). This response
was blocked by a single dose of an Hcrt receptor 1 antagonist, suggesting an
implication of Hcrt peptides on one of their receptors. In contrast, 1-Hz light pulses
did not result in a signiﬁcant change. This study established, for the ﬁrst time, a
causal link between frequency-dependent electrical activity of LHHcrt/Ox neurons and
sleep-to-wake transitions.
This arousal effect was strongly dependent on sleep pressure and activation of
norepinephrine neurons from the Locus coeruleus (LCNE). Indeed, sleep pressure
gated the arousal action of LHHCRT neuron on sleep (Carter et al. 2009). Interest-
ingly, and in addition to already described LHHcrt/Ox-TMNHist intra-hypothalamic
circuits (Brown et al. 2012; Eriksson et al. 2001), norepinephrine cells from the LC,
rather than histaminergic cells, mediate part of this arousal effect (Carter et al. 2010)
at least for spontaneous sleep-wake transitions. Importantly, optogenetic stimulation
of LCNE neurons induced a rapid arousal transition (<2 s) from both NREM and
REM sleep, while their silencing extended sleep duration. Interestingly, prolonged
stimulation of LCNE neurons was able to maintain wakefulness for a much longer
period than Hcrt; however, accumulating sleep pressure eventually induced sleep
despite the strong LCNE tone induced by semi-chronic optogenetics (trains of
200 5-ms pulses delivered at 20 Hz every minute for 1 h). These ﬁndings
demonstrated the reliability of optogenetics to functionally dissect circuits and
functions of sleep-to-wake transitions and arousal systems in general and opened
new avenues to systematically manipulate speciﬁc features of sleep in the mamma-
lian brain.
One question that arose from these behavioral studies was the synaptic role of
Hcrt peptides and glutamate, which is also produced by LHHcrt/Ox cells. To address
this, Schöne et al. used optogenetics to study the release of Hcrt peptide and
Fig. 1 (continued) Termination of the REM sleep episode is always followed by a transition to
wakefulness. This ﬁgure shows representative cortical EEG (top) and neck muscle EMG recording
(bottom) across sleep-wake states in freely moving mice. In between the EEG and the EMG
recordings, the same EEG trace, yet ﬁltered in different frequency bands characteristic for the
three different vigilance states (indicated to the left of each trace), is presented
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Fig. 2 Example recordings from in vitro or in vivo characterizations of projections involved in
sleep-wake control. (a) Photomicrograph showing ChETA-EYFP-expressing MCH terminals in
TMN area. Scale bar: 200 μm. Inset, ChETA-EYFP-expressing MCH terminals (green) contacting
histamine cell (red). Scale bar: 10 μm. (b, c) IPSCs (black) were recorded in TMN histamine and
non-histamine neurons from Tg (Pmch-Cre) animals transduced with ChETA-EYFP viruses. (c)
Optically evoked responses (black traces) were blocked by bicuculline (BIC, red traces). (d) Mean
amplitude of evoked IPSCs from Tg (Pmch-Cre) before and after bath application of BIC. (e)
Schematic of genetic targeting and surgical implantation of opto-tetrode (32 ch) in the TRN.
EEG/EMG electrodes are not shown. (f) Photomicrographs of coronal section showing ChETA-
EYFP-expressing LHGABA terminals (top) intermingled with GAD-67+ cells in the posterior TRN
(bottom). Scale bar: 20 μm. (g) Representative EEG/EMG recordings before, during, and after
single optical stimulation (blue bars) in ChETA-YFP (top) and YFP (bottom) animals during
spontaneous NREM sleep induced rapid transitions to wakefulness in freely moving mouse. (h)
Mean latencies of NREM sleep-to-wake transitions upon optogenetic stimulation in ChETA
(N ¼ 7) and control animals (N ¼ 5). ** P < 0.001, *** P < 0.0001. (h) Mean latencies of
NREM sleep-to-wake transitions upon optogenetic stimulation in ChETA and control animals.
** P < 0.001, *** P < 0.0001. (i) Representative EEG (top) delta (0.5–4 Hz) oscillation (middle),
EMG (red), and corresponding heat map EEG power spectrum (bottom) in response to local optical
silencing (yellow bar, 593 nm) of LHGABA-TRN circuit during NREM sleep. (j) Mean duration S.
E.M of NREM sleep episodes during baseline (left, black bar), optogenetic silencing in control
(white bar), and ArchT-EYFP (black bar) mice. ** P < 0.01, one-way multiple ANOVA followed
by Bonferoni post-hoc test. (k) Mean S.E.M average of normalized spectral power distribution of
cortical EEG signal in control animals (black trace) and ArchT-EYFP (green trace) animals upon
optical silencing. * P < 0.05 using unpaired two-tailed Student’s t-test between control and ArchT
animals. Modiﬁed from Jego et al. (2013) and Herrera et al. (2015)
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glutamate from Hcrt neurons by recording monosynaptically connected histamine
cells in an in vitro preparation (Schöne et al. 2014). They identiﬁed that LHHcrt/Ox
neuron optical stimulation evoked Hcrt receptor 2-dependent slow postsynaptic
currents. Blocking glutamate-driven spiking did not affect LHHcrt/Ox-driven spiking
and vice versa, suggesting isolation of outputs. Therefore, co-transmission rules in
LHHcrt/Ox-TMNHist circuit, and sleep-wake circuits in general, may translate distinct
features of cellular activity into parallel, nonredundant control signals through
downstream effectors.
Histamine (TMNHist) Beside the glutamatergic LHHcrt/Ox neurons, the posterior
hypothalamus contains histamine-secreting neurons that represent another cluster
of wake-active neurons. TMNHist cells possess all the machinery necessary to synth-
etize GABA and this mode of transmission had not been tested until recently.
Optogenetic activation of histamine cell in vitro disinhibits TMN cells themselves,
while indirectly suppressing the activity of sleep-promoting cells from the anterior
hypothalamus through local GABA interneurons (Williams et al. 2014). Further-
more, in vivo optogenetic activation of histaminergic neuron terminals in the
striatum and cortex evoked tonic (extra-synaptic) GABAA receptor chloride currents
onto medium spiny neurons and pyramidal neurons, respectively. Importantly, these
currents were abolished following genetic deletion of the vesicular GABA trans-
porter (VGAT) from histamine cell terminals, suggesting an inhibitory mode of
action (Yu et al. 2015). Altogether, these studies conﬁrmed the inhibitory nature
of the histamine cells, while the role of speciﬁc histamine receptor in mediating these
responses awaits further investigation.
Basal Forebrain Acetylcholine (BFAch) Several studies have probed the role of
cholinergic neurons from the basal forebrain in sleep-wake state modulation.
Consistently, it was found that optogenetic activation of BFAch neurons during
NREM sleep is sufﬁcient to elicit cortical activation and facilitate wakefulness
(Han et al. 2014; Irmak and de Lecea 2014). Prolonged duration of poststimulation
arousal was noticed (Irmak and de Lecea 2014). These effects were accompanied by
an overall decrease in the power across the 1–14 Hz frequency band. Consistent with
these ﬁndings, transient bilateral inactivation of BFAch neurons genetically targeted
with Arch-T prolonged NREM sleep and decreased the probability of awakening in
mice. Chronic silencing had minor effects on overall sleep-wake durations (Shi et al.
2015). This arousal effect is thought to be mediated by cholinergic modulation of
local cells including cortex-projecting inhibitory GABAergic cells (Brown and
McKenna 2015; Kim et al. 2015), rather than cholinergic modulation of cortical
circuits (Zant et al. 2016).
A careful analysis of these results reveals some interesting ﬁndings. First,
in contrast to LHHcrt/Ox and LCNE, the arousal effects of cholinergic modulation
were dependent on the ongoing sleep states, as photostimulation of cholinergic
neurons during REM sleep did not increase wakefulness. This last result suggests
a highly specialized, rather than a redundant, organization of arousal circuits in the
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mammalian brain. Second, the wake-promoting effects of cholinergic activation
were not signiﬁcant for stimulations preceded by long periods of NREM (Irmak
and de Lecea 2014). Although this could be due to the use of unilateral stimulation
instead of bilateral, or single 10 Hz pattern, it is consistent with other systems, such
as the LHHcrt/Ox and to a lesser extent the LCNE, whose wake-promoting effect
strongly depends on/is gated by sleep pressure (Carter et al. 2009). Third, this
absence of arousal transitions upon stimulation occurring at the end of NREM
episodes might actually favor a switch to REM sleep and its typical “cortical
arousal.” Finally, and in contrast to the melanin-concentrating hormone (MCH)
neurons in the LH that promote and extend REM sleep episodes when stimulated
during REM sleep (see below), the ratio of NREM-Wake and NREM-REM upon
BFAch optical stimulation was similar to natural transitions, suggesting a modula-
tory, rather than a switch-promoting, role of these cells. A recent study systemati-
cally recorded from ChR2-tagged cholinergic, glutamatergic, and parvalbumin-
positive (PV+) GABAergic neurons in the BF and reported that they were more
active during wakefulness and REM sleep (wake/REM active) than during NREM
sleep. Optogenetic activation of each cell type rapidly induced wakefulness. In
contrast, activation of somatostatin-positive (SOM+) GABA neurons promoted
NREM sleep, although only some of them were NREM sleep-active (Xu et al. 2015).
LHGABA Although most of the wake-promoting systems were thought to rely on
excitatory neurotransmission, inhibitory transmission in the hypothalamus was
recently identiﬁed as a strong arousal circuit. Juxtacellular studies originally showed
that the activity of GABAergic cells in the LH correlates mainly with wakefulness or
REM sleep states, suggesting specialized LH-based inhibitory circuits that control both
states (Hassani et al. 2009, 2010; Koyama et al. 2003). Indeed, a subset of LHGABA
cells makes monosynaptic contact onto GABAergic thalamus reticular nucleus (TRN)
neurons of the thalamus (LHGABA-TRNGABA) where they exert a strong inhibitory
tone both in vitro and in vivo (Herrera et al. 2015) (Fig. 2e–h). Optogenetic activation
of this circuit recapitulated state-dependent changes of TRN neuron activity in behav-
ing mice and induced rapid arousal (<2 s) from NREM, but not REM sleep (i.e.,
similar to BFAch, but at a much faster rate). Importantly, selective activation of the
LHGABA-TRNGABA circuit during deep anesthesia induced a sustained cortical arousal,
and often a recovery of muscle tone that is interpreted as a recovery of consciousness
in animals. In contrast, optogenetic silencing of LHGABA-TRNGABA increased the
duration of NREM sleep and the amplitude of delta (1–4 Hz) oscillations (Fig. 2i–k).
This later results suggest that modulation of TRN cell activity may represent a
permissive state to sleep homeostasis (Process S, see Borbély et al. 1989). Collectively,
this is the ﬁrst study to demonstrate that TRN cells integrate subcortical arousal inputs
selectively during NREM sleep and that they may participate in sleep intensity.
A recent study further identiﬁed a potent inhibition of anterior hypothalamus VLPO
cells by LHGABA neurons, which provides a possible additional pathway for promoting
rapid wakefulness (Venner et al. 2016). Chemogenetic stimulation of this pathway
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strongly promoted wakefulness, whereas its inhibition augmented NREM sleep with-
out altering REM sleep. Optogenetic manipulation of this circuit will be required
to compare the dynamics of wake promotion to those of the LHGABA-TRNGABA
projection.
VTA-Dopaminergic Circuit Midbrain dopamine neurons are classically involved
in reward processing, suggesting their participation in arousal, attention, and, possi-
bly, wakefulness. This modulation was conﬁrmed recently using ﬁber photometry of
VTA dopaminergic cell signals (Eban-Rothschild et al. 2016). Furthermore, the
same authors showed that VTA dopaminergic neurons are necessary for arousal
and that their inhibition suppresses wakefulness and promotes sleep-related nesting
behavior using opto- and pharmacogenetics approaches. Following these correlative
observations, chemogenetic and optogenetic activation and inactivation of VTA
dopaminergic neurons are both necessary and sufﬁcient for arousal and the effects
might be target speciﬁc.
Interestingly, the activity of these cells is also modulated across sleep-wake cycle,
with higher burst mode discharges during REM sleep than during NREM sleep
(Dahan et al. 2007), while reactivation of previously activated VTA dopaminergic
cell assemblies has been observed during slow wave oscillations in NREM sleep
(Valdés et al. 2015).
Sympathetic Tone One interesting study investigated the role of adrenergic C1
neurons that are located in the lower brainstem and that exert a sympatho-excitatory
effect in cardiovascular organs, yet that also project to the wake-promoting LC
(Burke et al. 2014). So far, these cells were known to act together with other cell
groups to mediate increases in breathing, blood pressure and to cause arousal
in response to hypoxia. Burke et al. (2014) now demonstrate that selective optical
activation of the C1 neurons in transgenic rats expressing Cre in tyrosine
hydroxylase-positive neurons increases breathing and blood pressure and produces
arousal from NREM sleep, suggesting a possible contribution to sleep disruption
associated with cardiovascular effects of apneas.
2.2 Transitions from Wakefulness to Sleep
Along with the many arousal centers identiﬁed in the brain, experimental evidence
for the existence of a sleep center has been converging towards the anterior hypo-
thalamus and the lateral-preoptic area in particular.
ANGABA and ANGABA Amassing correlative evidence identiﬁed the anterior
hypothalamus (AN), both the VLPO and the LPO, as sleep-promoting centers.
This was originally suggested by Constantin von Economo who described that
damage to this area in the brains of patients with persistent insomnia following the
inﬂuenza pandemic in the early years of the twentieth century (Von Economo 1930).
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This clinical ﬁnding was conﬁrmed in lesional studies in cat, rat, and mouse (Lu et al.
2000; McGinty and Sterman 1968; Nauta 1946; Sallanon et al. 1989; Saper et al.
2010), whereas warming of this region promoted sleep, probably through activation
of local GABAergic neurons whose activity is modulated across sleep-wake states,
and particularly high during NREM sleep. These neurons strongly project to the
arousal circuitry of the brain where they are thought to inhibit wake-promoting
neurons, which eventually induces sleep (Brown et al. 2012). However, the VLPO
area does not contain a neurochemically and functionally homogeneous cell popula-
tion (Modirrousta et al. 2004; Szymusiak et al. 1998), and its lesion dramatically,
reduces, but not fully suppresses sleep time (Lu et al. 2000). Of importance, it is
also involved in thermoregulation (Boulant 2000) and, possibly, parental behaviors
(Dulac et al. 2014).
In a recent chemo-genetic study, Zhang et al. showed that anesthesia- or sleep
recovery-tagged neurons from the lateral preoptic area were able to induce NREM
sleep, with the accompanying drop in body temperature. This result is important
since it is the ﬁrst study to demonstrate that (1) sedation (induced by dexmedeto-
midine, an α2-adrenergic agonist) and NREM sleep shares functional hypothalamic
pathways, but importantly, (2) activation of a subset of cells in the anterior hypo-
thalamus is causally involved in sleep regulation (Zhang et al. 2015). However, the
precise identiﬁcation of possible VLPO subpopulations and functional connectivity
is awaiting further investigation.
Pontine Control of NREM Sleep Recent optogenetic study identiﬁed a potential
additional “sleep center” that includes the GABAergic cells from the Parafacial zone
(PZ), a small nucleus located in the rostral medullary brainstem, adjacent to the cell
bodies of the ascending arousal system (Anaclet et al. 2014). Anaclet et al. showed
that PZ neurons express c-Fos after sleep but not after wakefulness, suggesting that
they are sleep-active, and that lesions of the PZ cells result in large and sustained
increases (50%) in daily wakefulness at the expense of NREM sleep. Furthermore,
half of these PZ cells express a marker for inhibitory neurons (VGAT) and genetic
removal of vesicular GABA/glycine transporter in PZ cells resulted in increased
wakefulness concomitant with a decrease of both NREM and REM sleep (Anaclet
et al. 2012). Causal evidence for a role of these PZGABA cells as NREM sleep-
promoting neurons was further shown using an optogenetic approach, possibly
through PZGABA->Parabrachial (PB)glu->BF (magnocellular neurons)-Cortex” cir-
cuitry (Anaclet et al. 2014), although this functional circuit relies on in vitro studies
so far.
Beside cholinergic inputs, pontine glycinergic inputs have been shown to inhibit
arousal-promoting midline thalamic circuits, through polysynaptic GABA and
glycinergic pathways (Giber et al. 2015). Interestingly, their optogenetic activation
evokes transient interruption of awake cortical activity in freely moving animals,
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while prolonged stimulation induced behavioral arrest. Altogether, these ﬁndings
suggest that long-range projecting inhibitory cells from the brainstem also partici-
pate in the forebrain and thalamic control of sleep and support a functional alterna-
tive dissociated from the “classical” anterior hypothalamus model.
Cholinergic Inputs to Thalamus Beside the PZ-PB complex, and together with
the progressive decrease of monoaminergic tone during transition from wakefulness
to NREM sleep, cholinergic inputs to the thalamus, and the TRN in particular, have
recently been shown to be involved in sleep transitions (Sun et al. 2013; Ye et al.
2010). Indeed, Ni et al. showed that optical stimulation of cholinergic inputs to the
TRN exerts a net activation of local GABAergic neurons through α7-containing
nicotinic acetylcholine receptors, although contrasting studies rather suggest the
involvement of muscarinic receptors (Beierlein 2014). Chronic optical stimulation
patterns ultimately promote sleep by decreasing sleep onset latency and extension
of NREM, but not REM, sleep duration, possibly by increasing sleep spindle
occurrence (Ni et al. 2016). Although these ﬁndings contrast to previous reports
on cholinergic control of arousal, they strongly suggest that arousal, and likewise
sleep-circuits, are organized in a specialized, rather than a redundant, scheme.
Following the convergence of these circuits onto thalamo-cortical (TC) networks,
several studies have tested whether direct activation of TC and cortico-thalamic
(CT) elements (TC-CT-TRN) induced sleep-like oscillations and sleep states.
Indeed, direct phasic optogenetic activation of TRN cells induced spindle-like
oscillations (Halassa and Acsády 2016; Halassa et al. 2011; Kim et al. 2012),
while its tonic activation rapidly induces slow wave activity (similar to sleep slow
waves) in a spatially restricted cortical area. These slow wave events are associated
with behaviorally relevant signs of sleep (however, arousal threshold not tested)
(Lewis et al. 2015).
We will ﬁnish this section by referring the reader to two studies that somewhat
conﬁrmed previous ﬁndings. Tsunematsu et al. showed that optical silencing
of LHHcrt/Ox reduced NREM sleep onset whereas optical stimulation of ChR2-
expressing astrocytes (using glial ﬁbrillary acidic protein (GFAP) promoter) in the
LH promoted both NREM and REM sleep during the 6-h stimulation sessions
(Tsunematsu et al. 2011, 2013). However, both studies are somewhat limited
by the absence of proper control experiments and the precise molecular and cellular
consequence of optogenetic activation of astrocytes (e.g., release mechanism),
respectively.
2.3 Transitions from NREM to REM Sleep
LHMCH Lesion studies link the AN with sleep, while the LH encompasses neurons
with arousal properties. However, in 2003, Verret et al. provided the ﬁrst evidence
for a role of MCH neurons in REM sleep control. As evidenced by functional
neuroanatomy, MCH neurons are active during a REM sleep rebound and icv
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injection of MCH peptides induced REM, and to a lesser extent, NREM sleep
(Verret et al. 2003). This hypothesis was further conﬁrmed by juxtacellular
recordings showing that MCH neurons maximally discharged during REM sleep
(Hassani et al. 2009). Acute optogenetic activation of MCH neurons (ChETA,
SSFO) at the onset of REM sleep extended the duration of REM, but not non-REM
sleep episodes. In contrast, their acute silencing (eNpHR3.0, ArchT) reduced the
frequency and amplitude of hippocampal theta rhythm, without affecting REM
sleep duration (Jego et al. 2013). In vitro activation of MCH neuron terminals
induced GABAA-mediated inhibitory postsynaptic currents (IPSCs) in wake-
promoting histaminergic neurons of the tubero-mammillary nucleus (TMN)
(Fig. 2a–d), while in vivo activation of MCH neuron terminals in TMN or medial
septum also extended the duration of REM sleep episodes. Interestingly, acute
stimulation of MCH neurons during NREM sleep facilitated the transitions
towards REM sleep (Jego et al. 2013; Tsunematsu et al. 2014). Consistent with
these studies, chronic optogenetic activation over hours of MCH cells increase sleep
(Konadhode et al. 2013).
Collectively, these results suggest that activation of MCH neurons promotes and
stabilizes REM sleep, possibly through inhibition of arousal circuits in the mamma-
lian brain. Although the effect on REM sleep was consistent across different
experimental approaches, they also revealed a facilitatory role for MCH neurons
on NREM sleep onset that strongly depends on the technology, stimulation parame-
ter, and species considered.
Consistent with Jouvet’s work on the role of brainstem nuclei in REM sleep, and
according to recent recording of cholinergic neurons ﬁring across sleep-wake states
(Boucetta et al. 2014), acute optogenetic stimulation of cholinergic neurons in the
LDT/PPT nuclei during NREM sleep promotes REM sleep with some delay
(~1 min) (Van Dort et al. 2015), similarly to MCH neurons (Jego et al. 2013).
However, in this set of experiment, the duration of REM sleep was not affected by
the optogenetic stimulation.
The medulla contains neurons that send rostral projections to the pons and
midbrain (dorsal part) and caudal projections to the spinal cord (ventral part) and
are maximally active during REM sleep (Fort et al. 2009; Weber et al. 2015).
For instance, cell-type-speciﬁc microendoscopic Ca2+ imaging conﬁrms previous
functional anatomy results showing that glutamatergic neurons in the laterodorsal
tegmental nucleus are maximally active during REM sleep, while the majority of
GABAergic neurons is maximally active during wakefulness (Cox et al. 2016).
Their optogenetic activation showed that GABA inhibitory circuit originating from
the ventral medulla reliably initiated REM sleep episodes and prolonged their
durations in mice, whereas inactivating these neurons had the opposite effect
(Weber et al. 2015). Although the ventral part of this nuclei is thought to control
motor atonia, rather than REM sleep itself, a possible pathway involves an inhibition
of REM-suppressing GABAergic neurons in the ventrolateral periaqueductal grey.
A recent study took advantage of the ontogeny of cells in the brainstem to
manipulate both NREM and REM sleep in this area using chemo-genetic tools
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(Hayashi et al. 2015). Although these cells share a common developmental origin
with neurons promoting wakefulness, interestingly, the authors identiﬁed excitatory
glutamatergic neurons that inhibit REM sleep and promote NREM sleep, whereas
some other GABA-releasing neurons act downstream to inhibit REM sleep. Chemo-
genetic reduction or prolongation of REM sleep was found to also affect slow-wave
activity during subsequent NREM sleep, implicating REM sleep in the regulation
of NREM sleep. Yet, the precise underlying mechanisms still remain unclear and
the time course of the effects described in this study is not compatible with that
of homeostatic sleep regulation, suggesting possible side-effect pertaining to
pharmacogenetics.
3 Optogenetics and Sleep Homeostasis
After prolonged periods of wakefulness, sleep pressure – which reﬂects a process
called “sleep homeostasis” (or process S) (Borbély et al. 1989; Franken et al. 2001;
Rechtschaffen et al. 1989; Saper et al. 2010) – increases and favors the onset of
sleep. The increased sleep pressure is accompanied by enhanced amplitude of low
frequency oscillations (delta frequency band: 0.5–4 Hz) in the cortical EEG in both
animals and human. Although its precise underlying mechanism remains unclear,
alterations in receptor and messenger signaling pathways, neural network synchro-
nization, and/or phase coupling (Fattinger et al. 2014; Mang and Franken 2015; Urry
and Landolt 2015; Dauvilliers et al. 2015; Greene and Frank 2010) from cortical or
subcortical structures support this evolutionarily conserved phenomenon.
Sleep homeostasis has been shown to block LHHcrt/Ox-mediated arousal during
sleep, suggesting a gating mechanism (Carter et al. 2009). More recently, we showed
that optogenetic silencing of LHGABA-TRNGABA circuitry alone was sufﬁcient to
enhance the amplitude of NREM sleep delta oscillations (Herrera et al. 2015),
suggesting a possible mechanisms for local and global modulation of sleep homeo-
stasis from subcortical structures. Finally, spindles are typically detected during
normal NREM sleep and consist of characteristic “waxing-and-waning” ﬁeld
potentials grouped into 9–15 Hz oscillations that last for ~1 s and occur several
time per minutes in the thalamus and the cortex (Barthó et al. 2014; Lüthi 2014).
4 Optogenetics and Brain Rhythms
Optogenetic approaches have also advanced our understanding of the mechanistic
and functional substrates of neural rhythms associated with sleep and wake states.
The separate consideration of how optogenetics help advance this ﬁeld is justiﬁed for
several reasons.
Brain rhythms represent the hallmarks of distinct states of sleep. Such electrical
patterns necessitate activation of particular ion channel classes, modes of synaptic
transmission, and discharge patterns over repetitive cycles of activity. For these reasons,
constant light stimulation will need to be replaced by appropriately temporally patterned
stimuli to initiate or maintain the cellular events underlying network oscillations.
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Moreover, whether or not brain rhythms can be generated depends on the particular state
of the neural circuitry, which includes its neuromodulatory conditions, cellular
excitabilities, and the synaptic strengths. The goal of this chapter is to highlight cases
in which optogenetically manipulated rhythms were successfully obtained and analyzed
in terms of similarity to their natural counterparts. These cases help to illustrate the
revolutionary power of optogenetics and to foresee its capacity to generate further
landmark insights on the role of these rhythms for sleep.
4.1 Optogenetic Manipulation of Brain Rhythms in Sleep
and Wake States
Sleep states represent an assembly of super-imposed rhythms that are key to the
scoring of these in both humans and animals. Although many of the cellular details
of these rhythms are known, a better deﬁnition and understanding of their initiation,
spread, and termination mechanisms, as well as their function in sleep-speciﬁc
alterations in arousal threshold, consciousness, and ofﬂine processing are warranted.
Sleep Spindles Optogenetic induction of brain rhythms has been particularly suc-
cessful in cases in which some of the key pacemaker elements were known from
prior electrophysiological work. One well-documented case is sleep spindles, known
to occur predominantly during human sleep stage N2 and to arise from reverberating
neuronal activity within the reciprocal circuits of TC cells and TRN. Optogenetic
control of spindles is of great interest as sleep spindles are key elements in the
operations of the sleeping brain that control arousal threshold and memory consoli-
dation (Astori et al. 2013).
The basic mechanism of sleep spindle generation was re-probed through opto-
genetically activating TRN cells that were rendered light-sensitive through using
Cre-driver lines for genes involved in the life cycle of the neurotransmitter GABA.
Halassa et al. (2011) were the ﬁrst to use animals expressing ChR2 under the control
of the vesicular GABA transporter (VGAT). In these animals, they stimulated the
TRN in vivo unilaterally using an optic ﬁber implanted over its sensory sectors. EEG
spindles could be observed through giving single light pulses to the TRN, which
induced 4–5 waves in the frequency band of 10–15 Hz. These clearly outlasted the
duration of the light stimulus, indicating that a network rhythm had been generated.
The same light stimulus also caused a pause in TC cell activity that was followed by
rebound burst discharge, a pattern required for sleep spindle generation. Importantly,
the success of spindle induction was dependent on brain state, being most easily
induced during NREM sleep and hardly at all in wake and REM sleep. A similar
approach was taken by Barthó et al. (2014), who used PV-Cre or VGAT-Cre driver
lines to express ChR2 and implanted the optic ﬁber over sensory TRN. Single light
pulses elicited spindles that were detected as rhythmic multiunit activity in TC cells
in urethane anesthesia. In this study, optogenetic triggering of spindles was also used
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to demonstrate that the duration of sleep spindles is the result of a complex interac-
tion between the burst propensity of TRN cells and background modulatory effects.
In these two studies, spindle patterns were produced that resembled closely
those observed naturally. Moreover, both studies demonstrated a state-dependence
of spindle occurrence that indicated a preference for synchronized brain states
typical for non-REM sleep.
Kim et al. (2012) used Thy1-ChR2 mice to excite TRN neurons through bilateral
delivery of repetitive 8 Hz light pulses. EEG patterns followed these repeated light
pulses faithfully as long as they were continued, but stopped immediately thereafter,
indicating that no self-sustained rhythm was produced that outlasted the light exposure.
“Spindle-like” rhythms could thus be produced through entraining a network into a
rhythm using enforced neuronal recruitment independently of the current circuit state.
Supporting this interpretation is the fact that spindles were observed throughout all
vigilance states, with no major difference between waking and non-REM sleep.
Slow Waves The cellular mechanisms of slow waves, which are characteristic for
stage N3 of human NREM sleep, are the focus of three studies. These investigated
the recruitability of the anesthetized corticothalamic system when exposed to light
stimulation at frequencies corresponding to the slow waves (1–2 Hz). Stroh et al.
(2013) optogenetically stimulated layer 5 neurons in a mouse line with ChR2
expression conﬁned to layer 5 in ketamine-xylazine anesthesia. Anesthetized cortical
circuits show an elevated excitability in 1-s intervals that facilitates an avalanche-
like network recruitment to both synaptically and intrinsically generated excitation.
A similar conclusion was taken by Kuki et al. (2013) who stimulated at various
depths in motor cortex of the W-TChR2V4 rat line that expresses ChR2 throughout
excitatory and inhibitory neurons predominantly in deeper layers. David et al. (2013)
found that repeated light stimuli (0.75–1.5 Hz) to ChR2-expressing somatosensory
thalamus entrained cortical activity to this frequency through generating an up-
down-state sequence that closely followed the evoked response to the thalamic
input. This sequence was clearest in amplitude at 1.5 Hz, whereas it became
markedly smaller at frequencies >2 Hz. The entrainment was dependent on the
occurrence of low-threshold calcium spikes in the thalamus, known to underlie burst
discharge in these cells. Low-frequency synchronized rhythmic activity in the
thalamus can thus shift the frequency of slow waves in the cortex within the range
of 1–2 Hz, and exert a desynchronizing effect if occurring more rapidly.
Beltramo et al. (2013) used the rbp4-cre mouse line to drive ChR2 expression
selectively in layer 5. Although ~14% of pyramidal neurons expressed ChR2,
low-intensity light with a 0.5 s on-off periodicity was sufﬁcient to reliably generate
depolarized states in layer 5 neurons through synaptic inputs driven by ChR2 that
propagated to upper cortical layers. Conversely, comparable optogenetic manipula-
tion of layer 2/3 neurons did not lead to persistent recruitment of other cortical
layers. Moreover, optogenetic inhibition of a subgroup of layer 5 neurons was
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sufﬁcient to interrupt spontaneous up states. 1 Hz rhythmic light exposure also
boosted slow waves in non-REM sleep of freely moving mice. This study conﬁrms
earlier observations in carnivores in favor of layer 5 neurons as hubs for the
generation of slow waves (Sanchez-Vives and McCormick 2000).
Gamma Rhythms Two in vitro studies demonstrate an induction of rhythms in the
gamma frequency range (~40–75 Hz) through using temporally varying optogenetic
stimuli, such as ramps in somatosensory cortex of mice expressing ChR2 in layer 2/3
cortical neurons (Adesnik and Scanziani 2010) or theta-modulated sinusoidal stimuli
in the CA1 area of the hippocampus (Butler et al. 2016). The generation of activity in
this frequency range in reduced preparations, notably including layer 2/3 of single
cortical barrels (Adesnik and Scanziani 2010), supports the idea that local circuits are
able to generate gamma rhythms in response to speciﬁc sensory drives or states of
memory processing.
Hippocampal Rhythms Optogenetic approaches recently were successfully used
for probing mechanisms of hippocampal ripple generation. The hippocampus
generates fast ﬁeld oscillations at 150–300 Hz that appear as short-lasting events
prominently in the CA1 area during states of NREM sleep, but also during quiet
wakefulness (Colgin 2016). Basic mechanisms of generation and propagation within
hippocampus remain open (Buzsáki 2015). Ripples are central to sleep-dependent
memory consolidation and implied in the replay of fragments of wake-related events.
To date, however, only two studies provide evidence that chronic (>10 days)
attenuation of hippocampal ripples during the hour following learning slows down
the acquisition of hippocampus-dependent spatial memory tasks (Ego-Stengel and
Wilson 2010; Girardeau et al. 2009). Optogenetic control over ripples promises to
clarify the exact role of these rhythms in sleep.
To date, several studies successfully have demonstrated optogenetic control over
ripples. Using a hippocampal slice preparation in which spontaneous ripple genera-
tion occurs, Schlingloff et al. (2014) found that, in slices from PV::ChR2 expressing
mice, light pulses evoked ripples closely resembling spontaneous events. Interest-
ingly, these evoked ripples could also be elicited even when excitatory synaptic
transmission was pharmacologically abolished, suggesting that PV neuron-
dependent inhibitory circuitry can generate activity within ripple frequencies.
Using the light-gated chloride pump eNpHR 3.0, silencing PV-neurons largely
abolished the ripples. This study thus demonstrates that combining activating and
silencing optogenetic approaches provides valuable insight into mechanisms of
rhythm generation.
Two studies have identiﬁed powerful mechanisms of how ripple occurrence
is regulated through external inputs. Vandecasteele et al. (2014) show that opto-
genetic stimulation of cholinergic afferents into the hippocampus rapidly and almost
completely suppressed ripples in both urethane-anesthetized and freely moving
animals, while enhancing theta oscillations. Cholinergic hippocampal modulation
thus promotes a theta-dominated hippocampal state that is typical for active
Optogenetic Dissection of Sleep-Wake States In Vitro and In Vivo 141
behaviors, such as exploration and learning, while suppressing sleep-related
rhythms, such as the ripples.
Amodulatory action of median raphe on hippocampal ripples was identiﬁed through
driving ChR2 or eNpHR in median raphe neurons. Ripple occurrence was suppressed
when median raphe projections were stimulated, whereas ripple frequency increased
when median raphe activity was silenced (Wang et al. 2015). Further optogenetic
analysis revealed that serotoninergic but also non-serotoninergic neurons within the
median raphe each accounted for part of this effect. Wang et al. also found that
suppressing ripples for 4 h after contextual fear conditioning attenuates recall the
next day (Wang et al. 2015), thus relating ripple occurrence to learning.
Another important case that documents the usefulness of optogenetic tools is the
hippocampal theta rhythm that is found during both active exploration and REM
sleep. In addition to cholinergic inputs (see Schlingloff et al. 2014), septal
glutamatergic (Fuhrmann et al. 2015) or GABAergic inputs (Bender et al. 2015) in
awake animals contribute to this rhythm, yet the role of the distinct cellular groups
in exploration or REM sleep-related brain states has not been deﬁned yet. Fuhrmann
et al. (2015) used awake mice expressing ChR2 under the promoter of the vesicular
glutamate transporter 2 (VGlut2) and found that rhythmically entrained hippocampal
rhythms occurred when illuminating glutamatergic medial septal neurons at stimu-
lation frequencies of 6–12 Hz. Intriguingly, the frequency of these rhythms was
proportional to the running speed of the mice, indicating that glutamatergic neurons
within the septum correlate locomotion with hippocampal ﬁring rates. Hippocampal
rhythms, measured through local ﬁeld potential recordings in head-ﬁxed animals,
were tightly phase-locked to the light pulses, but continued occasionally once light
stimulation was terminated. Combining these light stimulation patterns with in vivo
whole-cell recording, a cellular mechanism involving dis-inhibition of pyramidal
cells through stratum oriens interneurons was described. The theta rhythm associated
with REM sleep is the subject of a separate chapter (see above) and necessitates
hypothalamic MCH neurons (Jego et al. 2013) as well as septal GABAergic neurons
(Boyce et al. 2016).
In conclusion, many of the major vigilance state-related related rhythms have
gained in understanding through optogenetic investigation, with the following major
results. (1) Key pacemaker elements such as TRN neurons for spindles, hippocampal
PV neurons for ripples, or layer 5 cortical neurons for slow waves were identiﬁed
and conﬁrmed prior studies. (2) Novel cellular mechanisms of rhythm generation
were described and linked to behavioral aspects of vigilance states. (3) Novel affer-
ent modulatory pathways controlling these rhythms were described. Next important
steps in the ﬁeld, to which optogenetics will undoubtedly contribute, are the exact
temporal coordination between rhythms during vigilance states and their role in
sensory perception and memory consolidation. Furthermore, the exact role of mod-
ulatory pathways, such as those converging on thalamus and hippocampus, will need
to be elucidated in terms of the control they occur on the global and local occurrence
of rhythms in the brain.
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4.2 Optogenetic Probing of Brain Rhythms in Memory Processes
Optogenetic suppression of rhythms has proved extremely useful in assessing their
role in memory consolidation. Wang et al. (2015) took a ﬁrst step in this direction
through speciﬁcally suppressing ripples through median raphe input following a
hippocampal-dependent contextual fear conditioning procedure. Such manipulation
deteriorated recall in the animals in which light suppressed the ripples, but not in
control animals. This ﬁnding extends pioneering studies on the role of ripples
in hippocampal memory formation, in which electrical stimulation of ventral hippo-
campus disrupted ripple occurrence and attenuated performance in a spatial maze
(Ego-Stengel and Wilson 2010; Girardeau et al. 2009). Most recently, instead of
suppressing neural rhythms, a study exploited the idea of reproducing slow wave
activity following a sensorimotor detection task (Miyamoto et al. 2016). Slow waves
were generated in mice expressing ChR2 speciﬁcally in layer 5 in a manner that
reproduced the coherence between somatosensory and motor circuits during the task.
This artiﬁcially induced synchronization enhanced memory and was even sufﬁcient
to overcome the memory deﬁcits caused by sleep deprivation (Miyamoto et al.
2016). In this elegant study, optogenetics could thus help to identify, for the ﬁrst
time, the critical synaptic pathways and interactions between cortical areas that lead
to perceptual memory.
The advantage of optogenetic inhibition was also used recently to speciﬁcally
suppress the hippocampal theta rhythm during REM sleep while leaving sleep
architecture, including the timing of REM sleep, largely untouched (Boyce et al.
2016). This was achieved through optogenetic suppression of medial septal GABA-
ergic neurons in a VGAT Cre driver line previously injected with AAV containing a
ﬂoxed ChR2 gene. Continuous illumination of the medial septum temporally locked
to REM sleep episodes suppressed theta rhythm generation speciﬁcally and thus
allowed to probe behavior in animals that had spent REM sleep time without theta
rhythm. This led to an impairment of contextual memory consolidation as assessed
by a novel object recognition task and fear conditioning, while other memories
remain intact.
In addition to manipulating rhythms to elucidate their role, optogenetic tools
also help to disrupt sleep architecture in speciﬁc ways, thereby overcoming the
limitations of conventional sleep deprivation techniques. These latter ones are
typically associated with many confounding factors, such as stress or sensory over-
stimulation (Longordo et al. 2009). The idea to disrupt sleep speciﬁcally was tested
by Rolls et al. (2011) who used optogenetic activation of hypocretin neurons to wake
up mice from non-REM sleep regularly, yet without interfering with other vigilance
states or with total sleep duration. Sleep thus essentially became more fragmented,
yet its architectural and spectral properties were otherwise preserved. Under these
conditions, mice showed deﬁcits in a hippocampus-dependent object recognition
task. To date, this is the cleanest approach relating fragmented sleep to altered
cognitive performance.
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5 Perspectives
Optogenetic tools provide bidirectional control of genetically deﬁned neuronal
populations with unprecedented temporal resolution and neurochemical speciﬁcity.
Therefore, it is not exaggerating to state that optogenetic methods have leveraged
research on sleep and wake states to a truly systems-oriented ﬁeld with causal and
dynamic insights from molecular to behavioral levels. As methods continue to be
reﬁned, long-awaited landmark progress in both mechanistic and functional aspects
of sleep and wakefulness is within reach. First and foremost, the neural circuitry
underlying the control of vigilance state will be further deﬁned and this will range
from understanding the deepest sleep stage up to the highest levels of arousal and
attention. To give just one example, optogenetic control of a major sleep-controlling
brain area, the ventrolateral preoptic (VLPO) circuitry has just started (Venner et al.
2016). It is likely that the cellular identities of VLPO neurons, the role of peptidergic
synaptic transmission, and the projection pathways involved in sleep will unravel a
hitherto unrecognized complexity of NREM sleep control that will allow to under-
stand further the regulation of NREM sleep states, the transitions to REM sleep, the
homeostatic control of NREM, as well as the circuitry control of NREM sleep depth.
In addition to VLPO, NREM sleep-promoting brainstem areas were recently
described, indicating that a hierarchy of structures is responsible for NREM-sleep
speciﬁc attributes of brain, muscular, and autonomic system. Clearly, a major task
will be to elaborate on these hierarchies to determine the “leaders” and “followers,”
the communication between these, the distinct tasks they take, and the signals they
integrate. Optogenetic silencing strategies are ideal for this goal, as already ex-
empliﬁed by the studies of Carter et al., who started elaborating the hierarchical
links between wake-promoting systems (Carter et al. 2013). In yet another step, a full
understanding of a vigilance state will need to provide a comprehensive deﬁnition
of physiological parameters, moving towards a unifying model of sleep that de-
lineates the crosstalk with the sensory periphery, and with cardiac, metabolic, and
temperature control systems. Optogenetic approaches, combined with novel genetic
methods, hold the potential to deconstruct vigilance states as bodily states to which
major organs contribute.
Light-triggered brain rhythms extend the mechanistic understanding of vigilance
states, to which classic electrophysiology has provided many of the cellular and
circuit basics. The topology of rhythms on local and global scales, the temporal
integration of different rhythmic events, and the cross-talk of rhythms in different
brain structures are all fundamental to advance the functional understanding of these
rhythms. Importantly, light-triggered rhythms need to be compared in waveform and
time course to their natural counterparts. The recruitment of cellular compartments,
proﬁles of sinks and sources in laminated structures, synaptic inputs, and topological
distribution are other elements to be explored using timed and reproducible oscil-
latory events initiated by light.
Analyses on the mechanics of sleep and wakefulness will provide clues to the
roles of brain structures and rhythms in sleep functions related to recovery, homeo-
stasis, and plasticity. The paper by Rolls et al. (2011), already discussed in this
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chapter, is an exemplary case for identifying novel approaches on sleep’s implication
in learning and memory through selectively interfering with one hierarchically high
brain area implied in wakefulness initiation. Optogenetic targeting of cellular kernels
of rhythms will also help elucidate actions of somnogens on sleep, daytime cogni-
tion, and memory, which in turn can provide indications to designing more speciﬁc
pharmacological strategies.
On the therapeutic side, optogenetic strategies to interfere or drive brain activity
related to states of sleep and wakefulness are already ongoing. Closed-loop stimula-
tion to trigger light stimuli in response to ongoing events, such as individual
sleep rhythms, turns out to be extremely successful not only to probe their role
(Miyamoto et al. 2016), but also to prevent pathological perversions of these, such as
it occurs during certain forms of epilepsies (Paz et al. 2013). In this latter case, once
slow rhythmic hyperactivity started, optogenetic closed-loop control was used to
inhibit activity in key neurons, thereby effectively anticipating and preventing
hypersynchrony. Thus, although optogenetic techniques are currently not amenable
for therapeutic purposes, they will deﬁnitely inspire techniques and targets based on
feedback to improve sleep or render it more efﬁcient in terms of its beneﬁcial effects.
6 Conclusive Remarks
Optogenetics have guided the way into a new area of neuroscience in general, and
into identifying key brain structures and projections involved in vigilance state
transition in particular. Still, the overall hierarchy of events needs to be elaborated.
Many brain areas involved in NREM or REM sleep generation are now identiﬁed,
but still it is not clear how they communicate with each other and how the transitions
between these is regulated by bodily states, homeostatic control, and pathological
conditions.
While unprecedented in speciﬁcity and dynamics, optogenetic tools do show
limitations. Not only are they invasive techniques that require complex tools, but
they are also limited in the speciﬁcity once targeted brain areas are really small or
consist of highly intermixed neuronal populations for which there is no good genetic
marker available yet. This holds true in particular for brainstem within which many
of the key areas involved in vigilance state initiation and maintenance reside.
Furthermore, optogenetic stimulation may lead to discharge patterns that do not
reproduce those occurring naturally, questioning whether the amount and type of
neurotransmitter released naturally could be reproduced (Arrigoni and Saper 2014).
For example, the release of neuropeptides typically requires more intense, more
prolonged, or burst discharge patterns. Clearly, unless optogenetics are controlled
for in terms of the faithfulness of reproducing natural neuronal activity and synaptic
transmission, they risk to provide false estimations of the roles of brain structures
in vigilance state control.
Optogenetic tools are currently being complemented by genetical engineering
techniques allowing to drive neuronal activity using pharmacological agents.
Amongst these, Designer receptor exclusively activated by designer drugs
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(DREADDs) can be virally transfected in a manner similar to ChR2 and lead to the
expression of G-protein-coupled receptors activated by intraperitoneal injection of a
selective ligand. These have already become a technological standard and turn out to
be extremely useful for studies of brain states, as they allow for stable manipulation
of neuronal activity over periods from minutes to hours (Fuller et al. 2015). How-
ever, DREADDs suffer from similar limitations as optogenetic tools in terms of the
speciﬁcity limited by the genetic construct and the injection size. Moreover, their use
has led to unexpected results in terms of the regulation of REM and NREM sleep
states (Hayashi et al. 2015).
Notwithstanding these limitations, the advent of optogenetics and related
methods had an extraordinary impact not only in experimental sleep research but
also in system neurosciences in general. The future reﬁnement of the optogenetics
tools and targeting methods will undoubtedly shine light on the brain mechanisms
underlying the states of sleep, wakefulness, and to a broader extend consciousness
and reveal basic functions of sleep for the brain, the mind, and the body.
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Abstract
Over the past decade, basic sleep research investigating the circuitry controlling
sleep and wakefulness has been boosted by pharmacosynthetic approaches,
including chemogenetic techniques using designed receptors exclusively
activated by designer drugs (DREADD). DREADD offers a series of tools that
selectively control neuronal activity as a way to probe causal relationship between
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neuronal sub-populations and the regulation of the sleep-wake cycle. Following
the path opened by optogenetics, DREADD tools applied to discrete neuronal
sub-populations in numerous brain areas quickly made their contribution to the
discovery and the expansion of our understanding of critical brain structures
involved in a wide variety of behaviors and in the control of vigilance state
architecture.
Keywords
Arousal · Chemogenetic · Designer Receptor Exclusively Activated by Designer
Drugs (DREADD) · Non-REM sleep · Paradoxical sleep · Pharmacogenetic ·
REM sleep · Slow-wave sleep · Wakefulness
1 Introduction
The development of new hypnotic and wake-promoting medications relies on a solid
understanding of the neurochemical mechanisms and brain circuits regulating sleep
and wakefulness to improve speciﬁcity of action with enhanced safety and efﬁciency.
Over the past decade, basic sleep research investigating the circuitry controlling sleep
and wakefulness has been boosted by pharmacosynthetic approaches, some of which
can be perceived as an ideal pharmacotherapeutic strategy involving G-protein-
coupled receptor (GPCR) signaling. Indeed GPCRs represent the largest class of
neuronal signal-transducing molecules capable of modulating neuronal ﬁring (see for
review Farrell and Roth 2013) and have proven to be the most highly favorable class
of drug targets in modern pharmacology (Drews 2000; Wise et al. 2004). In this
context, the development of designed receptors exclusively activated by designer
drugs (DREADDs) has already proven its relevance to molecular therapy implicating
GPCR-linked pathways in the modulation of the circadian rhythm and sleep-wake
cycle and in many behaviors and disorders including eating- and addictive-related
behaviors or autonomic dysfunctions (see for review Urban and Roth 2015).
Similar to optogenetic approaches (see Adamantidis and Lüthi 2018), the primary
goal of DREADD technique applied to systems neuroscience is to offer a series of
tools that selectively control neuronal activity as a way to probe causal relationship
between neuronal subpopulations and behavior. Its basic principle consists in
introducing exogenous genes into neurons that enable them to respond to speciﬁc
exogenous chemical ligands that have no interfering pharmacological effect. These
tools provide a powerful combination of genetic speciﬁcity and spatial precision for
a potential multiplexed control (multiple chemogenetic actuators controlling simul-
taneously or sequentially different neuronal pathways) that are critical for a systems-
level understanding of brain functions. However, in contrast with optogenetics,
DREADD technique lacks a temporal resolution to control the activation or silencing
of neurons within milliseconds. On the other hand, it further mimics longer-term
modulation of neuronal signaling associated with pharmacotherapeutic strategies
targeting GPCRs (see for review Urban and Roth 2015) and could be better suited for
large brain structures instead of volume-limited control through optic ﬁbers. The
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expansion of pharmacosynthetic approaches not only offers multiple ways to control
neuronal excitability but also allows to study and control gene transcription and
translation, protein-protein interactions, enzymatic function, and protein stability
(see for review Sternson and Roth 2014).
This chapter ﬁrst draws up the principles of the DREADD technology that has
been the most widely used in sleep research, followed by a discussion on the
potential limitations and concerns that were recently raised in the literature. This
section intends to identify and clarify the risks associated with DREADDs in order to
control and support future experiments and bring a better perspective at the reading
of the ﬁndings emerging from DREADDs in sleep research. Next we will review the
experiments deconstructing arousal- and sleep-promoting circuits and their resulting
discoveries and discuss their signiﬁcance in the face of past knowledge and future
directions.
2 Description of Pharmacosynthetic Tools
Two techniques emerged over the past decade to remotely control neuronal activity
in vivo: optogenetics based on engineered opsins (see Adamantidis and Lüthi 2018)
and pharmacosynthetic approaches including DREADD-based chemogenetics
utilizing engineered GPCRs and pharmacologically selective actuator molecules
(PSAM) utilizing chimeric ligand-gated ion channels (LGIC) that both selectively
interact with synthetic small molecules (see for review Farrell and Roth 2013;
Sternson and Roth 2014). In basic sleep research using rodent models, the DREADD
technology referred to as the third generation of muscarinic GPCR-based
chemogenetics (Armbruster et al. 2007) has been the most broadly adopted tool.
2.1 Principles of the DREADD Technology
The DREADDs were ﬁrst generated from the human M3 muscarinic receptors
subjected to random mutagenesis in the yeast and screened from absence of drug-
dependent growth assays in the presence of clozapine N-oxide (CNO). Resulting
surviving mutants (hM3DGq) evolve receptors that are activated only by CNO and
lack activation by their native ligand, acetylcholine (ACh) (Dong et al. 2010). CNO
is an inactive metabolite of the atypical antipsychotic clozapine. It was chosen for its
ability to penetrate the central nervous system and for its favorable pharmacokinetics
and inert pharmacology (Bender et al. 1994; Armbruster et al. 2007). However, few
reports raised concerns that CNO could be interconverted to clozapine in various
species (Lofﬂer et al. 2012; Gomez et al. 2017). While a small fraction of
interconverted CNO is established in humans, primates, and guinea pigs, the occur-
rence of this process in rodents is still debated and is further addressed in the next
section. Still in vitro, CNO activation of the hM3DGq mutant in transfected neurons
triggers Gq-coupled signaling leading to membrane depolarization through
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phospholipase C/PIP2-mediated inhibition of voltage-activated KCNQ potassium
channels (Armbruster et al. 2007; Alexander et al. 2009).
Using a similar design scheme, a second mutated human M4 receptor coupled to
Gi proteins (hM4DGi) was generated leading to neuronal hyperpolarization
mediated by G-protein-coupled inwardly rectifying potassium channels (GIRKs)
upon CNO application (Armbruster et al. 2007; Zhu et al. 2014). In vivo validation
of DREADD-driven neuronal activation or inhibition has been reported in numerous
studies conjointly with major behavioral consequences (see for review Sternson and
Roth 2014). However so far, only few groups combined CNO administration and
direct in vivo unit recordings to examine and directly control CNO-driven DREADD
effects on the spontaneous neuronal activity and ﬁring discharge. Most of these
studies conﬁrmed modiﬁcations of neuronal activities by ex vivo electrophysiologi-
cal recordings in brain slices or by indirect methods involving the labeling of the
cFos immediate early gene, as a marker of neuronal activation.
A third DREADD construct was generated from a chimeric muscarinic-
adrenergic receptor that selectively activates Gαs signaling pathways (rM3/β1Gs)
promoting cAMP production through the activation of adenylate cyclase (Guettier
et al. 2009; Farrell et al. 2013). Its ﬁrst use was applied to pancreatic β-cells in vitro
and in vivo to deconstruct insulin secretion signaling pathway (Guettier et al. 2009).
Unlike hM3DGq or hM4DGi receptors, a small degree of constitutive activity from
transfected cells has been reported with rM3/β1Gs leading to a modest basal
phenotype (Guettier et al. 2009). Interestingly, the speciﬁc activation of the different
G-coupled pathways using DREADD approaches was interrogated to deconstruct
the intracellular control of circadian pacemaking activity of suprachiasmatic nucleus
(SCN) neurons in vitro (Brancaccio et al. 2013). This study showed that, although
CNO-mediated induction of Gs signiﬁcantly increases calcium/cAMP-responsive
elements in a larger degree than Gq, the activation of Gq-dependent pathway in a
subset of SCN neurons, but not Gs or Gi, selectively reprograms the circadian
oscillations of intracellular calcium and transcriptional/posttranslation feedback
loop rhythms in the entire SCN (Brancaccio et al. 2013). This reorganization
requires a VIPergic signaling revealing a Gq-intracellular calcium-VIP leitmotif
that determines the intrinsic network encoding of SCN circadian time (Brancaccio
et al. 2013). In addition to a broad remote control of neuronal activity, this work
illustrates a major potential of DREADDs to interrogate the relationship between
G-coupled pathways, cytosolic signaling, and the transcriptional feedback loops
with neuronal activity.
The DREADD genes are expressed via transgenic or viral approaches for condi-
tional gene targeting. The most commonly used method to obtain high-expression
levels of DREADD consists in Cre-dependent viruses carrying the DREADD trans-
gene under the control of strong ubiquitous promoters (such as EF1α, hSyn) injected
in speciﬁc Cre-driver lines. The vast library of Cre-driver knock-in and bacterial
artiﬁcial chromosomes (BAC) transgenic mice available today offers thousands of
targeting possibilities. Still conﬁrmation of the speciﬁcity of the Cre expression in the
desired genetically deﬁned cell population by the absence of ectopic expression at
least in the region of interest when using viral vector approach is required. The
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activation of GPCR signaling pathways using DREADDs has revealed remarkably
speciﬁc behavioral and physiological inﬂuences for a variety of neuronal, but also
non-neuronal, cell types that are often intermingled with populations having different
or even opposite functions (see for review Sternson and Roth 2014; Roth 2016). Sleep
studies using DREADDs are further detailed in the next sections (Sect. 3) and listed in
Table 1. The main advantages of this technology are as follows: (1) it can be
minimally invasive as CNO can be administered orally in drinking water; (2) CNO
kinetics involve a prolonged modulation of neuronal activity (minutes to hours) with
physiological relevance to canonical and conserved GPCR signaling pathways;
(3) there is no specialized equipment required as all chemical actuators are commer-
cially available; (4) it allows a large-scale control of a diffuse neuronal ensemble,
which is challenging to illuminate with optogenetics, while it still allows subdomain
speciﬁc targeting with local injections; and ﬁnally (5) it is a relatively inert interven-
tion upon the CNO doses used. The main disadvantage of the DREADD system is the
lack of precise temporal control in comparison with what is achieved with
optogenetics. Compounds with enhanced pharmacokinetic properties and light-
activated photocaged compounds allowing for more precise control over time of
the DREADD receptor activation are still under development (see for review
Sternson and Roth 2014). Other disadvantages related to CNO and inherent
properties of GPCRs are further discussed in the following sections (Sects. 2.2 and
2.3).
2.2 What to Keep in Mind Before DREADD Use?
For a comprehensive understanding of the DREADD technology and a more effec-
tive use, inherent properties of GPCRs should be kept in mind. Many GPCRs show a
considerable amount of basal, ligand-independent activity implying that a GPCR can
activate its G protein in the absence of an agonist (see for review Kobilka and Deupi
2007). Therefore a major concern for chemogenetic approaches is the possibility that
high levels of expression of an engineered protein might have effects in the absence of
chemical activation (Conklin et al. 2008). This constitutive activity has been
questioned and examined for DREADD receptors. To date, none of the studies
using hM3DGq or hM4DGi have reported a basal phenotype implying no detectable
constitutive activity. Lifelong and considerably high levels of expression that were
attained using either a genetically encoded tetracycline-sensitive induction system or
viral transduction of hM3DGq or hM4DGi were not reported to have any abnormality
from basal electrophysiological, behavioral, or anatomical characterizations
(Alexander et al. 2009; Zhu et al. 2014; see for review Roth 2016). However, the
lack of report does not imply the absence of basal activity. A relatively low constitu-
tive activity was found with the rM3/β1Gs construct looking at cAMP and inositol
phosphate basal levels from transfected cells, which were not apparent with hM3DGq
(Guettier et al. 2009). However, no detectable electrophysiological, behavioral, or
anatomical phenotype was reported in a rM3/β1Gs transgenic mouse (Farrell et al.
2013). To counteract this issue if any basal activity is observed, cautions on titrating
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and lowering the level of DREADD expression using diluted viral preparations or
using a weaker promoter should be considered.
Another conceptual issue relates to the fact the GPCRs can activate more than one
G-protein isoform and can also signal through G-protein-independent pathways
involving β-arrestin (see for review Roth 2016). Thus, it questions under which
conditions β-arrestin signaling is activated and whether the effects observed on
neuronal activity and behavior result from canonical or noncanonical (G-protein-
independent) signaling. To date, there have been no reports suggesting that the
actions of CNO-mediated neuronal silencing or excitation, through hM4DGi and
hM3DGq, respectively, could be explained by other mechanisms than altered neu-
ronal ﬁring. Without excluding alternative pathways, the argument developed in
favor of major canonical signaling is based on several studies applying optogenetics
and DREADDs on the same neuronal populations that globally show equivalent
effects in nature and magnitude. However, some differences between optogenetics
and DREADD studies are still observed. This is notably the case when manipulating
hypothalamic peptidergic systems such as hypocretin/orexin (Hcrt/Orx)- or melanin-
concentrating hormone (MCH)-containing neurons and examining their impact on
sleep macroarchitecture (see Sect. 3.5). While optogenetic stimulation of Hcrt/Orx
neurons induces sleep fragmentation without affecting global sleep or wake amounts
(Rolls et al. 2011; Bonnavion et al. 2015), DREADD activation results in prolonged
wake and sleep deprivation over several hours (Sasaki et al. 2011). Many factors
here can have an impact underlying such differences including viral transduction
versus transgenic mice, or photostimulation paradigms versus CNO-driven activa-
tion, whose impact on Hcrt/Orx neuronal ﬁring in vivo is unknown. Still an
additional factor to consider could relate to the activation of differential downstream
effector pathways and physiological changes that could favor multiple transmitters’
co-release (see for review Bonnavion et al. 2016; Schöne and Burdakov 2017).
Interestingly, a DREADD that signals exclusively via β-arrestin has been developed
(Nakajima and Wess 2012) allowing to tackle in vivo the speciﬁc behaviors down-
stream of β-arrestin signaling.
One last concern with GPCR inherent properties relates to possible desensitiza-
tion and subsequent DREADD receptor downregulation following repeated admin-
istration of CNO. As with many GPCRs undergoing signiﬁcant downregulation only
following hours of agonist treatment, chronic treatment with CNO might result in
diminished responses or might induce a shift in the dose-response curve to higher
concentrations due to DREADD receptor desensitization and internalization. How-
ever, the degree of desensitization greatly depends on the extent to which receptors
are expressed. When DREADD expression is quite high, lower concentrations of the
chemical actuator are needed to achieve a maximal response (see for review Roth
2016). Therefore, considering the very high levels and density of virally or
transgenically induced DREADD expression, it is likely that the cellular responses
will be less sensitive to repeated CNO than when the mutated receptors are expressed
at lower levels. So far, no signiﬁcant desensitization was seen or reported using viral
or transgenic approaches.
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2.3 The CNO Versus Clozapine Case
Before the expansion of the CNO/DREADD system use, former studies focusing on
clozapine metabolism showed that clozapine is converted into its N-oxide metabolite
CNO but that a reversible pathway exists for a small fraction of CNO back-
metabolized to clozapine in guinea pigs and humans (Jann et al. 1994; Chang
et al. 1998). From the start, this observation challenged the mechanisms of action
of CNO in vivo and questioned whether this conversion could also occur in other
species including rodents and nonhuman primates. From many reports, CNO
appeared to be pharmacologically and behaviorally inert in rodents (Bender et al.
1994; Armbruster et al. 2007; Alexander et al. 2009; Guettier et al. 2009). However,
recent studies performed in mice, rats, and monkeys further investigated this possi-
bility by measuring the presence of clozapine following CNO administration
through various assays (Hellman et al. 2016; Gomez et al. 2017; Raper et al.
2017). Additionally, the blood-brain permeability of CNO has been reexamined
(Hellman et al. 2016; Ji et al. 2016; Nagai et al. 2016; Gomez et al. 2017; Raper et al.
2017). These recent papers emphasize three major points: (1) the afﬁnity of cloza-
pine to bind DREADDs is higher than CNO (Gomez et al. 2017); (2) CNO may not
cross the blood-brain barrier (Hellman et al. 2016; Gomez et al. 2017; Raper et al.
2017); and (3) CNO can be converted to clozapine under certain doses in monkeys
and rodents (Hellman et al. 2016; Gomez et al. 2017; Raper et al. 2017).
The ﬁrst point was made based on binding data and suggests that clozapine could
be more potent than CNO in activating DREADDs. Still, several studies showed that
CNO efﬁciently and rapidly controls neuronal ﬁring both in vitro and in vivo
(Alexander et al. 2009; Krashes et al. 2011; Parnaudeau et al. 2013; Alcacer et al.
2017). Importantly, it is also possible that clozapine, even at very low doses, can
activate endogenous receptors in addition to its action on DREADDs. Thus, to
appropriately compare efﬁciencies and kinetics of clozapine and CNO on targeted
neurons and neighbor cells, both drugs should be examined in parallel with in vitro
and/or in vivo electrophysiological recordings. In addition, Gomez and colleagues
performed locomotor behavioral tests to examine the effects of both CNO and “sub-
threshold concentrations of clozapine in dopamine D1 receptor-Cre mice expressing
hM4DGi transgene in the striatum and control GFP mice (Gomez et al. 2017). Their
results suggest that 1 mg/kg CNO would be equivalent to 0.01 mg/kg clozapine to
control locomotion in striatal D1-hM4Di-expressing mice without affecting locomo-
tion in control animals. However, the lack of locomotor effects in control mice
treated with sub-threshold concentrations of clozapine does not imply that it would
not affect other behaviors or cognitive processes. Plus, this efﬁciency on DREADD-
transfected neurons is limited to one neural system for now and should be further
tested over DREADD-validated ones on various behavioral responses. The need for
developing alternative compounds appears critical, but the switch to clozapine
should be carefully considered.
To conclude the last two other points, Gomez and colleagues ﬁrst employed PET
imaging and autoradiography in rats and mice that shows low-to-no signal of
radiolabeled CNO in brain tissue, which is contrasting with similar experiments
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also performed in transgenic DREADD mice showing a highest contrast of radio
signals for DREADD versus background with CNO than with clozapine (Ji et al.
2016). The major argument resides in the fact that the radiolabeled CNO signal could
have been due to converted radiolabeled clozapine. Indeed, contrasting results from
clozapine/CNO plasma measurements were reported in rodents and in monkeys
detecting clozapine after CNO systemic injections (Hellman et al. 2016; Gomez
et al. 2017; Raper et al. 2017) or not (Alexander et al. 2009; Guettier et al. 2009;
Nagai et al. 2016). It still remains elusive to explain or reconcile these differences.
Importantly, if such conversion happens, it primarily occurs in the liver through
cytochrome P450 enzymes, which are also present in the brain but at very low levels
(Mahler and Aston-Jones 2018). In addition, several studies demonstrated that CNO
efﬁciently activates signaling pathways on cell cultures and on diverse mammalian
and drosophila neuronal systems, in a shorter time frame than what is observed for
CNO/clozapine conversion (see for review Roth 2016). Indeed, Gomez and
colleagues reported that clozapine metabolized from CNO accumulates over time
such that its effects may be strongest 2–3 h after CNO injection. Based on the short
plasma half-life of CNO within 2 h (Alexander et al. 2009; Guettier et al. 2009), most
studies so far examined its effects within this ﬁrst 2-h period. However, late-onset
effects on behavior were not necessarily analyzed outside this 2-h window and
should be further monitored from now on.
It becomes clear that CNO is not an inert ligand upon the dose used. “Safe” doses
to administer in a systemic manner range from 0.1 to a maximum of 3 mg/kg in order
to avoid or minimize this interconversion. Also, in light of the low distribution in the
central nervous system of CNO, its delivery route could be revised using local
intracerebral (i.c.) injections (Stachniak et al. 2014; Vazey and Aston-Jones 2014)
instead of systemic administration to enhance its actions locally but involves a more
invasive approach.
Finally the critical point that these studies highlighted is the importance of
controlling and comparing CNO effects in appropriate DREADD-free control
animals, in addition to vehicle injections in the same DREADD-expressing subjects.
Ultimately these comparisons within and between subjects will reinforce the signiﬁ-
cance and speciﬁcity of action of CNO. Indeed most studies limited their results
comparing CNO to vehicle/saline injections, while growing evidences from mice,
rats, and monkeys studies report endogenous effects of CNO at certain doses in
control DREADD-free animals (Eldridge et al. 2015; MacLaren et al. 2016; Gomez
et al. 2017; Varin et al. 2018). Taken the possible conversion of CNO and the
sedative properties of clozapine (Hinze-Selch et al. 1997), these controls are crucial
in sleep studies. Indeed, a recent study using DREADD approaches to control and
modulate hypothalamic MCH neurons across the sleep-wake cycle showed that
CNO at the doses of 5 and 10 mg/kg increases slow-wave sleep and inhibits REM
sleep in control wild-type mice (Varin et al. 2018).
Altogether, these recent ﬁndings calling to re-evaluate the use of CNO at certain
doses through a systemic delivery route stress the need to develop and test alternative
compounds. Interestingly, non-CNO chemical actuators for DREADDs have been
tested such as a newly developed actuator named compound 21, and the
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FDA-approved hypnotic compound perlapine, both highly selective for hM3DGq
(Chen et al. 2015). Importantly, compound 21 is not back-metabolized via normal
routes to clozapine or related compound and thus represents a good alternative to
CNO (Chen et al. 2015). Perlapine has a modest afﬁnity for certain biogenic amine
receptors such as 5-HT2A, 5-HT6, 5-HT7 and D4, but appears to have more than a
10,000-fold selectivity for activating hM3DGq versus muscarinic receptors (Chen
et al. 2015). With careful titration to deﬁne sub-threshold doses, application of
perlapine in conjunction with DREADD-targeted activation could still be quite
relevant to study sleep-wake circuits notably in models of insomnia, and sedative
processes.
3 CNO-DREADD Experiments in Sleep Studies
The following sections review the major ﬁndings identifying the role of deﬁned
cell populations in the regulation of the sleep-wake cycle that emerged from
pharmacosynthetic approaches in rodents over the past 10 years (Fig. 1). So far, the
techniques employed appear to be exclusive to the use of the CNO/DREADD system.
Following up on the later concerns about the use of CNO and its possible
conversion to clozapine, most of the sleep studies presented here used CNO deliv-
ered systemically under the critical dose of 3 mg/kg. Although the majority of the
literature compared CNO effects to vehicle injections on their main ﬁgures, most
studies examined whether CNO at the dose employed had any endogenous effects on
DREADD-free control animals. So far in sleep studies, only one study explicitly
reported undesired sleep effects from CNO injections in wild-type mice at the dose
of 5 and 10 mg/kg (Varin et al. 2018). To have a clear vision of the procedures
employed, we drew up a table integrating all the studies presented here summarizing
the neuronal system and brain structure targeted, viral or transgenic approaches,
CNO dose used, and the major effects found on sleep-wake states (see Table 1) (Fig. 1).
3.1 GABA Systems
For the last decade, the use of both optogenetic and DREADD techniques
highlighted the multifaceted role of the major inhibitory neurotransmitter GABA
in sleep and wakefulness processes. Although the role of GABA in sleep induction
and maintenance is well established since most of the hypnotic treatments targets
GABAA receptors (Watson et al. 2012), the identiﬁcation of the GABAergic
populations involved remained elusive. Part of the reasons come from the fact that
GABAergic neurons are often intertwined among other neurons utilizing different
neurotransmitters but also that several neuronal populations previously thought to
release only glutamate (Glu), ACh, dopamine (DA), or histamine (His) also release
GABA (see for review Tritsch et al. 2016). These complex conﬁgurations prevented
the access and possibility to question the respective function and physiological role
of GABA neurotransmission until transgenic animals and gene targeting techniques
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including optogenetic and DREADD were developed. Thanks to these approaches,
our understanding of sleep circuits integrating multiple GABAergic systems has
been considerably revised for a predominant role of various GABA neurons in the
control of the sleep-wake cycle (see for reviews Brown and McKenna 2015; Luppi
et al. 2017) (Fig. 1). We review here the different studies using DREADD approaches
on various GABAergic populations that evidenced a role for GABA neurotransmis-
sion in the enhancement and maintenance of both sleep and wake states (Fig. 1).
3.1.1 GABAergic Sleep-Promoting Neurons of the Preoptic Area
A large body of evidence indicates that GABAergic neurons of the preoptic area
(POA) of the anterior hypothalamus play a crucial role in slow-wave sleep (SWS)
(Luppi et al. 2017). Indeed the CNO-induced excitation of GABAergic neurons in
the whole preoptic area resulted in an increase in SWS amounts during both the
diurnal inactive and the nocturnal active photoperiods (Saito et al. 2013). More
speciﬁcally, a dense population of SWS-active GABAergic neurons were found in
the median (MnPO) and the ventrolateral (VLPO) preoptic nuclei, evidenced by a
high number of cFos-positive neurons (immediate early gene used as a marker of
neuronal activation) correlating with time spent in SWS (Luppi et al. 2017). How-
ever, the causal role of these different populations in the MnPO and VLPO in the
initiation and maintenance of SWS still needed to be conﬁrmed. Besides, the POA is
composed of a mixture of mostly GABAergic sleep-active, wake-active, and state-
indifferent neurons (Takahashi et al. 2009). Interestingly, a group of researchers took
advantage of this consistent cFos pattern in the POA elicited by sleep enhancement
following either total sleep deprivation or sedation, to control the activity of these
sleep-active neurons and test their causal role in sedation and sleep (Zhang et al.
2015). To do so, Zhang and colleagues employed a Fos-TRAP/TetTag-DREADD
approach. This approach consists in the expression of a cFos-promoter inducible
hM3DGq gene selectively in the POA, MnPO, or lateral POA (LPO), by TetTagging
(Reijmers et al. 2007). More speciﬁcally, hM3DGq gene is only turned on following
cFos expression induced by neuronal activation that in turn drives tTA expression.
Temporal control over tTA-TRE recombination, and thus cFos-dependency, is
achieved through doxycycline administration and removal. As a result, neurons
that have been activated in vivo by a stimulus are tagged with hM3DGq and can
be speciﬁcally reactivated later by systemic CNO injection. To examine the causal
relationship between these neurons and sleep, TetTagging is performed during
recovery sleep following total sleep deprivation or during sedation induced by the
adrenergic α2 agonist, dexmedetomidine. Importantly, reactivating either sleep
rebound-tagged or sedation-tagged neuronal populations produces sustained SWS,
20 min after CNO injections, together with a lower body temperature suggesting that
α2 adrenergic-induced sedation and recovery sleep share homologous hypothalamic
circuitry (Zhang et al. 2015). Single-cell RT-qPCR revealed that a majority of
TetTagged POA neurons are GABAergic (84%) and the remaining cells
glutamatergic. This study brings the proof of concept that some MnPO and LPO
GABAergic neurons are not only passive sleep-active neurons but are indeed
major effectors in SWS induction. In another study, downstream targets of POA
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GABAergic neurons were further examined with optogenetics highlighting wake-
active histaminergic (His) neurons of the tuberomammillary nucleus (TMN) as a
major target to inhibit in order to elicit SWS (Chung et al. 2017). In agreement with
this observation, acute optogenetic silencing of TMN His neurons rapidly induces
SWS (Fujita et al. 2017).
The next three discoveries using DREADDs on GABAergic neurons allowed
to identify three novel systems involved in the promotion or facilitation of sleep in
mice.
3.1.2 GABAergic Sleep-Promoting Neurons in the Rostral Medulla
Early experiments 60 years ago suggested that the caudal brainstem contains
SWS-promoting system (see for review Anaclet and Fuller 2017). While most
studies focused on the rostral hypothalamus and in particular the POA as a major
structure at the core of sleep onset and maintenance mechanisms since von
Economo’s ﬁrst observations (Economo 1930), seminal work proposing the hypoth-
esis of a brainstem sleep system was dismissed until recently and further examined
with DREADDs. The newly identiﬁed neuronal ensemble located lateral and dorsal
to the facial nerve in the rostral medullary brainstem, named the parafacial zone
(PZ), was ﬁrst evidenced by a state-speciﬁc cFos pattern related to sleep (Anaclet
et al. 2012). Those sleep-active neurons express the vesicular GABA/glycine trans-
porter (VGAT) also known as vesicular inhibitory amino acid transporter (VIAAT).
Using transgenic VGAT-cre mice in combination with cre-dependent viral vector
carrying DREADDs, Anaclet and colleagues challenged both the sufﬁciency and
necessity of PZ GABAergic neurons to control sleep-wake states (Anaclet et al.
2014). Upon CNO-mediated activation of hM3DGq-expressing GABAergic
neurons in the PZ, animals quickly express a predominance of SWS state within
the ﬁrst hour during their nocturnal active period, lasting for 3 h. This increase of
SWS was observed at the expense of both wakefulness and REM sleep and is
associated with increased cortical slow-wave activity (Anaclet et al. 2014). Recipro-
cally, CNO-induced inhibition of hM4DGi-expressing PZ neurons during the inac-
tive diurnal period rapidly and strongly decreases SWS (Anaclet et al. 2014). One
puzzling result harvested in this study is the consistent inhibition of REM sleep
observed following both the activation and the inhibition of PZ GABAergic neurons.
This effect remains unclear and could depend on parallel circuits impacting on REM
sleep initiation and its EEG features. However this effect coupled to the absence of
REM sleep rebound also questions the maintenance of a natural sleep physiological
regulation after CNO-induced activation or inhibition of PZ neurons.
Using optogenetic-mediated circuit mapping, Anaclet and colleagues dissected
the circuitry underlying PZ GABAergic promotion of SWS. They observed that
neurons in the parabrachial nucleus (PB) projecting to the magnocellular basal
forebrain (BF) receive monosynaptic inhibitory inputs from GABAergic PZ neurons
and that BF neurons projecting to the dorsomedial prefrontal cortex (dmPFC)
receive monosynaptic excitatory inputs from glutamatergic PB neurons (Anaclet
et al. 2014). Previous work performed by the same group also demonstrated that the
PB to BF pathway is critical for the desynchronization of the cortical EEG (Fuller
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et al. 2011). This follow-up study shows a direct inhibitory control of PZ VGAT
neurons onto PB neurons projecting to the BF (Anaclet et al. 2014). Thus, the
authors hypothesize that the PB inhibition applied by PZ neurons would decrease
the major excitatory inputs to dmPFC-projecting neurons in the BF that would in
turn modulate cortical activity and result in disrupted arousal. This brainstem-
forebrain-cortex pathway involving medullary release of GABA would act in paral-
lel to the reticulo-thalamo-cortical pathway (Llinas and Steriade 2006) to control
behavioral and electrocortical arousal. However the causal relationship of this series
of inhibitions and activations of different brain structures and neuronal
subpopulations occurring cooperatively to control behavioral arousal remains to be
established.
3.1.3 Subthalamic GABAergic Control of Sleep
Another study investigating the organizational complexity of the diencephalon
highlighted a subset of GABAergic neurons located in the ventral zona incerta
(ZI) in the control of sleep (Liu et al. 2017). This subset of GABAergic neurons is
characterized by the expression of a LIM homeodomain transcription factor gene,
Lhx6, early in development. Using a Lhx6-cre transgenic mice, the researchers
conﬁrmed the presence of this marker in GABAergic neurons co-expressing
GAD1 and VGAT, distinct from Hcrt/Orx and MCH neurons, in a zone extending
from the ventral ZI through the dorsomedial (DMH) and lateral (LH) hypothalamus
to the posterior hypothalamus (Liu et al. 2017). The ﬁrst link associating ZI Lhx6/
GABAergic neurons activity with sleep was shown by the circadian distribution of
cFos staining in ZI Lhx6 neurons with increased cFos levels correlating with
circadian times associated with high sleep pressure (Liu et al. 2017). However,
puzzling results were obtained on cFos levels after a 6-h sleep deprivation alone or
in combination with 1 h of recovery sleep. Both conditions elevate cFos in ZI Lhx6
neurons in a similar manner, which does not discriminate whether cFos pattern
reﬂects purely wake- or sleep-active neurons or neurons integrating sleep pressure
(Liu et al. 2017). Using DREADD, Liu and colleagues directly assessed whether the
manipulation of ZI Lh6x GABAergic neuron signaling modulates sleep. In vivo, the
selective activation of hM3DGq or hM4DGi receptors in ZI Lh6x neurons affects
SWS amounts in a bidirectional manner, promoting or reducing SWS, respectively
(Liu et al. 2017). However these effects are observed from 4 to 6 h after CNO
injection during the diurnal inactive period. These late-onset effects are surprising
and could be interpreted as unspeciﬁc or attributed to CNO conversion to clozapine
(see Sect. 2.3). However, the CNO dose used here is among the lowest (0.5 mg/kg)
which would dismiss any major effects of late interconversion of CNO to clozapine.
In addition, CNO injection in control DREADD-free animals was reported to be
inert. More immediate effects are observed when CNO is delivered during the active
nocturnal period enhancing SWS with increased delta power. However, inconsistent
results were found on REM sleep: no effect was observed when CNO was injected
during the active phase, while a bimodal effect occurred when CNO was
administered during the inactive period characterized by an immediate inhibition
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followed by long-lasting enhancement of REM sleep. Further connectivity studies
would be necessary to interpret these effects on REM sleep.
An alternative way to interpret these results would be that ZI Lh6x neuron
activation is related to the integration of sleep pressure and sleep need. This would
explain the late-onset SWS-promoting effects observed after neuronal excitation as
well as the absence of increase in SWS amounts in the second half of the diurnal
inactive period, after the inhibition of Lhx6 neurons. Experiments involving total
sleep deprivation and inhibition of ZI Lh6x neurons during sleep deprivation or
immediately in the beginning of the recovery period would better address this view.
Moreover, mapping experiments show that ZI Lh6x neurons form an interconnected
local network, which could partly explain slow-onset for SWS enhancement, imply-
ing that other ZI GABAergic neurons would be involved in either wake-promoting
processes or REM suppression (Liu et al. 2017). However, another study showed
that global DREADD activation of ZI VGAT-expressing neurons does not exhibit
any increase in wakefulness following CNO injections at 0.3 mg/kg (Venner et al.
2016).
Tracing experiments indicated that ZI Lh6x neurons receive inputs from various
brain structures both unrelated and related to the control of sleep-wake cycle (Liu
et al. 2017). Among these structures, Liu and colleagues focused on reciprocal
connections that ZI Lh6x neurons share with the lateral hypothalamus (LH). They
observed that both GAD2-expressing GABAergic cells and Hcrt/Orx neurons of the
LH are directly inhibited after ZI Lh6x optogenetic activation (Liu et al. 2017). As a
result, they hypothesized that part of the mechanisms involved in ZI Lh6x-driven
enhancement of sleep requires inhibition of the wake-promoting neurons of the
LH. Consistently, direct inhibition of a subpopulation of GABAergic (VGAT-
expressing) cells in the LH induces SWS, mainly through a disinhibition of the
thalamic reticular nucleus (Herrera et al. 2015). Moreover, inhibition of LH GAD2-
expressing neurons reduces physical activity and locomotion (Kosse et al. 2017).
However, overall, modest effects result from ZI Lh6x DREADD activation consid-
ering that CNO-induced enhancement of sleep occurs with delay and is limited to
increased amounts but unchanged SWS bout mean duration or wake-to-sleep
transitions. Thus, it is unlikely that ZI Lh6x GABAergic neurons act as primary
effectors in SWS induction as POA or PZ neurons do.
To apprehend the complexity of diencephalic and mesencephalic neuronal
networks regulating sleep-wake cycles, modeling approaches could further inform
on the hierarchical organization of these parallel circuits and their dynamics and
could in particular better identify and position the role of ZI Lh6x GABAergic
neurons and their relative involvement in sleep promotion of sleep pressure
mechanisms. Besides, further investigations are necessary to track down functional
diversity among ZI GABAergic neurons.
3.1.4 Sleep Control in the Basal Ganglia
At last, by investigating the mechanisms by which adenosine promotes sleep
(Bjorness and Greene 2009), two groups of researchers recently identiﬁed alternative
pathways in the basal ganglia (BG) circuitry necessary and sufﬁcient to generate
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slow-wave activity and a behavioral state resembling sleep using DREADDs (Oishi
et al. 2017; Yuan et al. 2017). The BG is composed of four major nuclei including
the striatum (caudate and putamen, CPu), which is the primary input nucleus, globus
pallidus (GP), subthalamic nucleus (STN), and substantia nigra pars reticulata (SNr)
as the major output nucleus. The BG is strongly interconnected with the cortex,
thalamus, and midbrain structures including the DA-enriched ventral tegmental area
(VTA) and substantia nigra pars compacta (SNc), as well as many other brain areas
from the limbic system (Graybiel 2008). The striatum is divided into three territories,
a dorsolateral (DLS), a dorsomedial (DMS), and a ventral domain also named
nucleus accumbens (NAc), associated with distinct functions in regard to their
cortical and limbic inputs (Graybiel 2008). These subdivisions, topographically
connected with cortical and subcortical structures, carry information related to
sensorimotor, associative, and limbic functions, respectively. The striatum is seen
as a hub orchestrating BG functions including action control, skill learning, habit
formation, incentive motivation, and goal-directed behaviors (Graybiel 2008;
Balleine and O’Doherty 2010; Jin and Costa 2010). The BG activity during sleep-
wake states has been largely underexplored, while dysfunction of the striatum is
frequently associated with sleep disturbances (see for review Lazarus et al. 2012).
Some studies indicated two major points: (1) several distinct ﬁring patterns in BG
nuclei across the sleep-wake cycle (Magill et al. 2000; Urbain et al. 2000) and
(2) activity changes in striatal neurons from cyclic, fast active ﬁring to highly
irregular ﬁring during sleep-to-wake transition (Mahon et al. 2006), suggesting
distinct striatal processing depending on arousal state. In addition, the striatum is
composed predominantly of GABAergic medium spiny output neurons (MSNs)
divided into two populations: those expressing dopamine D1-receptors, directly
projecting to the globus pallidus pars interna (GPi)/SNr, and those expressing
adenosine A2A and dopamine D2 receptors, projecting to the globus pallidus pars
externa (GPe) involving multiple nodes down to the SNr (Durieux et al. 2011).
These two neuronal subpopulations form the “direct” (dMSNs) and “indirect”
(iMSNs) pathways of the BG thought to act concomitantly but antagonistically
during action selection to execute appropriate motor and cognitive responses (see
for reviews Balleine and O’Doherty 2010; Jin and Costa 2010). In this context, the
recent studies using DREADDs to tackle the role of A2A-expressing iMSNs, known
as action suppressors, in the control of vigilance states further challenge the exis-
tence of parallel sleep-wake regulatory pathways and question the function of BG in
sleep as well as the role of the hypnogenic factor adenosine (Oishi et al. 2017; Yuan
et al. 2017).
Using hM3DGq and hM4DGi cre-dependent viral vectors targeting A2A-Cre-
expressing iMSNs in the striatum, two groups of researchers observed that
DREADD control of iMSNs located in the core region of the NAc (Oishi et al.
2017) and in the dorsal striatum in its rostral extension (Yuan et al. 2017) inﬂuences
sleep in a bidirectional manner. DREADD hM3DGq activation of iMSNs in both
striatal regions results in the promotion of a state resembling SWS, characterized by
slow and high-voltage EEG. Reciprocally, hM4DGi-dependent inhibition of iMSNs
reduces SWS amounts. Previous work examining the effects of local infusion of A2A
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agonist showed that adenosine-mediated activation in the ventral striatum elicits
both SWS and REM sleep in rats (Satoh et al. 2006). However, here, DREADD
hM3DGq activation of both ventral and dorsal iMSNs promotes SWS without
affecting REM sleep amounts. Subtle differences are also observed between the
two striatal subdivisions on SWS facilitation evoked by A2A-iMSNs activation,
which is underlined by an increase in the number of SWS episodes with NAc core
activation (Oishi et al. 2017) and, on the other hand, by a lengthening of SWS
episodes with rostro-dorsal activation (Yuan et al. 2017).
Both DREADD-driven effects on sleep increase are recapitulated by optogenetic
stimulation of iMSNs in the NAc core (Oishi et al. 2017) or stimulation of dorsal
iMSN terminals in the GPe (Yuan et al. 2017). However, kinetics of effects between
optogenetics and DREADD activation importantly differ when targeting NAc core
iMSNs (Oishi et al. 2017). The optogenetic-induced sleep-like state is almost
immediate, while CNO-promoting effects appear only in the second hour after
i.p. injection. In comparison, sleep induction resulting from hM3DGq activation of
PZ neurons occurs rapidly after 15–20 min following injection for a similar dose of
CNO (Anaclet et al. 2014; Oishi et al. 2017). This comparison cannot be made with
DREADD activation of dorsal iMSNs as the dose of CNO employed was higher.
Importantly, CNO-mediated activation of hM3DGq-expressing iMSNs was found to
increase the response to depolarizing stimuli but does not induce any spiking per se
(Alcacer et al. 2017). Unlike optogenetics (Oishi et al. 2017), DREADD activation
of iMSNs through hM3DGq pathway likely increases the neuronal excitability but
does not excite neurons, which still requires further in vivo conﬁrmations. However,
it might explain the differences in CNO versus optogenetic kinetics. In contrast,
DREADD-dependent Gi inhibition of NAc core iMSNs seems to induce a reduction
of SWS amounts more rapidly within the ﬁrst hour following i.p. injection (Oishi
et al. 2017). Interestingly in both regions, NAc core and rostro-dorsal striatum,
presumed inhibition of hM4DGi-expressing iMSNs decreases SWS amounts for at
least 4 h without inducing (Oishi et al. 2017; Yuan et al. 2017) or affecting
homeostatic sleep rebound after sleep deprivation (Oishi et al. 2017), suggesting
that rebound mechanisms may involve different pathways.
As a result, the involvement of the striatal indirect pathway in sleep induction is
puzzling. Oishi and colleagues proposed that NAc iMSNs would act ahead of POA
sleep-active neurons upon the inﬂuence of adenosine levels, by depressing the
arousal circuitry in BF, which, in turn, would release POA sleep-promoting system.
On the other hand, Yuan and colleagues were also able to promote SWS by directly
inhibiting with DREADD the downstream target neurons of dorsal iMSNs in the
GPe that are also inhibitory cells expressing parvalbumin (PV). Moreover, the
selective lesion of PV neurons in the GPe abolished the increase in SWS caused
by DREADD activation of iMSNs (Yuan et al. 2017), suggesting that the activation
of A2AR neurons in the striatum inhibits GPe PV neurons to promote SWS. These
alternative circuits emerging from the striatum require further investigations notably
including in vivo monitoring of iMSNs activity across the natural sleep-wake cycle
in addition to tracing studies from the NAc core and GPe to further support their role
in SWS induction. Interestingly, sleep-wake cycle is not altered by photostimulation
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of iMSNs in the shell region of the NAc (Oishi et al. 2017) or by DREADD
activation of the caudal part of the dorsal striatum (Yuan et al. 2017), suggesting
specialized functions in the different striatal territories for the modulation of vigi-
lance states.
It is important to keep in mind that the primary functions of the striatum are
critical for behaving animals and thus arousal, in order to process multiple signals
and execute motor control and action selection. Even if it does not necessarily imply
that these neurons cannot have a role in sleep, the papers mentioned above focused
their analysis on sleep-related parameters. However sleep and wake patterns are
organized in a continuum and should not be considered as segregated events. The
DREADD activation of NAc core iMSNs induces a concomitant reduction of
locomotor activity (Oishi et al. 2017), but wakefulness amounts and waking EEG
pattern have not been reported to further inform on mice levels of arousal or
alertness. Reciprocally, DREADD inhibition of the NAc indirect pathway was
found to increase ambulatory activity (Carvalho Poyraz et al. 2016), and DREADD
inhibition of iMSNs in the dorsal striatum is only efﬁcient in increasing wake during
the active dark period (Yuan et al. 2017). However, activation of the latter neurons is
also accompanied by decreased wake amounts with shortened mean duration (Yuan
et al. 2017). This mixture of behaviors is critical when the dorsal striatopallidal
pathway is involved as its activation through DREADD was also found to control
general motor output (Alcacer et al. 2017). Therefore, it is still questionable whether
the effects observed here reﬂect SWS induction or loss of motor control progres-
sively driving the animals to enter into an immobile quiet state of wakefulness harder
to distinguish from sleep. Alternatively, the effects described above could depend on
an inhibition of wake maintenance mechanisms, which would ultimately and indi-
rectly facilitate sleep onset. For future investigations, it is capital to examine closely
iMSNs activity from distinct striatal subdivisions during spontaneous sleep-wake
states to better characterize a potential role in sleep promotion and wake mainte-
nance and challenge the inﬂuences of the direct pathway by opposition. In addition
to the deconstruction of state transitions, it would be interesting to address the
functions of BG in sleep that could be relevant to learning and memory processes.
3.1.5 GABA: Not Just a SWS Driver
GABA was ﬁrst considered to act as the principle driver for SWS by silencing
waking systems. However, recent ﬁndings using optogenetics and DREADD
highlighted a more complex role for GABA neurotransmission in all vigilance states.
DREADD approaches contributed to distinguish two types of GABA cells with the
primary function to either promote waking or repress REM sleep, located in the
hypothalamus, in the BF and cortex, or in the brainstem, respectively (see for review
Luppi et al. 2017). The contributions of GABA from the BF in various features of
waking will be addressed in a following section reviewing the role of ACh (see Sect.
3.3.2). Cortical GABAergic interneurons, principally PV neurons, have been shown
to exert a critical role in the generation of gamma rhythm during waking, which was
mainly investigated and recapitulated with optogenetics (see Adamantidis and Lüthi
2018). We will thus review here three papers using DREADDs highlighting the
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diverse role of GABA in different brain regions (Fig. 1): promoting wake through
the hypothalamus in the LH (Venner et al. 2016) and in the bed nucleus of the stria
terminalis (BNST) (Kodani et al. 2017) and suppressing REM sleep in the ventro-
medial medulla (Chen et al. 2017).
Wake-Promoting GABAergic Neurons in the Hypothalamus
Optogenetics identiﬁed for the ﬁrst time a subpopulation of GABAergic neurons in
the LH, targeted by the expression of VGAT transporter in a VGAT-IRES-Cre line,
responsible for a rapid switch from SWS to waking state involving a direct control of
the thalamic reticular nucleus (TRN) as well as on the locus coeruleus and the
periventricular thalamus (Herrera et al. 2015). Interestingly, using DREADDs in a
similar transgenic VGAT-IRES-Cre mouse, Venner and colleagues described a
GABAergic neuronal subpopulation in the LH qualitatively displaying a similar
projection pattern in the POA and the pontine tegmentum but lacking axonal
innervation of the TRN (Venner et al. 2016). Some slight differences in the localiza-
tion of transfected neurons could explain such a difference: GABAergic cells in a
more dorsal position within the LH and may be overﬂowing in the ZI could
preferentially innervate the TRN. However an extensive description of the
transfected area is missing to support this hypothesis or even formulate an alternative
one. Despite these anatomical considerations, CNO-mediated activation of
hM3DGq-expressing GABAergic neurons in the LH results in sustained waking,
whereas the inhibition of the same neurons increases SWS amounts. The wake-
facilitating effects of the stimulation of these GABAergic neurons could be mediated
through their dense innervation of the POA and in particular the VLPO. However,
previous work described that VGAT-expressing neurons in the LH ﬁre maximally
during SWS or REM sleep (Hassani et al. 2010) or increase their ﬁring transiently
after the transition from SWS to wake (Herrera et al. 2015). Moreover, a partially
distinct population of GABAergic cells expressing GAD65 (GAD2) were found to
be involved in stress-induced increase in locomotion downstream of Hcrt/Orx
neurons (Kosse et al. 2017). All these results question the cellular complexity and
heterogeneity of GABAergic neurons in the LH that serves as a major hub in
multiple physiological responses and in particular where numerous allosteric factors
affecting sleep-wake architecture could be integrated (see for reviews Bonnavion
et al. 2016; Herrera et al. 2017).
One of these allosteric modulations could arise from the BNST, which is a
constituent of the extended amygdala and plays a key role in stress responses and
anxiety (Lebow and Chen 2016). Indeed, GABAergic GAD67 (GAD1)-expressing
neurons of the BNST send dense axonal projections to the LH as well as to other brain
areas involved in waking control such as the TMN, the locus coeruleus (LC), the
dorsal raphe nucleus (DRN), or the dorsal deep mesencephalic reticular nucleus
(dDpMe) (Kodani et al. 2017). The acute activation of these neurons using
optogenetic stimulation during SWS episodes or a more sustained activation using
DREADD tools resulted in increased wakefulness associated with an increased
activation of Hcrt/Orx neurons in the LH and noradrenergic neurons in the LC
quantiﬁed through cFos immunodetection. Interestingly, the arousal effects induced
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by DREADD-mediated activation of GABAergic BNST neurons was reversed by the
administration of the dual Hcrt/Orx receptor antagonist DORA-22, whereas it was not
the case for the acute optogenetic activation of the same neurons (Kodani et al. 2017).
Thus, GABAergic BNST neurons could play a key role in the SWS-to-wake transi-
tion without recruiting Hcrt/Orx neurons, while their sustained activation would
involve Hcrt/Orx neurons to maintain waking. Additionally, the axonal projection
of GABAergic BNST neurons to the LH was previously found to strongly drive food
consummatory behaviors (Jennings et al. 2013). Thus, BNST neurons could provide
a powerful allosteric modulation of LH neurons and potent other brain structures to
drive and maintain arousal required for food-related behavior completion.
GABAergic Control of Waking in the Ventral Medulla
Multiple studies over the years highlighted the importance of GABAergic/
glycinergic (GABA/Gly) neurons in the ventral medulla in the control of muscle
atonia associated with REM sleep potentially acting as inhibitory premotor neurons
through their descending projections to the spinal cord (Fraigne et al. 2015).
Recently, one paper using DREADD probed the role in the control of wakeful-
ness and REM sleep atonia of GABA/Gly neurons in the ventromedial medulla at
different levels in the rostrocaudal extent of the medulla (Chen et al. 2017). Chen and
colleagues studied in parallel two portions of the ventromedial medulla: the ventro-
medial medulla rostral to the inferior olive (pSOM) and the rostral ventromedial
medulla (RMV). Anatomically, RMV comprises the rostral raphe magnus (RMg),
the raphe interpositus (RIP) nucleus, and the medial portion of the rostral
gigantocellular reticular nucleus (Gi), whereas pSOM comprises the caudal part of
the RMg, a centromedial portion and pars alpha of the Gi (GiA), and the rostral raphe
obscurus nucleus (ROb). Diphtheria toxin-mediated ablation of either pSOM
neurons or RMV neurons does not produce signiﬁcant alteration in the sleep-wake
architecture. However, lesions of the pSOM area cause an increase in phasic brief
muscle activity during REM sleep recorded in the dorsal neck muscles without
affecting tonic atonia. This suggests a role of pSOM neurons in the repression of
twitches-like events during REM sleep. DREADD-mediated activation of RMV
neurons whatever their neurochemical identity in rats induces increase in waking
at the expense of both SWS and REM sleep, whereas activation of pSOM neurons
unexpectedly induces a suppression of REM sleep compensated by a non-signiﬁcant
increase in waking and associated with a non-signiﬁcant decrease in SWS. No effect
was observed on REM sleep atonia or twitches-like events during REM sleep. The
effect of pSOM neurons activation in rats was replicated in mice by speciﬁcally
targeting DREADD expression in GABA/Gly neurons in the pSOM area. The above
results reinforce the critical contribution of some GABA/Gly neuronal
subpopulations in the control of REM sleep atonia and wake entry. It also contributes
to highlight the complexity of neuronal networks controlling either REM sleep or
REM sleep atonia in the ventral medulla. Indeed one population of GABA/Gly
neurons in the ventral medulla located mostly in the lateral paragigantocellular
nucleus (LPGi) and in the most ventral portion of the caudal Gi was found to be
important in the promotion of REM sleep through ascending projections to the
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ventrolateral periaqueductal gray (Weber et al. 2015). Conversely the suppression of
GABA/Gly neurotransmission in adjacent neurons in the GiA, GiV and RMg causes
a loss of muscle atonia during REM sleep associated with increased twitches
mimicking symptoms of REM sleep behavior disorder (RBD) (Valencia Garcia
et al. 2018). The upstream neurons of these systems controlling REM sleep onset
or REM sleep atonia would be the glutamatergic neurons of the sublaterodorsal
nucleus (SLD), the main REM sleep-promoting center, whose loss-of-function
impedes REM sleep and produces similar RBD-like phenotype (Valencia Garcia
et al. 2017).
3.2 Glutamatergic Systems
Multiple glutamatergic (Glu) neuronal populations were identiﬁed to contribute to the
regulation of vigilance states. In comparison with the GABAergic systems that
roughly facilitate sleep occurrence, Glu neurons hold a more versatile position (Fig. 1).
3.2.1 Glutamatergic Neurons in the Diencephalon
A ﬁrst group of Glu neurons whose role in sleep-wake control has been evaluated
using DREADD is located in the supramammillary nucleus (SUM) (Pedersen et al.
2017). Located in the caudal hypothalamus, the SUM exerts strong modulatory
effects on the hippocampal formation and temporal cortex, in particular in relation
to the control of theta rhythms (Thinschmidt et al. 1995). These neurons seem to play
important roles during wakefulness in the control of anxiety-related behaviors,
physiological stress, and defensive actions (see for review Pan and McNaughton
2004). In relation with sleep-wake regulation, SUM neurons strongly express the
immediate early gene cFos after a REM sleep hypersomnia following REM sleep
deprivation using the platform-over-water method and seem to be important for the
activation of the dentate gyrus (DG) associated with REM sleep hypersomnia and
theta rhythm during REM sleep (Renouard et al. 2015). Importantly, the majority of
DG-projecting SUM neurons might be able to release both Glu and GABA (Soussi
et al. 2010; Billwiller et al. 2017).
Chemogenetic interrogation of the role of SUM neurons in sleep-wake control
was performed by injecting AAVs carrying cre-dependent DREADD constructs in
the posterior hypothalamus of VGlut2-cre mice (Pedersen et al. 2017). The resulting
transfected area indeed covered the entirety of the SUM but also extended more
caudally in some portions of the posterior hypothalamus and the lateral hypothala-
mus. CNO-induced stimulation of hM3DGq-transfected neurons results in sustained
wakefulness lasting from 6 to 10 h. This effect is almost completely abolished when
knocking down VGlut2 in hM3DGq-expressing neurons. The remaining wake-
promoting effects could be mediated through GABA release from the same neurons
as CNO-induced stimulation of VGAT-expressing neurons produces similar effects.
However, the size of transfection sites and the atypical absence of sleep rebound
following prolonged wakefulness might raise the question about the speciﬁcity of
the effects observed. Moreover, activation of DREADD-transfected Glu neurons
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increases theta rhythms, which is consistent with previous reports (see for review
Pan and McNaughton 2004), and promotes gamma oscillations. The latter observa-
tion should be interpreted with caution as EEG gamma rhythms can be easily
contaminated by muscle activity (Buzsáki and Schomburg 2015). Conversely,
CNO-induced inhibition of Glu neurons in a large area covering the SUM only
produces slight effects with a small increase in sleep amounts and number of sleep
episodes (Pedersen et al. 2017). Spectral analysis also indicates a reduction in theta
oscillations during wake and a slowdown of theta rhythm during REM sleep that are
consistent with previous observations during wake or REM sleep after deletion of
SUM neurons (Pan and McNaughton 2004; Renouard et al. 2015).
Based on the contributions of SUM neurons in anxiety-related behaviors, stress,
and defensive responses, the nature of the evoked-awakening and arousal state
resulting from SUM DREADD-driven excitation remains unclear, whether it could
actually be associated with high stress levels and anxiety. As with other arousal
systems such as the Hcrt/Orx neurons (Bonnavion et al. 2015) and LC noradrenergic
cells (McCall et al. 2015), sustained activation of such system with either semi-
chronic optogenetic photostimulation or DREADD-driven activation might engage
stress responses. However, considering the extension of the viral diffusion here,
some of these neurons could also correspond to numerous posterior hypothalamic
neurons, distinct from His neurons, displaying either a wake-active or a wake/REM
sleep-active activity proﬁle (Takahashi et al. 2006). Further investigations examin-
ing the activity proﬁle of these neurons with particular regard to theta rhythm
modulation during active wake and also during REM sleep would help in identifying
the role of SUM in sleep/wake regulation. Considering the diversity of SUM
neurons, anatomical studies of their respective connectivity would also further
precise their position in sleep-wake regulatory networks.
3.2.2 Glutamatergic Control of Sleep-Wake Cycle in the Pontine
Tegmentum
Glutamatergic neurons of the pontine reticular formation have a determinant role in
sleep-wake state control (see for review Watson et al. 2011). Alongside the reticular
formation, more deﬁned nuclei containing REM-sleep-active Glu cells such as the
laterodorsal (LDT) and pedunculopontine (PPT) tegmental nuclei and the
sublaterodorsal nucleus (SLD) arose (see for review Brown et al. 2012). More
recently, Hayashi and colleagues identiﬁed a subpopulation of neurons that derive
from the cerebellar rhombic lip (a part of the developing hindbrain), transiently
expressing the transcription factor Atoh1 at embryonic day 10.5 (E10.5), and that
migrate to the pontine tegmentum (Hayashi et al. 2015). Atoh1 cells are either
cholinergic or Glu neurons. A speciﬁc targeting of Atoh1 neurons was achieved
by crossing Atoh1-CreERT2 mice with mice carrying a Cre-dependent tetracycline
transactivator (tTA) transgene (CAG-LSL-tTA). Cre recombination and tTA expres-
sion in Atoh1 neurons were obtained with tamoxifen administration at E10.5
(Hayashi et al. 2015). AAVs carrying a tTA-dependent hM3DGq transgene were
subsequently infused in either the medial or the lateral portion of the Atoh1 cell ﬁeld
in adult offspring. Thus, medial Atoh1 cells are localized in the ventral LDT and
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medial parabrachial nucleus (PBm), and lateral Atoh1 cells are localized in the
lateral portion of the PB (PBl). At the physiological level, in an extensively con-
trolled experimental design, the authors observed that CNO-induced stimulation of
medial or lateral Atoh1 cells increases SWS amounts and inhibits REM sleep or
enhances wakefulness at the expense of both SWS and REM sleep, respectively
(Hayashi et al. 2015). These effects seem to be mediated by Glu Atoh1 cells as the
exact same effects were reproduced in transgenic mice obtained by crossing Atoh-
CreERT2mice with either CaMkIIa-LSL-tTA or VGlut2-LSL-tTAmice, in which tTA
expression only occurs in Glu cells from the Atoh1 lineage (Hayashi et al. 2015).
This nicely designed study led to the identiﬁcation of two subpopulations of Glu
cells that derive from the same developmental lineage and contribute to two distinct
and yet complementary aspects of sleep regulation: lateral Atoh1 neurons that favor
wake at the expense of sleep and medial Atoh1 neurons that facilitate SWS at the
expense of REM sleep. These two subpopulations would act as gatekeepers of sleep
and REM sleep, respectively.
Furthermore, Hayashi and colleagues dissected the neuronal pathway responsible
for the REM sleep inhibiting effect of Glu medial Atoh1 neurons. They observed that
these neurons densely innervate the dorsal deep mesencephalic reticular nucleus
(dDpMe), which, alongside ventrolateral periaqueductal gray (vlPAG) GABAergic
neurons, project and inhibit SLD neurons to suppress REM sleep (Fort et al. 2009;
Sapin et al. 2009). CNO-mediated excitation of GABAergic dDpMe neurons
expressing hM3DGq recapitulates the phenotype observed after the stimulation of
medial Atoh1 cells, i.e., a decrease in REM sleep and an increase in SWS (Hayashi
et al. 2015). Reciprocally, the inhibition of the same neurons expressing hM4DGi
facilitates REM sleep onset. The latter effect is thus hypothesized to be mediated by
a disinhibition of SLD REM sleep-promoting neurons.
Interestingly, wake-promoting lateral Atoh1 neurons partially overlap with
neurons expressing Glu calcitonin gene-related peptide (CGRP) located in the
external part of the lateral PB (PBel) (Bester et al. 1997; Yokota et al. 2015) As
for Atoh1 lateral cells, the activation of CGRP positive cells using cre-dependent
expression of hM3DGq in CGRP-CreER mice results in increasing wake at the
expense of both SWS and REM sleep (Kaur et al. 2017). Moreover, optogenetic
acute activation of these neurons during sleep reduces latency from sleep to wake-
fulness. PBel CGRP neurons, which are strongly activated in the context of hyper-
capnia (Yokota et al. 2015), appear to mediate their awakening signal through
multiple excitatory projections into the central nucleus of the amygdala, the BF,
and the LH. Altogether, these ﬁndings can be quite relevant to study circuit
dysfunctions associated with obstructive sleep apnea or developmental defects that
might occur in sudden infant death syndrome (SIDS) involving reduced CO2
responses.
Finally, DREADD-mediated stimulation of a larger proportion of the PB complex
was found to produce sustained wakefulness for more than 10 h (Qiu et al. 2016a).
Similar wake-promoting effects are partially recapitulated by using a retrograde-
driven expression of hM3DGq receptors in PB neurons projecting to the POA and
the BF or projecting to the lateral and posterior hypothalamus. Conversely, no effect
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is observed by stimulating PB neurons projecting to the midline and intralaminar
thalamus (Qiu et al. 2016a). Strikingly, this sustained wakefulness is not followed by
sleep rebound even after 4 days of daily CNO administration. In addition, cFos
staining after this subchronic CNO treatment reveals a strong level of activation in
many arousal-related centers including the LC, the TMN, the cholinergic BF, and the
LH Hcrt/Orx neurons and in sleep-promoting areas, namely, the VLPO or the
PZ. Indeed, the PB was found to be the main output structure of the sleep-promoting
PZ (Anaclet et al. 2012, 2014) (Sect. 3.1.2). This cFos pattern that resembles both
wake and sleep states is quite confusing and leaves open the question of the
physiological relevance of this model and the multifaceted role of the PB complex
in sleep/wake regulations.
3.3 Cholinergic Systems
Another major group of systems constitutive of the ascending arousal systems
include cholinergic (ACh) neurons located in the pedunculopontine (PPT) and
laterodorsal (LDT) tegmentum nuclei and in the basal forebrain (BF) (see for review
Fort et al. 2009). These neurons are mostly active during both waking and REM
sleep in association with cortical activation characterizing these two vigilance states.
DREADD approaches brought signiﬁcant revision on the role of ACh from both the
BF and brainstem by highlighting the cell diversity including GABAergic and
glutamatergic neurons in these brain areas and their respective contributions (Fig. 1).
3.3.1 Pontine Cholinergic Systems
Localized within LDT and PPT nuclei, ACh neurons in the mesencephalic tegmen-
tum have long been associated with cortical desynchronization during waking and
REM sleep (Steriade 2004; Boucetta et al. 2014) through projections to the forebrain
and to the brainstem reticular formation. Moreover, acute optogenetic stimulation of
ACh cells in either the PPT or the LDT during SWS leads to REM sleep onset within a
minute (Van Dort et al. 2015). However ACh neurons are also intermingled with
GABAergic and Glu cells that could contribute to sleep architecture, as they are
maximally active during waking or REM sleep or both (Boucetta et al. 2014).
Recently, one study tried to dissect the respective contributions of ACh, GABAergic,
and Glu cells in the PPT using DREADD-mediated cell-speciﬁc modulation of their
activity (Kroeger et al. 2017). CNO-mediated activation of VGlut2-expressing PPT
cells results in increased waking for at least 4 h at the expense of SWS and a complete
inhibition of REM sleep. This CNO-induced waking is mostly composed of quiet
wake in the nest and is associated with increased levels of anxiety. Conversely,
inhibition of the same neuronal group increases SWS, reduces waking, and lets
REM sleep amounts unaffected (Kroeger et al. 2017). CNO-mediated excitation of
hM3DGq-expressing ACh neurons of the PPT increases light SWS at the expense of
deep SWSwithout affecting either wake or REM sleep amounts in sharp contrast with
results harvested using optogenetic stimulation of the same neurons (Van Dort et al.
2015). This discrepancy could be due to a low transfection rate (about 20%) of
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cholinergic cells obtained by Kroeger and colleagues. However, in an attempt to
reconcile these ﬁndings, CNO-induced stimulation of PPT ACh cells could primarily
facilitate the appearance of a transition sleep state between SWS and REM sleep, thus
gating REM sleep onset (Mandile et al. 1996; Vescia et al. 1996). Eventually, the
activation of local GABAergic neurons only mildly reduces REM sleep despite the
fact that identiﬁed GABAergic cells in the PPT discharge maximally during REM
sleep only or during both wake and REM sleep across the spontaneous sleep-wake
cycle (Boucetta et al. 2014). Generally, as clearly stated by the authors, the overall
results should be interpreted with caution as targeting precisely and speciﬁcally a
small brain area in mice using viral vectors is challenging, especially in the pontine
tegmentum that concentrate multiple nuclei antagonistically regulating the sleep-
wake architecture.
3.3.2 Basal Forebrain Control of Sleep-Wake Cycle
Numerous studies pointed out a key role of BF, and especially BF ACh neurons, in
the regulation of the sleep-wake cycle in particular in relation to cortical activation
during waking or REM sleep (see for review Fort et al. 2009). However it remains
unclear which BF neuronal subpopulations contribute to a given vigilance state and
how they interact with each other and affect BF projection areas. In addition to ACh
neurons, BF contains intermingled Glu and GABAergic cells that are also likely to
play pivotal roles in sleep-wake regulation. Over the last few years, multiple studies
tried to decipher the relative contributions of these subpopulations using either
optogenetics or DREADDs.
In vivo recordings of channelrhodopsin-2-tagged neurons in the magnocellular
preoptic area (MCPO) and the nucleus of the horizontal limb of the diagonal band
(HDB) conﬁrmed that ACh and Glu BF neurons display higher ﬁring rates during
wakefulness and REM sleep than during SWS (Xu et al. 2015). Interestingly, when
considering GABAergic cells, two subpopulations with opposite modulation during
spontaneous sleep-wake cycles emerged: parvalbumin (PV)-expressing are more
active during wake and REM sleep, whereas some somatostatin (SOM)-containing
cells would discharge maximally during SWS (Xu et al. 2015). The subsequent
optogenetic activation of these subpopulations conﬁrmed the above correlative
characterization: stimulation of BF ACh neurons results in increased transition
probability from SWS-to-wake or to a lesser extent from SWS-to-REM sleep;
stimulation of either Glu or PV-expressing neurons facilitates wakefulness at the
expense of SWS; and stimulation of SOM-containing neurons increases SWS at the
expense of wakefulness (Han et al. 2014; Xu et al. 2015).
The same deconstruction of BF subpopulation contributions to sleep physiology
was also conducted through DREADD-mediated modulation of their activity.
CNO-mediated stimulation of ACh neurons in the HDB, the MCPO, the substantia
innominata (SI), and the ventral pallidum (VP) does not modify the sleep-wake
architecture but decreases slow-wave activity during SWS (Anaclet et al. 2015).
Conversely, the same approach restricted to ACh cells in the HDB, the MCPO, and
the SI results in increased wakefulness associated with decreased slow-wave activity
during SWS (Chen et al. 2016). Moreover, the CNO-driven inhibition of the same
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neurons produced the exact opposite phenotype (Chen et al. 2016). DREADD-
mediated stimulation of Glu cells in the HDB, MCPO, SI, and VP is inefﬁcient on
sleep architecture and mildly decreases delta power during SWS (Anaclet et al.
2015). In contrast, CNO-induced stimulation of GABAergic neurons in the whole
BF increases wake during more than 6 h at the expense of both SWS and REM sleep
associated with an increase in EEG spectral power in the alpha and gamma bands
(Anaclet et al. 2015). The latter effects on gamma rhythms would preferentially
involve BF PV-expressing neurons (Kim et al. 2015).
The above studies provided additional clues into the respective contributions of
various BF cellular subpopulations into the regulation of sleep-wake architecture as
well as their contributions to brain oscillatory activities associated with either wake
or SWS. However inconsistent observations were reported and could be dependent
on the extent of the brain area considered: some restricted their targeting strategy to
the HDB/MCPO region (Xu et al. 2015; Chen et al. 2016), whereas other included
the VP (Han et al. 2014; Anaclet et al. 2015). The anatomical delineation of the
sleep/wake-related BF may be a critical point, and the question to incorporate a
given brain region into the “classical” ascending activating systems should be further
addressed and discussed. Indeed, the VP is part of the basal ganglia, and thus its
activation can directly inﬂuence motivation and locomotor behaviors through the
limbic loop (see for review Root et al. 2015). An additional recruitment of VP could
explain the long-lasting wake-promoting effect of GABAergic neuron stimulation
obtained by Anaclet and colleagues (2015) in comparison with a more localized
optogenetic stimulation of PV neurons in the HBD/MCPO (Anaclet et al. 2015; Xu
et al. 2015). As a consequence, redeﬁning the respective contributions of
the different subregions (i.e., HDB, MCPO, SI, VP) would be a critical point to
address. As the projection patterns of VP neurons differ from MCPO/HDB neurons,
associating genetic tagging to retrograde mapping strategies would be of great use, in
particular in mice in which targeting a small region with viral delivery is highly
challenging.
3.4 Monoaminergic Systems
3.4.1 Serotonin
Serotonergic (5-HT) neurons located in the raphe nuclei belong to the ascending
arousal system that triggers cortical activation during wake. Indeed, most of 5-HT
neurons discharge maximally during wake, decrease their ﬁring rate during SWS,
and are silent during REM sleep (McGinty and Harper 1976; Rasmussen et al. 1984;
Sakai 2011). As a result, extracellular 5-HT levels are higher during wake than
during sleep both in the raphe nuclei and in brain areas targeted by 5-HT neurons
(Portas et al. 2000). Nevertheless, 5-HT can also contribute to increase sleep
propensity, as ﬁrst observations showed that either lesions of 5-HT neurons of the
raphe system or inhibition of 5-HT synthesis induce a severe insomnia which could
be reversed by restoring 5-HT synthesis (Jouvet 1999). Importantly, enhancing 5-HT
tone by systemic administration of selective serotonin reuptake inhibitors (SSRIs)
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has been repeatedly reported to inhibit REM sleep across species (Slater et al. 1978;
Sommerfelt and Ursin 1987; Maudhuit et al. 1994; Monaca et al. 2003). Thus, upon
the different approaches used, while 5-HT was ﬁrst believed to be a neuromodulator
of sleep, it is now further thought to promote cortical activation while impeding
REM sleep onset during wake. Still its role in sleep-wake regulation remains very
unclear, and these differential effects involve complex modalities of action and
multiple receptors in various brain structures (Ursin 2002) challenging investigations
over 5-HT system.
Despite the development of novel techniques including DREADD and opto-
genetics, the reassessment of 5-HT role in sleep has been underexplored. Interest-
ingly, the very ﬁrst in vivo validation using inhibitory DREADD approach was
implemented to the entire 5-HT system (Ray et al. 2011). Conditional intersectional
genetics were used to switch on expression of the hM4DGi transgene in virtually all
serotonergic neurons of Slc6a4 (5-HT transporter)-cre or Pet1-Flpe mice (Ray et al.
2011). Acute inhibition of the entire 5-HT system, following CNO i.p. injection
(10 mg/kg), induces a dramatic drop in body temperature and disrupts chemoreﬂex
in response to CO2 elevation. This ﬁrst in vivo approach validating DREADD
inhibitory control applied a unique dose of CNO that is now considered extremely
high. However this study acutely shutting down the 5-HT system was aimed to
model homeostatic dysfunctions involving signiﬁcant 5-HT abnormalities occurring
in fatal or life-threatening disorders such as in the sudden infant death syndrome
(SIDS).
More recently, interesting ﬁndings using DREADD and optogenetic approaches
have shown that 5-HT neurons of the dorsal raphe (DR) inhibit the pathological
intrusion of REM sleep into wake in a mouse model of narcolepsy, highlighting a
pharmacogenetic approach for the amelioration of narcolepsy (Hasegawa et al. 2014,
2017).
Narcolepsy, which is characterized by excessive daytime sleepiness and cata-
plexy, is associated with the loss of Hcrt/Orx neurons (Dauvilliers et al. 2003). Mice
lacking Hcrt peptides, Hcrt neurons, or Hcrt receptors recapitulate human narcolepsy
phenotypes (Taheri et al. 2002; Hasegawa et al. 2014). In particular, there are two
features that these models share with human pathology: inability to maintain
consolidated wakefulness and abrupt behavioral arrests with muscle atonia resem-
bling cataplexy. In their ﬁrst study, Hasegawa and colleagues investigated the
primary wake-active target of Hcrt neurons that could mediate the suppression of
narcoleptic symptoms and showed that 5-HT cells of the dorsal raphe (DR) and
noradrenergic (NA) cells of the LC have differential roles (Hasegawa et al. 2014).
First, in narcoleptic mice devoid of Hcrt/Orx receptors, the restoration of Hcrt2-R in
DR 5-HT cells prevents cataplexy-like episodes (CLEs) and restores REM sleep
amounts, whereas wake fragmentation persists. In contrast, restoration of Hcrt1-R in
LC NA neurons corrects wake fragmentation by increasing mean duration of wake
episodes and decreasing the number of wake episodes, without affecting CLEs or
REM sleep hypersomnia (Hasegawa et al. 2014). Next, to further examine whether
activation of 5-HT DR neurons and NA LC neurons could rescue narcoleptic
symptoms, Hasegawa and colleagues implemented DREADD approach in another
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model of narcoleptic mice in which Hcrt/Orx neurons are speciﬁcally ablated
(orexin/ataxin-3 mice). To combine this approach in their model, they used viral
vectors stereotaxically injected into the DR or LC carrying DREADD transgene
expression under the control of promoters speciﬁc to 5-HT or NA neurons (Pet-1 or
PRSx8, respectively) of Hcrt/Orx-ablated mice. Importantly, DREADD activation of
DR 5-HT neurons and LC NA neurons reverses the occurrence of CLEs and wake
fragmentation, respectively, as seen when restoring Hcrt/Orx receptor expression
(Hasegawa et al. 2014). This study allowed the identiﬁcation of two pathways
differentially regulating narcoleptic symptoms that highlights a critical role of DR
5-HT neurons in regulating REM sleep excess and CLE prevention, while LC NA
system would rather control wakefulness maintenance.
In their latest work, Hasegawa and colleagues further investigated how DR 5-HT
neurons mediate the suppression of CLEs (Hasegawa et al. 2017). By reproducing
optogenetically the anti-cataplectic effects of DR 5-HT activation in orexin/ataxin-3
mouse model, they showed that stimulation of DR 5-HT ﬁbers directly into the
amygdala was sufﬁcient to suppress the occurrence of CLEs, but did not correct
REM sleep hypersomnia or wake fragmentation (Hasegawa et al. 2017). The
photostimulation of 5-HT terminals also induced decreased expression of cFos in
the amygdala in comparison with the non-stimulated condition in narcoleptic mice,
suggesting that 5-HT may inhibit the amygdala to suppress CLEs. To further conﬁrm
the importance of the inhibition of amygdala activity to prevent CLEs, the authors
employed direct DREADD inhibition of amygdala neurons by locally injecting a
pair of AAV vectors: AAV-EF1α-DIO-hM4Di-mCherry and AAV-SynI-iCre in
orexin/ataxin-3 narcoleptic mice. CNO treatment substantially reduces CLEs in
comparison with saline treatment (Hasegawa et al. 2017). Consistently with 5-HT
effects, DREADD inhibition of the amygdala does not improve wake fragmentation.
In a complementary DREADD approach in these mice, Hasegawa and colleagues
expressed the excitatory hM3DGq DREADD transgene in the amygdala and
observed that CNO-driven activation of the amygdala signiﬁcantly increases the
occurrence of CLEs without affecting wake fragmentation (Hasegawa et al. 2017).
Thus, chemogenetic manipulations of amygdala activity modulate speciﬁc
symptoms of narcolepsy resembling cataplexy in a bidirectional manner in orexin/
ataxin-3 narcoleptic mice. Finally, the authors designed a nice combination of
molecular tools with optogenetics to demonstrate the speciﬁc involvement of DR
5-HT-amygdala pathway in the suppression of Hcrt-dependent CLEs showing that
the anti-cataplectic effects of restoring Hcrt2-R in DR 5-HT neurons were blocked
with the optogenetic inhibition of the amygdala in narcoleptic mice lacking both
Hcrt receptors (Hasegawa et al. 2017).
In narcoleptic patients as well as in narcoleptic dogs and mice, cataplexy is most
often triggered by positive emotions (Dauvilliers et al. 2003; Taheri et al. 2002). The
DREADD results obtained in this study further link the amygdala, which is impor-
tant for emotional processing, to the complex physiopathology of narcolepsy. It also
suggested that the control of 5-HT on the excess of REM sleep and cataplexy in
narcoleptic mice involves distinct pathways and mechanisms, as DREADD activa-
tion of DR 5-HT improved both excessive REM sleep duration and CLEs in
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narcoleptic mice but optogenetic stimulation of 5-HT ﬁbers in the amygdala or direct
DREADD activation of amygdala neurons only modulated CLEs. It still poses
certain questions on the nature of the anti-cataplectic actions of 5-HT in the amyg-
dala whether it might be associated to fear or reward processing. The amygdala is a
complex structure characterized by a central nucleus and a basolateral complex with
diverse functions, responding to both aversive (fear) and positive (reward) signals
(see for review Janak and Tye 2015). It remains discussed whether 5-HT neurotrans-
mission in the amygdala participates to the acquisition of cued conditioned fear (see
for review Bauer 2015), but it still questions whether 5-HT-mediated suppression of
CLEs in the amygdala could be produced by fear. Further investigations on amyg-
dala subnuclei and pathways involved in this model should help in shedding light on
the circuit and mechanisms underlying these effects and better identify the role of
5-HT in narcolepsy.
3.4.2 Noradrenaline
The main source of noradrenaline (NA) in the central nervous system is supplied by
the locus coeruleus (LC) through diverse and widespread efferent projections.
Similarly to histamine and serotonergic systems, LC NA neurons are wake-active
with the particularity that they start to ﬁre before the onset of wake, suggesting a role
in wake induction (Aston-Jones and Bloom 1981; Takahashi et al. 2010). During
wakefulness, LC NA neurons show distinct tonic and phasic patterns of activity:
tonic discharge rate is positively correlated to states of arousal with notable increase
in ﬁring when the animals encounter unexpected novelty or perform operant-
discrimination tasks, while phasic activations characterized by brief excitatory
component followed by a longer duration of inhibition are associated with discrete
sensory stimuli (see for reviews Aston-Jones et al. 1999; Sara 2009). Other studies
have also associated tonic and phasic activation of LC neurons in response to
stressors (see for review Aston-Jones et al. 1999). LC NA neurons cease ﬁring just
before the onset of SWS and remain silent during both SWS and REM sleep
(Takahashi et al. 2010). The robust wake-promoting actions of LC NA neurons
were further evidenced with optogenetics (Carter et al. 2010). Stimulating LC NA
neurons optogenetically at 5 Hz induces arousal and can trigger wakefulness from
NREM sleep (Carter et al. 2010). However in contrast with histamine system (see
Sect. 3.4.4) (Fujita et al. 2017), acute inhibition of LC NA neurons does not
immediately alter the behavioral status of the mice by switching from wake to
sleep (Carter et al. 2010). Indeed, only a 1-h-long semi-chronic inhibition progres-
sively drives an increase of sleep amounts at the expense of wakefulness (Carter
et al. 2010). To date, in our knowledge, pharmacogenetic manipulation of LC NA
neurons in sleep studies has been used in one study in rats investigating the causal
relationship between LC NA activity and general anesthetic state (Vazey and Aston-
Jones 2014). By generating a vector allowing hM3DGq transgene expression in LC
NA neurons using the synthetic dopamine-β-hydroxylase (DBH) promoter PRSx8 in
rats, Vazey and Aston-Jones tested the role of LC NA activation during general
anesthesia and in the emergence from it. To do so, CNO was ﬁrst administered
locally and unilaterally into the LC while monitoring the cortical EEG of deeply
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anesthetized rats under continuous isoﬂurane (2%) exposure. The authors observed
that CNOmicroinjection in LC-hM3DGq rats leads to cortical EEG activation with a
signiﬁcant decrease in delta band power and increase in theta band power, in
comparison with either vehicle microinjections or LC-mCherry control rats (Vazey
and Aston-Jones 2014). DREADD-driven activation of LC NA neurons during
anesthesia also induces an increase in total EEG power consistent with less burst
suppression in cortical EEG, which is a measure of anesthetic depth, indicating a
transitioning state away from deep anesthesia. Consistently, systemic CNO activa-
tion of LC NA neurons accelerates emergence from isoﬂurane anesthesia measured
by rapid return of righting reﬂex after discontinuation of isoﬂurane, and that was
shown to be mediated through both β and α1 adrenergic receptors (Vazey and Aston-
Jones 2014). These ﬁndings showed that selective activation of LC NA neurons is
sufﬁcient and powerful enough to overcome the general anesthetic effects of artiﬁ-
cially strong GABAergic inhibition, and trigger arousal. LC NA neurons speciﬁc
implication and efﬁciency to promote arousal has been also highlighted in mice
models of narcolepsy in which DREADD activation of LC NA neurons corrects
wake fragmentation associated with narcolepsy (Hasegawa et al. 2014) (see Sect.
3.4.1).
Application of DREADD technique to LC NA neurons has been also used to
stimulate degenerating neurons and test beneﬁcial effects of increasing brain NA
levels on cognitive impairments in a mouse model of Down syndrome (Rorabaugh
et al. 2017) and in a rat model of Alzheimer’s disease (Fortress et al. 2015). In both
models DREADD stimulation of LC NA neurons results in cognitive improvements.
Interestingly, another recent study using DREADD control established a causal
relationship between LC NA neurons activity and stress-induced anxiety showing
that hM4DGi-driven inhibition of LC NA neurons during stress prevents subsequent
anxiety-like behavior, and in contrast, increased tonic hM3DGq-driven activation of
LC NA neurons is sufﬁcient to promote anxiety-like and aversive behavior (McCall
et al. 2015). Interestingly, the authors found that the effects of LC stimulation on
acute anxiogenic responses are blocked by the β-adrenoreceptor antagonist, whereas
the aversive effects require α1-adrenoceptor activity, suggesting that acute stress-
induced anxiety and aversive behaviors are driven by distinct circuits. Indeed, NA
has simultaneously excitatory and inhibitory signaling through α1/β receptors and
α2 receptors, respectively. While NA system produces arousal and deepens cogni-
tion, or takes part in stress-induced responses, selective pharmacological activation
of α2 receptors produces deep SWS. This class of α2 receptor selective agonists
belongs to prominent sedative drugs used for long-term sedation in hospital inten-
sive care units (dexmedetomidine) or in veterinary clinics to sedate animals
(xylazine) (see for review Yu et al. 2018). Thus, apart from arousal-promoting
functions covering various physiological and cognitive processes or emotional
responding, NA can also have sleep-promoting contributions (Grivel et al. 2005).
All together these studies highlight the diversity of functions of NA that should be
further addressed in light of the complex input/output organization of the LC
(Schwarz et al. 2015) but should also integrate arousal-enhancing actions originating
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from other groups of NA-releasing cells including brainstem A1 and A2 nuclei
(Berridge 2008).
3.4.3 Dopamine
Among monoamines, dopamine (DA) seems to hold a notable position, being
excluded from the “classical” ascending wake-promoting monoaminergic systems.
This might be the consequence of the initial demonstration of an absence of change
in neuronal activity of VTA DA cells across the natural sleep-wake cycle (Miller
et al. 1983; Steinfels et al. 1983).
One recent paper using DREADD among other methods contributed to reintegrate
DA neurons in sleep-wake regulating networks (Eban-Rothschild et al. 2016). Using
ﬁber photometry on GCaMP-expressing DA neurons, the authors observed that, at a
population level, DA neurons of the ventral tegmental area (VTA) are more active
during wake and REM sleep than during SWS. Interestingly, the change in ﬂuores-
cence is signiﬁcantly higher during REM sleep bouts than waking bouts. This might
be linked to the actual discharge pattern of VTADA neurons across the natural sleep-
wake cycle and the bursting pattern they display during REM sleep or during
wakefulness in relation to appetitive or rewarding events (Dahan et al. 2007). This
observation is also consistent with microdialysis measurements of DA in the NAc or
the mPFC that revealed increased concentration of DA during wake and REM sleep
compared to SWS (Léna et al. 2005). Using DREADD techniques, Eban-Rothschild
and colleagues found that hM4DGi-driven inhibition of VTA DA neurons soon after
the onset of the dark active photoperiod results in decreased wakefulness
compensated by an increase in both SWS and REM sleep (Eban-Rothschild et al.
2016). These effects even persisted when animals are facing a salient stimulus such as
palatable food, female mouse, or predator odor. Strikingly, the inhibition of VTADA
also facilitates the appearance of active nest-building behavior prior to fastened sleep
onset only in the context of an absence of available nest. The authors suggested that
these observations indicate that VTA DA neuron activity is necessary for preparatory
sleep-related behaviors.
Conversely, optogenetic stimulation of VTA DA neurons during diurnal inactive
period results in short-onset awakening (Eban-Rothschild et al. 2016), and the same
effect was observed after DREADD hM3DGq activation of the whole VTA (Sun
et al. 2017). The above optogenetic effect was replicated by stimulating DA
terminals speciﬁcally in the NAc, in the DLS, and in the central nucleus of the
amygdala, but not in the mPFC (Eban-Rothschild et al. 2016). Similarly, a deletion
of SNc DA neurons in rats increases waking, whereas the optogenetic stimulation of
DA terminals in the dorsal striatum inhibits wake in favor of SWS (Qiu et al. 2016b).
One of the main targets of DA cells in the context of sleep-wake regulation would
thus lie in the striatum. As a consequence, when VTA/SNc DA neurons are active,
D1-expressing dMSNs in the striatum would be activated, whereas D2/A2A-
expressing iMSNs facilitating sleep onset (Oishi et al. 2017; Yuan et al. 2017)
would be inhibited (Sect. 3.1.4). These results thus provide evidence for a role of
midbrain DA neurons in facilitating waking maintenance, in particular in the context
of aversive or rewarding stimuli requiring an alerting response.
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Midbrain DA cells are also strongly active during REM sleep and display a
characteristic bursting ﬁring pattern (Dahan et al. 2007) associated with large DA
release (Léna et al. 2005) whose function remains unresolved. One possibility would
be an involvement of DA transmission in memory consolidation processes. Indeed,
the activity of VTA DA neurons seems to be associated with theta rhythm (see for
review Orzeł-Gryglewska et al. 2015) that is preeminent during REM sleep, and
multiple evidences highlighted a causal role of REM sleep in episodic memory
consolidation (Datta et al. 2004; Inostroza et al. 2013; Ravassard et al. 2016) with a
particular focus on theta rhythm (Nishida et al. 2009; Popa et al. 2010; Boyce et al.
2016). Moreover theta rhythm during REM sleep could putatively contribute to
implicit memory formation (Santos et al. 2008). Midbrain DA neurons could thus
play a signiﬁcant role in memory consolidation, especially with respect to the
sequential hypothesis (Ambrosini and Giuditta 2001; Giuditta 2014; Sara 2017),
which proposes that “irrelevant” information would be downgraded during SWS,
whereas “relevant” information would be tagged maybe through cell ensemble
reactivations and then, sequentially, integrated into preexisting memories during
REM sleep, thanks to fast theta oscillations and the expression of transcription
factors that both seem to be under the inﬂuence of DA signal (Orzeł-Gryglewska
et al. 2015; Rioult-Pedotti et al. 2015; Wieland et al. 2015).
3.4.4 Histamine
Until recently, the brain histaminergic (His) system was critically understudied in
comparison with other arousal monoaminergic circuits. The use of optogenetics,
DREADD approaches, and genetic models revealed important ﬁndings on the His
neurotransmission and function (Fig. 1).
His neurons of the hypothalamic tuberomammillary nucleus (TMN) display
unique electrophysiological signatures characterized by a slow pacemaking activity
(1–5 Hz) (Reiner and McGeer 1987) that is tightly coupled to behavioral arousal and
is the most wake-speciﬁc ﬁring pattern of any cell type identiﬁed in the brain to date
(Vanni-Mercier et al. 2003; Takahashi et al. 2006; Sakai et al. 2010). His neurons
start to ﬁre after waking onset, increase ﬁring during attentive waking, and cease
their activity before sleep onset to remain silent during all stages of sleep (Vanni-
Mercier et al. 2003; Takahashi et al. 2006; Sakai et al. 2010). These data suggested
that His neurons would play a role in the maintenance of wakefulness and in
adapting optimal levels of arousal necessary for cognitive processes (Lin et al.
2011b). It also suggested that the cessation of His activity may be necessary for
sleep induction, which was recently evidenced by optogenetic approaches (Chung
et al. 2017; Fujita et al. 2017). Genetic loss-of-function manipulations and pharma-
cological data provide a consistent picture because impairment to the His neuro-
transmission results in sleepiness and behavioral deﬁcits (Lin 2000; Parmentier et al.
2002; Anaclet et al. 2009), whereas its enhancement promotes wakefulness and
displays pro-cognitive effects (see for review Haas et al. 2008; Schwartz 2011).
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Recently, novel insights on His control of arousal and synaptic mechanisms
associated with His neurotransmission were achieved in a complete study combining
DREADD technique, optogenetics, and genetic models (Yu et al. 2015). First, Yu and
colleagues observed that a sustained activation of the His system, using conditional
Cre-mediated expression of hM3DGq in histidine decarboxylase (HDC)-expressing
neurons (HDC-Cre), induces a strong behavioral change assessed by hyperlocomotion
in an open ﬁeld (Yu et al. 2015). TheCNOdose used in this studywas quite high (5mg/
kg), and effects were compared with saline i.p. injections. In light of the recent studies
questioning CNO endogenous effects, further controls should be examined in future
studies. However, if there were any endogenous effects of CNO through clozapine
conversion, we could expect opposite behavioral responses as shown by Gomez and
colleagues in a similar open ﬁeld test (Gomez et al. 2017). The main question of this
approach was to test the ability of the His system to evoke excitatory behavioral
responses with a large activation of the His neurotransmission. As a result, DREADD
activation of His neurons under high dose of CNO leads to long-lasting hyperactivity
(Yu et al. 2015).Unfortunately, effects on sleep-wake cycle and EEG remain unknown.
Most importantly, by questioning the functional role of the presence ofGABA in the
vastmajority ofHis neurons (Takeda et al. 1984; Senba et al. 1985; Trottier et al. 2002),
Yu and colleagues showed that most His neurons use VGAT to release GABA and
highlighted the importance of GABA co-release in controlling behavioral arousal
(Yu et al. 2015). They showed that conditional knockdown and knockout mice with
disrupted GABA function in His neurons are hyperactive, exhibiting hyperlocomotion
and decreased amounts of sleep conﬁned to the night in comparison with control mice
(Yu et al. 2015). Using optogenetic stimulation of HDC-ChR2 ﬁbers, they further
demonstrated ex vivo that GABA is being directly released from His ﬁbers in the
neocortex and striatum. Interestingly in the VLPO, His axons do not release GABA
when stimulated optogenetically but instead activate GABA interneurons by His
release to suppress the activity of long-range projecting sleep-promoting neurons
(Williams et al. 2014). Apart from technical differences, Yu and colleagues suggest
that these contrasting results with neocortical neurons might be due to a subpopulation
of His neurons projecting to the VLPO devoid of GABA (about ~20%), which is
intriguing to test by further histological and tracing investigations considering the
growing evidences of diversity among His neurons (Blandina et al. 2012; Fujita et al.
2017). Moreover, the striatum is also composed of a diversity of cells including two
types of MSNs and various interneurons (Durieux et al. 2011). Thus, additional
recordings in the distinct striatal neuronal populations should be conducted to precisely
deﬁne the nature and mechanisms of His actions in the BG circuitry (Bolam and
Ellender 2016).
The study led by Yu and colleagues emphasized a major phenomenon observed
in other monoaminergic systems as subsets of 5-HT and DA neurons also have the
ability to release Glu or GABA fast neurotransmitters through different vesicular
transporters (see for review Lőrincz and Adamantidis 2017). As a consequence, it
highlights the need to dissect in vivo effects with a circuit-level approach combining
various techniques monitoring neuronal activity and/or release, notably when using
DREADD or optogenetic approaches. Even if neurochemical speciﬁcity can be
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achieved through genetic targeting, certain effects attributed to monoamine release
can be in fact mediated or counteracted by fast neurotransmission. Why His-GABA
neurons use contradictory signals remains an open question that is well-discussed by
Yu and colleagues proposing that it could either serve to stop networks getting too
excited by an overactive His system, which may have deleterious consequences on
sleep and mental health as seen in their models. Conversely, it could actually better
shape cognitive responses together with His, notably at the level of the cortex in
adjusting the balance between synaptic excitation and inhibition to enhance
processing (see discussion Yu et al. 2015).
Finally, the His system has emerged as an attractive therapeutic target for the
treatment of neuropsychiatric and neurodegenerative diseases. His regulates its own
release through autoinhibitory H3 receptors (H3R) (Lin et al. 2011a). Selective H3R
blockers enhance both the ﬁring rate of His neurons and His release (Lin et al.
2011a). Interestingly, administration of H3R blockers dramatically enhances the
high-frequency component of neocortical EEG rhythms in cats, mice, and humans
and improves attention and facilitates learning in rodent models (see for review
Schwartz 2011), lending support to the role of His in higher cognitive processes.
Selective blockers are now gaining entrance in clinical trials showing tremendous
promise as a therapeutic intervention in schizophrenia, dementias, sleep disorders,
and other conditions for its wake-promoting and pro-cognitive effects (Schwartz
2011). Thus, it is timely to further our understanding on the role and actions of TMN
His neurons and His-GABA neurons in arousal and cognition.
3.5 Peptidergic Systems
3.5.1 Hypocretin/Orexin
Localized in the lateral hypothalamus, hypocretin/orexin (Hcrt/Orx)-secreting
neurons are key contributors to wakefulness stabilization (Bonnavion and De
Lecea 2010), and dysfunction of the Hcrt/Orx system is linked to narcolepsy (see
Sects. 3.4.1 and 3.4.2). Pharmacosynthetic modulation of Hcrt/Orx neurons activity
revealed that the CNO-elicited activation of hM3Dq-expressing Hcrt/Orx neurons
increases wake at the expense of both SWS and REM sleep, whereas their inhibition
facilitates SWS and decreases wake and REM sleep amounts (Sasaki et al. 2011).
However, a more detailed description of the sleep-wake architecture after CNO/
DREADD-driven control is still missing as acute optogenetic activation of Hcrt/Orx
neurons during SWS produces Hcrt peptide-dependent awakening within a minute,
whereas acute inhibition of the same neurons during wake accelerates SWS onset
(Adamantidis et al. 2007; Tsunematsu et al. 2011). Hcrt/Orx neurons seem of
particular importance for wake consolidation and proper control of sleep-wake
dynamics without strongly affecting daily wake amounts (Hara et al. 2001; Diniz
Behn et al. 2008, 2010; Kantor et al. 2009; De Lecea 2012). During wakefulness,
Hcrt/Orx cells are not constantly ﬁring and become stimulated in association with
signals that require increased wakefulness (Yamanaka et al. 2003; Mileykovskiy
et al. 2005; Williams et al. 2007; Bonnavion et al. 2015; González et al. 2016).
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Altogether these ﬁndings reinforce the unique position of Hcrt/Orx neurons among
wake-active systems that may thus be regarded as computational comparators
generating an error signal to recalibrate arousal levels in comparison to the difference
between the actual state and required arousal (Kosse and Burdakov 2014).
3.5.2 Melanin-Concentrating Hormone
Neurons expressing melanin-concentrating hormone (MCH) are a molecularly
deﬁned neuronal subpopulation largely distributed throughout the extent of the LH
and ZI. Several experiments pointed out a pivotal contribution of MCH-secreting
neurons in the control of sleep and in particular REM sleep. Indeed both optogenetic
(Jego et al. 2013; Konadhode et al. 2013; Tsunematsu et al. 2014) and DREADD-
mediated stimulations (Vetrivelan et al. 2016; Varin et al. 2018) of MCH neurons
unfailingly result in facilitated REM sleep onset and increased REM sleep amounts.
However, inconsistent and puzzling results on SWS were harvested by these studies,
probably due to heterogeneous experimental and technical procedures. Indeed, the
semi-chronic optogenetic stimulation of MCH neurons during 24 h extends SWS
only during the nocturnal active phase by increasing the number of SWS bouts
(Konadhode et al. 2013). Their acute stimulation at the onset of a given SWS episode
lets the duration of the ongoing episode unaffected (Jego et al. 2013), whereas SWS
amounts and the mean duration of SWS episodes are decreased upon continuous
optogenetic stimulation of MCH neurons for 3 h during the light inactive photope-
riod (Tsunematsu et al. 2014). In an attempt to solve these discrepancies, two groups
recently examined the effects on sleep of the DREADD-mediated modulation of
MCH neuron activity (Vetrivelan et al. 2016; Varin et al. 2018). The ﬁrst study
(Vetrivelan et al. 2016) analyzed the effects on sleep of CNO-induced activation of
hM3DGq-expressing MCH neurons and conﬁrmed previous evidences indicating
that the stimulation of MCH neurons favors REM sleep onset and consolidation. The
second one (Varin et al. 2018) combined the utilization of both hM3DGq and
hM4DGi DREADD effectors. Varin and colleagues consistently conﬁrmed the
REM sleep-facilitating effect of MCH neuron activation and additionally observed
that CNO-mediated stimulation of MCH neurons results in decreased SWS amounts,
whereas the inhibition of MCH neurons resulted in the opposite phenotype. These
effects were accompanied with modiﬁcations in SWS delta rhythmic activities
suggesting that MCH neurons could participate in increasing SWS depth (Varin
et al. 2018). Thanks to their observations using both excitatory and inhibitory
DREADD tools and a multiple CNO doses design, the authors consequently pro-
posed a novel formulation of the role of MCH neurons in sleep physiology, that is,
MCH neurons would be involved in basic mechanisms occurring primarily during
SWS aimed at deepening SWS to pave the way for SWS-to-REM sleep transition to
occur.
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4 Conclusion and Perspectives
Following the path opened by optogenetics more than a decade ago, the develop-
ment and use of pharmacosynthetic tools quickly made their contribution to the
discovery and the expansion of our understanding of critical brain structures and
neuronal subpopulation involved in a wide variety of behaviors and in particular in
the control of vigilance state architecture.
We now end up with a large – but probably not exhaustive – set of brain structures
that are key modulators or serve executive functions in the control of the sleep-wake
cycle (Fig. 1). This leads to a complex network of deeply interconnected and
heterogeneous neuronal subpopulations (Fig. 2). Deciphering this complexity and
unscrambling the hierarchical organization of the sleep-wake regulating network
constitute a challenging task that sleep scientists are now facing. Indeed this chal-
lenge is particularly prominent when attempting to describe and quantify the series
of activations and inhibitions of different brain structures and neuronal
subpopulations occurring cooperatively and concurring to sharp and complete
transitions between vigilance states.
In front of this demanding task, multiple novel tools offer new possibilities to
move a step forward in our understanding of sleep physiology. Recent advances in
in vivo electrophysiology provide opportunities to record multiple cellular
subpopulations that can additionally be identiﬁed by optogenetic tagging at the
same time in different brain regions in order to draw a ﬁner picture of neuronal
dynamics during vigilance states and transitions between states (Vyazovskiy et al.
2011; Herrera et al. 2015; Weber et al. 2015; Xu et al. 2015).
The hierarchical organization of sleep-wake systems could be probed by
multiplexing various genetically encoded actuators or sensors. For instance,
DREADD-mediated strategy can be expanded by coupling “classical” muscarinic
receptor mutants with the recently developed inhibitory kappa-opioid DREADD that
is activated by salvinorin B instead of CNO (Vardy et al. 2015). With this strategy
two different neuronal populations can be inhibited or activated and inhibited at the
same time or independently (Rapanelli et al. 2017). A similar approach could rely on
the use of “PSAM-PSEM” actuators (see for review Sternson and Roth 2014).
Moreover a similar experimental design can be drawn with optogenetics using the
combination of both inhibitory and excitatory channels (Kleinlogel et al. 2011;
Carter et al. 2012) and the use of red-shifted mutants of channelrhodopsin or
halorhodopsin (Chow et al. 2010; Chuong et al. 2014; Klapoetke et al. 2014). On
top of this profusion of various actuators, elegant genetic tagging of multiple
neuronal subpopulations can be achieved through the use of intersectional strategies
in transgenic animals expressing multiple recombination enzymes such as cre and
ﬂippase, under the control of different promoters (Fenno et al. 2014; He et al. 2016).
Although challenging, this approach could be even expanded by adding an
extra layer of control with the use of tetracycline-controlled transcriptional activation
systems, which can be reversibly turned on and off in the presence of doxycycline
(Zhang et al. 2015). And obviously, genetically encoded actuators can be
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multiplexed with genetically encoded sensors such as calcium indicators or voltage-
sensitive ﬂuorescent proteins (Kim et al. 2016).
Finally, the complexity of sleep physiology and the complexity of neuronal
networks on which it depends should inspire the use of more and more sophisticated
metrics to acutely and precisely dissect sleep-wake architecture and dynamics,
together with subtle regulatory mechanisms. Among these metrics can be mentioned
Markov’s chain analysis (Kim et al. 2009; Bianchi et al. 2012; Stephenson et al.
2013), survival analysis of sleep and wake episode duration (Lo et al. 2002, 2004;
Blumberg et al. 2005; Diniz Behn et al. 2008; Varin et al. 2016), or EEG or LFP
analysis using two dimensional map of behavioral state (Gervasoni et al. 2004;
Dzirasa et al. 2006; Diniz Behn et al. 2010). All together, the above methods should
provide new ways to analyze and decipher the precise temporal, hierarchical, and
dynamical organization of vigilance states.
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Abstract
Sleep and wakefulness are highly complex processes that are elegantly orchestrated
byﬁne-tuned neurochemical changes among neuronal and non-neuronal ensembles,
nuclei, and networks of the brain. Important neurotransmitters and neuromodulators
regulating the circadian and homeostatic facets of sleep-wake physiology include
melatonin, γ-aminobutyric acid, hypocretin, histamine, norepinephrine, serotonin,
dopamine, and adenosine.Dysregulation of these neurochemical systemsmay cause
sleep-wake disorders, which are commonly classiﬁed into insomnia disorder,
parasomnias, circadian rhythm sleep-wake disorders, central disorders of hyper-
somnolence, sleep-related movement disorders, and sleep-related breathing
disorders. Sleep-wake disorders can have far-reaching consequences on physical,
mental, and social well-being and health and, thus, need be treatedwith effective and
rational therapies. Apart from behavioral (e.g., cognitive behavioral therapy for
insomnia), physiological (e.g., chronotherapy with bright light), and mechanical
(e.g., continuous positive airway pressure treatment of obstructive sleep apnea)
interventions, pharmacological treatments often are the ﬁrst-line clinical option to
improve disturbed sleep and wake states. Nevertheless, not all patients respond to
pharmacotherapy in uniform and beneﬁcial fashion, partly due to genetic differences.
The improved understanding of the neurochemical mechanisms regulating sleep and
wakefulness and the mode of action of sleep-wake therapeutics has provided a
conceptual framework, to search for functional genetic variants modifying indi-
vidual drug response phenotypes. This article will summarize the currently known
genetic polymorphisms that modulate drug sensitivity and exposure, to
partly determine individual responses to sleep-wake pharmacotherapy. In addi-
tion, a pharmacogenetic strategy will be outlined how based upon classical and
opto-/chemogenetic strategies in animals, as well as human genetic associations,
circuit mechanisms regulating sleep-wake functions in humans can be identiﬁed.
As such, experimental human sleep-wake pharmacogenetics forms a bridge span-
ning basic research and clinical medicine and constitutes an essential step for the
search and development of novel sleep-wake targets and therapeutics.
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1 Introduction
Wakefulness and sleep are complex behavioral processes, which are elegantly
orchestrated by ﬁne-tuned interactions of neurotransmitter and neuromodulator
systems within deﬁned wake-sleep circuits of the brain. Over the past 100 years,
clinical observations in patients suffering from sleep-wake disorders and basic
research spanning from in vitro preparations and animal models to healthy human
volunteers have led to a widely accepted neurobiological model underlying the
physiological alterations between wakefulness and distinct sleep states (for review,
see Holst et al. 2016). More speciﬁcally, wakefulness and cortical arousal are
thought to be governed primarily by concerted activity in upper brain stem and
hypothalamic nuclei, which produce acetylcholine (ACh), norepinephrine (NE),
serotonin (5-HT; 5-hydroxy-tryptamine), dopamine (DA), histamine (His), and
hypocretin (Hcrt; aka orexin) as their neurotransmitters. These nuclei activate
thalamus, cortex, and spinal cord and inhibit the sleep-promoting ventrolateral
preoptic (VLPO) area of the hypothalamus.
The regulation of sleep differs substantially between the non-rapid eye movement
(NREM) and rapid eye movement (REM) sleep states. NREM sleep is supposed to
be promoted by GABA (γ-aminobutyric acid)- and galanin-containing neurons
originating in VLPO and median preoptic nuclei of the hypothalamus. These nuclei
inhibit the wake-promoting arousal systems described above. On the other hand,
REM sleep exhibits both “wake-like” and “sleep-like” characteristics. “Wake-
on”-“REM-on” basal forebrain (BF) and brain stem nuclei containing ACh and
glutamate activate the BF and cortex, induce muscle atonia, and promote rapid eye
movements. In addition, hypothalamic neurons containing melanin-concentrating
hormone suppress the activity of “wake-on”-“REM-off” cell groups, which primar-
ily include the upper brainstem monoaminergic nuclei.
Powerful new tools to interrogate sleep-wake regulating circuits, including
sophisticated optogenetic and chemogenetic experiments, have revealed new molec-
ular and cellular markers, as well as novel network mechanisms and pathways in
sleep-wake regulation. These recent insights may necessitate an adaptation of the
basic sleep-wake neurochemistry described above. They have been discussed in
comprehensive reviews and other chapters of this book (Adamantidis and Luthi
2018; Saper and Fuller 2017; Tyree and de Lecea 2017; Eban-Rothschild et al. 2018;
Luppi and Fort 2018; Varin and Bonnavion 2018) and are not the focus of this
chapter. In this article, ﬁrstly, genetic aspects of the current pharmacotherapy of
sleep-wake disorders will be reviewed. Secondly, an experimental pharmacogenetic
strategy to identify circuit mechanisms underlying sleep-wake regulation in humans
will be outlined.
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2 Current Sleep-Wake Pharmacotherapy in a Nutshell
Based on the “standard model” of sleep-wake circuitry, subtle changes in important
neurotransmitters and neuromodulators (including NE, 5-HT, DA, His, Hcrt, melato-
nin, glutamate, ACh, GABA, and adenosine) regulate not only the transitions among
the behavioral states wakefulness, REM sleep, and NREM sleep but also their
maintenance (Holst and Landolt 2018). Dysregulation of these ﬁne-tuned neuro-
chemical systems can lead to sleep-wake disturbances. According to the third edition
of the International Classiﬁcation of Sleep Disorders, sleep-wake disturbances are
subdivided into the following major diagnostic sections: insomnia disorder, circadian
rhythm sleep-wake disorders, sleep-related breathing disorders, sleep-related move-
ment disorders, central disorders of hypersomnolence, parasomnias, and other sleep
disorders (American Academy of Sleep Medicine 2014). Some of these pathologies
are typically treated with pharmacological agents as summarized and reviewed in Part
III of this book (insomnia and circadian rhythm sleep-wake disorder, Spiegelhalder
et al. (2017); hypersomnias and sleep-related movement disorders, Baumann (2018)).
All drugs presently used to treat the symptoms of sleep-wake disorders interfere with
the neurochemical and neuromodulatory systems mentioned above (Idzikowski
2014; Holst et al. 2016). Thus, although the “standard model” of the neuroanatomical
and neurochemical regulation of wakefulness and sleep will have to be adapted, it
provides a useful conceptual framework for understanding the effects of the
medications currently used to improve sleep and wake states (Fig. 1).
2.1 Insomnia Disorder
Drug treatment can be useful for short-term alleviation of insomnia symptoms.
When combined with behavioral therapy, pharmacological treatments show durable
improvements in sleep patterns (Riemann and Perlis 2009). Conceptually, disturbed
sleep can be pharmacologically improved by compounds that either promote sleep or
dampen the wake-promoting systems.
Agonistic modulators of GABAA receptors such as benzodiazepines and Z-drugs
(e.g., zolpidem) enhance the inhibitory inputs of GABA-containing neurons that
inhibit the ascending arousal pathways (Finelli et al. 2000). These compounds act as
positive allosteric modulators and, at higher doses, as agonists of GABAA receptors.
They are prescribed for the short-term pharmacological treatment of insomnia
disorder and show demonstrated efﬁcacy in shortening sleep latency and improving
sleep maintenance (Dresler et al. 2014). Absolute effect sizes, however, may be
rather small when compared to placebo (Wilt et al. 2016). In standard clinical
practice of pharmacologically treating insomnia, benzodiazepines and Z-drugs
have largely replaced the previously used barbiturates.
The dual orexin receptor antagonist (DORA), suvorexant, was recently approved
by the US Food and Drug Administration (FDA) for treating insomnia disorder in
adults (Wilt et al. 2016). Suvorexant acts by antagonizing wake-promoting Hcrt
neurons located in the lateral hypothalamus. Some authors claim that suvorexant
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elicits more physiological sleep than benzodiazepines (Patel et al. 2015). Neverthe-
less, the compound seems to mainly prolong REM sleep and stage 2 sleep, with
marginal effect on deep slow-wave sleep (Hoyer and Jacobson 2013).
Drugs antagonizing key monoaminergic nuclei of the ascending arousal pathways
commonly cause sleepiness. One example of such a mode of action is the blockade
of H1 receptors to antagonize wake promotion by His. “Antihistamines” such as
diphenhydramine and doxylamine have long been available over the counter and are
sometimes used to treat insomnia. Similarly, tricyclic and heterocyclic
antidepressants and antipsychotics are often associated with sleepiness, probably
related to their antihistamine and possibly other “off-target” receptor interactions
(such as anticholinergic effects). Low doses of doxepin are FDA-approved to treat
insomnia by promoting sleep onset (Goforth 2009). Other sedating antidepressant
Fig. 1 Schematic representation of sleep-wake disorders according to the International Classiﬁca-
tion of Sleep Disorders (ICSD) currently amenable to pharmacotherapy for improved sleep and
wake state (thus excluding sleep-related breathing disorders). Blue shading: drugs used to improve
sleep in insomnia disorder, parasomnias, and circadian rhythm sleep-wake disorders. Red shading:
drugs to improve wake state in central disorders of hypersomnolence. Green shading: drugs to
reduce periodic limb movements in sleep (PLMS) in sleep-related movement disorders. Mel
melatonin, MT1/2 melatonin MT1 and MT2 receptors, 5-HT serotonin, 5-HT2C serotonin-2C recep-
tor,GABA γ-aminobutyric acid,GABAAGABAA receptor,GABABGABAB receptor,His histamine,
H1 histamine H1 receptor, H3 histamine H3 receptor, VGCC voltage-gated calcium channel, DA
dopamine,DAT dopamine transporter,D2/3/4 dopamine D2, D3 and D4 receptors, Ado adenosine, A1/
2A adenosine A1 and A2A receptors, NE norepinephrine, Hcrt hypocretin. " ampliﬁcation of
neurotransmission; # inhibition of neurotransmission
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and antipsychotic medications are more and more commonly prescribed “off-label”
as sleeping pills (Proctor and Bianchi 2012; Krystal et al. 2013). Apart from H1 and
muscarinic ACh receptors, some of these agents (e.g., mirtazapine) have high
afﬁnity for 5-HT2A and adrenergic α1 receptors. Blockade of these receptors
facilitates sleep. Conversely, these compounds often also inhibit 5-HT and NE
reuptake transporters and antagonize 5-HT2C and α2 receptors and thus promote
wakefulness, which detracts from the sleep-promoting effects of blocking the H1
receptors (Krystal et al. 2013).
2.2 Parasomnias
The most commonly used drugs for NREM sleep parasomnias are intermediate- and
long-acting benzodiazepines and antidepressants (Castelnovo et al. 2018). The
pharmacologic treatment of REM sleep behavior disorder presently relies primarily
on the benzodiazepine, clonazepam, whereas melatonin and melatonin receptor
agonists may be equally efﬁcacious with less unwanted effects (McGrane et al.
2015; Castelnovo et al. 2018).
2.3 Circadian Rhythm Sleep-Wake Disorders
The circadian resetting effects of melatonin are well documented. Interference with
both melatonin MT1 and MT2 receptor subtypes contributes to the distinct phase-
response proﬁle of melatonin (Burgess and Emens 2018). Melatonin alone or in
combination, as well as different melatonin analogues, are available either without
prescription or as regulatory-approved drugs. There is increasing interest in the
potential of melatonin-based therapies in the treatment of disturbed sleep (Alston
et al. 2018). These therapies offer potential to treat sleep and mood disorders,
especially when circadian rhythm disturbances are also present. Such disorders
include insomnia induced by shifted sleep-wake cycles in healthy individuals,
insomnia in older adults, delayed sleep-wake phase disorder, non-24-hour sleep-
wake disorder (N24HSWD), seasonal affective disorder, and major depressive
disorder (Alston et al. 2018; Burgess and Emens 2018). Prolonged-release melatonin
(Circadin®) has been approved for chronic insomnia in patients older than 55 years.
In combination with antihistamines, GABA-ergic hypnotics, herbal extracts, or
bright light therapy, prolonged-release melatonin may improve hypnotic efﬁcacy
(Saxvig et al. 2014; Rivara et al. 2015). Apart from N24HSWD, the MT1/2 receptor
agonist, tasimelteon, may also be useful in certain patients with insomnia, advanced
sleep phase syndrome, and delayed sleep phase syndrome (Lankford 2011).
Ramelteon received FDA approval for treatment of insomnia in older adults, and
the MT1/2 agonist/5-HT2C receptor antagonist, agomelatine, has EMA and TGA
(Therapeutic Goods Administration, Australia) approval for major depressive
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disorder. Agomelatine phase shifts the circadian system and improves sleep in
depressed patients, although its usefulness for primary sleep disorders is debated
(De Berardis et al. 2015).
2.4 Central Disorders of Hypersomnolence
Central disorders of hypersomnolence are characterized by excessive daytime sleep-
iness (EDS), often despite apparently normal quality, duration, and timing of
nocturnal sleep. These disorders include narcolepsy type-1 (characterized by deﬁ-
cient Hcrt in cerebrospinal ﬂuid), narcolepsy type-2, and idiopathic hypersomnia.
Their pharmacological treatment focuses on the management of EDS, with addi-
tional treatment of cataplexy, which is typically present in patients with narcolepsy
type-1 (Baumann 2018).
Modaﬁnil and its (R)-enantiomer, armodaﬁnil, are FDA-approved ﬁrst-line
treatments of EDS in narcolepsy (Mignot 2012; Abad and Guilleminault 2017).
While the mode of action of (ar)modaﬁnil is complex and may involve NE, 5-HT,
His, Hcrt, glutamate, and GABA, it increases DA-ergic neurotransmission and
blocks the DA reuptake transporter (DAT) (Wisor et al. 2001; Volkow et al. 2009;
Wisor 2018).
Amphetamine and its derivatives are treatments of second choice against EDS in
narcolepsy (Abad and Guilleminault 2017). These compounds actively promote the
presynaptic release of DA and dampen DAT function (Mignot 2012). They cause
autonomic arousal and psychomotor agitation and have strong addictive properties.
Stimulants such as methylphenidate and mazindol are speciﬁc DAT inhibitors.
Methylphenidate is FDA-approved for narcolepsy. Preliminary evidence also
suggests therapeutic efﬁcacy for mazindol (Nittur et al. 2013).
Certain antidepressants such as bupropion, venlafaxine, and clomipramine that
block the reuptake transporters for DA (DAT), NE (NET), and/or 5-HT (SERT) are
typically used against cataplexy in narcolepsy type 1 (Mignot 2012). Tricyclic
antidepressants strongly reduce REM sleep and cataplectic attacks without affecting
EDS (Houghton et al. 2004). They have undesired anticholinergic and antihistaminic
properties and prolonged use can cause tolerance. Dual NET-SERT inhibitors or
selective NE and 5-HT reuptake inhibitors (SSRIs) may provide alternative options
to treat cataplexy (Houghton et al. 2004). Finally, monoamine oxidase (MAO)
inhibitors such as selegiline are used “off-label” against cataplexy and EDS (Thorpy
and Dauvilliers 2015).
The adenosine A1 and A2A receptor antagonist, caffeine, is the most widely used
stimulant worldwide. Caffeine can improve vigilance in susceptible, sleep-deprived
individuals (Gottselig et al. 2006; Rétey et al. 2007) yet probably has insufﬁcient
potency in patients with clinical EDS (Banerjee et al. 2004). Sleepy people may use
caffeine excessively to improve alertness (Urry et al. 2017), and a positive correla-
tion between disease severity and habitual caffeine use was observed in patients with
narcolepsy-cataplexy (Mitler et al. 1998). Intake of 200–300 mg per day, which is
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typical in Western societies, is generally well tolerated and does not posit a known
health risk (Loftﬁeld et al. 2018).
The safe improvement of wakefulness in hypersomnolent patients has so far
proved difﬁcult, despite the fact that the abovementioned compounds are potent.
Based on the rationale that sleep and wakefulness form a functional continuum and
that improved sleep also improves the quality of wakefulness, γ-hydroxybutyrate
(GHB or the sodium salt of γ-hydroxybutyric acid, sodium oxybate) is currently the
ﬁrst-line, FDA-approved agent for cataplexy and EDS in patients with narcolepsy
(Thorpy and Dauvilliers 2015; Abad and Guilleminault 2017). This rapid sedative
may also alleviate sleep disruption in narcolepsy. The exact mode of action of GHB
is unknown. GHB is an endogenous short-chain fatty acid that exhibits high afﬁnity
for GHB receptors (KD  30–580 nM) and low afﬁnity for GABAB receptors
(KD  2.6–16 μM) (Mamelak 2009). The stabilization of sleep continuity by
supraphysiological doses of GHB may be predominantly mediated by agonistic
stimulation of GABAB receptors. Thus, the GABAB receptor agonist, baclofen,
may also be useful in treating patients with narcolepsy (Huang and Guilleminault
2009; Black et al. 2014).
Histamine H3 receptor inverse agonists such as pitolisant provide a promising
new class of wake-promoting medications with possible pro-cognitive properties
(Stocking and Letavic 2008). The H3 receptor is an inhibitory autoreceptor on
presynaptic neurons, which attenuates the release of His and other excitatory
neurotransmitters when activated (Lin et al. 2011).
It has been postulated that Hcrt neurons continuously integrate information from
multiple processes, to modulate the propensity to stay awake or to fall asleep (Eban-
Rothschild et al. 2018). The ﬁring of Hcrt neurons in the lateral/posterior hypothala-
mus promotes wakefulness. Intranasal delivery of Hcrt peptide may reduce wake-
REM sleep transitions and slightly improve attention after sleep in patients with
narcolepsy-cataplexy (Weinhold et al. 2014).
2.5 Sleep-Related Movement Disorders
The pharmacologic treatment of restless legs syndrome (RLS) and periodic limb
movement disorder during sleep traditionally relies on the dopamine D2 receptor
agonists, pramipexole, ropinirole and rotigotine (Baumann 2018). These dopami-
nergic agents, and in particular L-dopa, carry the risk of augmentation, i.e.,
aggravated RLS symptoms with continued medication use (Trenkwalder and Paulus
2010). Iron supplementation in case of iron deﬁciency, benzodiazepines, and opiates
may also be effective and are often used as secondary treatments (Winkelmann et al.
2018). Prolonged-release oxycodone-naloxone, a combined opioid analgesic and
opioid receptor antagonist, has recently provided an additional option for refractory
RLS (Trenkwalder et al. 2013).
Because of the frequently observed augmentation with dopaminergic agents, an
international task force recently recommended α2β receptor ligands of voltage-gated
calcium channels, such as gabapentin and pregabalin, as ﬁrst-line option to treat
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restless legs (Garcia-Borreguero et al. 2016). Gabapentin and pregabalin are structur-
ally related to GABA, increase GABA concentration the human brain (Cai et al.
2012), and inhibit calcium currents. The derivative gabapentin enacarbil was recently
approved by FDA for RLS. In contrast to the dopaminergic drugs, gabapentin
enacarbil does not lead to augmentation.
Based on the hypothesis that brain iron deﬁciency in RLS is associated with a
hypoadenosinergic state, a preliminary study recently suggested that the nonselec-
tive ENT1/ENT2 (equilibrative nucleoside transporter) inhibitor, dipyridamole, has
signiﬁcant therapeutic effects on sensory and motor symptoms, as well as sleep
(Garcia-Borreguero et al. 2018).
2.6 Sleep-Related Breathing Disorders
Sleep-related breathing disorders include upper airway obstructions (obstructive
sleep apnea [OSA]) and ceased or decreased ventilatory effort (central sleep
apnea) during sleep. While OSA is most commonly treated with continuous positive
airway pressure (CPAP) therapy, the therapeutic success of CPAP and other avail-
able therapies is often hampered by limited compliance or efﬁcacy (Hedner and Zou
2018). These and other reasons warrant the scientiﬁc search for pharmacological
remedies of OSA. Nevertheless, currently no pharmacologic alternatives to CPAP
are available. Promising research has recently characterized different phenotypes of
OSA, which may unearth novel strategies and targets for drug development (Hedner
and Zou 2018).
3 Variable Drug Response Genetics
3.1 Gene Polymorphisms Modulating Drug Sensitivity
and Exposure Can Determine Individual
Pharmacotherapeutic Responses
It has long been recognized that not all patients respond to pharmacotherapy in a
uniform and beneﬁcial fashion. How a therapeutic compound affects the organism
and its physiology (pharmacodynamics) and how the organism acts on such a
compound (pharmacokinetics) are highly individual processes, which are, in part,
genetically determined. Pharmacogenetic approaches aim at elucidating genetically
determined interindividual differences in drug responses, with the goal to discrimi-
nate responders from nonresponders and to minimize toxicity and adverse drug
reactions. Such studies have shown that single nucleotide polymorphisms (SNPs),
variable-number-tandem-repeat (VNTR) polymorphisms, copy number variations,
and insertions/deletions in genes regulating the pharmacodynamics (e.g., receptors,
ion channels, enzymes, immune molecules) of medications and/or their pharmaco-
kinetics (e.g., metabolizing enzymes, transporters, plasma protein binding) contrib-
ute to wanted and adverse actions of pharmacotherapeutic agents (Evans and Relling
1999; Sadee and Dai 2005; Roden et al. 2011; Holst et al. 2016).
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Genes modulating the pharmacodynamic response to a pharmacological treat-
ment may code for the direct targets of drugs (e.g., receptors) or for proteins that
synthesize, clear, or degrade the endogenous ligands of these targets (e.g.,
neurotransmitters). Functional genetic variation in these genes, thus, possibly affects
drug sensitivity.
The ﬁeld of pharmacogenetics has historically focused on genetically determined
differences in the activity of drug-metabolizing enzymes. Functional variants of
genes encoding such enzymes can modulate exposure to therapeutic agents and,
thus, their efﬁcacy and toxicity. For example, more than 80% of all clinically used
drugs are metabolized by cytochrome-P450 (CYP) isoenzymes that are encoded in
humans by 57 genes of 3 major families (Ingelman-Sundberg 2004). Functional
variants of the CYP1A2, CYP2D6, CYP2C8/9, CYP2C19, and CYP3A4/5 genes are
of particular interest because they have been associated with altered clinical
outcomes (Evans and Relling 1999; Ingelman-Sundberg 2004). Other known
genetic variants affecting drug exposure include conjugation enzymes, such as
uridine-50-diphospho-glucuronosyltransferase (UGT) and N-acetyltransferase
2 (NAT2), and drug transporters, including solute carrier (SLC) and ATP-binding
cassette (ABC) transporter families (Kerb 2006).
The main targets for the wanted effects, as well as the main metabolism and
excretion pathways of the sleep-wake therapeutics introduced in the previous
paragraphs, are summarized in Table 1. In the following section, known genetic
differences in pharmacodynamics and pharmacokinetics of these drugs and drug
classes will be reviewed. The contents of this section have been elaborated and
updated based on a recent comprehensive overview (Holst et al. 2016). For
that purpose, PubMed searches were performed between March 2015 and July
2018, including as search terms all generic drug names mentioned below AND
(“pharmacogenetics” OR “polymorphism” OR “CYP” OR “therapy”). A total of
79 references was identiﬁed, yet those articles whose content was unrelated to the
present review are not cited here.
3.2 Pharmacotherapy of Insomnia Disorder and Parasomnias
3.2.1 Benzodiazepines, Z-Drugs, and Barbiturates
Genetic variants of the α subunits of GABAA receptors alter the sensitivity to
benzodiazepines and Z-drugs in transgenic animals (Tobler et al. 2001; Cope et al.
2004; Kopp et al. 2004), the treatment responses to antiepileptic drugs (Hung et al.
2013), and the sensitivity toward diazepam in alcoholic patients (Iwata et al. 1999).
No studies on the relevance of GABAA receptor polymorphisms for variable hyp-
notic effects of benzodiazepines and Z-drugs in insomnia patients are currently
available.
Most benzodiazepines and Z-drugs are degraded by CYP3A4/5 and CYP2C19
isoenzymes (Hohmann et al. 2016). Genetic variants of these enzymes affect the
pharmacokinetics of various members of these drug classes (Park et al. 2006; Shen
et al. 2013). Individual CYP isoenzyme metabolizer status is important for
216 H.-P. Landolt et al.
Ta
b
le
1
C
ur
re
nt
ly
av
ai
la
bl
e
ph
ar
m
ac
ol
og
ic
al
tr
ea
tm
en
ts
of
sl
ee
p-
w
ak
e
di
so
rd
er
s
D
ru
g
cl
as
s
A
pp
ro
ve
d
co
m
po
un
d
S
le
ep
-w
ak
e
in
di
ca
tio
n(
s)
W
an
te
d
sl
ee
p-
w
ak
e
ef
fe
ct
(s
)
M
ai
n
m
od
e
of
ac
tio
n
fo
r
sl
ee
p-
w
ak
e
ef
fe
ct
M
ai
n
m
et
ab
ol
is
m
/e
xc
re
tio
n
pa
th
w
ay
s
B
en
zo
di
az
ep
in
es
Q
ua
ze
pa
m
E
st
az
ol
am
F
lu
ra
ze
pa
m
T
ri
az
ol
am
T
em
az
ep
am
In
so
m
ni
a
Im
pr
ov
ed
sl
ee
p
P
os
iti
ve
ag
on
is
tic
m
od
ul
at
io
n
of
G
A
B
A
A
re
ce
pt
or
s
C
Y
P
3A
4/
5,
C
Y
P
2C
19
,U
G
T
is
oe
nz
ym
es
,N
A
T
2
C
lo
na
ze
pa
m
P
ar
as
om
ni
as
Im
pr
ov
ed
sl
ee
p
P
os
iti
ve
ag
on
is
tic
m
od
ul
at
io
n
of
G
A
B
A
A
re
ce
pt
or
s
C
Y
P
3A
4/
5,
N
A
T
2
Z
-d
ru
gs
Z
ol
pi
de
m
(E
s)
Z
op
ic
lo
ne
Z
al
ep
lo
n
In
so
m
ni
a
Im
pr
ov
ed
sl
ee
p
P
os
iti
ve
ag
on
is
tic
m
od
ul
at
io
n
of
G
A
B
A
A
re
ce
pt
or
s
C
Y
P
3A
4,
al
de
hy
de
ox
id
as
e
B
ar
bi
tu
ra
te
s
B
ut
ab
ar
bi
ta
l
S
ec
ob
ar
bi
ta
l
In
so
m
ni
a
(r
ar
el
y
us
ed
)
Im
pr
ov
ed
sl
ee
p
G
A
B
A
A
re
ce
pt
or
ag
on
is
m
C
Y
P
1A
2,
C
Y
P
2C
9/
10
,C
Y
P
3A
4
G
H
B
/B
A
B
A
B
re
ce
pt
or
ag
on
is
t
S
od
iu
m
ox
yb
at
e
N
ar
co
le
ps
y
R
ed
uc
ed
ca
ta
pl
ex
y
an
d
im
pr
ov
ed
w
ak
e
st
at
e
(E
D
S
)
G
H
B
/G
A
B
A
B
re
ce
pt
or
ag
on
is
m
G
H
B
de
hy
dr
og
en
as
e
!
su
cc
in
ic
ac
id
!
K
re
bs
cy
cl
e
!
C
O
2
ex
ha
la
tio
n
D
O
R
A
S
uv
or
ex
an
t
In
so
m
ni
a
Im
pr
ov
ed
sl
ee
p
H
cr
t-
1/
2
re
ce
pt
or
an
ta
go
ni
sm
C
Y
P
3A
4/
5,
C
Y
P
2C
19
A
nt
ih
is
ta
m
in
es
D
ip
he
nh
yd
ra
m
in
e
D
ox
yl
am
in
e
(I
ns
om
ni
a)
Im
pr
ov
ed
sl
ee
p
H
1
re
ce
pt
or
an
ta
go
ni
sm
C
Y
P
2D
6,
C
Y
P
1A
2,
C
Y
P
2C
9
T
C
A
D
ox
ep
in
e
In
so
m
ni
a
Im
pr
ov
ed
sl
ee
p
H
1
re
ce
pt
or
an
ta
go
ni
sm
C
Y
P
2D
6,
C
Y
P
2C
19
T
eC
A
M
ir
ta
za
pi
ne
In
so
m
ni
a
Im
pr
ov
ed
sl
ee
p
H
1
re
ce
pt
or
an
ta
go
ni
sm
,5
-
H
T
2
A
an
ta
go
ni
sm
C
Y
P
2D
6,
C
Y
P
1A
2,
C
Y
P
3A
4 (c
on
tin
ue
d)
Clinical and Experimental Human Sleep-Wake Pharmacogenetics 217
Ta
b
le
1
(c
on
tin
ue
d)
D
ru
g
cl
as
s
A
pp
ro
ve
d
co
m
po
un
d
S
le
ep
-w
ak
e
in
di
ca
tio
n(
s)
W
an
te
d
sl
ee
p-
w
ak
e
ef
fe
ct
(s
)
M
ai
n
m
od
e
of
ac
tio
n
fo
r
sl
ee
p-
w
ak
e
ef
fe
ct
M
ai
n
m
et
ab
ol
is
m
/e
xc
re
tio
n
pa
th
w
ay
s
M
el
at
on
in
M
el
at
on
in
/
C
ir
ca
di
n®
(p
ro
lo
ng
ed
re
le
as
e)
A
du
lt
in
so
m
ni
a

55
ye
ar
;
N
24
H
S
W
D
;
D
S
P
D
;
tr
an
si
en
t
in
so
m
ni
a;
S
A
D
Im
pr
ov
ed
sl
ee
p
an
d
w
ak
e
st
at
e
M
T
1
/2
re
ce
pt
or
ag
on
is
m
C
Y
P
1A
2
!
S
ul
ph
am
et
ho
xy
m
el
at
on
in
(u
ri
ne
),
C
Y
P
3A
4
M
el
at
on
in
ag
on
is
ts
R
am
el
te
on
S
le
ep
on
se
t
in
so
m
ni
a
in
ol
de
r
ad
ul
ts
Im
pr
ov
ed
sl
ee
p
M
T
1
/2
re
ce
pt
or
ag
on
is
m
C
Y
P
1A
2,
C
Y
P
3A
4
T
as
im
el
te
on
N
24
H
S
W
D
;
tr
an
si
en
t
in
so
m
ni
a
Im
pr
ov
ed
sl
ee
p
an
d
w
ak
e
st
at
e
M
T
1
/2
re
ce
pt
or
ag
on
is
m
C
Y
P
1A
2,
C
Y
P
3A
4
A
go
m
el
at
in
e
M
D
D
A
nt
id
ep
re
ss
an
t/
an
xi
ol
yt
ic
,
be
ne
ﬁ
ci
al
ef
fe
ct
on
sl
ee
p
5-
H
T
2
C
an
ta
go
ni
sm
/M
T
1
/
2
re
ce
pt
or
ag
on
is
m
C
Y
P
1A
2,
C
Y
P
3A
4
P
sy
ch
os
tim
ul
an
ts
M
et
hy
lp
he
ni
da
te
N
ar
co
le
ps
y
Im
pr
ov
ed
w
ak
e
st
at
e
(E
D
S
)
N
E
T
-D
A
T
in
hi
bi
tio
n
C
E
S
1
M
et
ha
m
ph
et
am
in
e
N
ar
co
le
ps
y
Im
pr
ov
ed
w
ak
e
st
at
e
(E
D
S
)
N
E
,D
A
,a
nd
5-
H
T
re
le
as
e
N
E
T
-
D
A
T
in
hi
bi
tio
n
U
ri
na
ry
ex
cr
et
io
n
as
pa
re
nt
dr
ug
an
d/
or
D
-a
m
ph
et
am
in
e
C
af
fe
in
e
n/
a
Im
pr
ov
ed
w
ak
e
st
at
e
(E
D
S
)
A
1
/2
A
re
ce
pt
or
an
ta
go
ni
sm
C
Y
P
1A
2
W
ak
e
pr
om
ot
in
g
ag
en
ts
(A
r)
M
od
aﬁ
ni
l
N
ar
co
le
ps
y,
sh
if
tw
or
k
sl
ee
p
di
so
rd
er
,O
S
A
Im
pr
ov
ed
w
ak
e
st
at
e
(E
D
S
)
U
nk
no
w
n,
D
A
T
in
hi
bi
tio
n
A
m
id
e
hy
dr
ol
ys
is
,C
Y
P
-m
ed
ia
te
d
ox
yg
en
at
io
n
5-
H
T
/N
E
re
-
up
ta
ke
in
hi
bi
to
r
V
en
la
fa
xi
ne
M
D
D
,n
ar
co
le
ps
y
R
ed
uc
ed
ca
ta
pl
ex
y
S
E
R
T
/N
E
T
in
hi
bi
tio
n
C
Y
P
2D
6
218 H.-P. Landolt et al.
H
3
in
ve
rs
e
ag
on
is
t
P
ito
lis
an
t
N
ar
co
le
ps
y
Im
pr
ov
ed
w
ak
e
st
at
e
(E
D
S
)
an
d
re
du
ce
d
ca
ta
pl
ex
y
H
3
re
ce
pt
or
in
ve
rs
e
ag
on
is
m
C
Y
P
3A
4,
C
Y
P
2D
6
D
2
/3
ag
on
is
ts
P
ra
m
ip
ex
ol
e
P
D
,R
L
S
R
ed
uc
tio
n
of
P
L
M
S
D
2
/3
/4
re
ce
pt
or
ag
on
is
m
U
ri
na
ry
ex
cr
et
io
n
of
un
ch
an
ge
d
dr
ug
(>
90
%
)
R
op
in
ir
ol
e
P
D
,R
L
S
R
ed
uc
tio
n
of
P
L
M
S
D
2
/3
/4
re
ce
pt
or
ag
on
is
m
C
Y
P
1A
2
R
ot
ig
ot
in
e
P
D
,R
L
S
R
ed
uc
tio
n
of
P
L
M
S
D
2
/3
/4
re
ce
pt
or
ag
on
is
m
C
Y
P
2C
19
,U
G
T
en
zy
m
es
α 2
δ
re
ce
pt
or
lig
an
d
G
ab
ap
en
tin
R
L
S
,i
ns
om
ni
a
R
ed
uc
tio
n
of
P
L
M
S
,i
m
pr
ov
ed
sl
ee
p
U
nk
no
w
n,
bi
nd
in
g
to
α 2
δ
su
bu
ni
t
of
V
G
C
C
U
ri
na
ry
ex
cr
et
io
n
of
un
ch
an
ge
d
dr
ug
D
O
R
A
du
al
or
ex
in
re
ce
pt
or
an
ta
go
ni
st
s,
T
C
A
tr
ic
yc
lic
an
tid
ep
re
ss
an
ts
,
T
eC
A
te
tr
ac
yc
lic
an
tid
ep
re
ss
an
ts
,
5-
H
T
5-
hy
dr
ox
yt
ry
pt
am
in
e,
se
ro
to
ni
n,
N
E
no
re
pi
-
ne
ph
ri
ne
,
H
3
hi
st
am
in
e
H
3
re
ce
pt
or
,
H
cr
t
hy
po
cr
et
in
,
D
2
do
pa
m
in
e
D
2
re
ce
pt
or
,
N
24
H
SW
D
no
n-
24
-h
ou
r
sl
ee
p-
w
ak
e
di
so
rd
er
,
D
SP
D
de
la
ye
d
sl
ee
p
ph
as
e
di
so
rd
er
,S
A
D
se
as
on
al
af
fe
ct
iv
e
di
so
rd
er
,M
D
D
m
aj
or
de
pr
es
si
ve
di
so
rd
er
,O
SA
ob
st
ru
ct
iv
e
sl
ee
p
ap
ne
a,
P
D
P
ar
ki
ns
on
’s
di
se
as
e,
R
L
S
re
st
le
ss
le
gs
sy
nd
ro
m
e,
E
D
S
ex
ce
ss
iv
e
da
yt
im
e
sl
ee
pi
ne
ss
,
P
L
M
S
pe
ri
od
ic
lim
b
m
ov
em
en
ts
in
sl
ee
p,
G
H
B
γ-
hy
dr
ox
yb
ut
yr
at
e,
H
1
hi
st
am
in
e
H
1
re
ce
pt
or
,
M
T
1
/2
re
ce
pt
or
s
m
el
at
on
in
M
T
1
an
d
M
T
2
re
ce
pt
or
s,
5-
H
T
2
A
se
ro
to
ni
n-
2A
re
ce
pt
or
s,
5-
H
T
2
C
se
ro
to
ni
n-
2C
re
ce
pt
or
s,
D
A
T
do
pa
m
in
e
tr
an
sp
or
te
r,
SE
R
T
se
ro
to
ni
n
tr
an
sp
or
te
r,
N
E
T
no
re
pi
ne
ph
ri
ne
tr
an
sp
or
te
r,
A
1
/2
A
re
ce
pt
or
s
ad
en
os
in
e
A
1
an
d
A
2
A
re
ce
pt
or
s,
V
G
C
C
vo
lta
ge
-g
at
ed
ca
lc
iu
m
ch
an
ne
ls
,
C
Y
P
cy
to
ch
ro
m
e-
P
45
0
is
oe
nz
ym
es
,
U
G
T
ur
id
in
e-
50
-d
ip
ho
sp
ho
-g
lu
cu
ro
ny
ltr
an
sf
er
as
e,
N
A
T
2
N
-a
ce
ty
ltr
an
sf
er
as
e
2,
C
E
S1
ca
rb
ox
yl
es
te
ra
se
1,
C
O
M
T
ca
te
ch
ol
-O
-m
et
hy
ltr
an
sf
er
as
e,
M
A
O
B
m
on
oa
m
in
ox
id
as
e
ty
pe
-B
Clinical and Experimental Human Sleep-Wake Pharmacogenetics 219
the correct dosing of these hypnotics, to optimize efﬁcacy and avoid adverse actions,
such as daytime impairment and next-morning sedation (Lozupone et al. 2017).
Some benzodiazepines (e.g., lorazepam, clonazepam, nitrazepam) are
glucuronidated by UGT isoenzymes or acetylated by NAT2. Glucuronidation is a
xenobiotic elimination reaction mainly occurring in the liver. Polymorphisms in
some UGT genes affect lorazepam clearance. One case documented prolonged
sedation after lorazepam, due to absence of the isoenzyme UGT2B7 (Siller et al.
2014). Furthermore, NAT2 polymorphisms causing “slow acetylator” phenotypes
impair the metabolism of clonazepam in vitro (Toth et al. 2016).
3.2.2 Dual Orexin Receptor Antagonists
While genetic variants of HCRTR1/2 receptors and Hcrt synthesis are frequent
(Thompson et al. 2014), their functional and pharmacological signiﬁcance are not
well understood. The current development of Hcrt receptor antagonists as novel
hypnotics should take these genetic variants into account, to better understand the
variability in drug efﬁcacy and side effects (Hoyer and Jacobson 2013; Thompson
et al. 2014). For example, in vitro and in vivo characterization of the metabolism and
disposition of suvorexant in humans determined that CYP3A4/5 are the predominant
enzymes mediating oxidation of this compound (Cui et al. 2016).
3.2.3 Antihistamines
Large interindividual differences are observed in the sedative effects of diphenhy-
dramine, which appear to be due to drug metabolism rather than genetic variants of
His H1 receptors. The isoenzymes CYP2D6, CYP1A2, CYP2C9, and CYP2C19
contribute to diphenhydramine metabolism (Akutsu et al. 2007). Three CYP2D6
ultra-metabolizers reported paradoxical excitation rather than sedation on diphenhy-
dramine treatment (de Leon and Nikoloff 2008), and the CYP2D6*10 allele was
identiﬁed as a risk factor for antihistamine-induced sleepiness in Japanese adults
(Saruwatari et al. 2006).
3.2.4 Sedating Antidepressants and Antipsychotics
Pharmacogenetic studies of mirtazapine established several polymorphisms that
modulate its hypnotic and antidepressant efﬁcacy. For example, the c.-998G>A
polymorphism (SNP-Id: rs6311) of the gene encoding the 5-HT2A receptor (HTR2A)
determined mirtazapine-induced sleep improvements in patients with major depres-
sive disorder (MDD) (Kang et al. 2007). Mirtazapine also binds to DA, NE, and ACh
receptors. Consistent with this pharmacological proﬁle, also rs28363170 of the
DAT1 gene encoding the DAT (aka SLC6A3, solute carrier family 6 member 3)
and distinct polymorphisms of ARRB1 (β arrestin 1), COMT (catechol-O-
methyltransferase), MAOA, and MAOB (monoamine oxidase isoenzymes A and B)
genes affect responses to mirtazapine in patients with MDD (reviewed in Holst et al.
2016). These studies illustrate that sleep-promoting agents may act on multiple
systems, and polymorphisms of genes regulating different neurotransmitters may
mutually inﬂuence the efﬁcacy of a given drug.
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Polymorphisms of theHTR2A gene were also associated with treatment outcomes
in depressed patients treated with SSRIs (Kato and Serretti 2010). The variants
c.371T>C of HTR1B (5-HT1B receptor; SNP-Id: rs130060) and c.102C>T of
HTR2A (SNP-Id: rs6313) affect binding afﬁnity of the 5-HT2A receptor antagonist,
ketanserin (Brüss et al. 1999; Holmes et al. 2007). These polymorphisms may
modulate slow-wave sleep promotion by 5-HT2A receptor antagonists that are currently
in development.
Apart from genetic differences in drug targets, genetically determined metabolizer
status modiﬁes clearance of doxepin (metabolized by CYP2D6, CYP2C9, and
CYP2C19) (Kirchheiner et al. 2002) and (es)mirtazapine (primarily metabolized by
CYP2D6) (Brockmöller et al. 2007). Fatal poisoning with both drugs was associated
with defective CYP2D6 enzymes (Neukamm et al. 2013). Nevertheless, systematic
review of the available data indicates that the current evidence is insufﬁcient to
conclude that CYP2D6 poor metabolizers are more prone to adverse effects of
doxepin than more extensive/rapid metabolizers (Haufroid and Hantson 2015).
Driving performance in healthy volunteers was more impaired after esmirtazapine
administration in poor rather than in rapid CYP2D6 metabolizers (Ramaekers et al.
2011).
3.3 Pharmacotherapy of Circadian Rhythm Sleep-Wake Disorders
3.3.1 Melatonin and Melatonin Analogues
Several polymorphisms in the melatonin receptor genes, MTNR1A and MTNR1B,
were identiﬁed (Ekmekcioglu 2006), and MT2 receptor gene variants were
associated with type-2 diabetes (Karamitri et al. 2013). One study suggested a
relevant association between polymorphism rs2119882 of MTNR1A (proposed to
affect promoter activity) and insomnia symptoms in schizophrenia (Park et al. 2011).
The development of melatonin receptor agonists for insomnia and circadian rhythm
sleep-wake disorders would beneﬁt from pharmacogenetic studies, taking into
account functional polymorphisms of melatonin receptors.
Melatonin is synthesized from 5-HT, metabolized almost exclusively in the liver
by CYP1A2, and excreted as sulphatoxymelatonin in urine (Claustrat et al. 2005).
The plasma concentration of melatonin after oral ingestion was higher in individuals
with *1A/*1A than with *1F/*1F genotypes of CYP1A2 (Härtter et al. 2006).
Furthermore, autistic patients with slow CYP1A2 metabolism due to *1F/*1A or
*1A/*1A genotypes showed decreasing potency of melatonin to improve sleep
problems (Braam et al. 2013). Finally, Chinese carriers of a *1A and other
CYP1A2 variants appear to metabolize agomelatine more slowly than carriers of
the *1F allele (Song et al. 2014). Interestingly, sulphatoxymelatonin was recently
proposed as a potential biomarker of brain 5-HT status in severe genetic disorders
affecting 5-HT biosynthesis (Batllori et al. 2017).
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3.4 Pharmacotherapy of Central Disorders of Hypersomnolence
3.4.1 (Ar)Modafinil and Stimulants
Individual effects of standard doses of (ar)modaﬁnil and stimulants such as methyl-
phenidate and amphetamines have been associated with genetic variants of proteins
regulating endogenous neurotransmitter degradation and transmission. For example,
the activity of the monoamine-metabolizing enzyme, COMT, depends on several
known genetic variants, including the functional c.472G>A (p.Val158Met) poly-
morphism (SNP-Id: rs4680) (Chen et al. 2004). This common valine-to-methionine
substitution drastically reduces enzymatic activity, leading to elevated prefrontal
cortex (PFC) dopaminergic tone in Met/Met homozygotes when compared to
Val/Val homozygotes (Tunbridge et al. 2006). The treatment response with
modaﬁnil in narcolepsy patients differs widely among COMT genotypes. To control
EDS, patients (female and male) with the Val/Val genotype of rs4680 need almost
100 mg more modaﬁnil per day than patients with the Met/Met genotype
(Dauvilliers et al. 2002). Intriguingly, as will be outlined below, the impact of this
polymorphism on modaﬁnil’s efﬁcacy may be opposite in narcolepsy patients and
sleep-deprived healthy volunteers.
Apart from genetic variance modulating monoaminergic neurotransmission,
variants in the gene encoding the P-glycoprotein drug transporter ABCB1 (ATP
binding cassette subfamily B member 1) may partly explain individual therapeutic
response to modaﬁnil treatment in narcolepsy (Moresco et al. 2016).
Both the Val-allele of rs4680 of COMT and the 9R-allele of rs28363170 of DAT1
(see below) were associated with a pronounced response to methylphenidate
(Kereszturi et al. 2008; Froehlich et al. 2011) and enhanced risk of
methamphetamine-induced psychosis and abuse (Ujike et al. 2003; Li et al. 2004).
Preliminary data further indicate that CYP2D6 extensive/ultra-rapid metabolizers
could show an elevated risk for central nervous system risk adverse effects of
methamphetamine (Haufroid and Hantson 2015). Yet, more work is needed to
conﬁrm this association.
3.4.2 Venlafaxine
Converging evidence from multiple studies indicates that CYP2D6 poor
metabolizers are especially prone to adverse effects caused by venlafaxine (Haufroid
and Hantson 2015), whereas no signiﬁcant association with clinical response was
found with polymorphisms of the ABCB1 gene (Moresco et al. 2016).
3.4.3 Caffeine
Wake promotion and sleep disruption by the adenosine receptor antagonist, caffeine,
are highly variable in patients and healthy people. The reasons for the pronounced
interindividual differences in caffeine effects on sleep remain incompletely under-
stood. Shared environmental factors contribute to poor sleep quality associated with
sustained high caffeine consumption (Treur et al. 2018). In addition, a population-
based survey in roughly 1,000 participants indicated that caffeine reduces sleep
efﬁciency more potently in G/A allele carriers than in G/G homozygotes of
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polymorphism rs73598374 of the gene encoding the adenosine metabolizing
enzyme, adenosine deaminase (Mazzotti et al. 2011). This study, however, was
not controlled and awaits replication.
Caffeine is mainly metabolized by CYP1A2, which shows 10- to 200-fold
interindividual differences in enzymatic activity (Fredholm et al. 1999; Gunes and
Dahl 2008). Consistent with the notion that the rate of caffeine metabolism is
heritable (Rasmussen et al. 2002), a common C/A polymorphism in intron 1 of the
CYP1A2 gene (SNP-Id: rs762551) was found to affect caffeine half-life in blood
plasma, such that A/A-allele carriers (CYP1A2*1F) metabolize caffeine faster than
C-allele carriers (Sachse et al. 1999). Nevertheless, health status, gender, and age, as
well as lifestyle factors (such as habitual smoking and caffeine consumption, both
known to induce CYP1A2 enzymatic activity), also play important roles for the
metabolism of caffeine to its primary metabolite, paraxanthine (e.g., Urry et al.
2016).
Disturbed sleep causes some people to voluntarily abstain from caffeine.
Genome-wide association (GWA) studies examined genetic contributions to caf-
feine consumption in humans. In 47,341 participants of European descent, two
polymorphisms regulating transcriptional activation of CYP1A2 determined habit-
ual caffeine intake, one located in the bidirectional promoter region of the CYP1A1-
CYP1A2 locus (SNP-Id: rs2470893) and one located in the aryl hydrocarbon recep-
tor (AHR) (SNP-Id: rs4410790) gene (Cornelis et al. 2011). Intriguingly, a second
study with more than 10,000 participants of European ancestry, located two other
polymorphisms in the same genes, rs2472297 (CYP1A1-CYP1A2) and rs6968865
(AHR) (Sulem et al. 2011). These GWA studies support a role for CYP1A2 in the
pharmacogenetics of caffeine. In addition, variants of ADORA2A (gene encoding
adenosine A2A receptors) also inﬂuence caffeine preference (Cornelis et al. 2011)
and sleep disruption by caffeine (Rétey et al. 2007; Byrne et al. 2012).
Because melatonin is also degraded by CYP1A2, caffeine and melatonin compete
for the same metabolizing enzyme. The half-life of caffeine during melatonin release
may be prolonged and, in turn, caffeine consumption may delay the nocturnal peak
of melatonin (Härtter et al. 2006; Braam et al. 2013). Habitual caffeine intake should,
thus, be taken into account to understand individual efﬁcacy of melatonin and novel
melatonin receptor agonists.
3.4.4 g-Hydroxybutyrate (GHB)
So far, no studies have investigated the relevance of functional genetic variants of
GABAB receptors or polymorphisms related to GHB metabolizing pathways for
individual drug responses in narcolepsy patients treated for EDS and cataplexy. By
contrast, GHB intolerance was proposed to possibly arise from reduced activity of
the GABA metabolizing enzyme, succinic semialdehyde dehydrogenase (Berner
2013).
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3.5 Pharmacotherapy of Sleep-Related Movement Disorders
3.5.1 Dopamine D2/3 Receptor Agonists
Polymorphisms of DRD2 and DRD3 genes (encoding dopamine D2 and D3
receptors) impact the effects of the dopamine receptor agonists used to treat RLS
(Agundez et al. 2013). Pharmacogenetic evidence also linked a Ser9Gly polymor-
phism of DRD3 (SNP-Id: rs6280) with response to pramipexole in Parkinson’s
disease (PD) patients, but not with the Taq1A polymorphism of DRD2 (SNP-Id:
rs1800497) (Liu et al. 2009). In another study, however, both rs1800497 and aMspI
polymorphisms of DRD3 (SNP-Id: rs4646996) were related to discontinued use of
pramipexole and ropinirole in PD (Arbouw et al. 2009).
The D2 receptor agonist ropinirole is degraded by CYP1A2 and to a lesser extent
by CYP3A4 (Kaye and Nicholls 2000), whereas the metabolic pathways for
pramipexole are not yet clear (Agundez et al. 2013). A polymorphism of the gene
encoding the solute carrier protein SLC22A1 (SNP-Id: rs622342) was linked to
higher doses of pramipexole and reduced survival time after initiation of L-dopa
therapy (Becker et al. 2011). These effects may be caused by reduced drug uptake
from the small intestine.
3.5.2 Ligands of a2d Subunit of Voltage-Gated Calcium Channels
Mutations and deletions of the CACNA2D1 gene coding for the α2δ subunit family,
which has ﬁve isoforms targeted by gabapentin and pregabalin, were linked to
several medical disorders and increased sensitivity to opioid treatment (Rhodin
et al. 2013). Moreover, a CACNA1A mutation in mice leading to impaired G
protein-coupled inhibition was associated with reduced sleep induction by adenosine
and wake promotion by caffeine (Deboer et al. 2013). Interestingly, recent evidence
indicates that genetic variants of CACNA1C are associated with sleep latency and
sleep quality (Byrne et al. 2013; Parsons et al. 2013). It may, hence, be expected that
such polymorphisms modulate the efﬁcacy of drugs or environmental inﬂuences that
affect sleep.
Gabapentin-like compounds undergo negligible metabolism and are primarily
eliminated as unchanged drug by renal excretion. The c.1507C>T polymorphism
(SNP-Id: rs1050152) of the gene encoding the solute carrier protein SLC22A4
affects gabapentin transport in vitro, yet homozygous T-allele carriers showed no
enhanced renal clearance of gabapentin when compared to carriers of the “wild-
type” C-allele (Urban et al. 2007).
4 Pharmacogenetic Dissection of Sleep-Wake Circuitries
in Humans
As mentioned above, converging lines of research employing optogenetic and
chemogenetic methods in animal models have pointed to new structures and
pathways regulating sleep and wakefulness. For example, dopaminergic signaling
appeared for a long time to have no crucial role in sleep-wake regulation.
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Accumulating evidence now suggests that antagonistic adenosinergic-dopaminergic
interactions particularly in the striatum play important roles in sleep-wake regulation
(for reviews, see Lazarus et al. 2017; Wisor 2018). Based on this evidence, A2A-D2
receptor-positive striatopallidal cells may serve as new target for therapeutic inter-
vention in sleep-wake disorders. Preclinical human pharmacology provides a bridge
between basic (sleep-wake) research and clinical (sleep-wake) medicine and is an
essential step in the development of novel (sleep-wake) therapeutics.
Rational treatments of sleep-wake disorders should strengthen the physiological
processes underlying sleep-wake regulation. According to this rationale, an “ideal”
novel hypnotic can be expected to promote the same physiological processes that
underlie elevated sleep need and increased sleep intensity, as reﬂected by the
prevalence of theta/alpha (~6–10 Hz) and delta (<4 Hz) frequency activity in the
electroencephalogram (EEG) in wakefulness and sleep. Sleep deprivation, the stron-
gest challenge of the sleep-wake-dependent, homeostatic facet of sleep-wake regu-
lation, not only alters in highly predictable fashion electrical brain activity in these
frequencies but also impairs a wide range of measures derived from neurobehavioral
performance tasks. In the laboratory, neurobehavioral deﬁcits of sleep deprivation
are accurately indexed by increased lapses and slowed reaction times on the psycho-
motor vigilance task (PVT). This task has been considered a gold-standard measure-
ment of sustained vigilant attention in sleep-wake research (Lim and Dinges 2010).
Performance on the PVT is reliably impaired by elevated sleep need and reﬂects
distinct changes in neuronal activity (Nir et al. 2017; Maire et al. 2018). Importantly,
these consequences of sleep deprivation vary widely among individuals and are in
part genetically determined (Van Dongen et al. 2004; Lim et al. 2012). Intriguingly,
however, the neurophysiological and neurobehavioral variables do not typically
show a clear association with each other but rather develop seemingly indepen-
dently. Thus, it has been suggested that the neurophysiological and neurobehavioral
consequences of sleep loss are likely governed by separate mechanisms. In the
following section, an experimental pharmacogenetic approach to systematically
dissect these sleep-wake regulatory processes in healthy humans will be outlined.
Collectively, the results demonstrate distinctly different roles for adenosinergic and
dopaminergic pathways in the regulation of sleep-wake-dependent neurophysiologi-
cal and behavioral functions of the brain.
4.1 ADOAR2A Gene Variants Contribute to Caffeine Sensitivity
and Neurophysiological and Behavioral Effects of Sleep
Deprivation
Through competitive blockade of adenosine A1 and A2A receptors in the central
nervous system, caffeine attenuates the buildup of sleep pressure during wakefulness
and delays the endogenous circadian clock (Landolt et al. 2004; Burke et al. 2015).
The interference with these physiological sleep-wake regulatory mechanisms
can disturb the quality of sleep (Clark and Landolt 2017). The heritability of
coffee-attributed sleep disturbances equals roughly 40% (Luciano et al. 2007).
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The major psychostimulant ingredient of coffee is caffeine (Fredholm et al. 1999),
which blocks A2A receptors to promote wakefulness (Huang et al. 2005). The human
ADORA2A gene is located on chromosome 22q11.2, and functional genetic variation
of ADORA2A is an important determinant of sleep disruption by caffeine. More
speciﬁcally, a combined sleep deprivation and caffeine study provided evidence that
the c.1976T>C polymorphism of ADORA2A (SNP-ID: rs5751876) modulates indi-
vidual sensitivity to subjective and objective effects of caffeine on sleep (Rétey et al.
2007). Remarkably, this notion was conﬁrmed in a large GWA study in 2,402 twins
and their families (Byrne et al. 2012). The polymorphism rs5751876 forms linkage
disequilibria with several other variants of ADORA2A that modulate actions of
caffeine on sleep and attentional domains that are commonly impaired by sleep
deprivation (Bodenmann et al. 2012; Renda et al. 2015). In addition, caffeine-
sensitive and caffeine-insensitive individuals appear to be differently affected by
sleep loss (Rétey et al. 2006). This observation supports the notion that the func-
tional state of A2A receptors determines the accumulation of sleep need during
prolonged wakefulness, both in mice and humans (Hayaishi et al. 2004; Bodenmann
et al. 2012; Landolt et al. 2012; Rupp et al. 2013).
4.2 Adenosine A2A Receptors, Dopamine Transporters,
and Dopamine D2 Receptors Are Co-localized in the Striatum
The distribution of adenosine receptors in the central nervous system is highly
heterogeneous. The A2A receptor subtype is primarily expressed in the striate nuclei
(caudate nucleus, putamen, nucleus accumbens [NAc], globus pallidus) and olfac-
tory tubercle (Fig. 2). Accumulating evidence suggests that the striatum, the NAc in
particular, plays critical roles in wake promotion by caffeine and in sleep-wake
regulation (Lazarus et al. 2011; Zhang et al. 2013; Holst and Landolt 2015). Apart
from widespread glutamatergic inputs from several cortical and subcortical areas, the
striatum receives dopaminergic inputs via axons originating in the substantia nigra
pars compacta and the ventral tegmental area (VTA) of the brainstem. Extracellular
dopamine levels in NAc and medial PFC ﬂuctuate across sleep-wake states in rats
(Lena et al. 2005). Combined behavioral, chemogenetic, and optogenetic
manipulations in freely moving mice suggest a fundamental role for the VTA
dopaminergic circuitry in maintaining wakefulness and linking motivated behaviors
with sleep-wake regulation (Eban-Rothschild et al. 2016; Oishi et al. 2017a).
Similar to adenosine A2A receptors, also the dopamine reuptake transporter
(DAT) is highly expressed in the striatum (Fig. 2). The DAT transports extracellular
dopamine from the synaptic cleft into the presynaptic terminals for repackaging into
vesicles. The deletion of the dat gene in mice reduces NREM sleep time and
increases wakefulness (Wisor et al. 2001). Intriguingly, the Dat/ knockout mice
are hypersensitive to the wake-promoting effects of caffeine. More speciﬁcally,
relative to wild-type littermates, the knockout animals exhibit a threefold and
ﬁvefold greater increase in wake time after 2.5 and 10 mg/kg caffeine administration
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when compared to vehicle (Wisor et al. 2001). Based on these data in animals, it was
hypothesized that functional variance not only in CYP1A2 and ADORA2A (see
above) but also in the DAT1 gene may modulate the response to caffeine in humans.
4.3 DAT1 Genotype Modulates Caffeine Sensitivity
and Neurophysiological and Behavioral Effects of Sleep
Deprivation
The human DAT1 gene contains a common VNTR polymorphism in its 30-untranslated
region. Linkage and associations of this polymorphism (SNP-ID: rs28363170) with
various psychiatric disorders (e.g., attention-deﬁcit hyperactivity disorder, PD, alco-
holism, schizophrenia) have been reported, suggesting that it is functionally relevant
(Pinsonneault et al. 2011). In addition, in vitro studies revealed an effect of this
polymorphism on gene expression (Pinsonneault et al. 2011). The VNTR can exist
in forms of 3–13 repeats, but two alleles are most common: 9 repeats (9R) or
10 repeats (10R) of a 40-bp sequence in exon 15. Several studies in humans
quantiﬁed striatal DAT availability with SPECT (single photon emission computer
tomography) and PET (positron emission tomography): these studies consistently
reported lower striatal DAT binding in 10R homozygotes when compared to 9R
allele carriers. On average, 10R homozygotes exhibit 10–15% lower striatal DAT
availability than 9R allele carriers (Costa et al. 2011; Faraone et al. 2014). Are 10R
homozygotes, thus, more sensitive to caffeine than 9R carriers, analogous to Dat/
mice?
Indeed, this seems to be the case. In a survey among 485 individuals, a signiﬁ-
cantly larger proportion of 10R homozygotes (39%) rated themselves as being
Fig. 2 A2A receptors, dopamine transporters (DAT), and D2 receptors are co-localized on dorsal
and ventral striatal neurons. The distribution volumes (color-coded) of selective radioligands that
bind to these receptors and transporters on the level of the basal ganglia in humans were
reconstructed with single photon emission computer tomography (123I-MNI 420) and positron
emission tomography (11C-cocaine and 11C-raclopride) imaging. The ﬁgure has been composed
of published data by Seibyl et al. (2012), Volkow et al. (2012)
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sensitive to psychostimulant action of caffeine when compared to 9R allele carriers
(Holst et al. 2014). In the case of 9R homozygotes, only 2 out of 23 individuals (9%)
were caffeine sensitive. The respective number was 33% in 9R/10R heterozygotes.
A subsequent controlled study in the laboratory conﬁrmed that the DAT1 VNTR
predicts the effect of caffeine on EEG markers of sleep need. The stimulant
attenuated the rebound in EEG slow waves following prolonged wakefulness in
DAT1 10R homozygotes only (Holst et al. 2014). From the perspective of sleep-
wake regulatory mechanisms, it is important to note that this polymorphism
associated with the repercussions of sleep deprivation on sleep EEG markers of
increased sleep drive (Holst et al. 2014). In addition, it modulated time-on-task
effects and performance instability on the PVT, as well as on the effects of the DAT
inhibitor, modaﬁnil, on markers of sleep need (Lim et al. 2012; Holst et al. 2014;
Satterﬁeld et al. 2017). Taken together, convergent ﬁndings in animals and humans
suggest that A2A receptors and DAT are involved in the wake-promoting effects of
caffeine and modaﬁnil. They further indicate that adenosine-dopamine interactions
in the striatum are important for sleep-wake regulation and the behavioral
consequences of sleep deprivation.
4.4 DRD2 Genotype Modulates Neurophysiological
and Neurobehavioral Consequences of Sleep Deprivation
Increasing evidence demonstrates the presence of co-expressed A2A-D2 receptor
complexes on distinct subpopulations of medium spiny neurons, the principle
neuronal cell type of the dorsal and ventral striatum (Azdad et al. 2009; Ferre
et al. 2010; Casado-Anguera et al. 2016). Brain imaging also demonstrates that D2
receptors are mainly expressed in the striatum (Fig. 2). Striatal outputs are primarily
composed of two types of projection neurons: indirect medium spiny neurons
(iMSNs) that express D2-type receptors and direct medium spiny neurons expressing
D1-type receptors (Ferre et al. 2010; Yager et al. 2015). Activation of iMSNs causes
a net inhibition of the thalamus, which is part of the fronto-striatal circuit (Yager
et al. 2015). Brain imaging of human subjects while performing a working memory
task revealed that gene variants encoding DAT and D2 receptor proteins interact to
regulate fronto-striatal circuit activity (Bertolino et al. 2009). Moreover, striatal D2
receptor availability after sleep deprivation is reduced when compared to baseline
(Volkow et al. 2012) and regulates brain activation during performance of a visual
attention task (Tomasi et al. 2016).
The DRD2 gene includes a functional c.957C>T polymorphism (SNP-ID:
rs6277) that affects levels and stability of mRNA such that C-allele carriers exhibit
15–20% enhanced striatal D2 receptor availability when compared to T-allele
carriers (Hirvonen et al. 2009). This polymorphism alone and in interaction with
the presence of either 9R and 10R alleles of DAT1 was found to modulate the
evolution of waking EEG markers of accumulating sleep pressure, subjective sleepi-
ness, as well as performance on the PVT across prolonged waking (Holst et al.
2017). More speciﬁcally, individuals homozygous for the C allele of DRD2 and the
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10R allele of DAT1 were more severely affected with attentional lapses after 40 h of
wakefulness than other genotypic variants. A recent study conﬁrmed that homozy-
gous carriers of the C allele of the DRD2 c.957C>T polymorphism are impaired by
sleep deprivation in vigilant attention (Whitney et al. 2017). Remarkably, however,
the same individuals were resilient to the effects of prolonged waking on reversal
learning, a measure of cognitive ﬂexibility (Whitney et al. 2017). Consistent with the
notion that the consequences of sleep deprivation are trait-like but task-speciﬁc, the
data collectively suggest that striato-thalamo-cortical dopaminergic pathways con-
tribute to the regulation of neurophysiological and neurobehavioral consequences of
sleep loss in humans.
4.5 COMT Genotype Modulates Neurobehavioral Consequences
of Sleep Deprivation Without Affecting Neurophysiological
Markers of Elevated Sleep Need
The COMT gene encodes the main enzyme degrading catecholamines in the PFC,
COMT, which regulates dopaminergic neurotransmission by converting DA to
3-methoxytyramine (Matsumoto et al. 2003). The genotype of the Val158Met
polymorphism of COMT (SNP-Id: rs4680) has a consistent impact on PFC func-
tioning (Egan et al. 2001; Tunbridge et al. 2006; Bodenmann et al. 2009b). Never-
theless, some effects of this genetic variant only become apparent when the DA
system is challenged, such as after sleep deprivation (Bodenmann et al. 2009a;
Satterﬁeld et al. 2018; Valomon et al. 2018). More speciﬁcally, Val/Val, Val/Met,
and Met/Met allele carriers perform similarly in baseline. Yet, after a night without
sleep, Val/Met heterozygotes produced twice as many attentional lapses than
Met/Met homozygotes (Valomon et al. 2018). Furthermore, the wake-promoting
agent modaﬁnil was virtually ineffective in mitigating impaired PVT performance
after sleep loss in Met/Met homozygotes. By contrast, in homozygous Val/Val allele
carriers, the same dose of modaﬁnil maintained virtually optimal performance
throughout 40 h of wakefulness (Bodenmann et al. 2009a).
To test the hypothesis that PFC dopaminergic signaling regulated by COMT
causally contributes to neurobehavioral and neurophysiological markers of sleep
loss, the interaction of COMT genotype, tolcapone, and sleep deprivation on lapses
of attention and neurophysiological markers of sleep-wake regulation was
investigated in a controlled laboratory study. Tolcapone is a brain penetrant inhibitor
of COMT that leads to speciﬁc increases in PFC dopaminergic tone without affect-
ing striatal dopaminergic transmission (Farrell et al. 2012). It was expected that
tolcapone would mitigate the effects of sleep deprivation primarily in Val/Val
homozygotes because it counteracts the overactive COMT and associated deﬁcit in
PFC dopaminergic function. Unexpectedly, tolcapone had no beneﬁcial effect in
any COMT genotype. By contrast, it increased attentional lapses even further,
particularly in Val/Met and Met/Met allele carriers (Valomon et al. 2018). The
data suggest an inverted U-shape relationship between PFC dopaminergic signaling
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and sustained attention after sleep loss. They further demonstrate that beyond and
above COMT genotype, a preexisting sleep debt strongly impacts on the effects of a
pharmacological increase of dopaminergic neurotransmission on brain functions.
In contrast to these behavioral effects, genetically determined and pharmaco-
logically induced differences in COMT activity do not affect established EEG
markers of elevated sleep pressure in wakefulness and sleep challenged by acute
total sleep deprivation (Bodenmann and Landolt 2010; Valomon et al. 2018).
4.6 Converging Evidence for Distinct Adenosinergic/
Dopaminergic Pathways Mediating Neurophysiological
and Behavioral Consequences of Sleep Loss
Among the four major dopaminergic pathways in the brain, three pathways
originating in the midbrain are especially important for interpreting the ﬁndings
discussed above. They consist of the nigrostriatal pathway projecting from the
substantia nigra to the dorsal striatum (caudate nucleus and putamen), which is
involved in motor control; the mesolimbic pathway originating in the VTA and
innervating several structures of the limbic system (including the NAc), which is
associated with reward, cognition, reinforcement, and motivational salience; and the
mesocortical pathway, also originating in the VTA, yet having widespread
projections to the cerebral cortex, being essential for normal cognitive functions of
the dorsolateral PFC, attentional control, motivation, and emotional processes. The
regulation of DA metabolism and uptake and, thus, dopaminergic neurotransmission
depends on the different pathways, such that DAT and D2 receptors regulate
nigrostriatal/mesolimbic circuit activity, while COMT controls dopaminergic trans-
mission in the mesocortical pathway.
The systematic human pharmacogenetic dissection of adenosine-associated loci
and dopamine-related loci discussed above demonstrates that the distinct
adenosinergic-dopaminergic signaling pathways differently modulate the response
to sleep loss and wake-promoting agents on neurophysiological markers of sleep
need and neurobehavioral deﬁcits (Fig. 3). The ADORA2A c.1976T>C polymor-
phism (Rétey et al. 2007; Rupp et al. 2013), an ADORA2A haplotype (Bodenmann
et al. 2012), the DAT1 VNTR polymorphism (Holst et al. 2014; Satterﬁeld et al.
2017), and the DRD2 c.957C>T polymorphism (Holst et al. 2017; Whitney et al.
2017) modulate both EEG and distinct behavioral markers of elevated sleep need
and the effects of caffeine and modaﬁnil on these markers. The ﬁndings suggest that
striatal iMSNs, which co-express high densities of adenosine A2A and dopamine D2
receptors, mediate these consequences of sleep loss. It is tempting to speculate that
the NAc is essential in these processes. Thus, elegant studies in animal models have
demonstrated that caffeine and modaﬁnil promote wakefulness by blocking A2A
receptors on GABAergic neurons of the NAc that co-express A2A and D2 receptors
(Lazarus et al. 2011; Qiu et al. 2016; Oishi et al. 2017b). These neurons have major
projections to the ventral pallidum and may induce sleep by inhibiting the ascending
arousal pathways and the thalamus.
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In contrast to ADORA2A, DAT1, and DRD2, genetic variation of COMT did not
impact on neurophysiological markers of sleep need (Bodenmann et al. 2009a;
Valomon et al. 2018). Nevertheless, COMT genotype and pharmacologic interfer-
ence with PFC dopaminergic tone with modaﬁnil and tolcapone consistently affect
the consequences of sleep loss on PVT lapses (Bodenmann et al. 2009a; Valomon
et al. 2018). Given that tolcapone leaves striatal dopaminergic neurotransmission
unaltered, this ﬁnding strongly indicates that the mesocortical pathway contributes to
the regulation of attentional lapses during prolonged wakefulness without affecting
sleep-wake regulatory mechanisms.
Tolcapone
Caﬀeine
Mesolimbic and 
nigrostriatal pathways
EEG markers of
sleep homeostasis
Sustained aƩenƟon
MesocorƟcal pathway
Sustained aƩenƟon
Modafinil
Modafinil
Dorsal
striatum
Nucleus accumbens
(ventral striatum)
COMT
A2A - D2 - DAT
Ventral tegmental area
Substan?a
nigra
Fig. 3 Pharmacogenetic dissection of adenosinergic-dopaminergic pathways with caffeine (A2A
receptor antagonist), modaﬁnil (DAT inhibitor), and tolcapone (COMT inhibitor) reveals different
contributions of dopaminergic pathways to sleep-wake regulation and behavioral consequences of
sleep loss. The mesolimbic/nigrostriatal dopaminergic pathway (blue) regulates neurophysiological
markers of sleep homeostasis in wakefulness and sleep and contributes to impaired sustained
attention. Together with animal studies, ﬁndings support the notion that the nucleus accumbens,
which expresses high densities of dopamine D2 and adenosine A2A receptors, may be an essential
player in these functions. The mesocortical dopaminergic pathway (red) does not affect neurophys-
iological markers of sleep deprivation. COMT catechol-O-methyltransferase, DAT dopamine
transporter
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5 Concluding Remarks
5.1 Prospects of Pharmacogenetics for Personalized Sleep-Wake
Medicine and New Drug Discovery
Not only gene polymorphisms but a host of environmental factors, including
epigenetics, as well as comorbidity and co-medications, cause variability in expres-
sion and function of drug targets and pharmacokinetic processes in each individual.
The genotyping of single genes is, thus, of limited use for guiding individual
pharmacotherapy. Rather, the implementation of deep phenotyping strategies to
test individual target and enzyme functions likely provides a more promising
approach to achieve personalized dosing of sleep-wake drugs (e.g., Hohmann
et al. 2016; Urry et al. 2016).
Powerful new tools to interrogate sleep-wake regulating circuits have revealed
new molecular and cellular markers, as well as novel network mechanisms and
pathways that regulate wakefulness and sleep. While the ascending arousal system
was ﬁrst described as a reticular network of neurons projecting widely to the cortex
and the spinal cord (Moruzzi and Magoun 1949), it has become clear in the last few
years that wakefulness and sleep are governed by distinct populations and subtypes
of neurons (Varin and Bonnavion 2018). Although speciﬁc, these neuronal systems
are often redundant and reinforce each other. Future research should clarify their
causal associations with sleep homeostasis and the circadian clock, as well as sleep
and circadian rhythm disturbances in humans. For example, it should be clariﬁed
whether A2A-D2 receptor-positive striatopallidal neurons regulate sleep homeostasis
or rather promote sleep in the absence of motivational stimuli (cf. Oishi et al. 2017b).
Such studies may identify critical targets within newly identiﬁed sleep and circadian
pathways for pharmacological interventions.
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Abstract
Central disorders of hypersomnolence are characterized by daily periods of
irrepressible need to sleep or daytime lapses into sleep, as deﬁned in the current
version of the International Criteria of Sleep Disorders. Thus, the unifying
symptom is excessive daytime sleepiness which is not caused by any other
sleep-wake disorder. Relevant disorders including narcolepsy type 1 and
2, idiopathic hypersomnia, Kleine-Levin syndrome, and insufﬁcient sleep syn-
drome will be discussed. Other central disorders of hypersomnolence include
hypersomnias due to medical or psychiatric disorders or because of medication or
substance use.
In sleep-related movement disorders, the cardinal symptom consists of simple,
often stereotyped movements occurring during sleep. The most frequent disorder
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in this category of sleep-wake disorders is restless legs syndrome, which is often
associated with period limb movements during sleep.
Keywords
Excessive daytime sleepiness · Hypersomnia · Multiple sleep latency test ·
Narcolepsy · Polysomnography · Restless legs
1 Central Disorders of Hypersomnolence
Central disorders of hypersomnolence (formerly known as hypersomnias) (Table 1)
are characterized by daily periods of irrepressible need to sleep or daytime lapses
into sleep, as deﬁned in the current version of the International Criteria of Sleep
Disorders (AASM 2014).
1.1 Narcolepsy Type 1
Narcolepsy type 1, formerly known as narcolepsy with cataplexy, is a chronic
hypersomnia disorder which is characterized by excessive daytime sleepiness and
symptoms of disturbed rapid eye movement (REM) regulation.
Table 1 Central disorders of hypersomnolence and sleep-related movement disorders, classiﬁed
along the International Criteria for Sleep Disorders, third edition (ICSD-3) (AASM 2014)
Central disorders of hypersomnolence
Narcolepsy type 1
Narcolepsy type 2
Idiopathic hypersomnia
Kleine-Levin syndrome
Hypersomnia due to a medical disorder
Hypersomnia due to a medication or substance
Hypersomnia associated with a psychiatric disorder
Insufﬁcient sleep syndrome
Sleep-related movement disorders
Restless legs syndrome
Periodic limb movement disorder
Sleep-related leg cramps
Sleep-related bruxism
Sleep-related rhythmic movement disorder
Benign sleep myoclonus of infancy
Propriospinal myoclonus at sleep onset
Sleep-related movement disorder due to a medical disorder
Sleep-related movement disorder due to a medication or substance
Sleep-related movement disorder, unspeciﬁed
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Epidemiology Narcolepsy affects about 1–2 in 4,000 people and usually begins in
childhood or adolescence (Hublin et al. 1994; Scammell 2015), yet there are
signiﬁcant differences in prevalence between different populations. Most epidemio-
logical studies in narcolepsy are burdened with limitations. For instance, most are
only questionnaire-based. There are few epidemiological studies based on multiple
sleep latency tests (MSLT). There is, however, increasing evidence that MSLT
criteria for narcolepsy are neither intraindividually stable nor speciﬁc for narcolepsy
(Trotti et al. 2013; Marti et al. 2009). Misinterpretation of MSLT results therefore
might have caused an overestimation of narcolepsy in some studies. In addition,
there is a marked diagnostic delay due to unawareness of the disorder and its
symptoms both in patients and in treating physicians (Taddei et al. 2016). This
delay not only causes impairment of quality of life of affected patients but also most
likely leads to an underestimation of the frequency of narcolepsy. Altogether, there
are no unambiguous epidemiological studies in the ﬁeld.
Symptomatology Chronic excessive daytime sleepiness is mandatory for the diag-
nosis of narcolepsy type 1 (AASM 2014). It is deﬁned as increased sleep propensity
during daytime, which may lead to sleep attacks even in non-adequate situations.
Such sleepiness is present every day, also when patients allow themselves adequate
sleep times. Nighttime sleep and short naps usually improve sleepiness for a brief
period of time which typically does not exceed 1–2 h.
Narcolepsy type 1 patients typically suffer from cataplexy, i.e., loss of voluntary
muscle tone upon emotions that is not accompanied by a decrease or loss of
consciousness. This loss of muscle tone is often only partial, e.g., affecting head
or neck muscles, but may also manifest itself with generalized muscle tone loss and
consecutively with falls. The duration of cataplexy attacks is usually only seconds to
few minutes. Longer attacks up to status cataplecticus may occur upon discontinua-
tion of anti-cataplectic treatment. Although typical cataplexy is considered patho-
gnomonic for narcolepsy type 1, its presence is no longer sufﬁcient to make the
diagnosis in chronically sleepy patients (AASM 2014). Like hallucinations and sleep
paralysis, cataplexy is interpreted as intrusion of REM sleep-like behavioral states
into wakefulness (Scammell 2015).
Hallucinations that occur when patients fall asleep (hypnagogic) or wake up
(hypnopompic) are reported by many narcolepsy patients and may affect different
sensory systems. Most often, however, they are visual and somehow threatening.
Sleep paralysis also occurs during transitions between wakefulness and sleep and
lasts seconds to few minutes. During such episodes, patients cannot move their
voluntary muscles, but eye movements and breathing are unimpaired. Neither
hallucinations nor sleep paralysis are speciﬁc for narcolepsy.
Most narcolepsy patients complain about disturbed, i.e., fragmented nocturnal
sleep. They often wake up during the night but then quickly fall back into sleep.
Other symptoms that are more prevalent than in the general population are increased
body weight, depression, obstructive sleep apnea, periodic limb movements during
sleep, and parasomnias.
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Pathophysiology Narcolepsy type 1 is considered a disorder of hypocretin (orexin)
signaling deﬁciency, as it has been shown to be associated with a selective and
almost complete loss of wakefulness-promoting hypocretin neurons in the postero-
lateral hypothalamus (Peyron et al. 2000; Thannickal et al. 2000). Hypocretin
deﬁciency is conceptualized to underlie not only excessive daytime sleepiness and
enhanced REM sleep pressure but also state behavioral instability, i.e., enhanced
likelihood to switch from wakefulness to sleep and vice versa (Saper et al. 2005)
(Fig. 1).
The cause of hypocretin neuronal loss is still unclear, but several observations
indicate an autoimmune cause: the selectivity of neuronal destruction, the tight
association with human leukocyte antigen (HLA) alleles, particularly
HLA-DQB1*06:02, and the assumption that streptococcal and H1N1 inﬂuenza A
virus infection and H1N1 vaccination might act as triggers (Cvetkovic-Lopes et al.
2010; Hallmayer et al. 2009; Mignot et al. 2001; Kornum et al. 2017). Nevertheless,
the ﬁnal proof for an autoimmune cause is still lacking.
The ﬁnding of a marked increase of wake-maintaining histamine neurons in the
tuberomammillary nucleus in narcolepsy type 1 patients suggests that other neuro-
transmitter systems are likely to contribute to the clinical picture in those patients
(Valko et al. 2013; John et al. 2013).
Diagnosis The current diagnostic criteria request chronic excessive daytime sleepi-
ness and one of the following ﬁndings: either pathologically decreased cerebrospinal
ﬂuid hypocretin levels or a combination of typical cataplexy and typical ﬁndings on
the MSLT, i.e., a low mean sleep latency below 8 min and multiple sleep-onset rapid
eye movement (REM) sleep periods in 4–5 nap opportunities (AASM 2014). In the
presence of low hypocretin levels, the diagnosis is usually straightforward and can
Fig. 1 Hypocretin (orexin) neurons (gray circle) in the posterolateral hypothalamus excite wake-
promoting monoaminergic (white pentagon) and cholinergic (white hexagon) in the brainstem and
posterior hypothalamus. In addition, it is assumed that these neurons stabilize the ﬂip-ﬂop switch
between sleep and wakefulness. GABAergic and galaninergic neurons (black square) in the
ventrolateral preoptic area inhibit hypocretin and other wake-promoting neuronal systems and
ultimately promote sleep (Adapted and simpliﬁed from Saper et al. 2005)
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be considered solid, yet the alternative criteria of cataplexy in combination with low
mean sleep latencies can be misleading. Cataplexy is usually not observed in the
doctor’s practice and therefore relies on patient’s history. The diagnosis of cataplexy
can be difﬁcult, even for experienced specialists (Pizza et al. 2018). In addition, low
MSLT mean sleep latencies are common in society, mostly due to widespread
insufﬁcient sleep. In narcolepsy, mean sleep latencies are typically very low, i.e.,
below 3–4 min. In case of any diagnostic doubts – given the therapeutic
consequences – a lumbar tap should be performed to measure hypocretin levels.
HLA-DQB1*06:02 can be assessed, but due to the fact that this allele is also
common in the non-narcoleptic population, only negative HLA ﬁndings are helpful
in the diagnosis, as they make the diagnosis of narcolepsy type 1 most unlikely.
Treatment Most patients are treated with a combined non-pharmacological (e.g.,
sleep hygiene with scheduled daytime naps) and pharmacological approach. In many
countries worldwide, stimulants such as modaﬁnil (100–400 mg daily), armodaﬁnil
(100–250 mg per day), or methylphenidate (10–60 mg per day) are approved for the
treatment of excessive daytime sleepiness (Scammell 2015; Kornum et al. 2017). A
novel inverse histamine H3 receptor agonist, pitolisant (9–36 mg daily), has been
approved in several countries to improve sleepiness, and recent evidence suggests
that the compound might also exert some beneﬁcial effect on cataplexy (Szakacs
et al. 2017). Sodium oxybate, an agonist on GABAB and possibly speciﬁc gamma-
hydroxybutyric acid (GHB) receptors, is administered twice at night (at bedtime and
3–4 h later, up to 9 g per day) and consolidates nocturnal sleep and improves
sleepiness but also cataplexy, hallucinations, and sleep paralysis. Alternative – and
mostly off-label – strategies to reduce cataplexy consist of antidepressants that
increase serotonin and/or noradrenaline neurotransmission, e.g., the serotonin-
noradrenaline reuptake inhibitor venlafaxine (37.5–300 mg per day).
1.2 Narcolepsy Type 2
Narcolepsy type 2 is characterized by excessive daytime sleepiness in combination
with increased REM sleep pressure. In contrast to narcolepsy type 1 with its speciﬁc
biomarker (deﬁcient hypocretin in cerebrospinal ﬂuid) and clear-cut clinical and
electrophysiological ﬁndings, the diagnosis of narcolepsy type 2 is burdened with
unspeciﬁc ﬁndings and therefore challenging (Baumann et al. 2014). The current
diagnostic criteria require chronic sleepiness and a positive MSLT (as in narcolepsy
type 1: mean sleep latency 8 min and two or more sleep-onset REM periods), but
MSLT results appear particularly unreliable in narcolepsy type 2 (Ruoff et al. 2018).
In addition, there is no history of cataplexy, and hypocretin levels in cerebrospinal
ﬂuid – if measured – are within the normal range (AASM 2014). Most importantly,
any other cause for these symptoms should be excluded. As insufﬁcient sleep can
produce sleepiness and positive MSLT ﬁndings, this differential diagnosis should be
ruled out before making the diagnosis of narcolepsy type 2 (see below).
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Because of the high level of diagnostic vagueness, the real epidemiology of
narcolepsy type 2 remains obscure. On the one hand, given the long diagnostic
delay between narcolepsy symptoms and diagnosis, it is conceivable that narcolepsy
type 2 is underdiagnosed (Taddei et al. 2016). On the other hand, however, the
clinical and electrophysiological overlap with insufﬁcient sleep syndrome makes it
even more likely that narcolepsy type 2 is heavily overdiagnosed (Marti et al. 2009).
Even more, it remains open whether or not narcolepsy type 2 is a distinct entity or
merely a prodromal phase of narcolepsy type 1 which often begins with excessive
sleepiness, whereas cataplexy can emerge years later. In the absence of biomarkers
for the disease, therefore, there is a need of large multicenter studies applying strict
clinical and electrophysiological assessments to obtain a better view on narcolepsy
type 2.
To diagnose narcolepsy type 2, actigraphy over at least 7 days should be recorded
prior to polysomnography and MSLT, to rule out insufﬁcient sleep or shift work. In
case that actigraphy is not reimbursed by insurance or not available, sleep logs
should be administered, although poor compliance can produce invalid results.
Likewise, medical or environmental conditions that might cause sleepiness should
be searched for. Positive HLA-DQB1*06:02 can be indicative of narcolepsy, yet is
unspeciﬁc.
The therapy of excessive daytime sleepiness is the same as in narcolepsy
type 1 (see above).
1.3 Idiopathic Hypersomnia
Idiopathic hypersomnia is a chronic neurological disorder, which presents with
excessive daytime sleepiness, non-restorative sleep, and typically increased sleep
duration per 24 h. As indicated by nomenclature, the underlying pathophysiology is
not known.
Epidemiology The prevalence of idiopathic hypersomnia is unknown, yet its
frequency is considered much lower than narcolepsy (Trotti 2017). Using
population-based data of 19,136 noninstitutionalized individuals, some authors
found a combination of excessive daytime sleepiness with non-restorative sleep of
at least 9 h in 0.5% of the population, but as much as these symptoms may be typical
for idiopathic hypersomnia, they are not speciﬁc, as there might be a signiﬁcant
overlap with depression and other neuropsychiatric disorders (Ohayon et al. 2013).
Symptomatology As in narcolepsy, the core symptom of idiopathic hypersomnia is
chronic excessive daytime sleepiness, i.e., irresistible need to fall asleep during
daytime, including unwanted episodes of daytime sleep. As always, sleepiness
must not be caused by any other sleep-wake, medical, neurological, or psychiatric
disorder. A very typical expression of idiopathic hypersomnia is prolonged nocturnal
sleep, usually above 10 h per day. In addition, patients with idiopathic hypersomnia
typically report that sleep is not refreshing, neither nocturnal sleep nor daytime naps.
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A prolonged and marked difﬁculty to wake up after sleep that is referred to as sleep
inertia or sleep drunkenness is a helpful clinical sign to distinguish idiopathic
hypersomnia from other central disorders with hypersomnolence (Kretzschmar
et al. 2016). This clinical feature impairs quality of life of patients with idiopathic
hypersomnia considerably, as affected subjects never feel fully refreshed (Ozaki
et al. 2012). In addition, many patients report subjective cognitive deﬁcits, e.g.,
memory or attention problems.
Diagnosis Apart from excessive daytime sleepiness, increased sleep need per 24 h
is the most important diagnostic feature. The current diagnostic criteria demand
chronic subjective sleepiness, absence of cataplexy, absence of enhanced REM sleep
pressure upon polysomnography or MSLT tests, and either short MSLT mean
latencies (below 8 min) or a total sleep time of at least 11 h per 24 h on a 24-h
polysomnography or wrist actigraphy over at least 7 days with unrestricted sleep
opportunities (AASM 2014). Notably, insufﬁcient sleep must be ruled out. While
these criteria are clearly improved compared to the previous edition of the diagnostic
manual – in the absence of speciﬁc biomarkers – some uncertainty remains. Because
the test-retest reliability of the MSLT must be considered poor (Trotti et al. 2013),
sleepiness and the absence of cataplexy or enhanced REM sleep pressure are
probably not speciﬁc enough for a deﬁnite diagnosis of idiopathic hypersomnia.
Therefore, actigraphy should be performed whenever possible, ﬁrst to exclude
insufﬁcient sleep syndrome and second to prove increased sleep need, i.e.,
hypersomnia sensu strictu. Polysomnography should reveal very high sleep efﬁ-
ciency (usually above 95%), and 24-h polysomnography, if performed, can be
helpful to show long and highly consolidated nocturnal sleep. In addition, in the
absence of sleep inertia, the diagnosis of idiopathic hypersomnia should be doubted.
Treatment Non-pharmacological treatment strategies such as good sleep hygiene
with regular sleep periods and scheduled daytime naps are largely ineffective, mostly
due to sleep inertia. On the other hand, in a recent survey among patients suffering
from hypersomnia disorders, caffeine intake was reported by more than 80% of
idiopathic hypersomnia patients to be a beneﬁcial “non-pharmacological” strategy to
help manage the symptoms of the disease (Neikrug et al. 2017). Only recently, few
randomized and controlled trials in idiopathic hypersomnia patients have been
published, yet all pharmacological medication of those patients at present remains
off-label. Given their outcomes, it must be concluded that modaﬁnil partially reduces
subjective excessive daytime sleepiness and increases vigilance, but patients remain
signiﬁcantly affected even on treatment (Mayer et al. 2015; Philip et al. 2014). It has
been reported that a signiﬁcant portion of idiopathic hypersomnia patients achieved
complete symptom control with stimulants (Ali et al. 2009). Unfortunately, we
cannot conﬁrm this ﬁnding in our population of idiopathic hypersomnia patients.
In the contrary, we ﬁnd pharmacological treatment of sleepiness and sleep inertia in
those patients largely unsatisfying. Whether or not additional or alternative treatment
strategies such as other stimulants, antagonistic modulation of GABAA receptors
(e.g., clarithromycin), gamma-hydroxybutyrate, or histamine H3 receptor inverse
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agonists are helpful for therapy-refractory idiopathic hypersomnia, patients need to
be examined in future studies. Only clarithromycin has been studied for the treat-
ment of non-narcoleptic hypersomnia disorders and exerted some beneﬁcial effects
on sleepiness but not on vigilance (Trotti et al. 2015).
1.4 Kleine-Levin Syndrome
Kleine-Levin syndrome is a rare central disorder of hypersomnolence of unknown
origin, with recurring episodes of hypersomnia in combination with neuropsy-
chiatric symptoms.
Epidemiology There are no large epidemiological studies of Kleine-Levin syn-
drome, yet it is considered a very rare disease which affects mostly adolescents
(Lavault et al. 2015).
Symptomatology The key symptom is recurrent hypersomnia, i.e., repeated
episodes of sleepiness, tiredness, and increased sleep times. The average sleep
time per 24 h during those episodes is 18 h, and patients are not refreshed after
sleep yet remain exhausted, tired, and irritable (Arnulf et al. 2008). When awake,
patients often exhibit marked neuropsychiatric disturbances during those episodes,
including cognitive impairment, apathy, confusion, altered perception up to dereali-
zation, abnormal behaviors such as hyperphagia or hypersexuality, and psychiatric
symptoms including decreased mood, anxiety, aggressiveness, or regressive behav-
ior (Arnulf 2015). In addition, migraine-like symptoms such as headache and photo-
and phonophobia are not uncommon. Episodes last usually a few days up to months,
but the mean duration is 13 days (Lavault et al. 2015). Episodes occur regularly, with
a mean interval between episodes of 6 months (Arnulf 2015). Beyond the age of
30 years, the disease often disappears.
Diagnosis The current diagnostic criteria demand recurrent episodes of severe
sleepiness lasting 2 days up to several weeks, usually more often than once per
year and at least every 18 months, with at least one neuropsychiatric feature during
the episode and normal alertness, cognition, mood, and behavior between episodes
(AASM 2014). Sleep recordings are not mandatory, but a 24-h polysomnography
during episodes conﬁrms increased sleep duration. Brain imaging is usually normal,
and EEG recordings during episodes reveal unspeciﬁc slowing of background
activity (Papacostas and Hadjivasilis 2000).
Treatment Symptomatic therapy of Kleine-Levin syndrome is challenging.
Stimulants can be probed during episodes, and neuropsychiatric symptoms can
be treated with classical compounds, e.g., benzodiazepines against anxiety or
neuroleptics against psychotic symptoms. Relatives or caregivers should be
informed about aberrant behaviors during episodes and about monitoring regular
food intake during episodes to avoid unwanted weight gain.
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1.5 Insufficient Sleep Syndrome
Insufﬁcient sleep syndrome is not a pathology-driven disease but a collection of
symptoms, particularly excessive daytime sleepiness, caused by chronic sleep
restriction and/or irregular sleep-wake behavior.
Epidemiology Given the laborious conﬁrmation of clear-cut insufﬁcient sleep
syndrome (see below), epidemiological studies are uncommon and mostly unreli-
able. A Japanese cross-sectional study, for instance, performed a web-based ques-
tionnaire in young adults and diagnosed insufﬁcient sleep syndrome in 11% (Morita
et al. 2015). If we interpret shift work as an important contributor to insufﬁcient
sleep, then prevalence number may rise up to 29% (Kecklund and Axelsson 2016).
Symptomatology Leading symptom is chronic excessive daytime sleepiness, but
sleepiness is usually improved or even absent during holidays with prolonged
nocturnal sleep hours or without shift work. Subjects with insufﬁcient sleep syn-
drome are prone to reduced performance, error-proneness, poor academic perfor-
mance, impaired decision-making, increased risk-seeking, and neuropsychiatric
symptoms including depression, irritability, and impulsiveness (Van Dongen et al.
2003; Lee et al. 2015; Maric et al. 2017).
Diagnosis The current diagnostic criteria require chronic excessive daytime sleepi-
ness (AASM 2014). In addition, the patients’ sleep time must be shorter than
expected for age, sleep duration is longer on weekends or during vacation, the
patient curtails sleep time by an alarm clock or similar strategies, and extension of
total sleep time results in resolution of symptoms.
Although the listing of insufﬁcient sleep syndrome in the ICSD-3 criteria is most
important, the diagnostic criteria as such pose some signiﬁcant challenges:
First, it is difﬁcult to establish whether a patient’s sleep time is usually shorter
than expected for age, as there is a large variability of individual sleep need in
society, including long- and short-sleepers. In addition, the criteria offer history-
taking, sleep logs, or actigraphy for assessing usual sleep times, but particularly
history-taking and sleep logs largely depend on self-perception, forthrightness, and
compliance, and a deﬁcit in any of those traits produces false results.
Second, how much longer should an individual sleep during weekends or
vacations to fulﬁll the criteria? Is a 1-h difference enough, or should it be at least
2 h, or should it be decided on an individual basis?
Third, the criterion of extending total sleep time and repeating sleepiness tests is
important, but most sleep laboratories will not be able (i.e., refunded) for repeated
objective measurements of sleepiness before and after sleep extension, and
actigraphy to monitor sleep extension is not reimbursed in many countries. Thus,
feasibility of this criterion must be questioned, given the actual reimbursement
policies.
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Fourth, the circadian aspect of insufﬁcient sleep is completely neglected. For
instance, insufﬁcient sleep because of shift work or because of irregular sleep times
because of social distractions is not taken into account in the current criteria.
Treatment Causal therapy would be to prolong sleep duration, along with a regular
sleep-wake pattern, but experience tells that this is difﬁcult for many affected
subjects. Shift workers cannot simply change their sleep habits without endangering
their job, and young adults are often not ready to abstain from two or three party
nights with very late bedtimes. Altogether, the issue of insufﬁcient sleep syndrome
remains exigent, both from a diagnostic and from a therapeutic perspective.
2 Sleep-Related Movement Disorders
In sleep-related movement disorders, the cardinal symptom consists of simple, often
stereotyped movements occurring during sleep (AASM 2014) (Table 1).
2.1 Restless Legs Syndrome
Restless legs syndrome is one of the most prevalent neurological disorders and is
characterized by an urge to move the limbs, mostly the legs, with a circadian pattern
and a predominance during periods of rest and with improvement upon moving.
Epidemiology In Europe, the prevalence of restless legs syndrome may be higher
than 5%, whereas it is below 1% in African countries (Koo 2015). Women are more
often affected than men. Several conditions are associated to restless legs syndrome,
particularly iron deﬁciency, end-stage renal disease, and pregnancy.
Symptomatology and Diagnosis The diagnosis of restless legs syndrome depends
primarily on the description of symptoms by the affected patient. The current
diagnostic guidelines essentially rely on four criteria (AASM 2014; Allen et al.
2014):
1. Urge to move the legs, typically accompanied by unpleasant sensations in
the legs.
2. Symptoms get worse during rest.
3. Symptoms get worse during evening and night hours.
4. Moving the legs improves urge and unpleasant symptoms.
In addition, it is required to exclude potential mimics of restless legs syndrome,
such as rheumatoid disorders, akathisia, painful legs and moving toes, positional
discomfort, sleep-related cramps, or myalgia (Hening et al. 2009).
In addition, supportive criteria can help making a correct diagnosis, particularly in
patients with doubtful symptom presentation (AASM 2014; Allen et al. 2014):
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1. Positive family history with affected ﬁrst-degree relatives.
2. Symptoms respond clearly to dopaminergic treatment.
3. Presence of periodic limb movements during sleep.
Periodic limb movements during sleep can be assessed with polysomnography or
with leg actigraphy and consist of repetitive Babinski-like leg movements occurring
every 5–90 s (Iber et al. 2007; Cippà et al. 2013). Importantly, periodic limb
movements during sleep are not at all speciﬁc for restless legs syndrome, as they
can be observed in more than 25% of recorded healthy subjects (Haba-Rubio et al.
2016).
Pathophysiology Three factors appear signiﬁcantly to contribute to the expression
of restless legs syndrome: (1) dopamine-related pathology, (2) iron deﬁciency, and
(3) genetics. Dopaminergic drugs are most effective to treat restless legs syndrome,
yet novel evidence points toward a hyperdopaminergic state involved in the disease
(Earley et al. 2014). Similarly, iron replacement often improves restless legs syn-
drome considerably in patients with low or even normal iron and ferritin levels, and
altered brain iron acquisition has been observed in restless legs syndrome (Connor
et al. 2011). Finally, several genome-wide association studies revealed restless legs
syndrome susceptibility loci (Stefansson et al. 2007; Winkelmann et al. 2007, 2011).
Treatment Before considering pharmacological treatment, current medication
should be carefully checked. Dopamine antagonists such as neuroleptics or
metoclopramide should be discontinued, if possible. If depression is present,
bupropion is considered a ﬁrst-line treatment, as there is evidence that it does
not – opposed to other antidepressants – worsen restless legs syndrome (Bayard
et al. 2011).
At the same time, iron panels should be assessed early in all patients, as restless
legs syndrome is tightly linked to iron deﬁciency. The current expert-driven
guidelines note that ferric carboxymaltose (1,000 mg) is effective for treating
moderate to severe restless legs syndrome in those with serum ferritin <300 μg/l
and could be used as ﬁrst-line treatment in adults. Furthermore, the expert panel
states that oral iron (65 mg elemental iron) is possibly effective for treating restless
legs syndrome in those with serum ferritin 75 μg/l (Allen et al. 2018).
A combined task force published guidelines for the ﬁrst-line treatment of restless
legs syndrome (Garcia-Borreguero et al. 2016). The task force recommends
α2β receptor ligands for the ﬁrst-line treatment of restless legs, with gabapentin
(600–1,200 mg per day) being approved in several countries including the USA and
Japan. This recommendation is based on the observation that dopaminergic agents
pose the highest risk for augmentation (see below). Alternative ﬁrst-line treatment
options remain dopaminergic agents, preferably in low doses (pramipexole, up to
0.5–0.75 mg; ropinirole, up to 4 mg; rotigotine, up to 3 mg – all of them approved for
restless legs syndrome treatment in many countries), to keep the risk of augmenta-
tion as low as possible. Levodopa is more likely to cause augmentation than
dopamine receptor agonists (Bassetti et al. 2011). Opioids can be considered for
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patients with treatment-refractory restless legs syndrome, by individually weighing
opioid risks and beneﬁts.
Augmentation The main features of augmentation include (1) earlier begin of
symptoms in the day compared to before medication was started, (2) need of higher
doses or earlier medication intake to control symptoms compared to when medica-
tion was started, (3) increased intensity of symptoms since medication was started,
and/or (4) spreading of symptoms to formerly unaffected parts of the body (typically
the arms and hands) (Garcia-Borreguero et al. 2016). The incidence rate of augmen-
tation appears being highest with levodopa, high with shorter-acting dopamine
receptor agonists, and lower with longer-acting dopamine receptor agonists
(Garcia-Borreguero et al. 2016).
If augmentation is diagnosed, exacerbating factors should be eliminated, i.e., low
serum ferritin or exacerbating drugs. In case of mild augmentation, two options are
recommended (Garcia-Borreguero et al. 2016): to keep the same dopamine receptor
agonist but to split the same dose, to advance the dose toward earlier intake, or to
increase dose but keep it below approved daily dose or, alternatively, to switch to an
α2β receptor ligand or a low-dose longer-acting dopamine receptor agonist such as
transdermal rotigotine. In case of failure of these strategies or of severe augmenta-
tion, it is recommended to reduce or better to eliminate shorter-acting dopamine
receptor agonists and to start with rotigotine or another longer-acting dopamine
receptor agonist or an α2β receptor ligand or a long-acting opiate.
2.2 Other Sleep-Related Movement Disorders in Adults
Periodic limb movement disorder is diagnosed in the presence of periodic limb
movements during sleep in combination with either insomnia or excessive daytime
sleepiness but without symptoms of restless legs syndrome. The entity, however,
remains to some extent controversial, and diagnosis and treatment should be made
and initiated with reluctance.
Sleep-related leg cramps are characterized by painful nocturnal cramps or muscle
contractions during wakefulness or sleep. Cramps beyond the distal limbs or during
daytime should prompt a search for an underlying neuromuscular disorder. There are
no thorough studies nor approved medication for sleep-related leg cramps.
Sleep-related bruxism presents with clenching or grinding of teeth during sleep
and may lead to dental erosion, temporal headache, jaw muscle pain, and arousal of
bedpartners. To protect teeth, dental appliances are usually recommended, whereas
pharmacological interventions (i.e., with benzodiazepines or botulinum toxin) are
clearly second line.
Sleep-related rhythmic movement disorder, including body rocking or head
banging, is diagnosed in the presence of rhythmic and markedly stereotyped body
movements at the transition from wakefulness to sleep, which are not of epileptic
origin and which ultimately lead to sleep disruption with daytime consequences or to
injuries. These behaviors are frequent in infants and become rarer later on, yet they
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may sometimes persist into adulthood. Clonazepam can be probed as off-label
treatment.
Propriospinal myoclonus is a rare form of spinal myoclonus at sleep onset, which
typically starts in midthoracic muscular segments and then propagates down and up
in the spinal cord (Antelmi and Provini 2015). This propagation can produce typical
irregular and jerky movements such as sitting up or jackknife-like movements.
Diagnosis and exclusion of a functional movement disorder warrants a combined
polysomnography with multi-segmental electromyography electrodes.
3 Summary
Apart from narcolepsy type 1, the pathophysiology of neurological sleep-wake
disorders remains largely unknown. Similarly, narcolepsy type 1 is the only
hypersomnia or sleep-related movement disorder which can be diagnosed with
speciﬁc biomarkers. The treatment of hypersomnia disorders is still primarily
based on stimulants and restless legs syndrome on α2β receptor ligands or dopami-
nergic drugs. Whether or not hypocretin-based treatments or immunotherapies will
be successfully introduced in narcolepsy remains elusive. Also, novel noninvasive
non-pharmacological technologies for hypersomnia disorders are not available as
of yet.
Conﬂicts of Interest Dr. Baumann reports no conﬂicts of interests in regard to this work.
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Abstract
Insomnia and circadian rhythm sleep disorders affect large proportions of the
population and have pronounced effects on quality of life and daytime perfor-
mance. While the neurobiology of insomnia is not yet fully understood, circa-
dian rhythm sleep disorders are assumed to be caused by a mismatch between the
individual circadian phase position and the desired sleep–wake schedule.
Benzodiazepines and non-benzodiazepine positive allosteric GABAA receptor
modulators improve sleep onset and maintenance in the short-term treatment of
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insomnia. However, tolerance and dependence are important side effects. Sedat-
ing antidepressants are frequently prescribed for insomnia, however, only few
randomised controlled trials have been published so far. Melatonin and melato-
nin receptor agonists are considered to be an option for the treatment of insomnia
especially because of their minimal abuse potential and safety. First data on
orexin (aka hypocretin) receptor antagonists are promising, however, the risk-
benefit ratio needs to be further evaluated. With respect to circadian rhythm
sleep disorders, there is solid evidence from meta-analyses supporting the use of
melatonin in jet lag disorder to accelerate entrainment to the new time zone, and
in delayed sleep phase disorder to advance sleep–wake rhythms. In addition to
that, there is evidence supporting the use of melatonin in patients with shift work
disorder in order to promote daytime sleep after night shifts.
Keywords
Aetiology • Circadian rhythm sleep disorders • Insomnia • Pharmacological
treatment
1 Definition and Epidemiology
Insomnia is a common mental disorder characterised by difficulties initiating or
maintaining sleep associated with impairments of daytime functioning (American
Psychiatric Association 2013; Morin et al. 2015). Approximately 6–10% of the
population suffers from insomnia meeting diagnostic criteria (Ohayon 2002).
Women are more frequently affected than men (Zhang and Wing 2006) and there
is an increasing prevalence with older age (Ohayon 2002). In most patients with
insomnia, the disorder is a chronic condition. More than 70% of those experiencing
insomnia today will still suffer from it next year (Morin et al. 2009a). While often
viewed as a nuisance symptom in clinical practice, chronic insomnia is associated
with a severely reduced quality of life (Kyle et al. 2010) and cognitive impairments
(Fortier-Brochu et al. 2012). Furthermore, longitudinal studies suggest that insom-
nia is a risk factor for other mental disorders, especially depression (Baglioni et al.
2011), as well as for cardiovascular morbidity and mortality (Laugsand et al. 2011,
2014; Sofi et al. 2014). In line with this, insomnia leads to a huge increase in health
care consumption, work disability and absenteeism, and, consequently, to very high
costs for our societies (Le´ger and Bayon 2010). For the US, the costs of insomnia
due to low work performance and absenteeism have been estimated to exceed
60 billion $ per year (Kessler et al. 2011).
It is assumed that circadian rhythm sleep disorders are also very common
although the exact prevalence rate is unknown (Sack et al. 2007a). They are
characterised by a misalignment between the endogenous circadian rhythm and
the natural external day–night rhythm (Bjorvatn and Pallesen 2009). These
disorders include conditions that are related to exogenously determined alterations
in sleep timing (e.g. shift work disorder and jet lag disorder), as well as disorders
that are related to endogenous causes (e.g. delayed sleep phase disorder and
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advanced sleep phase disorder). Older age appears to be a risk factor for shift work
intolerance (Sack et al. 2007a) and advanced sleep phase disorder (Sack et al.
2007b). On the contrary, younger age appears to be a risk factor for delayed sleep
phase disorder (Sack et al. 2007b), which may also be more prevalent in men than in
women (Adan and Natale 2002). Moreover, clinical experience suggests that
circadian rhythm sleep disorders are typically associated with complaints of insom-
nia or daytime sleepiness associated with daytime impairments and reduced quality
of life.
2 Aetiology
Despite the above-mentioned huge socio-economic impact of chronic insomnia, the
neurobiological mechanisms are not yet fully understood. Some of the most fre-
quently cited models of the disorder suggest that cognitive, emotional and physio-
logical hyperarousal are important factors for the development and maintenance of
insomnia (Riemann et al. 2010, 2015; Espie et al. 2006; Harvey 2002; Perlis et al.
1997). While it is difficult to find a formal definition of this construct in the
scientific literature, it is usually assumed that hyperarousal is the opposite of the
relaxation state required for restorative sleep. Cognitive hyperarousal involves
excessive worry and rumination which have been frequently shown to be associated
with insomnia (e.g. Spiegelhalder et al. 2012; Ferna´ndez-Mendoza et al. 2010). In
contrast, there are surprisingly few empirical studies investigating the role of
emotional processes for insomnia (Baglioni et al. 2010). These data suggest that
dysfunctional emotional reactivity may mediate the interaction between cognitive
and physiological hyperarousal and may thus contribute to the maintenance of
insomnia. Physiological hyperarousal is assumed to be reflected in increased
electroencephalographic (EEG) beta power (Perlis et al. 2001), an increased num-
ber of arousals during REM sleep (Feige et al. 2008; Riemann et al. 2012),
increased cortisol levels (Vgontzas et al. 2001), increased body temperature
(Lack et al. 2008), as well as increased heart rate and altered heart rate variability
during sleep (Stein and Pu 2012). Despite this literature, the central nervous system
correlates, underpinnings and consequences of hyperarousal in insomnia are largely
unknown thereby deterring the development of neurobiologically informed treat-
ment approaches. For example, the spatial localisation of brain activity related to
increased EEG beta power during sleep has not been investigated in patients with
insomnia up to now. Furthermore, it is unclear how increased beta power interferes
with sleep-promoting brain circuits and leads to the subjective experience of sleep
initiation and maintenance problems.
To investigate brain function in insomnia patients, some researchers used posi-
tron emission tomography or single photon emission computed tomography (Hasler
et al. 2012; Nofzinger et al. 2004; Smith et al. 2002). A frequently cited study by
Nofzinger et al. (2004) reported an increased brain metabolism in a distributed
network of cortical and subcortical brain regions including the ascending reticular
activating system, hypothalamus, thalamus, amygdala, hippocampus, insula, and
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anterior cingulate and prefrontal cortices. These findings suggested an association
of insomnia with alterations in the general arousal system, the emotion-regulating
system, and the cognitive system leading to the assumption that insomnia is a
disorder of corticolimbic overactivity that interferes with sleep-promoting brain
structures (see also Saper et al. 2005, p. 1262). In addition to this literature,
functional magnetic resonance imaging (fMRI) studies suggest that insomnia
patients’ daytime performance in neuropsychological tasks is associated with a
hypoactivation of task-related brain areas, especially in fronto-striatal networks
(Stoffers et al. 2014; Drummond et al. 2013; Altena et al. 2008). A further fMRI
study suggests that insomnia patients show an increased amygdala reactivity to the
presentation of sleep-related stimuli (Baglioni et al. 2014), which is in line with the
literature on preferential attention allocation to sleep-related stimuli in those with
insomnia (Harris et al. 2015). Moreover, it is a plausible hypothesis that insomnia is
characterised by functional alterations of the default-mode network as this network
is involved in self-referential processing, introspection, worry and rumination
(Hamilton et al. 2011). However, the evidence concerning this hypothesis is
currently inconclusive (Regen et al. 2016; Drummond et al. 2013). Most impor-
tantly with respect to pharmacological treatments, there are several studies using
magnetic resonance spectroscopy to investigate γ-aminobutyric acid (GABA)
levels in patients with insomnia. The majority of these studies suggest decreased
GABA levels in those with insomnia (Meyerhoff et al. 2014; Plante et al. 2012;
Winkelman et al. 2008), however, it should be noted that there are also conflicting
findings (Morgan et al. 2012; Spiegelhalder et al. 2016).
With respect to the aetiology of circadian rhythm sleep disorders, it is crucial
to understand the function of the so-called master circadian clock in the
suprachiasmatic nucleus. This well-described group of neurons generates a 24-h
rhythm via an autoregulatory feedback loop which can be influenced by light or
melatonin (Lu and Zee 2006). While the delayed sleep phase disorder is assumed to
be caused by an abnormally delayed circadian clock (Weitzman et al. 1981), the
opposite is assumed for the advanced sleep phase disorder. Both disorders involve a
continuing mismatch between the schedule desired by the individual or the social
environment and the individual circadian rhythm leading to daytime impairment. In
shift work disorder and jet lag disorder, the requirements of the environment are
altered which also leads to a continuing or temporary mismatch with the individual
circadian rhythm.
3 Treatment
There are a variety of treatments for insomnia (Morin et al. 2015; Bootzin
and Epstein 2011; Riemann and Perlis 2009). The most commonly used are
benzodiazepines (BZs) and non-benzodiazepine positive allosteric GABAA recep-
tor modulators (GARMs; Huedo-Medina et al. 2012; Glass et al. 2005; Duendar
et al. 2004; Nowell et al. 1997), off-label treatment with sedating antidepressants
(Buscemi et al. 2007), melatonin and melatonin receptor agonists (Kuriyama et al.
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2014), herbal substances (Leach and Page 2015) and cognitive behavioural therapy
for insomnia (Trauer et al. 2015; Wu et al. 2015). Moreover, orexin (aka
hypocretin) receptor agonists have been and currently are developed for the treat-
ment of insomnia (e.g. Michelson et al. 2014). Both BZs/GARMs and melatonin/
melatonin receptor agonists have also been investigated in the context of circadian
rhythm sleep disorders and are frequently used in these conditions.
It should be noted that cognitive behavioural therapy for insomnia is considered
by many, including us, as the first-line treatment for insomnia and both timed light
exposure and behavioural interventions targeting sleep–wake schedules are
recommended treatments for circadian rhythm sleep disorders. However, the cur-
rent chapter focuses exclusively on pharmacological approaches to treating insom-
nia and circadian rhythm sleep disorders.
3.1 Pharmacological Treatment with BZs and GARMs
BZs and GARMs are probably the most widely prescribed pharmacological
substances for the treatment of insomnia (see Table 1). These substances vary
considerably in half-life ranging from 2–4 h (zolpidem) to 48–120 h (flurazepam).
In addition, many of the BZs have pharmacologically active metabolites with
substantially longer half-life. The intake of substances with long half-life is
associated with a substantial risk of daytime impairment on the following day,
the intake of substances with short half-life is usually limited with respect to the
effects on sleep maintenance problems. The onset of action of BZs/GARMs is
rapid, and most of these drugs are recommended to be taken just shortly prior to or
even after going to bed.
Table 1 Benzodiazepines and non-benzodiazepine agonistic GABAA receptor modulators
frequently used for the treatment of insomnia
Drug Usual dose (mg) t½ (h)
Benzodiazepines
Flunitrazepam 0.5–2 16–35
Flurazepam 15–30 48–120
Lormetazepam 0.5–1 8–15
Nitrazepam 5–10 25–35
Temazepam 10–30 8–20
Triazolam 0.125–0.250 1.4–4.6
Agonistic GABAA receptor modulators (non-benzodiazepine structure)
Zolpidem 5–10 2–4
Zopiclon 3.75–7.5 5–6
Nonhypnotics sometimes used to aid sleep
Clonazepam 0.5–3 30–40
Diazepam 5–10 30–100
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The mechanism of BZs and GARMs is an allosteric modulation of the GABA-A
receptor complex (Downing et al. 2005). BZs and GARMs bind to this receptor
complex which increases the inhibition caused by GABA. GARMs bind more
specifically to a certain type of GABA-A receptors than BZs, however, it is a
matter of debate whether this leads to a different pharmacological profile of these
substances. In general, the inhibitory mechanism of BZs and GARMs is compara-
bly powerful as GABA-A receptors are ubiquitous in the central nervous system,
comprising up to 30% of all synapses (Mendelson 2005). The GABA-A receptor is
also involved in the anxiolytic, muscle relaxant, and anticonvulsant effects of BZs
and GARMs which are associated with some of the most frequently observed side
effects of these substances (e.g. risk of nocturnal falls associated with muscle
relaxation).
Several meta-analyses on the efficacy of BZs and GARMs in the short-term
treatment of insomnia have been published. The first of these included studies on
several BZs as well as zolpidem (half-life of approximately 2.5 h) as the most
widely prescribed GARMs (Nowell et al. 1997). Twenty-two randomised, double-
blind, placebo-controlled clinical trials with 1,894 patients were included in this
analysis. The median duration of treatment with BZs or GARMs was 7 days. The
combined effect sizes for all substances in comparison to placebo were 0.71 for
total sleep time, 0.56 for sleep onset latency, 0.65 for the number of nocturnal
awakenings, and 0.62 for sleep quality (all statistically significant), thus indicating
medium-sized effects.
Duendar et al. (2004) analysed potential differences between BZs and GARMs.
In this meta-analysis, 24 randomised, double-blind, placebo-controlled clinical
trials with 3,909 patients were included with a treatment duration between 1 night
and 6 weeks. Only few statistically significant differences between specific
substances were revealed, e.g. there was some evidence suggesting that zaleplon
has a more pronounced effect on sleep onset latency and a less pronounced effect on
total sleep time than zolpidem. In summary, the authors concluded that BZs and
GARMs do not differ substantially from each other with respect to their efficacy
and safety profiles. Moreover, the authors stated that the quality of the data was
limited by non-standardised outcomes and a variety in the level of information
provided across studies which made study comparisons difficult to make.
Another meta-analysis focused on the efficacy and risks of using BZs and
GARMs in elderly patients with insomnia (age >60 years; Glass et al. 2005). In
this meta-analysis, 24 randomised, double-blind, placebo-controlled clinical trials
with 2,417 patients were included. In comparison with placebo, BZs and GARMs
had small but significant effects on total sleep time, the number of awakenings and
sleep quality, however, cognitive adverse events were 4.8 times more common,
psychomotor adverse events were 2.6 times more common, and reports of daytime
fatigue were 3.8 times more common in the intervention groups. Moreover, an
increased incidence of falls and motor vehicle accidents was reported with active
drugs compared to placebo. Accordingly, the main conclusion of the authors of this
meta-analysis was that in elderly patients the benefits of BZs and GARMs may not
justify the risks.
266 K. Spiegelhalder et al.
A further meta-analysis on the efficacy of GARMs was provided by Huedo-
Medina et al. (2012) who focused on the analysis of datasets from the US Food and
Drug Administration. These data contain all published and unpublished trials up to
the date of drug approval and are, thus, less prone to publication bias than the data
used in previous meta-analyses. Overall, 13 studies with 4,378 patients were
analysed. The combined effect size for the GARMs compared to placebo was
0.36 for polysomnographically determined sleep onset latency which was the
primary outcome of the meta-analysis. However, there were no statistically signifi-
cant effects of GARMs on those variables that were investigated in a smaller
number of studies, namely polysomnographically determined total sleep time,
wake after sleep onset or number of awakenings.
Given the chronic nature of insomnia, long-term pharmacological treatment is an
important issue that needs to be addressed, especially with respect to the abuse
potential of BZs and GARMs (see Hajak et al. 2003). This has led to prescription
guidelines restricting the intake of BZs and GARMs to 3–4 weeks. This creates,
however, a paradoxical situation, keeping in mind that insomnia is a chronic
disorder. Unfortunately, there are only few published investigations on the long-
term treatment with BZs and GARMs. Ancoli-Israel et al. (2005) investigated an
open-label phase in which patients self-administered zaleplon for up to 12 months
following two randomised, double-blind placebo-controlled clinical trials. The
safety profile in this sample was similar to the one observed in the short-term trials,
and, most notably, discontinuation of zaleplon intake was not associated with
rebound insomnia. In another study, Krystal et al. (2003) investigated the effects
of eszopiclone in a randomised, double-blind, placebo-controlled clinical trial
including 788 insomnia patients. The initial gains in sleep continuity were
remarkably stable across the 6-month treatment period and there was no evidence
of tolerance. Krystal et al. (2008) provided another randomised, double-blind,
placebo-controlled clinical trial in which zolpidem was administered for up to
6 months. Again, an absence of tolerance to drug effects was reported and there
was no rebound effect during the first three nights of discontinuation. However,
Morin et al. (2009b) reported that co-administration of zolpidem in addition to
cognitive behavioural therapy for insomnia reduces the long-term therapeutic
effect of the psychotherapy. In summary, there is still too little data on the
development of tolerance, abuse and dependence in the context of BZ and
GARM administration. From our point of view, these issues are, however, of
utmost importance for the evaluation of BZs and GARMs for the treatment of
chronic insomnia.
In the context of circadian rhythm sleep disorders, clinical guidelines recom-
mend BZs or GARMs as an option for jet lag-induced insomnia in short-term
treatment and as an option to promote daytime sleep in night shift workers
(Morgenthaler et al. 2007). However, the balance of risks and benefits is not clear
and the abuse potential of these substances and potential carryover effects after
daytime use need to be considered.
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3.2 Pharmacological Treatment with Sedating Antidepressants
Sedating antidepressants like amitriptyline, doxepin, mirtazapine, trazodone,
trimipramine or agomelatine are frequently used off-label for the treatment of
insomnia (Bertisch et al. 2014; Walsh and Schweitzer 1999). These substances
are approved for the treatment of depression and are usually used at lower doses in
the context of insomnia treatment. As half-lives range from 9 h (trazodone) to 30 h
(amitriptyline), all of these substances are associated with a significant risk of next-
day impairments. Sedating antidepressants are a heterogeneous class of substances
acting on several neurotransmitter systems in the CNS. The sedating properties are
assumed to be mainly driven by the antagonism at the histamine H1 receptor.
Anticholinergic effects are responsible for many of the adverse effects, e.g.,
decreased salivation, decreased gastrointestinal motility or increased heart rate.
Polysomnographic investigations in depressed individuals indicate that sedating
antidepressants improve sleep continuity, trazodone increases the amount of slow
wave sleep, and amitriptyline and doxepin suppress rapid eye movement sleep
(Buysse et al. 2005). Moreover, doxepin and mirtazapine are assumed to increase
the number of periodic limb movements during sleep and the incidence of the
restless legs syndrome.
Only few randomised, double-blind, placebo-controlled clinical trials on the
efficacy and safety of sedating antidepressants in the context of clinically diagnosed
insomnia have been published. The largest number of clinical trials supporting the
efficacy of sedating antidepressants for insomnia has been published for doxepin.
The recommended dose for insomnia treatment in adults is 3–6 mg 1 h prior to
bedtime (Krystal et al. 2010, 2011; Roth et al. 2007; for studies using larger doses,
see also Rodenbeck et al. 2003; Hajak et al. 2001). Doxepin has potent histamine H1
receptor-blocking activity, a bioavailability of about 25%, and a plasma half-life of
around 17 h (51 h for one of its main metabolites desmethyldoxepin). The most
commonly observed side effects in clinical trials were fatigue, dizziness, dry mouth,
constipation and hypotension. However, at dosages 6 mg, the safety profile of
doxepin was indistinguishable from placebo in a recent clinical trial (Krystal et al.
2011). In summary, the effects on sleep in insomnia patients appear to be significant
but smaller than the ones of BZs and GARMs (Winkler et al. 2014; Buscemi et al.
2007).
Walsh et al. (1998) investigated the efficacy of trazodone (50 mg) in comparison
with zolpidem (10 mg), and placebo in a randomised, double-blind, clinical trial
that included 306 insomnia patients. During the first week of treatment, both
trazodone and zolpidem produced significant gains in comparison with placebo in
terms of sleep onset latency and total sleep time. However, during the second week
of treatment, only the zolpidem group maintained a significantly shorter sleep onset
latency in comparison with placebo.
In the only randomised, double-blind clinical trial on trimipramine in insomnia
patients, Riemann et al. (2002) investigated the efficacy of this substance in
comparison with lormetazepam (1 mg) and placebo in 60 insomnia patients. The
study design allowed flexible dosing of trimipramine in the range of 50–200 mg.
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Active treatment was administered for 4 weeks followed by a 2-week discontinua-
tion phase. Trimipramine significantly increased polysomnographically determined
sleep efficiency in comparison to placebo while lormetazepam did not. The impact
on subjective variables was also more pronounced in the trimipramine group than in
the lormetazepam group. In addition, there was no evidence for rebound insomnia
or withdrawal symptoms in the trimipramine group during 2 weeks of drug discon-
tinuation. However, adverse events were reported in 79% of patients in the
trimipramine group, 78% of patients in the placebo group, but only 33% of patients
in the lormetazepam group.
In summary, more data is needed to evaluate the efficacy and safety of sedating
antidepressants for the treatment of insomnia. Moreover, there is no evidence
concerning the use of these substances in the treatment of circadian rhythm sleep
disorders (Morgenthaler et al. 2007). The clinical trials summarised above suggest
that sedating antidepressants are effective in alleviating insomnia symptoms. Thus,
given the minimal abuse potential, these substances are a therapeutic alternative to
BZs and GARMs. However, the adverse events profile and the need of cardiovas-
cular monitoring during active treatment should be borne in mind when using
sedating antidepressants in the clinical management of insomnia.
3.3 Pharmacological Treatment with Melatonin and Melatonin
Receptor Agonists
Melatonin is an endogenous hormone produced by the pineal gland. The rhythm of
secretion of melatonin is generated by the suprachiasmatic nucleus: the secretion is
suppressed during daytime, increases in the evening, and peaks during nighttime
(Claustrat et al. 2005). Light is able to suppress melatonin secretion (Lewy et al.
1980). As a synthetic pharmacological substance, melatonin is available as an over-
the-counter medication in the US. Moreover, both melatonin and melatonin recep-
tor agonists are also available as synthetic drugs on a physician prescription basis
(ramelteon in the U.S.; Circadin in Europe). Ramelteon is a melatonin receptor
agonist acting at both the MT1 and MT2 receptor subtypes and has been approved
by the US Food and Drug Administration for the treatment of sleep onset problems.
Circadin is a prolonged-release formulation of melatonin acting also at both
melatonin receptor subtypes as an agonist and has been approved by the
European Medicines Agency for the short-term treatment (3 months) of insomnia
patients who are aged 55 or over.
The rationale for using melatonin in insomnia is based on findings that the
endogenous hormone is critically involved in the regulation of circadian rhythms
and sleep–wake patterns. Melatonin is also supposed to be involved in retinal light
sensitivity, systemic immunity, antioxidative defences and glucose regulation
(Claustrat et al. 2005). Over-the-counter melatonin has a half-life of 40–60 min,
ramelteon of approximately 1.4 h, and Circadin of approximately 2.5 h. The
recommended doses are 3–5 mg for over-the-counter melatonin, 8–16 mg for
ramelteon, and 2 mg for Circadin.
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In a recent meta-analysis, clinical data from randomised, double-blind placebo-
controlled trials of ramelteon for insomnia have been summarised by Kuriyama
et al. (2014). This meta-analysis included 13 clinical studies with 5,812 insomnia
patients. The mean treatment duration was 38 days. The intake of ramelteon led to
significant improvements in subjective sleep onset latency and sleep quality as well
as polysomnographically determined total sleep time and sleep efficiency. How-
ever, the effects were comparably small and, thus, of questionable clinical rele-
vance. Overall, melatonin and melatonin receptor agonists are considered to be an
option for the treatment of insomnia especially because of their minimal abuse
potential and safety. Overall, the published literature on over-the-counter melato-
nin, ramelteon, and Circadin does not suggest any serious adverse effects of these
substances including a lack of impact on next-day performance.
Herxheimer and Petrie (2002) performed a meta-analysis on studies investi-
gating the efficacy of melatonin for jet lag disorder and came to a very positive
evaluation of its effectiveness for this condition. The authors also concluded that
the evidence suggests that the positive effects of melatonin are probably greater
when more time zones are crossed, and probably smaller for westward travels (see
also Beaumont et al. 2004). A further meta-analysis focused on the effects of
melatonin on delayed sleep phase disorder (van Geijlswijk et al. 2010). The analysis
of nine randomised, double-blind, placebo-controlled clinical trials including
317 adults and children suggested that melatonin has pronounced effects on the
clock hour of sleep onset and reduces sleep onset latency significantly by approxi-
mately 23 min. Thus, the authors concluded that melatonin is effective in advancing
sleep–wake rhythms in patients with delayed sleep phase disorder. Accordingly,
clinical guidelines recommend the use of melatonin in jet lag disorder to accelerate
entrainment to the new time zone, and in delayed sleep phase disorder to advance
sleep–wake rhythms, and, in addition to that, in patients with shift work disorder
(prior to daytime sleep). Moreover, the intake of melatonin is recommended to be
considered as an option in advanced sleep phase disorder with the aim of delaying
sleep–wake rhythms (Morgenthaler et al. 2007).
3.4 Pharmacological Treatment with Orexin Receptor
Antagonists
In 2014, the first orexin receptor antagonist, suvorexant, has been approved by the
US Food and Drug Administration for the treatment of sleep-onset and sleep-
maintenance insomnia. In the lateral hypothalamus, about 70,000 orexin neurons
are involved in generating and maintaining wakefulness. Preclinical work suggests
that blocking these neurons leads to a reduction of arousal and improved sleep onset
and maintenance. Suvorexant is an antagonist at both the orexin A receptor and the
orexin B receptor (Yin et al. 2015) and the first hypnotic substance that suppresses
wakefulness by acting on the orexinergic system. This is in contrast to the more
common pharmacological approach to strengthen the sleep drive (e.g. by the intake
of BZs and GARMs). Some substances that specifically block either the orexin A
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receptor or the orexin B receptor are currently in development, however, as there
are no published clinical trials on these substances, the effects of receptor selectiv-
ity remain unknown.
Clinical trials on the effects of suvorexant are promising and show that it is
effective for up to a year without significant rebound insomnia (Herring et al. 2012,
2016; Michelson et al. 2014). Most notably, Michelson et al. (2014) conducted a
phase 3 study comparing suvorexant (n ¼ 522) with placebo (n ¼ 259) in a 1-year
treatment phase and a 2-month discontinuation phase. In this trial, suvorexant had
sustained effects on subjective total sleep time (60 min increase in the suvorexant
group vs. 33 min in the placebo group), the number of adverse events during the
1-year treatment phase was similar in both groups, and the data from the discontin-
uation phase did not suggest significant rebound or withdrawal effects. However,
we have previously commented that somnolence was reported by 13% of the
patients in the suvorexant group compared with only 3% of the patients in the
placebo group (Riemann and Spiegelhalder 2014). While somnolence was reported
to be mostly mild or moderate in severity in this clinical trial and a further study
does not suggest pronounced effects on next-morning driving performance
(Vermeeren et al. 2015), it should be noted that the development of another orexin
receptor antagonist, almorexant, was stopped in 2011 after concerns about side
effects were raised. Of further note, the published data on the efficacy of suvorexant
is more compelling for daily doses of 30–40 mg in comparison of daily doses of
10–20 mg (see Michelson et al. 2014). However, based on safety considerations, the
US Food and Drug Administration clearly stated that the total daily dose of
suvorexant should not exceed 20 mg (see also Kripke 2015 for a critical evaluation
of the risk-benefit ratio of suvorexant).
Up to now, there is no evidence concerning the use of orexin receptor
antagonists in the clinical management of circadian rhythm sleep disorders.
3.5 Pharmacological Treatment with Herbal Substances
Herbal substances have been used as over-the-counter sleep medications for
centuries. The substances that have been most rigorously studied are valerian,
chamomile, kava and wuling. A recently published meta-analysis identified
ten randomised, controlled trials investigating the efficacy of these substances in
insomnia, however, there were not statistically significant differences between any
herbal substance and placebo for any of the measures of clinical efficacy (Leach and
Page 2015). Moreover, the majority of studies did not describe the methodology in
sufficient detail, to assess the scientific quality of this research. To the best of our
knowledge, there are no randomised, double-blind, placebo-controlled clinical
trials on the efficacy of herbal substances for circadian rhythm sleep disorders.
Thus, in summary, there is currently no evidence supporting the use of herbal
substances for insomnia or circadian rhythm sleep disorders.
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4 Summary
BZs and GARMs like zolpidem (the most commonly prescribed drug for insomnia)
improve sleep onset and maintenance in the short-term treatment of insomnia.
However, tolerance and dependence are important side effects, which have led to
prescription guidelines restricting the intake of BZs and GARMs to 3–4 weeks. This
creates a paradoxical situation, keeping in mind that insomnia is a chronic disorder.
Sedating antidepressants are frequently prescribed for insomnia, however, only few
randomised controlled trials have been published so far. Melatonin and melatonin
receptor agonists are considered to be an option for the treatment of insomnia
especially because of their minimal abuse potential and safety, however, the effects
on sleep onset and maintenance appear to be smaller than the ones of BZs, GARMs
and sedating antidepressants. First data on orexin receptor antagonists for insomnia
are promising, however, the risk–benefit ratio needs to be further evaluated. With
respect to herbal substances, there is currently no evidence supporting their use in
patients with insomnia.
Cognitive-behavioural therapy for insomnia is a safe and effective alternative to
pharmacological treatment, and, most importantly, it does exert stable long-term
effects (e.g. Morin et al. 2009b). However, there is a substantial proportion of
subjects who do not respond or remit during treatment. In particular, adherence to
the behavioural strategies is known to be extremely difficult due to increased
daytime sleepiness during the initial phase of implementation (Kyle et al. 2014).
Furthermore, CBT-I is not largely available and mainly offered in specialised
research settings. Insofar the present situation reflects a very dreary outlook for
patients with chronic insomnia and new treatment strategies are urgently needed
that are safe and effective.
With respect to circadian rhythm sleep disorders, there is solid evidence from
meta-analyses supporting the use of melatonin in jet lag disorder to accelerate
entrainment to the new time zone, and in delayed sleep phase disorder to advance
sleep–wake rhythms. In addition to that, there is evidence supporting the use of
melatonin in patients with shift work disorder in order to promote daytime sleep
after night shifts. In addition, timed light exposure and behavioural interventions
targeting sleep–wake schedules are recommended treatments for circadian rhythm
disorders.
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Abstract
Current GABAergic sleep-promoting medications were developed pragmati-
cally, without making use of the immense diversity of GABAA receptors.
Pharmacogenetic experiments are leading to an understanding of the circuit
mechanisms in the hypothalamus by which zolpidem and similar compounds
induce sleep at α2βγ2-type GABAA receptors. Drugs acting at more selective
receptor types, for example, at receptors containing the α2 and/or α3 subunits
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expressed in hypothalamic and brain stem areas, could in principle be useful as
hypnotics/anxiolytics. A highly promising sleep-promoting drug, gaboxadol,
which activates αβδ-type receptors failed in clinical trials. Thus, for the time
being, drugs such as zolpidem, which work as positive allosteric modulators at
GABAA receptors, continue to be some of the most effective compounds to treat
primary insomnia.
Keywords
Benzodiazepine • GABA-A receptor • GABA-B receptor • Gaboxadol •
Histamine • Sedation • Steroid • THIP • Z-drug • Zolpidem
1 Introduction
For primary insomniacs, those otherwise healthy people who cannot get to sleep or
maintain sleep, cognitive behavioural therapy is recommended as the first route to
better sleep (Schroeck et al. 2016; Wafford and Ebert 2008). If this fails, sleeping
medication is then prescribed. These medications, known as sedatives or hypnotics,
are generally controlled substances, requiring a medical doctor’s authorization. In
this chapter, we look at the sedatives/hypnotics used to treat primary insomnia that
work by enhancing inhibitory GABAergic transmission. There have been various
reviews on sleep medication and GABAA receptors (Greenblatt and Roth 2012;
Lancel and Steiger 1999; Nutt and Stahl 2010; Wafford and Ebert 2008; Winsky-
Sommerer 2009). In spite of the passage of time, these reviews remain excellent
resources on drug structures, the history of how these drugs were developed and
their clinical effects. The GABAA receptor drug zolpidem (Ambien) remains the
first pharmacological line of attack for treating insomnia (Bertisch et al. 2014;
Lancel and Steiger 1999; Mignot 2013; Nutt and Stahl 2010). One survey of about
32,300 adults (healthy and not in hospital) found that 3% of them (about 970 people)
had been prescribed zolpidem for insomnia in the preceding month (Bertisch et al.
2014). In fact, in the USA, there were 53.4 million prescriptions for zolpidem
(Ambien) in 2010 (Greenblatt and Roth 2012). This amounted in 2006 to $1.5
billion of sales for the company that then principally marketed zolpidem, Sanofi
(Morris 2013).
2 Natural Sleep and Hypnosis/Sedation
Sedatives are substances that depress the central nervous system, producing calm-
ness and relaxation, less anxiety and more sleepiness; and hypnotics are defined as
substances which induce sleep, so the words “sedative” and “hypnotic” tend to be
used interchangeably (Wafford and Ebert 2008). In the GABA field, there is much
work done on selective anxiolytics that do not cause sedation, but an anxiolytic drug
is also likely to be sleep promoting if sleep latency was measured in a calm
environment – in practice, for humans, it would be unlikely that there would be
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an anxiolytic that does not influence sleep propensity, since relaxation is part of the
preparation for getting ready to sleep.
Some hypnotic/sedative drugs induce vigilance states partially resembling natu-
ral NREM sleep, with a delta to theta ratio in the EEG that could be classified as
NREM-like. The power of the EEG at different frequencies reflects the degree of
synchronization of neural currents at those frequencies in the neocortex and hippo-
campus. A sleep-like EEG produced by a sedative/hypnotic often has a high delta to
theta frequency power ratio but sometimes with an overall lower power than
occurring in NREM sleep, which may represent a less deep sleep. For certain
compounds (e.g. propofol, etomidate, barbiturates, inhalational compounds), as
drug dosage is increased, sedation deepens into general anaesthesia (Franks 2008;
Franks and Lieb 1994; Garcia et al. 2010), and the EEG becomes flat, with periodic
bursts of large amplitude spikes, a phenomenon termed “burst suppression” (see for
example Fig. 6 in Reynolds et al. 2003).
In this chapter, we take drug-induced sedation/hypnosis to mean a NREM-like
activity measured in the EEG, reduced or zero movement with the subject being
harder to arouse and with a lower body temperature. Even within this drug-induced
sedative/hypnotic state, there are differences between drugs and receptor classes.
Sedation is easier to define on human subjects, because verbal responses and visual
observation reveal if the person is conscious or in an intermediate state and this can
be combined with EEG, heart rate and respiratory recordings (polysomnography).
Sedation as a concept has been used rather loosely in experiments on animals.
Researchers studying sedation, especially with regard to benzodiazepine and
zolpidem action, have tended to separate drug-induced sedation and drug-induced
sleep into separate concepts: e.g. benzodiazepine-induced sedation and
benzodiazepine-induced sleep. This has added some confusion to the field (Tobler
et al. 2001; Winsky-Sommerer 2009). This distinction came about because many
experimental studies have defined an animal as sedated by just one parameter,
which is if the animal moves less in the open-field assay following drug treatment or
if it becomes ataxic. But often the EEG was not measured in these studies on
sedation (Crestani et al. 2000; McKernan et al. 2000; Rudolph et al. 1999). Animals
could be quietly awake or have a changed motor function independent of sleep
through, e.g. catalepsy or cerebellar interference. When, for example, Purkinje cells
in the mouse cerebellum were made selectively sensitive to zolpidem, zolpidem
given systemically to these mice caused ataxia and reduced the time they could stay
on a rotating rod, but the mice were not sedated (Wulff et al. 2007). An EEG
analysis on sedation is more incisive, because reduced or changed movement alone
is an insufficient criterion to define sedation, and as part of the EEG scoring,
movement is implicitly measured, as the EMG is used to help score the vigilance
states.
Although we think that reduced movement alone is not an adequate criterion to
define sedation, it has also been argued that there is too much reliance on the EEG to
characterize vigilance states, without paying enough attention to the obvious
feature of how the animal appears visually (Coenen and van Luijtelaar 1991).
There is sometimes a dissociation between the EEG and the behaviour of the
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animal, so that “a quantitative analysis of the EEG alone might give misleading
information about the effects of a compound on the state of vigilance” (Coenen and
van Luijtelaar 1991). The anaesthetic urethane, whose molecular targets are still
unknown, produces strong and sustained theta in the EEG (Coenen and van
Luijtelaar 1991). A strong delta power component in the EEG does not always
mean NREM sleep or sedation either. The EEG can contain a strong delta profile in
fear-induced freezing (frontal cortex) (Karalis et al. 2016) or following atropine
administration (Qiu et al. 2015) or following THIP and muscimol administration,
where mice are awake, but have NREM-like oscillations in their prefrontal cortex
(Vyazovskiy et al. 2005, 2007; Winsky-Sommerer et al. 2007), and also awake
GABAA receptor δ subunit knockout mice have strong δ oscillations. In the case of
muscimol, the state produced is catalepsy, where the animals do not move because
the muscles have no tone, similar to REM sleep, but the mice are not asleep
(Vyazovskiy et al. 2007).
3 The Perfect Sleeping Pill?
A good “sleeping pill” should reduce the time to enter NREM sleep (reduce “sleep
latency”) and allow only limited awakenings, and most researchers assume that
sleep-promoting medication should aim to reproduce the sleep EEG profile and
architecture (order and length and EEG power of NREM and REM sleep) found in
natural sleep. Other practical considerations are that a sleeping pill compound
should occupy its receptor sites quickly and have a short half-life so that it on the
one hand increases sleep time but on the other does not give “hangover effects”
such as daytime sleepiness or reduced daytime alertness (Nutt and Stahl 2010).
Zolpidem meets most of these requirements well. The ideal sleep-promoting com-
pound should also have low addictive potential and not cause rebound insomnia
when the drug is withdrawn. Unsurprisingly, no sedative could be yet described as
“perfect”. Problems with even the best sleeping medications include “confusional
arousal” and ataxia and risk of injury if awakening occurs whilst on the medication
(Frey et al. 2011; Mignot 2013) and rebound insomnia if use is discontinued
(Mignot 2013) (see Sect. 5 below). There can also be serious side effects if sleep-
promoting medication is taken with other medications that suppress neuronal
activity, e.g. mixing zolpidem with narcotic pain killers or alcohol. Some people,
particularly the elderly, who take zolpidem have more risk of car accidents the next
day if they are driving (Booth et al. 2016). In fact, starting around 2006, there are
various stories in the media of zolpidem (Ambien)-induced delirium and people
acting strangely under the drug’s influence during sleep walking – it is unclear if
these aberrant behaviours are really due to zolpidem (see Morris 2013).
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4 Activating GABAergic Neurons Generally Promotes Sleep:
GABAA Receptor Positive Allosteric Modulators (PAMs)
and GABA Agonists Induce Sleep
γ-Aminobutyric acid (GABA), the main inhibitory transmitter in the mammalian
brain, works on the ionotropic (GABAA) and metabotropic (GABAB) receptor
classes. The natural sleep-promoting circuitry in the brain uses sleep-active
GABAergic neurons to inhibit wake-active neurons in wake-promoting circuitry
(Chung et al. 2017; Lin et al. 1989; Nitz and Siegel 1996; Sherin et al. 1998; Uygun
et al. 2016) (Fig. 1). Hence, it might seem intuitively obvious that enhancing
GABAergic transmission throughout the brain with positive allosteric modulators
(PAMs) of GABAA receptors, and thus enhancing network inhibition, will induce
sedation. And indeed, with a few interesting exceptions, this is the case.
Most effective hypnotics/sedatives and anaesthetics developed to date enhance
GABA’s action at GABAA receptors, working as PAMs at the receptor. Most drugs
were developed and marketed without knowledge of their GABAA receptor targets,
and this knowledge was gained often only decades after the drugs were first in use
(Franks 2008). PAM compounds do not usually work on the GABAA receptors by
themselves but require GABA to bind to the receptor as well. By causing GABA to
prolong the duration of the inhibitory postsynaptic currents through GABAA
receptors, PAMs enhance ongoing GABAergic transmission. These drugs, which
have varied molecular structures and come from multiple classes of compound,
include amobarbital (barbiturates); compounds acting as agonists at the benzodiaz-
epine site, e.g. zolpidem (an imidazopyridine), zaleplon (a pyrazolopyrimidine) and
zopiclone (a cyclopyrrolone); and the benzodiazepines, e.g. diazepam, flurazepam,
quazepam, temazepam and triazolam (Bertisch et al. 2014; Gottesmann et al. 1998;
Lancel and Steiger 1999; Nutt and Stahl 2010). Two current major intravenous
anaesthetics used during hospital operations to induce and maintain general anaes-
thesia, etomidate and propofol, are also selective PAMs at GABAA receptors
(Franks 2008). At low concentrations, general anaesthetics produce sedation. As
the drug concentrations increase, the difference in principle between propofol and
zolpidem, why the first can induce and maintain general anaesthesia, whilst the
other is only a sleeping pill which cannot induce more than sleep, is that probably
propofol prolongs IPSCs more than zolpidem and it is a more potent PAM. In
addition, propofol works on all GABAA receptor types, whereas benzodiazepines
and zolpidem are more restricted in which receptors they can activate.
Hans Selye, who discovered and conceptualized the physiological responses to
stress, also first observed that the endogenous steroid progesterone could cause
sedation (Gunn et al. 2015; Herd et al. 2007; Lancel and Steiger 1999). Decades
later it was discovered that reduced versions of progesterone, i.e. some of its
metabolites, are potent PAMs of GABAA receptors (Harrison and Simmonds
1984; Lan et al. 1990; Lancel et al. 1999; Majewska et al. 1986) and these
progesterone metabolites (e.g. allopregnanolone) produce behavioural effects,
e.g. sedation/sleep and anxiolysis, broadly similar to other PAMs of GABAA
receptors except that steroids work on a wider range of subunit combinations and
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Fig. 1 Schematic of how GABAergic afferents from the preoptic area (POA) of the hypothalamus
inhibit wake-promoting histamine neurons and how zolpidem enhances this natural inhibitory
pathway to induce sleep. (a) During wakefulness, there is a basal GABAergic tone from the POA
afferents (green) onto the histamine neurons in the tuberomammillary area (TMN). These wake-
active neurons project widely (red arrows) to release histamine to promote aspects of arousal. In
addition to GABA, the GABAergic afferents release a range of peptides (e.g. CCK, CRH, TAC1)
into the tuberomammillary area (Chung et al. 2017). The GABAA receptors located postsynapti-
cally on the histamine neurons are probably mixtures of α1βγ2 and α2βγ2 receptors. The γ1 and ε
subunits are also expressed in some histamine neurons (May et al. 2013). (b) At the onset of
NREM sleep and during NREM sleep, the GABAergic afferents have increased activity (thicker
green line), hence depressing histaminergic activity (thin red arrows). Similar scenarios would
also be happening at other ascending aminergic centres, e.g. the locus coeruleus and dorsal raphe.
(c) After taking zolpidem, the drug will act as a PAM on the postsynaptic GABAA receptors to
enhance the GABA afferent input onto histamine neurons and inhibit them, effectively mimicking
the situation occurring in natural NREM sleep shown in panel (a) (Uygun et al. 2016)
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are not just “dependent” on γ2-subunit-containing GABAA receptors (Herd et al.
2007) (see Sect. 6 for details on the subunits). Allopregnanolone (t1/2¼ just 35 min)
was improved to give ganaxolone with better oral bioavailability and a longer half-
life. This drug is highly sedative and could, in principle, be used to treat insomnia,
as well as epilepsy and anxiety. In fact, allopregnanolone is a potent sedative before
anything else, and therefore drug developers have concentrated on reducing its
sedative properties so that it can be used for other treatments. The synthetic steroid-
like derivative UCI-50027 is more anxiolytic than sedative as assessed by its effect
on movement (Hogenkamp et al. 2014). This illustrates the difficulty for drug
developers interested in new sleeping medications. The intellectual property
space for these drugs is crowded, and there are no strong commercial advantages
in having a steroid-based sedative, as opposed to benzodiazepines or zolpidem.
5 Addiction and Rebound Insomnia
Barbiturates, the original sedatives in use since the beginning of the twentieth
century, and benzodiazepines have generally fallen out of use as sleep-promoting
agents. Barbiturates are simply dangerous because of the risk of overdose and lethal
if taken at too high a dose because they can directly gate the GABAA receptors and
depress breathing and cardiac regulation centres. Hence, barbiturates are now only
used in specialist medical applications and until recently on “death row”. Similarly,
the benzodiazepine drugs Librium and Valium, household names in the 1960s, were
used decades before it was understood that they were PAMs of GABAA receptors
(Mohler 2015; Randall 1961). The benzodiazepine triazolam (Halcion) ran into legal
trouble when patients committed criminal offences and had accidents whilst having
this drug prescribed for sleep (Mignot 2013). Consequently, in the USA triazolam is
prescribed at a lower dose, and in the UK it is not available, having been banned as a
“sleeping pill” in 1991. Both classes of drugs are addictive, and tolerance emerges,
and rebound insomnia appears when the drugs are withdrawn, so that the patient
sleeps even less well than before. Rebound insomnia is an interesting phenomenon
and presumably indicates that GABAA receptors on neurons in the sleep regulatory
circuitry have become downregulated with continuous PAM use; without the drug,
the relevant neurons are not sufficiently inhibited by endogenous GABAergic
transmission. The circuitry and neurons involved are unknown, but it would be
good to know what these are as we may then have a more precise understanding of
the mechanisms involved. It could well be that PAMs down-modulate GABAA
receptors on neurons that control the homeostatic sleep circuitry – the receptors on
these neurons (e.g. orexin and melanin-concentrating hormone neurons) are
dynamically modulated by the sleep drive (Toossi et al. 2016).
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6 GABAA Receptors: A Family of Subunits Assembled
to Make Many Subtypes of Receptor (Opportunities
to Discover PAMs That Selectively Promote Sleep
and Anxiolysis)
The GABAA receptor drugs in clinical use have been discovered pragmatically
without using knowledge about the molecular structures of the receptors. We will
now look at the receptors on which these drugs act, because pharmacologists hope
to design more precise drugs based on the structure of the receptors. GABAA
receptors were first cloned in 1987 and are now fairly well understood at the
structural level (Levitan et al. 1988; Miller and Aricescu 2014; Mohler 2015;
Olsen 2015; Pritchett et al. 1989; Puthenkalam et al. 2016; Schofield et al. 1987;
Seeburg et al. 1990; Shivers et al. 1989; Sieghart 2015; Sigel and Steinmann 2012).
They are GABA-gated chloride channels, in the same gene superfamily as glycine
receptors, nicotinic acetylcholine receptors and serotonin 5-HT3 receptors. There
are six alpha (α1–α6) subunit genes, three beta (β1–β3) subunit genes, three gamma
(γ1–γ3) subunit genes and one delta (δ) subunit gene; additionally, there are also
epsilon (ε), theta (θ) and pi (π) subunit genes and three rho (ρ) subunit genes. The
subunit genes are differentially expressed throughout the brain and enteric nervous
system (Fritschy and Mohler 1995; Moragues et al. 2002; Pirker et al. 2000; Seifi
et al. 2014; Sinkkonen et al. 2000; Wisden et al. 1988, 1992). Because the subunits
can assemble in different combinations, there are many subtypes of GABAA
receptor. We still do not know precisely how many.
Five subunits are arranged in a ring with the chloride channel at the centre. For
the best studied types of GABAA receptor, the ring usually contains two α subunits,
two β subunits and a γ or δ subunit. Two GABA molecules activate the receptor,
binding at the α and β subunit interfaces. There are many mechanistic possibilities
for PAM drugs to enhance (or sometimes decrease) GABA’s action at the receptor
complex. The receptor complex contains binding sites for allosteric modulators,
which bind within the membrane helices, such as the propofol binding site at the
interface between the extracellular domain and transmembrane domain 2 (Franks
2015; Yip et al. 2013), or the benzodiazepine and z-drug binding site between the α
and γ2 subunit interfaces (Ogris et al. 2004; Puthenkalam et al. 2016). A few drugs
work at the GABA binding site – between the α and β subunits – these drugs are
known as orthosteric ligands (THIP/gaboxadol and muscimol) and mimic GABA’s
agonist actions (Puthenkalam et al. 2016).
For current drugs the important target combinations of receptor subunits are
α1βγ2, α2βγ2, α3βγ2, α4βγ2, α4βδ and α5β1/2/3γ2 receptors. Benzodiazepines and
the “z-drugs” (e.g. zolpidem, zopiclone) require an α and γ2 subunit in the receptor
complex (Cope et al. 2004; Ogris et al. 2004; Pritchett and Seeburg 1990; Pritchett
et al. 1989; Seeburg et al. 1990); for these drugs the type of β subunit is less
important. Receptors that contain the γ2 subunit are enriched in the postsynaptic
area but are also present extrasynaptically (Fig. 2). Synaptic locations would also be
expected for receptors that contain the γ1 or the γ3 subunits, but receptors with
these subunits have been relatively little studied (Herb et al. 1992) and are
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expressed in just a few cell types. Notably the γ1 gene is expressed in the medial
preoptic-hypothalamic area, a sleep regulatory centre (Wisden et al. 1992). The
synaptic receptors with the γ2 subunits convey fast synaptic inhibition (Brickley
and Mody 2012). Receptors that contain the δ subunit do not get targeted to the
postsynaptic area and are extrasynaptic (Brickley and Mody 2012) (Fig. 2). Acti-
vation of extrasynaptic GABAA receptors by GABA diffusing from the synapse, or
being released non-synaptically, produces “tonic inhibition”, which is a sustained
-subtype
Effects of drugs 
on sleep and
other parameters:
Sleep onset latency:
Sleep continuity:
Total sleep time:
in frequency< 10 Hz
in spindle frequency
sedation
GABA GABA
none reported
YES NO
NOYES
cognitive impairment &
amnesic effects
not altered & sustain attention
during sleep restriction
REM sleep:
REM sleep latency:
EEG power:
Residual effects:
Effects on cognitive 
performance:
Development of 
tolerance and/or 
dependance:
Rebound insomnia:
GABAA sub-type modulated by sedative-hypnotics:
extrasynaptic receptors extrasynaptic 
receptors
synaptic receptors
GABA
BZ & Z-drugs -subtype
GABA agonists
in frequency< 10 Hz
in spindle frequency
Fig. 2 Summary of how sleep-promoting drugs work on synaptic (αβγ2 type) and extrasynaptic
(αβγ2 and αβδ) GABAA receptors. The differing types of sleep produced by benzodiazepines
(BSz), z-drugs such as zolpidem and GABA agonists such as gaboxadol are summarized in the
table. This figure and table have been adapted from (Winsky-Sommerer 2009)
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(hence the word “tonic”) activation of GABAA receptors, with no precise temporal
resolution (Brickley and Mody 2012). Agonists (GABA mimetics) such as 4,5,6,7-
tetrahydroisoxazolo(5,4-c)pyridin-3-ol (THIP – also known as gaboxadol) act pref-
erentially on δ subunit-containing receptors (Fig. 2). The αβγ2-containing GABAA
receptors outside synapses also contribute to tonic inhibition.
7 Benzodiazepines and “Z-Drug”-Induced Sleep/Sedation:
Mechanisms and Circuitry
Benzodiazepines such as diazepam and the z-drugs (e.g. zolpidem) reduce the time
to sleep (decrease sleep latency), increase sleep continuity and total sleep time,
decrease REM sleep and increase REM sleep latency (Lancel and Steiger 1999;
Winsky-Sommerer 2009) (Fig. 2). In terms of the EEG, these drugs induce a
NREM-like state, with a higher delta-to-theta ratio, but the power of the EEG in
this range is reduced (relative to the power in natural NREM sleep) (Fig. 3). Spindle
frequency power (12–14 Hz) is also increased relative to the power of spindles in
natural sleep. Lower power in the NREM range induced by these drugs might mean
a less deep sleep or a less restorative sleep. Zolpidem-induced sleep has decreased
EEG power in the 5–16 HZ range, relative to that in natural sleep, and
benzodiazepines depress the EEG power even further (Winsky-Sommerer 2009)
(Fig. 3). It is not clear what these changes in power relative to natural sleep really
mean for efficacy. It could be perfectly adequate sleep, sufficient to treat insomnia,
especially because these drugs are not intended to be taken permanently. For
example, the benzodiazepine triazolam substantially depresses NREM EEG
power but does not interfere with synaptic plasticity during sleep, whereas
zolpidem does actually interfere with plasticity, but the EEG power reduction
compared with normal sleep is less (Seibt et al. 2008). This work was done on
the developing visual cortex of kittens; Seibt et al. conclude: “Our findings demon-
strate that alterations in sleep architecture do not necessarily lead to impairments in
sleep function. Conversely, hypnotics that produce more “physiological” sleep
based on polysomnography may impair critical brain processes, depending on
their pharmacology” (Seibt et al. 2008).
Diazepam and the other benzodiazepines work as PAMs on α1βγ2, α2βγ2,
α3βγ2 and α5βγ2 receptors and do not differentiate between them, whereas
zolpidem enhances GABA’s action mainly on three GABAA receptor subtypes:
α1βγ2, α2βγ2 and α3βγ2 (Pritchett and Seeburg 1990; Pritchett et al. 1989);
zolpidem has the highest binding affinity at α1βγ2-containing receptors but only
by 20-fold, meaning that in practice at normal doses in vivo zolpidem also acts as a
PAM at α2βγ2 and α3βγ2 receptors (Pritchett and Seeburg 1990; Uygun et al.
2016), and zolpidem cannot really be called an “α1-selective compound”, even
though this term is frequently used. Some benzodiazepines and zolpidem will also,
to some extent, enhance GABA’s action at αβγ1-type receptors (Khom et al. 2006).
The GABAA receptor targets for benzodiazepines and zolpidem are widespread,
and so these drugs will influence nearly all aspects of brain function and do cause
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many side effects. An important advance for potentially improving drug selectivity
at GABAA receptors came with the discovery that one particular histidine (H) in the
extracellular domain of the alpha subunits, H101, determined if benzodiazepines
could bind to the receptor complex (Wieland et al. 1992). This discovery was made
because it was noticed that two of the alpha subunits, α4 and α6, formed
benzodiazepine-insensitive GABAΑ receptors when expressed as recombinant
α4βγ2 or α6βγ2 subunits combinations (Luddens et al. 1990; Wisden et al. 1991)
and that this was because the α4 and α6 subunits contained an arginine R101 and
not H101 at their presumed benzodiazepine binding sites (Wieland et al. 1992).
When this residue in α1, α2, α3 or α5 was mutated to an R, benzodiazepines could
no longer potentiate the GABA response at recombinant α(Η101R)βγ2 receptors
(Wieland et al. 1992). This mutation was exploited to make a series of knock-in
mice where the α1, α2, α3 and α5 subunit genes were systematically mutated in the
codon encoding the key histidine H101, so that R101 was incorporated into the
subunit instead. These “αH101R” mice were used to behaviourally dissect the roles
of the different GABAA receptor subtypes in responding to benzodiazepines and
z-drugs such as zolpidem (Mohler 2015; Rudolph et al. 1999), whereby particular
GABAA receptor subtypes had lost the ability to be modulated by diazepam
(a pharmacogenetic loss of function experiment). For example, it was found that
benzodiazepines do not reduce anxiety in α2H101R mice (Low et al. 2000) and that
α1H101R do longer get sedated by benzodiazepines or zolpidem (the mice keep
moving after drug injection) (Crestani et al. 2000; McKernan et al. 2000; Rudolph
et al. 1999). Thus αβγ2-type GABAA receptors with α2 receptors were suggested to
contribute to the anxiety-reducing effects of benzodiazepines; those receptors with
α1 subunits contribute to the sedative effects of zolpidem and benzodiazepines
(Rudolph et al. 1999). In recent experiments, all four lines of αH101R point mutant
mice have been bred together to generate either HRRR (order is α1, α2, α3 and α5),
RHRR, RRHR or RRRH mice (a pharmacogenetic restriction of function method),
so that GABAA receptors with only one of the α subunits are now enhanced by
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diazepam (Ralvenius et al. 2015). With this series of mouse lines, it was found that
GABAA receptors with the α5 subunit, and not the α2 subunit, are the main
receptors regulating anxiolysis in response to diazepam (Behlke et al. 2016). In
the original, and even new, experiments with “α1H101R” and HRRR mice on
“sedation”, the EEG was not measured. But even in the new HRRR experiments,
α1-containing GABAA receptors seem to be the only target for diazepam to reduce
movement and hence cause “sedation” (Ralvenius et al. 2015).
In a separate series of studies from those on sedation (reduced movement)
discussed above, the single H to R point mutant α subunit mice were used to
explore the effects of diazepam and zolpidem on the EEG and sleep latency. For
diazepam, the α1H101R mutation did not alter the sleep latency or sleep length, so
α1-containing receptors are not involved in diazepam’s hypnotic actions (Tobler
et al. 2001). Similarly, α3 H to R point mutant mice had unchanged hypnotic
responses to diazepam (Kopp et al. 2003). Instead, it seemed to be the α2 subunit
that was partially required (Kopp et al. 2004a). Similarly, the α1-containing GABA
receptors are not responsible for zolpidem’s ability to promote sleep. In mice with
α1 subunits made insensitive to zolpidem by the H101R mutation, zolpidem
reduces latency to NREM sleep and prolongs NREM sleep time as well as it does
in wild-type mice (Kopp et al. 2004b). Thus, although this seems to contradict the
sedation data mentioned above (based on inhibiting movement), where zolpidem
acts through the α1-type receptors to induce “sedation”, zolpidem’s sleep-
promoting effects must come from enhancing GABA’s actions at GABAA receptors
with α2 and/or α3 subunits (Kopp et al. 2004b). [Note: there has been quite a lot of
work done to find α2- and α3-selective anxiolytic PAMs, but it would be surprising
if such drugs were not also sedatives]. However, the α1H101R mice show that α1-
containing receptors are needed for zolpidem to produce its characteristic decrease
in the EEG power (frequencies between 5 and 16 Hz of zolpidem-induced NREM
sleep relative to that found in natural NREM sleep (Kopp et al. 2004b). Zolpidem
might induce NREM sleep in part by potentiating histamine neurons in the posterior
hypothalamus (see Sect. 11). In the end, it is still curious why there is a disconnect
between the α1-type GABAA receptors as sedative promoting and the α2-type
receptors as sleep promoting. With hindsight, both types of receptor are involved
in promoting different subcomponents of sleep.
The reticular thalamus and layer VI of the neocortex are enriched in their
expression of α1β2γ2- and α3β2γ2-type receptors (Wisden et al. 1988, 1992).
These sites are expected to control thalamocortical oscillations such as the δ
oscillation in NREM sleep. However, the global α3 knockout mouse had no obvious
sleep-wake phenotype, although possibly another GABAA receptor subtype was
upregulated on the reticular thalamic neurons, as the α3 KO cells still had IPSCs
(Winsky-Sommerer et al. 2008). The α3 H to R (loss of function for diazepam) mice
were studied to provide more information. However, the effects of diazepam given
to these mice on sleep and EEG were no different to mice with diazepam-sensitive
α3 subunits (Kopp et al. 2003). Given the recent discovery of the excitatory GABA
projection from the lateral hypothalamus to the reticular thalamus, one might
speculate that some of the reticular thalamic α3βγ2 receptors would contribute to
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net excitation and wakefulness, whereas α3-containing receptors on, e.g. the locus
coeruleus, could contribute to sedation (see Sect. 11).
8 Wake-Promoting GABAergic Pathways: Zolpidem Can
Promote Transient Arousal from a Small Subset
of Patients with Disorders of Consciousness
Some GABAergic pathways, especially some originating in the hypothalamus and
brainstem, are actually wake promoting (Chung et al. 2017; Herrera et al. 2016;
Venner et al. 2016), and so enhancing the synaptic transmission at their projection
sites selectively would be expected to promote wakefulness. For example, some
lateral hypothalamic GABAergic neurons project to the GABAergic reticular
thalamus neurons (Herrera et al. 2016). Selectively activating these lateral hypo-
thalamic GABAergic neurons produces wakefulness and even emergence from
general anaesthesia (Herrera et al. 2016). Thus, selectively enhancing this
feedforward inhibition with a GABAA receptor PAM would probably produce
wakefulness. But in practice, current sleep-promoting drugs work all over the
brain; this wake-promoting effect of the PAM at this synapse is probably swamped
by the net inhibitory effect at most other synapses where PAMs enhance
GABAergic inhibition. In cats and juvenile ferrets, benzodiazepines and zolpidem
can promote arousal (Hsu et al. 2009; Lancel and Steiger 1999). There are some
spectacular findings that zolpidem can promote transient arousal from rare types of
disorders of consciousness (coma) – but the circuit mechanisms remain unclear
(Chatelle et al. 2014; Williams et al. 2013). Perhaps in some types of disorders of
consciousness, selective pathways, such as the lateral hypothalamic-reticular thala-
mus route mentioned above, are stimulated by zolpidem, and that this is possible
because the normal sleep-promoting GABAergic pathways are damaged. Only 5%
of patients with disorders of consciousness respond to zolpidem by transiently
awakening, and the effect is small when done double-blind and placebo controlled
(Thonnard et al. 2013).
9 Extrasynaptic GABAA Receptors, d Subunits and Sleep
An important class of GABAA receptors exists exclusively outside the synapse and
contains δ subunits (Brickley and Mody 2012). Delta-containing receptors are
involved in tonic inhibition, sensing extrasynaptic GABA. This type of inhibition
may be used physiologically as a gain control system. In the forebrain, the δ subunit
is paired primarily with the α4 and α1 subunits (Fig. 4). In thalamic relay neurons,
which have some of the highest expression of α4 and δ subunits in the brain and
which also co-express the α1 and β2 subunits, the receptor could be α4β2δ or
α1α4β2δ (Shivers et al. 1989; Wisden et al. 1991, 1992). The α1βδ subunit
combination also exists in the neocortex and hippocampus on selective GABAergic
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b, Gaboxadol and potential novel GABA-A receptor drug-induced sleep
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Fig. 4 Possible novel GABAA receptor targets in the hypothalamus and ascending arousal
neurons. (a) Wakefulness is sustained in part by ascending aminergic neurons such as the
histaminergic neurons in the tuberomammillary nucleus (TMN) and the noradrenergic neurons
in the locus coeruleus (LC). These release histamine (His) and noradrenaline (NA) widely
throughout the neocortex (Ctx) and other regions. (b) Gaboxadol activates α1α4βδ receptors in
the thalamus (T) to induce NREM sleep by promoting δ-type oscillations. Speculative novel
targets for yet undiscovered sleep-promoting drugs that work via GABAA receptors could be the
ascending arousal neurons and neurons on the preoptic area (POA) of the hypothalamus. These
areas express various GABAA receptor subunit gens such as the γ1, ε and θ subunit genes. The
predominant α subunit genes expressed in these areas tend to be the α2 and α3 subunit genes. The
receptor subunit combinations in these areas, apart from the obvious one of α1β3β2 and α2β3γ2 in
histamine neurons, have not been clearly elucidated. Some drugs could work to supress wakeful-
ness by dampening down the histamine and noradrenaline systems. Other drugs might interfere
with wake-promoting GABAergic projections (not shown) in the POA area
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interneuron types, especially the parvalbumin types (Ferando and Mody 2015;
Milenkovic et al. 2013).
Gaboxadol (or THIP) is a direct GABA mimetic ligand at δ-containing
receptors. Mice with genetically deleted δ subunits are unresponsive to muscimol
and THIP (Winsky-Sommerer et al. 2007). The δ-containing receptors are insensi-
tive to benzodiazepines, but their GABA-activated currents are potentiated by
steroids and propofol, and this depends on the level of extrasynaptic GABA
(Houston et al. 2012). It was suggested that GABA acting at δ-containing
GABAA receptors at thalamic extrasynaptic GABAA receptors on thalamic relay
cells might induce slow wave activity – the delta oscillations of NREM sleep
(Wafford and Ebert 2006) (Fig. 4), although δ receptors are certainly dispensable
for this, as global δ knockout mice have normal sleep-wake cycles and vigilance
states (Winsky-Sommerer et al. 2007). But THIP does increase the tonic conduc-
tance on mouse thalamic relay neurons, and this could in theory promote delta
NREM-like oscillations (Belelli et al. 2005), although clearly there are other
δ-containing GABAA receptors in the mouse forebrain (perhaps on GABA
interneurons) where THIP acts to counteract sleep and instead promotes agitation
and actually delays sleep.
In mice, THIP definitely would not be regarded as a sleep-promoting drug
(Alexandre et al. 2008; Winsky-Sommerer et al. 2007) – in fact, quite the opposite.
A similar acting drug, muscimol, in mice promoted catalepsy and delayed sleep
onset (Vyazovskiy et al. 2007). But there are big species differences in the way this
drug works. Studies on rats suggested THIP would be a good drug to promote sleep
(Lancel and Langebartels 2000). In rats, THIP increased the amount and depth of
NREM sleep (Lancel and Langebartels 2000). Based on the results in rats, THIP/
gaboxadol went into human clinical trials to test if the drug promoted sleep (the
drug had already been used many times before in human trials for treating tardive
dyskinesia and cancer pain, and many patients had previously reported sleep as a
side effect). It was generally well tolerated and seemed to promote sleep as well as
zolpidem (Fig. 2). In contrast to zolpidem, gaboxadol enhances delta power in
NREM sleep in humans (Dijk et al. 2010; Lundahl et al. 2007, 2012). Also in
contrast to zolpidem, gaboxadol caused no rebound insomnia on drug withdrawal
(Hajak et al. 2009). But in 2007 gaboxadol failed in Phase III for sleep studies,
although it is not quite clear why. Studies with the drug’s efficacy in sleep on
primary insomnia outpatients gave conflicting results. Some groups found at 15 mg/
kg it promotes sleep, decreasing latency and increased the feeling of wakefulness
after sleep in studies conducted on patients using sleep diaries (N ¼ 742) (Hajak
et al. 2009). As the size of the samples were scaled up, other studies on humans
found that gaboxadol (THIP) at 10 mg/kg had no effect on sleep (Roth et al. 2010).
At 15 mg/kg, it failed to reduce sleep latency consistently in clinical trials with, for
example, one patient group reporting sleep-promoting effects, another not (Roth
et al. 2010). Some inconsistent effects were reported for the prolongation of sleep
duration, with the drug having effects in females but not males. Some people
complained of nausea and dizziness and some severe adverse effects as the dose
was increased (Lundahl et al. 2007). This could be because another target of THIP/
GABA Receptors and the Pharmacology of Sleep 293
gaboxadol is the α6βδ receptor, which is expressed on cerebellar granule cells
where it generates a tonic inhibitory GABA-activated current (Brickley et al. 2001;
Luddens et al. 1990; Shivers et al. 1989; Wisden et al. 1992). Thus, on cerebellar
granule cells, THIP is likely to stimulate the tonic conductance mediated by
extrasynaptic GABA and acutely modulating gain control of motor systems and
the vestibular reflex – hence dizziness. An improved sleep-promoting drug for
humans might need to target only α4βδ-type receptors – these are not expressed
in the cerebellum. Gaboxadol is not sold in the USA and has no FDA approval. It is
now unlikely to ever appear as a sleep-promoting drug commercially. A PAM,
DS-2, that works selectively at δ-containing GABAA receptors (Wafford et al.
2009) does not seem to have been tested for its effects on sleep promotion.
Strangely, THIP/gaboxadol still seems like it would be an excellent sleep-
promoting drug for some. Hamilton Morris’ compelling account in Harper’s Mag-
azine of private gaboxadol ingestion (which took place in 2013 after clinical trials
had ceased) is recommended reading (Morris 2013) .
10 GABAB Receptors and Sleep Promotion
GABAB receptors are dimeric G protein-coupled receptors that produce slow
metabotropic inhibition and are essential to prevent over excitation and the emer-
gence of seizures (Gassmann and Bettler 2012; Pin and Bettler 2016). Functionally,
the slow GABAB-mediated inhibition is quite similar to the tonic conductance
inhibition arising from δ-type GABAA receptors. GABAB receptors are located
extrasynaptically, often on presynaptic terminals of, e.g. glutamate or GABA
neurons. Activating GABAB receptors opens K
+ channels or closes voltage-gated
Ca2+ channels, reducing transmitter release from terminals. At the cellular level,
activation of GABAB receptors is inhibitory, but at the network level, activating
these receptors can produce either net excitatory or inhibitory effects. GABAB
receptors acting presynaptically to decrease GABA release could be excitatory or
inhibitory at the network level, depending on whether the GABAergic neuron is
inhibiting another GABAergic terminal or a glutamatergic excitatory terminal.
Compared with GABAA receptors, there is no substantial receptor diversity for
GABAB receptors. All GABAB receptors are made from two subunits, GABAB1
and GABAB2. There are two subtypes of GABAB receptor because of two splice
versions of the GABAB1 gene, GABAB1a and GABAB1b, that pair with GABAB2.
Modulator proteins or auxiliary subunits (e.g. potassium channel tetramerization
(KCTD) proteins KCTD8, KCDT12, KCTD12b and KCTD16), which are
expressed cell type selectively, may increase the functional diversity of GABAB
receptors and allow more flexibility for developing drugs (Pin and Bettler 2016).
Given that the two GABAB receptor subunits are widely expressed in the brain
forming receptors that contribute to every aspect of brain function, it seems unlikely
that conventional specific GABAB receptor agonists will selectively interfere with
sleep and not have profound side effects. Indeed, GABAB receptor agonists cannot
be used for treating primary insomnia.
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Drugs active at GABAB receptors do promote sleep/sedation, but some of the
sedation could result from off-target effects. The best established GABAB agonist is
baclofen. But in mice with GABAB receptors deleted, baclofen still promoted a
delayed NREM sleep (Vienne et al. 2010). In mice and rats, the drug GHB
(γ-hydroxybutyric acid, the sodium salt is called sodium oxybate) promotes seda-
tion: hypo-locomotion, NREM sleep with increased delta power in the EEG and
decreased body temperature (Kaupmann et al. 2003; Vienne et al. 2012; Wisor et al.
2006) – the drug also increases delta power during wakefulness (Vienne et al.
2012). The drug needs to be used at a high dose to get these effects (50–150 mg/kg)
(Vienne et al. 2010) or 300 mg/kg (Wisor et al. 2006). In mice with deleted GABAB
receptors, GHB no longer induces sedation but still binds with high affinity to
neuronal membranes (Kaupmann et al. 2003). Thus, GHB causes sedation by
activating GABAB receptors. GHB has a low affinity at these receptors – typically
3 mM GHB is needed to activate endogenous GABAB receptor responses on
neurons (Connelly et al. 2013). The function and identity of the high-affinity
GHB binding site remain a mystery – GHB does not activate αβδ GABAA
receptors, so these are not the target (Connelly et al. 2013). In spite of its unclean
pharmacology, GHB can help reduce the symptoms of patients suffering from
narcolepsy with cataplexy (Black et al. 2014). In mice, baclofen similarly reduces
the symptoms of narcolepsy with cataplexy, in part by promoting high delta power
NREM sleep (Black et al. 2014); again, it is unclear if this is due to GABAB
receptor activation or due to an off-target effect.
GABAB receptor inhibition is embedded throughout the sleep-wake circuitry.
Mice with genetically deleted GABAB receptors (global knockouts) are unhealthy
and lose weight and have seizures and disrupted sleep, with sleep being fragmented
and with reduced power across all EEG frequencies (Vienne et al. 2010). If we try
to look more selectively, mice with GABAB receptors selectively removed from
wake-promoting orexin neurons in the mouse lateral hypothalamus have a strongly
fragmented sleep-wake pattern, with many more transitions between wake and
NREM sleep, and upregulation of GABAA receptors on these neurons (Matsuki
et al. 2009). The overall amount of sleep and wake in these mice was unaffected by
the GABAB receptor deletion – the increased fragmentation was due to more
transitions between all vigilance states but no sign of cataplexy – there were no
abnormal transitions from wake to REM sleep, for example (Matsuki et al. 2009).
But in contrast, selectively deleting GABAB receptors from histaminergic neurons
does not alter any parameter of the sleep-wake cycle, so GABAB receptor modula-
tion of the histamine system is dispensable (Zecharia et al. 2012).
11 GABAA Receptors Expressed on Nodal Points of the Sleep-
Wake Circuitry as Drug Targets for Sleep?
Some GABAA receptors are highly expressed in nodal points of circuitries that
control vigilance states. So, activating GABAA receptors on these nodes will
influence activity in many other parts of the brain. Injecting barbiturates, muscimol
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(GABAA receptor agonist) or propofol into a small area of the rat brain stem, the
mesopontine tegmental area, induces anaesthesia, presumably because some key
hub neurons (whose identity is unknown) that have far-reaching projections have
been inhibited (Abulafia et al. 2009; Minert and Devor 2016). Similarly, injecting
GABA agonist drugs (muscimol) into the posterior hypothalamus of awake cats
produces NREM sleep, presumably because of the inhibition of wake-promoting
histamine neurons, as these are hub neurons that promote wakefulness and influ-
ence many brain areas simultaneously (Lin et al. 1989; Nelson et al. 2002; Uygun
et al. 2016) (Fig. 1).
We saw previously that based on global α2H101R mice, zolpidem is most likely
acting to promote sleep through α2βγ2 and/or α3βγ2 GABAA receptors (Kopp et al.
2004b). The α2 subunits are expressed in hypothalamic areas (Wisden et al. 1992),
such as on histaminergic neurons (Fritschy and Mohler 1995; Sergeeva et al. 2005).
By using a genetic γ2 swap method, whereby zolpidem-sensitive γ2F77 subunits
are swapped cell type selectively into a γ2F77I mouse, which is insensitive to
zolpidem (Cope et al. 2004), selectively augmenting the active GABA input onto
hypothalamic histamine neurons by systemic zolpidem administration decreased
NREM sleep latency and enhanced sleep time but notably without reducing the
power of the oscillations in the 5–16 HZ range of the EEG, so more resembling
natural NREM sleep (Uygun et al. 2016) (Fig. 3). This suggests that zolpidem could
in part induce sleep by enhancing GABA’s actions on histamine neurons.
Some of the most obscure (or, at least, functionally less well studied) and
therefore potentially interesting GABAA receptor subunits are significantly
expressed in areas of the brain that regulate homeostatic functions such as sleep.
In particular, the γ1, ε and θ subunits have enriched expression in preoptic-
hypothalamic and some brain stem areas (May et al. 2013; Moragues et al. 2002;
Sergeeva et al. 2005; Sinkkonen et al. 2000; Wisden et al. 1992) (Fig. 4). A
significant feature is that these hypothalamic and brainstem areas frequently use
α2 and α3 subunit expression. Triazolam is effective as a PAM at α1βγ1 receptors,
as to some extent is zolpidem (Khom et al. 2006). This work could be developed
further to look for, e.g. α2βγ1-selective ligands. Similarly, a drug selectively
working at GABAA receptors containing α3, ε and θ subunits would be interesting
to investigate for its sleep-promoting properties. Expressing recombinant ε and θ
subunits with the α3 and β1 subunit reduces sensitivity to many PAMs (propofol,
etomidate, pregnenolone and flurazepam) but increases GABA and gaboxadol
sensitivity 100-fold (Ranna et al. 2006). The θ-containing receptors could still be
potentiated by etomidate (Ranna et al. 2006). It is possible that the ε subunit could
function as a β-like subunit (Jones and Henderson 2007). Compared with the
αβγ2 and α1/4βδ class of GABAA receptors, not enough work has been done on
the ε and θ subunits to give us a full understanding of the GABAA receptors to
which they contribute.
In rodents, GABAA receptors assembled from α2, α3, ε and θ subunits could be
targets for drugs that promote sleep or anxiolysis (Belujon et al. 2009) (Fig. 4).
Similar to the histaminergic and other ascending aminergic groups, noradrenergic
neurons in the locus coeruleus (LC) project widely throughout the brain and promote
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arousal and enhanced cognitive function. Adrenergic LC neurons fire selectively
during wakefulness, and thus inhibiting their activity will enhance anxiolysis and
sleep. In particular, although lesions of the LC do not influence the amounts of
wakefulness, rats with LC lesions do go to sleepmore quickly in a novel environment
(Gompf et al. 2010). A similar anxiolytic effect was found with selective deletions of
γ2-containing GABAA receptors from histaminergic neurons – no change in the
overall sleep-wake cycle was produced, but the mice went to sleep more quickly in a
novel environment (Zecharia et al. 2012). Thus, a (novel) drug that reduces LC or
histamine function by enhancing GABAA receptors on these neurons would be
anxiolytic and sleep promoting (Fig. 4). The α2 and α3 subunits are found in separate
clusters on the cell bodies and dendrites of rat noradrenergic LC neurons (Corteen
et al. 2011). These neurons also express the unusual ε and θ subunits (Belujon et al.
2009; Sinkkonen et al. 2000), and histamine neurons also express the ε gene
(Sergeeva et al. 2005). So, receptors assembled from either α2, ε and θ or α3, ε
and θ might be interesting as potential targets for sleep- or anxiolytic-promoting
drugs (Fig. 4). A caveat is that in humans, but not rodents, noradrenergic neurons
express the γ2 subunit (Hellsten et al. 2010). This would mean that human LC
neurons would be targets for PAMs that selectively modulate α2βγ2- and α3βγ2-
type receptors and these α2- or α3-preferring drugs would probably be sedative too
(Hellsten et al. 2010). It is unclear what the functional contribution of ε and θ subunit
contributions would be if the γ2 subunit is also present on LC neurons – presumably a
complex mix of receptors is present. The native subunit compositions of ε- and
θ-containing receptors in human LC neurons and human hypothalamic neurons
would need to be established – e.g. α2β3θε or α2θε or α2β3γ2 combinations.
Again, given the differences in the way different species respond to some drugs
(see in particular the section above on gaboxadol – Sect. 9), we would need to be
cautious in using mice as a system to work up new sleep-promoting drugs.
12 Perspectives
The most “natural” way to induce sleep is sleep deprivation, even if this is not a
practical therapy and has frequently been used as a form of torture. The drive to
sleep increases in proportion to the amount of time spent awake, until the drive
becomes so overwhelming that sleep is unpreventable. Nevertheless, the type of
sleep that emerges through this route of sleep deprivation is physiological and is
termed recovery sleep. This recovery sleep represents the process of sleep homeo-
stasis: catching up on lost sleep with a longer and deeper sleep (as defined by
enhanced EEG δ power for the first stage of NREM sleep) (Landolt et al. 2000). The
circuitry controlling sleep homeostasis is not understood in detail, although it does
require the preoptic hypothalamus (Zhang et al. 2015), but the mechanisms under-
lying sleep homeostasis could be one future route to inducing a natural sleep
artificially. Current GABAergic medications, such as zolpidem, all discovered
without any appreciation of how sleep-promoting circuitry works, do not induce a
natural type of recovery sleep and thus are likely to use different mechanisms from
GABA Receptors and the Pharmacology of Sleep 297
natural sleep (Landolt et al. 2000; Wisor et al. 2006). It seems we were on a new
threshold for GABAergic sleep medication with gaboxadol, which actually
enhances NREM-type δ power in humans, but the drug failed in clinical trials.
On the other hand, the α2 adrenergic agonist dexmedetomidine seems to use the
same circuitry in the lateral preoptic hypothalamus to that activated in recovery
sleep, albeit with marked hypothermia and changes in blood pressure, and so
compounds based on this drug mechanism, targeting the recovery sleep aspect,
might be further developed to promote sedation (Zhang et al. 2015). Not enough is
known about sleep circuitry to understand if more precise medications will be
possible. In the meantime, hypnotic drugs such as zolpidem will continue to be
widely used.
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Abstract
Melatonin and melatonin agonists offer novel treatments for sleep and mood
disorders, particularly where circadian misalignment is also present. The therapies
offer both phase-shifting and sleep-promoting effects and have shown potential to
treat advanced and delayed sleep-wake phase disorder, non-24-h sleep-wake
cycle, jetlag, shift work disorder, insomnia, seasonal affective disorder and
major depressive disorder.
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1 Introduction
There is increasing interest in the potential of melatonin and melatonin agonists to
treat sleep and mood disorders. Melatonin has phase-shifting (Arendt and Rajaratnam
2008) and sleep-promoting (Wyatt et al. 2006) effects and has shown potential in
treating sleep disorders, particularly where circadian misalignment is also present
(Arendt and Rajaratnam 2008). It has also shown promise for treating seasonal
affective disorder (SAD) (Lewy et al. 2006), a mood disorder characterised by
circadian misalignment. Recent evidence shows melatonin and melatonin agonists
also offer potential to treat other sleep and mood disorders such as some types of
insomnia and major depressive disorder. However, the mechanisms underlying these
effects are unclear. We review the role of melatonin in the circadian regulation of
sleep and mood and the phase-shifting and sleep-promoting properties of exogenous
melatonin and melatonin agonists and outline how melatonin and melatonin agonists
might be used for treatment of various sleep and mood disorders.
2 Endogenous Melatonin and the Sleep-Wake Cycle
First isolated by Lerner et al. (1958), melatonin (N-acetyl-5-methoxytryptamine) is a
hormone produced in the pineal gland primarily during darkness (Lynch et al. 1975).
The timing of melatonin secretion is controlled by the circadian pacemaker, in the
suprachiasmatic nuclei (SCN) of the anterior hypothalamus, via GABAergic inhibi-
tion and glutamatergic stimulation of the paraventricular nucleus and sympathetic
noradrenergic stimulation of the pineal gland (Klein and Moore 1979; Perreau-Lenz
et al. 2003; Perreau-Lenz et al. 2004; Reppert et al. 1981). Measurement of melato-
nin concentration (through the dim light melatonin onset, DLMO) is regularly used
by researchers to determine a person’s biological night (Lewy et al. 2006; Lewy et al.
1985), as the production of the hormone rises in the evening and falls during the
morning hours (Arendt and Rajaratnam 2008). While the role of melatonin is not
fully understood, its role in modulating the circadian system and controlling the
sleep-wake system is increasingly recognised (Rajaratnam et al. 2009a). Prior to
melatonin onset is the time of day referred to as the wake maintenance zone when
sleep propensity is lowest (Lavie 1986; Strogatz et al. 1987). At the same time
endogenous melatonin rises, there is an abrupt transition from increased wakefulness
to high sleep propensity (Dijk and Cajochen 1997; Lavie 1997). Peak melatonin
concentration is associated with low core body temperature, alertness, mental per-
formance, metabolic functions and maximum sleep propensity (Rajaratnam and
Arendt 2001). Endogenous melatonin appears to support sleep by inhibiting the
circadian system’s wake-promoting drive (Lavie 1997; Sack et al. 1997).
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The circadian effects of melatonin are mediated by melatonin receptors MT1 and
MT2 located within the SCN (Reppert et al. 1996). Animal models have shown some
evidence for divergent roles of MT1 and MT2 receptors. Studies in knockout mice
demonstrate that activation of the MT1 receptor appears to inhibit SCN neuronal
ﬁring, while the MT2 receptor is more important in mediating the phase-shifting
effect of melatonin (Liu et al. 1997), although this is not widely agreed in humans
and the exact role of the receptors is not yet understood (Liu et al. 2016).
3 Circadian Timing and Amplitude of Melatonin and Their
Relationship to Mood
Disruptions in circadian rhythms, including endogenous melatonin production,
appear to underlie not only disturbances in sleep but also disturbances in mood.
For example, disruptions in the rhythms of the release of melatonin have been found
in major depressive disorder (MDD) (Li et al. 2013), and depression severity has
been found to correlate with delayed melatonin secretion; the more delayed, the
more severe the depressive symptoms (Emens et al. 2009). In delayed sleep-wake
phase disorder, circadian misalignment has been found to be associated with
increased depressive symptoms (Murray et al. 2017). For patients suffering from
SAD, adjusting phase to a more ideal time improves mood (Lewy et al. 2005a).
Compared with patients in earlier stages of affective disorders, patients in later stages
have been found to have reduced levels of melatonin secretion and melatonin onsets
closer to sleep onset (shorter “phase angles”), lower subjective sleepiness and poorer
performance on neuropsychological tests of verbal memory (Naismith et al. 2012).
Reduced amplitude has also been found during depression (Avery et al. 1982;
Buckley and Schatzberg 2010; Souêtre et al. 1989), and amplitude reduction has
been found to correlate with symptom severity (Souêtre et al. 1989). Meanwhile,
recovery has been associated with normalising amplitude (Avery et al. 1982; Szuba
et al. 1997).
4 Physiological Mechanisms Behind Effects of Melatonin
and Melatonin Agonists
The physiological mechanisms behind the sleep-facilitating and phase-shifting
effects of melatonin and melatonin agonists remain to date unclear. Sleep-facilitating
effects may be related to melatonin inhibiting SCN multiunit activity (Shibata et al.
1989; Stehle et al. 1989). As SCN electrical activity is high in the day and low at
night, melatonin-induced inhibition may create a “night-like” SCN state during the
day (Colwell 2011). In humans, this may be especially important in promoting sleep
during the “wake maintenance zone”, when the signal for wakefulness from the
clock appears strongest (Shekleton et al. 2013). Thermoregulatory effects may also
provide an explanation. For example, melatonin-induced sleepiness has been found
to occur in parallel with a reduction in the thermoregulatory set point, and heat loss is
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linked to increased sleepiness (Hughes and Badia 1997; Krauchi et al. 2006). The
phase-shifting effects of melatonin may be explained by the activation of melatonin
receptors in the SCN, which both inhibit neuronal activity and phase shift circadian
ﬁring rhythms (Dubocovich 2007). The phase-shifting effects of melatonin have
been found to be mediated by activation of melatonin receptors in the SCN in rodent
studies (Hunt et al. 2001).
5 Exogenous Melatonin and Melatonin Agonists
The therapeutic potential offered by exogenous melatonin utilises its phase-shifting
and sleep-promoting effects. Exogenous melatonin phase shifts circadian rhythms
according to a phase response curve (PRC); the direction and magnitude of the phase
shift depend on the circadian time at which melatonin is administered (Burgess et al.
2008, 2010; Lewy 2010; Redman 1997; Sharkey and Eastman 2002). In addition to
its phase-shifting properties, exogenous melatonin appears to support sleep by
attenuating the wake-promoting drive from the circadian system (Lavie 1997;
Sack et al. 1997). This sleep-promoting property means it could be used to enhance
sleep scheduled out of phase with endogenous melatonin production, a treatment
useful for shift workers, individuals suffering from jet lag and patients with
advanced or delayed sleep phase syndrome (Wyatt et al. 2006). Indeed, exogenous
melatonin may only be efﬁcacious in promoting sleep if taken where endogenous
melatonin is not present (Wyatt et al. 2006).
Exogenous melatonin and melatonin agonists have shown potential for treating
circadian rhythm sleep-wake disorders, including non-24-h sleep-wake disorder,
insomnia and delayed sleep phase disorder and mood disorders including seasonal
affective disorder and major depressive disorder. Table 1 sets out the potential
treatments offered by each compound, including the dose for each indication and
current regulatory approval in Australia, the USA and Europe.
6 Potential Treatments
6.1 Circadian Rhythm Sleep-Wake Disorders
In circadian rhythm sleep-wake disorders, sleep disruption is likely to be due to an
altered circadian system or misalignment between the endogenous circadian system
and an individual’s required sleep-wake schedule (American Psychiatric Association
2013). Those most at risk of suffering include shift workers, people travelling across
time zones (Rajaratnam et al. 2009b) and individuals suffering from chronic circa-
dian rhythm disorders such as advanced or delayed sleep-wake phase disorder
(Dahlitz et al. 1991). Melatonin is a potentially effective treatment for circadian
rhythm sleep-wake disorder because of its ability to phase-shift the circadian clock,
including the circadian rhythm of sleep-wakefulness and multiple endogenous
rhythms (Rajaratnam et al. 2003; Rajaratnam et al. 2004; Vandewalle et al. 2007).
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Table 1 Potential treatments for melatonin and melatonin agonists
Compound
Primary
mechanism Indication Dose for indication
Regulatory approval
FDA EMA TGA
Melatonin High afﬁnity
for MT1 and
MT2 receptors
Circadian rhythm sleep-
wake disorder
1.5 mg at beginning of
sleep opportunity
(Rajaratnam et al. 2003)
No No Yes
Non-24-h sleep-wake
disorder in blind
0.3 mg or less per day
(Lewy et al. 2005c)
Transient insomnia
induced by shifted sleep-
wake cycle (e.g. jet lag,
shift work, advanced or
delayed sleep phase
disorder)
0.3 mg and 5.0 mg –
efﬁcacious only if taken
when endogenous
melatonin absent,
i.e. during a person’s
biological day (Wyatt
et al. 2006)
Seasonal affective
disorder (SAD)
Up to 0.3 mg/day –
optimal administration
when plasma DLMO
and mid-sleep are 6 h
apart. Evening
administration for
prototypical patients
(Lewy et al. 2005b)
Delayed sleep-wake phase
disorder
0.3–5 mg – optimal
treatment 3–6 h before
DLMO, lower doses
preferred (van
Geijlswijk et al. 2010)
Tasimelteon Melatonin
analogue
Non-24-h sleep-wake
disorder in blind
20 mg 1 hour before
desired sleep time
(Lockley et al. 2015)
Yes Yes No
High afﬁnity
for MT1 and
MT2
Transient insomnia
induced by shifted sleep-
wake cycle in healthy
individuals (e.g. jet lag,
shift work)
50–100 mg 30 min
before bedtime
(Rajaratnam et al.
2009b)
Ramelteon Melatonin
analogue
Insomnia in older adults 4–8 mg taken nightly
(Roth et al. 2006)
Yes No No
High afﬁnity
for MT1 and
MT2 and low
afﬁnity for
MT3
Beta-methyl-6-
chloromelatonin
(LY156735)
Melatonin
analogue
Transient insomnia from
shift in sleep time
5 mg per day (Nickelsen
et al. 2002)
No No No
High-afﬁnity
agonist for
MT1 and MT2
receptors
Primary insomnia 20–100 mg (Zemlan
et al. 2005)
Circadin® Slow-release
melatonin
application
Insomnia in adults over 55 2 mg taken 1–2 h before
bed (Lemoine et al.
2007b)
No Yes Yes
High afﬁnity
for MT1 and
MT2 receptors
(continued)
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The size and direction of the shift will depend on the internal circadian time of
administration, but in general, melatonin taken in the afternoon/early evening will
advance the circadian clock, and taken in the morning, it will delay it (Khalsa et al.
2003). Administration of 1.5 mg of melatonin has been found to advance the timing
of sleep and endogenous circadian rhythms in healthy adults (Rajaratnam et al.
2003). Melatonin has been found to advance the timing of sleep so that it occurs
during the wake maintenance zone, without affecting the percentage of REM sleep.
The percentage of stage 2 sleep and sleep spindle activity does increase, and the
percentage of stage 3 sleep decreases with melatonin (Rajaratnam et al. 2004).
6.2 Non-24-h Sleep-Wake Disorder
Melatonin is the preferred treatment for totally blind people, many of whom suffer
from non-24-h sleep-wake disorder, a disorder characterised by an inability to
synchronise to the 24-h day through light exposure. A common complaint of
non-24-h sleep-wake disorder is sleep-wake disruption including insomnia and
daytime sleepiness (Lockley et al. 2015). A number of studies have shown melatonin
to be effective at entraining blind people suffering from non-24-h sleep-wake
disorder (Sack et al. 1999a; Sack et al. 1999b; Sack et al. 2000; Sack et al. 1990),
and entrainment has been reported at low dosages that do not exceed typical
physiological levels, with most participants entraining with 0.3 mg or less (Lewy
et al. 2005c). In addition to melatonin, tasimelteon (VEC-162), a compound with
high afﬁnity for the MT1 and MT2 receptors, has been able to entrain free-running
blind people and improve sleep when 20 mg is taken once per day 1 h before target
bedtime (Lockley et al. 2015) (Fig. 1). Continued use is required to maintain
improvements. Tasimelteon is the ﬁrst circadian drug to be approved by the Food
and Drug Administration (FDA) in the USA and the European Medicines Agency
(EMA) (Lockley et al. 2015).
Table 1 (continued)
Compound
Primary
mechanism Indication Dose for indication
Regulatory approval
FDA EMA TGA
Agomelatine Melatonin
analogue
Major depressive disorder
(moderate to severe)
25–50 mg per day (Olié
and Kasper 2007)
No Yesa Yes
Selective
agonist at
MT1 and MT2
receptors
Antagonist at
the
serotonergic
receptor
subtypes
5-HT2B and
5-HT2C
FDA US Food and Drug Administration, EMA European Medicines Agency, TGA Therapeutic
Goods Administration (Australia)
aEMA warns against use in ages over 75 because of risk of liver toxicity
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6.3 Transient Insomnia Induced by Shifted Sleep-Wake Cycle
The sleep-promoting effects of melatonin (Lavie 1997; Sack et al. 1997) suggest that
the hormone could be used to enhance sleep scheduled out of phase with endogenous
melatonin production, a treatment potentially useful for shift workers, individuals
suffering from jet lag and patients with advanced or delayed sleep-wake phase
disorder (Wyatt et al. 2006). In the study by Wyatt et al. (2006), both physiologic
(0.3 mg) and pharmacologic (5.0 mg) doses of exogenous melatonin improved sleep
efﬁciency when the sleep opportunity occurred out of phase with endogenous
melatonin production. However, the beneﬁt of exogenous melatonin was not seen
if endogenous melatonin was present, making melatonin an unsuitable treatment for
promoting sleep in a person’s biological night (Wyatt et al. 2006).
The melatonin agonist tasimelteon may be beneﬁcial for sufferers of transient
insomnia brought about by an abrupt shift in the sleep-wake cycle, such as is
experienced with jet lag and shift work. Transient insomnia is experienced as
impaired sleep initiation, sleep maintenance or both. Rajaratnam et al. (2009b) tested
tasimelteon for treatment of insomnia associated with shifted sleep and wake time in
healthy individuals (Fig. 2). Following an abrupt advance in sleep time, doses of
10, 20, 50 and 100 mg tasimelteon improved sleep initiation and maintenance and
shifted endogenous circadian rhythms. A 50 mg dose of tasimelteon taken 30 min
before bedtime was consistently efﬁcacious in improving polysomnographic and
self-reported sleep initiation and maintenance outcome variables, while maximal
circadian phase shift was found with a 100 mg dose.
Other melatonin agonists have also shown potential as treatments for insomnia.
Randomised controlled trials show ramelteon, an agonist approved by the FDA, to
be a well-tolerated treatment option for insomnia (Borja and Daniel 2006). In a study
Fig. 1 The pattern of subjective night-time and daytime sleep and acrophases from serial 48-h
measurements of urinary 6-sulphatoxymelatonin (aMT6s) for four totally blind patients. Measures
of aMT6s acrophase are indicated by red stars. Sequential study days during the screening phase
and randomisation phase (starting day 0) are shown on the y-axis, and clock time is double-plotted
on the x-axis. The length of each sleep episode is indicated by black lines, and measures of aMT6s
acrophase are indicated by red stars. Tasimelteon was able to produce 24-h entrainment (left), while
placebo was not (right) (Modiﬁed from Lockley et al. 2015, Lancet)
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Fig. 2 Sleep-promoting and circadian rhythm phase-shifting effects of tasimelteon. Sleep efﬁ-
ciency data (mean values at hourly intervals) are presented as colour-contour plots, with 0% sleep
efﬁciency shown in dark blue and 100% in red, for inpatient day baseline, treatment days 1, 2 and
3. The baseline sleep episode was from 2300 to 0700 h; sleep episodes during treatment days were
from 1800 to 0200 h. TD treatment day. Tasimelteon at all doses resulted in greater sleep efﬁciency
when the circadian clock promoted wakefulness (Modiﬁed from Rajaratnam et al. 2009, Lancet)
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of older adults, nightly doses of 4 mg or 8 mg of ramelteon over a period of 5 weeks
reduced patient reports of sleep-onset latency (Roth et al. 2006). Another treatment
option for those suffering from sleep problems associated with a shift in sleep time is
the agonist beta-methyl-6-chloromelatonin (LY156735). Healthy participants have
been shown to adapt to a simulated time shift after taking 5 mg of the compound
(Nickelsen et al. 2002). Meanwhile, 20, 50 and 100 mg of LY156735 were found to
decrease subjective and objective measures of sleep latency in participants with
primary insomnia (Zemlan et al. 2005), and 2 mg of the prolonged-released melato-
nin application Circadin® taken 1–2 h before bed has been found to reduce sleep
latency and improve sleep quality and morning alertness in insomnia patients aged
over 55 years (Lemoine et al. 2007b).
6.4 Delayed Sleep-Wake Phase Disorder
Meta-analyses have concluded that melatonin is an effective treatment for delayed
sleep-wake phase disorder (DSWPD), with melatonin advancing sleep-wake timing
and endogenous melatonin in patients with DSWPD (Buscemi et al. 2005; van
Geijlswijk et al. 2010). DSWPD is characterised by the inability to fall asleep and
to wake at conventional times (American Psychiatric Association 2013), with sleep
onset usually after midnight and wake after midday (Rahman et al. 2010). Individuals
at risk of DSWPD are more likely to report absenteeism and disruption to school,
work, social and family life (Rajaratnam et al. 2015). Reported biomarkers of
DSWPD include delayed plasma melatonin concentration and core body temperature
(Oren et al. 1995). The meta-analysis conducted by van Geijlswijk et al. (2010)
examined ﬁve studies in adults and four in children. The adult trials showedmelatonin
advanced mean endogenous melatonin onset by 1.18 h and clock hour of sleep onset
by 0.67 h. Sleep-onset latency was decreased by 23.27 min. The dose administered to
adults and children was generally 5 mg per day; one study by Mundey et al. (2005)
compared 0.3 mgwith 3mg and found both doses effective at advancing the circadian
phase of endogenous melatonin. Based on their meta-analysis, van Geijlswijk et al.
(2010) suggest melatonin treatments for DSWPD be administered 3–6 h before
DLMO using small doses to avoid high melatonin levels during late night or early
morning. While early administration is recommended, the optimum timing of admin-
istration is yet to be determined.
6.5 Seasonal Affective Disorder (SAD)
Patients with SAD tend to have delayed endogenous rhythms, including DLMO
and temperature rhythm (Avery et al. 1997; Dahl et al. 1993), and moving from an
ideal circadian phase is related to symptom severity in patients with SAD (Lewy
et al. 2005a). In such cases, melatonin-induced phase shift may help. Patients with
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SAD may beneﬁt from treatment that involves DLMO testing and melatonin
administration to cause an optimal phase angle. In SAD patients, between 0.075
and 0.1 mg of melatonin was given every 2 h from either the early morning or
afternoon, with no more than 0.3 mg per day. Optimal mood was found when
plasma DLMO (deﬁned as time after plasma melatonin levels continuously exceed
10 pg/ml threshold) and mid-sleep were 6 h apart (Lewy et al. 2005b). The ideal
timing between DLMO and sleep is associated with optimal mood, before and
after treatment with melatonin (Lewy et al. 2006). Importantly, timing of the
melatonin dosage is crucial for SAD patients and depends on whether the patient
is phase-delayed or phase-advanced. For example, morning melatonin (which
induces a phase delay) can make a prototypical phase-delayed SAD patient more
depressed, and afternoon/evening melatonin can worsen the mood of an atypical
phase-advanced SAD patient (Lewy et al. 2005b).
6.6 Major Depressive Disorder
Although melatonin may assist SAD patients, it does not effectively treat other
types of depression (Carman et al. 1976; Dalton et al. 2000), except perhaps in
combination with existing antidepressant treatments (Hickie and Rogers 2011).
However, the melatonin agonist agomelatine (S20098), which also binds to
the serotonergic receptor subtypes 5-HT2B and 5-HT2C (Arendt and Rajaratnam
2008), does offer potential as an antidepressant drug (Hickie and Rogers 2011).
Agomelatine has chronobiotic, antidepressant and anxiolytic effects and, in the
short term, has been found to be as effective as antidepressant drugs venlafaxine,
ﬂuoxetine and sertraline, with the added beneﬁt of improved subjective sleep
(Hickie and Rogers 2011). Depressed patients taking the compound have reported
improved sleep quality and reduced waking after sleep onset (Lemoine et al.
2007a). Objective measures also show sleep improvements in these individuals.
Following doses of 25/50 mg per day of agomelatine, improvements in sleep
efﬁciency, slow-wave sleep and the distribution of delta activity throughout the
night following have been measured using polysomnography (Quera-Salva et al.
2010). A randomised trial of agomelatine (25–50 mg) in patients with moderate to
severe major depressive disorder reported signiﬁcant improvement in depression
severity using the Hamilton Rating Scale for Depression compared to controls
(Olié and Kasper 2007). In addition to the sleep improvement beneﬁts, because the
compound does not increase serotonin levels, there appear to be fewer side effects
than traditional depression treatments (Hickie and Rogers 2011). However, the
EMA does warn that further measures should be put in place to minimise the risk
of liver toxicity and warns against its use in people aged over 75 (European
Medicines Agency 2014).
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7 Administration, Dosage and Safety Profile
The most common form of melatonin administration is oral tablets and capsules,
although intravenous solutions, intranasal sprays, transbuccal patches and transder-
mal creams have also been used (Rajaratnam et al. 2009a).
The doses administered in melatonin studies have varied. Deacon and Arendt
(1995) found a signiﬁcant dose response when comparing 0.05, 0.5 and 5 mg, and
Sharkey and Eastman (2002) found a dose-dependent phase shift when comparing
0.5 and 3 mg. However, generally researchers conclude there is no dose-response
effect (Mundey et al. 2005; Wyatt et al. 2006). In some cases, smaller phase shifts
seen from higher doses of melatonin have been explained by high doses spilling over
into the wrong zone of the melatonin phase response curve (Lewy et al. 2006).
Doses required for effective treatment with melatonin agonists are comparatively
higher than the natural compound (Arendt and Rajaratnam 2008). Improvements in
depressive severity have been found with doses of 25–50 mg of agomelatine (Olié
and Kasper 2007), and ramelteon improves insomnia at daily doses of 4–8 mg (Roth
et al. 2006). Transient insomnia can be alleviated with doses of between 10 and
100 mg tasimelteon (Rajaratnam et al. 2009b), and 20 mg daily has been effective at
entraining free-running blind people (Lockley et al. 2015).
Melatonin and melatonin agonists have been found to be safe during occasional,
short-term use (Rajaratnam et al. 2009b). However, caution should still be taken,
particularly as the regulation of these products varies across the USA, Europe and
Australia. Potential side effects of melatonin and melatonin agonists include
increased sleepiness and impaired neurobehavioural performance (Cajochen et al.
1997; Deacon and Arendt 1995; Graw et al. 2001) emphasising that the timing of
administration is important to consider. Agonists appear to offer a good safety proﬁle
(Arendt and Rajaratnam 2008). However, currently there is insufﬁcient data to show
if agonists are preferable to the natural compound (Arendt and Rajaratnam 2008).
The effects of long-term use are also unknown.
8 Conclusion
The phase-shifting and sleep-promoting effects of melatonin plus additional effects
of melatonin agonists on melatonin and serotonin receptors have shown promise for
novel treatments for a variety of circadian, sleep and mood disorders. Importantly,
the main advantage melatonin and its agonists offer over traditional sleep and
depression treatments is that they assist to restore circadian function which is often
misaligned in these disorders (Rajaratnam et al. 2009b) and which is increasingly
thought to be a causal mechanism and part of the aetiology of sleep and mood
disorders. Treatments that fail to address the misaligned circadian system present in
sleep and mood disorders may not fully address the underlying causes, and for this
reason, further investigation on the potential for melatonin-based treatments should
be undertaken.
Advances of Melatonin-Based Therapies in the Treatment of Disturbed Sleep. . . 315
References
American Psychiatric Association (2013) DSM 5. American Psychiatric Association, Washington,
DC
Arendt J, Rajaratnam SMW (2008) Melatonin and its agonists: an update. Br J Psychiatry 193
(4):267–269. https://doi.org/10.1192/bjp.bp.108.050955
Avery DH, Wildschiødtz G, Rafaelsen OJ (1982) Nocturnal temperature in affective disorder.
J Affect Disord 4(1):61–71
Avery D, Dahl K, Savage M, Brengelmann G, Larsen L, Kenny M, Eder DN, Vitiello MV, Prinz P
(1997) Circadian temperature and cortisol rhythms during a constant routine are phase-delayed
in hypersomnic winter depression. Biol Psychiatry 41:1109–1123. https://doi.org/10.1016/
S0006-3223(96)00210-7
Borja NL, Daniel KL (2006) Ramelteon for the treatment of insomnia. Clin Ther 28:1540–1555.
https://doi.org/10.1016/j.clinthera.2006.10.016
Buckley TM, Schatzberg AF (2010) A pilot study of the phase angle between cortisol and melatonin
in major depression – a potential biomarker? J Psychiatr Res 44(2):69–74. https://doi.org/10.
1016/j.jpsychires.2009.06.012
Burgess HJ, Revell VL, Eastman CI (2008) A three pulse phase response curve to three milligrams
of melatonin in humans. J Physiol 586(2):639–647. https://doi.org/10.1113/jphysiol.2007.
143180
Burgess HJ, Revell VL, Eastman CI (2010) Human phase response curves to three days of daily
melatonin: 0.5 mg versus 3.0 mg. J Clin Endocrinol Metab 95(7):3325–3331. https://doi.org/10.
1210/jc.2009-2590
Buscemi N, Vandermeer B, Hooton N, Pandya R, Tjosvold L, Hartling L, Baker G, Klassen TP,
Vohra S (2005) The efﬁcacy and safety of exogenous melatonin for primary sleep disorders: a
meta-analysis. J Gen Intern Med 20(12):1151–1158. https://doi.org/10.1111/j.1525-1497.2005.
0243.x
Cajochen C, Kräuchi K, Wirz-Justice A (1997) The acute soporiﬁc action of daytime melatonin
administration: effects on the EEG during wakefulness and subjective alertness. J Biol Rhythms
12:636–643. https://doi.org/10.1177/074873049701200619
Carman JS, Post RM, Buswell R, Goodwin FK (1976) Negative effects of melatonin on depression.
Am J Psychiatry 133:1181–1186
Colwell CS (2011) Linking neural activity and molecular oscillations in the SCN. Nat Rev Neurosci
12(10):553–569. https://doi.org/10.1038/nrn3086
Dahl K, Avery DH, Lewy AJ, Savage M, Brengelmann G, Larsen L, Vitiello MV, Prinz P (1993)
Dim light melatonin onset and circadian temperature during a constant routine in hypersomnic
winter depression. Acta Psychitar Scand 88:60–66
Dahlitz MJ, Alvarez B, Vignau J, English J, Arendt J, Parkes JD (1991) Delayed sleep-phase
syndrome: response to melatonin. Lancet 337:1121–1124
Dalton EJ, Rotondi D, Levitan RD, Kennedy SH, Brown GM (2000) Use of slow-release melatonin
in treatment-resistant depression. J Psychiatry Neurosci 25:48–52
Deacon S, Arendt J (1995) Melatonin-induced temperature suppression and its acute phase-shifting
effects correlate in a dose-dependent manner in humans. Brain Res 688:77–85
Dijk DJ, Cajochen C (1997) Melatonin and the circadian regulation of sleep initiation, consolida-
tion, structure, and the sleep EEG. J Biol Rhythms 12(6):627–635
Dubocovich ML (2007) Melatonin receptors: role on sleep and circadian rhythm regulation. Sleep
Med 8(3):34–42. https://doi.org/10.1016/j.sleep.2007.10.007
Emens J, Lewy AJ, Mark J, Arntz D, Rough J (2009) Circadian misalignment in major depressive
disorder. Psychiatry Res 168:259–261. https://doi.org/10.1016/j.psychres.2009.04.009
European Medicines Agency (2014) EMA conﬁrms positive beneﬁt-risk for antidepressant
Valdoxan/Thymanax (agomelatine) [Press release]. http://www.ema.europa.eu/ema/index.jsp?
curl¼pages/news_and_events/news/2014/09/news_detail_002173.jsp&
mid¼WC0b01ac058004d5c1
316 M. Alston et al.
van Geijlswijk IM, Korzilius HPLM, Smits MG (2010) The use of exogenous melatonin in delayed
sleep phase disorder: a meta-analysis. Sleep 33(12):1605–1614
Graw P, Werth E, Krauchi K, Gutzwiller F, Cajochen C, Wirz-Justice A (2001) Early morning
melatonin administration impairs psychomotor vigilance. Behav Brain Res 121(1–2):167–172
Hickie IB, Rogers NL (2011) Novel melatonin-based therapies: potential advances in the treatment
of major depression. Lancet 378:621–631. https://doi.org/10.1016/S0140-6736(11)60095-0
Hughes RJ, Badia P (1997) Melatonin and sleep: sleep-promoting and hypothermic effects of
daytime melatonin administration in humans. Sleep 20(2):124–131
Hunt AE, Al-Ghoul WM, Gillette MU, Dubocovich ML (2001) Activation of MT(2) melatonin
receptors in rat suprachiasmatic nucleus phase advances the circadian clock. Am J Physiol Cell
Physiol 280(1):C110–C118. https://doi.org/10.1152/ajpcell.2001.280.1.C110
Khalsa SB, Jewett ME, Cajochen C, Czeisler CA (2003) A phase response curve to single bright
light pulses in human subjects. J Physiol (Lond) 549(Pt 3):945–952
Klein DC, Moore RY (1979) Pineal N-acetyltransferase and hydroxyindole-O-methyltransferase:
control by the retinohypothalamic tract and the suprachiasmatic nucleus. Brain Res 174:245–262
Krauchi K, Cajochen C, Pache M, Flammer J, Wirz-Justice A (2006) Thermoregulatory effects of
melatonin in relation to sleepiness. Chronobiol Int 23(1–2):475–484. https://doi.org/10.1080/
07420520500545854
Lavie P (1986) Ultrashort sleep-waking schedule. III. ‘Gates’ and ‘forbidden zones’ for sleep.
Electroencephalogr Clin Neurophysiol 63(5):414–425
Lavie P (1997) Melatonin: role in gating nocturnal rise in sleep propensity. J Biol Rhythms
12:657–665
Lemoine P, Guilleminault C, Alvarez E (2007a) Improvement in subjective sleep in major depres-
sive disorder with a novel antidepressant, agomelatine: randomized, double-blind comparison
with venlafaxine. J Clin Psychiatry 68:1723–1732
Lemoine P, Nir T, Laudon M, Zisapel N (2007b) Prolonged-release melatonin improves sleep
quality and morning alertness in insomnia patients aged 55 years and older and has no
withdrawal effects. J Sleep Res 16:372–380
Lerner AB, Case JD, Takahashi Y, Lee TH, Mori W (1958) Isolation of melatonin, the pineal gland
factor that lightens melanocytes. J Am Chem Soc 80(10):2587
Lewy A (2010) Clinical implications of the melatonin phase response curve. J Clin Endocrinol
Metab 95(7):3158–3160. https://doi.org/10.1210/jc.2010-1031
Lewy AJ, Sack RL, Singer CM (1985) Immediate and delayed effects of bright light on human
melatonin production: shifting “dawn” and “dusk” shifts the dim light melatonin onset (DLMO).
Ann N Y Acad Sci 453:253–259
Lewy A, Leﬂer BJ, Emens J, Bauer VK (2005a) The circadian basis of winter depression. Proc Natl
Acad Sci 103(19):7414–7419. https://doi.org/10.1073/pnas.0602425103
Lewy AJ, Emens JS, Leﬂer BJ, Bauer VK (2005b) In winter depression (SAD), the sweet spot
for the 10pg/mL plasma dim light melatonin onset (DLMO) is six hours before mid-sleep.
Neuropsychopharmacology 30:562–563
Lewy AJ, Emens JS, Leﬂer BJ, Yuhas K, Jackman AR (2005c) Melatonin entrains free-running
blind people according to a physiological dose-response curve. Chronobiol Int 22:1093–1106.
https://doi.org/10.1080/07420520500398064
Lewy AJ, Emens J, Jackman A, Yuhas K (2006) Circadian uses of melatonin in humans.
Chronobiol Int 23(1–2):403–412. https://doi.org/10.1080/07420520500545862
Li SX, Liu LJ, Xu LZ, Gao L, Wang XF, Zhang JT, Lu L (2013) Diurnal alterations in circadian
genes and peptides in major depressive disorder before and after escitalopram treatment.
Psychoneuroendocrinology 38:2789–2799. https://doi.org/10.1016/j.psyneuen.2013.07.009
Liu C, Weaver DR, Jin X, Shearman LP, Pieschl RL, Gribkoff VK, Reppert SM (1997) Molecular
dissection of two distinct actions of melatonin on the suprachiasmatic circadian clock. Neuron
19(1):91–102
Advances of Melatonin-Based Therapies in the Treatment of Disturbed Sleep. . . 317
Liu C, Clough SJ, Hutchinson AJ, Adamah-Biassi EB, Popovska-Gorevski M, Dubocovich ML
(2016) MT1 and MT2 melatonin receptors: a therapeutic perspective. Annu Rev Phamacol
Toxicol 56:361–383. https://doi.org/10.1146/annurev-pharmtox-010814-124742
Lockley SW, Dressman MA, Licamele L, Xiao C, Fisher DM, Flynn-Evans EE, Hull JT, Torres R,
Polymeropoulos MH (2015) Tasimelteon for non-24-hour sleep–wake disorder in totally blind
people (SET and RESET): two multicentre, randomised, double-masked, placebo-controlled
phase 3 trials. Lancet 386(10005):1754–1764. https://doi.org/10.1016/s0140-6736(15)60031-9
Lynch H, Wurtman R, Moskowitz M, Archer M, Ho M (1975) Daily rhythm in human urinary
melatonin. Science 187:169–171
Mundey K, Benloucif S, Harsanyi K, Dubocovich ML, Zee P (2005) Phase-dependent treatment of
delayed sleep phase syndrome with melatonin. Sleep 28(10):1271–1278
Murray JM, Sletten T, Magee M, Gordon C, Lovato N, Bartlett DJ, Kennaway D, Lack LC,
Grunstein RR, Lockley SW, Rajaratnam SM, Delayed Sleep on Melatonin (DelSoM) Study
Group (2017) Prevalence of circadian misalignment and its association with depressive
symptoms in delayed sleep phase disorder. Sleep 40(1). https://doi.org/10.1093/sleep/zsw002
Naismith SL, Hermens DF, Ip TK, Bolitho S, Scott E, Rogers NL, Hickie IB (2012) Circadian
proﬁles in young people during the early stages of affective disorder. Transl Psychiatry 2:e123.
https://doi.org/10.1038/tp.2012.47
Nickelsen T, Samel A, Vejvoda M, Wenzel J, Smith B, Gerzer R (2002) Chronobiotic effects of the
melatonin agonist LY 156735 following a simulated 9h time shift: results of a placebo-
controlled trial. Chronobiol Int 19(5):915–936
Olié JP, Kasper S (2007) Efﬁcacy of agomelatine, a MT1/MT2 receptor agonist with 5-HT2C antago-
nistic properties, in major depressive disorder. Int J Neuropsychopharmacol 10(5):661–673. https://
doi.org/10.1017/S1461145707007766
Oren DA, Turner EH, Wehr TA (1995) Abnormal circadian rhythm of plasma melatonin and body
temperature in the delayed sleep phase syndrome. J Neurol Neurosurg Psychiatry 58:379
Perreau-Lenz S, Kalsbeek A, Garidou ML, Wortel J, van der Vliet J, van Heijningen C,
Simonneaux V, Pévet P, Buijs RM (2003) Suprachiasmatic control of melatonin synthesis in
rats: inhibitory and stimulatory mechanisms. Eur J Neurosci 17(2):221–228
Perreau-Lenz S, Kalsbeek A, Pevet P, Buijs RM (2004) Glutamatergic clock output stimulates
melatonin synthesis at night. Eur J Nuerosci 19:318–324
Quera-Salva MA, Lemoine P, Guilleminault C (2010) Impact of the novel antidepressant
agomelatine on disturbed sleep-wake cycles in depressed patients. Hum Psychopharmacol 25
(3):222–229. https://doi.org/10.1002/hup.1112
Rahman SA, Kayumov L, Shapiro CM (2010) Antidepressant action of melatonin in the treatment
of delayed sleep phase syndrome. Sleep Med 11(2):131–136. https://doi.org/10.1016/j.sleep.
2009.07.013
Rajaratnam SMW, Arendt J (2001) Health in the 24-hour society. Lancet 358:999–1005. https://doi.
org/10.1016/S0140-6736(01)06108-6
Rajaratnam SMW, Dijk DJ, Middleton B, Stone BM, Arendt J (2003) Melatonin phase-shifts human
circadian rhythmswith no evidence of changes in the duration of endogenousmelatonin secretion
or the 24-h production of reproductive hormones. J Clin Endocrinol Metab 88:4303–4309.
https://doi.org/10.1210/jc.2003-030460
Rajaratnam SMW, Middleton B, Stone BM, Arendt J, Dijk DJ (2004) Melatonin advances the
circadian timing of EEG sleep and directly facilitates sleep without altering its duration in
extended sleep opportunities in humans. J Physiol 561(Pt 1):339–351. https://doi.org/10.1113/
jphysiol.2004.073742
Rajaratnam SMW, Cohen DA, Rogers NL (2009a) Melatonin and melatonin analogues. Sleep Med
Clin 4:179–193. https://doi.org/10.1016/j.jsmc.2009.02.007
Rajaratnam SMW, Polymeropoulos MH, Fisher DM, Roth T, Scott C, Birznieks G, Klerman EB
(2009b) Melatonin agonist tasimelteon (VEC-162) for transient insomnia after sleep-time shift:
two randomised controlled multicentre trials. Lancet 373(9662):482–491. https://doi.org/10.
1016/s0140-6736(08)61812-7
318 M. Alston et al.
Rajaratnam SMW, Licamele L, Birznieks G (2015) Delayed sleep phase disorder risk is associated
with absenteeism and impaired functioning. Sleep Health 1(2):121–127. https://doi.org/10.
1016/j.sleh.2015.03.001
Redman JR (1997) Circadian entrainment and phase shifting in mammals with melatonin. J Biol
Rhythms 12(6):581–587
Reppert SM, Perlow MJ, Ungerleider LG et al (1981) Effects of damage to the suprachiasmatic area
of the anterior hypothalamus on the daily melatonin and cortisol rhythms in the rhesus monkey.
J Neurosci 1:1414–1425
Reppert SM, Weaver DR, Godson C (1996) Melatonin receptors step into the light: cloning and
classiﬁcation of subtypes. Trends Pharmacol Sci 17(3):100–102
Roth T, Seiden D, Sainati S, Wang-Weigand S, Zhang J, Zee P (2006) Effects of ramelteon on
patient-reported sleep latency in older adults with chronic insomnia. Sleep Med 7(4):312–318.
https://doi.org/10.1016/j.sleep.2006.01.003
Sack RL, Stevenson J, Lewy AJ (1990) Entrainment of a previously free-running blind human with
melatonin administration. Sleep Res 19:404
Sack RL, Hughes RJ, Edgar DM, Lewy AJ (1997) Sleep-promoting effects of melatonin: at what
dose, in whom, under what conditions, and by what mechanisms? Sleep 20(10):908–915
Sack RL, Brandes RL, DeJongh EA, Pen S, Nordstrom S, Lewy AJ (1999a) Melatonin entrains
free-running circadian rhythms in a totally blind person. Sleep 22:S138
Sack RL, Brandes RL, Lewy AJ (1999b) Totally blind people with free-running circadian rhythms
can be normally entrained with melatonin. Sleep Res Online 2:624
Sack RL, Brandes RW, Kendall AR, Lewy AJ (2000) Entrainment of freerunning circadian
rhythms by melatonin in blind people. N Engl J Med 343:1070–1077. https://doi.org/10.1056/
NEJM200010123431503
Sharkey KM, Eastman CI (2002) Melatonin phase shifts human circadian rhythms in a placebo-
controlled simulated night-work study. Am J Physiol Regul Integr Comp Physiol 282(2):R454–
R463. https://doi.org/10.1152/ajpregu.00135.2001
Shekleton JA, Rajaratnam SMW, Gooley JJ, Van Reen E, Czeisler CA, Lockley SW (2013)
Improved neurobehavioral performance during the wake maintenance zone. J Clin Sleep Med
9(4):353–362. https://doi.org/10.5664/jcsm.2588
Shibata S, Cassone VM, Moore RY (1989) Effects of melatonin on neuronal activity in the rat
suprachiasmatic nucleus in vitro. Neurosci Lett 97(1–2):140–144
Souêtre E, Salvati E, Belugou JL, Pringuey D, Candito M, Krebs B, Ardisson JL, Darcourt G (1989)
Circadian rhythms in depression and recovery: evidence for blunted amplitude as the main
chronobiological abnormality. Psychiatry Res 28:263–278
Stehle J, Vanecek J, Vollrath L (1989) Effects of melatonin on spontaneous electrical activity of
neurons in rat suprachiasmatic nuclei: an in vitro iontophoretic study. J Neural Transm 78
(2):173–177
Strogatz SH, Kronauer RE, Czeisler CA (1987) Circadian pacemaker interferes with sleep onset at
speciﬁc times each day: role in insomnia. Am J Physiol 253(1):R172–R178
Szuba MP, Guze BH, Baxter LRJ (1997) Electroconvulsive therapy increases circadian amplitude
and lowers core body temperature in depressed subjects. Biol Psychiatry 42(12):1130–1137
Vandewalle G, Middleton B, Rajaratnam SMW, Stone BM, Thorleifsdottir B, Arendt J, Dijk DJ
(2007) Robust circadian rhythm in heart rate and its variability: inﬂuence of exogenous
melatonin and photoperiod. J Sleep Res 16(2):148–155. https://doi.org/10.1111/j.1365-2869.
2007.00581.x
Wyatt JK, Dijk D, Ritz-De Cecco A, Ronda JM, Czeisler C (2006) Sleep-facilitating effect of
exogenous melatonin in healthy young men and women is circadian-phase dependent. Sleep 29
(5):609–618
Zemlan FP, Mulchahey JJ, Scharf MB, Mayleben DW, Rosenberg R, Lankford A (2005) The
efﬁcacy and safety of the melatonin agonist beta-methyl-6-chloromelatonin in primary insom-
nia: a randomized, placebo-controlled, crossover clinical trial. J Clin Psychiatry 66(3):384–390
Advances of Melatonin-Based Therapies in the Treatment of Disturbed Sleep. . . 319
Dopamine and Wakefulness:
Pharmacology, Genetics, and Circuitry
Jonathan P. Wisor
Contents
1 Genetic Insights into Dopaminergic Regulation of Sleep and Wakefulness . . . . . . . . . . . . . . . 323
2 Experimental Insights into Dopaminergic Regulation of Sleep and Wakefulness . . . . . . . . . 324
3 Through What Circuitry Do Ventral Tegmental Area Cells Promote Arousal? . . . . . . . . . . . 328
4 Synthesis: Dopaminergic/Adenosinergic Interactions in the Striatum Mediate Effects of
Sleep Deprivation on Prefrontal Cortex-Dependent Performance . . . . . . . . . . . . . . . . . . . . . . . . . . 330
References . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 332
Abstract
Over the period of decades in the mid to late twentieth century, arousal-promoting
functions were attributed to neuromodulators including serotonin, hypocretin,
histamine, and noradrenaline. For some time, a relatively minor role in regulating
sleep and wake states was ascribed to dopamine and the dopamine-producing
cells of the ventral tegmental area, despite the fact that dopaminergic signaling is
a major target, if not the primary target, for wake-promoting agents. In recent
years, due to observations from human genetic studies, pharmacogenetic studies
in animal models, and the increasingly sophisticated methods used to manipulate
the nervous systems of experimental animals, it has become clear that dopami-
nergic signaling is central to the regulation of arousal. This chapter reviews this
central role of dopaminergic signaling, and in particular its antagonistic interac-
tion with adenosinergic signaling, in maintaining vigilance and in the response to
wake-promoting therapeutics.
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Dopamine and Wakefulness: Key Concepts
• Genetic variation in dopaminergic signaling pathways inﬂuences the nega-
tive impacts of sleep loss and the response to wake-promoting therapeutics
used to mitigate those negative impacts.
• Dopaminergic signaling from the ventral tegmental area varies across
vigilance states and regulates sleep/wake state timing.
• Dopamine/adenosine interactions in the striatum are positioned as a key
mediator of the impacts of sleep loss on cortical arousal state.
The regulation of sleep and wakefulness is a function of the interactions of widely
projecting sleep-promoting and wake-promoting systems. The serotonergic cells of
the raphe nuclei, noradrenergic cells of the locus coeruleus (LC), hypocretinergic
cells of the lateral hypothalamus/perifornical area (LH/PFA), and histaminergic cells
of the tuberomammillary nucleus (TMN) are among the most well-recognized wake-
promoting neuromodulatory systems (reviewed in McGinty and Szymusiak 2011).
The activity of raphe, LC, LH/PFA, and TMN cells is greatest in wakefulness, and
drops precipitously at sleep onset, as do extracellular levels of the neuromodulators
they produce in the central nervous system. Pharmacological perturbations or
lesioning of these systems results in disruption of sustained wakefulness. Thus, the
concerted activity of these systems is regarded as a critical mediator of sustained
wakefulness and the performance of waking activities.
Dopaminergic signaling did not play a central role in the model of wake-
promoting systems that emerged in the late twentieth century, and not without
reason. The activity of cells in dopaminergic nuclei (substantia nigra, SN and ventral
tegmental area, VTA) was not found to be consistently state-dependent across
studies (Miller et al. 1983; Steinfels et al. 1983; Trulson and Preussler 1984).
Extracellular dopamine concentration in the CNS was also not found to vary as a
function of state across studies (de Saint Hilaire et al. 2000; Shouse et al. 2000;
Trulson and Preussler 1984). Lesioning of dopaminergic cell body-containing
regions did not alter sleep timing (Jones et al. 1973). Yet it has become clear over
the last couple of decades that dopaminergic regulation of cortical arousal was a
missing component in this conceptual model. Relatively recent work demonstrates
that (1) genetic variation in dopaminergic signaling pathways inﬂuences the negative
impacts of sleep loss and the response to wake-promoting therapeutics used to
mitigate those negative impacts; (2) dopaminergic signaling from the VTA varies
across vigilance states and regulates sleep/wake state timing; and (3) dopamine/
adenosine interactions in the striatum are positioned as a key regulator of cortical
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arousal state and arousal-dependent functions. This chapter reviews these three
concepts with the intention of giving the reader insights into how they might be
applied to improve functioning in an increasingly sleep-deprived world.
1 Genetic Insights into Dopaminergic Regulation of Sleep
and Wakefulness
Polymorphisms in loci involved in dopamine metabolism or dopaminergic signaling
have been associated with sleep/wake timing, or vigilance-related phenotypes
(reviewed in Dauvilliers et al. 2015; Holst et al. 2016). Catechol-O-methyltransferase
(COMT) eliminates dopamine by converting it to 3-methoxytyramine. A single-
nucleotide polymorphism in COMT results in a valine for methionine substitution
that increases dopamine metabolism by roughly four-fold (Lachman et al. 1996). This
polymorphism associates with (1) time-on-task effects in the psychomotor vigilance
task, a measure of fatigue during sustained wakefulness (Lim et al. 2012), (2) the
severity of EEG changes indicative of increased sleep drive during partial sleep
restriction (4 h time in bed per night) (Goel et al. 2011), and (3) the therapeutic
efﬁcacy of the widely prescribed wake-promoting therapeutic, modaﬁnil during
conditions of sleep deprivation (SD) (Bodenmann et al. 2008).
The D2 dopamine receptor (DRD2) is located both on dopaminergic terminals
as an autoreceptor and on postsynaptic cells as a neuromodulatory receptor. This G
protein-coupled receptor reduces neuronal excitability by reducing cyclic AMP
concentration and suppressing voltage-gated Ca2+ currents (Sanders-Bush and
Hazelwood 2011). A non-coding polymorphism (C957T; one that changes the
codon, but not the resulting amino acid sequence in the protein) in the DRD2 gene
was found to associate with (1) deﬁcits in reversal learning in association with 62-h
total SD (Van Dongen et al. 2017; a measure of cognitive ﬂexibility) and (2) the
severity of PVT lapses emerging with SD (Holst et al. 2017). Another non-coding
(in this case, intronic) polymorphism was found to associate with self-reported
habitual sleep duration (Cade et al. 2016). It is difﬁcult to interpret the signiﬁcance
of these associations, as the functional consequences of the noncoding DRD2
polymorphisms are unknown. It is possible that theDRD2 locus is in close proximity
to the relevant functional polymorphism. One of the three above-mentioned studies
linking DRD2 to a sleep phenotype (Holst et al. 2017) also found an interaction of
the DRD2 polymorphism with a polymorphism in gene encoding the cell membrane
dopamine transporter (DAT) in affecting the severity of PVT lapses during SD. The
DAT transports dopamine from the extracellular milieu into dopaminergic terminals
for repackaging into vesicles. A variable number tandem repeat (VNTR) polymor-
phism in the 30 untranslated region of the DAT locus, of which the most common
alleles are a 9-repeat or 10-repeat, confers differential expression: individuals har-
boring the 9-repeat allele express DAT at higher levels than those harboring the
10-repeat, according to a meta-analysis of in vivo imaging data with labeled DAT
ligands (Faraone et al. 2014). Individuals homozygous for the 10-repeat allele of
DAT and the C allele of DRD2 were more severely affected with PVT lapses after
40 h of SD than other genotypic variants (Holst et al. 2017). TheDAT polymorphism
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has further been associated with (1) variability in time on task effects in the
psychomotor vigilance task (Lim et al. 2012), (2) the severity of EEG changes
indicative of increased sleep drive during SD (Holst et al. 2014), and (3) the effects
of modaﬁnil on EEG markers of sleep need (Holst et al. 2014).
Also of note from the perspective of sleep regulatory mechanism is the fact
that the DAT VNTR polymorphism predicts the effects of the most widely used
(non-prescription) wake-promoting agent, caffeine (Holst et al. 2014) on EEG
markers of sleep need. Caffeine is dependent on the adenosine 2a receptor
(ADORA2a), where it acts as an inverse agonist [Fernandez-Duenas et al. 2014
#7141] for its wake-promoting effect (Huang et al. 2005). This fact coupled with the
considerable body of evidence implicating adenosine in mediating the accumulation
of sleep need over time (reviewed in Basheer et al. 2004) suggest that adenosinergic
signaling via ADORA2a in the brain is a key mediator of sleep need. The genetic
linkage of dopamine to caffeine sensitivity points to the striatum, where dopamine
and adenosine interact antagonistically (see below), as a possible nexus for
mediating the effects of sleep loss on vigilance. In fact, polymorphisms in ADORA2a
are known to confer sleep-related phenotypes (reviewed in Landolt 2011). It is worth
mentioning this genetic linkage here, before we consider more mechanistic studies
on the dopaminergic/adenosinergic axis of sleep regulation. Much like the DAT
VNTR polymorphism, both a single nucleotide polymorphism in ADORA2a (Retey
et al. 2007) and ADORA2a haplotype (Bodenmann et al. 2012) predict sensitivity to
caffeine at EEG and behavioral levels. The single nucleotide polymorphism also
predicted resiliency to sleep restriction (seven consecutive nights of restriction to 3 h
in bed) (Rupp et al. 2013). The parallels between adenosine-associated loci and
dopamine-related loci in modulating the response to sleep loss and wake-promoting
agents do not indicate a mechanistic relationship between the two systems at
the cellular level in regulating vigilance. However, experimental and theoretical
considerations described in the remainder of this chapter make a compelling case for
this mechanistic relationship.
2 Experimental Insights into Dopaminergic Regulation
of Sleep and Wakefulness
The above summarized human genetic studies that link dopaminergic signaling, and
potentially its interactions with adenosinergic signaling, to sleep regulation have
been complemented by increasingly sophisticated studies in animal models. Collec-
tively, the two bodies of work converge on dopaminergic/adenosinergic interactions
as a mediator of manifestations of sleepiness during protracted wake. The impor-
tance of dopaminergic groups, and in particular the VTA in promoting wakefulness
was neglected for many years, because while electrolytic lesions of VTA suppressed
behavioral arousal, they did not alter the timing or quality of electroencephalograph-
ically deﬁned arousal (Jones et al. 1973). Nor did dopamine-speciﬁc neurochemical
lesion of the VTA (hypocretin-saporin; Gerashchenko et al. 2006) alter the timing
or quality of electroencephalographically deﬁned arousal. Electrophysiological
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recordings of the activity of these cells also failed to detect modulation of the
activity of presumed dopaminergic cells in either the VTA or SN across sleep
wake states (Miller et al. 1983; Steinfels et al. 1983; Trulson and Preussler 1984).
Thus, authors were led to conclude that the dopaminergic cell groups of the VTA and
SN, in contrast to their monoaminergic kindred in the raphe, TMN, LC, and the
hypocretinergic cells of the LH/PFA, do not serve a wake-promoting function within
the CNS.
However, more recent work in animal models, in addition to the genetic data cited
above, causes a rethinking of this role for dopaminergic signaling. In vivo pharma-
cological studies, including work on the mechanism of action of modaﬁnil (reviewed
in Wisor 2013), have ascertained the arousal-promoting role of dopaminergic sig-
naling. The collective observations that modaﬁnil binds to the dopamine transporter
at physiologically relevant concentrations (Loland et al. 2012; Mignot et al. 1994;
Schmitt and Reith 2011), that systemic modaﬁnil administration elevates extracellu-
lar dopamine concentration in the striatum (Murillo-Rodriguez et al. 2007; Wisor
et al. 2001; Zolkowska et al. 2009), and that genetic inactivation of the dopamine
transporter nulliﬁes its wake-promoting effect (Wisor et al. 2001) indicate that its
action as a dopamine transporter inhibitor underlies its wake-promoting effect. Other
putative actions [including modulation of gap junctional communication (Urbano
et al. 2007; Garcia-Rill et al. 2007)] may be secondary to its action at the dopamine
transporter. Any effect hypothetically mediated by a target other than DAT must be
veriﬁed by assessing this effect in DAT-deﬁcient animals.
If an agent such as modaﬁnil increases arousal by elevating extracellular dopa-
mine, then dopamine receptors are a presumed target for this mechanism. In general,
dopaminergic signaling is necessary for arousal, as pharmacological depletion of
dopamine results in intrusions of slow wave sleep (SWS)-like EEG synchronization
in awake, behaving mice (Dzirasa et al. 2006). But which receptors are involved?
Pharmacological studies support an arousal-inducing effect for DRD2-based dopa-
minergic signaling in general, and in the response to modaﬁnil in particular. Genetic
inactivation of Drd2 in nocturnal rodents, or pharmacological antagonism of DRD2
nulliﬁes the arousing effect of modaﬁnil (Qu et al. 2008). Genetic or pharmacologi-
cal inactivation of Drd2 in nocturnal rodents results in a failure to sustain wake in
contexts wherein wake normally predominates (in the hours after dark onset or
immediately after introduction to a novel environment; Qu et al. 2010). These data
offered a compelling case for the role of dopaminergic signaling via DRD2 receptors
in maintaining arousal. However, such studies based on either constitutive genetic
manipulations or systemic pharmacological manipulations failed to offer insights
into the speciﬁc circuitry underlying the arousal-promoting role of dopaminergic
signaling.
Work within the last few years using sophisticated targeting of dopaminergic and
dopaminoceptive cell populations has addressed this limitation of the prior work.
Modern experimental tools, all of which can be applied to neurochemically deﬁned
cell populations via cell type-speciﬁc genetic manipulations involving the enzyme
Cre recombinase, were critical to this achievement: (1) in vivo imaging of the
activation of neuronal populations across sleep and wake states; (2) in vivo
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optogenetic electrical activation of neurons with millisecond precision; and
(3) in vivo chemogenetic potentiation/inhibition of neurons over periods of minutes
to hours, coinciding with sleep/wake cycling (Fig. 1). The Cre recombinase enzyme,
isolated from bacteria in the 1980s (Abremski and Hoess 1984), catalyzes recombi-
nation of DNA at speciﬁc recognition sites. When driven by a mammalian promoter
that is expressed in a cell type-speciﬁc manner (for instance the tyrosine hydroxylase
promoter that is expressed in catecholaminergic cells exclusively), Cre recombinase
activity will occur in that cell type exclusively. The studies described below used
mice harboring a germ line transgene (Th-Cre) in which the tyrosine hydroxylase
(Th) promoter drives Cre recombinase expression. A second transgenic construct,
delivered by viral transfection via brain cannulation in these studies (Fig. 1), houses
an inactive coding sequence that can only be activated by Cre-mediated recombina-
tion. So viral transfection of an experimental DNA construct into the VTA of
animals in which the Th promoter drives Cre recombinase expression, for instance,
Recombination-dependent viral construct
• Fluorescent Ca2+indicator
• Chemogenetic activator/inactivator
(minutes-hours)
• Optogenetic activator
                 (milliseconds-seconds)
TH-
Cre Glu
GABA
Glu
GABA
Glu
GABA
DA cell-specific experimental outcomes
• DA cells are more active in wake/REM than SWS
• DA cell activation promotes wakefulness
• DA cell inhibition promotes sleep initiation  
VTA
Fig. 1 Recent technologies targeting dopaminergic cells selectively in experimental rodents have
yielded insights into dopaminergic regulation of sleep and wakefulness (Eban-Rothschild et al.
2016; Oishi et al. 2017). Genetically engineered viral constructs contain coding sequences for the
ﬂuorescing Ca2+ indicator GCamp6f, the chemogenetic designer G protein-coupled activating
(hM3Dq) and inactivating (hM4Di) receptors, or the optogenetic blue light sensitive cation channel
Channelrhodopsin-2. These constructs are silenced in their native state and must be unsilenced by
Cre recombinase-dependent recombination. The animal receiving viral infusions via intracerebral
cannulation harbors a germ line transgene in which the tyrosine hydroxylase (Th) promoter drives
expression of Cre recombinase only in tyrosine hydroxylase-positive neurons. As a result, only
TH-positive dopaminergic cells at the site of infusion (VTA) will undergo recombination-
dependent activation of the viral transgene. Any experimental effects or observations can then be
attributed to the dopaminergic population in the VTA and its dopaminoceptive targets
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results in Cre recombinase-dependent activation of that construct in the VTA
dopaminergic population. Three such experimentally useful DNA constructs have
been applied to gain insights into the role of the VTA dopaminergic population in
sleep/wake regulation. First, viral transfection of a construct encoding the calcium-
sensing protein GCaMP6f allowed for real-time in vivo microscopic monitoring of
dopaminergic neuronal activity to demonstrate state speciﬁc activation of VTA cells.
Results showed both a tonic elevation of calcium concentration and more frequent
calcium transients, taken as evidence of a barrage of synaptic inputs, during both
REMS and wake relative to NREMS (Eban-Rothschild et al. 2016). This result is
arguably more deﬁnitive than previously applied electrophysiological approaches
(de Saint Hilaire et al. 2000; Shouse et al. 2000; Trulson and Preussler 1984), which
made assumptions about the dopaminergic cell type based on ﬁring properties rather
than neurochemical phenotype.
The second cell type-speciﬁc manipulation of these cells, which was ultimately
responsible for demonstrating a unique role for the VTA, speciﬁcally, and not the
SN, in maintaining wakefulness, was the chemogenetic approach. With chemo-
genetics, a viral transfection is used to confer expression of a G protein-coupled
receptor (known as a Designer Receptors Exclusively Activated by a Designer Drug
or DREADD) to the cell type of interest. The G protein-coupled receptor has been
engineered to be responsive to clozapine N-oxide (CNO) and to be unresponsive to
any known endogenous ligand. Expression of this DREADD is under the control of
Cre recombinase, which means in the current context, when targeted to the VTA by
cannula-mediated viral transfection, that DA cells expressing Cre recombinase will
express the receptor of interest. Mice are then treated systemically with CNO to
activate the DREADD, resulting in profound inhibition of the activity of the
VTA-DA cells exclusively. This chemogenetic silencing of VTA-DA cells pro-
foundly disrupted behavior. When administered in a home cage environment 2 h
into the dark phase of the LD 12:12 cycle, CNO triggered SWS in animals harboring
the DREADD selectively in VTA-DA cells (Eban-Rothschild et al. 2016). When
faced with three highly motivating stimuli (an opportunity to eat, a potential mate, or
a perceived predator), the mice subjected to CNO prior to the stimulus instead
transitioned into sleep. Moreover, when placed in a novel environment, CNO-
treated mice engaged in nesting behavior, interpreted by the authors as a manifesta-
tion of sleep drive. A very recently published study highlights the necessity for
rigorous design in experiments involving CNO: in fact, it is not CNO but its
metabolite clozapine that serves as the ligand for the DREADD (Gomez et al.
2017). Because clozapine is a ligand for multiple endogenous receptors and affects
both sleep timing and EEG markers for sleepiness (Gronli et al. 2016), there is the
concern that the response to CNO administration might be mediated by off-target
effects of clozapine. In the study reporting sleep-promoting effects of VTA inhibi-
tion (Eban-Rothschild et al. 2016), wild type control mice (mice not subjected to
viral DREADD infection) in the same environmental condition as DREADD-
expressing mice engaged in exploratory behaviors rather than nesting and sleep
after CNO administration, as expected from mice placed acutely in a novel environ-
ment. VTA control of wakefulness seems ethologically relevant in the sense that it
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maintains wakefulness, even in the face of sleep pressure, when the environmental
context provides a compelling motivational force, either positive (mating and feed-
ing opportunities) or negative (vulnerability to predation) to maintain wakefulness.
In a similar approach (Oishi et al. 2017), Dat-Cre mice were subjected to
adenovirus transfection of a Cre recombinase-dependent chemogenetic inhibitor
construct targeted exclusively to either VTA or SN. Exposure to a chemogenetic
activating ligand resulted in Fos expression in vivo and ﬁring in vitro for both VTA
and SN. But only VTA transfection resulted in sustained wakefulness. This effect
was blocked by DRD2 antagonist raclopride but not a DRD1 antagonist. The same
effect was not seen with chemogenetic inactivation of the dopaminergic cells of the
SN (Oishi et al. 2017). The latter observation addresses the previously iterated
concern over off-target effects of clozapine, as it shows that anatomically restricted
DREADD expression, not just exposure to CNO, is necessary for the CNO response.
So the VTA population seems to be the unique source of dopaminergic ﬁbers that
promote wakefulness, and this function is dependent on DRD2.
A third experiment involving optogenetics conﬁrmed that activation of VTA-DA
cells is sufﬁcient to promote arousal in an acute fashion (Eban-Rothschild et al.
2016). In optogenetics, a bacterially derived blue light sensitive ion channel is
expressed in neurons, where it can be activated by light emitted from a microscopic
ﬁber optic cable embedded in the brain (Deisseroth 2011). For the purpose of
targeting the VTA-DA cells, a viral Cre recombinase-dependent optogenetic con-
struct was administered into the VTA of Th-Cremice. Optogenetic stimulation of the
VTA, or of regions receiving its projections (nucleus accumbens, NAc, central
amygdala, CeA, and dorsolateral striatum, DLS) during SWS resulted in a decrease
in the latency to awaken from sleep (Eban-Rothschild et al. 2016). A 6-h period of
continuous optogenetic stimulation at a time of day when rodents exhibit a high
propensity to sleep under baseline conditions, the ﬁrst 6 h of the daily 12-h light
phase, resulted in sustained wakefulness throughout the 6-h stimulation session.
Independent work veriﬁes that VTA-DA activation is a powerful arousing stimulus:
optogenetic activation of the VTA is sufﬁcient to induce arousal of mice from
isoﬂurane anesthesia (Taylor et al. 2016).
3 Through What Circuitry Do Ventral Tegmental Area Cells
Promote Arousal?
So cell type-speciﬁc manipulations of the VTA-DA cells with optogenetic and
chemogenetic approaches shows an obligatory role for these cells in driving arousal.
To understand the role of these cells in context, it is ﬁrst necessary to ask how VTA
DA cells themselves become activated in association with wakefulness. Multiple input
sources are potential mediators of the wake-related activation of these cells (Oishi
and Lazarus 2017). They receive signiﬁcant glutamatergic innervation from the
periaqueductal gray, lateral habenula, and VTA itself (reviewed in Oishi and Lazarus
2017). Likewise, there are GABAergic inputs to the VTA from some of the same
areas, the roles of which in sleep/wake regulation have not been characterized. Classic
sleep regulators (raphe serotonergic cells, laterodorsal tegmentum cholinergic cells,
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lateral hypothalamus) innervate the VTA, but whether these VTA-speciﬁc projections
from these widely projecting sleep regulatory populations are critical in sleep regula-
tion is unknown. The pattern of activation of these cells (elevated in both wake and
REMS relative to SWS; Eban-Rothschild et al. 2016) coincides with that of acetylcho-
line release but not that of monoaminergic or hypocretinergic cells (Siegel 2011).
Cholinergic terminals innervate (Garzon et al. 1999) and excite (Xiao et al. 2016) VTA
dopaminergic cells. Thus, it seems likely that the sleep/wake cycle related activity of
VTA-DA cells is inﬂuenced by cholinergic inputs.
By what projections does the VTA sustain wakefulness? Wakefulness induced by
chemogenetic activation of VTA-DA cells requires DRD2 activation, as it is blocked
by systemic administration of the DRD2 antagonist raclopride (Oishi et al. 2017).
But DRD2 receptors and DA terminals are widespread in the brain, so this informa-
tion does not implicate a speciﬁc circuit in the wake-promoting effect of dopamine.
Evidence to date points to the striatum, speciﬁcally the ventral portion of the
striatum, the NAc as a critical site for DRD2-mediated waking. The NAc is a critical
regulatory nexus for sleep regulation (reviewed in Oishi and Lazarus 2017). In this
region, extracellular dopamine levels vary in inverse proportion to cortical synchro-
nization, a hallmark measure of sleep need (Lena et al. 2005). Optogenetic stimula-
tion of dopaminergic terminals in the NAc, but not in other dopamine-enriched
regions (medial prefrontal cortex or central nucleus of the amygdala), is sufﬁcient to
maintain wakefulness continuously over 6 h in the face of accumulating sleep need
(Eban-Rothschild et al. 2016). Lesion of the NAc eliminates the wake promoting
effect of modaﬁnil (Qiu et al. 2012). Selective elimination of ADORA2a receptors in
the NAc results in loss of the wake-promoting effects of caffeine (Lazarus et al. 2011).
These last two observations indicate a role for cells of the NAc in responses to the
antagonistic wake-promoting dopaminergic and sleep-promoting adenosinergic
signaling mechanisms. And in fact, the antagonism plays out at the cellular level.
Medium spiny neurons make up the vast majority of cells in the NAc and can be
divided into two classes (Kim and Palmiter 2008). Those of the basal ganglia direct
path are positive for DRD1 and adenosine receptor A1. Those of the indirect path are
positive for DRD2 and ADORA2a. Since the latter two have been implicated by
both genetics and pharmacology in behavioral and EEG responses to sleep loss, this
population is especially of interest. It is necessary to consider any putative sleep/
wake regulatory function for the DRD2/ADORA2a subpopulation of medium spiny
neurons of the NAc in the context of their role in the basal ganglia. The direct and
indirect pathways of the basal ganglia are parallel and very much intertwined
pathways (Blumenfeld 2002). The net effect of the direct pathway on the cerebral
cortex is activation and the net effect of the indirect pathway on the cerebral cortex is
inhibition. In this context, it is intriguing that there are both sleep-active (Tellez
et al. 2012) and wake-active (Callaway and Henriksen 1992; Tellez et al. 2012)
populations of cells in the NAc. As a matter of speculation, dominance of the indirect
path over the direct path would provide a possible mechanism for inhibitory
mechanisms to predominate throughout the cortex and promote synchronization
characteristic of sleep onset. While the effect of targeting the indirect pathway on
EEG-deﬁned sleep has not been studied, behavioral quiescence is reported to occur
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upon chemogenetic activation of the NAc cells that participate in the indirect
pathway (Zhu et al. 2016). DRD2/ADORA2a-positive cells project widely to
numerous brain areas (Zhang et al. 2013), and are thus poised to play a role in the
complex orchestration of events associated with sleep and the deﬁcits associated
with sleep loss.
As a working model, we might consider their role in regulating forebrain
functions via interactions with the prefrontal cortex. Prefrontal cortex dependent
reward-oriented executive functions deteriorate as a result of SD (Gujar et al. 2011;
Venkatraman et al. 2007, 2011) Changes in cerebral blood ﬂow (Braun et al. 1997),
glutamate concentration (Dash et al. 2009), and glucose utilization (Maquet 1997) in
association with sleep are more robust in the prefrontal cortex than other regions. SD
triggers a decline in glutamatergic transmission from prefrontal cells: medial pre-
frontal cortex (mPFC)-to-nucleus accumbens (NAc) glutamatergic transmission is
selectively weakened following acute SD (Liu et al. 2016). Deterioration of prefron-
tal cortex-dependent, reward-oriented executive functions as a result of SD (Gujar
et al. 2011; Venkatraman et al. 2007, 2011; Whitney et al. 2015) can be understood
in the context of dopamine/adenosine interactions within the basal ganglia.
4 Synthesis: Dopaminergic/Adenosinergic Interactions
in the Striatum Mediate Effects of Sleep Deprivation
on Prefrontal Cortex-Dependent Performance
The observations summarized so far can be used to synthesize a novel conceptual
model for the emergence of performance deﬁcits during SD: performance deﬁcits in
reward-oriented executive functions are the product of increasing activation of the
DRD2/ADORA2a-positive population of medium spiny neurons in the striatum,
speciﬁcally, the ventral striatum (i.e., NAc) across time spent awake. The rationale
for this model is as follows. DRD2 and ADORA2a have been linked through genetic
and pharmacological studies to EEG and behavioral markers of sleep that emerge
during SD. These two receptors interact antagonistically in a unique population of
striatopallidal (those that project primarily to the globus pallidus, external, GPe)
medium spiny neurons of the striatum, which serve in the indirect pathway of the
basal ganglia (Fig. 2). In the well-rested state, DRD2 receptors activate the G protein
Gi, resulting in suppression of cyclic adenosine monophosphate (cAMP) concentra-
tion in the cell. This effect is countered (minimally in the well-rested state due to
relatively low levels of adenosine) by ADORA2a-induced Gs activation, which
promotes the accumulation of cAMP. The effect of DRD2 receptors becomes
less prominent with time awake for two reasons: ﬁrst, DRD2 receptors are down-
regulated in striatum as a result of SD (Volkow et al. 2012). Second, reduced
cholinergic tone as a result of increased adenosine accumulation with time awake
(Basheer et al. 2004) disfacilitates dopaminergic VTA cells, reducing their activity.
There is no known evidence for changes in ADORA2a availability as a function of
sleep states. To the contrary, adenosinergic tone is elevated in the brain with SD
(Basheer et al. 2004). Thus, the net effect of SD on the striatopallidal neurons
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(elevated ADORA2a activation and less DRD2 activation) is to increase striato-
pallidal GABAergic medium spiny neuron activation. This increase leads, through a
5-synaptic pathway (Blumenfeld 2002), to a decline in prefrontal cortex activation
(Fig. 2). (1) An increase in the activity of the striatopallidal GABAergic medium
spiny neurons of the NAc causes a decrease in the ﬁring of globus pallidus external
(GPe) neurons. GABAergic GPe cells project to the subthalamic nucleus and inhibit
their postsynaptic targets (glutamatergic cells) there. (2) The net effect of activating
striatopallidal GABAergic medium spiny neurons during protracted wake is thus to
disinhibit the subthalamic nucleus by withdrawal of GPe GABAergic inputs. (3) Dis-
inhibition of the glutamatergic subthalamic nucleus facilitates the activation of its
target cells, the GABAergic cells of the globus pallidus, internal (GPi). (4) Activation
of the GABAergic cells of the Gpi results in inhibition of the glutamatergic thalamic
cells that project to the medial prefrontal cortex, (5) decreasing medial prefrontal
cortical activation. This pathway provides a means to explain why glutamatergic
outputs from prefrontal cortex mPFC are selectively weakened following acute SD
(Liu et al. 2016). The model could be tested in experimental animals: deterioration of
performance on reward-oriented tasks should be precipitated in well-rested animals
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Fig. 2 Adenosinergic/dopaminergic interactions in the striatum mediate effects of sleep depriva-
tion on prefrontal cortex. The indirect path is a multi-synaptic circuit that regulates prefrontal
cortical executive functions via feedback from the basal ganglia. The indirect pathway is initiated by
glutamatergic projections from the prefrontal cortex to striatum (not shown). The pathway is
modulated antagonistically via dopaminergic projections to the striatum, which suppress intracel-
lular cAMP synthesis via DRD2 receptors, and accumulated extracellular adenosine, which
promotes intracellular cAMP synthesis via ADORA2a receptors on the same striatal population.
From the striatum, a 5-synaptic pathway provides feedback to the prefrontal cortex. Glutamatergic
neuronal populations and their primary projections are schematized in green and GABAergic
neuronal populations in red. Reduced DRD2 tone and elevated ADORA2a tone over time awake
drive an increase in striatal interneuron excitability. The net effect of sleep deprivation-induced
striatal activation is the suppression of prefrontal activity and with it executive function
Dopamine and Wakefulness: Pharmacology, Genetics, and Circuitry 331
by selective activation of the DRD2/ADORA2A positive striatopallidal cells and
reversed in sleep-deprived animals by silencing the activity of these cells. Ascertain-
ment of these predictions will identify DRD2/ADORA2A positive striatopallidal
cells as a target for therapeutic intervention in the face of sleep loss or poor quality
sleep. Similarly, the deleterious effects of SD on reward-oriented executive functions
in humans (Gujar et al. 2011; Venkatraman et al. 2007, 2011; Whitney et al. 2015)
should be reversed by inverse ADORA2a agonists such as caffeine. While
somnolytic effects of caffeine are universally recognized, the efﬁcacy of caffeine
in the context of reward-oriented functions, speciﬁcally, remains to be quantiﬁed.
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Abstract
Ketamine, a drug with rapid antidepressant effects and well-described effects on
slow wave sleep (SWS), is a useful intervention for investigating sleep–wake
mechanisms involved in novel therapeutics. The drug rapidly (within minutes to
hours) reduces depressive symptoms in individuals with major depressive
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disorder (MDD) or bipolar disorder (BD), including those with treatment-
resistant depression. Ketamine treatment elevates extracellular glutamate in
the prefrontal cortex. Glutamate, in turn, plays a critical role as a proximal
element in a ketamine-initiated molecular cascade that increases synaptic
strength and plasticity, which ultimately results in rapidly improved mood. In
MDD, rapid antidepressant response to ketamine is related to decreased waking
as well as increased total sleep, SWS, slow wave activity (SWA), and rapid eye
movement (REM) sleep. Ketamine also increases brain-derived neurotrophic
factor (BDNF) levels. In individuals with MDD, clinical response to ketamine is
predicted by low baseline delta sleep ratio, a measure of deficient early night
production of SWS. Notably, there are important differences between MDD and
BD that may be related to the effects of diagnosis or of mood stabilizers.
Consistent with its effects on clock-associated molecules, ketamine alters the
timing and amplitude of circadian activity patterns in rapid responders versus
non-responders with MDD, suggesting that it affects mood-dependent central
neural circuits. Molecular interactions between sleep homeostasis and clock
genes may mediate the rapid and durable elements of clinical response to
ketamine and its active metabolite.
Keywords
Brain-derived neurotrophic factor (BDNF) • Circadian • Major depressive
disorder • Neuroplasticity • Slow wave sleep • Suicidality
1 Introduction
The glutamatergic N-methyl-D-aspartate (NMDA) receptor antagonist ketamine is
a rapid-acting antidepressant with immediate clinical utility. It is also a valuable
research intervention that provides insights into the development of novel
treatments for mood disorders. Ketamine rapidly (within minutes to hours) reduces
depressive symptoms in individuals with major depressive disorder (MDD) or
bipolar disorder (BD), including in patients with treatment-resistant depression
(Diazgranados et al. 2010a; Murrough et al. 2013; Zarate et al. 2012); treatment
effects may last for up to 7 days in some individuals. Importantly, the drug may also
reduce suicidal ideation in patients (DiazGranados et al. 2010b; Price et al. 2009;
Zarate et al. 2012), suggesting an important treatment option for this population
with urgent clinical needs.
Disrupted sleep patterns and circadian rhythms have long been associated with
depressive disorders (Gillin et al. 1979; Wehr and Goodwin 1983). Relatedly, sleep
deprivation (SD) was suggested to have rapid chronotherapeutic effects on both
sleep homeostasis and mood (Borbe´ly and Wirz-Justice 1982; Wirz-Justice and
Van den Hoofdakker 1999). In addition, the mood stabilizer lithium was recently
found to have beneficial molecular effects on the circadian clock; a full discussion
of lithium’s effects on circadian function is beyond the scope of this chapter. We
refer interested readers to several excellent reviews on this subject (Gould and
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Manji 2002; Lenox et al. 2002; McCarthy et al. 2012; Gould and Manji 2005).
Interestingly, in addition to its antidepressant effects, ketamine has well-described
effects on slow wave sleep (SWS) (Duncan et al. 2013b; Duncan and Zarate 2013),
and is thus a useful intervention for investigating the sleep–wake mechanisms
involved in novel therapeutics.
Recent research has identified both sleep homeostatic (sleep slow waves) and
circadian components that both modulate and mediate the antidepressant and
antisuicidal effects of ketamine. The relevant mechanism(s) of action is an area
of active investigation, and includes release of glutamate, the major excitatory
neurotransmitter in the brain. A sequence of molecular and cellular events follows
this glutamate release. These include increased α-amino-3-hydroxy-5-methyl-4-
isoxazolepropionic acid (AMPA) neurotransmission, activation of the mammalian
target of rapamycin (mTOR) signaling pathway, and increased brain-derived
neurotrophic factor (BDNF) activity. Ketamine also activates clock-associated
gene molecules (Bellet et al. 2011), including those within reward circuits of the
nucleus accumbens (Zhao et al. 2014).
Taken together, the evidence gathered to date highlights a rich field of clinical
and preclinical results that can be fruitfully explored to identify links between
circadian/sleep wake systems and the development of novel rapid antidepressant
treatments. To further understand the homeostatic process of sleep and how it
relates to the development of novel therapeutics, recent investigations have focused
on glutamatergic-associated molecular and SWS associations that parallel
ketamine’s rapid antidepressant effects. This chapter will review current insights
drawn from sleep and circadian system research related to the development of novel
interventions.
2 Glutamatergic Function in Sleep and Circadian Systems
Distribution of metabotropic glutamate R2/R3 receptors is widespread, including in
the prefrontal cortex (PFC), hippocampus, and the reticular and sensory thalamic
nuclei, all of which have been implicated in neuropsychiatric syndromes (Wright
et al. 2013). Glutamate is co-localized within orexin (also known as hypocretin)
neurons of the dorsal lateral hypothalamus, which also have widespread distribution
throughout the brain (Peyron et al. 1998). These neurons, whose deficiency is the
cause of narcolepsy/cataplexy, become hyperactive after SD and metabolic chal-
lenge (Willie et al. 2001; Sakurai 2007).
As regards circadian regulation of sleep–wake patterns, synchronization
between environmental light dark cycles and internal biological circadian rhythms
is mediated in part by release of glutamate from the retinohypothalamic tract
(RHT). The consequent light response of light sensitive clock genes (Roecklein
et al. 2009) and their downstream molecular events – which ultimately affects sleep
quality – are affected by this glutamate-initiated sequence of clock-associated
effects.
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Ketamine treatment elevates extracellular glutamate in the PFC (Bagley and
Moghaddam 1997; Homayoun and Moghaddam 2007). In addition, glutamate plays
a critical role as a proximal element in a ketamine-initiated molecular cascade that
increases synaptic strength and plasticity, which ultimately results in rapidly
improved mood. Glutamatergic effects are common to interventions with rapid
antidepressant properties such as SD, electroconvulsive therapy (ECT) (Murck
et al. 2009), and ketamine. For instance, SD (extended wakefulness) increases the
availability of metabotropic glutamate receptors of subtype 5 (Hefti et al. 2013) and
alters glutamatergic function (Benedetti et al. 2009). Increased cortical excitability,
as measured by gamma activity, has been associated with ketamine treatment
(Cornwell et al. 2012) as well as with increased prior wake time (Huber et al.
2013); both have glutamatergic underpinnings.
2.1 Ketamine-Induced Glutamatergic Signaling Initiates
a Cascade of Molecular, Cellular, and BDNF-Associated
Events
The rapid antidepressant properties of ketamine and one of its key metabolites,
(2R,6R)-hydroxynorketamine (HNK) (Zanos et al. 2016), induce altered
glutamatergic signaling and upregulation of AMPA receptors, consistent with
previously described findings of increased synaptic strength and plasticity
(Duman and Aghajanian 2012). Interestingly, in the study by Zanos and colleagues,
(2R,6R)-HNK was essential to ketamine’s antidepressant effects. Furthermore, the
(2R,6R)-HNK enantiomer was responsible for behavioral, EEG, electrophysiologi-
cal, and cellular antidepressant-related actions in mice without inducing any
ketamine-related side effects. The specific sequence from ketamine infusion to
improved mood, cognition, and behavior includes: (1) increased glutamate release;
(2) early activation and upregulation of AMPA receptors; and (3) activity-
dependent release of BDNF (Li et al. 2010; Maeng and Zarate 2007). Ultimately,
these events activate the mTOR signaling pathway, affecting downstream changes
in dendritic spines and local synaptic protein synthesis, including BDNF (Duman
and Aghajanian 2012). BDNF secretion, activation of the tropomyosin-receptor-
kinase B (TrkB) receptor, and downstream trafficking lead to further dendritic
structural complexity, spine and BDNF synthesis, synaptic plasticity, and strength-
ened local circuitry (Duman and Aghajanian 2012; Maeng and Zarate 2007).
Downstream to these events, polymorphisms such as BDNF Val66Met also
contribute to the altered functional effects of BDNF trafficking (Chen et al. 2004;
Egan et al. 2003). Enhanced synaptic plasticity and neuronal synchronization
resulting from changes in critical local neuronal circuits – especially in areas
involved in mood and behavior – converge to produce rapid antidepressant effects
(Maeng and Zarate 2007; Zarate et al. 2006). As discussed later in Sects. 2.3, 3.1,
and 4, below, changes in BDNF, SWS, and mood are present in patients who
respond to ketamine.
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2.2 Clues to Rapid Antidepressant Mechanisms of Ketamine
and Sleep Deprivation Are Found Within Core Elements
of Sleep and Circadian Systems
In mood disorders, both homeostatic and circadian processes are dysregulated, with
significant impact on sleep–wake cycles, circadian rhythms of body temperature,
hormones, behavior, and mood. Patients with MDD often, but not uniformly,
exhibit disturbed sleep. For example, several studies have reported an absence of
disturbed sleep patterns in individuals with MDD (Frey et al. 2012; Quitkin et al.
1985; Antonijevic 2006), suggesting that distinctions such as typical versus atypical
subtypes, gender, or other co-morbidities may be involved. Disturbed sleep is
generally characterized by decreased sleep and sleep continuity, low levels of
SWS and slow wave activity (SWA, defined as EEG activity between 1 and 4 Hz
in non-rapid eye movement (NREM) sleep), short rapid eye movement (REM)
latency, and increased and early morning waking (Gillin et al. 1979; Duncan et al.
1979; Kupfer et al. 1985; Pillai et al. 2011; Benca et al. 1992). Many of these
disturbances are consistent with abnormal function of the sleep homeostat (SWS
deficiency) and central clock (temperature and hormone rhythms). Notably, many
of these features have been incorporated within the two-process model of sleep–
wake regulation (described next) in which a sleep homeostat (modeled by Process
S) interacts with the central circadian clock (modeled by Process C) to influence
human sleep behavior and mood. Numerous chronotherapeutic sleep interventions,
such as partial SD and sleep phase advance have been evaluated within this model
for their capacity to alter homeostatic mechanisms and to affect interactions
between sleep homeostatic and circadian processes. For instance, the antidepressant
properties of bright light – the major signal responsible for synchronizing internal
circadian timing to the external day – are used during bright light therapy.
The two-process model of human sleep–wake regulation (Borbe´ly 1982) has
been used to measure the timing, duration, and structure of human sleep (Dijk and
Czeisler 1995) with important implications for health and depression. In healthy
individuals, extended prior wakefulness is associated with a homeostatic increase in
the level of “S,” measured by increased SWS/SWA (a surrogate marker of “S”)
during recovery sleep. The “S”-deficiency hypothesis of depression (Borbe´ly 1987;
Borbe´ly and Wirz-Justice 1982) posits that both sleep disturbances and depressive
symptoms are related to low levels of “S.” The rapid antidepressant effects of SD
therapy in depression are hypothesized to increase “S” toward normal levels, as
indicated by elevated SWS/SWA during early recovery (Borbe´ly and Wirz-Justice
1982). Key elements of this hypothesis have further provided a basis for launching
promising investigations regarding the molecular effects of SD and their role in
rapid antidepressant effects, with predictions based on synaptic homeostasis
(Tononi and Cirelli 2006).
The mechanism of action of rapid-acting antidepressants may be complex,
involving temporal and quantitative differences in BDNF and synaptic plasticity
(by SD and partial SD) on the one hand, and altered timing of the central clock (e.g.,
by bright light therapy) on the other. The timing of these events, along with the
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course of mood changes, provides important clues regarding their relative contri-
bution to both the rapid expression of antidepressant response and the maintenance
of that response (Kuhn et al. 2016). The fact that SD does not consistently elevate
BDNF (Kuhn et al. 2016; Ibrahim et al. 2011) suggests that declines in BDNF after
extended wakefulness might have a protective effect against excessive cortical
excitability and plasticity (Kuhn et al. 2016). Both SD and bright light therapy
[as well as selective serotonin reuptake inhibitors (SSRIs)] produce rapid changes
(within 12 h) in both SWA levels and clock-gene expression (Cuesta et al. 2009; Uz
2005), respectively. However, the rapid antidepressant response latencies of these
interventions vary, ranging from hours (in the case of ketamine, SD, and partial
SD), to several days (bright light therapy and sleep phase advance), to weeks for
SSRIs (Rush et al. 2006). The distinct molecular pathways activated by homeostatic
versus circadian-linked interventions may contribute differently to the rapid onset
of antidepressant effects, particularly compared to the persistence (durability) of
any such effects.
Chronotherapies that control the duration of prior waking – and, therefore, sleep
homeostatic mechanisms [e.g., dark therapy and “extended-night” interventions
(Wehr et al. 1998; Wirz-Justice et al. 1999; Barbini et al. 2005)] – reduce symptoms
of mania, hypomania, and rapid cycling in BD (Barbini et al. 2005; Wehr et al.
1998; Wirz-Justice et al. 1999). Thus, controlled sleep–wake schedules, regulation
of sleep homeostasis, and underlying pathways of synaptic plasticity (including
glutamatergic function) may inform our understanding of sleep homeostasis and
SWS as modulating elements of mood and novel mechanisms of mood stabilizers.
The role of interacting homeostatic and circadian systems in developing novel
treatment interventions is discussed later.
2.3 Sleep Slow Waves and Evoked Potentials Are Markers
of Synaptic Plasticity
Sleep EEG and evoked potentials are useful markers of altered synaptic plasticity in
humans (Huber et al. 2004, 2006), and evidence from these studies is consistent
with the synaptic homeostasis hypothesis (Tononi and Cirelli 2006). High-density
EEG studies have shown that interventions such as rotation learning and high-
frequency transcranial magnetic stimulation (TMS) associated with synaptic poten-
tiation in local cortical circuits lead to local increases in SWA during subsequent
sleep (Huber et al. 2004). Interventions such as arm immobilization, which is
associated with synaptic depression, lead to a local reduction in SWA (Huber
et al. 2006). Computer simulations indicate that sleep SWA directly reflects synap-
tic strength due to changes in neural synchronization and recruitment (Esser et al.
2007; Vyazovskiy et al. 2007).
In addition, several studies that directly examined the effects of BDNF on EEG
SWS also noted a close relationship between SWA and BDNF (Faraguna et al.
2008; Huber et al. 2007). These studies found that SWA was increased by
intrahemispheric infusion of BDNF, by behavioral interventions that increase
342 W.C. Duncan Jr. et al.
central levels of BDNF, and by the plasticity-related genes Arc, Homer, and NGFI-
A (Huber et al. 2007). Conversely, SWA was diminished by BDNF antagonism
(Faraguna et al. 2008). The fact that acoustic suppression of SWA was associated
with diminished perceptual learning (Aeschbach et al. 2008) suggests that
decreased SWS levels could contribute to cognitive and memory deficits in some
depressed patients. Interestingly, human carriers of the BDNF Met allele of the
Val66Met polymorphism produce less SWS (Bachmann et al. 2012) and also
display altered mood response to ketamine (Laje et al. 2012), thus establishing a
link between genetic variants of BDNF, SWA, and mood.
3 Clinical Effects of Ketamine on Sleep and Mood
As noted above, ketamine increases SWS, memory, and plasticity, and elevates
slow wave production (Campbell and Feinberg 1996; Feinberg and Campbell 1993)
in addition to its antidepressant effects. Ketamine’s effects on SWS suggest a
possible association between this agent’s rapid antidepressant effects and its
plasticity-related effects. These effects on both mood and sleep have been specifi-
cally explored in MDD and BD.
In MDD, rapid antidepressant response to ketamine was linked to decreased
waking, as well as increased total sleep, SWS, SWA, and REM sleep (Fig. 1)
(Duncan et al. 2013b). Furthermore, clinical response to ketamine was predicted in
MDD by a low baseline delta sleep ratio (defined as the quotient of SWA in the first
to the second NREM episode), a measure of deficient early night production of
SWS (Duncan et al. 2013a), and the abnormal production of SWS during the sleep
period. Normalizing the deficient early night production of SWS by increasing early
production of SWS in the first non-REM period (Fig. 1, lower panel) appears
critical to ketamine’s rapid antidepressant effects. Notably, although increased
sleep slow waves were not present on Day 1 post-ketamine infusion, increased
total sleep, REM sleep, and sleep efficiency (i.e., decreased time spent awake after
sleep onset) were associated with antidepressant response (Duncan et al. 2013b) on
Day 2 post-ketamine treatment, indicating their association with a more prolonged
antidepressant response.
Increasing the early nighttime production of SWS (Fig. 1, upper panel) may be
important to ketamine’s rapid antidepressant effects. Interestingly, sleep slow
waves are markers of neuronal plasticity that are similarly increased using other
(non-ketamine) novel therapies, further implicating sleep and circadian systems in
mood response. For instance, the effects of repetitive TMS (rTMS) on plasticity
(Cohen et al. 2010) involve both sleep–wake and/or circadian-dependent processes.
Applying rTMS to the left dorsolateral prefrontal cortex (DLPFC) increased SWA
at F3 (Saeki et al. 2013), indicating locally enhanced synaptic plasticity, similar to
ketamine’s plasticity-related effects on SWS (Duncan et al. 2013b). In that rTMS
study, SWA production was particularly enhanced during the first half of the sleep
period (Saeki et al. 2013). This result echoes the early night effects of ketamine (see
Fig. 1, top panel) in which ketamine elevated the early night peak in SWA, followed
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by a progressive decline in SWA levels during the remaining sleep period (Duncan
et al. 2013b). This homeostatic nighttime decline, common to ketamine and to other
novel therapeutics, is consistent with a pattern of synaptic downscaling that follows
the gradual rise of daytime synaptic potentiation and elevated SWA at sleep onset.
Interestingly, an important discrepancy between MDD and BD was found when
examining ketamine’s effects on SWS in BD patients who were receiving mood
stabilizer therapy. Increased SWS production in response to ketamine was not
observed in this sample of BD patients, in contrast to the results obtained for
MDD patients. Although rapid antidepressant effects as well as improved sleep
were observed (Duncan and Zarate 2013), ketamine infusions reduced SWA levels
in BD during non-REM episodes 1 and 3. This result has two possible
interpretations. First, the finding is consistent with sleep differences between
MDD and BD patients. Genetic factors influence REM sleep expression (Kupfer
and Ehlers 1989) and this, in turn, indirectly affects SWS expression; the result is
thus consistent with underlying genetic differences between MDD and BD. These
differences may stem from complex and unstable waking patterns during mania and
Fig. 1 Slow wave activity
(SWA, top) during non-REM
episodes (cycles) 1–3
(NR1,2,3) and selected sleep
measures (bottom) in patients
with major depressive
disorder (MDD; n ¼ 30)
compared during baseline
(BL, grey bars) and the first
night (D1) after ketamine
infusion (KD1, black bars).
All patients had severe,
treatment-resistant MDD at
the time of ketamine
treatment. The lower panel
shows that in patients with
MDD, ketamine significantly
improved sleep quality
[increased Total Sleep (TS),
slow wave sleep (SWS), and
percent time spent in rapid
eye movement sleep (REM
%)], and decreased the
percent of time spent awake
(W%) on D1. Ketamine also
increased early production of
SWA during NR1, thus
enhancing the nighttime
decline in SWA across
successive non-REM
episodes. (* p < 0.05)
344 W.C. Duncan Jr. et al.
hypomania (Linkowski et al. 1986) that potentially influence and confound mea-
surement of SWS expression in BD. Second, the result is consistent with studies
indicating that mood stabilizers per se influence SWS expression. The ongoing use
of mood stabilizers (i.e., lithium) during ketamine infusion may thus have affected
SWS and could confound any study of ketamine-induced slow wave production
(Duncan and Zarate 2013).
More provocatively, this result could also suggest that the effect of mood
stabilizers on SWS also contributes to their mood stabilizing properties. Controlling
mood cycles by stabilizing day-to-day variations in SWS may be a property shared
by dark-therapy/extended bed-rest interventions (i.e., chronotherapeutic interven-
tions that impose fixed bed-rest schedules; these control the duration of prior
wakefulness, thereby minimizing night-to-night fluctuations in SWS and ultimately
stabilizing mood). This finding may echo a recent report that SWS levels correlate
with mood (Eidelman et al. 2010) such that low SWS levels are associated with
reduced future mania. Thus, a property of mood stabilizers might be their ability to
minimize night-to-night fluctuations in SWS.
3.1 Ketamine’s Rapid Effects on Mood, Sleep Slow Waves,
and BDNF Levels Are Consistent with Increased Synaptic
Plasticity
Response to ketamine infusions also suggest links between neuroplasticity, SWS,
and mood on the one hand, and the neurotrophin BDNF on the other. Increased
BDNF levels have been associated with several rapid-acting antidepressant
interventions (Duncan et al. 2013b; Giese et al. 2014; Haile et al. 2014; Gorgulu
and Caliyurt 2009), underscoring its key role in the rapid response mechanism.
Beyond the association with rapid mood response, the magnitude of BDNF and
SWS levels were correlated in ketamine responders (Duncan et al. 2013b), a finding
consistent with the preclinical effects of BDNF on SWS production (Huber et al.
2007). Furthermore, the magnitude of BDNF levels measured 4 h post-ketamine
infusion predicted mood response 3 days post-infusion (Haile et al. 2014),
suggesting that these acute levels might provide a marker of durable response.
3.2 Ketamine’s Rapid Antisuicidal Effects Reverse Late-Night
Waking
An area of increasing interest is ketamine’s ability to rapidly (within minutes to
hours) reduce suicidal thoughts in individuals with treatment-resistant depression
(DiazGranados et al. 2010b; Murrough et al. 2015; Price et al. 2009, 2014; Zarate
et al. 2012). No FDA-approved medications presently exist for acute suicidal
thoughts, and rapid-acting treatments are critically needed for this psychiatric
emergency. Ketamine’s impact on suicidal thoughts has been shown to occur
independently of its antidepressant effects (Ballard et al. 2014) and has been
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associated with specific neuroimaging biomarkers, specifically glucose metabolism
in the infralimbic cortex (BA 25) (Ballard et al. 2015). This suggests that
investigations of ketamine use in suicidal individuals could identify potential
biomarkers of antisuicidal response and elucidate the neurobiological underpinnings
of acute suicide risk.
Interestingly, suicide risk has also been linked to sleep difficulties. Self-reported
sleep difficulties are associated with subsequent death by suicide (Bernert et al.
2014; Gunnell et al. 2013), and the association between subjective sleep difficulties
and suicidal thoughts and behaviors has been found to occur independently of
depressive symptoms (Pigeon et al. 2012).
More objective measures of suicidal thoughts or past behaviors have been
associated with polysomnography-defined increased REM sleep percentage, REM
activity, REM duration, and decreased sleep efficiency (Agargun and Cartwright
2003; Sabo et al. 1991). Evidence of seasonality and suicidal behavior, including
altered circadian psychomotor activity in suicidal individuals, suggests altered
chronobiological activity in suicidal patients (Hiltunen et al. 2011; Verkes et al.
1996). Chronotherapeutics – including SD in conjunction with lithium, sleep phase
advance, and bright light therapy (triple chronotherapy), as well as cognitive
behavioral therapy with SD (Breitstein et al. 2014) – have been associated with
rapid reductions in suicidal thinking (Benedetti et al. 2014; Sahlem et al. 2014),
suggesting that sleep may be a particularly important modifiable risk factor for
acutely suicidal patients.
Interestingly, ketamine’s antisuicidal effects may also involve the circadian
sleep–wake system. First, the hours of 12:00 a.m. to 5:00 a.m. may be an especially
high-risk time for suicide deaths (Perlis et al. 2016), suggesting a particular
circadian interval of risk. Second, in initial investigations of this time period across
EEG sleep, wakefulness over the course of the night, particularly in the 4:00–4:59
a.m. hour, was associated with suicidal thoughts the next day in a sample of
depressed inpatients (Ballard et al. 2016); this effect was independent of age,
gender, diagnosis (MDD vs. BD), or depressive symptom severity. Third, in
evaluating wakefulness after ketamine administration, antisuicidal response (that
is, complete next-day remission of suicidal thoughts) was associated with reduced
wakefulness, even when adjusting for baseline sleep (Vande Voort et al. 2016).
Taken together, these results point to the potential importance of sleep and circa-
dian rhythms in ketamine’s antisuicidal effects and indicate the need for further
evaluation of BDNF, clock-gene expression, and cortisol on this process.
4 Ketamine’s Interactive Effects on Sleep and Circadian
Systems
While some ketamine studies indicate a relationship between BDNF levels and
SWS amplitude, other studies describe a diurnal and/or circadian component to
plasticity-evoked changes that implicate both sleep homeostatic/plasticity
mechanisms and circadian-related processes. For example, effective rapid
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antidepressant interventions appear related to BDNF regulation as well as circadian
and homeostatic sleep systems. The presence of a diurnal rhythm for BDNF in
partial SD responders (Giese et al. 2014) suggests a similarity between circadian
system variations in BDNF and the circadian effects of other rapid-acting treatment
interventions. Similar to SD and sleep homeostatic challenges on clock-gene
expression [for a review, see (Franken and Dijk 2009)], other novel therapeutics
(such as rTMS) affect clock and circadian function. Plasticity associated with rTMS
was found to correlate with cortisol awakening response, a circadian biomarker
related to peripheral circadian CLOCK genes (Clow et al. 2014); in addition, rTMS
treatment increased REM latency, another circadian marker, also consistent with
linkage between rTMS antidepressant effects and circadian rhythms (Cohrs et al.
1998).
5 Ketamine Alters Circadian Amplitude and Timing in MDD
Interactions between molecular and neural elements of the circadian clock and the
sleep homeostat regulate the expression and timing of the human sleep–wake
pattern. Chronotherapies are hypothesized to alter mood, in part by altering the
timing and expression of this central clock (Benedetti et al. 2007a). Bright light
therapy (Wirz-Justice and Terman 2012), low-dose melatonin (Lewy et al. 2002),
and the novel therapeutic drug agomelatine (Kasper and Hamon 2009; Kasper et al.
2010) share the common property of altering the timing and expression of the
central clock. The fact that glutamate is a key transmitter that functions to
resynchronize the timing of the central clock with the external light–dark cycle
suggests that it may also alter central circadian timing during clinical intervention.
As noted above, glutamate levels are altered by ketamine infusion. As regards
the circadian clock in particular, ketamine alters the timing and amplitude of
circadian activity patterns in MDD rapid responders versus non-responders
(Fig. 2). While consistent with preclinical studies of ketamine’s effects on circadian
clock-gene-related molecules, the finding indicates that the effect is mood-
dependent. Specifically, on day 1, the day after ketamine infusion (Fig. 2, left
panel) rapid responders to ketamine showed phase-advanced (early) timing of the
24-h of activity pattern (as evidenced by higher AM and lower PM activity counts)
relative to non-responders. Also, 2 days after the infusion (D3, right panel),
responders showed an increased amplitude of the 24-h pattern of motor activity
whereas non-responders did not, suggesting that the amplitude of the rhythm is
more likely to be associated with durability of the mood response (given that the
amplitude increases in day 3 responders) than with acute response – note, for
instance, the similar amplitudes in day 1 responders versus non-responders. The
mood-dependent properties may incorporate effects on clock-gene pathways, pos-
sibly within the expression of mood-associated circuits that contribute to durable
clinical response. The early timing of the activity pattern on day 1 is also consistent
with the beneficial effects of SD, which are associated with advanced timing of the
circadian system (Benedetti et al. 2007b).
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6 Do Homeostatic and Circadian Systems Interact to Affect
Ketamine’s Antidepressant Properties?
SWS-associated neural plasticity (Duncan et al. 2013b) as well as clock genes and
their associated molecules (Bunney and Bunney 2012, 2013) have both been linked
to ketamine’s rapid antidepressant effects. Clear delineation of the temporal rela-
tionship between clock-gene activation versus sleep homeostatic mechanisms can
inform our understanding of how these processes contribute to rapid antidepressant
response. This requires close examination of day-to-day clinical mood changes on
the one hand, and specific changes in clock genes and sleep homeostasis on the
other.
In the case of sleep homeostasis, clinical studies have found that rapid antide-
pressant response and SWS-related changes in neural plasticity both occur within
12 h of ketamine infusion (Duncan et al. 2013b; Duncan and Zarate 2013). In
contrast to conventional antidepressant treatments, rapid-acting interventions such
as SD and ketamine infusion quickly increase SWS production, highlighting the
role of increased “S” and SWS as markers of rapid mood response. Underlying the
role of SWS-associated processes in the onset of rapid response are neurotrophin
release and neuronal plasticity; these are produced both by the rapid-acting effects
of SD and the rapid-acting antidepressant ketamine.
Clinical studies have not directly examined ketamine’s effects on clock-gene
expression. In contrast, preclinical studies have shown rapid clock-gene-associated
effects after ketamine infusion but, as discussed here, their role in mediating rapid
Fig. 2 Day 1 and Day 3 patterns of wrist activity for ketamine-treated patients who responded
(>50% decrease in Montgomery-Asberg Depression Rating Scale (MADRS) score) within 1 day
of ketamine infusion compared with non-responders. (Left panel) Responders (R, red) compared
with non-responders (NR, blue) 1 day after ketamine infusion (Day 1). (Right panel) Responders
(R, red) who maintained the 50% decrease in MADRS score compared with patients who did not
meet response criteria (NR, blue) on Day 3. The raw MADRS scores for each group are shown as
inserts for each day. On Day 1, the phase of the 24-h pattern of activity in ketamine responders
differed from non-responders ( p ¼ 0.0038). On Day 3 the amplitude ( p ¼ 0.0488) of the 24-h
pattern significantly differed between responders and non-responders. Group sizes are: D1
(R ¼ 21, NR ¼ 30) and D3 (R ¼ 13, NR ¼ 35)
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antidepressant response is unclear. For example, like ketamine, SSRIs and bright
light exposure produce rapid clock-gene related effects in preclinical studies
(Cuesta et al. 2009; Uz 2005), as well as demonstrated effects in MDD (Li et al.
2013; Rush et al. 2006). However, unlike ketamine, SSRIs often require 5 weeks for
their antidepressant effects to manifest (Posternak and Zimmerman 2005; Rush
et al. 2006), which is inconsistent with a rapidly acting antidepressant clock-gene
mechanism; nevertheless, a chronic mechanism involving clock gene effects might
be relevant (Li et al. 2013). Similarly, bright light therapy has rapid effects on
clock-gene expression but requires several days for an antidepressant response to
manifest (Benedetti et al. 2007a; Duncan 2009). Thus, the extent to which clock-
gene effects are both necessary and sufficient for a rapid and/or durable antidepres-
sant response is an important question that requires further examination of the
specific circadian phase-dependent elements that both moderate and mediate rapid
and durable response effects.
The fact that sleep homeostasis and clock genes interact at the molecular level
(Franken 2013; Franken and Dijk 2009) allows for interacting effects that mediate
clinical response. Subsequent to the initial events that trigger the cascade of
molecular and plasticity-associated events – for which SWS is an important marker
– the interaction between homeostatic and circadian clock processes (Archer et al.
2014) could be critical for sustaining antidepressant response.
7 Strategies for Prolonging Ketamine’s Mood Response
Although ketamine provides rapid relief from depressive symptoms – with a
response rate of approximately 70% within 24 h (Machado-Vieira et al. 2010) –
its effects are often short-lived, and most patients relapse within 7 days. Therefore,
an important goal of ongoing research is to identify mechanisms of durable
response to ketamine. This approach might include pairing activation of: (a) the
acute rapid response mechanism with, (b) a response maintenance mechanism. The
fact that repeated chronotherapies, or chronotherapies combined with conventional
treatments, extend acute rapid antidepressant effects (e.g. of single SD or partial SD
interventions), suggests that repeat chronotherapies might be effectively used for
extending ketamine treatment, or that incorporating their mechanisms of action
may extend beneficial effects, but this remains to be evaluated.
7.1 Sleep, Naps, and Post-ketamine Relapse
For an individual who has experienced a rapid antidepressant response to ketamine,
the night of sleep that follows the infusion is not predictably followed by relapse.
This contrasts with the fact that few SD responders (5–10%) remain euthymic after
recovery sleep (Benedetti et al. 1999; Benedetti and Colombo 2011). Furthermore,
the rapid clinical benefits of both SD and partial SD are: (a) reduced by naps and
microsleeps during extended waking and prior to remission itself, and (b) reduced
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by naps and recovery sleep during remission (Benedetti and Colombo 2011;
Hemmeter et al. 2010; Wiegand et al. 1987). The fact that relapses can be limited
(or response extended) by repeated episodes of sleep phase advance (Benedetti
et al. 2001; Berger et al. 1997) indicates that sleep per se is not sufficient for relapse,
but that sleep stage, circadian phase, or other factors influence relapse (Wiegand
et al. 1986, 1987, 1993) [see also (Hemmeter et al. 2007)]. To our knowledge,
whether or not the extended antidepressant effects of sequentially applied
chronotherapeutics (e.g., partial SD, sleep phase advance) are linked with extended
cortical excitability and mood response remains unknown. However, the contribu-
tion of microsleeps, napping, and reduced sleep times on extending response and
delaying relapse have not been carefully examined following ketamine.
Interestingly, the extension of chronotherapeutic benefits and their interaction
with ECT and rTMS have also been investigated. One study found that rTMS
(administered over the left DLPFC) prolonged the effects of SD (Eichhammer et al.
2002), but a second study found that active rTMS (left DLPFC) was not superior to
sham rTMS in stabilizing the antidepressant effects of SD (Kreuzer et al. 2012;
Eichhammer et al. 2002).
Drug interventions have also been used to extend the rapid antidepressant effects
of chronotherapies. While chronotherapies, particularly bright light therapy, aug-
ment the effects of antidepressant medications (Lam and Kennedy 2015), the
augmenting effects of an antidepressant and mood stabilizer (sertraline and lithium)
with three chronotherapies (SD; bright light therapy; sleep phase advance) also
showed rapid benefits in BD with persisting effects (Wu et al. 2009). In a study of
39 BD patients (13 of whom were treatment-resistant and 23 of whom were
medicated with lithium and/or an SSRI), three interventions of SD plus bright
light therapy reduced Hamilton Depression Rating Scale (HAM-D) scores by
50% in 26 of the 39 patients (Benedetti et al. 2007b). In a third study, the use of
a mood stabilizer (lithium) combined with SD and bright light therapy alleviated
suicidal ideation and mood symptoms (Benedetti et al. 2014). The benefits of
combination therapies with ketamine have not been fully evaluated. Differences
are evident in the observation that the antidepressant effects of ketamine in BD
patients maintained on mood stabilizers (lithium and valproate) are not remarkably
greater or more prolonged than those in drug-free MDD patients (Diazgranados
et al. 2010a; Ionescu et al. 2015).
While naps blunt rapid antidepressant response to SD or partial SD (Dallaspezia
and Benedetti 2011), pharmacological treatments that reduce microsleeps/naps
(i.e., modafinil, caffeine, flumazenil) do not substantially enhance the rapid antide-
pressant response associated with SD (Beck et al. 2010; Hemmeter et al. 2007).
However, one case report found that modafinil reduced napping and increased
clinical benefit during SD (Even et al. 2005). On the other hand, enhanced vigilance
associated with the benzodiazepine receptor antagonist flumazenil prolonged rapid
antidepressant response to SD to the day after recovery sleep (Hemmeter et al.
2007), possibly by affecting the dynamics of process “S.”
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7.2 Molecular Associations with Extended Response
Extended antidepressant response has also been investigated at the molecular level.
One study found that the glycogen synthase kinase (GSK) promotor variant
(rs334558*C) interacts with the long/short form of the serotonin transporter
(5-HTTLPR) 5HT allele to extend post-SD antidepressant response after recovery
sleep (Benedetti et al. 2012), suggesting a molecular target for serotonergic
interventions that might prolong response. Extended mood benefits from SD by
the drug flumazenil, which affects sleep homeostasis (Hemmeter et al. 2007), and
by BDNF release subsequent to ketamine infusion (Haile et al. 2014), also suggest a
path for investigating extended ketamine mood effects, sleep homeostasis, and
plasticity (Laje et al. 2012; Bachmann et al. 2012). Whether the active ketamine
metabolite 2R,6R-HNK (Zanos et al. 2016) could also extend clinical antidepres-
sant response is an important question.
8 Summary and Future Directions
The past decade has been a period of steady progress in developing new strategies
for rapidly treating mood disorders, and understanding the antidepressant
mechanisms of the glutamatergic drug ketamine has been a critical part of this
progress. Ketamine’s rapid effects on sleep and clock-gene related pathways have
provided mechanistic antidepressant links with previously established, rapid-acting
chronotherapeutic interventions. Overall, ketamine’s capacity to increase
neurotrophic activity and synaptic strength, normalize sleep, and reinforce the
circadian system are seen as critical elements for rapid antidepressant mood effects.
Moving forward, two important areas of clinical development are needed. First,
the ability of repeated infusions to extend ketamine’s antidepressant effects is
being evaluated. Extended effects are reminiscent of sequentially applied chrono-
therapeutic effects; elucidating whether repeated treatments are also associated
with plasticity-associated sleep markers and molecular changes such as ketamine-
associated cortical excitability will be critical for developing interventions with
durable effects. Second, the potential antisuicidal effects of ketamine highlight the
need for more research into the relationship between suicide risk, sleep, and
circadian rhythms. One common pathway for ketamine’s rapid antidepressant
effects may be normalization of the circadian sleep/wake system transcriptome
that, in turn, may compensate for clock-gene variant effects or for insufficient
sleep caused by numerous behavioral or environmental factors. The recent identi-
fication of ketamine’s active metabolite (2R,6R-HNK) (Zanos et al. 2016) will be
an important element in identifying future novel treatments with fewer side effects
and more durable clinical benefits.
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Abstract
The classic endogenous somnogen adenosine promotes sleep via A1 and A2A
receptors. In this chapter, we present an overview of the current knowledge
regarding the regulation of adenosine levels, adenosine receptors, and available
pharmacologic and genetic tools to manipulate the adenosine system. This is
followed by a summary of current knowledge of the role of adenosine and its
receptors in the regulation of sleep and wakefulness. Despite strong data
implicating numerous brain areas, including the basal forebrain, the tubero-
mammillary nucleus, the lateral hypothalamus, and the nucleus accumbens, in
the adenosinergic control of sleep, the complete neural circuitry in the brain
involved in the sleep-promoting effects of adenosine remains unclear. Moreover,
the popular demand for natural sleep aids has led to a search for natural
compounds that can promote sleep via adenosine receptor activation. Finally,
we discuss the effects of caffeine in man and the possible use of more selective
adenosine receptor drugs for the treatment of sleep disorders.
Keywords
Adeno-associated virus • Astrocytes • CGS 21680 • DREADD • Istradefylline •
Modafinil • Non-rapid eye movement sleep • Optogenetics • Prostaglandin D2 •
Slow-wave sleep
1 The Concept of a Sleep Substance
The neural and cellular basis of the need for sleep or, alternatively, the “sleep drive”
remains unresolved, but can be conceptualized as a homeostatic pressure that builds
up during the waking period and dissipates during sleep. One potential mechanism
is that the gradual accumulation of one or more endogenous somnogenic factors
during wake is the underpinning of sleep homeostatic pressure. Rosenbaum
presented the first formal hypothesis that sleep is regulated by humoral factors in
1892 (Rosenbaum 1892), and Ishimori (Ishimori 1909; Kubota 1989) and Pieron
(Legendre and Pieron 1913) independently demonstrated the existence of sleep-
promoting chemicals a few years later. Both Ishimori and Pieron proposed, and
indeed established, the presence of hypnogenic substances or “hypnotoxins” in the
cerebrospinal fluid of sleep-deprived dogs (Inoue´ et al. 1995). Over the past
century, several additional putative hypnogenic substances implicated in the sleep
homeostatic process have been identified [for review, see Urade and Hayaishi
(2011)], including prostaglandin D2 (Qu et al. 2006; Ueno et al. 1982) [for review,
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see Urade and Lazarus (2013)], cytokines (Krueger et al. 1984) [for review, see
Krueger et al. (2011)], adenosine (Porkka-Heiskanen et al. 1997), anandamide
(Garcia-Garcia et al. 2009), and the urotensin II peptide (Huitron-Resendiz et al.
2005). Extensive evidence suggests that sleep regulation is interrelated with
components of the host defense (immune) system, such as pro-inflammatory
cytokines (Krueger and Majde 2003; Krueger et al. 2001; Mullington et al. 2000,
2001) and prostaglandins (Lazarus et al. 2007; Oishi et al. 2015; Urade and Lazarus
2013; Ushikubi et al. 1998). Several excellent reviews of the different theories of
how neural switching occurs between sleep and wakefulness are available [for
example, Fuller et al. (2015); Saper et al. (2005, 2010)]. In the present chapter,
we focus on the possible role of adenosine as a sleep substance.
2 Adenosine in Physiology and Pathophysiology
Adenosine is a neuromodulator and not a neurotransmitter. Although it is released
from nerve endings, its formation can be increased by various processes in all types
of cells, and in all parts of these cells. Furthermore, the basal level of adenosine
depends only on fundamental cell biology and is independent of nerve activity.
Adenosine acts on four evolutionarily well-conserved receptors that are present on
most if not all cells. Adenosine fulfills physiologic and pathophysiologic functions
(Fredholm 2014).
2.1 Regulation of Adenosine Levels
Adenosine is formed by hydrolysis of adenosine monophosphate (AMP) or S-
adenosylhomocysteine (Fredholm 2007; Schrader 1983). Adenosine is formed
from S-adenosylhomocysteine by the enzyme S-adenosylhomocysteine hydrolase,
which can also act to trap adenosine in the presence of excess L-homocysteine. This
takes place intracellularly and the fact that the enzyme is bidirectional ensures the
constant presence of a finite concentration of adenosine in the cell. The formation of
adenosine from 50-AMP can occur both intracellularly and extracellularly,
mediated by different enzymes. The intracellular 50nucleotidase generates adeno-
sine, which can be used to generate AMP by adenosine kinase. This bidirectional
reaction ensures the constant presence of a finite intracellular concentration of
adenosine in the range of 10 to a few hundred nanomolar (nM) under physiologic
conditions (Ballarin et al. 1991).
The fact that the intracellular concentration of adenosine is not zero ensures that
there is also a not insubstantial extracellular concentration of adenosine, because all
cells appear to possess one or more equilibrative purine transporters (Geiger and
Fyda 1991). Extracellular adenosine is increased when an adenine nucleotide is
released. Extracellular adenosine is formed by the conversion of ATP to adenosine
by a series of ecto enzymes on the cell surface. Extracellular ATP can be released
from various cell types by multiple mechanisms, including co-release from storage
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vesicles together with other hormones (neurotransmitter), a “kiss-and-run” mecha-
nism (MacDonald et al. 2006), lysosome exocytosis (Zhang et al. 2007), controlled
release through pannexin hemichannels (Chekeni et al. 2010; Elliott et al. 2009),
release from inflammatory cells or vascular endothelia through connexin hemi-
channels and channels such as P2X7 receptors (Chen et al. 2006; Faigle et al. 2008;
Linden 2006), and uncontrolled leakage from necrotic cells (Eltzschig 2009).
Extracellular ATP and adenosine diphosphate (ADP) are broken down to AMP
via many different ecto enzymes, especially CD39 (Yegutkin 2008). In the brain,
the AMP formed is then broken down to adenosine only via ecto-50-nucleotidase,
CD73 (Resta et al. 1998). Importantly, the levels of extracellular adenine nucleo-
tides are particularly high when cell membranes are broken, which allows the high
intracellular content to escape. Thus, trauma in any form is associated with elevated
levels of adenine nucleotides, as is blood sampling because most methods for this
lead to a breakdown of blood platelets. AMP is also released directly from apoptotic
cells (Yamaguchi et al. 2014).
ADP is released by platelets (Hollopeter et al. 2001), and ATP can be released
by many different cells, including endothelial cells (Bodin and Burnstock 1998),
astrocytes (Guthrie et al. 1999), and neurons (Fields and Stevens 2000), via many
different mechanisms (Burnstock and Verkhratsky 2012). In the brain, extracellular
adenosine might originate from neurons (both nerve terminals and postsynaptic
components) and from surrounding non-neuronal cells such as glial cells (Halassa
et al. 2007, 2009). For example, using inducible, astrocyte-specific transgenic
dominant negative SNARE mouse approaches, Haydon’s group suggested that
astrocytes are an important source of extracellular adenosine via gliotransmission
(Halassa et al. 2009). ATP released from neurons (both nerve terminals and
postsynaptic components) also contributes to extracellular adenosine production
via the CD73 enzyme, the only enzyme that degrades AMP to adenosine in the
brain (Lovatt et al. 2012; Wall and Dale 2013). In striatal neurons, extracellular
adenosine formed via CD73 may preferentially act at the A2A receptor as extracel-
lular CD73 is selectively co-expressed (Ena et al. 2013) and is physically associated
with A2A receptors in striatopallidal neurons (Augusto et al. 2013). Under patho-
logic conditions, such as cortical seizures, adenosine-mediated synaptic depression
is independent of CD73 activity and not a consequence of astrocytic (or neuronal)
ATP release, but is due to the activation of postsynaptic neurons, which leads to the
release of adenosine, thus constituting an autonomic feedback mechanism that
suppresses excitatory transmission during prolonged activity (Lovatt et al. 2012).
It may also be that under physiologic conditions, such as those involved in sleep and
wakefulness, adenosine is generated in a similar CD73-independent manner.
Adenosine levels are decreased by the enzyme adenosine deaminase (ADA; this
enzyme is particularly important when adenosine levels are high) and by uptake
into cells other than those that produced it. In these cells, the adenosine taken up is
rapidly phosphorylated to AMP by adenosine kinase. The formation and removal of
extracellular adenosine determine its levels. Under basal conditions, these levels are
low, usually in the order of 30–300 nM (Ballarin et al. 1991). Under more extreme
conditions, such as mild hypoxia or strenuous exercise, the levels can approach
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1 μM or more, and in severely traumatic situations, including local ischemia, can
reach up to several tens of μM (Fredholm 2007).
To link adenosine levels to sleep, one must be able to measure adenosine levels
in the brain but adenosine levels rapidly change in both the blood and tissue upon
sampling and tissue samples must be frozen within a second or less to preserve
in vivo levels. Such rapid inactivation is difficult to achieve, even with focused
microwave techniques, and hence measuring regional adenosine brain levels by
sampling tissue is highly problematic. Microdialysis could be a feasible method,
but as already demonstrated in the first reports using this technique, it takes a long
time to overcome the consequences of the initial traumatization required to insert
the microdialysis probes (Ballarin et al. 1991; Benveniste et al. 1989; Zetterstrom
et al. 1982). Furthermore, if the probe is allowed to remain in the tissue too long it
will be covered with glial cells that hamper the exchange of purines (Benveniste
et al. 1989). Electrochemical methods were recently used to measure local adeno-
sine levels (Dale and Frenguelli 2012), but this method is also associated with
caveats. Thus, reported adenosine levels in sleep and wakefulness should not be
uncritically accepted.
2.2 Adenosine Receptors
Extracellular adenosine reacts with one of the four adenosine receptors, A1, A2A,
A2B, and A3 (Fredholm et al. 2011). If these receptors are expressed at the same
level (~200,000 receptors/cell), adenosine appears to be equally potent at A1, A2A,
and A3 receptors (Fig. 1), and the levels of adenosine occurring under basal
physiologic conditions are sufficient to activate these receptors. The data suggest
that higher concentrations of adenosine are needed to activate A2B receptors.
Nevertheless, it is important to remember that the potency of an agonist such as
adenosine on its receptor depends on the number of receptors available, i.e., in the
presence of only a few receptors higher adenosine concentrations are required to see
an effect. Local expression of the A1 and A2A receptors appears to be higher than
that of the other two receptors (Fredholm et al. 2005a). Thus, these two receptor
types may be primarily involved in sleep regulation.
First, we briefly discuss how the role(s) of adenosine in physiology and patho-
physiology can be determined.
3 How Do We Learn About the Roles of Adenosine?
3.1 Receptor Antagonists Including Caffeine
To assess the in vivo actions of adenosine receptors, selective pharmacologic tools
are crucial. Over the last 20 years, medicinal chemistry has generated agonists and
antagonists with high affinity (Kd values in the low nM range) and selectivity
(>100–200-fold over other adenosine receptor subtypes) for the human variants of
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each of the four receptors (Fredholm et al. 2011). Most of the known adenosine
receptor agonists are derivatives of purine nucleosides, either adenosine or
xanthosine, while adenosine receptor antagonists have diverse structures (Müller
and Jacobson 2011). Many A2A-selective antagonists from different structural
classes have been developed, including 8-(3-chlorostyryl)caffeine, MSX-2, and
its water-soluble prodrugs MSX-3, ZM 241385, SCH-58261, and KW6002. In
addition, radioactive, and more recently, fluorescent, ligands of adenosine receptors
were also developed and introduced for drug screening and monitoring in vivo
receptor occupancy in humans.
Caffeine, the most widely consumed arousal-promoting psychostimulant, is a
classic nonselective adenosine receptor antagonist, although it is rather weakly
potent at adenosine receptors (Ki  10 μM). At doses commonly consumed by
humans, caffeine produces its profound arousal effect by partial (estimated to be
25–50%) and nonselective (similar affinity for both A1 and A2A receptors) blockade
of adenosine receptors (Fredholm et al. 1999). Caffeine is metabolized to
paraxanthine and theophylline (Arnaud 2011). These metabolites are more potent
than caffeine as inhibitors of A1 and A2A receptors. Therefore, elimination of
caffeine does not predict the elimination of adenosine receptor blockade and
hence the effects of caffeine administration.
Importantly, several A2A receptor antagonists are in clinical trials for Parkinson’s
disease (PD), including istradefylline (KW6002), SYN-115, and preladenant
(SCH-442416). Phase IIB and III clinical trials with A2A receptor antagonists showed
a very consistent and excellent safety profile in more than 3,000 patients with
advanced PD (Hauser et al. 2011; Jenner et al. 2009). The safety profile of these
Fig. 1 Schematic illustration of the ability of adenosine to activate the four adenosine receptors.
Note that A1, A2A, and A3 receptors are activated by basal levels of adenosine at sites where the
receptor number is high. In contrast, A2B receptors are mostly activated in pathologic conditions
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A2A receptor antagonists is entirely consistent with the widespread use of the
nonselective adenosine receptor antagonist caffeine in 70% of the human population.
Importantly, this provides an opportunity to rapidly translate A2A receptor antagonists
to achieve pharmacologic control of the sleep–wake cycle.
3.2 Receptor Knockouts and Other Genetic Targeting
Techniques
Over the past two decades, genetic knockout (KO) models for all four G-protein-
coupled adenosine receptors were generated by targeted deletion of critical exons
(Fredholm et al. 2005b; Wei et al. 2011). These adenosine receptor KOmodels have
provided insights into the physiologic function of modulation of the sleep–wake
cycle by overcoming the limitations of pharmacologic agents with partial specific-
ity and by targeting the adenosine receptor in defined cellular populations. For
example, the use of A2A receptor KO models can overcome concerns about the
partial specificity of A2A receptor antagonists (particularly after focal injection at
relatively high concentrations), and convincingly demonstrated that the sleep-
promoting effect of A2A receptor agonists and caffeine-induced arousal effect are
mediated by A2A receptors (not A1 receptors). Global A1 and A2A receptor KO
approaches, however, have intrinsic limitations of the confounding developmental
effect and lack of cell-type specificity (Fredholm et al. 2005b). To overcome these
limitations, conditional KO of some adenosine receptor genes in defined brain
regions (e.g., forebrain versus striatum) and cell-type (e.g., neurons versus
astrocytes) has been achieved using the Cre-loxP system [for review see Fuller
et al. (2015); Wei et al. (2011)]. Brain-regional deletion of A2A receptors has been
achieved in the forebrain (i.e., striatum, cortex, hippocampus) (Bastia et al. 2005;
Yu et al. 2008) and striatum (Shen et al. 2008). Local deletion of A1 receptors in
hippocampal CA1 or CA3 neurons and A2A receptors in the nucleus accumbens
(NAc) has also been achieved by local injection of adeno-associated virus (AAV)
vectors containing the cre transgene into the brains of mice carrying loxP-flanked
A1 receptor (Scammell et al. 2003) or A2A receptor (Lazarus et al. 2011) genes. The
conditional KO strategy permits a temporal and regional specificity that has uncov-
ered previously under-appreciated functions of adenosine receptors in the basal
ganglia for controlling the sleep–wake cycle (see detailed discussion below). In
addition, the development of AAV carrying short-hairpin RNA targeted to produce
site-specific silencing of the A2A receptor gene allowed for the clear demonstration
in rats that the arousal effect of caffeine is mediated by A2A receptors in the NAc
shell (Lazarus et al. 2011). Lastly, the recent development of optogenetics based on
specific local modulation of neuronal activity using genetically engineered optical
switches (e.g., channelrhodopsin) (Boyden et al. 2005; Deisseroth 2014; Yizhar
et al. 2011) or chemogenetics to study G-protein signaling in freely behaving
animals by the directed molecular evolution of designer receptors exclusively
activated by designer dugs (DREADD) (Farrell et al. 2013; Giguere et al. 2014)
has refined our understanding of novel brain circuits underlying the sleep–wake
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cycle (Fuller et al. 2015). Recently, a probe for selective optogenetic control of A2A
receptor signaling (optoA2A receptor) was developed (Li et al. 2015).
4 Adenosine and Sleep
4.1 Adenosine Levels During Sleep and Wakefulness
Adenosine has long been known to represent a state of relative energy deficiency:
ATP depletion and the elevation of extracellular adenosine levels are positively
correlated (Kalinchuk et al. 2003) and positively associated with sleep (Porkka-
Heiskanen et al. 1997). Adenosine levels in samples collected from several brain
areas of cats during spontaneous sleep–wake cycles by in vivo microdialysis were
higher during non-rapid eye movement (non-REM, NREM) sleep than wakefulness
for all probed brain areas (Porkka-Heiskanen et al. 1997, 2000). Moreover, in vivo
microdialysis experiments in the brain of cats also revealed that adenosine
concentrations specifically increase twofold in the basal forebrain (BF) during a
prolonged 6-hour period of wakefulness compared with that at the beginning of
sleep deprivation (Porkka-Heiskanen et al. 1997, 2000).
Sixty years have passed since the discovery of the hypnotic effect of adenosine
in the mammalian brain (Feldberg and Sherwood 1954); however, the brain cell
types involved in the sleep-promoting effects of adenosine remain unclear. In
principle, adenosine (and ATP, which is rapidly degraded to adenosine) can be
released from neurons or glia cells. Genetically engineered mice that selectively
express a dominant negative SNARE domain in astrocytes to nonspecifically block
the release of ATP exhibit decreased concentrations of extracellular adenosine
(Pascual et al. 2005). Although the amount of wakefulness, NREM, and REM
sleep in these mice is indistinguishable from that in wild-type mice, these mice
exhibit reduced slow-wave activity and recovery sleep after sleep deprivation
(Halassa et al. 2009), suggesting that adenosine released from astrocytes is involved
in the accumulation of sleep pressure. Direct proof is still lacking, however, and
thus the exact sources of adenosine remain unknown.
The late Miodrag Radulovacki and colleagues extensively investigated the
effects of adenosine on wakefulness. They used the ADA inhibitor deoxy-
coformycin to increase the levels of adenosine in the central nervous system of
rats and found that REM and NREM sleep were increased (Radulovacki et al.
1983), further supporting a hypnotic role for adenosine.
Adenosine is reported to promote sleep by acting through A1 or A2A receptors,
but the relative contribution of these receptors to sleep induction remains contro-
versial (Basheer et al. 2004; Huang et al. 2007). Indirect evidence by comparison of
the effects of caffeine, the A1 receptor antagonist 8-cyclopentyltheophylline, and
the nonselective A1/A2A receptor antagonist alloxazine on sleep in rats (Virus et al.
1990) might partially account for the prevailing opinion that the A1 receptor is more
important in sleep–wake regulation than the A2A receptor. The aforementioned
pharmacologic approach and related studies, however, have non-trivial limitations,
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particularly with respect to data interpretation. For example, receptor antagonists
are difficult to compare due to differences in solubility, blood–brain-barrier perme-
ability, and neuropharmacodynamics, and most importantly, have “off-target”
effects, especially at higher concentrations. Moreover, the diffuse expression of
inhibitory A1 receptors in the brain may have differential effects on sleep and
wakefulness in a region-specific manner (Ochiishi et al. 1999a, b; Reppert et al.
1991; Rivkees et al. 1995). The advent of genetically engineered systems, including
transgenic animals and recombinant viral vectors, and findings in humans have
convincingly established over the last decade a pivotal role of A2A receptors in the
regulation of sleep and wakefulness (Holst and Landolt 2015; Lazarus et al. 2012,
2013).
4.2 Effects of A1 Receptors
The A1 receptor agonist N
6-cyclopentyladenosine produces dose-dependent
increases in slow-wave activity in electroencephalography during NREM sleep
when administered systemically or intracerebroventricularly in rats (Benington
et al. 1995), but lateral ventricle infusions of N6-cyclopentyladenosine in mice do
not change the amounts of observed NREM and REM sleep (Urade et al. 2003),
which may indicate opposing effects on sleep and wakefulness in different areas of
the brain. For example, adenosine acting via A1 receptors induces sleep by
inhibiting arousal-related cell groups in the BF, such as the horizontal limb of the
diagonal band of Broca and the substantia innominata (Fig. 2a) (Alam et al. 1999;
Strecker et al. 2000). Moreover, adenosine may promote sleep by A1 receptor-
mediated inhibition of glutamatergic inputs to cortically projecting cholinergic and
γ-aminobutyric acid (GABA) neurons of the BF (Yang et al. 2013). Adenosine
could also promote sleep by suppressing hypocretin/orexin neurons in the lateral
hypothalamus, because an A1 receptor agonist produced NREM and REM sleep
and the receptor’s antagonist induced wakefulness (Fig. 2b) (Thakkar et al. 2008).
ADA is predominantly localized in the tuberomammillary nucleus (TMN) of the
brain and the TMN is enriched in histamine neurons containing A1 receptors,
thereby suggesting that the histaminergic arousal system is actively regulated
by adenosine in the TMN. In fact, bilateral injections of the A1 receptor agonist
N6-cyclopentyladenosine into the rat TMN significantly increase the amount of
NREM sleep (Fig. 2c) (Oishi et al. 2008). Moreover, bilateral injections of adeno-
sine or the ADA inhibitor coformycin into the rat TMN also increase NREM sleep,
which is completely abolished by co-administration of the selective A1 receptor
antagonist 1,3-dimethyl-8-cyclopenthylxanthine. These results indicate that endog-
enous adenosine in the TMN suppresses the histaminergic system via A1 receptors
to promote NREM sleep. Interestingly, single-nucleotide polymorphism analyses
have identified a human genetic ADA variant with low enzymatic activity that is
linked to the enhancement of deep sleep and slow-wave activity during sleep
(Bachmann et al. 2012; Mazzotti et al. 2012; Re´tey et al. 2005). By contrast,
activation of A1 receptors in the lateral preoptic area of the hypothalamus by
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local infusion of an A1 receptor agonist promotes wakefulness (Methippara et al.
2005).
4.3 Effects of A2A Receptors
CGS 21680, a highly selective A2A receptor agonist, produces profound increases in
NREM and REM sleep after infusion into the subarachnoid space underlying the
ventral surface region of the rostral BF in rats or into the lateral ventricle of mice
(Satoh et al. 1996; Urade et al. 2003). In vivo microdialysis experiments
demonstrated that infusions of CGS 21680 into the BF inhibit the release of
Fig. 2 Circuit basis of sleep–wake regulation. Model 1 (shown in panel a): adenosine inhibits the
release of acetylcholine from the basal forebrain (BF) cholinergic neurons to produce slow-wave
sleep. Model 2 (shown in panels b–d): a flip–flop switching mechanism involving mutually
inhibitory interactions between sleep-promoting neurons in the ventrolateral preoptic area
(VLPO) and wake-promoting neurons in the hypothalamus [i.e., histaminergic tuberomammillary
nucleus (TMN)], and brainstem [i.e., noradrenergic locus coeruleus (LC), serotonergic dorsal
raphe nucleus (DR), and cholinergic laterodorsal tegmental nucleus (LDT)]. The flip-flop switch
between the VLPO and hypothalamus and brainstem is stabilized by orexin/hypocretin (OX/Hcrt)
inputs from the lateral hypothalamus (LHA). Adenosine acts as an endogenous somnogen and
promotes sleep via inhibitory A1 receptors (A1) in the basal forebrain, VLPO, LHA, and TMN and
excitatory A2A receptors (A2A) in the nucleus accumbens (NAc) and VLPO (Huang et al. 2007,
2011; Lazarus et al. 2012, 2013). Other abbreviations: Ach acetylcholine, 5-HT serotonin, NE
norepinephrine
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histamine in both the frontal cortex and medial preoptic area in a dose-dependent
manner, and increase the release of GABA in the TMN of the hypothalamus, but not
in the frontal cortex (Hong et al. 2005). CGS 21680-induced blocking of histamine
release is antagonized when the TMN is perfused with the GABA antagonist
picrotoxin, suggesting that the A2A receptor agonist induces sleep by inhibiting
the histaminergic system through an increase in GABA release in the TMN. It was
previously proposed that sleep is promoted by activating sleep neurons in the
ventrolateral preoptic area (VLPO) and reciprocal suppression of histaminergic
wake neurons in the TMN through GABAergic and galaninergic inhibitory projec-
tions (Sherin et al. 1996, 1998). The existence of two distinct types of VLPO
neurons in terms of their responses to serotonin and adenosine was demonstrated
by intracellular recordings of VLPO neurons in rat brain slices (Fig. 2b). VLPO
neurons are uniformly inhibited by the arousing neurotransmitters noradrenaline
and acetylcholine, and primarily inhibited by an A1 receptor agonist. Serotonin
inhibits type-1 neurons but excites type-2 neurons, whereas an A2A receptor agonist
postsynaptically excites type-2, but not type-1 neurons. These results implicate the
involvement of type-2 neurons in the initiation of sleep, whereas type-1 neurons
contribute to sleep consolidation as they are only activated in the absence of
inhibitory effects from the arousal systems (Gallopin et al. 2005).
The administration of CGS 21680 into the rostral BF, however, produces c-fos
expression not only in the VLPO, but also within the NAc shell and the medial
portion of the olfactory tubercle (Satoh et al. 1999; Scammell et al. 2001). Interest-
ingly, direct perfusion of the A2A receptor agonist into the NAc induces NREM and
REM sleep that corresponds to about three-quarters of the amount of sleep
measured when the A2A receptor agonist is infused into the subarachnoid space
(Satoh et al. 1999). These results may indicate that A2A receptors within or close to
the NAc predominantly promote sleep (Fig. 2a). Acting opposite to adenosine,
caffeine enhances wakefulness because it acts as an antagonist of both A1 and A2A
receptor subtypes (Fredholm et al. 1999). Experiments using global genetic KOs of
the A1 and A2A receptors revealed that A2A receptors, but not A1 receptors, mediate
the arousal-inducing effect of caffeine (Huang et al. 2005). The specific role of A2A
receptors in the basal ganglia (BG) was investigated using powerful tools for site-
specific gene manipulations, such as conditional KO mice of the A2A receptor based
on the Cre/lox technology or local infection with AAV carrying short-hairpin RNA
of A2A receptors to silence the expression of the receptor subtype (Lazarus et al.
2011). Deletion of A2A receptors selectively in the NAc shell blocked caffeine-
induced wakefulness (Fig. 3). Excitatory A2A receptors within the NAc shell must
be tonically activated by adenosine for caffeine to be effective as an A2A receptor
antagonist. This tonic activation probably occurs in the NAc shell because sufficient
levels of adenosine are available under basal conditions and A2A receptors are
abundantly expressed throughout the striatum, including the NAc shell (Rosin et al.
1998; Svenningsson et al. 1999). Thus, activation of A2A receptors in the NAc shell
contributes to the restraint of the arousal system, whereby caffeine overrides the
“adenosine brake” to promote wakefulness. Interestingly, deletion of the dopamine
transporter (DAT), which is responsible for the re-uptake of dopamine (Giros and
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Caron 1993), in mice reduces NREM sleep, increases wakefulness, and unmasks
hypersensitivity to the wake-promoting effects of caffeine (Wisor et al. 2001). The
last observation may indicate that the expression of NAc D2 receptors working
opposite to A2A receptors is involved in the arousal effect of modafinil, a
wakefulness-promoting compound. Despite the fact that stimulating A2A receptors
leads to decreased affinity for dopamine at D2 receptors via intramembrane
interactions and to a reduction in Gi-protein coupling of the D2 receptor for the
inhibition of cAMP production (Fuxe et al. 2003), adenosine and its antagonists,
such as caffeine, can modulate the activity of medium spiny projection neurons in
the striatum via A2A receptors independently of D2 receptors (Aoyama et al. 2000;
Chen et al. 2001). Interestingly, humans with a genetic reduction of striatal DAT
show an elevated sensitivity to caffeine stimulation and increased homeostatic
response when they are sleep deprived (Holst and Landolt 2015).
The study of NAc adenosine-mediated modulation of the sleep–wake cycle led
to a new proposal that the BG represents a key structural element for the control of
sleep and wakefulness (Lazarus et al. 2011, 2012). Dysfunction in the BG, such as
PD and Huntington’s disease and lesions in the BG, results in a wide range of
disorders of movement, cognition, and sleep–wake function (Adler and Thorpy
2005; Dale et al. 2004; Goodman and Barker 2010; Obeso et al. 2000; Wetter et al.
2000). In fact, bilateral lesions using ibotenic acid to kill intrinsic neurons in the
striatum (caudoputamen), internal and external globus pallidus (GPe), subthalamic
nucleus, substantia nigra (pars reticulata or compacta), or thalamus revealed that
Fig. 3 The arousal effects of caffeine are abolished in rats with site-specific deletion of A2A
receptors (A2AR) in the shell of the nucleus accumbens (NAc). To identify the neurons on which
caffeine acts to produce arousal, A2A receptors were focally depleted by bilateral injections of
adeno-associated virus carrying short-hairpin RNA for the A2A receptor into the core (dashed
green line in the left panel) or shell (dashed red line in the right panel) of the nucleus accumbens of
rats (Lazarus et al. 2011). Typical hypnograms that show changes in wakefulness and in rapid eye
movement (REM) and non-REM (NREM) sleep after administration of caffeine at a dose of
15 mg/kg indicate that rats with shell, but not core, knockdown of the A2A receptors showed a
strongly attenuated caffeine arousal.Green and red areas in the hypnograms represent wakefulness
after caffeine administration that correspond to the depletion of A2A receptors in the core and shell
of the nucleus accumbens, respectively
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bilateral lesions made in the striatum or specifically in the NAc result in a signifi-
cant reduction in time spent in wakefulness and fragmentation of both sleep and
wakefulness (Qiu et al. 2010). Only lesions in the caudate–putamen and globus
pallidus increased sleep by 10% and wake by 50%, respectively (Qiu et al. 2010).
Moreover, the complete deletion of D2 receptors, which are prominently, albeit not
exclusively, expressed in the BG, significantly decreases wakefulness with a con-
comitant increase in NREM and REM sleep and a drastic decrease in the NREM
sleep delta power (Qu et al. 2010). Excessive sleepiness in PD and other sleep
disorders are commonly treated with modafinil (Hogl et al. 2002; Minzenberg and
Carter 2007) and interestingly, the arousal effect of modafinil is exclusively
mediated by D1 and D2 receptors, with D2 receptors being of primary importance
(Qu et al. 2008). Based on these findings, it was proposed that activation of
A2A receptors leads to enhanced activity of GABAergic output neurons in the
striatopallidal pathway and subsequently arousal systems in the thalamus, hypo-
thalamus, brainstem, and ultimately the cerebral cortex are maintained under a
tight inhibitory control. In fact, stereotaxic-based brain microinjections of Cre-
recombinase-dependent AAV vectors carrying channelrhodopsin or DREADD into
the NAc of transgenic mice in which Cre-recombinase is expressed under the A2A-
receptor promoter robustly induced NREM sleep during selective activation of
striatopallidal neurons by light or the small molecule clozapine-N-oxide (Oishi Y,
Xu Q, et al., unpublished).
Moreover, a recent study found that blocking A2A receptors or A2A receptor-
expressing neurons in the olfactory bulb of rodents increases REM sleep,
suggesting the possibility that the olfactory bulb is a key site for regulating REM
sleep by the adenosine/A2A receptor system (Wang et al. 2016). Because olfactory
dysfunction can be ameliorated with an A2A receptor antagonist, for example,
caffeine or ZM 241385 (Prediger et al. 2005), it is possible that REM sleep and
the perception of odors are linked in the olfactory bulb. Interestingly, the ability to
smell is reduced in patients with REM sleep behavior disorder (Stiasny-Kolster
et al. 2007).
4.4 Effects of Natural Compounds on Sleep and Wakefulness via
Adenosine Receptors
Several studies recently demonstrated that a variety of natural compounds promote
sleep via adenosine receptor activation. In strong support of the role of A2A receptors
in the regulation of sleep, Japanese sake yeast supplementation improves the quality of
sleep in humans (Monoi et al. 2016) and sake yeast-induced NREM sleep was
abolished in mice by pretreatment with the A2A receptor antagonist ZM 241385
(Nakamura et al. 2016). Because sake yeast, but not other Saccharomyces cerevisiae
yeasts (e.g., baker’s and brewer’s yeast), contains a large amount of S-adenosyl-L-
methionine and the S-adenosyl-L-methionine metabolite methylthioadenosine, Urade
and colleagues suggested that the sleep-inducing effect of sake yeast is likely due to
the activation of A2A receptors by S-adenosyl-L-methionine or methylthioadenosine.
Adenosine and Sleep 371
In contrast, paeoniflorin, one of the principal active ingredients of Paeonia
Radix, shortens sleep latency and increases the amount of NREM sleep exclusively
via the activation of A1 receptors, a conclusion based on the finding that paeo-
niflorin effects can be blocked by treatment with an A1 receptor antagonist and are
absent in A1 receptor-KO mice (Chen et al. 2015). In addition, paeoniflorin signifi-
cantly increases the mechanical pain threshold, prolongs the thermal latency, and
increases NREM sleep in partial sciatic nerve ligation mice, a mouse neuropathic
pain model characterized by persistent pain and insomnia (Yin et al. 2015).
Therefore, the A1 receptor-mediated analgesic and hypnotic effects of paeoniflorin
may be of potential use for the treatment of neuropathic pain and associated
insomnia.
Moreover, N6-(4-hydroxybenzyl) adenine riboside isolated fromGastrodia elata
has hypnotic effects in mice (Zhang et al. 2012) and may dose-dependently increase
NREM sleep via mechanisms that involve A1 and A2A receptors. Finally,
cordycepin (3-deoxyadenosine), an adenosine analogue isolated from Cordyceps
fungi, promotes NREM sleep in rats, but it remains unclear if the sleep-inducing
effect is, in fact, mediated by adenosine receptors (Hu et al. 2013).
5 Effects of Caffeine in Man and the Possible Role of More
Selective Adenosine Receptor Drugs
Whereas the above data linking adenosine to sleep were obtained from animal
experiments, the evidence suggests that this link also holds true in humans. This is
largely due to the well-known effects of caffeine on sleep. Caffeine is the most
consumed psychoactive compound in the world. It is readily available through
dietary products, such as coffee, tea, soft drinks, and chocolate, but it is also added
to non-prescription medications, such as pain-relievers and cold remedies. Regard-
less of the source, worldwide average caffeine consumption is estimated to be just
under 80 mg/d, although the levels of intake in countries such as Sweden and
Finland are in the range of 400 mg caffeine per day (Fredholm et al. 1999). Caffeine
is widely used to promote wakefulness and to counteract fatigue in doses that are
well in the range where adenosine antagonism is the dominant effect. Some
individuals, however, experience anxiety and panic attacks (Chait 1992; Evans
and Griffiths 1991) at normal consumption levels, and this is more common at
higher doses. One study found that people with polymorphisms at the A2A-receptor-
gene are at risk of experiencing increased anxiety when consuming coffee, tea,
energy drinks, or other caffeine-containing products (Alsene et al. 2003). A2A
receptor polymorphisms also consistently modulate the objective and subjective
effects of caffeine on sleep quality and electroencephalogram (Bodenmann et al.
2012; Byrne et al. 2012; Re´tey et al. 2007).
Whether caffeine affects circadian rhythm and thereby alters the timing of sleep
is widely unknown; however, recent developments revealed caffeine effects on the
mammalian circadian clock. For example, caffeine delays the human circadian
melatonin rhythm by blocking A1 receptors (Burke et al. 2015). Chronic treatment
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with caffeine lengthens the circadian period of molecular oscillations in human
osteosarcoma U2OS cells expressing clock gene luciferase reporters. Further,
application of pharmacologic tools and small-interfering RNA knockdown revealed
that the effect of caffeine on molecular oscillation is attenuated by perturbation of
A1 receptor signaling but not ryanodine receptor or phosphodiesterase activity. This
finding establishes a possible molecular mechanism for the clinical observation in a
double-blind, placebo-controlled, ~49-day long, within-subject study that bedtime
caffeine consumption induces a ~40-min phase delay of the circadian melatonin
rhythm in humans. Another study revealed that caffeine increases the light sensi-
tivity of the mouse circadian clock (van Diepen et al. 2014).
Society demands the means to bend sleep to the needs of modern lifestyle instead
of the other way around and thus sleep-avoidance has become a popular research
topic. Scientists and clinicians worldwide are searching for new methods of keeping
people alert on limited sleep. Much more about the effects of coffee and other
beverages containing caffeine on sleep in man will be covered elsewhere in this
book [for review, see Clark and Landolt (2017)]. Moreover, consistent with the fact
that the arousal effect of caffeine in mice is exclusively mediated by A2A receptors,
emerging evidence supports the modulation of the sleep–wake cycle by A2A
receptor antagonists. For example, the newly developed dual adenosine A2A/A1
receptor antagonist JNJ-40255293 enhances wakefulness (Atack et al. 2014).
Moreover, since the clinical approval of the A2A receptor antagonist istradefylline
(KW-6002) for motor improvement in PD in Japan in 2013, a report of four cases
indicated that evening treatment with this antagonist reduces sleep duration in the
evening and increases daytime sleepiness in patients (Matsuura and Tomimoto
2015). Thus, A2A receptor antagonists may have considerable potential as eugeroics
(wakefulness enhancing drugs) while avoiding some of the aforementioned A2A-
independent side effects of caffeine (such as anxiety and disturbance of the circa-
dian rhythm) or negative effects of other psychostimulants, including dependence.
The possibility that stimulation of adenosine receptors could be used to pro-
mote sleep should also be considered. Currently, there are 60 million prescrip-
tions for sleeping pills in the USA each year, 43 million of which are for
the nonbenzodiazepine zolpidem, also known as Ambien. Benzodiazepines and
nonbenzodiazepines, both of which enhance the effect of the neurotransmitter
GABA at the GABAA receptor, are used for the treatment of insomnia and poor
sleep quality despite their wide range of disadvantages and safety issues, ranging
from low sleep quality by increasing light sleep at the expense of physiological
deep sleep to side effects (e.g., next-day sedation, cognitive impairment, and
amnesic effects) and the development of tolerance and dependence by long-term
administration. Because an A2A receptor agonist strongly increases sleep in wild-
type mice (Satoh et al. 1996; Urade et al. 2003), pharmacologic A2A receptor
activation may be an alternative strategy for the treatment of insomnia. Due to
the lack of brain-permeability, however, not all currently existing A2A receptor
agonists are suitable for treating the nervous system. If the observation in animals
that adenosine levels are elevated during prolonged wakefulness holds also true
for humans, a freely penetrating allosteric modulator may effectively enhance the
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sleep-inducing effect of endogenous adenosine and help people with insomnia to
fall asleep.
6 Conclusion
Here we demonstrated that adenosine is indeed one of the several somnogenic
substances that act in concert to ensure normal sleep–wake patterns. Adenosine
tends to increase sleep, but the source of the adenosine is still poorly understood.
Many cells and processes could play a role. Similarly, adenosine promotes sleep by
several mechanisms, in several locations, via A1 or A2A receptors. We emphasized
A1 receptor-mediated effects on histamine neurons and the A2A receptor-mediated
effects in the NAc. Both of these receptors are antagonized by caffeine – to a large
extent explaining the awakening effect of this common drug.
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Abstract
Mechanisms for elimination of metabolites from ISF include metabolism,
blood–brain barrier transport and non-selective, perivascular efflux, this last
being assessed by measuring the clearance of markers like inulin. Clearance
describes elimination. Clearance of a metabolite generated within the brain is
determined as its elimination rate divided by its concentration in interstitial fluid
(ISF). However, the more frequently measured parameter is the rate constant for
elimination determined as elimination rate divided by amount present, which
thus depends on both the elimination processes and the distribution of the
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metabolite in the brain. The relative importance of the various elimination
mechanisms depends on the particular metabolite. Little is known about the
effects of sleep on clearance via metabolism or blood–brain barrier transport,
but studies with inulin in mice comparing perivascular effluxes during sleep
and wakefulness reveal a 4.2-fold increase in clearance. Amongst the important
brain metabolites considered, CO2 is eliminated so rapidly across the blood–
brain barrier that clearance is blood flow limited and elimination quickly
balances production. Glutamate is removed from ISF primarily by uptake
into astrocytes and conversion to glutamine, but also by transport across the
blood–brain barrier. Both lactate and amyloid-β are eliminated by metabolism,
blood–brain barrier transport and perivascular efflux and both show decreased
production, decreased ISF concentration and increased perivascular clearance
during sleep. Taken altogether available data indicate that sleep increases
perivascular and non-perivascular clearances for amyloid-β which reduces its
concentration and may have long-term consequences for the formation of
plaques and cerebral arterial deposits.
Keywords
Amyloid-beta • Blood—brain barrier transport • Brain interstitial fluid volume •
Carbon dioxide • Cerebrospinal fluid • Clearance • Glutamate • Glymphatic
circulation • Inulin • Lactate • Metabolite elimination mechanisms • Perivascular
efflux • Perivascular spaces • Rate constant for elimination • Volume of
distribution
1 Introduction
All substances required for brain cell activity have ultimately to derive from outside
the brain. Likewise all metabolites created within the brain have to be eliminated in
one way or another. The principal routes of entry and exit are indicated in Fig. 1.
This review deals with the processes affecting elimination and how they may differ
between wakefulness and sleep.
1.1 How Is Clearance Defined?
The clearance of a substance from the brain is a statement of how easily that
substance can be eliminated. It is defined as
clearance ¼ rate of eliminationð Þ=concentration: ð1Þ
If rate of elimination is expressed as amount per unit time, e.g. with units
mol min1, and the concentration as amount per unit volume, e.g. with units
mol mL1, the clearance has the units of a volume flow, e.g. mL min1. Both
elimination rate and substance concentration can be measured and both are required
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to describe the processes of elimination. The rate of elimination itself is not a good
description because even if the elimination mechanism is unchanged, the rate can
and usually does vary with substance concentration. The concentration alone is not
a good description because it is affected by both production and elimination of the
substance of interest. During many studies of sleep it is only the changes in
concentrations of metabolites in interstitial fluid (ISF) or cerebrospinal fluid
(CSF) that have been reported. Whether these can be interpreted as changes in
rate of production of these metabolites or changes in their clearance can be difficult
to establish.
As an additional complication, it is not immediately obvious which concentra-
tion should be used. The metabolite may be both inside and outside of cells and
some of it may have precipitated. Probably the best choice is to use the exchange-
able concentration in ISF because that concentration can be measured, e.g. by
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Fig. 1 Routes by which substances enter and leave cerebrospinal fluid (CSF), interstitial fluid
(ISF) and the brain. The extracellular fluid of the brain consists of CSF filling the larger cavities
including the ventricles, cisterns and subarachnoid spaces and ISF filling the small spaces between
the cells of the brain parenchyma. CSF is secreted into the ventricles across the choroid plexuses
(1). There is rapid movement of O2, CO2, H2O and lipid soluble substances between blood and ISF
across the blood–brain barrier (2). Movements within the ISF (3) are primarily by diffusion and
there is also primarily diffusional exchange between ISF and CSF in the ventricles. Movements
between ISF and the CSF in the subarachnoid spaces and basal cisterns surrounding the brain
(5) are faster involving influx and efflux along the perivascular spaces (see Sect. 2.3) of the blood
vessels that penetrate the parenchyma. There is outflow of CSF across the arachnoid villi
(6) leading to the dural venous sinuses (including but not restricted to the superior sagittal sinus)
and along cranial nerves, most notably the olfactory nerve leading to the cribriform plate (7) and
thence to the nasal mucosa. There is also outflow of fluid associated with arteries or veins
(8) leading to lymph nodes in the neck. The traditional view of the directions of net CSF flow
from the choroid plexuses to the sites of outflow is indicated by the dotted lines with arrowheads.
Figure modified from Hladky and Barrand (2014)
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microdialysis (Cirrito et al. 2003), and the different elimination processes can be
described as depending upon it.
Though there are many different metabolites generated within the brain, this
review will consider in specific terms only a few important examples (CO2,
glutamate/glutamine, lactate and amyloid-β) and how their clearances differ or
may differ during periods of wakefulness and sleep. Comparing periods of wake-
fulness to periods of sleep, there is known to be increased nervous activity,
increased glucose and O2 consumption, increased lactate production and ISF lactate
concentration, progressive increases in glutamate concentrations in ISF and
increased production and ISF concentration of amyloid-β (Aβ) (Kennedy et al.
1981; Netchiporouk et al. 2001; Vyazovskiy et al. 2008b, 2009; Ball et al. 2010;
Porkka-Heiskanen and Kalinchuk 2011; Dash et al. 2012; Naylor et al. 2012;
Tononi and Cirelli 2014; Cedernaes et al. 2017). During non-rapid eye movement
sleep (nREM sleep or slow-wave sleep) all of these changes are reversed at least in
part. Thus, other things being equal, rates of elimination of these metabolites are
expected to decrease during sleep as their ISF concentrations decline.
1.2 Pharmacokinetic Considerations
Providing the rate of elimination of a substance is proportional to its concentration
then its clearance is a constant, independent of concentration. With only a few
exceptions, drugs in clinical use show constant clearance over their therapeutic
range. This makes dosing much simpler and safer. However, this may not be the
case with brain metabolites for which elimination processes may saturate. In these
situations clearance will decrease as concentration increases. Nevertheless, clear-
ance is still a much better description of the elimination processes than either the
rate of elimination or the rate constant for elimination described in the next section.
Averaged over a sufficient length of time, the concentration of any metabolite in
the extracellular fluid must take on the value at which its rate of production (and
release into the extracellular fluid) is balanced by its elimination. In terms of the
clearance, CL, and concentration, c, on average
CL c ¼ rate of elimination ¼ rate of production: ð2Þ
Hence if the metabolite concentration, c, is increased after awakening then either
the rate of production has increased or the clearance, CL, has decreased. Similarly if
c decreases on falling asleep either the rate of production has decreased or CL has
increased. Equation (2) is central to understanding control of the rate of elimination.
If at any time the rate of elimination doesn’t balance the rate of production, the
concentration and thus the rate of elimination will change until it does. Thus in a
very real sense so long as concentration can change the rate of elimination, that rate
is determined by the rate of production. Changes in clearance alter the concentra-
tion at which this balance of rates occurs.
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1.2.1 The Relationship between Clearance, Rate Constant
of Elimination, Volume of Distribution and Half-Life
Calculation of the clearance requires measurement of the concentration in ISF,
e.g. by microdialysis (Cirrito et al. 2003), which can be difficult. Thus, in many
studies either the rate constant, k, or half-life, t1/2, is reported instead. The rate
constant is defined by
k ¼ rate of eliminationð Þ=N ð3Þ
where N is the amount present. The units of the rate constant are thus reciprocal
time, e.g. min1. From Eqs. (1) and (3) it can be seen that the rate constant and
clearance are related, i.e. that k  N ¼ CL  c or CL/k ¼ N/c. Thus when
comparing clearances and rate constants what needs to be considered is the apparent
volume in which the substance of interest is distributed, defined as the volume of
distribution,
VD ¼ N=c: ð4Þ
If all of a metabolite is freely dissolved in ISF then the volume of distribution is
just the same as the volume of the solution, but if some is reversibly bound to cells
or in large aggregates or if it can rapidly enter and leave the cells, then the volume
of distribution can be much larger than the solution volume (compare the discussion
of soluble and exchangeable amyloid-β in Cirrito et al. 2003). The rate constant for
elimination of a substance depends not only on the processes of elimination
described by the clearance but also on the volume over which the substance is
distributed,
k ¼ CL=VD: ð5Þ
It is this dependence on distribution of the substance that makes the rate constant
less suitable than the clearance as a means for describing elimination.
Another parameter describing elimination is the half-life. This is the time taken
for the amount present to decrease by half if production is abruptly stopped. If the
decrease in amount remaining follows an exponential curve, the half-life and the
rate constant for elimination are simply related by
t1=2 ¼ 0:69=k: ð6Þ
Evaluation of half-lives and clearances using marker substances added to ISF
can provide important indications of the nature and routes of elimination of
particular metabolites. Marker substances such as albumin, inulin, mannitol and
sucrose are stable, water soluble, do not enter cells, do not aggregate, do not bind to
cell membranes and are very slow to cross the blood–brain barrier. Because these
exit the brain primarily by non-selective transport together with many other
components of ISF, they are used to describe elimination by perivascular pathways
(see Sect. 2.3). The volumes of distribution for these substances are all just equal to
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the volume of ISF, about 0.2 mL g1, measured values of the half-lives for these
substances are in the range of 2–4 h (Shibata et al. 2000; Groothuis et al. 2007; Ball
et al. 2010; Iliff et al. 2012) and the corresponding clearances are in the range of
0.6–1.2 μL g1 min1.
Metabolites with half-lives shorter than those for markers like albumin, inulin,
sucrose and mannitol must either be distributed over a smaller volume or have a
higher clearance. The volume cannot be smaller because within the parenchyma
these markers are already restricted to ISF. Thus any metabolite with a shorter half-
life must have a higher clearance, i.e. it is eliminated by other routes in addition to
the perivascular.
Because non-selective efflux via the perivascular route will contribute to the
elimination of every water soluble substance, half-lives longer than a few hours for
elimination from ISF imply either that clearance by this route is reduced, e.g. by
obstruction of the perivascular spaces, or there is more of the substance present than
expected from its concentration, i.e. the volume of distribution is larger.
2 Mechanisms of Elimination from the Brain Parenchyma
Ametabolite can be eliminated, i.e. removed, from the extracellular fluid of the brain
parenchyma by three types of mechanism, indicated in Fig. 2 as (a) further metabo-
lism, (b) transport across the blood–brain barrier to blood, and (c) perivascular efflux
along blood vessels. Elimination via the choroid plexuses of metabolites originating
in the parenchyma is likely to be small, because under normal circumstances, i.e. in
the absence of oedema, efflux from the parenchyma into the ventricles has been
perivascular spaces 
parenchymal cells 
interstitial spaces 
brain microvessels 
c) perivascular efflux 
b) blood-brain barrier transport
vascular outflow
a) further metabolism 
Fig. 2 Principal routes of metabolite clearance from ISF. A metabolite can: (a) enter cells where it
can undergo further metabolism, (b) be transported across the blood–brain barrier that separates
the interstitial fluid of the parenchyma from blood in the vasculature or (c) leave along with other
components of ISF as part of perivascular efflux. The perivascular “space” around the capillaries
may be (see text) the basement membrane between endothelial cells and astrocyte endfeet. The
location of the perivascular spaces around larger blood vessels is controversial: candidates include
a space between the vessel wall and the astrocyte endfeet and for arteries the basement membranes
of the smooth muscle layer. Some perivascular efflux enters the CSF in the sub-arachnoid spaces,
the remainder may follow vessel walls out of the brain to peripheral lymphatics (Yamada et al.
1991; Carare et al. 2008; Ball et al. 2010; Iliff et al. 2012) and for further discussion (Hladky and
Barrand 2014)
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found to be slow (Patlak and Fenstermacher 1975; Iliff et al. 2012; and discussion in
Hladky and Barrand 2014). However, when fluid is infused into the parenchyma
such efflux can be observed (Bedussi et al. 2015; McIntee et al. 2016).
2.1 Elimination by Further Metabolism
Further metabolism is often an important route of elimination for metabolic
intermediates such as lactate produced by partial metabolism of glucose (see
Sect. 3.3). It is also important in removing peptides including amyloid-β (Aβ)
(see Sect. 3.4). Further metabolism eliminates one metabolite but, obviously,
produces another. Metabolism of substances in the extracellular fluid often follows
uptake into cells either via specific transporters or endocytosis. Transfer by specific
transporters can be extensive and rapid, with persistence in the extracellular fluid
for only seconds or minutes rather than hours.
2.2 Elimination across the Blood–Brain Barrier
Elimination from the parenchyma across the interfaces between brain and blood is
primarily across the blood–brain barrier provided by the endothelial layer lining the
brain microvasculature. Transfer across this interface may occur by simple diffu-
sion across the membranes and cytoplasm of the endothelial cells. For instance
diffusion may account for most of the transport of CO2 between brain and blood and
is so rapid that it is blood-flow limited (discussed in Hladky and Barrand 2016) (see
Sect. 3.1). For larger or less lipid soluble metabolites interaction with specific
transporters is required and endothelial cells have transporters for a large variety
of substances (see the classic summaries Bradbury 1979; Davson and Segal 1996;
and more recent reviews Abbott et al. 2010; Strazielle and Ghersi-Egea 2013; Pan
and Kastin 2016). The presence of these transporters suggests that metabolites for
which there are transporters will be cleared more rapidly across the blood–brain
barrier than via perivascular routes but this may not always be the case, as will be
discussed below for lactate (see Sect. 3.3).
To be cleared across the blood–brain barrier a metabolite in ISF must by some
means reach the surface of the brain endothelial cells. Since the brain parenchyma
is very well vascularised the distances for transfer are short, usually less than 20 μm.
Diffusion over such short distances is rapid and rarely rate limiting. The metabolite
must also be able to cross the layer of glial endfeet surrounding the microvessels.
However, there are gaps between the endfeet (Mathiisen et al. 2010) and the gaps
are not sealed by tight junctions. Because there are enough gaps, the endfoot layer is
usually not rate limiting in comparison with transfer across the endothelial cells. If
there are specific transporters for a metabolite at the blood–brain barrier and the
concentration of the metabolite is low enough that the transporters are not saturated,
this route of clearance may correspond to half-lives within the extracellular solution
of less than 10 or 15 min.
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2.3 Elimination via Perivascular Pathways
Elimination by efflux via perivascular routes is of great importance because it
provides a method for removing anything that is water soluble and not too large
including occasional unwanted waste products that must not be allowed to accumu-
late over a lifetime. Perivascular elimination provides a mechanism that can deal
with the unexpected on a time scale of hours.
The clearance by perivascular efflux is the same or at least similar for substances
with a wide range of sizes as has been measured for markers such as mannitol,
inulin, sucrose, serum albumin, polyethylene glycols and various dextrans (Cserr
et al. 1977; Carare et al. 2008; Iliff et al. 2012). Every metabolite in ISF will be
cleared to some extent by this mechanism but its importance for any particular
metabolite will depend on whether or not there are other faster routes of clearance.
The markers listed here that have been used to determine the perivascular clearance
are those for which all other routes of elimination are negligible.
2.3.1 Routes of Perivascular Efflux
“Perivascular” is taken here to describe various possible routes available along the
walls of blood vessels but separated from the blood flowing through the vascular
lumen (see “Nomenclature”, p. 59 in Hladky and Barrand 2016).
There are two proposals for where substances move parallel to microvessels:
either primarily via the basement membranes separating the endothelial cells from
the astrocyte endfeet (Rennels et al. 1990; Carare et al. 2008) or distributed
throughout the extracellular space between the brain cells (see e.g. Iliff et al.
2012). Which is more important may depend on solute size. In either case the
distance to the nearest perivascular space adjacent to a larger vessel is likely to be
relatively small, e.g. 100–200 μm. At least over distances less than ~100 μm
diffusion is the dominant mechanism of transfer of solutes through the extracellular
spaces of gray matter (Nicholson and Sykova 1998; Nicholson 2001; Sykova and
Nicholson 2008; Asgari et al. 2016; Jin et al. 2016).
The route of solute efflux adjacent to larger vessels has been controversial
(Hladky and Barrand 2014; Tarasoff-Conway et al. 2015; Simon and Iliff 2016).
Efflux of markers along arteries has been seen in many studies (e.g. Szentistvanyi
et al. 1984; Carare et al. 2008; Arbel-Ornath et al. 2013), but others have found
convincing evidence for influx along arteries and suggestions of efflux along veins
(Rennels et al. 1990; Iliff et al. 2012). There is also disagreement over the principal
routes along arteries with some favouring an actual extramural perivascular space
between the vessel walls and the endfeet, see e.g. (Szentistvanyi et al. 1984;
Ichimura et al. 1991; Iliff et al. 2012; Arbel-Ornath et al. 2013; Bedussi et al.
2017) and others advocating instead an intramural perivascular pathway along the
basement membranes of the smooth muscle layer (Carare et al. 2008, 2013b;
Tarasoff-Conway et al. 2015) (see Appendix 1).
Some of the perivascular solute efflux from the parenchyma enters CSF from
which it is delivered partly to venous blood and partly to lymph. The remainder
appears to pass to lymph without first mixing with CSF (Bradbury et al. 1981;
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Szentistvanyi et al. 1984; Weller et al. 2009; Pollay 2010; Aspelund et al. 2015;
Louveau et al. 2015; Tarasoff-Conway et al. 2015; Bakker et al. 2016; Engelhardt
et al. 2016; Simon and Iliff 2016).
2.3.2 Mechanisms Driving Perivascular Solute Efflux
There have been three proposals for how substances are propelled along
perivascular pathways.
Proposal 1: there is secretion of fluid by the blood–brain barrier that provides a small
pressure gradient for outflow of ISF along perivascular spaces (see Cserr and
Ostrach 1974; Cserr et al. 1981; Szentistvanyi et al. 1984; Cserr and Patlak 1992).
This was a plausible suggestion when it was believed that the half-life for
clearance of solutes by outflow was of the order of 12 h. It now seems, however,
that such half-lives are 2–4 h (Shibata et al. 2000; Groothuis et al. 2007; Ball et al.
2010; Iliff et al. 2012). The flow required in order that the clearance can be via an
outflow of fluid with the same concentration of the solute as in the interstitial fluid
is >0.6 μL g1 min1 (calculated as 0.69 V/t1/2 ¼ 0.69  200 μL g1/240 min).
This is much larger than 0.1 μL g1 min1 which is at the high end of estimates
for the blood–brain barrier secretion rate (see Sect. 4.1 in Hladky and Barrand
2016). Hence outflow of the fluid secreted across the blood–brain barrier is
insufficient to account for perivascular clearance of solutes.
Proposal 2: there is convection in the perivascular spaces, arterial or venular, that
allows relatively rapid movements of solutes both inwards and outwards. In this
proposal movement in the interstitial spaces of the parenchyma is primarily by
diffusion but movements along the larger vessels cannot be just diffusion
because solutes added to CSF can appear in the parenchyma much too quickly
for diffusion over the distance involved, a millimeter or more (Rennels et al.
1990; Ichimura et al. 1991; Iliff et al. 2012). Increased rate of solute movement
along the perivascular spaces down a concentration gradient in either direction
may result from convective mixing (Bradbury et al. 1981; Hladky and Barrand
2014; Bakker et al. 2016), which is perhaps better called dispersion (Asgari et al.
2016). Diffusion may well be adequate for movement from the interstitial spaces
in the parenchyma to the perivascular spaces around the vessels because the
distances involved are sufficiently short (Jin et al. 2016).
Proposal 3: there is a pressure driven flow of CSF inwards along periarterial spaces
and into the parenchyma and outwards from the parenchyma along the
perivenous spaces. This has been called the glymphatic circulation (Iliff et al.
2012; Nedergaard 2013). However, it is unclear how the flow required, at least
0.6 μL g1 min (see proposal 1), can be driven through the parenchyma (Asgari
et al. 2016; Jin et al. 2016). Jin et al. have calculated solute concentrations and
fluid flows within the parenchyma assuming a realistic geometry; a range of
membrane permeabilities spanning the expected physiological values; and the
assumption that the ISF between the cells behaves as a free fluid with the
viscosity of water. They concluded that “little or no advective solute transport
is predicted to occur with physiological paravascular pressure differences” taken
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to be less than 5 mmHg. The minimum pressures required for advection (the
solute transport coupled to flow) to be important may be larger, perhaps much
larger, than Jin et al. have calculated if the contents of the interstitial spaces in
the brain have gel-like properties as for the extracellular spaces in the periphery.
These properties conferred by the presence of macromolecules include much
higher resistance to bulk flow than in simple solution (Levick 1987) with only
slight restriction of diffusion (Nicholson 1980; Nicholson and Sykova 1998;
Sykova and Nicholson 2008). Closely analogous effects are produced by adding
agar to solutions to reduce convection.
Further considerations arguing against the glymphatic hypothesis are that net
inward flow along periarterial spaces explains neither outward movements of
solutes along arteries (Bradbury et al. 1981; Szentistvanyi et al. 1984; Cserr and
Patlak 1992; Carare et al. 2008; Arbel-Ornath et al. 2013; Bedussi et al. 2017) nor
the continuation of rapid inward movement of large solutes when the proposed
glymphatic flow across the glial endfoot layer is hindered by deleting the major
water channel AQP4 (Iliff et al. 2012) as discussed in Hladky and Barrand (2014).
An important part of the driving force for either net flow or mixing in the
perivascular spaces is thought to be the periodic compression of the perivascular
pathways resulting from changes in blood pressure during the cardiac cycle
(Bradbury et al. 1981; Carare et al. 2008; Iliff et al. 2012, 2013; Bakker et al.
2016). It should be noted that the length of perivascular space around a cortical
vessel that is compressed at any one time is as long as the vessel (Bradbury et al.
1981; Asgari et al. 2016). Bradbury et al. (1981) were of the opinion that periodic
compression of this space “would cause to-and-fro movement of fluid in and out of
the brain” such that “A basis would be provided for substances in solution or
suspension to be moved either out of or into the brain depending on the relative
concentration in subarachnoid CSF.” The back-and-forth convective movements
would only be apparent using techniques with both a time resolution better than a
fraction of a second and good spatial resolution. With the techniques now available
all that would be seen would be accelerated movement down the concentration
gradient regardless of its direction.
2.4 How Do the Mechanisms Differ between Sleep
and Wakefulness?
There is surprisingly little known about how the elimination mechanisms described
above may differ between sleep and wakefulness and how these differences may
impact on the clearance of various metabolites. While rates of further metabolism
of metabolites are very likely to change, simply because their concentrations
change, very little is known about whether clearance due to further metabolism
differs between sleep and wakefulness. The little that is known about variations in
blood–brain barrier transporters between sleep and wakefulness has been discussed
by Pan and Kastin (2016) while diurnal changes in the activity of P-glycoprotein
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have been documented by Kervezee et al. (2014). Variations in the blood–brain
barrier clearance for amyloid-β are considered in Sections “Clearance across the
Blood–Brain Barrier” and 3.4.3.
In order to compare perivascular influx and efflux in awake, asleep or
anaesthetised mice, Xie et al. (2013) analysed the movements of three different
tracers: Texas red dextran (3kD) which enters the brain from CSF by perivascular
influx; inulin, which is eliminated from the brain almost entirely by perivascular
efflux; and tetramethylammonium (TMA) ions, whose diffusion within the paren-
chyma can be used to measure ISF volume. Their results demonstrated that for
awake mice compared to those that are either asleep or anaesthetised:
• influx of Texas red dextran (3kD) into the parenchyma following 30 min infu-
sion into the cisterna magna was ~95% less, a 20-fold reduction
• the rate constant for 14C-inulin elimination (¼0.69/t1/2) was ~63% smaller, a 2.7-
fold reduction (calculated assuming a single exponential decay)
• astrocytes were swollen while the extracellular space volume was about 38%
less, a 1.6-fold reduction (assessed from space available for diffusion of
tetramethylammonium (TMA) ions).
From their results one can calculate the change in clearance for inulin:
• using CL ¼ (rate constant)  V, the clearance is lower in awake mice than in
mice that are asleep by a factor of 1.6  2.7 ¼ 4.3, i.e. a 77% decrease.
Xie et al. proposed that the effects of awakening on extracellular volume and
clearance are mediated by noradrenergic activity because they noted that in the
presence of antagonists of noradrenergic transmission values of ISF volume and
influx of fluorescent markers were similar to those seen with mice that were asleep.
The importance of β-adrenoceptors in similar volume changes has been shown by
Sherpa et al. (2016).
Xie et al. (see also Kress et al. 2014) interpreted both the change in rate constant
for inulin efflux and the dramatic change in influx seen for Texas red dextran as
being consequences of a large change in the rate of glymphatic circulation (see
proposal 3, Sect. 2.3.2). They further concluded that it was the reduction in the
volume of the extracellular space during wakefulness inferred from the TMA
results that decreased the rate of glymphatic circulation. It is, however, difficult
to understand how a change in flow rate would have had a much smaller effect on
inulin clearance (<5-fold) than on dextran influx (~20-fold). From inspection of
Xie et al.’s published images, it appears likely that the dramatic effect on dextran
influx results not from changes within the parenchyma, such as alterations in the
volume of ISF, the properties of astrocyte endfeet or the tightness of the blood–
brain barrier, but rather from changes in delivery along the arteries in the subarach-
noid space produced in a manner that has yet to be explained. Altered delivery
might result from subtle variations in either the pressure differences between these
spaces and the cisterna magna or the dimensions of the subarachnoid spaces.
Metabolite Clearance During Wakefulness and Sleep 395
There may or may not be changes in interstitial and perivascular fluid flows
association with the changes in ISF volume reported in sleep-wake transitions.
Furthermore such changes in flows may or may not account for the difference in
inulin clearance. For the case against the importance of fluid flow and thus per force
against the importance of changes in the flow see Asgari et al. (2016) and Jin et al.
(2016) (see also Sect. 2.3.2).
In summary, perivascular clearance as measured using inulin is ~4-fold lower in
mice that are awake compared to those that are asleep. The reasons for this are not
completely clear (see also Sect. 3.4.3).
3 Clearance of Important Brain Metabolites
This section discusses the extent to which each of the elimination mechanisms
described above are involved in clearance of particular brain metabolites and how
differences between sleep and wakefulness affect these clearances.
3.1 Carbon Dioxide
In terms of molar amounts, by far the most important waste products of metabolism
in the brain are carbon dioxide and water. These are disposed of rapidly by diffusion
across the blood–brain barrier, the only sufficiently accessible interface between
brain and blood. In fact these transfers are so rapid that they are to a large extent
cerebral blood-flow limited.
3.1.1 Differences in CO2 Clearances between Sleep and Wakefulness
During slow-wave sleep rates of elimination are reduced simply because the rates of
production are less. However, pCO2 in the brain should fall rather less than the rate
of CO2 production because cerebral blood flow and hence CO2 clearance decreases
(for more detailed consideration see Sect. 6 in Hladky and Barrand 2016).
The obvious sleep related disorder of CO2 elimination is sleep apnea. In this
condition CO2 can still be transferred from brain to blood but, because of the
absence of adequate ventilation, CO2 accumulates in the whole body and pCO2
increases in the blood to the extent that net diffusion out of the brain can no longer
match production.
3.2 Glutamate and Glutamine
Handling of glutamate, glutamine and ammonium within the brain are interlinked
and are in addition linked to the handling of many other amino acids by transami-
nation reactions. Glutamine and ammonium are transported in both directions
across the blood–brain barrier. Glutamate in the brain arises primarily by deamina-
tion of glutamine in neurons and by transfer of amino groups from other amino
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acids to α-ketoglutarate. It enters ISF by neurotransmitter release from neurons (see
Fig. 3). Glutamate entry to the brain from the blood is negligible (Hawkins 2009).
Most glutamate is removed from brain ISF by uptake into astrocytes. This keeps
the extracellular glutamate concentration in the brain parenchyma well below that
in plasma. Within astrocytes the glutamate is converted to glutamine for recycling
to neurons (see Fig. 3). Glutamate also leaves the brain by being transported into
blood across the blood–brain barrier. Much of this glutamate leaving to blood is
produced from glutamine within the endothelial cells (Lee et al. 1998; Hawkins
et al. 2006). A role for the perivascular route in elimination of glutamine and
glutamate has apparently never been investigated, presumably because the rates
of elimination via this route would be expected to be small compared to reuptake
into cells and elimination across the blood–brain barrier.
3.2.1 Differences in Glutamate Levels between Sleep
and Wakefulness
Glutamate ISF concentrations are thought to increase progressively at night when
rats are often awake and to decrease to a basal level during the day when they are
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Fig. 3 Simplified view of the clearance of glutamate, glutamine and NH4
+. Glutamate (Glu)
enters the ISF primarily via release from glutaminergic neurons. It is removed primarily by uptake
into astrocytes where it is converted into glutamine (Gln), most of which returns to the neurons
where it is converted back to glutamate and stored ready for release. This cycle is shown with bold
arrows. The overall levels of both glutamate and glutamine appear to be determined primarily by
metabolism within astrocytes (metab in the figure) and elimination of glutamine across the blood–
brain barrier. Glutamate can enter the endothelial cells of the blood–brain barrier from the brain
but flux in the opposite direction is thought to be negligible because the only transporters for
glutamate in the abluminal membrane (facing the brain) are Na+-linked and glutamate is thus
driven into the cells by the gradient of Na+ (Hawkins et al. 2006, 2013). Most of the glutamate
transported from the endothelial cells to the blood is produced within the cells from glutamine
(Lee et al. 1998; Hawkins et al. 2006). The rates of elimination of glutamine and glutamate via
perivascular routes are unknown
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often asleep. There is a marked increase to a plateau when they are sleep-deprived
(Dash et al. 2009). The normal progressive changes may be a direct consequence of
increased release of glutamate from neurons associated with an upregulation of
synaptic transmission during wakefulness and its reversal during sleep (Vyazovskiy
et al. 2008a, 2009; Liu et al. 2010; Hulse et al. 2011; Lante et al. 2011). If there is a
decrease in ISF volume on awakening (see Sect. 2.4) this may contribute to the
increase in ISF glutamate concentration observed in the first half hour or so of
wakefulness. Increased concentration during wakefulness would be expected to
increase the rates of elimination across the blood–brain barrier.
3.3 Lactic Acid/Lactate
Lactic acid is the product of glycolysis and conversion of pyruvate to lactate and
can also be produced from metabolism of other substrates, including glutamate
(Sonnewald 2014). In solution almost all of it dissociates to lactate and H+. Lactic
acid production by metabolism in the brain cells and the possibility that the lactate
can be removed from the brain leaving the H+ behind have important consequences
for pH regulation (discussed in Sect. 6 of Hladky and Barrand 2016). The extent to
which lactic acid released from astrocytes is taken up by neurons and used as fuel
for their activity remains controversial (see e.g. Dienel 2012; Dienel and Cruz 2016;
Petit and Magistretti 2016).
One route for lactate removal from the brain is via efflux across the blood–brain
barrier mediated by MCT1 transporters that are present in both luminal and
abluminal membranes of the endothelial cells lining brain microvessels (see
Fig. 4). At this barrier there is also uptake of lactate from plasma because MCT1
facilitates transport in both directions (for references see p. 47 and footnote 26 of
Hladky and Barrand 2016). Under conditions where there is little lactate produc-
tion, i.e. in unstimulated anaesthetised rats, the amount of lactate released into ISF
was thought to be balanced by the amount removed via a barely detectable net
efflux across the blood–brain barrier (Hawkins et al. 1973; Siesj€o 1978; Dienel and
Cruz 2003).
Another possible pathway for lactate removal from the brain is via perivascular
efflux. However, in unstimulated anaesthetised rats this route is not expected to be
important. This is because it has been shown that the clearance for lactate (usually
referred to as the permeability-surface-area product, PS) via MCT1 at the blood–
brain barrier is about 60 μL g1 min1 in adult rats (Daniel et al. 1972; Drewes and
Gilboe 1973) and 100 μL g1 min1 in humans (Knudsen et al. 1991). These values
far exceed estimates of clearance via perivascular efflux as assessed using markers
like inulin, ~1 μL g1 min1 (see Sect. 1.2.1). However, this comparison may be
misleading for two reasons. Firstly, locally in regions of nervous activity ISF
concentration can be high and can saturate the MCT1 transporters. Secondly,
lactate can be distributed through the parenchyma by transfers within and between
astrocytes (see Fig. 4), a mechanism not available to the markers of perivascular
efflux. Lactate unlike the markers can be released from astrocyte endfeet adjacent to
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perivascular spaces of larger vessels from which efflux may be rapid (Ball et al.
2007, 2010; Gandhi et al. 2009a, b).
Indication that there are at least two routes of lactate elimination was obtained in
investigations of spreading depression in rats (Cruz et al. 1999). This is an extreme
condition in which there is extensive release of lactate, obvious net transport of
lactate out of the brain across the blood–brain barrier and obvious loss of lactate by
another, presumably perivascular route (Cruz et al. 1999; Ball et al. 2010).
Two routes of lactate elimination are also evident with the more physiological
scenario of general sensory stimulation (observed in rats with removal of a shelter
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Fig. 4 Production of lactate and its removal from the brain. Glucose (Glc) is shown entering the
brain in a region of activity. Lactate (Lac) generated in astrocytes within that region can be
transferred via gap junctions to other astrocytes and be released from endfeet either near
microvessels or larger vessels. MCT1 monocarboxylate transporter 1 and GLUT1 glucose trans-
porter 1 mediate passive transport down the concentration gradient for lactic acid or glucose
respectively. The arrows between blood and the perivascular spaces indicate the direction of net
transport. Transport in the perivascular pathway may be occurring along arteries or veins. In the
diagram heavy lines indicate the walls of arterioles and venules that are presumed to prevent
exchange of lactate. Diagram modified from Fig. 7c in Gandhi et al. (2009a)
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and gentle stroking over the body with a paint brush). Under these conditions more
lactate was produced within the brain and in the rest of the body and lactate
concentrations were increased in both ISF and plasma. Although there was
increased lactate exit across the blood–brain barrier this was nearly balanced by
increased entry and there was little change in the net movement. Thus the extra
lactate released within the brain must either have been distributed to regions outside
those assayed or removed via other, presumably perivascular routes (Madsen et al.
1999; Dienel and Cruz 2003, 2004).
At least some of the lactate that leaves via perivascular routes reaches the
meninges (Ball et al. 2010) and lymph nodes (Ball et al. 2010; Lundgaard et al.
2016). The rest reaches CSF from which a fraction will travel with CSF to venous
blood via the arachnoid villi and much of the remainder will be carried by the CSF
via the cribrifrom plate to the nasal mucosa. From there most of the lactate along
with other small solutes is expected to cross into venous blood in the peripheral
capillaries of the mucosa (Bradbury and Westrop 1983).
3.3.1 Differences in Lactate Clearances between Sleep
and Wakefulness
The concentration of lactate in ISF provides a useful indicator of whether an
experimental animal is awake or asleep with clear increases (by about 0.15 mM)
during wakefulness to a maintained level and subsequent decrease during sleep.
Naylor et al. (2012) used microbiosensors to measure the time course of lactate
concentration changes in the ISF of mice during the onset of individual episodes of
sleep and wakefulness. The half-lives both for increases on awakening or decreases
on falling asleep were short, 4–5 min. The obvious first suggestion to explain such
rapid changes is that the rates of production and release of lactate were rapidly
altered by brain activity with the concentration adjusting to the new rate with a half-
life governed by the clearance. However, the rapid changes could also be explained
by constant rate of release and rapid small changes in clearance (total by all routes).
If the clearance does change, the half-lives for the increases and decreases should
also differ (shorter when asleep), but for the small changes in concentration
observed (perhaps 15%), the difference in half-lives would be too small to be
determined.
Lundgaard et al. (2016) used microdialysis probes (that are considerably larger
than the microbiosensors (Naylor et al. 2012)) to measure lactate concentrations in
the brains of unrestrained mice exposed to a daily cycle of 12 h darkness and 12 h
light. Average concentrations measured in the light when the mice were asleep for
about 140 min of the 12 h were about 28% lower than those measured in the dark
when the mice were asleep for about 20 min of the 12 h. It is difficult to calculate
clearances in awake and sleeping mice from these concentrations partly because the
rates of release of lactate from the cells and rates of influx of lactate from blood are
likely to have differed (compare Madsen et al. 1999; Dienel and Cruz 2003) but also
because the animals were awake and asleep during parts of both periods.
In experiments designed to circumvent such difficulties, Lundgaard et al. looked
at three different treatments that had been shown in previous studies to reduce
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perivascular clearance as assessed by clearance of inulin (Plog et al. 2015): admin-
istration of acetazolamide, which reduces CSF production by the choroid plexuses;
knock-out of AQP4, which reduces the water permeability of astrocyte endfeet and
slows access of CSF-bourn-markers to ISF (Iliff et al. 2012); and puncture of the
cisterna magna, which allows drainage of CSF. None of these procedures produced
a significant change in the lactate concentration measured in the dark phase when
the mice were almost always awake suggesting that perivascular clearance was
then relatively unimportant. However all three interventions made 20–30% smaller
the decrease in lactate concentration observed between mice in the light (rarely
asleep) and the same mice in the dark (more often asleep). This is strong, though
circumstantial, evidence that perivascular clearance of lactate is more important
when the mice are asleep than when they are awake (Lundgaard et al. 2016). It is
unclear whether a reduction in lactate concentration during sleep has any beneficial
or harmful effect.
3.4 Amyloid-b
The Aβ polypeptides are a group of metabolites of some considerable interest
because of their association with Alzheimer’s disease. These polypeptides are
produced in the brain by cleavage of the membrane bound amyloid precursor
protein (APP) (see Fig. 5). Various functions have been ascribed to these and
other APP cleavage products for normal brain cell activity but it is the dispropor-
tionate generation in excess of elimination of the Aβ products that leads to their
aggregation, plaque formation and deposition around blood vessels.
Of the Aβ peptides formed in the brain, most work has focussed on Aβ1–40 and
Aβ1–42, these being present at the highest concentrations. They exist as monomers
in solution at low nanomolar concentrations and, particularly for Aβ1–42, also as
oligomers (Cirrito et al. 2003; Bell et al. 2007). Monomers and oligomers together
are sometimes referred to as soluble Aβ. In young animals only soluble Aβ is
detectable. However in older animals there are often deposits along cerebral arteries
(cerebral arterial angiopathy or CAA). These are mainly aggregates of Aβ1–40.
Large aggregates or plaques are also observed in the brain parenchyma; these are
mainly composed of Aβ1–42. Small changes in soluble Aβ concentrations may over
time produce important changes in the rate of formation of Aβ aggregates (Lomakin
et al. 1996; Harper and Lansbury 1997; Hortschansky et al. 2005; Iwata et al. 2005;
Yan et al. 2009; Ye et al. 2015). While it is not known which form of Aβ is
responsible for the toxic effects ascribed to it, current evidence appears to suggest
that within the parenchyma the main culprits are the oligomers (Lambert et al.
1998; Zerbinatti et al. 2004; Haass and Selkoe 2007; Nisbet et al. 2015; McIntee
et al. 2016).
3.4.1 Clearance of Ab from ISF
The following sections consider the pathways by which elimination of Aβ formed
in the brain can occur. In the young, Aβ is produced and present in soluble form and
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is eliminated as rapidly as it is produced with about 7–8% of the total soluble Aβ
being replaced each hour (Bateman et al. 2006; Mawuenyega et al. 2010). Mono-
meric and small oligomeric forms of Aβ are cleared from ISF by at least four routes:
incorporation into plaques, metabolism either extracellular or after uptake into cells
(Iwata et al. 2000; Van Uden et al. 2002; Saido and Iwata 2006; Bu 2009; Saido and
Leissring 2012; Kanekiyo et al. 2013; Ries and Sastre 2016), efflux across the
blood–brain barrier (Shibata et al. 2000; Bell et al. 2007; Zhao et al. 2015; Nelson
et al. 2016; Storck et al. 2016) and efflux via perivascular routes (Ball et al. 2010;
Iliff et al. 2012; Xie et al. 2013; Peng et al. 2016). The relative importance of these
mechanisms remains controversial (Tarasoff-Conway et al. 2015). Clearance of Aβ
from blood plasma is rapid with a half-life of a few minutes, primarily by metabo-
lism in the liver and spleen (Ghiso et al. 2004; Kandimalla et al. 2005).
Clearance by Aggregation?
In vitro studies have shown that aggregates can continue to grow at lower monomer
concentrations than are required for initial aggregation (see e.g. Harper and
Lansbury 1997). In humans, CSF concentrations of Aβ1–42 are lower when plaques
Fig. 5 Production of amyloid-β and other products by cleavage of membrane-bound amyloid
precursor protein, APP. Cleavage begins at either of two locations mediated by α-secretase or by
β-secretase, also called BACE1. These are mutually exclusive. One of the two products is released
on the luminal/non-cytoplasmic side of the membrane. The other remains in the membrane and is
then cleaved by a γ-secretase, which can cut at a number of closely spaced locations. The resultant
products are a short peptide, AICD, released into the cytosol and either p3 peptides (on the α,
non-amyloidogenic metabolic pathway) or Aβ peptides (on the β, amyloidogenic pathway). APP
cleavage may occur in transGolgi, plasma and endosomal membranes. Based on Haass et al.
(2012)
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are present in the parenchyma than when they are absent (Fagan et al. 2006; Potter
et al. 2013) implying that plaques can take up soluble Aβ1–42 fast enough to
decrease the concentration of soluble forms. In addition, once plaques are formed
there are no longer diurnal variations in the concentration of soluble Aβ1–42 (Roh
et al. 2012). In effect incorporation into aggregates reduces, at least temporarily, the
amount of soluble forms.
Some suggest that formation of both oligomers and aggregates is reversible (see
e.g. Harper and Lansbury 1997; Cirrito et al. 2003) though removal of “seeds” for
aggregates may be very slow (Ye et al. 2015); however others believe that aggre-
gation is effectively irreversible (Lomakin et al. 1996). In favour of the former
view, it was found that cutting the nerves fibres leading to terminals releasing Aβ in
a particular brain region led to plaques already formed within that region
disappearing over time (Lazarov et al. 2002). Similarly if Aβ production was
abruptly stopped using a γ-secretase inhibitor, the loss of Aβ exceeded the amount
of soluble Aβ initially present (Cirrito et al. 2003). Aggregates that can be
dissociated serve as a form of buffer and, if their dissociation is sufficiently rapid,
will increase the volume of distribution (see Sect. 1.2.1). Aggregates that cannot be
dissociated provide a route of elimination of the soluble forms.
Clearance by Uptake and Further Metabolism
It is clear from a number of studies that Aβ peptides can be metabolised further
within the brain with some enzymes being active against Aβ in the extracellular
spaces and some requiring that the peptides are first taken up into cells. Metabolites
have been detected in CSF early after injection of Aβ1–40 at high concentrations into
the parenchyma (Shiiki et al. 2004; McIntee et al. 2016). Important enzymes for
metabolism of Aβ include neprilysin, insulin degrading enzyme (IDE) and matrix
metalloproteases (MMPs) (Iwata et al. 2000, 2001; Van Uden et al. 2002; Tanzi
et al. 2004; Saido and Iwata 2006; Farris et al. 2007; Bu 2009; Miners et al. 2011;
Saido and Leissring 2012; Kanekiyo et al. 2013; McIntee et al. 2016; Ries and
Sastre 2016). Uptake of Aβ by LRP1 receptor-mediated endocytosis has been
shown to be important for intracellular metabolism in neurons, astrocytes and
vascular smooth muscle cells (Bu 2009; Kanekiyo et al. 2012; Kanekiyo and Bu
2014).
The rate of metabolism increases with Aβ concentrations well into the micro-
molar range (compare Shirotani et al. 2001) implying lack of saturation at physio-
logical concentrations. At low micromolar Aβ concentrations when the principal
blood–brain barrier transport process is saturated (see Section “Clearance Across
the Blood–Brain Barrier”) metabolism clearly plays the dominant role in elimina-
tion of Aβ peptides. However, the contribution of metabolism to elimination when
concentrations of the Aβ soluble forms are in the physiological, low nanomolar
range has been controversial. In favour of a substantial role Shiiki et al. (2004)
found in rats that blocking metabolism using the neprilysin inhibitor thiorphan did
produce an effect reducing the rate constant for elimination of 125I-Aβ1–40 by 34%
and this was when the Aβ concentration was in the low nanomolar range (see also
Ito et al. 2013). Perhaps the strongest evidence that metabolism is important as a
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normal clearance route comes from the observation that the amount of Aβ in the
parenchyma was increased, in some cases by 50–100%, in neprilysin null mice
(Iwata et al. 2001; Farris et al. 2007; see also Selkoe 2001) and by a similar amount
when Aβ degrading enzymes were chronically inhibited (Iwata et al. 2001;
Yin et al. 2006; Miners et al. 2011). Additional evidence that metabolism can in
principle be important for elimination was obtained in studies in transgenic mice
overexpressing neprilysin or IDE (Leissring et al. 2003).
Clearance across the Blood–Brain Barrier
The ways in which Aβ can be transported across the blood–brain barrier have been
explored by several different groups. Shibata et al. (2000) were the first to propose
that Aβ could cross the blood–brain barrier by LRP1-mediated transcytosis and that
this could account for the loss of 125I-Aβ1–40 from the brain that they observed by
following the fate of 125I. They showed that the loss of total 125I from the brain was
reduced by antibodies against LRP1, by RAP which binds to LRP1 and inhibits
binding of substrates and by apoE knockout (apoE may influence the interaction of
Aβ with LRP1). Furthermore the elimination process appeared to be saturable with
Km of 15 nM. These properties are consistent with elimination of
125I-Aβ1–40 being
primarily across the blood–brain barrier via an LRP1-dependent process. However
it should be kept in mind that demonstrating the importance of LRP1 is not the same
as demonstrating elimination via the blood–brain barrier because LRP1 is also
present on neurons, astrocytes and vascular smooth muscle cells where it can
mediate endocytosis of Aβ leading to its metabolism (Bu 2009; Kanekiyo et al.
2012; Kanekiyo and Bu 2014).
Because in Shibata et al.’s experiments there was loss of the radiotracer (125I)
from the brain, further metabolism of 25I-Aβ1–40 alone cannot explain the results.
The alternative explanation to transfer across the blood–brain barrier is that the
administered 125I-Aβ1–40 was degraded in the brain producing an 125I-containing
product that was itself effluxed (see e.g. Ito et al. 2013). Shibata et al. argued against
this possibility based on their finding that the total 125I remaining within the brain
could still be precipitated using TCA, i.e. that it was still attached to some form of
peptide, and that, in the instances where they checked, the peptide still migrated as
125I-Aβ1–40 in HPLC. Thus, if metabolism was an important part of the elimination,
the 125I-containing metabolites must have been eliminated so rapidly as to be
undetectable within the brain. This would appear to be unlikely (but see McIntee
et al. (2016) for rapid appearance of metabolites in CSF).
Results favouring some production of metabolites were presented by Shiiki
et al. (2004) who found from HPLC analysis of jugular venous blood that
radioactivity was present as both intact 125I-Aβ1–40 and metabolites. However
these assays required injection of ca. 30 higher concentrations of 125I-Aβ1–40
than would normally be seen. At these high concentrations efflux mechanisms at
the blood–brain barrier would have been saturated and metabolism, which is easily
demonstrated at high concentrations, would be relatively more important. Further-
more the metabolites may have been produced after efflux or possibly as part of
404 S.B. Hladky and M.A. Barrand
the efflux process. In Shiiki et al.’s hands using rats, the elimination rate constant
for 125I-Aβ1–40 was not reduced by RAP.
Subsequently, Bell et al. (2007) using mice reported that iodinated and
unlabelled human Aβ, detected by ELISA, were eliminated from the parenchyma
of mice at the same rate, that intact Aβ was present in plasma after 30 min, and that
this appearance in plasma was completely blocked by centrally administered anti-
LRP1 antibody. These findings reinforce the conclusions reached by Shibata et al.
(2000). Bell et al. also found that the rate constant for elimination of Aβ1–42 was
about half that for Aβ1–40. This could reflect either a doubling of the volume of
distribution or a halving of the clearance. A difference in the volume of distribution
is likely because in the parenchyma the concentration of exchangeable Aβ1–42 is
less than that for Aβ1–40 (Cirrito et al. 2003) but the amount of Aβ1–42 in aggregates
is greater. A difference in clearance is at least as plausible because Aβ1–40 has been
shown to have higher affinities than Aβ1–42 for LRP1-mediated binding and uptake
into the brain endothelial cells (Deane et al. 2004).
In further experiments not described here the properties of efflux across the
blood–brain barrier have been elucidated in considerable detail including the
importance of PICALM (Deane et al. 2004; Zhao et al. 2015; Nelson et al. 2016).
These studies leave little room for doubting that transcytosis of intact Aβ across this
barrier is important for Aβ elimination.
Results from several other studies support the idea that efflux of Aβ occurs at the
blood–brain barrier and that LRP1 is important in this elimination. Jaeger et al.
(2009) showed that a cocktail of phosphorothioate antisense oligonucleotides
against LRP-1 substantially decreased the loss of Aβ1–42 after intraparenchymal
injection. Using an in vitro system, Pflanzner et al. (2011) demonstrated LRP1-
dependent Aβ1–40 transport across monolayers of primary mouse brain capillary
endothelial cells, a transport not observed in monolayers of cells with genetically
modified LRP1. Roberts et al. (2014) confirmed that efflux of Aβ from brain to
blood occurs in vivo by finding that the concentration in venous blood leaving the
brain was 7.5% higher than that in arterial blood. Storck et al. (2016) developed a
mouse model in which LRP1 could be knocked out selectively in endothelial cells
and were able to show that the knockout reduced the initial rate of loss of 125I-
Aβ1–42 by 48% and increased the amount eventually retained. The increased
retention is explained if the slower loss allows more time for the 125I-Aβ1–42 to be
converted to a form, possibly an aggregate, that was unable to be removed from the
brain (see Appendix 2).
Taken together the evidence indicates that a major proportion of the Aβ elimi-
nation from the brain is dependent on LRP1 in the endothelial cells lining brain
microvessels and that the interaction with LRP1 brings about Aβ efflux across the
blood–brain barrier.
While LRP1-mediated transcytosis is the most widely considered means for
effluxing Aβ across the blood–brain barrier, P-glycoprotein may also have a role.
Aβ has been shown to be a substrate for P-glycoprotein, a multi-substrate efflux
pump located in the luminal membranes of brain endothelial cells. However how
this pump can mediate transport across the entire barrier has not been established.
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Its role appears to be in some way complementary to that of transcytosis (Cirrito
et al. 2005; Hartz et al. 2010; Ohtsuki et al. 2010; Erickson and Banks 2013;
Pan and Kastin 2014).
Clearance via Perivascular Routes
The perivascular route for elimination of Aβ peptides was investigated even before
other routes of elimination were implicated. In the initial studies, deposits of Aβ
were found along the external boundaries of arterial walls in the early stages of
deposition (Weller et al. 1998, 2000; see also Yamaguchi et al. 1992; Hawkes et al.
2012) but also throughout the smooth muscle layer of the arteries in the later stages
(Weller et al. 1998; Keable et al. 2016). These initial studies are consistent with
growth of the deposits adjacent to an efflux route along the outside of the arteries,
i.e. an extramural periarterial route.
Subsequently studies were undertaken using fluorescent dextran as a non-
metabolizable marker for substances of the size of Aβ. This was injected into the
parenchyma and within minutes fluorescence could be visualised throughout the
smooth muscle layer of the arterial walls (Carare et al. 2008). From this observation
it was proposed that both the fluorescent dextran and Aβ observed within the
smooth muscle layer were following the same intramural periarterial route of efflux.
There is at present no compelling evidence to decide between the intramural and
extramural routes. Whenever either dextran or Aβ was observed within the smooth
muscle layer it was at much higher density than in the adjacent regions of paren-
chyma (Carare et al. 2013a) suggesting that something must have concentrated or
trapped it in the smooth muscle layer. For Aβ there is in fact good evidence for
interactions of the peptides with components of the basement membrane matrix
(Hawkes et al. 2011; Zekonyte et al. 2016). However, the fact that Aβ or dextran
reaches the basement membranes within the smooth muscle layer does not prove
that these are the actual route of efflux. Rapid movement between a transport
pathway outside the muscle layer and the muscle layer itself is suggested by the
observation of Zervas et al. (1982) that both horseradish peroxidase and 3H-leucine
can rapidly enter the muscle layer of cerebral arteries from CSF.
Iliff et al. (2012) found that 1 h after injection of fluorescent tagged HyLyte-555-
amyloid β1–40 into mouse striatum it was seen adjacent to capillaries and the walls
of certain large veins. After injection of high concentrations of 125I-Aβ1–40, McIntee
et al. (2016) found that metabolites reached CSF within 5 min followed over tens of
minutes by intact 125I-Aβ1–40.
3.4.2 Relative Importance of the Different Routes for Elimination
of Ab
Attempts have been made to estimate the proportions of Aβ eliminated by the
various routes, i.e. by metabolism, by efflux across the blood–brain barrier and
by perivascular efflux. Shibata et al. (2000) and subsequently Xie et al. (2013)
observed that the half-time for the elimination of 125I-Aβ1–40 was much shorter than
could be explained by elimination via the perivascular route as indicated by the
half-life for elimination of inulin.
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To obtain an estimate for transfer across the blood–brain barrier Shibata et al.
assumed that the rate constant for perivascular elimination of 125I-Aβ1–40 was equal
to the rate constant for elimination of inulin, and subtracted this from the observed
rate constant. As they had concluded that metabolism played little part, this
non-perivascular elimination was held to be transfer across the blood–brain barrier.
However, the assumption that perivascular clearance is the same for 125I-Aβ1–40 and
inulin does not imply that the rate constants are the same. With equal clearances, the
rate constant for elimination of 125I-Aβ1–40 by the perivascular route should be
calculated as kAb , ISF¼ kinulin(Vinulin/VAb) (see Sect. 1.2.1). Because the volume of
distribution for 125I-Aβ1–40 is greater, possibly much greater, than that for inulin,
the estimate of the rate constant for the perivascular route for 125I-Aβ1–40 to be
subtracted from the total should be smaller than that for inulin. Thus their estimate
of the rate constant for the blood–brain barrier process, calculated as the difference,
should have been larger. This strengthens the conclusion that at low concentrations
of Aβ the non-perivascular process accounts for much more efflux of Aβ than the
perivascular process.
The data reported by Iliff et al. (2012) and Xie et al. (2013) have also shown
substantially faster elimination for Aβ than for inulin. In their studies on the
influence of AQP4 water channels on the movement of substances into and out of
the brain, they found that knockout of AQP4 reduced to a similar extent the rate
constants for elimination of inulin and Aβ. They argued from the result for inulin
that AQP4 reduces perivascular clearance and from the similar result for Aβ that a
large proportion of Aβ elimination was by the perivascular route. The second
contention is difficult to reconcile with the argument given in the preceding
paragraph that most Aβ elimination is by a non-perivascular mechanism. The
obvious alternative interpretation of the effects of AQP4 knock-out, consistent
with all the results, is that AQP4 knock-out reduces elimination by both
perivascular and non-perivascular routes (compare the discussion of the effects of
sleep in Sect. 3.4.3).
Ito et al. (2013) measured the rate constant for loss of intact human Aβ1–40 in
anaesthetised mice at micromolar concentrations high enough to saturate the
blood–brain barrier elimination mechanisms. Elimination should therefore have
been primarily by other routes. They found a value of the rate constant,
~0.032 min1, which is too large to be attributed to perivascular efflux and thus
represents elimination by metabolism. If as described in Section “Clearance by
Uptake and Further Metabolism” the rate of metabolism of Aβ is proportional to
its concentration, the rate constant measured by Ito et al. at high concentrations is
also the rate constant for elimination by metabolism at low concentrations. Bell
et al. (2007) using mice that had recovered from anaesthesia reported data from
which the total rate constant for elimination at low concentrations can be calcu-
lated as 0.016 min1 (see Section “Clearance Across the Blood–Brain Barrier” and
Appendix 1). This value is twofold smaller than the rate constant for metabolism
calculated by Ito et al. Bell et al.’s value may well be smaller because their mice
were awake, but nevertheless the comparison does suggest that metabolism is
important for Aβ elimination.
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To make comparisons between the elimination mechanisms, Roberts et al.
(2014) used measurements of: the turnover rate for Aβ (Potter et al. 2013); the
pool size for Aβ; the difference between Aβ concentrations in arterial blood and in
venous blood leaving the brain; and cerebral blood flow. They compared the rate at
which Aβ is effluxed to the blood (A-V difference times blood flow) with the total
rate of elimination (pool size  turnover rate  concentration). From this they
concluded that about 50% of Aβ elimination was by efflux from brain to blood
which they took to include both efflux across the blood–brain barrier and efflux to
CSF and thence to blood. They presumed that the rest of the elimination was via
metabolism. To separate efflux across the blood–brain barrier from perivascular
efflux, they estimated the latter as the product of the CSF concentration times an
assumed rate of outflow of CSF. On this basis they calculated that 25% of the
elimination was efflux across the blood–brain barrier, 25% was via CSF and the
remaining 50% was via metabolism.
Although their results do suggest that all of these mechanisms are involved, the
proportions Roberts et al. estimated may need revision for two reasons. Firstly, a
substantial, but unknown, fraction of Aβ leaving via the perivascular route and/or
CSF exits the brain to lymph and so does not appear in the venous blood samples
(see e.g. Dienel and Cruz 2008; Pappolla et al. 2014; and for further discussion
Hladky and Barrand 2014; Tarasoff-Conway et al. 2015; Hladky and Barrand
2016). Hence it does not contribute to the A-V difference and a larger fraction of
that difference will be a result of transport across the blood–brain barrier. The
fraction of Aβ leaving the brain via lymph may be substantial. The second reason is
that not all of the Aβ in CSF may have originated in the brain parenchyma which
means that their calculation of perivascular elimination as the rate of outflow via
CSF may be an overestimate. In summary the results of Roberts et al. suggest that
the fraction of Aβ leaving the brain across the blood–brain barrier may have been
underestimated and could be as high as 50%, that the fraction leaving by
perivascular efflux is indeterminate (but based on their evidence could be large)
and that the fraction left to be accounted for by metabolism may have been
substantially overestimated.
Further difficulties encountered in quantitative interpretation of efflux kinetics
are discussed in Appendix 2 but these do not compromise the conclusions of the
papers concerned and are unlikely to account for the discrepancies.
On balance the available data suggests a significant involvement in elimination
of Aβ from the brain for all three routes of elimination: further metabolism, efflux
across the blood–brain barrier and perivascular efflux (see also the views
expressed in Kanekiyo and Bu (2014) and in Ramanathan et al. (2015)).
3.4.3 Differences in Ab Clearances between Sleep and Wakefulness
How the routes of Aβ elimination differ during sleep and during wakefulness has
been investigated by Xie et al. (2013). They determined rate constants for elimina-
tion of added 125I-Aβ1–40 in awake and in sleeping mice and compared them to
those for inulin (see Table 1). They found in the awake and in sleeping mice that the
rate constant for elimination of Aβ was 4-fold and 3.3-fold greater respectively than
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that for inulin. Since the volume of distribution for Aβ is larger, perhaps much
larger, than that for inulin this implies a higher clearance (¼k  VD) for Aβ
implying in agreement with earlier results that most of the elimination is via
pathways other than perivascular. As discussed in Sections “Clearance Across the
Blood–Brain Barrier” and 3.4.2 it is likely that transcytosis across the blood–brain
barrier accounts for most of this elimination though further metabolism is likely to
contribute.
As evident from the values in Table 1, there is faster elimination during sleep for
both inulin and Aβ. Xie et al. argue that for each the change in the rate constant of
elimination results from a change in the glymphatic circulation occurring as a
consequence of a change in ISF volume (see Proposal 3 in Sect. 2.3.2 and Sect.
2.4). However, inspection of their data suggests that the explanation is more
complicated. From the non-selective nature of perivascular clearance it is a reason-
able approximation to assume that the perivascular clearances for Aβ and inulin are
the same. Because the volume of distribution for Aβ is at least as large as for inulin
(and possibly much greater, see Sect. 1.2.1), this means that the rate constant for Aβ
elimination via the perivascular route will be less than or equal to that for inulin.
Thus in awake mice the rate constant for Aβ elimination via the perivascular route
is 0.006 min1 and that for the non-perivascular route is between 0.018 and
0.024 min1. Similarly for asleep mice, the rate constant for the non-perivascular
route will be between 0.037 and 0.053 min1. The actual values for the two
conditions are both expected to be near the same end of these ranges. Thus it
appears that during sleep the rate constant for non-perivascular Aβ elimination may
be increased 2.1- to 2.2-fold. The volume of distribution of inulin is increased 1.6-
fold and its clearance ~4.3-fold (see Section “Clearance Across the Blood–Brain
Barrier”). The volume of distribution for Aβ should also increase but perhaps not by
so large a factor, so the non-perivascular clearance for 125I-Aβ1–40 appears to
increase by something between 2.1 and 3.5-fold.
In summary the effect of sleep on clearance of Aβ is not restricted to an effect on
clearance via the perivascular route but includes changes in Aβ clearances by
other routes. Whether or not the change between sleep and wakefulness in clear-
ance via the perivascular route is a consequence of an ISF volume alteration (see
Sect. 2.4), it is unlikely that ISF volume alterations can explain changes in the total
clearance of Aβ.
Table 1 Rate constants
for elimination of 125I-
Aβ1–40 and of inulin in
mice when awake and
during sleep (Xie et al.
2013)
Rate constant/min1
Inulin Aβ
Aβ
perivascular
Aβ
non-perivascular
Awake 0.006a 0.024a <0.006 0.018–0.024
Asleep 0.016a 0.053a <0.016 0.037–0.053
Ratios
Asleep/
awake
2.7 2.2 – 2.1–2.2
aValues from Fig. 3b,d in Xie et al. (2013)
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4 Summary
Clearance describes elimination. Clearance of a metabolite generated within the
brain is determined as its elimination rate divided by its concentration in ISF.
However, the more frequently measured parameter is the rate constant for elimina-
tion determined as elimination rate divided by amount present. The rate constant
depends on both the elimination processes and the distribution of the metabolite in
the brain, specified as the volume of distribution (see Sect. 1.2.1).
Three main types of process determine the clearance of any metabolite from
ISF: further metabolism (which eliminates the metabolite of interest, but of course
produces another), transport to blood across the blood–brain barrier, and non-
selective efflux via perivascular routes (see Sect. 2). Further metabolism, often
preceded by uptake into cells, and transfer across the blood–brain barrier are
important because they can be rapid. Perivascular clearance is important because
it can remove any water soluble substance that is not too large. Marker substances
used to characterise the perivascular route of elimination such as inulin, mannitol,
sucrose and albumin are highly water soluble, do not aggregate, do not bind to or
easily cross cell membranes, are not metabolized before being eliminated and are
not eliminated at a significant rate by any other mechanism. These all have
volumes of distribution near to the volume of ISF. If metabolites have volumes
of distribution larger than those of the markers, e.g. amyloid-β, this will mean that
their rate constant for perivascular elimination will be less than that for the
markers. If metabolites have half-lives shorter than those for the markers, this
means they must be eliminated by routes in addition to the perivascular route
leading to higher total clearances and hence the shorter half-lives (see Sect. 1.2.1).
The mechanisms underlying perivascular clearance have proved controversial.
There have been three proposals put forward (see Sects. 2.3.1 and 2.3.2). The first
proposal, now largely discounted as a major factor, is that fluid is secreted from
the blood into the parenchyma by the blood–brain barrier thence flowing out of the
parenchyma carrying water soluble metabolites with it. The second proposal is that
there is convective mixing or dispersion occurring in perivascular spaces that
greatly increases the rate of transfer of solutes in both directions. The third is
that there is a glymphatic circulation entailing flow of CSF into the parenchyma
via periarterial spaces, then flow through the parenchyma and finally flow out-
wards via perivenous spaces. At present the available evidence favours the second
proposal over the third. The many references in the literature (now in the
hundreds) to a role for the glymphatic circulation in the elimination of substances
from the brain can almost all be read as references to a role for perivascular
transport by whatever mechanism this occurs. Further work to establish this
mechanism is required.
Little is known about the effects of sleep on clearance via metabolism or blood–
brain barrier transport, but studies with inulin in mice comparing perivascular
effluxes during sleep and wakefulness have found increases of 2.6-fold in the rate
constant of elimination, 1.6-fold in the volume of distribution and 4.2-fold in the
clearance of inulin.
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Table 2 summarises the principal routes/mechanisms by which certain important
metabolites formed in the brain are eliminated and what is known of how their
elimination is modified by sleep.
CO2 (see Sect. 3.1) is eliminated by diffusion across the blood–brain barrier.
During sleep production decreases but the clearance of CO2 is also reduced because
cerebral blood flow is reduced and hence there is little change in CO2 concentration.
Glutamate (see Sect. 3.2) is synthesised in the brain from other amino acids and
added to the extensive pool of glutamate and glutamine recycling between
astrocytes and neurons. Elimination from the brain, which balances synthesis,
involves fluxes much smaller than those entailed in recycling. There are trans-
porters at the blood–brain barrier that allow efflux to blood without appreciable
transfer in the opposite direction. Some perivascular elimination will occur but is
expected to be minor in comparison with efflux across the blood–brain barrier.
Lactic acid/lactate is eliminated from ISF partly by uptake into cells and
metabolism to CO2 but where and to what extent this occurs have been highly
controversial. Efflux of lactic acid/lactate across the blood–brain barrier via specific
transporters is rapid for low lactic acid concentrations but saturates within the range
of concentrations that can be reached in ISF during nervous activity. Often
increased lactate concentrations in ISF occur under conditions that will also
produce increased lactate concentrations in plasma. These increased plasma
concentrations will lead to increased influx into the brain across the blood–brain
barrier offsetting the increased efflux. There is also an augmented form of
perivascular elimination of lactate that may entail transfer or shuttling of lactic
acid/lactate between astrocytes and release into periarterial and/or perivenous
spaces allowing rapid efflux from the parenchyma. At low lactate concentrations
the blood–brain barrier route is expected to be more important than perivascular
efflux, but at higher concentrations the perivascular route may account for much of
the net efflux.
Amyloid-β (Aβ) is also eliminated by all three of the major routes,
i.e. metabolism, transfer across the blood–brain barrier and perivascular efflux,
the relative proportions remaining controversial. Most but not all of the available
evidence suggests that, at the low concentrations of soluble Aβ encountered in vivo,
the perivascular route is the least important. Sleep increases the rate constants for
elimination both by blood–brain barrier transfer and perivascular efflux.
For all of the metabolites considered, the rates of production and elimination are
decreased during sleep. Changes in sleep may be particularly important for
metabolites for which small changes in the average concentration may, over a
prolonged period of time, have cumulative effects. The example considered here
is Aβ. Aβ is eliminated by multiple mechanisms and changes in any one of these
produce only modest changes in Aβ concentrations. However, even these modest
changes may be important over an extended time period. For Aβ, lack of slow-wave
(nREM) sleep may increase the average concentration of soluble Aβ over the day
which may lead to increased cumulative formation of vascular aggregates, cerebral
arterial angiopathy and parenchymal plaques. Each of these may have a role in the
development of Alzheimer’s disease. There are correlations between disruption of
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sleep, deposition of Aβ and the incidence of Alzheimer’s but as yet there is no
consensus as to any causal connections (Ju et al. 2014; Lucey and Bateman 2014;
Roh et al. 2014; Spira et al. 2014; Yaffe et al. 2014; Benedict et al. 2015; Sharma
et al. 2015; Sprecher et al. 2015; Cedernaes et al. 2017).
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Appendices
Appendix 1
The evidence that extramural perivascular spaces can exist is convincing as large
particles can be introduced into them (see e.g. Carare et al. 2008) and during influx
of fluorescent tracers the spaces protrude beyond the dimensions of the vessel walls
(see e.g. Figs. 2 and 3 in Iliff et al. 2012). The case against their normal existence
along arterioles and venules is largely that they are rarely seen in fixed, sectioned
tissue. However, spaces, particularly labile spaces, are likely to be difficult to fix, so
this type of evidence is not in itself compelling (see e.g. Fig. 2 in Bakker et al.
2016). Arbel-Ornath et al. (2013) used two-photon imaging to investigate the
position of a 3 kDa dextran during efflux following injection into the parenchyma.
Shortly after injection they saw fluorescence within the parenchyma, in peri-
vascular spaces surrounding small arteries and, at lower concentration, between
the smooth muscle cells.
There is extensive and convincing evidence that solutes can rapidly reach the
basement membranes between the smooth muscle cells (see e.g. Carare et al.
2013a), but it has not been established whether the solutes reach these locations
by movement along the basement membranes as favoured by Weller, Carare,
Hawkes and colleagues (see e.g. Morris et al. 2016) or via movement along the
vessels via extramural pathways and penetration from these into the basement
membranes within the vessel wall. This is discussed in Section “Clearance via
Perivascular Routes”. While it has been possible to observe solutes moving inwards
via extramural periarterial spaces (Iliff et al. 2012) and outwards via some
periarterial route (Dienel and Cruz 2008; Arbel-Ornath et al. 2013), so far it has
not been possible to observe solutes progressing via either perivenular or specifi-
cally intramural periarterial routes.
Appendix 2
In several papers the time courses of the amount of Aβ remaining in the brain have
been analysed using a scheme introduced by Shibata et al. (2000). In this an amount
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Aβ0 of the Aβ is assumed to be introduced initially into the parenchyma in a soluble
form. This soluble Aβ can either be effluxed with rate constant k1 or irreversibly
converted to a retained form with rate constant k2. The prediction of this scheme for
the time course can be derived as follows. If at any time t the amount of the soluble
form in the brain is Aβst and that of the retained form is Aβrt, then the total amount
remaining is Aβt ¼ Aβst + Aβrt and the changes with time of the amounts are
governed by
dAβst
dt
¼  k1þ k2ð ÞAβst ð7Þ
and
dAβrt
dt
¼ k2Aβst ð8Þ
The first of these differential equations has as its solution
Aβst ¼ Aβ0e k1þk2ð Þt, ð9Þ
which then allows the second to be solved,
Aβrt ¼ Aβ0a1 1 e k1þk2ð Þt
 
ð10Þ
and thus
Aβt ¼ Aβ0 a1þ a2e k1þk2ð Þt
h i
ð11Þ
where a1 ¼ k2/(k1 + k2) is the fraction of the Aβ that is eventually converted to the
retained form and a2 ¼ 1  a1 is the fraction eventually effluxed. This is to be
compared with the versions of the solutions for Aβt that have been used in various
studies. The version presented by Shibata et al. (2000)
Aβt ¼ Aβ0 a1þ a2½ ek1t ð12Þ
was also used by Deane et al. (2004), Bell et al. (2007) and Deane et al. (2008)
(Abhay Sagare, personal communication). Storck et al. (2016) used a partially
corrected version
Aβt ¼ Aβ0 a1þ a2½ e k1þk2ð Þt: ð13Þ
Use of Eqs. (12) or (13) may have affected the estimates of the fractions of Aβ
effluxed and retained. In Shibata et al., it may have led to a small overestimate of
the rate constant for efflux. In Bell et al., the fraction retained was small,
i.e. k2 k1, and Eq. (12) is then almost the same as Eq. (11). However, the units
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stated in the methods section of that paper for k1 and k2 were pmol min1 g1 while
those actually used in the calculations were min1 as in Shibata et al. The values
reported in Tables 1 and 2 are calculated rates of efflux with the units stated,
pmol min1 g1. These rates were calculated as the initial amount present,
~13 pmol/g ISF (assuming the mass of ISF is 1/10th that of the tissue), times the
corresponding rate constant obtained using Eq. (12) (Abhay Sagare, personal
communication).
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Abstract
The propensity for sleep is timed by the circadian system. Many studies have
shown that learning and memory performance is affected by circadian phase.
And, of course it is well established that critical processes of memory consolida-
tion occur during and depend on sleep. This chapter presents evidence that sleep
and circadian rhythms do not just have separate inﬂuences on learning and
memory that happen to coincide because of the circadian timing of sleep, but
rather sleep and circadian systems have a critical functional interaction in the
processes of memory consolidation. The evidence comes primarily from research
on two models of learning disability: Down’s syndrome model mice and Siberian
hamsters. The Down’s syndrome model mouse (Ts65Dn) has severe learning
disability that has been shown to be due to GABAergic over-inhibition. Short-
term, chronic therapies with GABAA antagonists restore learning ability in these
mice long-term, but only if the antagonist treatments are given during the dark or
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sleep phase of the daily rhythm. The Siberian hamster is a model circadian animal
except for the fact that a light treatment that gives the animal a phase advance on
one day and a phase delay on the next day can result in total circadian arrhythmia
for life. Once arrhythmic, the hamsters cannot learn. Learning, but not rhythmic-
ity, is restored by short-term chronic treatment with GABA antagonists. Like
many other species, if these hamsters are made arrhythmic by SCN lesion, their
learning is unaffected. However, if made arrhythmic and learning disabled by the
light treatment, subsequent lesions of their SCNs restore learning. SCN lesions
also appear to restore learning in the Ts65Dn mice. The collective work on these
two animal models of learning disability suggests that the circadian system
modulates neuroplasticity. Our hypothesis is that a previously unrecognized
function of the circadian system is to dampen neuroplasticity during the sleep
phase to stabilize memory transcripts during their transfer to long-term memory.
Thus, sleep and circadian systems have integrated roles to play in memory
consolidation and do not just have separate but coincident inﬂuences on that
process.
Keywords
Down’s syndrome · GABA · Memory · Siberian hamsters · Suprachiasmatic
nuclei
1 Interactions Between Sleep and Circadian Systems Are
Extensive
The timing of the daily sleep/wake cycle is a fundamental functional interaction
between the circadian system and sleep homeostasis that is widely recognized
(Borbely 1982; Daan et al. 1984; Dijk and Czeisler 1995). The purpose of this
chapter is to emphasize the need to understand functional interactions between
circadian and sleep processes at many levels that go beyond the timing of sleep
and wake. The master pacemaker of the mammalian circadian system is the
suprachiasmatic nucleus (SCN) that uses transcriptional/translational feedback
loops of clock genes to produce cellular oscillations (Buhr and Takahashi 2013).
When these cellular rhythms are synchronized, they generate a circadian output
signal that is projected largely to other areas of the hypothalamus including the
ventrolateral preoptic area (VLPO) that is a sleep control nucleus. SCN projections
also go to many areas beyond the hypothalamus such as the lateral septum, the
paraventricular nucleus of the thalamus, the habenula, and the periaqueductal gray
(Kriegsfeld et al. 2004). In addition to neural connectivity, the SCN may also release
diffusible signals (Silver et al. 1996). Thus, the central pacemaker inﬂuences directly
or indirectly a diversity of brain regions that control many physiological and
behavioral functions. Because endocrine controls have such widely spread effects
in the body, the regulation of neuroendocrine systems is of special signiﬁcance
(Kriegsfeld and Silver 2006). In addition, clock genes are expressed in a wide variety
of peripheral tissues providing temporal organization to molecular, cellular,
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biochemical, and physiological processes in most tissues and organs of the body
(Zhang et al. 2014).
Coincidently, many functions in peripheral tissues are inﬂuenced by sleep and
wake as shown by a plethora of experiments on animals and humans involving sleep
deprivation. These functions include behavioral (e.g., Jackson et al. 2013), metabolic
(e.g., Van Cauter et al. 2008), immune system (e.g., Ackermann et al. 2012), stem
cell (e.g., Rolls et al. 2015), endocrine (e.g., Van Cauter et al. 2004), oxidative stress
(e.g., Everson et al. 2014), bone metabolism (e.g., Everson et al. 2012), and many
others including overall macromolecular biosynthesis (Mackiewicz et al. 2007).
There is a large overlap between processes/functions affected by circadian
rhythms and by sleep. One way to conceptualize these overlaps is that the central
and peripheral circadian timing mechanisms coordinate and facilitate sleep functions
by controlling the underlying cellular and molecular processes so that necessary
substrates and enzymes are provided at the right times, and by putting tissues and
organs in proper states for maximum beneﬁt from whatever function is being carried
out. A consequence of that conceptual view is that circadian and sleep roles in many
or most processes are not simply separate factors inﬂuencing the same processes but
are integrated in their functions. Most studies of sleep or circadian inﬂuences on
variables of interest focus on one or the other. Sleep studies usually treat circadian
phase as a variable to be controlled for, and circadian studies try to avoid sleep
confounds through sleep deprivation or constant routine protocols. Rarely do
investigators ask whether there are important functional relationships between the
sleep and the circadian inﬂuences on their system of interest. In this chapter we
review the evidence that sleep and the circadian system play complementary and
critically integrated roles in one set of functions of interest to both ﬁelds of study –
learning and memory.
Both sleep and circadian phase have strong inﬂuences on learning and memory in
humans and other mammals as has been documented in two extensive reviews
(Rasch and Born 2014; Smarr et al. 2014). Both of those reviews barely touch
upon the involvement of the other system. Recent studies, however, reveal that sleep
and circadian systems do not simply have separate inﬂuences on learning and
memory, rather they work in concert to achieve ﬁdelity in memory consolidation.
Our views on this interaction derive principally from studies of two animal models of
learning disability: Down syndrome (DS) model mice and circadian-arrhythmic
Siberian hamsters.
2 Learning Disability of Down Syndrome Involves
GABAergic Over-Inhibition with Circadian and Sleep
Components
The Ts65Dn mouse model of Down syndrome has severe impairments of long-term
memory formation as shown by performance on the Morris water maze and radial
arm maze tests (Seregaza et al. 2006) as well as on the novel object recognition
(NOR) task (Dere et al. 2007; Fernandez et al. 2007; Colas et al. 2013). Possible
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cellular bases for cognitive deﬁcits in Ts65Dn mice have been reported in several
studies ranging from neuroanatomical (Belichenko et al. 2004) to electrophysiologi-
cal long-term potentiation (LTP) studies (Siarey et al. 1997; Kleschevnikov et al.
2004; Costa and Grybk 2005; Fernandez et al. 2007). A general inference from this
body of work was that GABAergic over-inhibition is a possible cause of cognitive
deﬁcits in Ts65Dn mice.
Pursuing the GABAergic over-inhibition hypothesis, Fernandez et al. (2007)
discovered that low, chronic doses of GABA antagonists, picrotoxin, bilobilide,
and pentylenetetrazole (PTZ) restored the ability of Ts65Dn mice to perform as well
as their 2N littermates in both NOR and spontaneous alternation (SA) tasks. The
remarkable aspect of these studies is that a chronic treatment regime of low daily
doses of the drugs for only 2 weeks results in a long-term normalization of the
performance of the Ts65Dn mice that lasts for months (Fernandez et al. 2007)
(Fig. 1). This study also showed that the PTZ treatment normalized the hippocampal
LTP in the Ts65Dn mice. As with the behavioral tests, short-term (2-week) courses
of daily dosing with GABA antagonists resulted in long-term (greater than 2 months)
normalization of LTP.
Further characterization of the PTZ therapy in Ts65Dn mice produced additional
interesting ﬁndings (Colas et al. 2013) (Fig. 2). First, the drug is effective at
extremely low doses. Whereas the dose used in the Fernandez et al. study was
3 mg/kg, Colas et al. showed that 0.03 mg/kg was effective (Fig. 2b). Second, the
therapy worked in young, middle-aged, and old Ts65Dn mice (Fig. 2b, c); thus, it
was not working through a developmental effect nor a mitigation of senescence
effect. Third, and most important for this discussion, the effectiveness of PTZ
depended on time of day of dosing. If the drug was administered during the dark
phase of the daily cycle, it had no effect (Fig. 2d). In addition, if the drug was
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Fig. 1 Effects of short, chronic course of PTZ dosing on performance of Ts65Dn mice and their 2N
littermates in the novel object recognition (NOR) test. Mice received daily doses of 3 mg/kg of PTZ
in milk or just milk alone for 2 weeks. After that treatment ended, the mice were subjected to NOR
testing with a 24-h delay between training and testing. If the mice spend equal times with the novel
and the familiar object, the discrimination score is 0. Deviations from 0 indicate that the mouse
spent more time exploring the new object than the previously experienced object. Whereas the PTZ
treatment had no effect on the performance of the 2N mice, it normalized the performance of the TS
mice to the levels shown by the 2N controls (Modiﬁed from Fernandez et al. 2007)
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administered during the light phase, but the mice were sleep deprived for 1.5 h
following dosing, the drug had no effect (Heller et al. 2014). Thus, GABAergic
antagonism with PTZ was effective in reducing the cognitive disability of Ts65Dn
mice, but its effectiveness was dependent on both circadian and sleep factors.
In a subsequent study, ﬂumazenil, a benzodiazepine competitive antagonist, also
was shown to be effective in long-term restoration of learning and memory in
Ts65Dn mice (Colas et al. 2017). The ﬂumazenil results are all the more remarkable
because of the very short half-life of this drug. A critical question is how a short-term
chronic treatment with GABAergic receptor antagonist drugs can produce an
extremely long-lasting improvement in learning and memory.
Early on, the potential importance of the circadian system in the learning disabil-
ity of DS led us to characterize the circadian rhythms of Ts65Dn mice in comparison
to their 2N littermates. Contrary to expectations, the Ts65Dn mice had more robust
circadian rhythms than their 2N littermates (Ruby et al. 2010). PTZ treatment did not
inﬂuence any of the measured circadian parameters. At the time, we were surprised
to see the robust circadian rhythms of the Ts65Dn animals, but subsequent work
discussed below supports the possibility that stronger signals from the SCN in
Ts65Dn mice may be a factor in their learning disability.
3 Circadian Arrhythmicity Can Cause Learning Disability
in Hamsters
The apparent lack of circadian dysfunction in the Ts65Dn mice was in striking
contrast to our previous work with another model of learning disability. We discov-
ered that circadian timing could be eliminated in Siberian hamsters by exposing them
to light for 2 h late at night, followed by a 3-h delay in onset of the next dark phase
PTZ
VEH
0
10
20
30
40
50
60
Baseline Day 1 Day 30
*
**
Fig. 3 Siberian hamsters made circadian-arrhythmic by a disruptive phase shift are not able to
perform on the NOR test, but if they receive a 2-week course of daily injections of PTZ (1 mg/kg),
they perform well on the NOR test on the day after the treatment ends and also 1 month later without
any additional dosing with PTZ (modiﬁed from Ruby et al. 2013)
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(i.e., 3-h delay of the light-dark cycle; Ruby et al. 1996, 2004). This method has been
termed the disruptive phase-shift (DPS) protocol (Prendergast et al. 2012). Being
able to render hamsters circadian-arrhythmic with a simple light treatment gave us
the opportunity to ask questions about the functions of circadian rhythms without
doing invasive procedures such as lesions of the SCN, or genetic manipulations such
as clock gene knockouts, or exposure of the animals to stressful conditions such as
constant light. The ﬁrst important ﬁnding with hamsters made circadian-arrhythmic
by the DPS method was that once arrhythmic, they exhibited substantial deﬁcits in
recognition memory (Ruby et al. 2008), but as in the Ts65Dn mice, memory was
restored by a 14-day injection regimen of PTZ (Ruby et al. 2013) (Fig. 3). PTZ
treatment did not, however, restore the hamsters’ circadian rhythms. Thus, whereas
learning disabled Ts65Dn mice had robust circadian rhythms, learning disability in
the hamster was associated with arrhythmia. The opposite results from these two
models of learning disability raised the question of how both circadian arrhythmicity
and stronger circadian rhythms could impair learning and memory.
4 Animals Made Arrhythmic by SCN Lesions Are Not
Learning Disabled
Many studies have demonstrated that rodents continue to perform well in learning
and memory tests after they have been made arrhythmic by SCN lesions. These
studies included passive avoidance tests (Stephan and Kovacevic 1978; Cain et al.
2012), recognition memory and water maze learning (Mistlberber et al. 1996; Phan
et al. 2011), spontaneous alternation and novel object recognition (Fernandez et al.
2014), and even conditioned time-place preference (Cain and Ralph 2009). Rodents
made arrhythmic by clock gene knockouts also show mild or no deﬁcits in spatial
working memory, contextual fear memory, and object recognition memory (Mulder
et al. 2013; Van der Zee et al. 2011; Wardlaw et al. 2014). However, Cry genes
appear to be required for time-place memory (Van der Zee et al. 2011). Two studies
in this assemblage caught our attention for a feature of the published data not noted
by the authors (Stephan and Kovacevic 1978; Mistlberber et al. 1996). After the
SCN was surgically ablated, animals seemed to improve performance in both
passive avoidance and discrimination tasks. These and other studies raise the
possibility that elimination of the SCN might have removed a circadian dampening
of cognitive performance.
5 An Output of the SCN Modulates Neuroplasticity
The difference between the hamsters made arrhythmic by the DPS treatment and the
rodents in SCN lesion studies is that the SCN remains functional in the hamsters
even though it no longer generates a circadian signal. In contrast, the lesioned
animals no longer had any SCN tissue. Measurements of clock gene RNAs in the
arrhythmic hamsters showed that circadian arrhythmia was due to a loss of molecular
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rhythms in the SCN (Grone et al. 2011). One potential inference from these studies is
that SCN activity modulates neuroplasticity in learning and memory. Could it be that
a continuous output from the SCN in the arrhythmic hamsters reduces
neuroplasticity necessary for learning at all times of day?
The SCN is a GABAergic nucleus (Moore and Speh 1993; Belenky et al. 2008),
and GABA receptor antagonism normalizes LTP in the dentate gyrus of hippocam-
pal slices from learning disabled Ts65Dn mice (Siarey et al. 1997; Kleschevnikov
et al. 2004; Costa and Grybk 2005; Fernandez et al. 2007). The hippocampus is
essential for the formation of long-term declarative memories and has multiple
inputs from different brain regions. The SCN does not project directly to the
hippocampus, but it does innervate one of the major inputs to the hippocampus,
the septal nuclei (Morin et al. 1994; Watts et al. 1987). Injections of GABAA
receptor agonists into the medial septum disrupt performance in hippocampal-
dependent learning tasks (Brioni et al. 1990; Parent et al. 1997; Degroot and Parent
2001; Krebs and Parent 2005). Thus, memory impairment in arrhythmic hamsters
may be due to continuous release of GABA from the SCN into the septum (Ruby
et al. 2008).
Fig. 4 Siberian hamsters made circadian-arrhythmic by a disruptive phase shift (a) lose the ability
to perform normally (b) on either a test of declarative memory (NOR) or a test of working memory
(SA). A complete lesion of the SCN, but not a partial lesion, restores their ability to perform
normally on these two tests of learning ability (modiﬁed from Fernandez et al. 2014)
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To test this hypothesis, hamsters were made circadian-arrhythmic by the DPS
treatment, which impaired both recognition and spatial working memory (Fernandez
et al. 2014). Next, these animals were subjected to stereotaxic thermolytic lesions of
the SCN. Of course, these animals were still circadian-arrhythmic, but when subse-
quently retested for memory, hamsters with complete lesions of the SCN regained
memory function and performed as well as rhythmic controls in tests of recognition
and spatial memory (Fig. 4). Those animals that were still learning-impaired either
had sham lesions or incomplete lesions that spared some SCN tissue (Fernandez
et al. 2014). These results are strong support for the idea that the SCN is directly or
indirectly responsible for the memory impairments found in hamsters made arrhyth-
mic by the DPS protocol.
If a continuously active SCN can impair learning and memory in the arrhythmic
hamsters, could an overly active SCN be responsible for the learning disability of the
Ts65Dn mice? We are currently investigating this possibility by testing the NOR
performance of Ts65Dn mice that were subjected to stereotaxic SCN lesions.
Following recovery from the lesion surgery, the circadian rhythmicity of each animal
is evaluated through actimetry under a light-dark cycle and in constant dark. This
project is still in progress, but preliminary results to date show that the SCN lesions
have no effect on the performance of the 2N mice in the NOR test, but the Ts65Dn
mice rendered arrhythmic by the lesion surgery performed better than unlesioned
Ts65Dn mice. Thus, in both animal models, the SCN might be directly or indirectly
responsible for the GABAergic over-inhibition causing learning impairment in the
Ts65Dn mice.
The idea that an intact SCN in Ts65Dn mice might interfere with memory as does
an arrhythmic SCN in the hamster model led us to hypothesize that a normal function
of the circadian system is to reduce or dampen neuroplasticity at a particular
circadian phase. Why should that be so? We propose that the answer resides in a
critical functional interaction and interdependency between the sleep and the circa-
dian system in the process of memory consolidation.
6 Memory Consolidation Occurs Predominantly
During Sleep
The foundation for mechanistic understanding of the role of the hippocampus in
declarative learning and memory was the discovery of hippocampal neurons that
ﬁred selectively in response to spatial location of a rat (O’Keefe and Dostrovsky
1971; O’Keefe and Nadel 1978) and were therefore called place cells. The involve-
ment of sleep in this learning process was pioneered by Wilson and McNaughton
(1994). They showed that sequences of place cell activity recorded when a rat ran a
maze were repeated when the rat was in subsequent NREM sleep. The authors
hypothesized from their results: “. . .initial storage of event memory occurs through
rapid synaptic modiﬁcation, primarily within the hippocampus. During subsequent
slow-wave sleep, synaptic modiﬁcation within the hippocampus itself is suppressed,
and the neuronal states encoded within the hippocampus are ‘played back’ as part of
a consolidation process by which hippocampal information is gradually transferred
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to the neocortex.” Extensive subsequent work (brieﬂy reviewed in Chapter “The
Function(s) of Sleep”) has characterized aspects of the last component of the Wilson
and McNaughton hypothesis, the transfer of newly acquired information from the
hippocampus to the neocortex (Siapas et al. 2005; Ji and Wilson 2007; Fujisawa and
Buzsaki 2011; Kitamura et al. 2017). This body of work ﬁts well with a model
proposed by Born and Wilhelm (2012) suggesting that both the hippocampus and
the cortex acquire information during wake, but the cortical representation is weaker
than the hippocampal. During sleep, the hippocampus tutors the cortex in a process
referred to as memory consolidation making the cortical engram stronger ensuring
long-term memory as the hippocampal record eventually weakens.
The ﬁrst part of the Wilson and McNaughton hypothesis stating that during sleep
“the synaptic modiﬁcation within the hippocampus itself is suppressed” probably
had its origin in an earlier study by Barnes et al. (1977) that measured in rats and
monkeys the sensitivity of cells in the fascia dentata of the hippocampus to
stimulation of their afferent ﬁbers. Their ﬁnding was that this measure of synaptic
excitability had a daily rhythm. In the rat it was higher during the dark phase than the
light phase, but in the monkey, it was higher during the light phase than the dark
phase. They ruled out light level as being a causative factor, and they also ruled out
sleep as a causative factor as all recordings were from awake moving animals. They
also conﬁrmed that the daily rhythm was circadian by conducting the recordings on a
blinded rat. Many subsequent studies of hippocampal sensitivity and LTP have
shown circadian variation. Many of these studies have been cited in an excellent
report on the circadian rhythms of LTP in mouse hippocampal slices (Chaudhury
et al. 2005). More recently a circadian rhythm of LTP has been demonstrated in
freely behaving rats (Bowden et al. 2012). The unavoidable conclusion from this
entire body of work is that the synaptic excitability of both diurnal and nocturnal
animals is lowest during the sleep phases of their circadian rhythms. We propose
from our work on learning disabled mice and hamsters that the dampening of
hippocampal excitability, and presumably neuroplasticity, during the sleep phase
is the functional contribution of the circadian system to the process of memory
consolidation.
7 Hypothesis: During Sleep the Circadian System Stabilizes
Memory Consolidation
Why should suppression of hippocampal neuroplasticity be necessary for memory
consolidation? We suggest that the reason is to prevent alteration of the hippocampal
engrams and thereby to ensure the ﬁdelity of the information being transferred into
long-term memory. The importance of memory reactivation and reconsolidation
during sleep has been clearly established by studies in which speciﬁc elements of
learning can be associated with a conditioned stimulus such as a tone or an odor, and
then the subject can be exposed to those conditioned stimuli during subsequent
sleep. The learning elements associated with the conditioned stimuli reintroduced
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during sleep are recalled better during the following waking phase (Rolls et al. 2013;
Rudoy et al. 2009; Rasch et al. 2007).
The interpretation of these studies is that experiencing the conditioned stimuli
during sleep reactivated the memory and that memory was then strengthened by the
subsequent reconsolidation. Presumably there are many different hippocampal
engrams reactivated, replayed, and reconsolidated during sleep. What is preventing
them from becoming mixed and thereby altered? Elegant experiments in the
Tonegawa lab at MIT have shown that engrams formed in a neutral context can be
labeled and then reactivated optogenetically. If such a neutral engram is activated
during a fear conditioning process in a different context, the initial neutral context
subsequently elicits strong fear responses (Ramirez et al. 2013). Thus, the mixing of
engrams in the awake animal can create a false memory. During sleep, the mixing of
engrams might be more likely because they are not delineated by sensory input, but
mixing is prevented by the dampening of hippocampal neuroplasticity.
The vulnerability for memories to modiﬁcation during sleep has been
demonstrated by stimulating reactivation and replay during sleep. As discussed in
Chap. 1, Rolls et al. (2013) showed that the emotional valence of fear conditioning
could be enhanced by re-exposure of the animal to the conditioning stimulus during
sleep. In this experiment, mice were subjected to foot shock following the condi-
tioning stimulus – a puff of a distinctive odor. During subsequent sleep they were
re-exposed to puffs of the conditioning odor or a control odor. When subsequently
tested in a novel context during wake, the mice that received the conditioning odor
showed more freezing (a sign of anxiety) than the mice that received the control
odor. The emotional valence of the memory had been altered. The converse experi-
ment took advantage of the fact that the reconsolidation of reactivated memories
requires protein synthesis. The sleep phase was preceded by injections of a protein
synthesis inhibitor into the amygdala, and then during sleep the mice were exposed
either to the conditioning odor or to a control odor. The mice exposed to the
conditioning odor, but not the control odor, showed a decrease in the emotional
valence of the memory when exposed to the conditioning stimulus during
subsequent wake in a novel context. Interestingly, if the conditioning stimulus
were presented only during wake episodes, there was no change in the emotional
valence of the memory. Presumably, if the conditioning stimulus induces replay of a
memory during sleep, that memory is strengthened unless a protein synthesis
inhibitor is present to interfere with the memory reconsolidation process. Thus, a
memory is vulnerable to being modiﬁed during sleep. We propose that the functional
contribution of the circadian system to the sleep-related process of memory consoli-
dation is to stabilize the hippocampal engram while it is being transferred to the
cortex, thus ensuring high ﬁdelity of long-term memory.
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8 Summary and Conclusions
The goal of this chapter is to encourage more integrated research on the interrelations
between sleep and circadian rhythms. Sleep researchers interested in exploring the
functions of sleep generally do not give consideration to circadian rhythms other
than to control for their inﬂuence. Similarly, circadian researchers rarely take sleep
into account other than efforts to eliminate it as a variable in their experiments.
Control of the timing of sleep by the circadian system is generally recognized, but
surely circadian rhythms have many more functional interactions with sleep.
Searches for sleep functions have included abundant molecular, cellular, physiolog-
ical, and behavioral variables. If all of those possible or putative sleep functions are
grouped as one component of a Venn diagram, and all circadian processes constitute
another component of a Venn diagram, there is huge overlap between them. All cells
have clock genes, and expression of those genes synchronized by the central
pacemaker in the SCN control many cellular functions. We should expect, therefore,
that many sleep functions are facilitated by being integrated with circadian pro-
cesses. As an example, this chapter describes evidence suggesting a previously
unrecognized role that the circadian system plays in learning and memory – the
stabilization of the memory consolidation process.
Insights came from studies of two animal models of learning disability, a Down
syndrome model mouse (Ts65Dn) and Siberian hamsters rendered circadian-
arrhythmic by a noninvasive, one-time light treatment called a disruptive phase
shift. Prior work on the Ts65Dn mouse showed that the learning disability was
due to GABAergic over-inhibition and was reversible with a short-term chronic
daily treatment with low-dose GABAergic receptor antagonists. The same treatment
restored learning and memory in the arrhythmic hamsters as well without restoring
their circadian rhythms. Prior work on many species including humans has shown
circadian rhythms in learning and memory, and the SCN is largely a GABAergic
nucleus. Thus, there is the possibility that the SCN is the direct or indirect source of
the GABAergic over-inhibition of the hippocampal circuits in the Ts65Dn mouse.
That suggestion is strengthened by the ﬁnding that the GABA receptor antagonist
dosing was only effective when delivered during the light phase of the daily rhythm
of the Ts65Dn mice. However, a serious difference exists between the two model
systems. The hamster learning disability was associated with circadian arrhythmia,
whereas the Ts65Dn mice had intact circadian rhythms. A possible explanation was
that the learning disabilities could be caused by excessive GABAergic inhibition at a
speciﬁc time of day. If the SCN is creating the GABAergic over-inhibition,
eliminating the SCN should restore learning abilities, which it does in the arrhythmic
Siberian hamster. Complete SCN lesions in the arrhythmic hamsters normalize their
ability to learn and remember. And, in preliminary experiments, the same appears to
be true of the Ts65Dn mouse.
The questions that arise out of this sequence of research ﬁndings is whether a
normal function of the circadian system is to dampen neuroplasticity responsible for
the formation of memories, and if so, what is its adaptive signiﬁcance. An extensive
and excellent literature has developed on the neurophysiology of the process of
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consolidation of short-term to long-term memory during sleep. For declarative
memories, this involves replay of hippocampal engrams and their sharing with the
cortex. Presumably this process involves many engrams shared between the hippo-
campus and the cortex over the course of a sleep phase. We have shown that
individual engrams produced by fear conditioning can be altered during sleep, and
the Tonegawa lab at MIT has shown that even during wake, engrams can become
falsely associated. Therefore, we propose that the circadian system interacts with the
sleep processes of memory consolidation to insure the ﬁdelity of the information
being consolidated into long-term memory.
In conclusion, we hope that this example of a functional interaction between sleep
and the circadian system that goes beyond the simple issue of timing will encourage
other sleep and circadian researchers to seek examples and mechanisms of integra-
tion rather than just treating one or the other system as a variable to be controlled.
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Abstract
Disturbances of the sleep-wake cycle are highly prevalent and diverse. The
aetiology of some sleep disorders, such as circadian rhythm sleep-wake disorders,
is understood at the conceptual level of the circadian and homeostatic regulation
of sleep and in part at a mechanistic level. Other disorders such as insomnia are
more difﬁcult to relate to sleep regulatory mechanisms or sleep physiology. To
further our understanding of sleep-wake disorders and the potential of novel
therapeutics, we discuss recent ﬁndings on the neurobiology of sleep regulation
and circadian rhythmicity and its relation with the subjective experience of sleep
and the quality of wakefulness. Sleep continuity and to some extent REM sleep
emerge as determinants of subjective sleep quality and waking performance. The
effects of insufﬁcient sleep primarily concern subjective and objective sleepiness
as well as vigilant attention, whereas performance on higher cognitive functions
appears to be better preserved albeit at the cost of increased effort. We discuss
age-related, sex and other trait-like differences in sleep physiology and sleep need
and compare the effects of existing pharmacological and non-pharmacological
sleep- and wake-promoting treatments. Successful non-pharmacological
approaches such as sleep restriction for insomnia and light and melatonin treat-
ment for circadian rhythm sleep disorders target processes such as sleep homeo-
stasis or circadian rhythmicity. Most pharmacological treatments of sleep
disorders target speciﬁc signalling pathways with no well-established role in
either sleep homeostasis or circadian rhythmicity. Pharmacological sleep thera-
peutics induce changes in sleep structure and the sleep EEG which are speciﬁc to
the mechanism of action of the drug. Sleep- and wake-promoting therapeutics
often induce residual effects on waking performance and sleep, respectively. The
need for novel therapeutic approaches continues not at least because of the
societal demand to sleep and be awake out of synchrony with the natural light-
dark cycle, the high prevalence of sleep-wake disturbances in mental health
disorders and in neurodegeneration. Novel approaches, which will provide a
more comprehensive description of sleep and allow for large-scale sleep and
circadian physiology studies in the home environment, hold promise for
continued improvement of therapeutics for disturbances of sleep, circadian
rhythms and waking performance.
Keywords
Circadian · Drug discovery · REM sleep · Sleep continuity · Sleep quality · Slow-
wave sleep · Wake quality
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1 Quantifying the Quality of Sleep and Wakefulness
1.1 A Multivariate Phenomenology
Sleep is a major determinant of well-being, mental and physical health and under-
standing sleep-health relations, and sleep disorders are dependent on adequate
quantiﬁcation of sleep. Sleep and wake states are characterised by constellations of
variables representing nearly all levels of system organisation ranging from gene
expression (O’Callaghan et al. 2018), neuronal ﬁring patterns (McKillop and
Vyazovskiy 2018), neurotransmitter release (Zant et al. 2016; Luppi and Fort
2018), endocrine and autonomic nervous system status (Morris et al. 2012; Fink
et al. 2018), body and brain temperature (Landolt et al. 1995), responsiveness to
external stimuli (Ermis et al. 2010), motor behaviour (Horner and Peever 2017) to
changes in consciousness (Casali et al. 2013). Which variables are essential to sleep
quality and how these variables contribute to sleep’s associations with well-being,
physical health and brain function remain, however, largely unknown even though
several hypotheses have been proposed.
Here we will summarise some recent developments in research on sleep physiol-
ogy, circadian rhythms and waking performance and their interrelations in humans
without sleep complaints and discuss some implications for the understanding and
development of non-pharmacological and pharmacological therapeutics for sleep
and circadian disorders.
1.1.1 Sleep
Sleep has a rich phenomenology consisting of both subjective and objective aspects,
and new facets continue to be reported. In humans, sleep comprises the subjective
experience of the cessation of consciousness (falling asleep), the presence of dreams
and nightmares or the feeling of not having slept all night. After waking up, the sleep
experience can be reported as sleep quality and sleep depth. At another level sleep is
a state of the brain and the body which in humans and animals can be quantiﬁed by
objective behavioural criteria such as immobility and arousal thresholds and by a
wide range of physiological variables. The electroencephalogram, electromyogram,
electrooculogram, electrocardiogram, endocrine parameters, and respiratory
parameters are among the physiological variables most commonly recorded in
laboratory studies of human sleep. A recording of these state variables is referred
to as a polysomnogram (PSG) (Berry et al. 2017) (see Fig. 1). Currently sleep is
primarily quantiﬁed by sleep staging based on EEG, EMG, and EOG signals. Sleep
is subdivided into non-rapid eye movement (NREM) sleep and rapid eye movement
sleep (REM). In the current sleep staging guidelines for humans, NREM sleep will
be further segmented in N1–N3 with N3 often referred to as slow-wave sleep (SWS).
Previously NREM sleep was subdivided in stages 1–4 with stages 3 + 4 being
combined as SWS. After sleep staging the sleep process is quantiﬁed by variables
such as the latency to sleep onset, the duration of the various sleep stages, the relative
contribution of sleep stages to total sleep time or the transitions between sleep stages.
NREM sleep typically precedes REM sleep, and the ultradian cycle of the alternation
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of NREM and REM sleep is one characteristic of interest. The duration of the
NREM-REM cycle scales in a lawful manner to body and brain size sleep suggesting
that it is closely linked to a primordial but as yet unknown function of sleep (Frank
and Heller 2019). Sleep can be further characterised by its continuity, i.e. are sleep
and wake episodes consolidated or are they interrupted by brief intrusions of the
other state. Sleep continuity can be quantiﬁed as sleep efﬁciency (i.e. total sleep
time/time in bed), wake after sleep onset, the number of awakenings, EEG arousals
or the distribution of the duration of uninterrupted sleep bouts as assessed by
survival analysis or other methods (Klerman et al. 2013; Svetnik et al. 2018).
Signal analysis-based approaches such as spectral analysis have been used to
further characterise sleep although these approaches are still not standard in most
research and clinical studies. Quantiﬁcation of speciﬁc electrophysiological phe-
nomena such as slow waves and sleep spindle oscillations (Dijk et al. 1993; Lazar
et al. 2015), muscle tone (Brunner et al. 1990a; Jeppesen et al. 2018) or heart rate
variability (Yang et al. 2018; Viola et al. 2008a) and changes thereof across the sleep
episode or in response to pharmacological and non-pharmacological sleep
manipulations have provided new insights into the sleep process. Quantiﬁcation of
slow waves through spectral analysis as power density in the low-frequency range
Fig. 1 Nocturnal sleep in a young adult. Hypnogram, spectrogram and time course of slow-wave
activity (SWA ¼ EEG power in the 0.75–4.5 Hz range). W wakefulness, R REM sleep, N1–N3
NREM sleep stages 1–3
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(0.75–4.5 Hz) and commonly referred to as slow-wave activity (SWA) has formed
the basis for quantiﬁcation of the homeostatic process in the two-process model of
sleep regulation (Borbély 1982; Daan et al. 1984). Topographical analyses using
multi-electrode EEG recordings have identiﬁed local aspects of sleep which may be
relevant to local recovery processes (Kattler et al. 1994; Huber et al. 2006), memory
consolidation (Rasch and Born 2013), the dream process (Siclari et al. 2017) or
maybe the lack of cessation of consciousness despite the presence of global sleep as
observed in insomnia (Riedner et al. 2016). Analyses of synchronisation across
multiple EEG derivations and EEG frequencies have shown that the three vigilance
states (Wakefulness, NREM and REM) are very different with REM sleep being the
most synchronised state (Achermann et al. 2016), even though the REM sleep EEG
is commonly described as desynchronised. Analyses of the temporal characteristics
of the EEG have revealed phenomena such as phase locking between slow
oscillations and sleep spindles (Klinzing et al. 2016) and ultra-slow oscillatory
processes in spindle activity with periods of approximately 50–75 s (Lecci et al.
2017; Lazar et al. 2018).
1.1.2 Wakefulness
Sleep research tacitly assumes that the quality of wakefulness relates, at least in part,
to the quality of sleep, although the reverse pathway is also plausible. Wakefulness is
subjectively experienced, with alertness, sleepiness and fatigue being commonly
used words to describe the quality of wakefulness. The subjective quality of wake-
fulness in terms of perceived alertness can be quantiﬁed with the Karolinska
sleepiness scale (Akerstedt et al. 2017) or the Epworth sleepiness scale (Johns
1991) or objectively assessed as the ability to stay awake using the maintenance of
wakefulness test or the propensity to fall asleep by the multiple sleep latency test
(Sullivan and Kushida 2008). The quality of wakefulness can be characterised by
absence or intrusion of sleep like electroencephalographic features such as theta
activity (Greneche et al. 2008; Cajochen et al. 1995). The quality of wakefulness can
be measured as the ability to remain vigilant and respond to stimuli in simple, and
rather boring, test conditions such as in the psychomotor vigilance test (Lim and
Dinges 2008). Finally, the quality of wakefulness may be assessed by the perfor-
mance on tasks probing more complicated brain functions like working memory,
executive function tests and the effort it takes to perform these tasks (Lo et al. 2012;
Groeger et al. 2014) and tasks related to our professional and social life, e.g. driving
(Shekari Soleimanloo et al. 2017).
The quality of wakefulness immediately following sleep is of special interest.
Following the transition from sleep to wakefulness as deﬁned by the PSG, it takes
the brain some time to reach full waking performance (Balkin et al. 2002; Santhi
et al. 2013). This process, referred to as sleep inertia, is relevant in operational
conditions, for example, when pilots take naps on long haul ﬂights, and may be
exacerbated by non-pharmacological (e.g. sleep restriction) (Balkin and Badia 1988)
and pharmacological (Boyle et al. 2012a; Cohen et al. 2010a) treatments of sleep
disturbances.
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Understanding how the different dimensions of sleep and wakefulness are inter-
related, e.g. which physiologic aspect of sleep predicts the subjective quality of
sleep, how sleep physiology relates to the quality of waking and how sleep- and
wake-promoting therapeutics affect wake and sleep quality, respectively, is one of
the challenges of sleep research and sleep medicine.
We will ﬁrst discuss how sleep physiology is regulated in response to sleep loss.
2 Homeostatic Regulation of Sleep Physiology
Homeostatic regulation of sleep physiology has been investigated since the early
days of modern sleep research. Most frequently used protocols are total sleep
deprivation, e.g. not sleeping at all for 40 or 64 h, repeated partial sleep deprivation
(e.g. a week of only 6 h of sleep per day), sleep extension, selective sleep deprivation
(e.g. suppression of SWS) and nap studies. Sleep propensity and sleep structure of
recovery sleep was the primary outcome measure in many of these studies. A major
limitation of most of these studies is that time in bed during recovery sleep was
restricted and sleep termination was thus not spontaneous. As a consequence the
homeostatic regulation of human sleep duration is not well documented.
2.1 Sleep Propensity and Sleep Continuity
Total sleep deprivation, repeated partial sleep deprivation and selective disruption of
SWS all lead to an increase in subjective and objective sleep propensity,
i.e. subjective sleepiness and a reduction in the latency to sleep onset. These
interventions also lead to a reduction in wake after sleep onset and the number of
awakenings, i.e. sleep continuity increases with increasing homeostatic sleep pres-
sure. Increasing time in bed, i.e. extending the nocturnal sleep opportunity (Bei et al.
2014, 2017; Skorucak et al. 2018) or taking naps and in particular naps in the later
part of the day (Werth et al. 1996), leads to increases in the objective and subjective
latency to sleep onset and also leads to a reduction in sleep continuity. Remarkably, a
large-scale observational study in the community indicated that short sleep is
associated with lower sleep efﬁciency and more awakenings, i.e. a pattern opposite
to that observed in interventional laboratory studies (Akerstedt et al. 2019). This
probably implies that short sleep in the community is caused by ‘sleep problems’
rather than imposed sleep restriction.
2.2 NREM Sleep, SWS and SWA
In humans NREM sleep is subdivided into N1, N2 and slow-wave sleep. Slow-wave
sleep and slow-wave activity, i.e. EEG power density in the low-frequency range
content of naps increases as naps are taken later in the day (Dijk et al. 1987a),
nocturnal slow-wave sleep is increased after acute total sleep deprivation
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(Borbély et al. 1981), and slow-wave sleep in nocturnal sleep is decreased after a nap
taken later in the day (Werth et al. 1996). Slow-wave sleep is only marginally
increased after repeated partial sleep deprivation (Brunner et al. 1993). Slow-wave
sleep deprivation leads to an increase of SWS in subsequent undisturbed sleep (Dijk
et al. 1987b; Dijk and Beersma 1989). These responses are consistent with a
saturating exponential increase of slow-wave sleep pressure with time awake (Dijk
et al. 1990a) and an approximately exponential decline of slow-wave sleep pressure
during sleep (Dijk et al. 1990b; Achermann et al. 1993). The time constants of these
functions are such that most of the dynamic range of slow-wave sleep is covered
within a normal 24-h sleep-wake cycle (Skorucak et al. 2018; Rusterholz et al.
2010). This implies that SWS is primarily responsive to acute variation in sleep and
wakefulness. Some data suggest that increasing the intensity of wakefulness through
physical exercise or exposure to particular waking experiences may lead to global or
local enhancement of slow-wave sleep (Horne and Moore 1985; Melancon et al.
2015; Huber et al. 2004).
2.3 REM Sleep
The homeostatic regulation of REM sleep is different from NREM sleep. Acute total
sleep deprivation has no major effect on REM sleep during subsequent recovery
sleep when the duration of recovery sleep is experimentally constrained (Borbély
et al. 1981). Repeated partial sleep deprivation, which is not associated with a loss of
SWS but is associated with a loss of REM sleep, leads to a REM sleep rebound
during recovery sleep (Brunner et al. 1990b; Skorucak et al. 2018). REM sleep
deprivation in the beginning of the sleep period leads to a rebound in the second half
of the same sleep period (Beersma et al. 1990). A typical characteristic of REM sleep
deprivation is that attempts to initiate REM sleep occur in clusters and increases in
the course of REM sleep deprivation (Endo et al. 1998). A pronounced REM sleep
rebound was also observed during withdrawal from REM sleep suppressing
antidepressants (Landolt and de Boer 2001). Some authors have suggested that
REM sleep’s homeostatic regulation is primarily related to NREM sleep preceding
REM sleep rather than preceding wakefulness (see Frank and Heller 2019).
It is often tacitly assumed that sleep after sleep loss is good sleep which implies
that more SWS, shorter sleep latencies and fewer awakenings are the hallmarks of
good sleep. Whether more SWS or more REM sleep is a positive characteristic
depends on whether one considers total sleep deprivation or partial sleep deprivation
the more natural challenge of sleep regulatory systems.
2.4 Age- and Sex-Related Differences in Sleep Physiology
Slow-wave sleep and slow-wave activity decline during the adult life span but so do
sleep spindle activity and REM sleep (Schwarz et al. 2017; Della Monica et al.
2018). Age-related reductions in REM sleep are probably underestimated because as
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mentioned, in most studies, time in bed was limited. Under ad libitum sleep
conditions, age-related reductions in REM sleep may be as large as reductions in
SWS (Klerman and Dijk 2008). Apart from changes in SWS and REM sleep,
reductions in sleep efﬁciency and increases in the number of awakenings are
consistently observed in healthy ageing. At the same time, the subjective quality
of sleep as reported by the sleeper, rather than construed by sleep researchers, may
not change much in healthy ageing (Akerstedt et al. 2016; Della Monica et al. 2018),
and this is commonly interpreted as a habituation to reduced objective sleep quality.
Sex differences in sleep physiology primarily concern slow-wave sleep with
women spending more time in slow-wave sleep and higher slow-wave activity
(Dijk et al. 1989a; Svetnik et al. 2017). The age-related decline in SWA appears
shallower in women than in men. Sleep continuity measures are not markedly
different between the sexes (Carrier et al. 2017; Della Monica et al. 2018).
2.5 Sleep Physiology and the Subjective Quality of Sleep
A personal experience-oriented approach to sleep may deﬁne good sleep as sleep
associated with sleep satisfaction or satisfactory alertness during the subsequent
waking day. Sleep research may aim to understand how subjective sleep quality
relates to objective aspects of sleep. When we only consider recent observational
studies in which sleep in participants without sleep complaints were assessed by
polysomnography, the consensus conclusion across these cross-sectional studies is
that sleep efﬁciency/continuity is a signiﬁcant determinant of reported sleep quality
and the feeling of being refreshed upon awakening (Akerstedt et al. 2016; Kaplan
et al. 2017a, b; Della Monica et al. 2018). This association is present across the adult
life span and according to one study is much stronger in women than in men (Della
Monica et al. 2018). Remarkably, these studies imply that deep sleep, i.e. SWS or
N3, is not a main determinant of subjective measures of sleep quality. In one study
REM sleep duration was positively associated with subjective sleep quality (Della
Monica et al. 2018) (see Fig. 2). It should be noted that even though signiﬁcant PSG
predictors were identiﬁed, they explained only a small portion of the variance in
subjective sleep quality.
2.6 Sleep Physiology and the Quality of Wakefulness
2.6.1 Observational Studies
How sleep is related to the quality of subsequent wakefulness is a key question when
we consider sleep as a process of recovery and preparation for the next wake episode.
Total sleep time is a correlate of subsequent waking quality such that in healthy
participants, self-reported and objectively assessed total sleep time associates with
alertness the next day as assessed by the multiple sleep latency test (MSLT)
(Klerman and Dijk 2005). Longitudinal studies have demonstrated that the night-
to-night variation in sleep duration is associated with subjective sleepiness
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(Akerstedt et al. 2013). When we consider performance on speciﬁc tasks as an
indicator of the quality of wakefulness, the picture emerging from observational
studies in which sleep duration was assessed by self-report becomes more complex.
For example, in a large-scale Internet-based study, it was found that both short and
long sleep were associated with reduced performance on reasoning and verbal skills
and no relationship between sleep duration and short-term memory performance was
observed (Wild et al. 2018). Similarly, in an analysis of UK biobank data, both short
and long sleep (self-reported) were associated with impaired performance, and the
complaint of insomnia was not associated with reduced performance (Kyle et al.
2017).
These observations imply that good sleep and waking function require an optimal
balance between sleep and wake duration. If ﬁnding the right sleep-wake balance is
indeed essential for obtaining good quality sleep and waking function, then a number
of questions emerge. What is ‘normal/optimal’ sleep duration and how to assess
sufﬁciency of sleep on an individual basis? In this context, individual differences in
sleep need and changes in sleep need across the adult life span may be considered.
Whether and how speciﬁc sleep stages predict the quality of wakefulness or brain
function, i.e. cognition, has been investigated in young and older participants. In a
comprehensive review of the literature addressing this question, it was concluded
that a speciﬁc contribution of a speciﬁc sleep stage to cognition has not been ﬁrmly
established (Scullin and Bliwise 2015). In one recent study, the association between
Fig. 2 Contribution of polysomnographically determined sleep variables to subjective sleep
quality. Effect size is quantiﬁed with Kendall’s tau after correcting for age and sex. Vertical lines
represent large, medium and small effect sizes. NAW number of awakenings, REM rapid eye
movement sleep, TST total sleep time, SEFF sleep efﬁciency, LPS latency to persistent sleep,
SWS slow-wave sleep, SWA slow-wave activity, SFA sleep spindle frequency activity. Modiﬁed
from Della Monica et al. (2018)
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nocturnal sleep and waking function was quantiﬁed across the healthy adult life span
by an extensive battery of subjective and objective measures. After a factor analysis
of the waking performance measures, it was found that SWS relates to a latent factor
labelled ‘Speed’ of performance and REM sleep to ‘Accuracy’. Importantly, sleep
continuity was found to be the strongest predictor of ‘Accuracy’, which contains
elements of executive function and working memory performance (Della Monica
et al. 2018) (see Fig. 3).
Several observational studies have focused on contributions of speciﬁc aspects of
sleep to other aspects of waking/brain function such as the association between sleep
spindles and memory consolidation (Lafortune et al. 2014) and slow-wave sleep and
metabolic clearance (e.g. Ju et al. 2018; Hladky and Barrand 2017). In the speciﬁc
contexts of these studies, evidence for the contribution of slow-wave sleep, sleep
spindles, REM sleep and sleep continuity to brain function has been reported
although the magnitude of these effects and relative importance of various aspects
of sleep remains to be established.
2.6.2 Interventional Studies
Interventional studies may provide more deﬁnitive insights into the relation between
sleep and waking function. Acute total sleep deprivation, selective disruption of
SWS and chronic sleep restriction all lead to an increase in subjective sleepiness and
a reduction in objectively or subjectively assessed latency to sleep onset, measured at
either habitual bedtime or during the daytime in the multiple sleep latency test
(Carskadon and Dement 1987; Dijk et al. 2010a; Lo et al. 2012). Many studies
have investigated the effects of sleep loss on aspects of brain function beyond
sleepiness. Most studies implemented acute total sleep deprivation, but some used
chronic partial sleep deprivation or selective disruption of SWS or sleep continuity
(Lowe et al. 2017; Lo et al. 2012; Skorucak et al. 2018; Groeger et al. 2014). The
most consistent ﬁnding is that sleep loss leads to impairment of vigilant attention.
Many other aspects of waking performance are also affected. These include working
memory, executive function, etc. Several studies have reported effects on memory
Fig. 3 Contribution of polysomnographically determined sleep variables to waking performance.
Performance factors were derived from a factor analysis of performance measures. Colour coding
represents Kendall’s correlation coefﬁcient, after controlling for sex and age. Note the negative
correlation between SWA measures and response time, i.e. more SWA implies faster response
times. A number of awakenings are negatively and REM sleep is positively correlated with
accuracy. Modiﬁed from Della Monica et al. (2018)
450 D.-J. Dijk and H.-P. Landolt
consolidation as well. Repeated partial sleep deprivation studies have established
that there is a progressive deterioration of waking performance and in particular of
sustained attention suggesting that adaptation to sleep restriction does not occur
(Van Dongen et al. 2003; Lo et al. 2012). It should be noted that repeated partial
sleep deprivation does not lead to a large deﬁcit in SWS but primarily to a deﬁcit in
REM sleep and N2, implying that the cognitive deﬁcits cannot be attributed to SWS,
but should be attributed to TST or REM sleep (Skorucak et al. 2018). It has been
hypothesised that the cognitive deﬁcits of sleep restriction were related to extension
of the wake period beyond 16 h (Van Dongen et al. 2003), but this hypothesis was
dismissed in a forced desynchrony study in which sleep-wake ratio was manipulated
within ‘days’ shorter than 20 h. Despite the fact that wake episodes were never
longer than 16 h, increasing the wake-sleep ratio nevertheless led to deﬁcits in
vigilant attention (McHill et al. 2018). This implies that it is simply the balance
between wake and sleep duration that determines waking function and not the
absolute duration of wakefulness.
Few studies have simultaneously assessed multiple aspects of waking function
but those studies that did have shown that higher cognitive functions are less affected
than relatively simple functions (e.g. sustained attention on the PVT) (see Fig. 4). In
fact, it appears that if the sleep-deprived brain is able to engage with a task, deﬁcits
are relatively small. However, at the same time, the self-reported effort markedly
increases. This suggests that insufﬁcient sleep, at least with the time span of a week
or so, does not lead to a fundamental inability of the waking brain to function even
when, for example, working memory tasks with a high executive load are to be
performed (Lo et al. 2012). The brain primarily struggles to stay awake and allocates
more effort to maintain performance. Increases in subjective sleepiness and objective
sleepiness and measures of effort are among the ﬁrst signs of experimentally induced
insufﬁcient sleep and are among the dependent variables with the largest effect sizes
(Balkin et al. 2004; Groeger et al. 2014; Lo et al. 2012). One major limitation of
Fig. 4 Effects on 1 week of
sleep restriction (6 h time in
bed) on the Karolinska
sleepiness scale (KSS), the
10% slowest reaction times on
the psychomotor vigilance
task (PVT), accuracy on the
sustained attention to response
task (SART) and accuracy of
the verbal 1-, 2-, and 3-back.
Modiﬁed from Lo et al. (2012)
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these studies is that assessment of higher brain function in a realistic context was
often not implemented. The implication is that functions such as creativity, complex
decision-making and planning may still be markedly affected by insufﬁcient sleep.
2.6.3 Individual Differences in Sleep Need and Response to Sleep Loss
Habitual long and short sleepers of approximately the same age differ in sleep
propensity and sleep need when we consider total sleep time as the relevant measure
of sleep propensity. However, nocturnal sleep latencies are longer in long sleepers,
and short sleepers show more signs of intrusion of sleepiness-related theta activity
during wakefulness (Aeschbach et al. 1996, 2001). Apparently long and short
sleepers differ in their ‘preferred’ or ‘tolerated’ level of sleepiness. Whether and
how this relates to homeostatic aspects of sleep regulation or to the longer circadian
biological night observed in long sleepers remain unclear (Aeschbach et al. 2003).
Ageing is a major determinant of sleep propensity. Self-reported sleep duration
and polysomnographically assessed total sleep time decline with age while at the
same time daytime sleepiness decreases (Roenneberg 2013; Dijk et al. 2010a;
Akerstedt et al. 2018). The most parsimonious explanation for these observations
is that sleep need, at least as measured by sleep propensity, declines with age
(Skeldon et al. 2016). An age-related reduction in the maximum capacity for sleep
and reduction in sleep propensity has been demonstrated convincingly in protocols
in which older and young adults spent 16 h in bed and this for several days. Older
people slept 1.5 h less than young adults (who slept 8.7 h) but nevertheless were less
sleepy (Klerman and Dijk 2008). That this reduction in the TST doesn’t just reﬂect a
reduced capacity for sleep but also for sleep need is supported by interventional
studies which demonstrate that in older people the detrimental effects of total acute
and repeated partial sleep deprivation are much smaller than in young people (Adam
et al. 2006; Landolt et al. 2012; Zitting et al. 2018; Schwarz et al. 2018). Observa-
tional studies have not always conﬁrmed these observations (Wild et al. 2018).
Individual differences in the deterioration of waking performance in response to
total sleep deprivation and repeated partial sleep deprivation are also observed when
only young adults are considered (Van Dongen et al. 2004; Rupp et al. 2012).
Several genetic variants associated with individual variation in sleep duration,
sleep timing and sleep structure have been identiﬁed (Doherty et al. 2018; Rhodes
et al. 2018; Viola et al. 2007; Archer et al. 2018). How genetic variants may affect
response to sleep manipulations and pharmacological agents for wake and sleep
promotion has been reviewed elsewhere (Bachmann et al. 2012; Holst et al. 2014;
Landolt et al. 2018).
2.7 Effects of Insufficient Sleep on Peripheral Physiology,
Endocrinology and the Blood Transcriptome
Insufﬁcient sleep not only affects brain function and waking performance but also
peripheral systems. This has been assessed by monitoring physiology during recov-
ery sleep from total or chronic partial sleep deprivation and during wakefulness
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following insufﬁcient sleep. Autonomic tone changes in response to sleep loss such
that during recovery sleep, there is shift to parasympathetic dominance as reﬂected in
measures of heart rate variability (Viola et al. 2008a). Several hormones respond to
insufﬁcient sleep such that testosterone is suppressed, and appetite-regulating
hormones ghrelin and leptin are up- and downregulated, respectively (Hanlon and
Van Cauter 2011). Several markers of immune function respond to insufﬁcient sleep
such that immune function appears impaired (Irwin and Opp 2017). Finally genome-
wide assessment of transcripts in whole blood has shown that sleep loss leads to
changes in transcripts implicated in chromatin modiﬁcation, gene expression regu-
lation, macromolecular metabolism and inﬂammatory, immune and stress responses
(Moller-Levet et al. 2013). Some of these changes may explain why and how
insufﬁcient sleep leads to adverse health outcomes such as obesity.
2.8 Sleep Physiology and Sleep Homeostasis as a Target
for Pharmacological and Non-pharmacological Therapeutics
2.8.1 Sleep Promotion
Improving sleep quality in general focuses on latency to sleep onset, total sleep time
and sleep continuity (maintenance) aspects such as wake after sleep onset or speciﬁc
aspects of sleep structure such as slow-wave sleep. Peripheral correlates of sleep
quality are in general not considered as target for sleep improvement.
Increasing homeostatic sleep pressure can improve latency to sleep onset, sleep
continuity and total sleep time within a given time in bed period. This can be
accomplished by increasing wake duration prior to sleep or by increasing the
intensity of wakefulness through either physical or maybe mental activity. Such an
approach may be useful in ageing and insomnia since in these conditions, optimal
homeostatic sleep pressure may not be achieved because of daytime napping or
excessive time in bed (Cross et al. 2015). Indeed, the recommended treatment of
insomnia, which is the complaint of difﬁculties initiating and maintaining sleep, is
cognitive behavioural therapy, the main component of which is thought to be sleep
restriction (Maurer et al. 2018). An alternative approach to increase homeostatic
sleep pressure may be to pharmacologically target the molecular signalling pathways
of sleep homeostasis. Emerging pathways are adenosine and prostaglandins (Holst
and Landolt 2018; Urade 2017; Korkutata et al. 2019) although approved drugs for
these targets are not yet available.
Available pharmacological approaches of insomnia may target wake after sleep
onset or sleep latency, but in general these approaches do not target the (largely
unknown) molecular signalling pathways of sleep homeostasis but instead focus on
inhibiting mechanisms related to ‘arousal’ and ‘wake promotion’, e.g. GABAergic,
histaminergic and orexinergic mechanisms (Landolt et al. 2018).
Since SWA/SWS is accurately regulated in acute sleep manipulation protocols, is
often considered a key indicator of sleep homeostasis, shows a marked age-related
decline and has been implicated in memory consolidation, it has been and remains a
target for sleep promotion and improvement (Mander et al. 2017; Wilckens et al.
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2018). Non-pharmacological approaches include exercise and neuromodulation
(Kredlow et al. 2015; Wilckens et al. 2018). In one type of neuromodulation,
acoustic stimuli are phase locked to spontaneous slow waves. This has been reported
to enhance slow waves in young people, but not in older people (Garcia-Molina et al.
2018). Whether this enhancement improves subjective sleep quality and waking
function has not been ﬁrmly established. Rocking stimulation has recently been
reported to increase SWS, spindle density in SWS and memory consolidation in
healthy young adults (Perrault et al. 2019).
Pharmacological enhancement of slow-wave sleep has been accomplished by
compounds that have different mechanisms of action. Agonists of the extra-synaptic
GABAA receptor such as gaboxadol, also known as THIP, reliably induce SWS and
SWA in healthy participants at baseline, in a model of transient insomnia (trafﬁc
noise, Dijk et al. 2012), a model of sleep onset insomnia (Mathias et al. 2001), a
circadian phase advance model (Walsh et al. 2007), older participants (Lancel et al.
2001) and insomnia patients (Lankford et al. 2008). Interestingly, the effects of
gaboxadol on sleep are much stronger in women than in men (Dijk et al. 2010b; Ma
et al. 2011; Roth et al. 2010).
These enhancements of SWS were accompanied by modest improvement in sleep
continuity and subjective sleep quality and in one report an improvement of daytime
sleepiness and waking performance (Walsh et al. 2008). Gaboxadol was not fully
developed as a treatment for insomnia, but its unique action on GABAA receptors
containing the delta subunit and its effects on sleep and the EEG remain intriguing.
The most commonly used drugs for the treatment of insomnia are allosteric
modulators of the GABAA receptor. In general these drugs do have hypnotic effects,
e.g. improve wake after sleep onset (WASO), but do not enhance SWS, although
zolpidem can enhance visually scored SWS (Bettica et al. 2012). Spectral analysis of
the sleep EEG has revealed that the effects of all GABAA receptor allosteric
modulators lead to a very similar spectral proﬁle with reductions in delta and theta
activity and enhancement in sigma activity (Arbon et al. 2015; Brunner et al. 1991;
Trachsel et al. 1990) (see Fig. 5). This proﬁle is very different from the spectral
changes induced by physiological enhancement of homeostatic sleep pressure
through sleep deprivation. The increase in visually scored SWS which is sometimes
reported following zolpidem administration appears to be related to an increase in
activity in very low-frequency slow waves (Landolt et al. 2000).
The hypnotic and EEG effects of GABAA receptor allosteric modulators can be
separated, i.e. they are mediated by different receptor systems, and the rich variety of
GABAA receptors remains a target for the pharmacological improvement of sleep
(Wisden et al. 2017). In addition to GABAA, GABAB receptors also appear to be
involved in sleep regulation. GABAB receptors mediate some of the effects of
gamma-hydroxybutyrate (GHB) and its sodium salt: sodium oxybate (SO). SO is
the current ﬁrst-line treatment of excessive daytime sleepiness and cataplexy in
narcolepsy type 1. GHB induces SWS (Van Cauter et al. 1997; Dornbierer et al.
2019) and sleep onset REM periods (Vienne et al. 2012) and has been reported to
improve performance (Walsh et al. 2010).
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Antagonists of serotonergic 5-HT2A and histaminergic H1 receptors the latter
being widely used as nonprescription drugs for the treatment of sleep disturbances
also enhance SWS. This maps on to the serotonergic and histaminergic pathways
implicated in sleep-wake regulation generation (Landolt et al. 2018; Yu et al. 2018).
The spectral proﬁle of these effects is much more similar, although not identical, to
the effects of sleep deprivation than the effects GABAA receptor allosteric
modulators, i.e. these antagonists induce an increase in delta and theta activity
(Dijk et al. 1989b; Landolt and Wehrle 2009). The pharmacological enhancement
of SWS by 5-HT2A antagonists is in general not accompanied by a shortening of
sleep latency, an improvement in sleep continuity or a subjective sleep quality
(Landolt et al. 1999). Alcohol is by many used as a sleep facilitator. It indeed hastens
sleep onset but leads to more wakefulness in the second half of the sleep period,
especially in older participants (Landolt et al. 1996). The effects of alcohol on EEG
power spectra are different from those induced by GABAA allosteric modulators
(Dijk et al. 1992a).
Sleep spindles are not a target in drug development for insomnia, even though
several benzodiazepines and z-drugs enhance sleep spindle activity, and these
changes have been related to changes in plasticity (Wisden et al. 2017).
Even though REM sleep deﬁcits have been reported in insomnia (Baglioni et al.
2014) and in other conditions such as Alzheimer’s disease (Winsky-Sommerer et al.
2018) and REM sleep is a positive predictor of subjective sleep quality and waking
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Fig. 5 (a) Effects of zolpidem and a dual orexin antagonist (SB-649868) on EEG power spectra in
NREM sleep (modiﬁed from Bettica et al. 2012). (b) Sex differences in the effects of zolpidem
(10 mg) and gaboxadol (5, 10, 15 mg) on EEG power spectra in NREM sleep. Modiﬁed from Dijk
et al. (2010b)
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performance (Della Monica et al. 2018), REM sleep enhancement does not appear to
have been a target for pharmacological treatments. In fact REM sleep enhancement
and reduced latencies to REM sleep observed after administration of orexin
antagonists, e.g. (Bettica et al. 2012), are considered as an unwanted effect because
of its potential link with narcolepsy and cataplexy (Jacobson et al. 2017).
Negative effects of hypnotics on waking performance after drug-enhanced sleep
remain widespread despite continuing efforts to reduce these residual effects. For
example, in one detailed analysis of the effects of zopiclone and eszopiclone, it was
found that for some aspects of performance residual effects lasted as long as 11 h
after dosing, i.e. until mid-late morning (Boyle et al. 2012a).
2.8.2 Wake Promotion
Extending sleep is one approach to reduce sleepiness caused by sleep restriction
although this approach is obviously not realistic in idiopathic hypersomnolence
(Baumann 2018).
Non-pharmacological approaches, other than extra sleep, to improve waking
function include light exposure. Light has now been shown in a large number of
experiments (both in humans and animals) to have direct alerting effects (Pachito
et al. 2018; Viola et al. 2008b; Gaggioni et al. 2014). The photoreceptor and
molecular and neuroanatomical signalling pathways have in part been elucidated
(LeGates et al. 2014). Considering characteristics of light as an important
non-pharmacological approach to improving alertness is relevant in view of the
time we spend indoors where we are exposed primarily to artiﬁcial light.
Pharmacological approaches to improve alertness/wakefulness include caffeine
(Wyatt et al. 2004) which through its adenosinergic action is thought to interact with
sleep homeostatic mechanisms and indeed disrupts sleep (Clark and Landolt 2017).
Although widely used, some of the effects of caffeine remain poorly understood. For
example, and somewhat paradoxical, caffeine consumption may be associated with
sleepiness (Wyatt et al. 2004). Patterns of caffeine consumption may suggest that it
is primarily used to reduce sleep inertia and new delivery systems for this application
have been developed (Newman et al. 2013).
Pharmacological approaches target the main wake-promoting systems such as the
dopaminergic and histaminergic (H3) systems (Landolt et al. 2018). More recently
the glutamatergic (AMPA receptor) system has been targeted for wake promotion. In
experimental medicine type of conditions, these compounds have been shown to
exert wake promotion as evidenced by longer latencies on the maintenance of
wakefulness test or reduction of theta activity in the wake EEG (Boyle et al.
2012b; James et al. 2011; Iannone et al. 2010). At the same time little evidence for
enhancement of cognition was observed. Furthermore, analyses of sleep following
administration of compounds to promote wakefulness have documented ‘residual’
effects such as prolonged sleep latency or changes in sleep structure and the sleep
EEG. Remarkably these effects were not observed after administration of modaﬁnil
(James et al. 2011; Bodenmann et al. 2012).
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3 Circadian Rhythmicity: Sleep and Waking Performance
Circadian rhythmicity together with sleep homeostasis shapes the timing and struc-
ture of the sleep-wake cycle in young and older people and in men and women (Dijk
and Czeisler 1995; Dijk et al. 1999; Wyatt et al. 1999; Santhi et al. 2016). Humans
are a diurnal species, and in adult humans, sleep normally occurs at night and
wakefulness during the day, although in modern industrialised societies with access
to artiﬁcial light and the many social constraints it may be unclear where the day
ends and the night begins (Skeldon et al. 2017; Walch et al. 2016). Sleep is not
always monophasic, and daytime naps occur in normal and pathological conditions.
Sleep timing can be measured against clock time, relative to the natural light-dark
cycle and relative to preferred sleep timing, and imposed work schedules but also in
relation to the many rhythmic circadian processes such as the hormones cortisol,
melatonin, core body temperature, etc. (Dijk and Lockley 2002).
The timing and duration of sleep are among the most accessible characteristics of
sleep, and dysregulation of these aspects may be related to circadian rhythm sleep
disorders, insomnia, hypersomnia, etc. (see below). The two-process model of sleep
regulation describes sleep timing as the result of the interaction of a circadian process
and a homeostatic process (Daan et al. 1984; Borbély et al. 2016). The homeostatic
aspect of sleep regulation relates to the contribution of sleep debt – as accrued during
wakefulness and dissipating during sleep – to overall sleep propensity. The circadian
process represents a clock-like intrinsically generated rhythm in sleep propensity.
Sleep timing is also strongly inﬂuenced by social constraints such as work schedules
and social obligations. Age-related and genetically determined differences in these
processes and their interactions as well as psychological phenomena such as rumi-
nation and apprehension will shape individual differences in sleep-wake timing and
the risk for sleep disturbances and sleep disorders (see Fig. 6).
3.1 Circadian Regulation of Sleep and Wakefulness
3.1.1 Circadian Rhythm of Sleep-Wake Propensity
The circadian process drives a rhythm in sleep-wake propensity and persists in the
absence of sleep. The sleep-wake propensity rhythm is closely associated with the
melatonin rhythm and the core body temperature rhythm. The waveform and timing
of this sleep-wake propensity rhythm are at ﬁrst glance somewhat paradoxical (Dijk
and Czeisler 1994). Multiple protocols have established that in participants without
sleep disturbances, the circadian drive for wakefulness increases during the waking
day and reaches a maximum in the evening hours. The zone of maximum circadian
drive for wakefulness, located just before the nocturnal (9–11 p.m.) increase in
plasma melatonin concentrations, has been referred to as the wake maintenance
zone (Strogatz et al. 1987). This drive for wakefulness then dissipates rapidly after
the rise of melatonin (see Fig. 7).
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The maximum circadian drive for sleep is located close to the nadir of the body
temperature rhythm which in healthy participant occurs at around 4–6 a.m. and has
been referred to as the sleep maintenance zone. When this circadian-driven sleep-
Circadian Homeostat
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Fig. 6 Schematic representation of the interaction between circadian rhythmicity, sleep homeosta-
sis and the light-dark cycle in the regulation of the sleep-wake cycle. Modiﬁed from Dijk and
Lockley (2002)
)
%(
ssenlufeka
W
z(
ninotale
M
-
)serocs
W
ak
ef
ul
ne
ss
 (%
)
-1
0
1
2
0
20
40
0 120 240 0 120 240 0
Circadian Phase (degrees)
0 degrees = melatonin maximum
4 12 20 4 12 20 4
Corresponding Time of Daya b
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wake propensity rhythm is dysfunctional, a consolidated sleep-wake cycle is no
longer observed (Dijk and von Schantz 2005; Czeisler and Gooley 2007).
3.1.2 Circadian Contribution to Sleep Structure, Sleep Continuity
and the Sleep EEG
The circadian pacemaker actively promotes REM sleep such that even when
expressed as a percentage of total sleep time, REM sleep propensity is maximal at
around 2 h after the nadir of the core body temperature rhythm (Dijk and Czeisler
1995). The density of rapid eye movement is highest when sleep occurs in the
evening hours, i.e. during the wake maintenance zone (Khalsa et al. 2002). Sleep
continuity or sleep consolidation is an important determinant of sleep quality. The
circadian process has a strong impact on this characteristic of sleep such that the
duration of awakenings is much shorter during the biological night than during
the biological day (Dijk et al. 2001).
The circadian pacemaker also modulates the EEG within sleep such that it
actively promotes sleep spindle activity at night. The duration of sleep spindles is
longer, their frequency is lower, and their amplitude is higher when sleep occurs at
night (Wei et al. 1999). It has been hypothesised that this circadian modulation of
sleep spindles may contribute to sleep consolidation (Dijk et al. 1997).
Slow waves are to a lesser extent modulated by circadian phase such that slow-
wave activity is slightly lower and their slope is shallower when sleep occurs at
night. The circadian modulation of the sleep and wake EEG, relative to the sleep-
related modulation, is dependent on topography such that it is largest in occipital and
smallest in frontal derivations (Lazar et al. 2015).
3.1.3 Intrinsic Circadian Period and Sleep Timing
Basic circadian rhythm research has established that the timing of the circadian clock
relative to the 24 h cycle is determined by the strength (i.e. amplitude) of the light-
dark cycle and the intrinsic, largely genetically determined, period of the circadian
clock. Assessment of the intrinsic period of the circadian clock requires specialised
protocols in which light input to the clock is absent (as in blind people) or distributed
evenly across the circadian cycle in protocols in which the sleep-wake cycle is
scheduled to a period several hours shorter or longer than the intrinsic circadian
period and light levels during waking are very low (Duffy et al. 2011). These
protocols have shown that on average, the intrinsic period is 24.15 h with a standard
deviation of 0.2 h. Longer intrinsic periods are associated with later timing of the
sleep-wake cycle, body temperature cycle, melatonin cycle and an evening-type
diurnal preference and longer time in bed during weekends (Wright et al. 2001;
Duffy et al. 2011; Lazar et al. 2013). Conversely, shorter periods are associated with
earlier sleep timing, morning preference, etc.
Circadian rhythmicity is present not only in the suprachiasmatic nucleus (SCN)
which hosts the master pacemaker driving the circadian sleep-wake propensity
rhythm but also in the periphery. Intrinsic periods assessed through circadian
reporter systems in cell cultures of ﬁbroblasts have a weak association with SCN
periods (Hasan et al. 2012).
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3.1.4 Light Input
Under normal conditions, the circadian process is synchronised to the 24 h cycle,
primarily by light. Exposure to light in the evening delays (slows down) the clock,
i.e. clock-timed events like the rise of melatonin will occur later. Light in the
morning will advance (speed up) the clock, and events such as the peak of the
cortisol rhythm will occur earlier (Duffy and Wright 2005). The human circadian
timing system is very sensitive to light, and ordinary room light exerts approximately
50% of the maximum effect of light (Zeitzer et al. 2000; Santhi et al. 2012). The
discovery of melanopsin-expressing light-sensitive ganglion cells has drawn atten-
tion to the spectral composition of light as a determinant of the circadian effective-
ness of light (Lucas et al. 2014). Blue light has been shown to be very effective, and
the increasing blue light content of our LED home lighting and the blue light content
of light emitted by the screens of our gadgets are now considered to be a determinant
of sleep timing (Czeisler 2013; Gringras et al. 2015).
The timing of the circadian clock is determined by the overall 24-h pattern of light
exposure, and sufﬁcient exposure to daylight is now jeopardised because we spend
most of our day indoors. Low levels of exposure to daylight, especially in the winter,
will increase the delaying effects of artiﬁcial evening light.
3.1.5 Circadian Regulation of Waking Function
The circadian clock also modulates waking function. Thus many aspects of perfor-
mance are impaired when performance is assessed in the early morning hours, at
around the core temperature nadir, whereas in the evening hours, performance is at
its maximum, even when homeostatic sleep pressure at these circadian phases is
identical (Dijk et al. 1992b; Wyatt et al. 1999). Importantly, the effects of circadian
phase on waking function interact with homeostatic sleep pressure. Deterioration of
performance in the early morning is severe when it is combined with high homeo-
static sleep pressure, either caused by acute sleep loss (Dijk et al. 1992b; Wyatt et al.
1999, 2004) or chronic sleep loss (Cohen et al. 2010b). These experiments have also
shown that during the wake maintenance zone, the brain appears to be resilient
against the effects of sleep loss. Brain correlates of the circadian and the wake
duration-dependent deterioration of vigilant attention have been documented (Muto
et al. 2016).
Although circadian misalignment affects many aspects of performance, effects
are strongest for sleepiness, vigilant attention and effort (Santhi et al. 2016) although
others have emphasised that the circadian system may signiﬁcantly modulate aspects
of higher cognitive function as well (Burke et al. 2015b).
3.1.6 Circadian Aspects of Sleep Disorders
The role of the circadian timing system in sleep disorders is well recognised.
Circadian rhythm sleep-wake disorders are a separate diagnostic category in both
the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5)
and the International Classiﬁcation of Sleep Disorders, Third Edition. These
disorders include delayed, advanced, irregular, non-24-h, shift work and jet lag
disorders. Causes of all of these disorders may be intrinsic, environmental or
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behavioural and social, e.g. work schedules. The contribution of the circadian timing
system to sleep disturbances in shift work and jet lag is obvious and in essence is
caused by inertia of the circadian pacemaker. The circadian clock takes longer to
shift than the acute displacement of the sleep-wake schedule imposed by either shift
work or rapid travel across time zones. As a consequence people attempt to sleep
during the biological day and to be awake and work during the biological night.
3.1.7 External Factors: Modern Light Exposure Patterns
as an Environmental and Lifestyle Factor Contributing
to Sleep-Wake Disturbances
Reduced or inappropriate light exposure or changes in light input pathways to the
clock are obvious putative mechanisms of circadian sleep-wake disorders. Indeed,
the contribution of the circadian timing system to the non-24-h sleep-wake disorders
often observed in the blind is now well documented with 63% of blind individuals
displaying circadian rhythms which are not appropriately synchronised to the
24-h day (Flynn-Evans et al. 2014). Inadequate or inappropriate light exposure,
such as excessive evening light, may contribute to delayed sleep and evidence for
this is now emerging. Indeed exposure to ordinary room light in the evening has been
shown to suppress melatonin and sleepiness, delay bedtime and prolong sleep
latency (Gooley et al. 2011; Santhi et al. 2012). Abnormal light exposure patterns
are observed in delayed sleep-wake disorders (Van der Maren et al. 2018; Wilson
et al. 2018). Furthermore individual differences in the circadian sensitivity to light
are emerging (Santhi et al. 2012) and increased sensitivity to light may be a
characteristic of delayed sleep-wake phase syndrome (DSPS) (Watson et al. 2018).
A major roadblock in the full exploration of the contribution of light exposure to
circadian sleep-wake disturbances is the lack of adequate and acceptable longitudi-
nal sensing systems for the intensity and spectral composition of retinal light
exposure. Nevertheless, some studies combining light exposure measurements and
mathematical modelling thereof have already shown that light exposure is a good
predictor of circadian phase (Woelders et al. 2017).
3.1.8 Intrinsic Factors: Genetic Variants and Differences in Circadian
Period Contributing to Sleep-Wake Disturbances
Genetic Variants
Evidence for the involvement of circadian rhythmicity in sleep timing abnormalities
may be derived from the various polymorphisms and mutations in genes which are
part of the molecular machinery generating circadian rhythms. Variations in the
period genes have been associated with familial advanced sleep phase syndrome and
DSPS. Some of these mutations and polymorphisms have been shown to shorten or
lengthen circadian period when introduced in animal or cell culture models (Shi et al.
2017). Maybe somewhat surprising, other clock gene variants do not seem to affect
circadian period even though they associate with variations in sleep timing (see
below). Many clock gene variants associate with variation in diurnal preference
(Kalmbach et al. 2017; Jones et al. 2016; Lane et al. 2016), and extremes of diurnal
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preferences may translate to circadian sleep timing disorders. The effects of circa-
dian variants to aspects of sleep other than its timing remain poorly characterised. It
is of interest that several studies have now shown that circadian variants not only
affect sleep timing but also sleep structure. For example, variants of the period genes
are associated with differences in N3, i.e. slow-wave sleep (Hasan et al. 2014;
Archer et al. 2018; Chang et al. 2016; Dijk and Archer 2010).
Circadian Period
Direct evidence for a contribution of intrinsic circadian factors such as abnormally
long or short intrinsic circadian periods to circadian sleep-wake disorders is growing.
Assessments of intrinsic circadian period in sleep disorders are rare, but it has been
reported that circadian period is longer in DSPS and non-24-h sleep-wake disorder
(Micic et al. 2016). It is often implied that developmental and age-related changes in
circadian period contribute to late sleep timing in adolescence and early sleep timing
in old age, but there is no solid evidence that the intrinsic circadian periods change
with age (Dijk et al. 2000; Crowley et al. 2018; Skeldon et al. 2016). However,
differences in circadian period as small as a few minutes may lead to substantial
difference in entrained phase (Wright et al. 2005), and few studies with the statistical
power to detect these small differences have been conducted. One example of small
differences in circadian period concerns sex differences with circadian period in
women being approximately 6 min shorter than in men (Duffy et al. 2011). This sex
difference in intrinsic period may explain the earlier preferred timing of bedtime
relative to clock time in women (Diurnal preference) and the earlier timing of the
melatonin and core body temperature rhythm relative to sleep in women (Cain et al.
2010).
Circadian Phase
Indirect evidence for a contribution of the circadian timing system to variation in
sleep timing stems from the observed associations between the timing of the
melatonin rhythm and the timing of sleep in people without sleep timing complaints
and in DSPS (Archer et al. 2008). Although this association implies that later timing
of the melatonin rhythm may lead to later sleep timing, it cannot be excluded that the
later sleep timing and associated light exposure lead to the delay of the melatonin
rhythm. Recent data show that the intrinsic timing of the melatonin rhythm, as
assessed by the dim light melatonin onset, is not delayed in almost half of DSPD
patients (Murray et al. 2017).
The circadian timing system may also contribute to non-circadian sleep disorders.
Insomnia with the prominent and persistent symptoms of difﬁculties initiating and
maintaining sleep is in general not considered a circadian sleep disorder. Yet
excessive strength of the evening wake maintenance zone or reduced circadian
promotion of sleep during the night may contribute to these symptoms. Recently it
was reported that in 10–22% of insomnia patients, the timing of sleep relative to the
melatonin rhythm is abnormal such that sleep is attempted to be initiated at an early
‘melatonin time’ (Flynn-Evans et al. 2017).
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3.1.9 Circadian Approaches to Treatment of Sleep-Wake Disturbances
In cases in which the cause of sleep-wake disturbances is clearly circadian, such as in
jet lag disorder or non-24-h sleep-wake disorders in the blind, treatments are
typically directed at the circadian timing system. Currently, abnormal timing of the
circadian sleep-wake propensity rhythm may be corrected by either timed light
exposure and light avoidance or administration of melatonin.
Light Treatment
Effects of time light exposure have been most extensively investigated in DSPS.
Exposure to bright light in the morning, sometimes combined with instructions to
avoid light in the evening, which theoretically should advance the sleep propensity
rhythm, has been shown to be effective in DSPS (Richardson et al. 2018; Auger et al.
2015a, b). Optimisation of light treatment will require further quantitative under-
standing of the effects of light exposure patterns on the phase and amplitude of the
circadian sleep-wake propensity rhythm. Current models for the effects of light do
neither account for the spectral composition of light or the effects of prior light
history on the sensitivity to light. Successful implementation of light therapy may
also require assessment of circadian phase because effects of light depend on
circadian phase, and, in some situation, like jet lag, circadian phase is not easily
predicted. Light treatment also requires light delivery or light input manipulation
systems that are easy to use and acceptable to users. Recent light treatment
approaches have focused on reducing the blue light content of light to which the
retina is exposed (Zerbini et al. 2018), and further development of methods by which
the 24-h light exposure pattern, at the work place and at home, can be manipulated is
a promising avenue for the treatment of some circadian rhythm sleep-wake
disorders.
Development of novel therapeutics focusing on the light input pathway to the
circadian system could target the anatomical and molecular pathways involved in
entrainment.
Melatonin Therapy
Melatonin therapy has been successfully implemented in circadian rhythm sleep-
wake disorders (Auger et al. 2015a, b) although the need for more research is
recognised (Auger et al. 2015a, b). Melatonin is in the ﬁrst instance an output of
the circadian timing system. Its synthesis in the pineal is driven by sympathetic
input, the rhythmicity of which is driven by the SCN such that in both nocturnal and
diurnal species plasma melatonin concentrations are high during the biologically
night and low during the biological day. This rhythm persists in constant darkness,
but light at night suppresses melatonin. Melatonin administration leads to an
increase in sleep propensity and shift of the sleep propensity rhythm, when it is
administered when endogenous levels are low. This has been demonstrated in forced
desynchrony protocols (Wyatt et al. 2006) and daytime sleep experiments
(Rajaratnam et al. 2004) in participants without melatonin deﬁciency or sleep timing
complaints. This effect is commonly referred to as the direct sleep-facilitating effect
of melatonin. Melatonin can also induce a change in the timing of the endogenous
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phase of rhythms driven by the SCN. Some of these phase markers include the
cortisol, core body temperature and endogenous melatonin rhythm (Rajaratnam et al.
2003). The direction of the shift depends on the endogenous circadian phase at
which melatonin is administered (Lewy et al. 1998). Circadian rhythms will be
advanced when melatonin is administered several hours before the endogenous rise
of melatonin, although the optimal timing has not been explored in great detail.
Evidence for melatonin’s effectiveness in delaying endogenous circadian rhythms is
more limited. The phase-advancing effects of melatonin have been successfully
exploited in several disorders such as DSPS (Sletten et al. 2018). Melatonin is also
used to treat sleep disturbances in developmental disorders such as autism (Gringras
et al. 2017). In all of these conditions, the largest effects are observed for latency to
sleep onset. The effectiveness of melatonin in these conditions may be related to a
combination of its direct sleep-facilitating and phase-shifting effects. Compared to
allosteric modulators of the GABAA receptor, melatonin has very minor effects on
slow-wave activity and EEG power spectra (Arbon et al. 2015).
Daily administration of melatonin can entrain non-synchronised rhythms, such as
observed in the blind, to the 24 h day (Lockley et al. 2000). Melatonin treatment has
also been advocated for the treatment of insomnia and in particular insomnia in older
people (Lemoine and Zisapel 2012). The rationale for this approach is that endoge-
nous melatonin levels may be too low in this particular patient group. The evidence
for melatonin deﬁciency in insomnia is however rather limited although timing of
melatonin may be abnormal in insomnia (see above).
Efforts have been made to optimise the dose of melatonin as well as the kinetics
by, for example, slow-release preparations for oral or dermal delivery (Lemoine and
Zisapel 2012; Aeschbach et al. 2009).
Effects of melatonin are mediated by M1 and M2 melatonin receptors which are
abundant in the SCN but also in other brain areas. Melatonin receptor agonists have
been developed for the treatment of insomnia (ramelteon) (Liu and Wang 2012) and
non-24 h sleep-wake disorders (tasimelteon) (Lockley et al. 2015). Whether these
agonists which have been approved are more effective than melatonin itself has not
been investigated.
Further development of the melatonin-based treatment of sleep-wake disorders
may beneﬁt from new methods to assess endogenous circadian phase, which now
requires collection of multiple samples under carefully controlled conditions. Sev-
eral promising approaches based on analyses of the blood transcriptome have
recently been developed (Laing et al. 2017; Wittenbrink et al. 2018).
3.1.10 Other Circadian Outputs and Novel Therapeutics for Sleep-Wake
Disturbances
Further exploitation of the profound circadian inﬂuence on the sleep-wake propen-
sity rhythm will require a better understanding of the neuroanatomical and molecular
pathways by which the circadian system interacts with sleep executive systems
generating sleep and wakefulness. An interesting example of interactions between
sleep and circadian mechanisms relates to adenosinergic mechanisms. Caffeine, well
known to affect sleep, also appears to affect the circadian timing system such that it
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delays phase, lengthens circadian period (Burke et al. 2015a) and affects light
sensitivity of the circadian timing system (van Diepen et al. 2014). Another example
relates to orexin. The orexin system is under circadian control but is also affected by
sleep deprivation (Deboer et al. 2004) and is implicated in sleep-wake regulation.
Orexin antagonists have been successfully developed for the treatment of insomnia
(Herring et al. 2018).
4 Novel Therapeutics and Sleep-Wake Regulation: Outlook
4.1 Continued Need and Opportunities
Given the high prevalence of sleep-wake disturbances and the imperfection of
current treatments of these disturbances, efforts to develop novel therapeutics will
continue and are warranted. These efforts will be informed by a better understanding
of the multifaceted nature of sleep-wake regulation and disturbances thereof. The
need for novel therapeutics is likely to increase because of the continued high
prevalence of shift work and associated sleep-wake disorders, demographic changes
with more people living longer and the increase in the number of people living with
dementia and associated disruption of sleep-wake cycles. The multidimensional
phenomenology of sleep and wakefulness implies that the treatment of disorders
of sleep and wakefulness, and the development of new sleep-wake therapeutics,
continues to require the input from a variety of scientiﬁc disciplines ranging from
molecular biology to clinical and cognitive psychology.
4.2 A More Comprehensive Phenomenology of Sleep and Sleep
Disturbances
Understanding the subjective complaints about sleep quality or complaints of
waking function attributed to poor sleep will remain a ﬁrst point of entry for sleep
medicine and the development of novel therapeutics. A better understanding of how
sleep complaints relate to sleep and circadian physiology will require a more
comprehensive phenomenology of healthy sleep and disturbed sleep. This extended
phenomenology may open up new avenues for the development of novel therapeu-
tics. Examples of this are already available. The complaint of not being able to fall
asleep is common to insomnia and circadian rhythm sleep-wake disorders (delayed).
The observation that insomnia patients experience difﬁculties sleeping irrespective
of time of day, whereas in delayed or advanced sleep phase syndromes, there are
times of day at which sleep-ability is normal, distinguishes the two disorders.
Although this may now appear to be trivial, it is only the recognition of the
importance of the circadian timing system in sleep-wake regulation that allowed
for this distinction and development of speciﬁc treatments. Within this context it
may be relevant to point out that in the treatment of circadian rhythm sleep-wake
disorders, sleep remains the relevant outcome measure, but the target for the
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pharmacological and non-pharmacological therapeutics is far removed from classi-
cal sleep neurotransmitter systems. By contrast, in insomnia, neurotransmitter
systems directly involved in sleep-wake regulation and associated processes such
as arousal remain the target. Early on in these programmes, sleep physiology
measures such as latency to sleep onset and wake after sleep onset are primary
outcome measures, even though in at least a sizable fraction of insomnia patients,
physiologically determined total sleep time is not severely abnormal (Vgontzas et al.
2013), and the complaint appears to be more related to the persistent mentation in the
presence of physiological sleep. A better understanding of the sleep experience or
the absence thereof and new EEG measures that better capture the sleep experience
are needed. Efforts in this direction are already underway and can be guided by a
simple question: what is the relation between sleep physiology and the sleep
experience?
No doubt the discovery of other novel therapeutics will be parsimonious and not
informed by any biased approach. Examples of current parsimoniously discovered
therapeutics include the wake-promoting compound modaﬁnil. It is only now that
the important role of the dopaminergic system in wake (and sleep) regulation is
recognised, providing a rational basis for modaﬁnil’s effects.
4.3 Short-Term vs Long-Term Treatment and Consequences
of Short and Long Sleep as a Risk Factor for Ill Health
It is understandable that approaches to the development of novel therapeutics are
primarily targeting acute and ongoing complaints about sleep. Successful treatments
of these complaints may not only resolve the acute complaints but also have long-
term health implications. Epidemiological studies indeed show that, for example, the
complaint of insomnia is associated with adverse physical and mental health
outcomes such as depression in particular (Sivertsen et al. 2014). Population-based
epidemiological studies also show that not only short sleep duration but also long
self-reported sleep duration predict negative health outcomes (Jike et al. 2018).
Whereas the sleep research ﬁeld, in which the ‘sleep as a recovery process’ is the
prevailing view, can easily envision pathways from short sleep to ill health, although
even these remain poorly deﬁned, the pathways from long sleep to ill health remain
unclear. In fact, it currently remains uncertain whether long sleep is an early
consequence of covert ill health or a cause. Whereas approaches to lengthen short
sleep can include advocating lifestyle changes, no currently accepted policy for long
sleep including excessive napping, which, for example, is highly prevalent in
dementia, is available.
A major limitation of the currently available epidemiology is that the exposure
assessment (sleep duration) is to the larger extent based on self-report. Limitations of
self-reported sleep duration are considerable, in particular, because the reporting
error appears to be correlated with health outcomes (Miller et al. 2015).
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4.4 Symptom Based vs Disorder (Nosology) Based
Traditionally the development of therapeutics was nosology or disorder based, and
the underlying assumption is that speciﬁc disorders have a speciﬁc aetiology which
can be targeted. This approach may work well in cases in which the disease or
disorder and its aetiology are clearly deﬁned. However, many disorders may be
rather heterogenous, symptoms may be common to several disorders, and disorders
may be closely related. For example, insomnia patients may display several anxiety-
related symptoms. In fact GWAS studies of insomnia show that the genetic
associations with insomnia and anxiety overlap to a considerable extent
(Hammerschlag et al. 2017). Furthermore, insomnia disorder may consist of various
subtypes with different aetiologies (Blanken et al. 2019). Thus insomnia with
objectively reduced TST and insomnia without objectively reduced TST may have
a different aetiology, different adverse consequences, etc. One approach to the
development of therapeutics may be to target symptoms, e.g. anxiety, rather than a
disorder, e.g. insomnia, and then target those insomnia patients who speciﬁcally
suffer from anxiety symptoms. Precise and comprehensive phenomenology is obvi-
ously key to such an approach.
4.5 Sleep as a Whole-Body Phenomenon
Quantiﬁcation of sleep often focuses on the brain. The EEG is a major source of
information about the sleep process, but sleep is obviously much more than changed
in neuronal ﬁring patterns. Changes affecting both the brain and the body include
temperature, cardiovascular, endocrine and many other variables. How peripheral
physiology contributes to the sleep process and its recovery value remains somewhat
under-investigated. For example, skin, body and brain temperatures are affected by
sleep, and as early as 1967, Monroe reported body temperature during sleep to
be higher in poor sleepers compared to good sleepers (Monroe 1967). Indeed,
manipulating peripheral and central thermoregulatory processes have been shown
to improve sleep in, for example, ageing (Te Lindert and Van Someren 2018). There
is extensive epidemiology pointing to associations between sleep duration and
obesity, and effects of sleep manipulation on appetite- and glucose-regulating
hormones have been reported. Yet, relatively little is known about the effects of
obesity or food intake on sleep. Future approaches to the development of novel
therapeutics may exploit some of these peripheral phenomena to improve sleep for
the brain and the body.
4.6 Interactions: Circadian Rhythmicity and Sleep-Wake History
The separate contribution of circadian rhythmicity and sleep-wake history (sleep
homeostasis) to sleep propensity and waking functions is well recognised. However,
the most important determinant of both sleep propensity and waking function is the
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combined action of circadian rhythmicity and sleep homeostasis. Thus, waking
performance at 6 a.m. close to the core body temperature nadir is not much impaired
at all if the participant has had sufﬁcient sleep prior to this time point. However,
performance at this circadian phase is severely impaired when the participant is
carrying an acute or chronic sleep debt. The implication for the development of
novel therapeutics is that identiﬁcation of the locus and mechanism of the interaction
between circadian and homeostatic signals may offer new insights and targets. Some
approaches are now emerging in preclinical research programmes in which local
circadian clocks in arousal-related structures are manipulated and their effects on
sleep-wake cycles are documented (Yu et al. 2014).
4.7 Monogenetic-Polygenetic, Monopharmacy vs Polypharmacy
Developing treatments of disorders of sleep and wakefulness necessarily implies the
targeting of relevant circuits, receptor systems, etc. The ever more detailed descrip-
tion of the multitude of, for example, receptor subtypes offers opportunities for
developing compounds with greater speciﬁcity for speciﬁc receptor subtypes. Like-
wise the ever more detailed description of the neuronal cell types regulating and
contributing to speciﬁc aspects of sleep, e.g. sleep initiation vs REM sleep regula-
tion, or EEG synchronisation. Such a speciﬁc targeted approach will be fruitful of
speciﬁc receptor subtypes contributing to speciﬁc sleep disorders. This may be true
in some cases, e.g. narcolepsy, even though even in this disorder, multiple
neuromodulators have been implicated, but not in other cases. For example, it is
unlikely that insomnia is caused by a deﬁciency in one particular GABAA receptor
subtype. These states such as insomnia are likely to be associated with changes in
constellations of biochemical signalling pathways. The implication is that a less
speciﬁc treatment approach or drug development programme may be more effective.
4.8 The Sleep Environment
One deﬁning aspect of sleep is partial disengagement from the environment, but the
sleeper is not completely disconnected from its environment. Environmental
inﬂuences on sleep and sleep disturbances may deserve more attention. Environ-
mental variables that can be considered to be relevant include temperature, humidity,
noise and light. With modern humans spending most of their time indoors, a closer
look at the indoor environmental environment may be warranted. Sleep-wake cycles
and their circadian regulation evolved in part as adaptation to environmental cycles
related to the earth rotation around its axis. The light-dark cycle is one prominent
example, but the natural darkness of the night is often hard to ﬁnd in urban
environments and the bedroom. Profound daily cycles in environmental temperature
in the natural environment are to some extent mirrored in the circadian rhythm of
body temperature which reaches a maximum during the later part of the day and a
minimum close to dawn. Yet, temperature cycles in our home environments
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including bedrooms are very different, and little is known about the potential impact
of environmental temperature cycles on sleep-wake cycles and their quality.
4.9 Large-Scale Sleep Studies in the Home Environment
New developments in electronics, electrode technologies and signal analysis have
enabled new recording and analyses approaches which have revealed novel aspects
of sleep phenomenology. New recording technologies and new scoring approaches
based on machine learning techniques using reduced montages will soon enable
large-scale sleep studies in the home environment (Peake et al. 2018; Mikkelsen
et al. 2019).
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